include,title,abstract,first_author,year,journal,doi,pubmed_id,authors,pubmed_type,publication_types,mesh,webofscience_id,central_id,openalex_id,title_length,title_word_count,title_sentence_count,abstract_length,abstract_word_count,abstract_sentence_count,language_title,language_abstract
false,effectiveness clonidine analgesic paediatric adenotonsillectomy,compare analgesic effect preoperative oral clonidine intraoperative intravenous fentanyl child undergo tonsillectomy adenotonsillectomy randomize control double blind study asa ii child age yr undergo adenotonsillectomy conduct tertiary care paediatric teach hospital either microgram kg clonidine po give min preoperatively micrograms kg fentanyl v give intraoperatively postoperatively visual analog pain score va record rest swallow every min first min every min two hour morphine mg kg v give va require mg kg codeine po mg kg acetaminophen po give sedation anxiety score record preoperatively haemodynamic change blood loss recovery score incidence vomit hypotension airway obstruction record child receive clonidine high incidence preoperative sedation receive fentanyl preinduction mean arterial pressure low clonidine group require intervention va score similar throughout observation period difference either number morphine codeine rescue administer incidence side effect oral clonidine effective analgesic sedative child undergo tonsillectomy adenotonsillectomy,Reimer EJ,1998,Can J Anaesth,https://doi.org/10.1007/bf03012457,10051933,Reimer EJ; Dunn GS; Montgomery CJ; Sanderson PM; Scheepers LD; Merrick PM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000082: Acetaminophen; D000233: Adenoidectomy; D000284: Administration, Oral; D000700: Analgesics; D018712: Analgesics, Non-Narcotic; D000701: Analgesics, Opioid; D001794: Blood Pressure; D002648: Child; D003000: Clonidine; D003061: Codeine; D003243: Consciousness; D003679: Deglutition; D004311: Double-Blind Method; D005260: Female; D005283: Fentanyl; D005500: Follow-Up Studies; D006801: Humans; D015994: Incidence; D007275: Injections, Intravenous; D007430: Intraoperative Care; D008297: Male; D009020: Morphine; D010147: Pain Measurement; D010149: Pain, Postoperative; D011292: Premedication; D014068: Tonsillectomy",,,https://openalex.org/W2082613933,79,10,1,1501,244,12,en,en
false,control trial sustain release bupropion nicotine patch smoking cessation,use nicotine replacement therapy antidepressant bupropion help people stop smoke conduct double blind placebo control comparison sustain release bupropion subject nicotine patch subject bupropion nicotine patch subject placebo subject smoke cessation smoker clinical depression exclude treatment consist nine week bupropion mg day first three day mg twice daily placebo well eight week nicotine patch therapy mg per day week mg per day week mg per day week placebo target day quit smoke usually day,Jorenby DE,1999,N Engl J Med,https://doi.org/10.1056/nejm199903043400903,10053177,Jorenby DE; Leischow SJ; Nides MA; Rennard SI; Johnston JA; Hughes AR; Smith SS; Muramoto ML; Daughton DM; Doan K; Fiore MC; Baker TB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000279: Administration, Cutaneous; D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D009538: Nicotine; D016540: Smoking Cessation; D013375: Substance Withdrawal Syndrome; D015430: Weight Gain",,,https://openalex.org/W2312609348,98,16,1,727,141,5,en,en
false,effect methylphenidate complex cognitive processing attention deficit hyperactivity disorder,three experiment conduct explore effect methylphenidate mph attention deficit hyperactivity disorder adhd diagnosis age performance complex visual memory search task result show effect mph vary information load low processing load mph help child adhd improve accuracy cost reaction time rt whereas high load high mph improve error rate slow rt without medication child adhd show high error rate slow rts across low high load young normal control child mph slow performance difficult high load condition argue drug improve self regulatory ability enable child adhd adapt differentially high low load,Berman T,1999,J Abnorm Psychol,https://doi.org/10.1037/0021-843x.108.1.90,10066996,Berman T; Douglas VI; Barr RG,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000367: Age Factors; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003071: Cognition; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008568: Memory; D008774: Methylphenidate; D011597: Psychomotor Performance; D011930: Reaction Time; D014796: Visual Perception",,,https://openalex.org/W2022904832,103,12,1,841,149,5,en,en
false,spinal clonidine prolongs labor analgesia spinal sufentanil bupivacaine,seek determine whether spinal clonidine micro sign g prolong analgesia spinal administration sufentanil micro sign g bupivacaine mg early first stage labor thirty patient randomize receive ml spinal injection sufentanil micro sign g bupivacaine mg without clonidine micro sign g use combine spinal epidural cse technique pain nausea pruritus sedation motor block blood pressure heart rate assess patient request additional analgesia analgesia significantly prolong patient receive spinal sufentanil bupivacaine clonidine v min p pain score side effect include motor block sedation hypotension similar group spinal clonidine significantly prolong labor analgesia spinal sufentanil bupivacaine without produce serious adverse side effect implication study effect spinal clonidine administer spinal sufentanil bupivacaine labor analgesia use combine spinal epidural technique conclude spinal clonidine significantly prolong labor analgesia spinal sufentanil bupivacaine without produce serious adverse effect anesth analg,D'Angelo R,1999,Anesth Analg,https://doi.org/10.1097/00000539-199903000-00020,10072008,D'Angelo R; Evans E; Dean LA; Gaver R; Eisenach JC,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D016362: Analgesia, Obstetrical; D000700: Analgesics; D000701: Analgesics, Opioid; D000779: Anesthetics, Local; D002045: Bupivacaine; D003000: Clonidine; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D017409: Sufentanil",,,https://openalex.org/W2021097359,80,10,1,1322,224,8,en,en
false,low dose clozapine treatment drug induce psychosis parkinson disease,drug induce psychosis difficult problem manage patient parkinson disease multiple open label study report treatment clozapine low ameliorate psychosis without worsen parkinsonism conduct randomize double blind placebo control trial low clozapine mg per day patient six site period month patient mean age year idiopathic parkinson disease drug induce psychosis least four week duration patient continue receive fix dos antiparkinsonian drug four week trial blood count monitor weekly patient mean dose clozapine mg per day patient clozapine group significantly improvement placebo group three measure use determine severity psychosis mean se score clinical global impression scale improve point patient receive clozapine compare point receive placebo p score brief psychiatric rating scale improve point patient receive clozapine compare point receive placebo p score scale assessment positive symptom improve point patient receive clozapine compare point receive placebo p seven patient treat clozapine improvement least three seven point clinical global impression scale compare one patient give placebo clozapine treatment improve tremor deleterious effect severity parkinsonism one patient clozapine discontinue leukopenia clozapine daily mg less safe significantly improve drug induce psychosis without worsen parkinsonism,Parkinson Study Group,1999,N Engl J Med,https://doi.org/10.1056/nejm199903113401003,10072410,Parkinson Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D010300: Parkinson Disease; D011605: Psychoses, Substance-Induced; D016896: Treatment Outcome",,,https://openalex.org/W4239283954,85,12,1,1994,336,12,en,en
false,predictor relapse follow response first episode schizophrenia schizoaffective disorder,background examine relapse response first episode schizophrenia schizoaffective disorder method patient first episode schizophrenia assess measure psychopathologic variable cognition social function biological variable treat accord standardize algorithm sample relapse analyse consist patient respond treatment index episode risk relapse result five year initial recovery cumulative first relapse rate confidence interval ci second relapse rate ci year recovery second relapse cumulative third relapse rate ci discontinue antipsychotic drug therapy increase risk relapse almost time hazard ratio initial relapse ci hazard ratio second relapse ci subsequent analyse control antipsychotic drug use show patient poor premorbid adaptation school premorbid social withdrawal relapse earlier sex diagnosis obstetric complication duration psychotic illness treatment baseline symptom neuroendocrine measure methylphenidate hydrochloride challenge response neuropsychologic magnetic resonance image measure time response initial episode adverse effect treatment presence residual symptom initial episode significantly relate time relapse conclusion high rate relapse within year recovery first episode schizophrenia schizoaffective disorder risk diminish maintenance antipsychotic drug treatment,Robinson D,1999,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.56.3.241,10078501,Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D015331: Cohort Studies; D005260: Female; D005476: Fluphenazine; D005500: Follow-Up Studies; D006212: Hallucinations; D006801: Humans; D008137: Longitudinal Studies; D008279: Magnetic Resonance Imaging; D009483: Neuropsychological Tests; D010349: Patient Compliance; D011247: Pregnancy; D011248: Pregnancy Complications; D011336: Probability; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012307: Risk Factors; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D055502: Secondary Prevention; D012720: Severity of Illness Index; D012737: Sex Factors; D016896: Treatment Outcome,,,https://openalex.org/W2154849243,106,14,1,1787,304,2,en,en
false,comparison risperidone placebo psychosis behavioral disturbance associate dementia,report find first large double blind placebo control study conduct evaluate efficacy safety risperidone treatment psychotic behavioral symptom institutionalize elderly patient dementia patient woman mean age year dsm iv diagnosis alzheimer disease vascular dementia mixed dementia significant psychotic behavioral symptom include patient randomly assign receive placebo mg day mg day mg day risperidone week primary outcome measure behavioral pathology alzheimer disease rating scale behave ad study complete patient baseline functional assessment stag score patient indicate severe dementia endpoint significantly great reduction behave ad total score psychosis aggressiveness subscale score see patient receive mg day risperidone placebo patient p p respectively week mg day risperidone superior placebo reduce behave ad aggression score p adverse event report patient receive mg day risperidone mg day common dose related adverse event extrapyramidal symptom somnolence mild peripheral edema frequency extrapyramidal symptom patient receive mg day risperidone significantly great placebo patient risperidone significantly improve symptom psychosis aggressive behavior patient severe dementia result show mg day risperidone appropriate dose elderly patient dementia,Katz IR,1999,J Clin Psychiatry,https://doi.org/10.4088/jcp.v60n0207,10084637,Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000374: Aggression; D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D003704: Dementia; D015140: Dementia, Vascular; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D015577: Geriatric Assessment; D006801: Humans; D007326: Institutionalization; D008297: Male; D010919: Placebos; D018967: Risperidone; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W1993818042,104,13,1,1790,308,10,en,en
false,tha improve word prim clonidine enhances fluency work memory alzheimer disease,investigate effect single administration cholinesterase inhibitor tetrahydroaminoacridine tha mg orally agonist clonidine g kg orally neuropsychologic performance two group patient alzheimer disease ad clonidine enhance spatial work memory verbal fluency effect spatial span word prim tha enhance word prim effect performance measure data suggest degeneration lc noradrenergic system cholinergic cell basal forebrain different functional consequence progression ad finally combine treatment noradrenergic cholinergic drug might produce qualitatively broad effect cognitive function either treatment alone effectively attenuate clinical dementia,Riekkinen P,1999,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(98)00093-1,10088136,Riekkinen P; Riekkinen M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000544: Alzheimer Disease; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008570: Memory, Short-Term; D018697: Nootropic Agents; D011597: Psychomotor Performance; D013619: Tacrine; D014705: Verbal Behavior",,,https://openalex.org/W1561544516,98,15,1,885,151,5,en,en
false,diuretic blocker adverse effect year plasma lipid lipoprotein profile men hypertension,concern base report short term adverse effect antihypertensive agent plasma lipid lipoprotein profile plpps complicate therapy hypertension compare long term year effect different antihypertensive drug placebo plpps multicenter randomize double blind parallel group clinical trial u veteran affair medical center total ambulatory men year old diastolic blood pressure dbps range mm hg take placebo randomize receive placebo antihypertensive drug hydrochlorothiazide atenolol captopril clonidine diltiazem prazosin drug titration patient dbp less mm hg follow year plasma lipid lipoprotein profile determine baseline initial titration year week regimen hydrochlorothiazide increase mg dl mmol l total cholesterol mg dl apolipoprotein b significantly different p decrease mg dl total cholesterol mg dl apob level receive prazosin placebo patient achieve positive dbp control use hydrochlorothiazide responder show adverse change plpps whereas nonresponders exhibit increase triglyceride total cholesterol low density lipoprotein cholesterol level plasma lipid lipoprotein profile change significantly among treatment group year except minor decrease high density lipoprotein level use hydrochlorothiazide clonidine atenolol none antihypertensive drug long term adverse effect plpps therefore may safely prescribe previously report short term adverse effect use hydrochlorothiazide limit nonresponders,Lakshman MR,1999,Arch Intern Med,https://doi.org/10.1001/archinte.159.6.551,10090111,Lakshman MR; Reda DJ; Materson BJ; Cushman WC; Freis ED,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D002216: Captopril; D003000: Clonidine; D004110: Diltiazem; D004232: Diuretics; D004311: Double-Blind Method; D006787: Hospitals, Veterans; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008055: Lipids; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged; D011188: Potassium; D011224: Prazosin; D013997: Time Factors; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2095656324,128,21,1,1876,305,6,en,en
false,selegiline induce postural hypotension parkinson disease longitudinal study effect drug withdrawal,united kingdom parkinson disease research group ukpdrg trial find increased mortality patient parkinson disease pd randomize receive mg selegiline per day l dopa compare take l dopa alone recently find therapy selegiline l dopa associate selective systolic orthostatic hypotension abolish withdrawal selegiline unwanted effect postural blood pressure result underlie autonomic failure aim study confirm previous find separate cohort patient determine time course cardiovascular consequence stop selegiline expectation might shed light mechanism drug cause orthostatic hypotension cardiovascular response stand head tilt study repeatedly pd patient receive selegiline drug withdrawn head tilt cause systolic orthostatic hypotension mark six pd patient selegiline one lose consciousness unrecordable blood pressure less degree orthostatic hypotension occur stand orthostatic hypotension ameliorate day withdrawal selegiline totally abolish day discontinuation drug stop selegiline also significantly reduce supine systolic diastolic blood pressure consistent previously undescribed supine pressor action study confirm previous find selegiline combination l dopa associate selective orthostatic hypotension possibility cardiovascular finding might result non selective inhibition monoamine oxidase amphetamine metamphetamine discus,Churchyard A,1999,Mov Disord,https://doi.org/10.1002/1531-8257(199903)14:2<246::aid-mds1008>3.0.co;2-p,10091617,Churchyard A; Mathias CJ; Lees AJ,article,D016430: Clinical Trial; D016428: Journal Article,"D000368: Aged; D000704: Analysis of Variance; D000978: Antiparkinson Agents; D001794: Blood Pressure; D004244: Dizziness; D004359: Drug Therapy, Combination; D004837: Epinephrine; D005260: Female; D006257: Head; D006339: Heart Rate; D006801: Humans; D007024: Hypotension, Orthostatic; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D010300: Parkinson Disease; D011187: Posture; D011446: Prospective Studies; D012642: Selegiline; D012720: Severity of Illness Index; D013375: Substance Withdrawal Syndrome; D013997: Time Factors",,,https://openalex.org/W2062309915,118,17,1,1812,272,8,en,en
false,gamma hydroxybutters ure zur therapie de alkoholentzugssyndroms bei intensivpatienten vergleich zweier symptomorientierter therapeutischer konzepte,unlabelled see gamma hydroxybutyrate ghb benzodiazepine interact gaba transmitter system investigate whether ghb replace conventional therapy use benzodiazepine treatment alcohol withdrawal syndrome icu set method chronic alcoholic include prospective randomize study follow development alcohol withdrawal syndrome patient randomly allocate ghb flunitrazepam group addition clonidine administer order treat autonomic sign withdrawal case hallucination occur haloperidol administer result significant difference efficacy treatment use duration mechanical ventilation intensive care unit stay group patient ghb group require significantly high dosage haloperidol significantly low dosage clonidine patient ghb group develop hypernatriaemia develop metabolic alkalosis conclusion symptom autonomic nervous system effectively prevent ghb evident low dosage requirement clonidine however ghb may sufficiently block hyperactivity dopaminergic system may hallucinogenic effect may evident high dosage haloperidol necessary due latter fact administration ghb recommend patient suffer aws icu set,Lenzenhuber E,1999,Anaesthesist,https://doi.org/10.1007/s001010050672,10093649,Lenzenhuber E; Müller C; Rommelspacher H; Spies C,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000472: Alkalosis, Respiratory; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D003000: Clonidine; D003422: Critical Care; D000431: Ethanol; D005260: Female; D005445: Flunitrazepam; D006220: Haloperidol; D006801: Humans; D006955: Hypernatremia; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012978: Sodium Oxybate; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W177478450,148,12,1,1560,251,12,de,en
false,stimulant medication withdrawal long term therapy child comorbid attention deficit hyperactivity disorder chronic multiple tic disorder,study examine change attention deficit hyperactivity disorder behavior motor vocal tic withdrawal long term maintenance therapy stimulant medication subject child attention deficit hyperactivity disorder chronic tic disorder receive methylphenidate n dextroamphetamine n minimum year child switch placebo double blind condition treatment effect assess use direct observation child behavior simulate clinic base classroom behavior rating scale complete parent clinician change group data frequency severity motor tic vocal tic placebo condition compare maintenance dose stimulant medication ie evidence tic exacerbation receive medication withdrawal reaction evidence tic exacerbation even rebound effect treatment maintenance dose also associate behavioral improvement attention deficit hyperactivity disorder behavior indicate continue efficacy abrupt withdrawal stimulant medication child receive long term maintenance therapy appear result worsen tic frequency severity nevertheless find preclude possibility drug withdrawal reaction susceptible individual,Nolan EE,1999,Pediatrics,https://doi.org/10.1542/peds.103.4.730,10103294,Nolan EE; Gadow KD; Sprafkin J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D013375: Substance Withdrawal Syndrome; D013981: Tic Disorders,,,https://openalex.org/W2068159905,157,18,1,1426,217,6,en,en
false,translate safety efficacy compliance economic value control release dosage form,advance control release cr dosage form relative newcomer pharmaceutical market study relate efficacy safety compliance benefit economic value literature review undertake assess cost effectiveness cr dosage form use measure purchase cost total treatment cost economic value improve therapeutic outcome compare non cr dosage form three therapeutic area examine cardiovascular therapy pain management estrogen replacement therapy cardiovascular therapy prescription cost sustain release sr verapamil significantly high conventional release verapamil however offset low physician hospital laboratory expenditure sr group compliance superior similarly patient receive sr diltiazem good prescription refill compliance use conventional formulation drug well significantly low aggregate healthcare cost year study period low cost sr verapamil diltiazem may relate good compliance cr nifedipine low daily acquisition cost conventional form simplify dosage regimen daily extend indication drug hypertension well angina reduce vasodilatory adverse effect reduce peak plasma drug concentration postdose rate increase concentration compare oral clonidine give twice daily transdermal clonidine give weekly high purchase cost associate improve compliance reduce adverse effect due control plasma concentration low nondrug health cost physician hospital laboratory cost low cost also find daily oral formulation various antihypertensive suggest economics type cr dosage form relate compliance cr metoprolol mg conventional release atenolol mg give daily provide effective beta adrenoceptor blockade conventional formulation cause deterioration sense well temporally associate sharp peaking plasma concentration peak occur either dose cr metoprolol deterioration sense well transdermal nitroglycerin glyceryl trinitrate compare long act oral nitrate improve quality life qol despite high incidence adverse effect headache dizziness skin irritation furthermore study formulation reduce angina attack sublingual nitroglycerin use hospitalisation emergency room use cost comparison transdermal product favour superior adhesion abstract truncate word,Cramer MP,1994,Pharmacoeconomics,https://doi.org/10.2165/00019053-199405060-00005,10150160,Cramer MP; Saks SR,article,D016428: Journal Article; D017418: Meta-Analysis,"D000701: Analgesics, Opioid; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003362: Cost-Benefit Analysis; D003692: Delayed-Action Preparations; D016527: Drug Costs; D015914: Estrogen Replacement Therapy; D006801: Humans; D010349: Patient Compliance; D011788: Quality of Life; D016896: Treatment Outcome",,,https://openalex.org/W1987365003,99,14,1,2876,467,17,en,en
false,guanfacine clonidine improve plan work memory performance human,present study compare use double blind placebo control design effect two alpha agonist clonidine microgram kg guanfacine microgram kg spatial work memory plan attentional set shift function think dependent central executive prefrontal cortex blood pressure subjective feeling sedation affect equally clonidine guanfacine microgram kg microgram kg dos clonidine disrupt spatial work memory medium dose effect microgram kg dos clonidine increase impulsive respond plan test microgram kg dose clonidine slow respond effortful level plan attentional set shift test microgram kg dose guanfacine improve spatial work memory plan guanfacine effect attentional set shift data indicate guanfacine improve plan spatial work memory clonidine dose dependently disrupt performance possible great selectivity guanfacine alpha adrenoceptor subtype may underlie difference clonidine,Jäkälä P,1999,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(98)00127-4,10192826,Jäkälä P; Riekkinen M; Sirviö J; Koivisto E; Kejonen K; Vanhanen M; Riekkinen P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000316: Adrenergic alpha-Agonists; D000328: Adult; D001288: Attention; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005625: Frontal Lobe; D016316: Guanfacine; D006801: Humans; D008568: Memory; D008606: Mental Processes; D009483: Neuropsychological Tests; D011597: Psychomotor Performance,,,https://openalex.org/W2024391265,89,14,1,1216,194,9,en,en
false,ziprasidone mg day mg day acute exacerbation schizophrenia schizoaffective disorder week placebo control trial,double blind study patient acute exacerbation schizophrenia schizoaffective disorder randomize receive either ziprasidone mg day n mg day n placebo n week ziprasidone statistically significantly effective placebo improve panss total bprs total bprs core item cgi panss negative subscale score p ziprasidone mg day significantly improve depressive symptom patient clinically significant depression baseline madrs mean p compare placebo percentage patient experience adverse event similar treatment group resultant discontinuation rare frequent adverse event associate ziprasidone generally mild dyspepsia nausea dizziness transient somnolence ziprasidone show low liability induce movement disorder weight gain result indicate ziprasidone effective well tolerate treatment positive negative depressive symptom acute exacerbation schizophrenia schizoaffective disorder,Daniel DG,1999,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(98)00090-6,10192829,Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M,article,"D016430: Clinical Trial; D017428: Clinical Trial, Phase III; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial",D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013844: Thiazoles,,,https://openalex.org/W2007865301,142,19,1,1212,211,7,en,en
false,neurotoxicity drug give intrathecally spinal,overall spinal drug clinical use poorly study spinal cord nerve root toxicity laboratory study indicate local anesthetic neurotoxic high concentration lidocaine tetracaine neurotoxic potential clinically use concentration however spinal anesthesia include lidocaine tetracaine long enviable history safety spinal analgesic morphine fentanyl sufentanil clonidine neostigmine seem low potential neurotoxicity base laboratory extensive clinical use antioxidant preservative excipients use commercial formulation seem low potential neurotoxicity addition summarize current information hope review stimulate future research spinal drug follow systematic approach determine potential neurotoxicity approach would examine histologic physiologic behavioral test several specie follow cautious histologic physiologic clinical test human volunteer patient terminal cancer refractory conventional therapy,Hodgson PS,1999,Anesth Analg,https://doi.org/10.1097/00000539-199904000-00023,10195528,Hodgson PS; Neal JM; Pollock JE; Liu SS,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000700: Analgesics; D000779: Anesthetics, Local; D000818: Animals; D017024: Chemotherapy, Adjuvant; D002986: Clinical Trials as Topic; D006801: Humans; D007278: Injections, Spinal; D016032: Randomized Controlled Trials as Topic; D013116: Spinal Cord; D013126: Spinal Nerve Roots",,,https://openalex.org/W2090823918,55,9,1,1156,181,7,en,en
true,long term methylphenidate therapy child comorbid attention deficit hyperactivity disorder chronic multiple tic disorder,study examine change attention deficit hyperactivity adhd behavior motor vocal tic long term treatment methylphenidate thirty four prepubertal child adhd chronic multiple tic disorder participate week double blind placebo control methylphenidate evaluation evaluate month interval year part prospective nonblind follow study treatment effect assess use direct observation child behavior simulate clinic base classroom behavior rating scale complete parent physician videotape simulate classroom score coder blind treatment status evidence group data motor tic vocal tic change frequency severity maintenance therapy compare diagnostic initial double blind placebo evaluation behavioral improvement demonstrate acute drug trial maintain follow evidence group data clinically significant adverse drug effect cardiovascular function growth end year treatment long term treatment methylphenidate seem safe effective management adhd behavior many necessarily child mild moderate tic disorder nevertheless careful clinical monitoring mandatory rule possibility drug induce tic exacerbation individual patient,Gadow KD,1999,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.56.4.330,10197827,Gadow KD; Sverd J; Sprafkin J; Nolan EE; Grossman S,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002908: Chronic Disease; D015897: Comorbidity; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004341: Drug Evaluation; D005500: Follow-Up Studies; D006801: Humans; D008774: Methylphenidate; D011446: Prospective Studies; D012720: Severity of Illness Index; D013981: Tic Disorders,,,https://openalex.org/W2044466939,134,15,1,1477,226,6,en,en
false,analysis separate interactive effect methylphenidate common classroom contingency,evaluate separate interactive effect common classroom contingency methylphenidate mph disruptive task behavior child diagnosis attention deficit hyperactivity disorder analogue condition consist contingent teacher reprimand brief time interaction alone conduct multielement design medication status mph placebo alternate across day superordinate multielement design result indicate behavioral effect mph influence one analogueue condition participant b time associate zero near zero level disruptive task behavior participant mph placebo condition implication clinical effectiveness mph possible behavioral mechanism action mph apply set discus,Northup J,1999,J Appl Behav Anal,https://doi.org/10.1901/jaba.1999.32-35,10201102,Northup J; Fusilier I; Swanson V; Huete J; Bruce T; Freeland J; Gulley V; Edwards S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000124: Achievement; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011678: Punishment; D012919: Social Behavior; D013334: Students,,,https://openalex.org/W2142468689,110,14,1,916,148,5,en,en
false,olanzapine versus haloperidol treatment schizoaffective disorder,effectiveness antipsychotic monotherapy schizoaffective disorder limit far constrain safety concern aim compare efficacy tolerability safety profile new pharmaceutical olanzapine haloperidol data assess dsm iii r schizoaffective subject large double blind prospective international study subject randomly allocate six week olanzapine mg haloperidol mg treatment responder follow one year double blind long term maintenance therapy olanzapine treat patient achieve statistically significant great improvement haloperidol treat patient overall measure efficacy include clinical response significantly olanzapine patient leave study early adverse event observe among receive olanzapine maintenance olanzapine treat patient continue experience additional improvement eps weight gain haloperidol olanzapine demonstrate substantial advantage conventional antipsychotic haloperidol management schizoaffective disorder,Tran PV,1999,Br J Psychiatry,https://doi.org/10.1192/bjp.174.1.15,10211146,Tran PV; Tollefson GD; Sanger TM; Lu Y; Berg PH; Beasley CM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011618: Psychotic Disorders; D016896: Treatment Outcome,,,https://openalex.org/W1974783484,81,15,1,1187,164,4,en,en
false,randomise double blind comparison incidence tardive dyskinesia patient schizophrenia long term treatment olanzapine haloperidol,tardive dyskinesia important side effect profile antipsychotic medication development tardive dyskinesia evaluate patient treat double blind randomly assign olanzapine haloperidol year tardive dyskinesia assess abnormal involuntary movement scale aim research diagnostic criterion tardive dyskinesia rd td define meeting rd td criterion two consecutive assessment risk tardive dyskinesia relative risk incidence rate incidence rate ratio estimate relative risk tardive dyskinesia overall follow period haloperidol n v olanzapine n ci base data follow initial six week observation patient underwent medication change aim assessment frequently every three day one year risk olanzapine n haloperidol n relative risk throughout follow period ci result indicate significantly low risk tardive dyskinesia olanzapine haloperidol,Beasley CM,1999,Br J Psychiatry,https://doi.org/10.1192/bjp.174.1.23,10211147,Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D006220: Haloperidol; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D012307: Risk Factors; D012559: Schizophrenia; D016019: Survival Analysis",,,https://openalex.org/W2002691423,162,20,1,1177,206,4,en,en
false,pre aid mortality morbidity among injection drug user amsterdam baltimore ecological comparison,mortality morbidity inject drug user amsterdam n baltimore n compare generate hypothesis role different health care system drug user policy universal care harm reduction versus episodic care criminalization respectively overdose suicide mortality twofold high amsterdam sufficient explanation find independent risk factor overdose suicide mortality recent inject polydrug use hiv seropositivity especially cd count mm high dose methadone maintenance associate low mortality incidence hospitalization emergency room visit substantially low amsterdam suggest high accessibility primary care amsterdam lower inpatient hospital visit presumably societal cost,van Ameijden EJ,1999,Subst Use Misuse,https://doi.org/10.3109/10826089909037245,10227114,van Ameijden EJ; Krol A; Vlahov D; Flynn C; van Haastrecht HJ; Coutinho RA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000662: Amphetamines; D015142: Baltimore; D002423: Cause of Death; D003042: Cocaine; D015331: Cohort Studies; D015897: Comorbidity; D003363: Cost Control; D003431: Cross-Cultural Comparison; D062787: Drug Overdose; D000431: Ethanol; D005260: Female; D006679: HIV Seropositivity; D006297: Health Services Accessibility; D003932: Heroin; D006760: Hospitalization; D006801: Humans; D008297: Male; D008691: Methadone; D009426: Netherlands; D012307: Risk Factors; D015819: Substance Abuse, Intravenous; D013405: Suicide; D015996: Survival Rate; D014481: United States",,,https://openalex.org/W2081331438,112,16,1,857,138,5,en,en
false,response methylphenidate boy attention deficit hyperactivity disorder,response methylphenidate examine boy age attention deficit hyperactivity disorder adhd double blind placebo control crossover design hyperactivity conduct problem significantly reduce methylphenidate treatment stimulant medication associate improvement test sustain attention work memory motor steadiness individual change study find show significant improvement hyperactivity home school level hyperactive behaviour within normal range high level hyperactivity school relatively low age significant predictor normalization hyperactivity least one set however predictor could classify correctly child clinical practice trial stimulant indicate adhd child show symptom sufficiently severe cause impairment home school,Zeiner P,1999,Acta Paediatr,https://doi.org/10.1111/j.1651-2227.1999.tb01100.x,10229041,Zeiner P; Bryhn G; Bjercke C; Truyen K; Strand G,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000704: Analysis of Variance; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D016002: Discriminant Analysis; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008568: Memory; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011237: Predictive Value of Tests; D011597: Psychomotor Performance,,,https://openalex.org/W2018129806,81,9,1,1008,164,7,en,en
false,stimulant medication,review short long term safety efficacy stimulant treatment child attention deficit hyperactivity disorder adhd medline search conduct randomize control trial review determine efficacy safety stimulant drug treat child adhd information obtain adverse event associate use include impact height weight gain childhood animal data review information tolerance sensitization impact high dose stimulant effect neuron development hepatic tumor human data dopamine transporter occupancy stimulant also include stimulant treatment study show robust short term efficacy good safety profile long term study number produce conclusive evidence careful therapeutic use medication harmful current evidence indicate stimulant show efficacy safety study last month,Greenhill LL,1999,J Am Acad Child Adolesc Psychiatry,https://doi.org/10.1097/00004583-199905000-00011,10230181,Greenhill LL; Halperin JM; Abikoff H,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D001289: Attention Deficit Disorder with Hyperactivity; D001824: Body Constitution; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W4250858368,21,2,1,1037,159,5,en,en
false,antipsychotic child adolescent,present critical overview available evidence efficacy safety antipsychotic agent child adolescent identify knowledge gap need research data adult relevant child discuss mainly report double blind placebo control study review child adolescent antipsychotic use treat psychotic variety nonpsychotic condition amount data base well design double blind placebo control study satisfactory sample size diagnostically homogeneous subject modest currently available standard antipsychotic definite role treatment child adolescent use agent limit mainly tardive withdrawal dyskinesia patient excessive sedation atypical antipsychotic critically assess compare psychosocial intervention effective combination type treatment evaluate,Campbell M,1999,J Am Acad Child Adolesc Psychiatry,https://doi.org/10.1097/00004583-199905000-00015,10230185,Campbell M; Rapoport JL; Simpson GM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000293: Adolescent; D000296: Adolescent Psychiatry; D014150: Antipsychotic Agents; D002648: Child; D002665: Child Psychiatry; D002986: Clinical Trials as Topic; D006801: Humans; D011618: Psychotic Disorders; D012107: Research Design; D016896: Treatment Outcome,,,https://openalex.org/W1999554211,42,5,1,1031,154,5,en,en
false,epidural clonidine bupivacaine sole analgesic agent abdominal surgery,rationale study compare high dose epidural clonidine commonly use agent bupivacaine perform give objective idea relative analgesic potency epidural clonidine sixty patient undergo intestinal surgery propofol anesthesia study induction patient receive epidurally dose microgram kg correct clonidine ml saline follow infusion microgram correct x kg x h ml h group n dose ml bupivacaine follow ml h bupivacaine group n dose ml bupivacaine follow ml h bupivacaine group n intraoperatively increase arterial blood pressure heart rate respond propofol mg kg treat intravenous alfentanil mg kg additional propofol give maintain adequate bispectral index epidural infusion maintain h case subjective visual analogue pain score cm rest cm cough patient give access patient control analgesia device anesthesia patient group require less propofol group mg vs mg mg p less alfentanil patient group mg vs mg p analgesia last min range min group versus min range min group min range min group p suggestion hemodynamic difference among three group except heart rate significantly reduce patient group sedation score significantly high group first h postoperatively result show high dos epidural clonidine potentiate general anesthetic provide efficient postoperative analgesia two bupivacaine dosage regimen investigate,De Kock M,1999,Anesthesiology,https://doi.org/10.1097/00000542-199905000-00020,10319784,De Kock M; Gautier P; Pavlopoulou A; Jonniaux M; Lavand'homme P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000005: Abdomen; D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D018712: Analgesics, Non-Narcotic; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D006801: Humans; D008875: Middle Aged; D010149: Pain, Postoperative; D015742: Propofol",,,https://openalex.org/W2062715857,97,14,1,2019,411,9,en,en
false,safety profile sustain release bupropion depression result three clinical trial,series study undertake assess safety profile sustain release sr bupropion treatment depress outpatient adult diagnosis major depression evaluate multicenter randomize double masked parallel group placebo control trial conduct private practice psychiatric outpatient clinic follow week single mask placebo lead period patient receive bupropion sr week study mg study mg study mg safety assessment include monitor adverse event patient discontinuation rate change weight vital sign clinical laboratory test result across study frequently report adverse event headache dry mouth nausea incidence adverse event similar difference bupropion sr placebo group exception dry mouth bupropion sr placebo dry mouth nausea insomnia occur significantly often bupropion sr treat patient patient receive placebo p nearly adverse event report study mild moderate less patient either group discontinue treatment prematurely adverse event death serious drug relate adverse event report sexual dysfunction report adverse event patient either group bupropion sr associate dose related weight loss study consistent pattern change observe vital sign result clinical laboratory test data clinical trial demonstrate favorable safety profile bupropion sr treatment depress outpatient,Settle EC,1999,Clin Ther,https://doi.org/10.1016/s0149-2918(00)88301-0,10321415,Settle EC; Stahl SM; Batey SR; Johnston JA; Ascher JA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D003863: Depression; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2108061862,93,13,1,1810,335,13,en,en
false,olanzapine versus placebo treatment acute mania,primary intent study compare efficacy safety olanzapine placebo treatment acute mania design involve random assignment double blind placebo control parallel group study week duration day screen period qualify patient assign either olanzapine n placebo n patient begin double blind therapy either olanzapine mg placebo give per day first day treatment daily dose could adjust upward downward clinically indicate one capsule olanzapine mg day within allow range one four capsule primary efficacy measure protocol define change baseline endpoint total score young mania rating scale clinical response define priori decrease baseline young mania rating scale total score olanzapine group experience significantly great mean improvement young mania rating scale total score placebo group basis clinical response criterion significantly olanzapine treat patient respond assign placebo somnolence dizziness dry mouth weight gain occur significantly often olanzapine statistically significant difference olanzapine treat placebo treated patient respect measure parkinsonism akathisia dyskinesia discontinuation treatment due adverse event occur olanzapine treatment group result study suggest compare placebo olanzapine superior efficacy symptom acute mania,Tohen M,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.5.702,10327902,Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006261: Headache; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010352: Patient Dropouts; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012890: Sleep; D016896: Treatment Outcome",,,https://openalex.org/W2109442247,57,9,1,1731,298,10,en,en
true,control trial high pemoline adult attention deficit hyperactivity disorder,despite increase awareness attentiondeficit hyperactivity disorder adhd adult limit number control pharmacologic study disorder stimulant medication magnesium pemoline cylert abbott laboratory abbott park il find effective treat adhd pediatric group test efficacy adult adhd use high daily previously study conduct week double blind placebo control crossover design study pemoline target daily dose mg kg per day adult patient dsm iii r iv adhd use standardize structure psychiatric instrument diagnosis measure improvement use separate assessment adhd depressive anxiety symptom baseline biweekly visit adhd outcome determine use adhd symptom checklist clinical global impression scale severity improvement adult adhd randomize trial complete protocol treatment pemoline final week week active phase best tolerate substantially low target dose mg kg per day mean dose mg kg per day mean sd mg pemoline significantly good reduce adhd symptom compare placebo z p use predefined reduction symptom indication improvement pemoline treat subject subject placebo group consider positive responder chi square p result indicate pemoline moderately effective treatment adhd adult although robust target adult prefer moderate dosing mg day give limit efficacy tolerability concern hepatic dysfunction pemoline consider second line medication treat adhd adult j clin psychopharmacol,Wilens TE,1999,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199906000-00009,10350032,Wilens TE; Biederman J; Spencer TJ; Frazier J; Prince J; Bostic J; Rater M; Soriano J; Hatch M; Sienna M; Millstein RB; Abrantes A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010389: Pemoline; D016896: Treatment Outcome,,,https://openalex.org/W1979465426,99,12,1,1989,357,13,en,en
false,schizophrenia schizoaffective disorder treat high olanzapine,,Fanous A,1999,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199906000-00015,10350037,Fanous A; Lindenmayer JP,article,D002363: Case Reports; D016430: Clinical Trial; D016422: Letter; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D012559: Schizophrenia",,,https://openalex.org/W2058694703,80,10,1,0,0,0,en,
false,event relate potential index auditory selective attention dependent amphetamine user,background aim present study investigate previously report attention relate impairment dependent amphetamine user use event relate potential erp index selective attention method erps record auditory selective attention task sit involve detect infrequent long duration target tone present among short duration tone vary location leave v right ear pitch low vs high amphetamine user n divide two group high dependence n low dependence n base amphetamine severity dependence scale score compare age match control group n result high dependence group show slow reaction time reduce early processing negativity peak n amplitude location relevant nontarget stimulus poor performance sit highly correlate deficit early processing also relate poor performance wechsler memory scale attention concentration index conclusion suggest severely dependent user suffer inability selectively enhance sensory processing relevant auditory information may produce poor automatic preferential processing relevant information increase load limit attentional resource,McKetin R,1999,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(98)00200-5,10356632,McKetin R; Solowij N,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D019969: Amphetamine-Related Disorders; D000662: Amphetamines; D000704: Analysis of Variance; D001288: Attention; D001307: Auditory Perception; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002540: Cerebral Cortex; D003072: Cognition Disorders; D003463: Cues; D004192: Discrimination, Psychological; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D016014: Linear Models; D008297: Male; D009433: Neural Inhibition; D012680: Sensitivity and Specificity; D012720: Severity of Illness Index; D013315: Stress, Psychological; D014836: Volition",,,https://openalex.org/W2061769579,94,11,1,1333,219,7,en,en
false,add clonidine lidocaine intravenous regional anesthesia prevents tourniquet pain,tourniquet pain often complicate use pneumatic tourniquet surgical procedure perform iv regional anesthesia clonidine contain local anesthetic solution good analgesic property plain solution use spinal epidural peripheral block test hypothesis addition clonidine may improve quality iv regional anesthesia especially tourniquet tolerance forty patient allocate randomly double blind randomize study receive ml lidocaine either ml isotonic saline clonidine micro sign g double cuffed tourniquet keep inflated patient complain pain lead release distal cuff pain tourniquet site surgical site distal part arm rat visual analog scale va verbal rating scale vrs every min tourniquet placement every min h tourniquet deflation motor blockade sedation arterial pressure heart rate also record va vrs score significantly low clonidine group min tourniquet inflation tolerance distal tourniquet also significantly longer clonidine group median range v min p motor blockade comparable two group pain different two group tourniquet release clonidine group experience high degree sedation conclude clonidine improve tourniquet tolerance add local anesthetic solution implication micro sign g dose clonidine add lidocaine improve tourniquet tolerance iv regional anesthesia anesth analg,Gentili M,1999,Anesth Analg,https://doi.org/10.1097/00000539-199906000-00024,10357339,Gentili M; Bernard JM; Bonnet F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000765: Anesthesia, Conduction; D000771: Anesthesia, Intravenous; D000779: Anesthetics, Local; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005542: Forearm; D006225: Hand; D006801: Humans; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010146: Pain; D010147: Pain Measurement; D011446: Prospective Studies; D013997: Time Factors; D014111: Tourniquets",,,https://openalex.org/W2086833356,90,11,1,1767,318,13,en,en
false,placebo control comparison antidepressant efficacy effect sexual functioning sustain release bupropion sertraline,sexual dysfunction frequently report side effect many antidepressant may result patient dissatisfaction noncompliance treatment regimen paper describe result first placebo control comparison efficacy safety effect sexual functioning sustain release bupropion bupropion sr selective serotonin reuptake inhibitor sertraline randomize double mask double dummy paralle group multicenter trial enrol patient moderate severe recurrent major depression patient treat bupropion sr mg sertraline mg placebo week patient depression sexual functioning assess weekly biweekly clinic visit safety assess regular monitoring adverse event vital sign body weight treatment group similar baseline term age sex race patient diagnosis moderate uncomplicated depression patient treat bupropion sr sertraline show similar improvement efficacy measure active treatment superior placebo improve score rating scale depression various time point significantly patient treat sertraline experience orgasmic dysfunction throughout study patient treat bupropion sr placebo p headache frequently report adverse event treatment group occur similar frequency group nausea diarrhea insomnia somnolence occur significantly patient sertraline group bupropion sr group respectively placebo group respectively dry mouth occur frequently bupropion sr sertraline placebo although difference significant change vital sign similar group similar small statistically significant decrease mean body weight see bupropion sr kg sertraline kg group whereas placebo group experience minor increase kg although bupropion sr sertraline similarly well tolerate effective treatment depression sertraline treatment often associate sexual dysfunction certain adverse event compare bupropion sr placebo therefore bupropion sr may appropriate choice antidepressant treatment sexually active patient,Croft H,1999,Clin Ther,https://doi.org/10.1016/s0149-2918(00)88317-4,10363731,Croft H; Settle E; Houser T; Batey SR; Donahue RM; Ascher JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D016642: Bupropion; D003692: Delayed-Action Preparations; D003865: Depressive Disorder, Major; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017060: Patient Satisfaction; D017367: Selective Serotonin Reuptake Inhibitors; D020280: Sertraline; D012735: Sexual Dysfunction, Physiological; D020018: Sexual Dysfunctions, Psychological",,,https://openalex.org/W2145911019,142,17,1,2616,478,15,en,en
false,pergolide mesylate cocaine abuse control preliminary trial,small control study conduct assess whether pergolide mesylate clinical promise treatment cocaine abuse prior embark large randomize double blind control trial fourteen individual place placebo week follow week single blind study place pergolide week follow placebo week another patient receive single blind placebo two week randomize week double blind placebo control multiple baseline design initially patient enrol study place risperidone n placebo n first week retention bad receive pergolide compare risperidone placebo neither risperidone pergolide efficacious reduce cocaine use placebo although early open study find pergolide show promise treatment cocaine abuse study support early finding compare agent active control placebo group may better predict whether promise new agent clinical utility compare standard open trial,Levin FR,1999,Am J Addict,https://doi.org/10.1080/105504999305929,10365192,Levin FR; McDowell D; Evans SM; Brooks D; Spano C; Nunes EV,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D019970: Cocaine-Related Disorders; D018491: Dopamine Agonists; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D010479: Pergolide; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D016037: Single-Blind Method; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W2170349643,68,10,1,1184,205,8,en,en
false,efficacy apraclonidine versus pilocarpine prophylaxis intraocular pressure spike argon laser trabeculoplasty,author compare efficacy apraclonidine versus pilocarpine prophylaxis post argon laser trabeculoplasty alt intraocular pressure iop spike prospective randomize clinical trial two hundred twenty eight eye patient primary open angle glaucoma undergoing alt study patient give drop either apraclonidine n pilocarpine n minute alt peri alt iop incidence post alt iop spike minute hour hour compare two group two group similar age race medical dependency post alt mean iop minute hour hour significantly low pre alt mean iop apraclonidine p pilocarpine p group incidence iop spike great mmhg hour post alt apraclonidine group pilocarpine group p chi square test apraclonidine prophylaxis group patient long term apraclonidine show significantly high incidence post alt iop spike patient without long term apraclonidine use eye v eye p addition peri alt pilocarpine prophylaxis tend less effective patient undergo long term pilocarpine therapy without statistical significance eye v eye p peri alt pilocarpine least effective effective apraclonidine post alt iop spike prophylaxis peri alt apraclonidine prophylaxis effective patient long term apraclonidine peri alt pilocarpine prophylaxis tend less effective patient undergo long term pilocarpine therapy pilocarpine consider first choice drug post alt iop spike prophylaxis especially patient treatment apraclonidine,Ren J,1999,Ophthalmology,https://doi.org/10.1016/s0161-6420(99)90260-9,10366082,Ren J; Shin DH; Chung HS; Birt CM; Glover BK; Juzych MS; Hughes BA; Kim C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D003000: Clonidine; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D015994: Incidence; D007429: Intraocular Pressure; D053685: Laser Therapy; D008297: Male; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D010862: Pilocarpine; D014130: Trabeculectomy",,,https://openalex.org/W2073271495,130,19,1,1983,372,7,en,en
false,choreoathetoid movement cocaine dependence,evaluate severity choreoathetoid movement cocaine dependent cd subject age match normal control subject choreoathetoid movement evaluate use abnormal involuntary movement scale aim sample cd normal control amphetamine dependent male subject cd subject significantly increase nonfacial limbs plus body aim subscore nonfacial aim score two group compare relation age significant age diagnosis interaction observe indicate difference group mark young age group facial aim score also increase young cd cohort year age comparison group young amphetamine dependent subject also show increase aim score increase choreoathetoid movement young cocaine amphetamine dependent subject may relate psychostimulant use absence difference choreoathetoid movement old cd subject normal control subject may represent age relate self selection effect,Bartzokis G,1999,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(98)00238-8,10376125,Bartzokis G; Beckson M; Wirshing DA; Lu PH; Foster JA; Mintz J,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000367: Age Factors; D000662: Amphetamines; D001264: Athetosis; D002819: Chorea; D019970: Cocaine-Related Disorders; D006801: Humans; D008297: Male; D008875: Middle Aged; D012720: Severity of Illness Index,,,https://openalex.org/W2070320964,46,5,1,1126,176,5,en,en
false,eeg correlate methylphenidate response among child adhd preliminary report,recent electrophysiologic study find fairly consistent difference child attention deficit hyperactivity disorder adhd age match control subject present study examine electroencephalogram eeg change associate double blind placebo control administration methylphenidate among child adhd subject child age primary diagnosis adhd brain electrical activity record electrode frontal central midline area baseline cognitive activation condition repeat measure anovas indicate child exhibit positive medication response reduction theta alpha well increase beta frontal region nonresponders show opposite pattern p significant correlation improvement vigilance task change beta activity frontal electrode emerge well preliminary find indicate different electrophysiologic correlate methylphenidate among adhd child medication responder nonresponders,Loo SK,1999,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(98)00250-9,10376129,Loo SK; Teale PD; Reite ML,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D001143: Arousal; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003071: Cognition; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D005625: Frontal Lobe; D006801: Humans; D008297: Male; D008774: Methylphenidate; D016896: Treatment Outcome,,,https://openalex.org/W1986377817,89,13,1,1125,161,4,en,en
false,behavioral electrophysiologic predictor treatment response stimulant child attention disorder,behavioral quantitative electroencephalography eeg technique use evaluate treatment response stimulant therapy child attention disorder sample child attention disorder evaluate conners diagnostic statistical manual mental disorder iii rating scale neurometric quantitative eeg month treatment stimulant significant quantitative eeg difference find normal control population n child attention problem quantitative eeg abnormality involve increase theta alpha power great frontal region frontal theta alpha hypercoherence posterior interhemispheric power asymmetry behavioral improvement stimulant treatment see child attention deficit hyperactivity disorder child attention deficit disorder degree correspondence behavioral quantitative eeg change pretreatment clinical quantitative eeg feature could predict treatment response sensitivity specificity combine behavioral quantitative eeg approach useful follow predict treatment response stimulant child attention disorder j child neurol,Chabot RJ,1999,J Child Neurol,https://doi.org/10.1177/088307389901400601,10385840,Chabot RJ; Orgill AA; Crawford G; Harris MJ; Serfontein G,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000293: Adolescent; D019958: Attention Deficit and Disruptive Behavior Disorders; D000697: Central Nervous System Stimulants; D002648: Child; D002653: Child Behavior Disorders; D003913: Dextroamphetamine; D004569: Electroencephalography; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011237: Predictive Value of Tests; D013881: Thioridazine; D016896: Treatment Outcome,,,https://openalex.org/W2094405126,117,14,1,1367,208,8,en,en
false,clozapine obsession patient recent onset schizophrenia psychotic disorder,increase emergence obsession compare young patient recent onset schizophrenia psychotic disorder take clozapine antipsychotic drug conduct retrospective cohort study subject consecutively admit patient diagnose dsm iii r schizophrenia schizoaffective disorder schizophreniform disorder psychotic disorder otherwise specify obsession diagnose accord dsm iv criterion clozapine treat subject subject treat antipsychotic drug experience emergence increase obsession p use clozapine associate emergence increase obsession early phase schizophrenia,de Haan L,1999,J Clin Psychiatry,https://doi.org/10.4088/jcp.v60n0603,10401913,de Haan L; Linszen DH; Gorsira R,article,D016428: Journal Article,D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D015331: Cohort Studies; D005260: Female; D006801: Humans; D008297: Male; D009771: Obsessive-Compulsive Disorder; D011618: Psychotic Disorders; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2166525546,98,12,1,731,106,3,en,en
false,risperidone versus haloperidol secondary memory new medication aid learning,introduction new generation antipsychotic medication treatment schizophrenia accompany grow interest neurocognitive effect drug present study compare effect risperidone haloperidol secondary memory group treatment resistant schizophrenia patient study design include baseline phase two double blind phase patient randomly assign medication two different dose condition fix dose flexible dose secondary memory assess baseline fix dose flexible dose phase use california verbal learn test cvlt six measure select form three factor general verbal learning ability retention learn strategy risperidone treat patient show great improvement haloperidol treat patient general verbal learning ability find characterize significant treatment effect cvlt measure learn acquisition recall consistency recognition memory control benztropine status difference measure learn acquisition recall consistency remain significant difference recognition memory weaken slightly p significant treatment effect note retention learn strategy find suggest risperidone may exert facilitate effect acquisition new verbal information effect appear due activation semantic encoding strategy,Kern RS,1999,Schizophr Bull,https://doi.org/10.1093/oxfordjournals.schbul.a033375,10416728,Kern RS; Green MF; Marshall BD; Wirshing WC; Wirshing D; McGurk SR; Marder SR; Mintz J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011939: Mental Recall; D008875: Middle Aged; D009483: Neuropsychological Tests; D011569: Psychiatric Status Rating Scales; D012153: Retention, Psychology; D018967: Risperidone; D014706: Verbal Learning",,,https://openalex.org/W2103782573,87,13,1,1553,241,9,en,en
false,article retract nefopam clonidine prevention postanaesthetic shivering,postanaesthetic shiver affect patient general anaesthesia may distress various drug use treat prevent postanaesthetic shiver ideal one yet find sixty patient undergo elective abdominal orthopaedic surgery general anaesthesia include randomise double blind study patient receive clonidine microgram kg nefopam mg kg saline placebo end surgery prior extubation nefopam clonidine significantly reduce incidence severity shiver comparison placebo recovery time end anaesthesia extubation significantly longer clonidine treat patient min either nefopam min placebo min group mean arterial blood pressure heart rate significantly low clonidine group compare group result suggest nefopam clonidine effective prevention postanaesthetic shivering however follow clonidine administration recovery time prolong hypotension significantly great nefopam,Piper SN,1999,Anaesthesia,https://doi.org/10.1046/j.1365-2044.1999.00849.x,10417466,Piper SN; Suttner SW; Schmidt CC; Maleck WH; Kumle B; Boldt J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000328: Adult; D000368: Aged; D000700: Analgesics; D018712: Analgesics, Non-Narcotic; D000768: Anesthesia, General; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009340: Nefopam; D010919: Placebos; D016528: Postanesthesia Nursing; D012768: Shivering",,,https://openalex.org/W2014788142,100,14,1,1230,213,9,en,en
false,agonist versus antagonist mild moderate hypertension,double blind double dummy parallel group trial use predominantly hispanic patient population mild moderate hypertension design compare efficacy safety acceptability monotherapy either transdermal clonidine apply week terazosin tablet take day patient admit transdermal clonidine group terazosin group one patient lose follow meet response criterion criterion include completion full week therapy small dose result seat diastolic blood pressure mm hg subsequent entrance week maintenance therapy phase end week maintenance phase mean seat diastolic blood pressure remain mm hg clonidine cohort terazosin cohort yet difference statistically significant significantly well response clonidine patient receive treatment consider adverse first dose effect experience terazosin one patient receive transdermal clonidine develop contact dermatitis withdraw study prematurely common side effect associate clonidine dry mouth fatigue associate terazosin headache fatigue compliance excellent group seventy nine percent patient find transdermal clonidine preferable oral regimen,Harris SI,1997,Am J Ther,https://doi.org/10.1097/00045391-199701000-00003,10423584,Harris SI; Alvarez C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000279: Administration, Cutaneous; D000284: Administration, Oral; D058668: Adrenergic alpha-1 Receptor Antagonists; D058647: Adrenergic alpha-2 Receptor Agonists; D000316: Adrenergic alpha-Agonists; D000317: Adrenergic alpha-Antagonists; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011224: Prazosin",,,https://openalex.org/W1985439185,64,6,1,1489,242,10,en,en
false,effect methylphenidate attention child attention deficit hyperactivity disorder adhd erp evidence,methylphenidate common treatment attention deficit hyperactivity disorder adhd show improve attention behaviour however precise nature methylphenidate specific aspect attention different dose level remain unclear study methylphenidate effect adhd neurophysiological perspective record event relate potential erps attention task performance normal control child adhd different dose condition twenty child adhd age match control assess continuous performance task require subject identify repeat alphabetic character erps behavioural measure record analyze trial correct response make adhd group assess drug baseline placebo low mg kg high mg kg dose level methylphenidate result show adhd group baseline impulsive inattentive control short p n latency long p latency low dose methylphenidate associate reduce impulsivity false alarm decrease p latency whereas high dose level associate reduce impulsivity less inattention hit well increase p n latency decrease p latency amplitude unaffected adverse effect high dose child result suggest differential dosage effect dissociation dose level aspect processing,Sunohara GA,1999,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(99)00023-8,10432470,Sunohara GA; Malone MA; Rovet J; Humphries T; Roberts W; Taylor MJ,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D007360: Intelligence; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D010775: Photic Stimulation; D010919: Placebos; D011930: Reaction Time; D012016: Reference Values; D014888: Wechsler Scales,,,https://openalex.org/W2047356397,116,17,1,1580,260,10,en,en
false,perceptual response interference child attention deficit hyperactivity disorder effect methylphenidate,fourteen child attention deficit hyperactivity disorder adhd normal control child compare respect stimulus response related process subject adhd take part two additional session methylphenidate placebo experiment performance electrophysiological measure p n p component event relate potential electromyogram emg activity measure eriksen flanker task group child reaction time rts arrow stimuli incongruent target long neutral stimulus response interference slow rts target alone stimulus perceptual interference child adhd make error incongruent stimulus show response interference correct response difference group response interference effect reaction time p n p latency emg onset find methylphenidate general enhance effect accuracy specifically reduce interference flank stimulus methylphenidate effect rt n p latency p amplitude latency emg activity conclusion methylphenidate influence response process contrast sharply find report author use sternberg memory search task,Jonkman LM,1999,Psychophysiology,https://doi.org/10.1111/1469-8986.3640419,10432791,Jonkman LM; Kemner C; Verbaten MN; Van Engeland H; Kenemans JL; Camfferman G; Buitelaar JK; Koelega HS,article,D016428: Journal Article,D000293: Adolescent; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002540: Cerebral Cortex; D002648: Child; D004311: Double-Blind Method; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D015999: Multivariate Analysis; D009433: Neural Inhibition; D010470: Perceptual Masking; D011597: Psychomotor Performance; D011930: Reaction Time; D014836: Volition,,,https://openalex.org/W2102391728,130,16,1,1370,226,9,en,en
false,population pharmacokinetics methylphenidate child attention deficit hyperactivity disorder,source individual variation plasma methylphenidate mp concentration usual clinical use establish evaluate series patient receive clinical treatment mp single plasma mp concentration determine child adolescent age year mean year clinically good responder mp treatment attention deficit hyperactivity disorder mp give twice daily schedule mean dose mg day patient three time daily mean dose mg day nonlinear regression model apply estimate overall population value mp clearance elimination half life assume one component model first order absorption elimination far assume clearance linearly relate body weight model incorporate patient dosage size schedule body weight time plasma sample iterated solution best fit hour confidence interval ci hour apparent clearance ml min kg ci ml min kg model explain overall variance mp concentration r p small subsample n second plasma sample draw time day dose correlation two concentration value relatively noninvasive approach use study allow assessment pharmacokinetic property medication condition appropriate clinical use special population child adolescent elderly,Shader RI,1999,J Clin Pharmacol,https://doi.org/10.1177/00912709922008425,10434228,Shader RI; Harmatz JS; Oesterheld JR; Parmelee DX; Sallee FR; Greenblatt DJ,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D001835: Body Weight; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D015331: Cohort Studies; D005260: Female; D006801: Humans; D008297: Male; D008657: Metabolic Clearance Rate; D008774: Methylphenidate; D012044: Regression Analysis",,,https://openalex.org/W2041491649,104,10,1,1631,305,10,en,en
false,neuropeptide response tracheal intubation anaesthetize child effect clonidine v midazolam premedication,determine tracheal intubation cause increase neuropeptide npy marker major adrenergic activation investigate rectal premedication clonidine microgram kg might capable attenuate stress response tracheal intubation compare midazolam microgram kg paediatric patient yr prospective randomization perform double blind manner induction anaesthesia isoflurane tracheal intubation perform norepinephrine npy concentration haemodynamic variable record tracheal intubation increase npy plasma concentration despite transient increase norepinephrine concentration heart rate arterial pressure significant difference two group conclude adrenergic stress reaction response tracheal intubation child short live limited magnitude indicate lack npy release,Bergendahl HT,1999,Br J Anaesth,https://doi.org/10.1093/bja/82.3.391,10434822,Bergendahl HT; Eksborg S; Kogner P; Lönnqvist PA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D014151: Anti-Anxiety Agents; D015415: Biomarkers; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007223: Infant; D007442: Intubation, Intratracheal; D008297: Male; D008874: Midazolam; D009478: Neuropeptide Y; D011292: Premedication; D011446: Prospective Studies; D013312: Stress, Physiological",,,https://openalex.org/W2097715705,124,17,1,989,156,6,en,en
false,pharmacokinetic pharmacodynamic model risperidone effect electroencephalography healthy volunteer,rationale cns active drug produce specific electroencephalographic change concentration effect relationship antipsychotic may elucidate adopt electroencephalography eeg effect measurement tool objective purpose present study determine concentration effect relationship risperidone assess eeg effect oral administration single dose risperidone healthy young male method nine healthy male volunteer receive mg single oral dose risperidone accord placebo control crossover design plasma level risperidone active metabolite hydroxyrisperidone measure radioimmunoassay quantitative eeg parameter obtain four frequency band spectral eeg analysis difference absolute power delta frequency band f lead risperidone placebo use drug effect parameter pharmacokinetic pharmacodynamic model hypothetical effect compartment kinetically link plasma first order process postulate curve fit non linear curve fit program nonlin result result show absolute power delta theta frequency band high risperidone administration placebo eeg lead maximum effect detect h administration drug hysteresis loop observe plot plasma concentration risperidone sum risperidone hydroxyrisperidone cp versus eeg effect subject linear model adequately describe relationship effect compartment concentration ce eeg effect two limb hysteresis cp effect plot collapse ce effect plot risperidone risperidone plus hydroxyrisperidone conclusion increase absolute power delta theta frequency band eeg induce single oral administration risperidone linear pk pd model fit well relationship effect compartment concentration ce eeg effect risperidone,Lee DY,1999,Psychopharmacology (Berl),https://doi.org/10.1007/s002130051003,10435394,Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D014150: Antipsychotic Agents; D004305: Dose-Response Relationship, Drug; D004569: Electroencephalography; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008954: Models, Biological; D000068882: Paliperidone Palmitate; D011743: Pyrimidines; D018967: Risperidone",,,https://openalex.org/W2034253210,111,10,1,2154,333,13,en,en
false,comparison olanzapine haloperidol cannabis induce psychotic disorder double blind randomize control trial,little control data exist treatment substance induce psychotic disorder study patient meet dsm iv criterion cannabis induce psychotic disorder randomly allocate receive either olanzapine haloperidol week double blind clinical trial significant outcome difference two group primary outcome measure brief psychiatric rating scale haloperidol olanzapine p clinical global impression cgi severity scale haloperidol olanzapine p cgi improvement scale haloperidol olanzapine p haloperidol group however develop significantly extrapyramidal side effect measure simpson angus scale haloperidol olanzapine p significantly p biperidin use extrapyramidal side effect haloperidol mg olanzapine mg group olanzapine appear effective haloperidol treatment cannabis induce psychotic disorder associate low rate extrapyramidal side effect,Berk M,1999,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199905002-00005,10435771,Berk M; Brook S; Trandafir AI,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002188: Cannabis; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011605: Psychoses, Substance-Induced",,,https://openalex.org/W1987447099,126,16,1,1139,191,6,en,en
false,double blind randomize placebo control clinical trial non prescription medication treatment obesity,phenylpropanolamine ppa benzocaine non prescription medication approve treat obesity dose ppa weight loss mg day ppa chemical similarity pseudoephedrine amphetamine methamphetamine benzocaine cause weight loss alter taste ppa central appetite suppression may induce additional weight loss combine study explore safety efficacy low dose ppa pseudoephedrine ppa benzocaine cause weight loss study compare ppa mg tid mg tid placebo week trial obese subject study compare pseudoephedrine mg day placebo week trial obese subject study compare group obese subject use ppa mg day benzocaine gum mg day ppa benzocaine gum placebo week ppa give twice weight loss placebo difference reach statistical significance pseudoephedrine different placebo induce weight loss ppa benzocaine group adverse event benzocaine group p placebo group p ppa group p without additional weight loss conclude study low dose ppa weight loss indicate pseudoephedrine effective weight loss add benzocaine phenylpropanolamine increase adverse effect without increase weight loss,Greenway F,1999,Obes Res,https://doi.org/10.1002/j.1550-8528.1999.tb00420.x,10440593,Greenway F; Herber D; Raum W; Herber D; Morales S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001067: Appetite Depressants; D001566: Benzocaine; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004809: Ephedrine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D004366: Nonprescription Drugs; D009765: Obesity; D010665: Phenylpropanolamine; D015431: Weight Loss",,,https://openalex.org/W2055344634,123,15,1,1487,261,9,en,en
false,development depression placebo control trial bupropion smoke cessation,article abstractbackground recent attention focus relationship depression smoking cessation article describe case severe depression occur multicenter trial use bupropion smoke cessation method subject participant randomize double blind placebo control study investigate efficacy bupropion smoke cessation data trial restrict subject rochester minn site order access medical record information depression diagnosis treatment follow first trial involve smoker receive active bupropion placebo week second trial smoker receive open label bupropion therapy week abstinent smoke end week n randomly assign week double blind relapse prevention phase result first trial participant experience major depression week treatment phase second trial none subject develop major depression week open label phase result trial across week treatment phase study n study n combine rate develop major depression subject none receive placebo receive active bupropion develop major depression second trial subject randomly assign week relapse prevention phase develop depression overall case trial past history major depression prior study entry none current major depression conclusion major depression may occur individual smoke cessation treatment bupropion,Patten CA,1999,J Clin Psychiatry,https://doi.org/10.4088/jcp.v60n0703,10453796,Patten CA; Rummans TA; Croghan IT; Hurt RD; Hays JT,article,"D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D016642: Bupropion; D016022: Case-Control Studies; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D010919: Placebos; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D055502: Secondary Prevention; D016540: Smoking Cessation; D000074606: Smoking Prevention,,,https://openalex.org/W1979840800,93,11,1,1850,339,14,en,en
false,safety amisulpride solian review clinical study,assess overall safety profile amisulpride base result clinical study perform patient suffer schizophrenia predominance positive negative symptom total patient randomly assign treatment amisulpride n haloperidol n risperidone n flupentixol n placebo n safety data collection perform use open reporting uku scale specific extrapyramidal side effect scale electrocardiogram record vital sign examination laboratory data collection amisulpride demonstrate satisfactory global safety profile range usually prescribe number patient least one extrapyramidal side effect high haloperidol patient compare amisulpride risperidone patient versus two latter group endocrine event similar rate observe amisulpride risperidone group versus respectively versus haloperidol group electrocardiogram result satisfactory confirm absence cardiovascular event overall laboratory safety profile amisulpride show clinically relevant abnormality liver function test haematological abnormality extensive clinical data confirm satisfactory safety profile amisulpride superior standard reference compound,Coulouvrat C,1999,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199907000-00002,10468313,Coulouvrat C; Dondey-Nouvel L,article,D016428: Journal Article; D017418: Meta-Analysis,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000077582: Amisulpride; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001772: Blood Cell Count; D018765: Dopamine Uptake Inhibitors; D004305: Dose-Response Relationship, Drug; D004562: Electrocardiography; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008111: Liver Function Tests; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013469: Sulpiride",,,https://openalex.org/W1989972780,65,15,2,1440,238,9,en,en
false,preoperative clonidine comedication within scope balance inhalation anesthesia sevoflurane oral surgery procedure,clonidine sevoflurane interest drug anaesthesia maxillo facial surgery present study perform discover far possible combine benefit sevoflurane fast modulation depth anaesthesia rapid emergence recovery clonidine reduction perioperative stress response prophylaxis postoperative shivering analgetic antiemetic anaesthetic save effect without compromise pharmacokinetic sevoflurane twenty eight patient include present double blind prospective study patient randomly treat infusion microgram kg clonidine group placebo group preoperatively anaesthesia standardized procedure fentanyl propofol rocuronium n sevoflurane antiemetic prophylaxis dhb perform depth anaesthesia control use spectral edge frequency target sef hz perioperative stress response assess note effect haemodynamic parameter map heart rate emergence recovery assess use establish standardized test confirm anaesthetic save property clonidine fentanyl hand difference mac sevoflurane value group keep steady target sef versus vol time emergence recovery significantly different even occurrence ponv va level postoperative analgesic requirement differ two group however incidence postoperative shiver significantly high placebo group stress response intubation extubation low clonidine group haemodynamic parameter clonidine group intraoperatively always baseline case make therapy hypotension bradycardia frequently necessary postoperatively majority patient show similar change parameter reach mark preoperative clonidine comedication seem complicate management anaesthesia hand beneficial early postoperative period e g stability haemodynamics prophylaxis shiver without compromise emergence recovery result show therapy clonidine good place end anaesthesia,Frank T,1999,Anaesthesiol Reanim,,10472699,Frank T; Thieme V; Olthoff D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000700: Analgesics; D000769: Anesthesia, Inhalation; D003000: Clonidine; D005260: Female; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008738: Methyl Ethers; D019647: Oral Surgical Procedures; D011229: Preanesthetic Medication; D000077149: Sevoflurane",,,https://openalex.org/W2399154864,133,19,1,2447,406,19,en,en
false,pharmakotherapie hyperkinetischer st rungen im erwachsenenalter,attention deficit hyperactivity disorder adhd often diagnose child major study prove symptom persist patient grow prevalence adult adhd underestimate classification system icd dsm iv allow diagnosis adult differ however childhood regard symptom diagnostic procedure require extensive exploration information parent school diagnostic interview procedure questionnaire self expert rating available date english speaking country apart counsel psychotherapeutic intervention pharmacotherapy third option especially stimulant prove efficient treatment alternatively tricyclic antidepressant consider agent play minor role clinical trial try evaluate efficacy different pharmacotherapeutic agent lack,Adam C,1999,Fortschr Neurol Psychiatr,https://doi.org/10.1055/s-2007-994986,10478300,Adam C; Döpfner M; Lehmkuhl G,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D006801: Humans; D007406: Interview, Psychological; D011569: Psychiatric Status Rating Scales; D011795: Surveys and Questionnaires",,,https://openalex.org/W135184902,63,5,1,935,142,9,de,en
false,treatment tardive dyskinesia systematic review meta analysis,systematic review aim collate randomize control trial rcts various intervention use treat tardive dyskinesia td appropriate combine data meta analysis clinical trial identify electronic search handsearches contact principal investigator data extract independently two reviewer outcome relate improvement deterioration side effect drop rate data pool use mantel haenzel odds ratio fix effect model treatment significant effect number need treat nnt calculate control clinical trial data extract trial intervention could identify rct derived evidence efficacy meta analysis show baclofen deanol diazepam effective placebo single rcts demonstrate lack evidence effect bromocriptine ceruletide clonidine estrogen gamma linolenic acid hydergine lecithin lithium progabide seligiline tetrahydroisoxazolopyridinol meta analysis find five intervention effective l dopa oxypertine sodium valproate tiapride vitamin e neuroleptic reduction marginally significant data single rcts reveal insulin alpha methyl dopa reserpine effective placebo significantly increase risk adverse event associate baclofen deanol l dopa oxypertine reserpine meta analysis impact placebo n show participant show improvement interpretation systematic review require caution individual trial identify tend small sample size many compound data one trial available meta analysis possible base small number trial despite concern review facilitate interpretation large diverse range treatment use td clinical recommendation treatment td make base availability rct derive evidence strength evidence presence adverse effect,Soares KV,1999,Schizophr Res,https://doi.org/10.1016/s0920-9964(99)00021-3,10480663,Soares KV; McGrath JJ,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,"D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D006801: Humans; D015201: Meta-Analysis as Topic; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2005762752,73,9,1,2181,367,17,en,en
false,risperidone treatment refractory schizophrenia,purpose study evaluate clinical safety efficacy risperidone compare haloperidol patient treatment refractory schizophrenia sixty seven medication unresponsive subject randomly assign treatment risperidone n haloperidol n day placebo washout period week double blind fix dose comparison trial follow week flexible dose phase measure clinical change quantify standard psychopathologic neuromotor instrument risperidone demonstrate clinical efficacy superior haloperidol total brief psychiatric rating scale bprs first week treatment risperidone show advantage haloperidol additional week overall improvement bprs week significantly good risperidone group haloperidol group risperidone treat subject significantly less likely haloperidol treat subject require concomitant anticholinergic medication week versus also significantly les observable akathisia versus significantly less severe tardive dyskinesia baseline characteristic correlate significantly risperidone response positive symptom conceptual disorganization akathisia tardive dyskinesia risperidone well tolerate effective subset patient treatment refractory schizophrenia positive psychotic symptom extrapyramidal side effect baseline appear powerful predictor subsequent response risperidone,Wirshing DA,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.9.1374,10484947,Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D010054: Brief Psychiatric Rating Scale; D018680: Cholinergic Antagonists; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W2170201623,49,4,1,1662,254,8,en,en
false,intravenous regional anesthesia use lidocaine clonidine,background clonidine add local anesthetic regimen various peripheral nerve block result prolong anesthesia analgesia author postulate use clonidine component intravenous regional anesthesia ivra would enhance postoperative analgesia method forty five patient undergo ambulatory hand surgery receive ivra lidocaine assign randomly blindly three group control group receive intravenous saline intravenous clonidine group receive microg kg clonidine intravenously ivra clonidine group receive microg kg clonidine part ivra solution operation patient pain sedation score analgesic use record result patient ivra clonidine group significantly long period subjective comfort require analgesic median range min min compare min min control group min min intravenous clonidine group p lt patient receive ivra clonidine report significantly low pain score h tourniquet deflation compare group require fentanyl postanesthesia care unit also require analgesic tablet mg acetaminophen mg codeine first h mean sd compare two group tablet control tablet intravenous clonidine p lt significant postoperative sedation hypotension bradycardia develop patient conclusion addition microg kg clonidine lidocaine ivra patient undergo ambulatory hand surgery improve postoperative analgesia without cause significant side effect first postoperative day,Reuben SS,1999,Anesthesiology,https://doi.org/10.1097/00000542-199909000-00015,10485774,Reuben SS; Steinberg RB; Klatt JL; Klatt ML,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000779: Anesthetics, Local; D003000: Clonidine; D004311: Double-Blind Method; D006225: Hand; D006801: Humans; D008012: Lidocaine; D008875: Middle Aged; D010149: Pain, Postoperative; D013564: Sympathetic Nervous System",,,https://openalex.org/W2120713954,62,7,1,1873,329,10,en,en
false,precision comparability adverse event rate new antidepressant,due scarcity clinical trial ct directly compare new antidepressant clinician reviewer often compare drug basis active drug placebo subtract adverse event rate aers publish reference physician desk reference united state compendium pharmaceutical speciality canada product monograph study examine suitability data method compare aers nine new antidepressant bupropion citalopram fluoxetine fluvoxamine moclobemide nefazodone paroxetine sertraline venlafaxine first author examine data precision comparability across drug analyze placebo arm aers confidence limit drug test homogeneity placebo arm aers across drug rationale placebo aer heterogeneity likely reflection heterogeneity nonpharmacologic factor among ct adverse event examine placebo aers find significantly heterogenous suggest significant nonpharmacologic heterogeneity across drug second use placebo aer heterogeneity measure nonpharmacologic heterogeneity author estimate degree active drug placebo subtract aers relate nonpharmacologic heterogeneity estimate degree association active drug placebo aers placebo subtract placebo aers also confidence limit placebo subtract aers calculate find active drug aers placebo subtract aers significantly correlate placebo aers suggest relationship nonpharmacologic heterogeneity placebo subtract aers less strongly relate active drug aers finally author discuss factor may associate observed heterogeneity offer suggestion may improve methodology reporting ct,Vida S,1999,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199910000-00005,10505583,Vida S; Looper K,article,D016428: Journal Article,"D018687: Antidepressive Agents, Second-Generation; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D009626: Terminology as Topic",,,https://openalex.org/W2315406452,75,10,1,1959,303,10,en,en
false,control double blind investigation clozapine discontinuation symptom conversion either olanzapine placebo,abrupt appearance clozapine discontinuation symptom represent particularly unique situation characterize double blind placebo control trial randomize double blind comparison placebo n olanzapine mg n day follow abrupt discontinuation clozapine mg day carry subject assess positive negative syndrome scale panss clinical global impression scale severity montgomery asberg depression rating scale madrs mini mental state evaluation subsequently group receive open label olanzapine mg day additional week statistically significantly placebo treated olanzapine treat patient experience clozapine discontinuation symptom p core symptom include delusion hallucination hostility paranoid reaction translate significantly high worsen baseline panss total panss general psychopathology subscale madrs among subject randomly assign receive placebo open label treatment olanzapine week group clinically stable suggest discontinuation symptom transient however subject randomly assign day placebo discontinuation segment achieve somewhat less global clinical improvement although pharmacologic interpretation speculative evidence clozapine discontinuation syndrome apparent case direct substitution pharmacologically similar agent olanzapine prevent syndrome clozapine discontinuation noncompliance consider differential assessment acutely emergent psychosis possibility subject experience clozapine discontinuation syndrome may take long less likely clinically restabilize warrant investigation,Tollefson GD,1999,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199910000-00007,10505585,Tollefson GD; Dellva MA; Mattler CA; Kane JM; Wirshing DA; Kinon BJ,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003024: Clozapine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W2312270175,128,16,1,1955,306,12,en,en
false,evaluation individual subject analog classroom set ii effect dose amphetamine adderall,multiple dependent variable graph subject participate double blind evaluation adderall plus positive methylphenidate placebo control condition five judge rank condition subject analysis individual subject indicate ranking concordant reliable across judge consensus rank assign subject analysis rank show condition differ significantly choice best condition judge across adderall mg confirm clinical impression individual difference optimal dose stimulant medication methodological graphical statistical method present article provide systematic reliable procedure evaluate relative response individual different stimulant medication,Wigal SB,1998,Psychopharmacol Bull,,10513460,Wigal SB; Swanson JM; Greenhill L; Waslick B; Cantwell D; Clevenger W; Davies M; Lerner M; Regino R; Fineberg E; Baren M; Browne R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000661: Amphetamine; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D003626: Data Display; D004311: Double-Blind Method; D006801: Humans; D015588: Observer Variation; D012107: Research Design,,,https://openalex.org/W47048920,113,21,2,898,147,6,en,en
false,treatment depression patient heart disease,patient depression likely patient without depression develop ischemic heart disease suffer cardiac relate death recent evidence suggest association depression increase cardiac mortality may part due increase platelet activity imbalance sympathetic parasympathetic activity make patient susceptible ventricular fibrillation available data suggest tricyclic antidepressant tcas may increase risk mortality patient ischemic heart disease three study selective serotonin reuptake inhibitor ssri include double blind randomize comparison paroxetine nortriptyline support conclusion ssri relatively benign cardiovascular profile therefore preferable tcas treatment depression patient risk cardiac event additional study need definitively establish cardiovascular safety ssri,Roose SP,1999,J Clin Psychiatry,,10513857,Roose SP; Spatz E,article,D016428: Journal Article; D016454: Review,"D018687: Antidepressive Agents, Second-Generation; D000929: Antidepressive Agents, Tricyclic; D016642: Bupropion; D015897: Comorbidity; D003645: Death, Sudden; D003866: Depressive Disorder; D004311: Double-Blind Method; D006327: Heart Block; D006331: Heart Diseases; D006801: Humans; D007024: Hypotension, Orthostatic; D017202: Myocardial Ischemia; D009661: Nortriptyline; D017374: Paroxetine; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D017367: Selective Serotonin Reuptake Inhibitors; D014693: Ventricular Fibrillation",,,https://openalex.org/W1900488432,55,9,1,1012,154,6,en,en
false,diagnosis attention deficit hyperactivity disorder use psychotropic medication young child,increase diagnosis treatment attention deficit hyperactivity disorder adhd elicit public professional concern research suggest trend warrant inclusion previously underdiagnosed child adult clear whether trend include young child identify pattern diagnosis treatment adhd young child time descriptive study michigan medicaid claim data inclusion criterion include record adhd diagnosis continuous medicaid eligibility month period age year young first date service diagnose adhd condition commonly comorbid adhd chronic health condition injury treatment psychological service psychotropic medication number ambulatory visit identify child age year young diagnose adhd many condition commonly comorbid adhd chronic health condition injury half receive psychotropic medication receive psychological service twenty two different psychotropic medication use pattern include psychotropic medication combination simultaneous use combination sequential use mean number ambulatory visit child age year young adhd diagnose receive markedly variable psychotropic medication regimen little information available guide practice presence comorbid condition injury attest child vulnerability resource must identify enable physician good respond compel need child family,Rappley MD,1999,Arch Pediatr Adolesc Med,https://doi.org/10.1001/archpedi.153.10.1039,10520611,Rappley MD; Mullan PB; Alvarez FJ; Eneli IU; Wang J; Gardiner JC,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000367: Age Factors; D000553: Ambulatory Care; D001289: Attention Deficit Disorder with Hyperactivity; D002675: Child, Preschool; D015897: Comorbidity; D005260: Female; D006801: Humans; D007223: Infant; D008297: Male; D008484: Medicaid; D001523: Mental Disorders; D008824: Michigan; D011613: Psychotherapy; D011619: Psychotropic Drugs; D014481: United States; D014947: Wounds and Injuries",,,https://openalex.org/W2086464859,111,13,1,1749,281,11,en,en
false,antipsychotic induce weight gain comprehensive research synthesis,purpose study estimate compare effect antipsychotic new one conventional one body weight comprehensive literature search identify english non english language article include data weight change antipsychotic treat patient agent meta analysis random effect metaregression estimate weight change week treatment standard dose comprehensive narrative review also conduct article yield quantitative information yield important qualitative information placebo associate mean weight reduction kg among conventional agent mean weight change range reduction kg molindone increase kg thioridazine among new antipsychotic agent mean increase follow clozapine kg olanzapine kg sertindole kg risperidone kg ziprasidone kg insufficient data available evaluate quetiapine week conventional new antipsychotic associate weight gain among new agent clozapine appear great potential induce weight gain ziprasidone least difference among new agent may affect compliance medication health risk,Allison DB,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.11.1686,10553730,Allison DB; Mentore JL; Heo M; Chandler LP; Cappelleri JC; Infante MC; Weiden PJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D014150: Antipsychotic Agents; D002986: Clinical Trials as Topic; D003024: Clozapine; D016001: Confidence Intervals; D004334: Drug Administration Schedule; D006801: Humans; D008972: Molindone; D010879: Piperazines; D010919: Placebos; D011618: Psychotic Disorders; D012107: Research Design; D013844: Thiazoles; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2111105929,69,8,1,1346,217,8,en,en
false,interscalene brachial plexus analgesia open shoulder surgery continuous versus patient control infusion,prospective randomize double blind study assess efficacy patient control analgesia pca continuous interscalene analgesia open shoulder surgery sixty patient divide three group h period receive via interscalene catheter continuous infusion bupivacaine sufentanil g ml clonidine g ml ml h group continuous infusion solution ml h plus pca bolus ml min group pca bolus ml min solution group pain score sensory block supplemental analgesia bupivacaine consumption side effect satisfaction score record h sensory block frequent pain control significantly well group group p group large paracetamol require bupivacaine consumption significantly less group group p satisfaction significantly high group group p side effect comparable three group conclude continuous interscalene analgesia require background infusion open shoulder surgery reduce local anesthetic consumption allow patient rapidly reinforce block shortly physiotherapy basal infusion rate ml h combine pca bolus ml min recommend technique implication study demonstrate continuous interscalene analgesia require background infusion provide efficient pain relief open shoulder surgery basal infusion ml h combine patient control analgesia bolus ml min seem appropriate technique,Singelyn FJ,1999,Anesth Analg,https://doi.org/10.1213/00000539-199911000-00024,10553837,Singelyn FJ; Seguy S; Gouverneur JM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D000779: Anesthetics, Local; D001917: Brachial Plexus; D002045: Bupivacaine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007260: Infusion Pumps; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010147: Pain Measurement; D010149: Pain, Postoperative; D011446: Prospective Studies; D012785: Shoulder Joint; D017409: Sufentanil",,,https://openalex.org/W2043325087,113,13,1,1801,329,13,en,en
false,olanzapine compare lithium mania double blind randomize control trial,neuroleptic establish efficacy mania control data use olanzapine mania however absent study patient meet dsm iv criterion mania randomly allocate receive either olanzapine lithium week double blind randomize control design significant outcome difference two group primary outcome measure brief psychiatric rating scale lithium olanzapine p clinical global impression cgi improvement scale lithium olanzapine p mania scale lithium olanzapine p olanzapine however significantly superior lithium cgi severity scale week lithium olanzapine p olanzapine differ lithium term treatment emergent extrapyramidal side effect measure simpson angus scale olanzapine appear least effective lithium treatment mania,Berk M,1999,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199911000-00003,10565800,Berk M; Ichim L; Brook S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D018692: Antimanic Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008094: Lithium; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales,,,https://openalex.org/W1981207331,83,12,1,1005,184,7,en,en
false,pharmacological treatment depression consult dr oscar,objective review pharmacological treatment depression evaluate current strategy treatment maximize benefit antidepressant medication quality evidence medline search january use head depression combination augmentation lithium triiodothyronine pindolol buspirone methylphenidate electroconvulsive therapy randomize control trial systematic overview consensus report recent high quality review often find reference paper retrieve scrutinize relevant report preference give recent article well design study recommendation academic group analyze main message optimization antidepressant therapy cornerstone pharmacological treatment depression symptom persist despite optimization strategy include substitution combination augmentation review sometimes refer decision base evidence support various strategy conclusion antidepressant work prescribe correctly awareness strategy use antidepressant evaluate effectiveness improve primary care physician ability treat common disorder,Berber MJ,1999,Can Fam Physician,,10587774,Berber MJ,article,D016428: Journal Article; D016454: Review,"D000928: Antidepressive Agents; D003866: Depressive Disorder; D004359: Drug Therapy, Combination; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012017: Referral and Consultation; D016896: Treatment Outcome",,,,66,10,2,1281,187,11,en,en
false,oral clonidine premedication enhances postoperative analgesia epidural morphine,study design evaluate effect oral clonidine premedication postoperative analgesia epidural morphine prospective randomize double blind design sixty consent patient schedule total abdominal hysterectomy randomly assign one three group n clonidine morphine group receive oral clonidine g kg min arrive operating room epidural morphine mg induction general anesthesia clonidine placebo group receive oral clonidine g kg epidural morphine placebo morphine group receive clonidine epidural morphine mg epidural catheter place l l interspace lidocaine use surgical anesthesia patient general anesthesia induce propofol maintain continuous infusion propofol nitrous oxide oxygen surgery four patient subsequently withdraw study surgery patient control analgesia use iv morphine use assess analgesic requirement morphine consumption determine every h surgery clonidine morphine placebo morphine group significantly less clonidine placebo group h surgery whereas clonidine morphine group significantly less placebo morphine group h surgery visual analog pain scale va score clonidine morphine group significantly low placebo morphine group h rest h movement similarly vas score clonidine morphine group significantly low clonidine placebo group h rest movement whereas va score clonidine placebo group significantly low placebo morphine group h rest movement incidence nausea pruritus similar group conclude combination oral clonidine epidural morphine produce potent long last postoperative analgesia either drug alone without increase incidence adverse effect major gynecologic surgery implication small dose epidural morphine often use postoperative analgesia find oral clonidine premedication g kg improve analgesic efficacy epidural morphine without increase incidence adverse side effect,Goyagi T,1999,Anesth Analg,https://doi.org/10.1097/00000539-199912000-00032,10589634,Goyagi T; Tanaka M; Nishikawa T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D015360: Analgesia, Epidural; D000700: Analgesics; D003000: Clonidine; D004311: Double-Blind Method; D004357: Drug Synergism; D005260: Female; D006801: Humans; D007044: Hysterectomy; D008875: Middle Aged; D009020: Morphine; D009294: Narcotics; D010149: Pain, Postoperative; D011292: Premedication; D011446: Prospective Studies",,,https://openalex.org/W1971792289,82,9,1,2490,407,12,en,en
false,month randomize clinical trial treatment strategy attention deficit hyperactivity disorder,previous study demonstrate short term efficacy pharmacotherapy behavior therapy attention deficit hyperactivity disorder adhd long term e month investigation compare treatment combination group child adhd combine type age year assign month medication management titration follow monthly visit intensive behavioral treatment parent school child component therapist involvement gradually reduce time two combine standard community care treatment community provider outcome assess multiple domain treatment treatment end point combine treatment medication management group continue medication assessment point data analyze intent treat random effect regression procedure group show sizable reduction symptom time significant difference among degree change adhd symptom child combine treatment medication management group show significantly great improvement give intensive behavioral treatment community care combine medication management treatment differ significantly direct comparison several instance oppositional aggressive symptom internalize symptom teacher rat social skill parent child relation read achievement combine treatment prove superior intensive behavioral treatment community care medication management study medication strategy superior community care treatment despite fact two third community treat subject receive medication study period adhd symptom carefully craft medication management superior behavioral treatment routine community care include medication combine treatment yield significantly great benefit medication management core adhd symptom may provide modest advantage non adhd symptom positive functioning outcome,,1999,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.56.12.1073,10591283,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D001008: Anxiety Disorders; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D003156: Community Mental Health Services; D015897: Comorbidity; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010342: Patient Acceptance of Health Care; D010349: Patient Compliance; D012017: Referral and Consultation; D012044: Regression Analysis; D016896: Treatment Outcome,,,https://openalex.org/W2601578636,105,11,1,2184,324,7,en,en
false,moderator mediator treatment response child attention deficit hyperactivity disorder,intent treat analysis study reveal medication management alone combine intensive behavioral treatment superior behavioral treatment community care reduce attention deficit hyperactivity disorder adhd symptom combine treatment show consistently great benefit community care across outcome domain disruptive internalize symptom achievement parent child relation social skill examine response pattern subgroup define baseline variable moderator variable relate treatment implementation mediator reconducted random effect regression rr analyse add factor define moderator sex prior medication use comorbid disruptive anxiety disorder public assistance mediator treatment acceptance attendance study outcome n uphold moderator subgroup boy girl child without prior medication child without comorbid disruptive disorder comorbid anxiety disorder moderate outcome participant without anxiety result parallel intent treat find anxiety disorder however behavioral treatment yield significantly well outcomes community care longer statistically different medication management combine treatment regard adhd relate internalize symptom family receive public assistance medication management yield decrease closeness parent child interaction combine treatment yield relatively great benefit teacher report social skill family high treatment acceptance attendance intent treat result upheld acceptance attendance particularly important medication treatment finally two third child give community care receive stimulant behavioral treatment significantly differ medication management superior subgroup exploratory analyse reveal study multimodal treatment study child attention deficit hyperactivity disorder mta result confirm across baseline variable treatment acceptance attendance child adhd plus anxiety behavioral treatment surpass community care approach medication base treatment regard parent report adhd symptom,,1999,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.56.12.1088,10591284,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D003156: Community Mental Health Services; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D016896: Treatment Outcome,,,https://openalex.org/W4247130871,105,11,1,2392,341,10,en,en
false,development clinical service attention deficit hyperactivity disorder,website u cooky enhance experience continue use site click continue agree cookie policy continue jama psychiatry homenew onlinecurrent issuefor author podcast publication jama jama network open jama cardiology jama dermatology jama health forum jama internal medicine jama neurology jama oncology jama ophthalmology jama otolaryngology head neck surgery jama pediatrics jama psychiatry jama surgery archive neurology psychiatry jn learn cmesubscribejobsinstitutions librariansreprints permission term use privacy policy accessibility statement american medical association right reserve search jama jama network open jama cardiology jama dermatology jama forum archive jama health forum jama internal medicine jama neurology jama oncology jama ophthalmology jama otolaryngology head neck surgery jama pediatrics jama psychiatry jama surgery archive neurology psychiatry input search term sign individual sign sign increate account access institution sign purchase option buy article rent article subscribe jama psychiatry journal,Taylor E,1999,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.56.12.1097,10591285,Taylor E,article,D016420: Comment; D016428: Journal Article,D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D003156: Community Mental Health Services; D005069: Evaluation Studies as Topic; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D015337: Multicenter Studies as Topic; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D016896: Treatment Outcome,,,https://openalex.org/W2060100041,77,7,1,1197,177,3,en,en
false,double blind methylphenidate trial,evaluate week randomize double blind methylphenidate placebo control trial mpt routine practice child attention deficit disorder school age child attention deficit hyperactivity disorder diagnostic statistical manual mental disorder fourth edition criterion enrol n trial pediatric tertiary care center eligible family n child eligible mpt give bottle identical capsule capsule contain random order placebo prescribe dose methylphenidate ritalin hydrochloride mg kg mg kg family give child capsule capsule noon family teacher physician blind order medication conners questionnaire conners parent questionnaire conners teacher questionnaire write comment complete parent teacher baseline end week mpt result know follow discussion physician family decide whether continue methylphenidate therapy family interview telephone month mpt forty three eligible child mean age month contact family find mpt difficult trial incomplete usually side effect family use mpt decide methylphenidate correct treatment choice child family use result exclusively remain family believe mpt helpful overall child good response methylphenidate treatment continue use long month month responder choose use mpt nine family choose use methylphenidate treatment however indicate participate mpt help make decision follow interview proportion methylphenidate user nonusers report improvement many area function include significantly less time spend homework user report reduce aggression p discipline problem p compare nonusers n mpt easily perform permit family decide whether use methylphenidate long term treatment attention deficit disorder attention deficit hyperactivity disorder regardless methylphenidate use lack use condition child improve follow,Kent MA,1999,Arch Pediatr Adolesc Med,https://doi.org/10.1001/archpedi.153.12.1292,10591309,Kent MA; Camfield CS; Camfield PR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D016009: Chi-Square Distribution; D002648: Child; D002675: Child, Preschool; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010349: Patient Compliance; D011795: Surveys and Questionnaires; D016896: Treatment Outcome",,,https://openalex.org/W2127122500,35,3,1,2546,458,16,en,en
false,adverse hemodynamic change laparoscopic cholecystectomy possible suppression clonidine premedication comparison intravenous intramuscular premedication,laparoscopic cholecystectomy adverse haemodynamic effect limit use risk patient heart disease apply particular significant hypertension etiology analyse detail review literature author confirm work involve patient incidence effect try suppress premedication clonidine catapresan boehringer patient give mg clonidine infusion minute operation patient mg clonidine route min operation standard anaesthesia administer highly significant drop incidence hypertension record operation systolic pressure p way administration well diastolic pressure p intravenous p intramuscular premedication premedication intravenous clonidine recommend routine procedure laparoscopic cholecystectomy,Málek J,1999,Rozhl Chir,,10596559,Málek J; Knor J; Kurzová A; Lopourová M,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D017081: Cholecystectomy, Laparoscopic; D003000: Clonidine; D005260: Female; D006801: Humans; D006973: Hypertension; D007273: Injections, Intramuscular; D007275: Injections, Intravenous; D008297: Male; D008875: Middle Aged; D011292: Premedication",,,https://openalex.org/W38821784,187,23,2,1009,166,10,en,en
false,sexual dysfunction associate treatment depression placebo control comparison bupropion sustain release sertraline treatment,study compare sexual functioning effect well safety efficacy bupropion sustain release bupropion sr sertraline three hundred sixty four patient normal sexual functioning recurrent major depression treat bupropion sr mg day sertraline mg day placebo week randomize double blind multicenter study patient depression sexual function overall safety assess regular clinic visit significantly p patient treat sertraline experience orgasm dysfunction compare patient treat bupropion sr placebo bupropion sr sertraline statistically significantly superior placebo improve score depression scale end study headache occur similar frequency group gastrointestinal disturbance occur frequently sertraline insomnia agitation occur frequently bupropion sr small decrease mean weight see active treatment placebo group experience minor increase mean weight bupropion sr sertraline generally well tolerate although sertraline often associate sexual dysfunction bupropion sr sertraline statistically superior placebo relieve depression end study bupropion sr may offer advantage sertraline treat depress patient concern sexual functioning,Coleman CC,1999,Ann Clin Psychiatry,https://doi.org/10.1023/a:1022309428886,10596735,Coleman CC; Cunningham LA; Foster VJ; Batey SR; Donahue RM; Houser TL; Ascher JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D016642: Bupropion; D003692: Delayed-Action Preparations; D003865: Depressive Disorder, Major; D018765: Dopamine Uptake Inhibitors; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012008: Recurrence; D017367: Selective Serotonin Reuptake Inhibitors; D020280: Sertraline; D020018: Sexual Dysfunctions, Psychological; D016896: Treatment Outcome",,,https://openalex.org/W2009578329,152,20,1,1508,242,10,en,en
false,lofexidine opiate detoxification review recent randomise open control trial,objective article review data recently publish trial lofexidine treatment opiate withdrawal particular attention evidence efficacy side effect particularly hypotension acceptability new treatment patient population author review data contain within peer review publish report clinical trial lofexidine compare detoxification use reduce opiate agonist methadone alpha adrenergic agonist clonidine five publish report clinical trial lofexidine identify peer review journal eight year publish within last three year three report compare lofexidine clonidine remain two compare methadone detoxification three comparison clonidine find lofexidine similar moderate effect withdrawal syndrome without extent problem hypotension comparison methadone show rapid resolution withdrawal symptom lofexidine particularly accelerate day lofexidine protocol problem hypotension encounter lofexidine adequately manage dose reduction acceptability treatment patient measure retention treatment appear great lofexidine clonidine although possibly less methadone lofexidine alpha adrenergic agonist increasingly use management opiate withdrawal notably uk available data indicate useful new addition armamentarium clinician future study explore application improve protocol new treatment set article review recent advance study lofexidine new treatment opiate detoxification examine background development introduction lofexidine u k data extent use u k treatment opiate addiction review provide publish evidence use lofexidine management opiate detoxification mainly concentrate data recent double blind randomise trial finally possible future role lofexidine field consider,Strang J,1999,Am J Addict,https://doi.org/10.1080/105504999305749,10598217,Strang J; Bearn J; Gossop M,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D003000: Clonidine; D006801: Humans; D008691: Methadone; D009292: Narcotic Antagonists; D009293: Opioid-Related Disorders; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W2171397714,92,13,1,2381,379,15,en,en
false,relative potency epidural intrathecal clonidine differs acute thermal pain capsaicin induce allodynia,clonidine approve u epidural administration treatment intractable neuropathic cancer pain also administer intrathecally indication epidurally intrathecally treatment acute postoperative pain purpose current study estimate relative potency clonidine epidural intrathecal route treatment capsaicin induce hyperalgesia allodynia model central hypersensitivity noxious heat model acute pain twenty four healthy volunteer randomize receive either intrathecal clonidine g epidural clonidine g rat pain peltier control thermode lumbar thoracic cervical dermatomal site drug administration addition rat pain intradermal capsaicin injection lumbar dermatome min clonidine injection describe area hyperalgesia allodynia mechanical stimulus clonidine effect differ route administration modality sensory test acute thermal pain intrathecal clonidine produce dose dependent analgesia lumbar thoracic cervical gradient whereas one dose epidural clonidine reduce thermal pain thoracic test site contrast potency clonidine reduce capsaicin induce allodynia similar two route injection hyperalgesia clonidine slightly potent intrathecal epidural injection data support clinical study non comparative trial suggest fold potency ratio intrathecal epidural administration clonidine acute pain fold potency ratio route mechanical hypersensitivity,Eisenach JC,2000,Pain,https://doi.org/10.1016/s0304-3959(99)00181-5,10601673,Eisenach JC; Hood DD; Curry R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000700: Analgesics; D001794: Blood Pressure; D002211: Capsaicin; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D005260: Female; D006358: Hot Temperature; D006801: Humans; D006930: Hyperalgesia; D007278: Injections, Spinal; D008297: Male; D010146: Pain",,,https://openalex.org/W2062771008,120,15,1,1835,301,8,en,en
false,pharmacokinetic analysis felodipine grapefruit juice interaction base irreversible enzyme inhibition model,aim ingestion grapefruit juice gfj alter pharmacokinetics various orally administer drug quantitative evaluation gfj drug interaction require proper clinical management patient method use felodipine model drug construct pharmacokinetic model base irreversible inhibition intestinal cytochrome p cyp gfj fit previously publised data felodipine er extend release formulation ratio cl gi int grapefruit juice ingestion nonlinear least square regression analysis estimate reaction rate constant gfj cyp k elimination rate constant cyp k result model give turnover rate cyp h correspond half life h agreement report value auc time profile felodipine er case different amount schedule gfj ingestion simulate use parameter value estimate model conclusion model lead important conclusion gfj felodipine interaction increase increase frequency amount gfj ingestion interval day gfj intake felodipine administration necessary gfj felodipine interaction avoid,Takanaga H,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00140.x,10606837,Takanaga H; Ohnishi A; Matsuo H; Murakami H; Sata H; Kuroda K; Urae A; Higuchi S; Sawada Y,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D019540: Area Under Curve; D001628: Beverages; D001682: Biological Availability; D002121: Calcium Channel Blockers; D002957: Citrus; D003198: Computer Simulation; D051544: Cytochrome P-450 CYP3A; D065607: Cytochrome P-450 Enzyme Inhibitors; D004791: Enzyme Inhibitors; D015736: Felodipine; D018565: Food-Drug Interactions; D005772: Gastrointestinal Transit; D006801: Humans; D007413: Intestinal Mucosa; D008099: Liver; D008297: Male; D008657: Metabolic Clearance Rate; D006899: Mixed Function Oxygenases; D008954: Models, Biological",,,https://openalex.org/W1847561584,116,13,1,1324,222,7,en,en
false,effect caffeine clozapine pharmacokinetics healthy volunteer,aim assess effect caffeine pharmacokinetics clozapine healthy volunteer method open label randomize crossover study nonsmoking healthy male volunteer subject receive single oral dose mg clozapine phase without concomitant intake caffeine mean dose mg day range mg day serum concentration clozapine metabolite desmethyl clozapine clozapine n oxide measure h period phase addition serum concentration caffeine metabolite paraxanthine monitor result increase mean clozapine auc p decrease mean oral clearance clozapine observe concomitant intake caffeine p compare intake clozapine statistically significant decrease mean ratio auc h desmethyl clozapine auc h clozapine auc h clozapine n oxide auc h clozapine observe caffeine phase p respectively oral clearance clozapine ratio auc h desmethyl clozapine auc h clozapine correlate paraxanthine caffeine ratio serum intake caffeine r p r p respectively conclusion result suggest caffeine daily mg inhibit metabolism clozapine extent might clinically significant certain individual,Hägg S,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00111.x,10606838,Hägg S; Spigset O; Mjörndal T; Dahlqvist R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D019540: Area Under Curve; D001711: Biotransformation; D002110: Caffeine; D000697: Central Nervous System Stimulants; D002851: Chromatography, High Pressure Liquid; D003024: Clozapine; D018592: Cross-Over Studies; D006801: Humans; D008297: Male; D013806: Theophylline",,,https://openalex.org/W1541888681,70,9,1,1567,292,9,en,en
false,validation bengali adaptation conners parent rating scale cpr,conners parent rating scale cpr use measure behavioural problem drug trial child many year study rural india aim validate translate version cpr use study anti epileptic drug side effect scale translate local dialect back translate pilot among healthy family revise version administer mother healthy child child epilepsy test internal reliability test retest reliability factor analysis perform cronbach alpha range subscales correlation coefficient retesting overall factor structure similar report original usa sample bengali version cpr hyperactivity index validity rural bengali child process demonstrate instrument usefully adapt local purpose,Pal DK,1999,Br J Med Psychol,https://doi.org/10.1348/000711299160211,10616134,Pal DK; Chaudhury G; Das T; Sengupta S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000704: Analysis of Variance; D000927: Anticonvulsants; D002648: Child; D002652: Child Behavior; D004827: Epilepsy; D005260: Female; D006801: Humans; D008297: Male; D010552: Personality Assessment; D011569: Psychiatric Status Rating Scales; D015203: Reproducibility of Results; D012424: Rural Population,,,https://openalex.org/W1963817404,80,15,1,975,160,5,en,en
false,randomize double blind control trial compare effect ibuprofen indomethacin cerebral hemodynamics preterm infant patent ductus arteriosus,prospective randomize control trial perform compare effect ibuprofen indomethacin cerebral hemodynamics measure use near infrared spectroscopy preterm infant treatment patent ductus arteriosus infant randomly assign three intravenous either indomethacin mg kg hourly ibuprofen mg kg hourly also receive dose saline primary end point study effect first dose cerebral blood flow cbf cerebral blood volume fifteen infant receive indomethacin receive ibuprofen group mean sd value cbf ml g min first dose indomethacin respectively change significant p contrast significant change cbf observe first dose ibuprofen respective value ml g min median interquartile range value change cerebral blood volume ml g first dose indomethacin group ibuprofen group difference two group significant p cerebral oxygen delivery change significantly first dose indomethacin group ibuprofen group significant reduction cbf cerebral blood volume cerebral oxygen delivery also occur h dose indomethacin significant change h dose saline indomethacin group h dos ibuprofen patent ductus arteriosus closure rate indomethacin ibuprofen respectively conclude ibuprofen unlike indomethacin adverse effect cerebral hemodynamics appear mediate patent ductus arteriosus closure,Patel J,2000,Pediatr Res,https://doi.org/10.1203/00006450-200001000-00009,10625080,Patel J; Roberts I; Azzopardi D; Hamilton P; Edwards AD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001921: Brain; D004311: Double-Blind Method; D004374: Ductus Arteriosus, Patent; D006801: Humans; D007052: Ibuprofen; D007213: Indomethacin; D007231: Infant, Newborn; D007234: Infant, Premature; D012039: Regional Blood Flow",,,https://openalex.org/W2078259637,167,21,1,1923,352,11,en,en
false,retract pretreatment oral clonidine attenuate cardiovascular response tracheal extubation child,study design evaluate effect diazepam clonidine orally give preoperatively cardiovascular response tracheal extubation child fifty child asa physical status age year undergo minor elective surgery inguinal hernia phimosis receive orally randomize double blind manner diazepam mg kg clonidine microgram kg n drug administer min inhalational induction anaesthesia standard general anaesthetic technique employ throughout maximum change heart rate hr systolic blood pressure sbp diastolic blood pressure dbp less patient receive clonidine receive diazepam hr v sbp v dbp v mean p conclusion compare diazepam give orally pretreatment oral clonidine attenuate haemodynamic change associate tracheal extubation child,Fujii Y,2000,Paediatr Anaesth,https://doi.org/10.1046/j.1460-9592.2000.00441.x,10632912,Fujii Y; Saitoh Y; Tanaka H; Toyooka H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000768: Anesthesia, General; D000932: Antiemetics; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D003975: Diazepam; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D007442: Intubation, Intratracheal; D008297: Male; D011183: Postoperative Complications; D013610: Tachycardia",,,https://openalex.org/W1535054265,120,20,1,984,179,6,en,en
false,dementia develop country consensus statement dementia research group,less one tenth population base research dementia direct towards two third case live develop part world dementia research group form redress imbalance encourage active research collaboration centre different develop country develop develop country group consist initially researcher attend symposium dementia research develop country hold alzheimer disease international conference note grow interest area many active researcher others wish start new study felt urgent need research quantify prevalence incidence explore regional variation international collaboration use harmonize methodology describe care arrangement people dementia quantify impact caregiver evaluate effectiveness newly implement service methodological problem need address particularly development culture education fair dementia diagnostic procedure good quality research generate awareness pioneer service development influence policy,Prince M,2000,Int J Geriatr Psychiatry,https://doi.org/10.1002/(sici)1099-1166(200001)15:1<14::aid-gps70>3.0.co;2-8,10637400,Prince M,article,D016446: Consensus Development Conference; D016428: Journal Article; D016454: Review,D017281: Cost of Illness; D003704: Dementia; D003906: Developing Countries; D019317: Evidence-Based Medicine; D014943: Global Health; D006292: Health Priorities; D006801: Humans; D015994: Incidence; D007391: International Cooperation; D020380: Needs Assessment; D011159: Population Surveillance; D015995: Prevalence; D012106: Research,,,https://openalex.org/W2121543279,95,15,2,1249,184,7,en,en
false,fact versus fancy concern multimodal treatment study attention deficit hyperactivity disorder,find multimodal treatment study child attention deficit hyperactivity disorder adhd mta much discus frequently misinterpret mischaracterized misinterpretation regard specific nature rationale study design effectiveness behavioural treatment arm possible advantage combine treatment single component medication management behavioural therapy intervention feasibility applicability mta treatment real world practitioner address careful interpretation mta find suggest adhd symptom carefully craft medication management approach superior behavioural treatment routine community care include medication non adhd area function example social skill academic performance combine treatment may offer modest advantage single component approach long term outcome past month intensive mta treatment well relative effectiveness respect remain unknown pending mta analysis mta treatment large consist evidence base best practice thus rather characterize treatment infeasible substantially superior outcome treatment versus routine clinical care across diverse set help set standard future treatment practice real world set despite important study limitation mta study virtue size scope length parallel group design explicit use manualized evidence base treatment comprehensive range outcome assessment set important benchmark future trial test new treatment childhood adhd define new standard optimal outcome achieve best clinical care,Jensen PS,1999,Can J Psychiatry,https://doi.org/10.1177/070674379904401003,10637676,Jensen PS,article,D016428: Journal Article; D016454: Review,"D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D002648: Child; D002675: Child, Preschool; D003131: Combined Modality Therapy; D019317: Evidence-Based Medicine; D006801: Humans",,,https://openalex.org/W2409917428,104,12,1,1883,291,8,en,en
false,nimh multimodal treatment study attention deficit hyperactivity disorder say yes drug alone,outcome merit limitation multimodal treatment study child attention deficit hyperactivity disorder adhd mta study describe discuss consideration give design issue make mta landmark study clinician researcher work adhd child include large heterogeneous sample state art treatment lengthy treatment period extensive documentation treatment manual attention pay treatment fidelity adherence also highlight facet design predispose study favour differentially positive outcome pharmacological relative behavioural treatment primary among fact outcome measure month intensive phase behaviour treatment therapeutic contact behaviour therapist end medication treatment active intensive phase finally outcome combine treatment condition mta discus context extant literature direction future research,Pelham WE,1999,Can J Psychiatry,https://doi.org/10.1177/070674379904401004,10637677,Pelham WE,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D006801: Humans; D009315: National Institute of Mental Health (U.S.); D016032: Randomized Controlled Trials as Topic; D014481: United States,,,https://openalex.org/W45256934,110,17,1,1125,181,6,en,en
false,lesson large trial mta study model evaluate treatment childhood psychiatric disorder,review methodology multimodal treatment study child attention deficit hyperactivity disorder adhd mta study implication design future child mental health treatment study characteristic large scale study envision trialists engage cardiovascular cancer research provide framework review key element mta study objective research question measurement sample exposure treatment discus important methodological decision mta investigator make mta study complex standardize carefully implement randomize control trial review mta study indicate future study align clearly either effectiveness efficacy objective question select study simple clear important measurement sample data collection must adhere principle simplicity ensure maximum participation methodological decision gear attain research objective effectiveness trial mean evaluate treatment high potential dissemination prove successful recruit new referral child mental health setting mta study raise standard technical excellence child treatment research draw attention fundamental issue large scale child treatment study include articulate objective question set priority measurement sample identify treatment evaluation high probability dissemination find effective,Boyle MH,1999,Can J Psychiatry,https://doi.org/10.1177/070674379904401005,10637678,Boyle MH; Jadad AR,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D006801: Humans; D008137: Longitudinal Studies; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W2415033868,114,19,1,1656,252,5,en,en
false,wake mta chart new course study treatment child attention deficit hyperactivity disorder,paper consider question address national institute mental health collaborative multimodal treatment study child attention deficit hyperactivity disorder adhd mta study pharmacological behavioural intervention year old adhd child first behavioural intervention represent viable treatment option family child adhd second relative benefit behavioural pharmacological intervention finally advantage combine behavioural pharmacological intervention child adhd absence secondary analysis mta primary intent treat analysis release date difficult interpret behavioural intervention represent viable option many family achieve via systematic titration follow medication management protocol yield large effect size unblinded primary symptom report behavioural treatment medication management use family community control condition finally combine medication behavioural management demonstrate benefit definitive conclusion await detailed presentation secondary analysis follow data,Cunningham CE,1999,Can J Psychiatry,https://doi.org/10.1177/070674379904401006,10637679,Cunningham CE,article,D016428: Journal Article; D016454: Review,"D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D003131: Combined Modality Therapy; D006801: Humans; D008774: Methylphenidate; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2409482832,131,22,1,1276,186,7,en,en
false,parental knowledge attention deficit hyperactivity disorder opinion treatment option impact enrolment adherence month treatment trial,study examine relationship parent knowledge attention deficit hyperactivity disorder adhd opinion treatment impact enrolment adherence pharmacological nonpharmacological intervention child adhd participant study parent child reach diagnostic criterion adhd refer treatment study adhd involve stimulant medication parent group mother complete modify version adhd knowledge opinion scale akos prior receive diagnostic feedback prior family decision participate month randomized trial medication methylphenidate placebo parent group train support treatment enrolment adherence monitor month trial family remain study month complete another modify akos high level knowledge adhd find relate favourable opinion parent group medication moreover parent knowledgeable adhd likely enroll pharmacological nonpharmacological treatment adherence pharmacological nonpharmacological treatment predict parental knowledge adhd opinion treatment parent knowledge adhd opinion treatment play significant role enrollment treatment child adhd provide information parent regard adhd prior offer treatment modality could favourable impact treatment enrollment hence treatment adherence,Corkum P,1999,Can J Psychiatry,https://doi.org/10.1177/070674379904401011,10637684,Corkum P; Rimer P; Schachar R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D001294: Attitude to Health; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D003071: Cognition; D003131: Combined Modality Therapy; D005260: Female; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D008774: Methylphenidate; D010290: Parents; D010349: Patient Compliance; D013997: Time Factors",,,https://openalex.org/W2420851163,161,22,1,1642,256,6,en,en
false,lack drug interaction mirtazapine risperidone psychiatric patient pilot study,open label non randomize pilot study perform inpatient need treatment antipsychotic risperidone antidepressant mirtazapine objective preliminarily assess possible pharmacokinetic interaction tolerability combination week single drug treatment phase risperidone mg bid mirtazapine mg nocte follow week combine drug treatment phase unchanged twelve patient enrol nine treat risperidone single drug phase result plasma level measurement available six patient indicate add mirtazapine risperidone alter steady state plasma concentration risperidone hydroxy metabolite data one patient suggest add risperidone mirtazapine result clinically relevant change plasma concentration either compound combination well tolerate major relevant adverse event observe add risperidone mirtazapine probably necessitate change dosage either drug extensive investigation need,Loonen AJ,1999,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(99)00054-1,10647097,Loonen AJ; Doorschot CH; Oostelbos MC; Sitsen JM,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000929: Antidepressive Agents, Tricyclic; D014150: Antipsychotic Agents; D003863: Depression; D003866: Depressive Disorder; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D004409: Dyskinesia, Drug-Induced; D004421: Dystonia; D005260: Female; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008803: Mianserin; D008875: Middle Aged; D000078785: Mirtazapine; D000068882: Paliperidone Palmitate; D010865: Pilot Projects; D011618: Psychotic Disorders; D011743: Pyrimidines; D018967: Risperidone; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W1992398211,100,15,1,1175,186,7,en,en
false,laboratory measure methylphenidate effect cocaine dependent patient receive treatment,two experiment examine effect methylphenidate male female patient enrol outpatient treatment program primary cocaine dependence first study component double blind efficacy trial wherein patient first test human laboratory initial responsiveness medication patient randomly assign receive either placebo methylphenidate treatment receive first dose human laboratory environment continue outpatient treatment methylphenidate give mg sustain release dose twice daily plus additional mg immediate release dose combine morning dose methylphenidate increase heart rate subjective rating however subjective effect primarily dysphoric nature significant effect limit increase anxiety depression anger profile mood state shaky jittery rating visual analog scale dysphoria lysergic acid diethylamide lsd scale addiction research center inventory methylphenidate increase cocaine crave rating suggest abuse potential e morphine benzedrine group drug like score etc none drug effect observe human laboratory clinical concern subject preclude continue outpatient study outpatient treatment completion patient bring back second double blind human laboratory study three mg immediate release methylphenidate administer ascend series precede follow placebo methylphenidate produce dose related increase heart rate subjective rating shaky jittery lsd dysphoria without significantly alter cocaine crave stimulant euphoria rating result suggest stimulant substitution type approach treatment cocaine dependence necessarily contraindicate cardiovascular toxicity medication abuse potential however also suggest subjective effect methylphenidate may positive enough adequate replacement approach,Roache JD,2000,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200002000-00011,10653210,Roache JD; Grabowski J; Schmitz JM; Creson DL; Rhoades HM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000339: Affect; D000704: Analysis of Variance; D000697: Central Nervous System Stimulants; D019970: Cocaine-Related Disorders; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged,,,https://openalex.org/W2331368560,96,10,1,2199,339,11,en,en
false,pilot study methyiphenidate clonidine combination adhd comorbid aggressive oppositional defiant conduct disorder,pilot comparison safety efficacy methylphenidate mph combine clonidine clonidine monotherapy mph monotherapy year old child diagnose attention deficit hyperactivity disorder adhd comorbid aggressive oppositional defiant disorder conduct disorder complete study design month randomize blind group comparison eight subject per group placebo comparison use three treatment group show significant improvement attention deficit impulsivity oppositional conduct disorder symptom assess parent teacher rating scale laboratory measure significant difference among treatment group find measure clonidine monotherapy group show significantly decrease fine motor speed result suggest safety efficacy clonidine alone combination mph treatment adhd aggressive oppositional conduct disorder,Connor DF,2000,Clin Pediatr (Phila),https://doi.org/10.1177/000992280003900102,10660814,Connor DF; Barkley RA; Davis HT,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003000: Clonidine; D019955: Conduct Disorder; D015986: Confounding Factors, Epidemiologic; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010865: Pilot Projects; D011569: Psychiatric Status Rating Scales; D011597: Psychomotor Performance; D016896: Treatment Outcome",,,https://openalex.org/W2109935740,137,21,1,997,155,7,en,en
false,effect bupropion nicotine craving withdrawal,rationale objective bupropion demonstrate efficacy smoke cessation give importance nicotine crave withdrawal smoke cessation process current study examine effect bupropion parameter smoke abstinence method day baseline phase ad lib smoking non depress smoker try quit permanently administer measure nicotine crave withdrawal symptom time measure cognitive performance five time daily participant assign randomly day treatment regimen bupropion mg day bupropion mg day placebo thereafter measure administer day abstinence close research ward result relative placebo mg bupropion significantly reduce abstinence associate increase rat depression difficulty concentrate irritability attenuate decrease positive affect result also suggest bupropion might positive effect performance measure withdrawal period effect observe crave anxiety restlessness hunger lack find crave measure may explain floor effect except first day abstinence neither drug placebo group show much crave elevation abstinence conclusion study result indicate bupropion ameliorate nicotine withdrawal symptom,Shiffman S,2000,Psychopharmacology (Berl),https://doi.org/10.1007/s002130050022,10663415,Shiffman S; Johnston JA; Khayrallah M; Elash CA; Gwaltney CJ; Paty JA; Gnys M; Evoniuk G; DeVeaugh-Geiss J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D009538: Nicotine; D010349: Patient Compliance; D011569: Psychiatric Status Rating Scales; D011597: Psychomotor Performance; D012890: Sleep; D012907: Smoking; D016540: Smoking Cessation; D013375: Substance Withdrawal Syndrome; D011795: Surveys and Questionnaires; D014029: Tobacco Use Disorder; D016896: Treatment Outcome",,,https://openalex.org/W2056579603,58,9,1,1476,237,10,en,en
false,effect clonidine premedication haemodynamic response fibreoptic bronchoscopy,usual haemodynamic response fibreoptic bronchoscopy increase heart rate blood pressure therefore compare prospective randomise double blind study effect two dos oral clonidine premedication g g placebo control group haemodynamic alteration patient undergo elective fibreoptic bronchoscopy significant increase blood pressure heart rate observe fibreoptic bronchoscopy control group clonidine g blunt haemodynamic response fibreoptic bronchoscopy p significant decrease systolic blood pressure mmhg observe patient premedicated g clonidine throughout study nine patient g clonidine group treat least hypotension compare control group time awaken significantly long patient premedicated g clonidine conclusion premedication g oral clonidine attenuate haemodynamic response fibreoptic bronchoscopy without cause excessive haemodynamic depression sedation data encourage administration clonidine premedication patient undergo fibreoptic bronchoscopy particularly risk coronary artery disease,Matot I,2000,Anaesthesia,https://doi.org/10.1046/j.1365-2044.2000.01215.x,10671847,Matot I; Kuras Y; Kramer MR,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D001999: Bronchoscopy; D003000: Clonidine; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D008875: Middle Aged; D011292: Premedication; D011446: Prospective Studies",,,https://openalex.org/W2137127582,86,10,1,1349,230,9,en,en
false,non linear pharmacokinetics mdma ecstasy human,methylenedioxymethamphetamine mdma commonly call ecstasy synthetic compound increasingly popular recreational drug little know pharmacology include metabolism pharmacokinetics human control set clinical trial design evaluation mdma pharmacological effect pharmacokinetics healthy volunteer total subject include pilot phase six receive mdma n n mg n second phase eight receive mdma mg n subject phenotyped cyp activity classify extensive metabolizers substrate mdma whose hepatic metabolism regulate enzyme plasma urine sample collect throughout study evaluation mdma pharmacokinetics body fluid analyse determination mdma main metabolite methylenedioxyamphetamine mda hydroxy methoxy methamphetamine hmma hydroxy methoxy amphetamine hma dose mdma administer increase volunteer show rise mdma concentration follow proportionality could indicative nonlinearity full range dos test constant recovery hmma urine combine increase mdma recovery seem point towards saturation inhibition mdma metabolism demethylenation step observation far support fact urinary clearance rather constant nonrenal clearance dose dependent previously postulate individual genetically deficient hepatic enzyme cyp caucasian people risk develop acute toxicity moderate mdma drug would accumulate body instead metabolize inactivate lack linearity mdma pharmacokinetics window compatible recreational use general phenomenon concern whole population independent cyp genotype imply relatively small increase dose mdma ingest translate disproportionate rise mdma plasma concentration hence subject prone develop acute toxicity,de la Torre R,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00121.x,10671903,de la Torre R; Farré M; Ortuño J; Mas M; Brenneisen R; Roset PN; Segura J; Camí J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D015104: 3,4-Methylenedioxyamphetamine; D000328: Adult; D019540: Area Under Curve; D001794: Blood Pressure; D018592: Cross-Over Studies; D003846: Deoxyepinephrine; D003971: Diastole; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006213: Hallucinogens; D006801: Humans; D006863: Hydrogen-Ion Concentration; D008297: Male; D008657: Metabolic Clearance Rate; D008694: Methamphetamine; D018817: N-Methyl-3,4-methylenedioxyamphetamine; D010865: Pilot Projects; D013997: Time Factors",,,https://openalex.org/W2164164342,57,11,1,2305,380,12,en,en
false,dopamine receptor occupancy olanzapine risperidone young patient schizophrenia,crucial characteristic antipsychotic medication occupancy dopamine da receptor assess striatal da receptor occupancy olanzapine risperidone young patient male female mean age year first episode schizophrenia use iodobenzamide ibzm spect occupancy da receptor significantly different olanzapine risperidone however subgroup prescribe dos da occupancy high risperidone mg group compare olanzapine mg group ibzm bind ratio decrease olanzapine dose r p indicate high da receptor occupancy high olanzapine dose akathisia positive symptom correlate ibzm bind ratio r p r p respectively prolactin prl level elevate risperidone olanzapine group comparable receptor occupancy level olanzapine group prl level correlate ibzm bind ratio r p conclusion olanzapine risperidone induce high striatal receptor occupancy dependent dose group formation low incidence prolactin elevation olanzapine compare risperidone may attribute low receptor occupancy,Lavalaye J,1999,Psychiatry Res,https://doi.org/10.1016/s0925-4927(99)00032-3,10688158,Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001549: Benzamides; D001569: Benzodiazepines; D001921: Brain; D001931: Brain Mapping; D003287: Contrast Media; D005260: Female; D006801: Humans; D007457: Iodine Radioisotopes; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011759: Pyrrolidines; D017448: Receptors, Dopamine D2; D018967: Risperidone; D012559: Schizophrenia; D015899: Tomography, Emission-Computed, Single-Photon; D016896: Treatment Outcome",,,https://openalex.org/W2048766195,96,13,1,1391,274,10,en,en
false,low dose clonidine neostigmine prolong duration intrathecal bupivacaine fentanyl labor analgesia,intrathecal opioid local anesthetic combination popular labor analgesia rapid effective pain relief duration analgesia limit study undertake determine whether addition clonidine neostigmine bupivacaine fentanyl would increase duration analgesia without increase side effect patient labor forty five healthy parturients active labor randomize receive ml dose one follow dextrose contain solution use combine spinal epidural technique bupivacaine mg fentanyl microg bf bf plus clonidine microg bfc bfc plus neostigmine microg bfcn pain sensory level motor block side effect maternal vital sign fetal heart rate systematically assess patient administer bfcn significantly long analgesia min receive bf min p bfc min p pain score block characteristic maternal vital sign apgar score maternal satisfaction side effect similar among group except nausea significantly great bfcn group p compare bfc addition clonidine neostigmine significantly increase duration analgesia bupivacaine fentanyl labor neostigmine cause nausea although serious side effect observe study safety must far address routine use multiple drug advocate,Owen MD,2000,Anesthesiology,https://doi.org/10.1097/00000542-200002000-00016,10691221,Owen MD; Ozsaraç O; Sahin S; Uçkunkaya N; Kaplan N; Magunaci I,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000759: Adjuvants, Anesthesia; D000316: Adrenergic alpha-Agonists; D000328: Adult; D016362: Analgesia, Obstetrical; D000779: Anesthetics, Local; D001034: Apgar Score; D002045: Bupivacaine; D002800: Cholinesterase Inhibitors; D003000: Clonidine; D005260: Female; D005283: Fentanyl; D006801: Humans; D007231: Infant, Newborn; D007278: Injections, Spinal; D009388: Neostigmine; D010147: Pain Measurement; D017060: Patient Satisfaction; D011247: Pregnancy",,,https://openalex.org/W2046030804,111,13,1,1551,276,5,en,en
false,olanzapine increase slow wave sleep evidence blockade central ht c receptor vivo,study aim determine effect atypical antipsychotic agent olanzapine polysomnogram healthy subject predict olanzapine via serotonin c ht c receptor blockade would increase slow wave sleep sw study effect single evening olanzapine mg mg orally polysomnogram healthy male volunteer use placebo control double blind cross design compare placebo mg mg olanzapine significantly increase sw sleep continuity measure subjective sleep quality addition mg olanzapine suppress rapid eye movement rem sleep increase rem sleep latency olanzapine mg mg produce substantial highly significant dose related increase sw human probably via blockade brain ht c receptor ht c receptor antagonism may account therapeutic adverse effect olanzapine therapy,Sharpley AL,2000,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(99)00273-5,10704958,Sharpley AL; Vassallo CM; Cowen PJ,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D017286: Polysomnography; D011985: Receptors, Serotonin; D017367: Selective Serotonin Reuptake Inhibitors; D012890: Sleep; D012895: Sleep, REM; D011795: Surveys and Questionnaires",,,https://openalex.org/W2087505840,95,14,1,988,182,4,en,en
false,use topical aqueous suppressant prevention postoperative intraocular pressure elevation par plana vitrectomy long act gas tamponade,determine whether topical aqueous suppressant therapy apply par plana vitrectomy gas tamponade prevents postoperative intraocular pressure iop elevation prospective nonrandomized comparative study forty one patient meet inclusion criterion underwent par plana vitrectomy gas tamponade sf c f year period treatment eye receive topical aqueous suppressant end surgery postoperative iop hour day week twenty one control treatment eye meet inclusion criterion iop mmhg measure hour control treatment day control treatment postoperatively show statistically significant difference group p hour trend toward significance p day eleven control three treatment eye iop spike mmhg hour day postoperatively p six control eye one treatment eye postoperative iop great mmhg pressure rise great mmhg see two control eye treatment eye use topical aqueous suppressant par plana vitrectomy long act gas tamponade effective prevent significant postoperative iop elevation case,Mittra RA,2000,Ophthalmology,https://doi.org/10.1016/s0161-6420(99)00083-4,10711900,Mittra RA; Pollack JS; Dev S; Han DP; Mieler WF; Pulido JS; Connor TB,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000287: Administration, Topical; D000959: Antihypertensive Agents; D001082: Aqueous Humor; D000068438: Brimonidine Tartrate; D003000: Clonidine; D005466: Fluorocarbons; D006801: Humans; D007429: Intraocular Pressure; D009798: Ocular Hypertension; D011446: Prospective Studies; D011810: Quinoxalines; D013449: Sulfonamides; D013459: Sulfur Hexafluoride; D013876: Thiophenes; D013999: Timolol; D014821: Vitrectomy",,,https://openalex.org/W1893395659,164,22,1,1331,244,4,en,en
false,rapid opiate detoxication outpatient treatment,variety detoxification method utilize treatment heroin withdrawal individual begin long term opiate free naltrexone program methadone decrease still widely use detoxication procedure rapid ultrarapid protocol include clonidine opiate receptor antagonist propose study compare efficacy different detoxification method investigate possible change naltrexone compliance ninety eight heroin addict individual study evaluate withdrawal symptom crave mood urine toxicologic screen drop rate therapy group clonidine day group b clonidine oxazepam baclofen ketoprofene naloxone naltrexone day group c methadone decrease dos day naltrexone compliance relapse rate evaluate month follow period rapid detoxification opiate antagonist group b induce slight transient withdrawal symptom result significantly low percentage heroin catabolites urine control detoxification procedure low negative positive craving less mood problem high compliance extend naltrexone treatment comparison clonidine group methadone group c early use naltrexone detoxification combination benzodiazepine clonidine facilitate extend naltrexone acceptance improve recovery outcome outpatient,Gerra G,2000,J Subst Abuse Treat,https://doi.org/10.1016/s0740-5472(99)00050-1,10716102,Gerra G; Zaimovic A; Rustichelli P; Fontanesi B; Zambelli U; Timpano M; Bocchi C; Delsignore R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000894: Anti-Inflammatory Agents, Non-Steroidal; D001418: Baclofen; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005260: Female; D018682: GABA Agents; D006556: Heroin Dependence; D006801: Humans; D008658: Inactivation, Metabolic; D007660: Ketoprofen; D008297: Male; D008691: Methadone; D009270: Naloxone; D009271: Naltrexone; D009292: Narcotic Antagonists; D009294: Narcotics; D010076: Oxazepam; D010349: Patient Compliance; D013375: Substance Withdrawal Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W1974086885,49,6,1,1531,241,7,en,en
false,randomize trial modafinil treatment excessive daytime somnolence narcolepsy,one two separate clinical trial evaluate efficacy safety modafinil novel wake promote agent patient excessive daytime sleepiness ed associate narcolepsy week randomize placebo control double blind center clinical trial patient randomize receive fix daily modafinil mg modafinil mg placebo placebo control week treatment discontinuation phase include evaluate effect withdrawal patient receive modafinil total patient naive modafinil receive study medication week trial patient receive study medication discontinuation phase treatment modafinil result significant improvement two objective measure ed multiple sleep latency test maintenance wakefulness test additionally patient self assessment sleepiness significantly improve measure epworth sleepiness scale level illness significantly reduce independent clinician assessment clinical global impression change nighttime sleep monitor nocturnal polysomnography adversely effect modafinil treatment compare placebo treatment frequent adverse experience headache significantly great modafinil placebo treatment discontinuation individual receive modafinil experience return ed baseline level treatment discontinuation patient experience symptom associate amphetamine withdrawal syndrome week daily use evidence development dependence dose level study data indicate modafinil excellent safety profile well tolerate modafinil effective treatment excessive daytime sleepiness narcolepsy show continue efficacy week daily use,,2000,Neurology,https://doi.org/10.1212/wnl.54.5.1166,10720292,,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D001559: Benzhydryl Compounds; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009290: Narcolepsy; D017286: Polysomnography; D011930: Reaction Time; D012890: Sleep; D014851: Wakefulness,,,https://openalex.org/W2551140411,95,14,1,2008,314,10,en,en
false,multicentre double blind randomize comparison quetiapine ici seroquel haloperidol schizophrenia,quetiapine ici seroquel new atypical antipsychotic agent similar binding profile original atypical antipsychotic clozapine clinical efficacy already demonstrate multiple fix dos mg day suggest comparable haloperidol mg day international week multicentre double blind randomize parallel group trial compare quetiapine haloperidol mg mg mean total daily respectively hospitalized patient acute exacerbation chronic subchronic schizophrenia dsm iii r order establish equivalence term efficacy nature tolerability profile especially term extrapyramidal symptom eps serum prolactin level quetiapine haloperidol produce clear reduction positive negative syndrome scale panss score clinical global impression cgi severity illness global improvement score day panss total score reduce quetiapine group haloperidol group p treatment quetiapine well tolerate haloperidol term eps demonstrate significant difference simpson scale abnormal involuntary movement scale score p although patient group elevate serum prolactin concentration baseline mean serum prolactin concentration decrease microg l quetiapine treat patient yet increase microg l patient treat haloperidol quetiapine effective well tolerate antipsychotic comparable efficacy haloperidol lack latter compound effect prolactin eps,Copolov DL,2000,Psychol Med,https://doi.org/10.1017/s0033291799001476,10722180,Copolov DL; Link CG; Kowalcyk B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1970892722,123,21,1,1763,292,5,en,en
false,effect isradipine dihydropyridine class calcium channel antagonist methamphetamine induce cognitive physiological change human,methamphetamine abuse euphoric effect stimulatory action cognitive function abuse however associate massive hypertension result stroke rupture aneurysm myocardial infarction examine utility isradipine dihydropyridine class calcium channel antagonist treat methamphetamine induce hypertension evaluate effect cognitive function mediate dopaminergic mechanism methamphetamine dose dependently increase vital sign systolic diastolic mean arterial pressure pulse rate parameter isradipine significantly reduce methamphetamine induced increase diastolic mean arterial pressure however potentially beneficial therapeutic effect offset significant reflex rise pulse rate methamphetamine also improve attention accuracy reason ability performance computerize cognitive function task methamphetamine cognitive improve effect alter significantly isradipine isradipine increase false respond rate without significant effect attentional task reason ability performance isradipine appear enhance cognitive function healthy human,Johnson BA,2000,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(99)00116-5,10731625,Johnson BA; Ait-Daoud N; Wells LT,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D019969: Amphetamine-Related Disorders; D002121: Calcium Channel Blockers; D002320: Cardiovascular Physiological Phenomena; D003071: Cognition; D018592: Cross-Over Studies; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D017275: Isradipine; D008297: Male; D008694: Methamphetamine; D008875: Middle Aged; D018697: Nootropic Agents,,,https://openalex.org/W2005522694,149,18,1,1292,190,9,en,en
false,acute psychological effect methylenedioxymethamphetamine mdma ecstasy attenuate serotonin uptake inhibitor citalopram,methylenedioxymethamphetamine mdma ecstasy recreational drug show release serotonin ht dopamine da animal effect mdma ht release block ht uptake inhibitor citalopram suggest mdma interacts ht uptake site unknown whether mechanism also responsible psychological effect mdma human investigate effect citalopram pretreatment mg iv psychological effect mdma mg kg po double blind placebo control psychometric study healthy human volunteer mdma produce emotional state heighten mood increase self confidence extroversion moderate derealization intensification sensory perception effect markedly reduce citalopram find suggest psychological effect mdma mediate via action ht uptake site increase ht release carrier expect animal study,Liechti ME,2000,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(99)00148-7,10731626,Liechti ME; Baumann C; Gamma A; Vollenweider FX,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D019969: Amphetamine-Related Disorders; D001921: Brain; D015283: Citalopram; D004311: Double-Blind Method; D005260: Female; D006213: Hallucinogens; D006801: Humans; D008297: Male; D018817: N-Methyl-3,4-methylenedioxyamphetamine; D009483: Neuropsychological Tests; D018697: Nootropic Agents; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2120113858,142,20,1,1033,177,7,en,en
false,hemodynamic adrenergic effect perioperative dexmedetomidine infusion vascular surgery,test dexmedetomidine agonist decrease heart rate blood pressure plasma norepinephrine concentration ability attenuate stress response emergence anesthesia major vascular operation patient schedule vascular surgery receive either dexmedetomidine n placebo n iv begin min induction anesthesia continue h end surgery patient receive standardize anesthesia heart rate arterial blood pressure keep within predetermine limit vary anesthetic level use vasoactive medication heart rate arterial blood pressure inhale anesthetic concentration monitor continuously additional measurement include plasma urine catecholamine emergence anesthesia heart rate slow dexmedetomidine bpm placebo bpm p percentage time heart rate within predetermine hemodynamic limit frequent dexmedetomidine p plasma norepinephrine level increase placebo group significantly low dexmedetomidine group immediate postoperative period p conclude dexmedetomidine attenuate increase heart rate plasma norepinephrine concentration emergence anesthesia implication agonist dexmedetomidine attenuate increase heart rate plasma norepinephrine concentration emergence anesthesia vascular surgery patient,Talke P,2000,Anesth Analg,https://doi.org/10.1097/00000539-200004000-00011,10735784,Talke P; Chen R; Thomas B; Aggarwall A; Gottlieb A; Thorborg P; Heard S; Cheung A; Son SL; Kallio A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D002395: Catecholamines; D003000: Clonidine; D020927: Dexmedetomidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D014656: Vascular Surgical Procedures",,,https://openalex.org/W4253209559,103,12,1,1580,253,9,en,en
false,comparison urapidil clonidine meperidine placebo prevent postanesthetic shivering,placebo control study perform evaluate efficacy urapidil compare clonidine meperidine prevent postanesthetic shivering common anesthesia administration may distress study patient undergo elective abdominal orthopedic surgery standardize general anesthesia surgery patient randomly assign one four group group n use double blind protocol group receive mg kg urapidil group b microg kg clonidine group c mg kg meperidine group saline placebo postanesthetic shivering score use five point scale clonidine meperidine significantly reduce incidence severity shiver comparison placebo whereas significant difference urapidil placebo group clonidine meperidine cause significantly prolong emergence time min respectively compare placebo min urapidil min confirm clonidine meperidine effective prevent postanesthetic shiver whereas urapidil set dosage effective patient receive clonidine meperidine prolong emergence time dosage use urapidil seem unable prevent postanesthetic shiver shiver irregular muscle activity common surgery anesthesia study compare urapidil antihypertensive drug prophylaxis two establish antishivering drug meperidine clonidine placebo dosage use unable show significant benefit urapidil,Piper SN,2000,Anesth Analg,https://doi.org/10.1097/00000539-200004000-00033,10735806,Piper SN; Maleck WH; Boldt J; Suttner SW; Schmidt CC; Reich DG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000328: Adult; D000368: Aged; D000768: Anesthesia, General; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008614: Meperidine; D008875: Middle Aged; D010879: Piperazines; D012768: Shivering",,,https://openalex.org/W2051812363,98,14,1,1722,291,12,en,en
false,functional deficit basal ganglion child attention deficit hyperactivity disorder show functional magnetic resonance imaging relaxometry,attention deficit hyperactivity disorder highly heritable prevalent neuropsychiatric disorder estimate affect school age child clinical hallmark inattention hyperactivity impulsivity often respond substantially treatment methylphenidate dextroamphetamine etiological theory suggest deficit corticostriatal circuit particularly component modulate dopamine develop new functional magnetic resonance imaging procedure relaxometry indirectly assess blood volume striatum caudate putamen boys year age steady state condition boy attention deficit hyperactivity disorder high relaxation time measure putamen bilaterally healthy control subject relaxation time strongly correlate child capacity sit still accuracy accomplish computerized attention task daily treatment methylphenidate significantly change relaxation time putamen child attention deficit hyperactivity disorder although magnitude direction effect strongly dependent child unmedicated activity state similar nonsignificant trend right caudate relaxation time measure thalamus differ significantly group affect methylphenidate attention deficit hyperactivity disorder symptom may closely tie functional abnormality putamen mainly involve regulation motor behavior,Teicher MH,2000,Nat Med,https://doi.org/10.1038/74737,10742158,Teicher MH; Anderson CM; Polcari A; Glod CA; Maas LC; Renshaw PF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D001921: Brain; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002648: Child; D005724: Ganglia; D006801: Humans; D008279: Magnetic Resonance Imaging; D008297: Male; D008774: Methylphenidate,,,https://openalex.org/W1542975971,155,17,1,1574,228,10,en,en
false,single multiple dose pharmacokinetics oral day osmotic control release oros methylphenidate hc formulation,methylphenidate use treatment attention deficit hyperactivity disorder adhd oros methylphenidate hcl osmotic control release delivery system design daily oral dose pharmacokinetics oros methylphenidate hcl mg qd sustain release sr methylphenidate mg qd immediate release ir formulation give three mg every hour tid compare adult addition single multiple dose pharmacokinetics oros formulation study follow oros methylphenidate hcl gradual increase mean methylphenidate plasma concentration peak concentration note hour sr formulation peak plasma concentration note hour follow ir regimen methylphenidate plasma concentration fluctuate tandem oral dose peak concentration note hour terminal half life methylphenidate similar three formulation dose normalized methylphenidate c max oros methylphenidate hcl significantly low ir sr methylphenidate bioavailability methylphenidate ppa oros methylphenidate hcl relative ir sr formulation complete mean methylphenidate auc terminal half life similar single ng h ml hour multiple ng h ml hour oros methylphenidate hcl,Modi NB,2000,J Clin Pharmacol,https://doi.org/10.1177/00912700022009080,10761165,Modi NB; Lindemulder B; Gupta SK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D019540: Area Under Curve; D001682: Biological Availability; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004244: Dizziness; D004305: Dose-Response Relationship, Drug; D006207: Half-Life; D006261: Headache; D006801: Humans; D008774: Methylphenidate; D008875: Middle Aged; D009325: Nausea; D009997: Osmotic Pressure",,,https://openalex.org/W2056363043,131,16,1,1453,246,11,en,en
false,evaluation sexual functioning depressed outpatient double blind comparison sustain release bupropion sertraline treatment,sexual dysfunction frequently report side effect many antidepressant include serotonin reuptake inhibitor bupropion antidepressant aminoketone class relatively free adverse sexual effect randomize double blind multicenter trial sustain release bupropion bupropion sr sertraline selective serotonin reuptake inhibitor find similarly efficacious treatment outpatient moderate severe depression report describe result double blind comparison sexual side effect profile bupropion sr sertraline two hundred forty eight patient receive diagnosis moderate severe major depression randomly assign receive treatment bupropion sr mg day sertraline mg day week eligible patient require stable relationship normal sexual function sexual functioning assess investigator clinic visit use investigator rat structured interview significantly great percentage sertraline treat patient men woman respectively develop sexual dysfunction compare bupropion sr treat patient respectively sexual dysfunction note early day sertraline treat patient dose mg day persist end week treatment phase four patient treat sertraline discontinue study prematurely sexual dysfunction give similar efficacy two drug treat depression bupropion sr may appropriate antidepressant choice sertraline patient sexual dysfunction concern,Segraves RT,2000,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200004000-00002,10770448,Segraves RT; Kavoussi R; Hughes AR; Batey SR; Johnston JA; Donahue R; Ascher JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000553: Ambulatory Care; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D020280: Sertraline; D012725: Sexual Behavior",,,https://openalex.org/W2317847751,140,17,1,1757,288,11,en,en
false,effect oral clonidine premedication side effect intravenous ketamine anesthesia randomize double blind placebo control study,study objective determine effect oral clonidine premedication hemodynamic change entire course ketamine anesthesia incidence postoperative adverse reaction design randomize prospective double blind placebo control study set department anesthesiology university tsukuba hospital ibaraki japan patient asa physical status ii patient undergo superficial surgery intervention placebo clonidine g kg clonidine g kg group receive respective dos oral clonidine minute prior surgery anesthesia induce ketamine mg kg intravenously iv trachea intubate anesthesia maintain nitrous oxide oxygen supplemental ketamine mg kg systolic blood pressure heart rate hr exceed mmhg bpm respectively measurement main result clonidine g kg group hr response tracheal intubation significantly less clonidine g kg group mean arterial pressure hr response significantly suppress compare placebo group intraoperative coefficient variation hr significantly less clonidine group placebo group incidence nightmare degree salivation significantly less clonidine g kg group placebo group conclusion oral clonidine g kg clonidine g kg attenuate cardiostimulatory effect clonidine g kg associate reduce incidence severity nightmare salivation attributable iv ketamine,Handa F,2000,J Clin Anesth,https://doi.org/10.1016/s0952-8180(99)00131-2,10773503,Handa F; Tanaka M; Nishikawa T; Toyooka H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000771: Anesthesia, Intravenous; D000778: Anesthetics, Dissociative; D018685: Anesthetics, Inhalation; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D004325: Dreams; D005260: Female; D006339: Heart Rate; D006801: Humans; D015994: Incidence; D007442: Intubation, Intratracheal; D007649: Ketamine; D008297: Male; D016343: Monitoring, Intraoperative; D009609: Nitrous Oxide; D010100: Oxygen; D010919: Placebos; D011183: Postoperative Complications; D011292: Premedication; D011446: Prospective Studies; D012472: Salivation; D013565: Sympatholytics",,,https://openalex.org/W1968494224,144,20,1,1616,266,10,en,en
false,levobupivacaine,unlabelled base find cardiotoxicity infrequently observe racemic bupivacaine show enantioselectivity e pronounce r enantiomer enantiomer levobupivacaine develop clinical use long act local anaesthetic majority vitro vivo human pharmacodynamic study nerve block indicate levobupivacaine similar potency bupivacaine however levobupivacaine low risk cardiovascular cns toxicity bupivacaine animal study human volunteer levobupivacaine less negative inotropic effect intravenous mg produce less prolongation qtc interval bupivacaine change indicative cns depression eeg evident levobupivacaine levobupivacaine long act dose dependent duration anaesthesia onset action minute various anaesthetic technique study surgical anaesthesia adult levobupivacaine provide sensory block hour epidural administration mg hour intrathecal mg hour brachial plexus block mg kg randomise double blind clinical study establish anaesthetic analgesic effect levobupivacaine largely similar bupivacaine dose sensory block tend long levobupivacaine bupivacaine amount difference minute epidural administration approximately hour peripheral nerve block epidural administration levobupivacaine produce less prolonged motor block sensory block differential see peripheral nerve block condition satisfactory surgery good pain management achieve use local infiltration peribulbar administration levobupivacaine levobupivacaine generally effective bupivacaine pain management labour effective management postoperative pain especially combine clonidine morphine fentanyl tolerability profile levobupivacaine bupivacaine similar clinical trial clinically significant ecg abnormality serious cns event occur use common adverse event associate levobupivacaine treatment hypotension conclusion levobupivacaine long act local anaesthetic clinical profile closely resemble bupivacaine however current preclinical safety toxicity data show advantage levobupivacaine bupivacaine clinical data compare levobupivacaine ropivacaine need role drug fully establish exclude pharmacoeconomic consideration levobupivacaine appropriate choice use place bupivacaine,Foster RH,2000,Drugs,https://doi.org/10.2165/00003495-200059030-00013,10776835,Foster RH; Markham A,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D000773: Anesthesia, Obstetrical; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D000818: Animals; D019540: Area Under Curve; D002045: Bupivacaine; D002319: Cardiovascular System; D004361: Drug Tolerance; D005260: Female; D006207: Half-Life; D006801: Humans; D009407: Nerve Block; D010149: Pain, Postoperative; D011247: Pregnancy; D016032: Randomized Controlled Trials as Topic; D013237: Stereoisomerism; D013329: Structure-Activity Relationship",,,https://openalex.org/W2049881401,15,1,1,2895,460,22,fr,en
false,novel analgesic adjunct brachial plexus block systematic review,article review current evidence efficacy add novel analgesic adjunct brachial plexus block goal prolong analgesic effect without disadvantage systemic side effect prolong motor block may also allow reduction total dose local anesthetic use novel adjunct study date include opioids clonidine neostigmine tramadol twenty four study review assess use specific inclusion criterion study satisfy criterion include final assessment satisfactory study assess inclusion systemic control group determine peripheral effect oppose possible systemic effect adjunct administer peripherally evidence regard analgesic benefit opioid adjunct remain equivocal evidence require routine use recommend clonidine appear significant analgesic benefit cause minimal adverse effect use dose microg data regard drug tramadol neostigmine sufficient allow recommendation study require,Murphy DB,2000,Anesth Analg,https://doi.org/10.1097/00000539-200005000-00023,10781465,Murphy DB; McCartney CJ; Chan VW,article,D016428: Journal Article; D017418: Meta-Analysis; D000078182: Systematic Review,"D000328: Adult; D000700: Analgesics; D000701: Analgesics, Opioid; D001917: Brachial Plexus; D003000: Clonidine; D006801: Humans; D009388: Neostigmine; D009407: Nerve Block",,,https://openalex.org/W1995432167,71,11,1,1204,197,8,en,en
false,bupropion sustain release versus paroxetine treatment depression elderly,depression serious widespread emotional disorder among elderly study compare efficacy safety bupropion sustain release sr selective serotonin reuptake inhibitor paroxetine treatment major depression elderly outpatient elderly year outpatient major depressive disorder dsm iv criterion evaluate week multicenter randomize double blind study compare bupropion sr mg day paroxetine mg day efficacy assess change score hamilton rating scale depression ham anxiety ham clinical global impression severity illness improvement scale safety assess monitor adverse event vital sign body weight total patient range age year randomly assign treatment bupropion sr n paroxetine n measurement efficacy similar treatment group group show improve score depression rating scale headache insomnia dry mouth agitation dizziness nausea occur patient group somnolence diarrhea constipation anorexia occur patient paroxetine group statistically significant difference group vital sign weight find bupropion sr paroxetine safe effective treatment depression elderly favorable side effect profile bupropion sr may provide safe effective nonserotonergic treatment alternative well suit antidepressant elderly,Weihs KL,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0309,10817105,Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000553: Ambulatory Care; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D015897: Comorbidity; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017374: Paroxetine; D011569: Psychiatric Status Rating Scales; D012307: Risk Factors; D012640: Seizures; D017367: Selective Serotonin Reuptake Inhibitors; D016896: Treatment Outcome",,,https://openalex.org/W2018434620,92,13,1,1671,289,8,en,en
false,oral clonidine postmenopausal patient breast cancer experience tamoxifen induce hot flash university rochester cancer center community clinical oncology program study,hot flash frequently report side effect tamoxifen treatment although hormone effective treatment safety questionable woman breast cancer therefore important evaluate nonhormonal treatment hot flash evaluate effectiveness oral clonidine control hot flash associate tamoxifen therapy postmenopausal woman breast cancer randomize double blind placebo control clinical trial university rochester cancer center community clinical oncology program postmenopausal woman breast cancer receive adjuvant tamoxifen therapy oral clonidine hydrochloride mg placebo week daily diary patient record number duration severity hot flash overall quality life score point scale week baseline period th th th week study patient placebo treatment group similar age duration tamoxifen use report frequency duration hot flash baseline dropout rate one hundred forty nine patient complete week follow mean decrease hot flash frequency great clonidine group placebo group week treatment compare ci difference week treatment compare ci difference patient receive clonidine likely patient receive placebo report difficulty sleep compare p significant difference see mean change quality life score point clonidine group compare point placebo group p week although median difference group oral clonidine mg effective tamoxifen induce hot flash postmenopausal woman breast cancer,Pandya KJ,2000,Ann Intern Med,https://doi.org/10.7326/0003-4819-132-10-200005160-00004,10819701,Pandya KJ; Raubertas RF; Flynn PJ; Hynes HE; Rosenbluth RJ; Kirshner JJ; Pierce HI; Dragalin V; Morrow GR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D018931: Antineoplastic Agents, Hormonal; D001943: Breast Neoplasms; D003000: Clonidine; D004311: Double-Blind Method; D005500: Follow-Up Studies; D019584: Hot Flashes; D006801: Humans; D010352: Patient Dropouts; D010919: Placebos; D017698: Postmenopause; D019057: Quality-Adjusted Life Years; D013629: Tamoxifen",,,https://openalex.org/W2022076582,186,24,1,1929,340,7,en,en
false,ondansetron give induction anesthesia reduces shiver general anesthesia,neurotransmitter pathway involve mechanism postanesthetic shiver pa poorly understood meperidine clonidine physostigmine effective treatment indicate opioid adrenergic anticholinergic system probably involved investigate effect ondansetron ht antagonist use treat postoperative nausea vomit intraoperative core peripheral temperature pa eighty two patient age yr undergo orthopedic general urological surgery randomize three group double blind placebo control study group n receive ondansetron mg iv group n receive ondansetron mg iv group c n receive saline iv immediately anesthetic induction core tympanic fingertip temperature dorsum middle finger record anesthesia induce iv fentanyl g kg propofol mg kg maintain minimum alveolar anesthetic concentration isoflurane nitrous oxide oxygen occurrence shiver document clinically recovery nurse staff unaware group assignment pa occur patient group c compare group p patient group p within group core temperature decrease peripheral temperature increase significantly significant difference among group time interval conclude ondansetron mg iv give induction anesthesia prevents pas without affect core peripheral redistribution heat general anesthesia suggest serotonergic pathway role regulation pa implication randomize double blind placebo control clinical study ondansetron mg iv give induction reduce incidence postanesthetic shivering compare saline anticipate core peripheral redistribution body temperature general anesthesia affect imply ondansetron probably act central inhibitory mechanism hydroxytryptaminergic pathway role regulate postanesthetic shivering,Powell RM,2000,Anesth Analg,https://doi.org/10.1097/00000539-200006000-00032,10825334,Powell RM; Buggy DJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000768: Anesthesia, General; D000932: Antiemetics; D001831: Body Temperature; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D017294: Ondansetron; D012768: Shivering; D012881: Skin Temperature",,,https://openalex.org/W1991078205,91,11,1,2282,392,14,en,en
false,longitudinal comparative study risperidone conventional neuroleptic treat patient schizophrenia,study compare long term month effectiveness risperidone rp conventional neuroleptic cns population chronic schizophrenia show suboptimal response cns randomize open parallel multicenter design use one hundred eighty four subject meet dsm iv criterion schizophrenia randomly assign receive either rp cn complete follow outcome measure take month include positive negative syndrome scale panss extrapyramidal symptom rating scale within month follow rp find superior cns term average change score baseline panss p proportion good responder define decrease total panss score p positive symptom effectiveness rp treatment tend increase time month percentage good responder rp group twice large cn group vs p superiority rp cns constant three dose category rp cn group maximum decrease psychopathology achieve low dose range worsen akathisia less frequent subject receive rp receive cns p conclusion study show compare cns rp beneficial treatment patient chronic schizophrenia benefit may appear long term treatment,Bouchard RH,2000,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200006000-00002,10831015,Bouchard RH; Mérette C; Pourcher E; Demers MF; Villeneuve J; Roy-Gagnon MH; Gauthier Y; Cliche D; Labelle A; Filteau MJ; Roy MA; Maziade M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D010352: Patient Dropouts; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2406471561,116,13,1,1576,308,11,en,en
false,risperidone treatment cocaine dependence randomize double blind trial,partial blockade multiple action cocaine one strategy cocaine dependence may treat risperidone hydroxytryptamine dopamine antagonist atypical antipsychotic candidate medication treatment cocaine dependence one hundred ninety three cocaine dependent subject enrol week randomize double blind placebo control trial subject initially receive either placebo mg risperidone subsequent change active mg mg subject attend clinic twice week provide urine sample obtain medication underwent one behavioral therapy session per week study terminate interim analysis retention bad mg active medication group side effect primarily associate mg dose although neither mg mg well accept subject reduction cocaine use associate risperidone result suggest although antagonist might useful treatment approach treatment opiate dependence risperidone unlikely find broad acceptance treatment seek population,Grabowski J,2000,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200006000-00003,10831016,Grabowski J; Rhoades H; Silverman P; Schmitz JM; Stotts A; Creson D; Bailey R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D003042: Cocaine; D019970: Cocaine-Related Disorders; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D010352: Patient Dropouts; D011613: Psychotherapy; D012008: Recurrence; D018967: Risperidone; D013997: Time Factors,,,https://openalex.org/W2242713226,83,12,1,1209,203,10,en,en
false,positron emission tomography study quetiapine schizophrenia preliminary finding antipsychotic effect transiently high dopamine receptor occupancy,quetiapine new atypical antipsychotic medication relatively little publish regard vivo effect dopamine type serotonin type ht receptor system follow study undertake explore effect across clinical dose range relate information clinical profile twelve patient schizophrenia randomly assign mg n mg quetiapine week treatment ht occupancy measure use positron emission tomography pet image hour last dose clinical efficacy adverse effect rating obtain baseline time pet scan week two additional patient include examine effect drug hour last dose quetiapine effective antipsychotic improve extrapyramidal symptom prolactin level elevation note baseline achieve result minimal occupancy hour last dose study additional subject reveal quetiapine give rise transiently high occupancy hour single dose decrease minimal level hour quetiapine show transiently high occupancy decrease low level end dose interval quetiapine low occupancy explain freedom extrapyramidal symptom prolactin level elevation data suggest transient occupancy may sufficient antipsychotic effect future study control nonpharmacological effect well activity receptor necessary confirm suggestion,Kapur S,2000,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.57.6.553,10839333,Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001921: Brain; D002250: Carbon Radioisotopes; D003987: Dibenzothiazepines; D065127: Dopamine D2 Receptor Antagonists; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D011388: Prolactin; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D020891: Raclopride; D017448: Receptors, Dopamine D2; D011985: Receptors, Serotonin; D012559: Schizophrenia; D012702: Serotonin Antagonists; D014055: Tomography, Emission-Computed; D016896: Treatment Outcome",,,https://openalex.org/W2009915820,175,25,1,1755,314,11,en,en
false,safety olanzapine compare antipsychotic drug,result control clinical trial confirm safety effectiveness study nonselected patient cohort treat accord routine clinical practice outpatient schizophrenia icd criterion enter prospective naturalistic study receive new prescription antipsychotic drug treatment assignment base purely clinical criterion study include experimental intervention safety evaluate collection spontaneous adverse event specific questionnaire extrapyramidal symptom global clinical status measure clinical global impression severity cgi global assessment function gaf scale patient include patient treat olanzapine monotherapy combine drug olanzapine group treat antipsychotic drug monotherapy combine drug control group statistical difference treatment group baseline regard age gender disease duration severity symptom olanzapine well tolerate effective study overall incidence adverse event significantly low olanzapine group compare control group p somnolence weight gain significantly frequent olanzapine group akathisia dystonia extrapyramidal syndrome hypertonia hypokinesia tremor significantly high control group clinical improvement endpoint measure mean change cgi gaf significantly high olanzapine group compare control group p result show olanzapine safe effective nonselected schizophrenic outpatient consistent efficacy safety profile olanzapine show previous control clinical trial,Gómez JC,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0503,10847307,Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000553: Ambulatory Care; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D015331: Cohort Studies; D004359: Drug Therapy, Combination; D006801: Humans; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1985485609,64,9,1,1939,306,9,en,en
false,medication continuation compliance comparison patient treat clozapine haloperidol,study compare medication continuation regimen compliance atypical antipsychotic medication clozapine versus conventional antipsychotic haloperidol data site double blind randomize clinical trial n use compare patient dsm iii r schizophrenia assign clozapine haloperidol term duration participation take randomly assign study drug continuation proportion prescribe pill take compliance multiple regression analysis use determine relationship baseline characteristic measure clinical change continuation entire sample patient assign medication patient assign clozapine continue take study drug mean week compare among patient assign haloperidol f df p difference find group proportion prescribe pill return timepoint among patient assign haloperidol poor continuation associate old great continuation receive public support among patient clozapine treatment continuation poor among african american patient great among patient show reduce clinical symptom akathisia continuation clozapine great even adjust factor continuation medication great clozapine haloperidol partly explain great symptom improvement reduce side effect difference find regimen compliance,Rosenheck R,2000,J Clin Psychiatry,,10847315,Rosenheck R; Chang S; Choe Y; Cramer J; Xu W; Thomas J; Henderson W; Charney D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000328: Adult; D001741: Black or African American; D014150: Antipsychotic Agents; D003024: Clozapine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D008297: Male; D010349: Patient Compliance; D010352: Patient Dropouts; D012044: Regression Analysis; D012559: Schizophrenia; D016896: Treatment Outcome; D016312: Treatment Refusal; D015430: Weight Gain,,,https://openalex.org/W2048123560,104,15,1,1626,248,7,en,en
false,atypical antipsychotic weightgain systematic review,review systematically data relate weight change atypical antipsychotic conduct medline search october cover period recover paper examine relevant report addition write pharmaceutical manufacturer practise clinician ask provide relevant report know eighty report mention change body weight retrieve data relate weight change variable quality weight change indicate variety measure majority report relate short term change atypical drug exception ziprasidone associate weight increase clozapine seem high risk weight gain follow olanzapine quetiapine probably low risk risperidone sertindole zotepine still low risk amisulpride ziprasidone appear associate weight gain absence compel data ranking must consider approximate preliminary long robust trial need,Taylor DM,2000,Acta Psychiatr Scand,https://doi.org/10.1034/j.1600-0447.2000.101006416.x,10868465,Taylor DM; McAskill R,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,D000077582: Amisulpride; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003024: Clozapine; D003987: Dibenzothiazepines; D003988: Dibenzothiepins; D006801: Humans; D007093: Imidazoles; D007211: Indoles; D000077152: Olanzapine; D010879: Piperazines; D010890: Pirenzepine; D000069348: Quetiapine Fumarate; D018967: Risperidone; D013469: Sulpiride; D013844: Thiazoles; D015430: Weight Gain,,,https://openalex.org/W2062250724,60,8,1,1116,183,11,en,en
false,low incidence persistent tardive dyskinesia elderly patient dementia treat risperidone,author study incidence tardive dyskinesia elderly institutionalize patient dementia treat risperidone participate week multicenter double blind study receive placebo one three risperidone patient mean age year alzheimer vascular mixed dementia enrol year open label study receive flexible risperidone persistent emergent tardive dyskinesia define accord score dyskinesia subscale extrapyramidal symptom rating scale mean modal risperidone dose mg day sd median length risperidone use day year cumulative incidence persistent emergent tardive dyskinesia among patient without dyskinesia baseline patient dyskinetic symptom baseline experience significant reduction severity dyskinesia patient receive mg day risperidone show significant improvement psychopathologic symptom year period although control group observe incidence persistent tardive dyskinesia risperidone seem much low see elderly patient treat conventional neuroleptic average optimal dose risperidone elderly dementia patient find mg day,Jeste DV,2000,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.157.7.1150,10873925,Jeste DV; Okamoto A; Napolitano J; Kane JM; Martinez RA,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D003704: Dementia; D015140: Dementia, Vascular; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004409: Dyskinesia, Drug-Induced; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D015994: Incidence; D008297: Male; D010919: Placebos; D018967: Risperidone; D012720: Severity of Illness Index; D016019: Survival Analysis; D016896: Treatment Outcome",,,https://openalex.org/W2109946269,105,14,1,1411,213,6,en,en
false,profile cognitive dysfunction chronic amphetamine heroin abuser,group subject whose primary drug abuse amphetamine heroin compare together age iq match control subject study consist neuropsychological test battery include conventional test also computerise test recognition memory spatial work memory plan sequence generation visual discrimination learn attentional set shift many test previously show sensitive cortical damage include selective lesion temporal frontal lobe cognitive deficit dementia basal ganglia disease neuropsychiatric disorder qualitative difference well commonality find profile cognitive impairment two group chronic amphetamine abuser significantly impair performance extra dimensional shift task core component wisconsin card sort test whereas contrast heroin abuser impair learn normally easy intra dimensional shift component group impair test spatial work memory however amphetamine group unlike heroin group deficient index strategic performance test heroin group fail show significant improvement two block sequence generation task train additionally exhibit perseverative behavior task two group profoundly equivalently impair test pattern recognition memory sensitive temporal lobe dysfunction result indicate chronic drug use may lead distinct pattern cognitive impairment may associate dysfunction different component cortico striatal circuitry,Ornstein TJ,2000,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(00)00097-x,10882838,Ornstein TJ; Iddon JL; Baldacchino AM; Sahakian BJ; London M; Everitt BJ; Robbins TW,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D019969: Amphetamine-Related Disorders; D000662: Amphetamines; D000704: Analysis of Variance; D001288: Attention; D002908: Chronic Disease; D003072: Cognition Disorders; D005260: Female; D003932: Heroin; D006556: Heroin Dependence; D006801: Humans; D007807: Language Tests; D008297: Male; D008568: Memory; D008875: Middle Aged; D009483: Neuropsychological Tests; D010364: Pattern Recognition, Visual; D011930: Reaction Time; D012718: Set, Psychology",,,https://openalex.org/W2008599960,75,10,1,1772,281,10,en,en
false,side effect low dose amphetamine administration stroke rehabilitation,read interest recent article fiorelli et al author confirm reliability hemorrhagic transformation ht diagnosis find could make either neuroradiologist trained neurologist however great clinical relevance fact find severe ht parenchymal hematoma ph ecass associate unfavorable outcome show table result emerge multicentre acute stroke trial italy mast analysis find severe ht often associate intraventricular subarachnoid bleed find together independent cerebral edema make prognosis unfavorable study severe ht ph definition ecass point significant space occupy effect include presence clot remote infarct area ecass investigator specifically assess effect intraventricular subarachnoid bleed prognosis find ht per se real adverse effect thrombolytic treatment wonder whether result ecass nih study publish point need confirmation funding prognostic significance intraventricular subarachnoid bleed implement new strategy prevent manage soon develop,Unwin H,2000,Stroke,https://doi.org/10.1161/01.str.31.7.1785-d,10884491,Unwin H; Walker-Batson D,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016422: Letter,D000661: Amphetamine; D000697: Central Nervous System Stimulants; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D020521: Stroke; D000071939: Stroke Rehabilitation,,,https://openalex.org/W1981705884,82,10,1,1416,249,5,en,en
false,clozapine augmentation safety efficacy,clozapine demonstrate efficacious refractory schizophrenia possibly schizoaffective well bipolar disorder substantial number patient still remain unresponsive one strategy treat refractory patient augment clozapine somatic treatment article review efficacy safety combination clozapine somatic treatment total article obtain manual well computerize medline search english language literature march control study exist case report series data great risk adverse effect seem associate clozapine combine benzodiazepine valproate lithium currently evaluate combination absolutely unsafe term efficacy data suggest number potential augmentation strategy although control data combination therapy clozapine common clinical practice despite lack empirical data benefit risk combination need systematically review,Chong SA,2000,Schizophr Bull,https://doi.org/10.1093/oxfordjournals.schbul.a033463,10885641,Chong SA; Remington G,article,D016428: Journal Article; D016454: Review,"D014150: Antipsychotic Agents; D003024: Clozapine; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D006801: Humans; D012559: Schizophrenia",,,https://openalex.org/W2121458109,43,6,1,1147,189,8,en,en
false,name speed performance stimulant effect indicate effortful semantic processing deficit attention deficit hyperactivity disorder,study investigate rapid automatized name effect stimulant medication school age child attention deficit hyperactivity disorder adhd without concurrent read disorder rd two adhd group adhd adhd rd control group healthy age match peer compare four variable color name speed letter name speed phonologic decode arithmetic computation discriminant function analysis dfa conduct predict group membership four variable load onto two discriminant function good specificity phonologic decode letter name speed arithmetic define first function color name speed define second function adhd group significantly slow color name control differ one another dfa correctly classify control group adhd rd adhd subset child adhd group participate subsequently acute randomize placebo control crossover trial three single mg methylphenidate methylphenidate selectively improve color name speed effect speed name letter digit find challenge tenet name speed deficit specific rd implicate name speed deficit associate effortful semantic processing adhd improve normalize stimulant medication,Tannock R,2000,J Abnorm Child Psychol,https://doi.org/10.1023/a:1005192220001,10885682,Tannock R; Martinussen R; Frijters J,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001289: Attention Deficit Disorder with Hyperactivity; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002648: Child; D004410: Dyslexia; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011930: Reaction Time; D014705: Verbal Behavior,,,https://openalex.org/W1548385953,140,16,1,1465,253,9,en,en
false,acute effect amphetamine early late follicular phase menstrual cycle woman,recent preclinical evidence indicate ovarian hormone estrogen progesterone may influence behavioral effect psychoactive drug interact directly neurotransmitter system central nervous system however study examine effect ovarian hormone subjective behavioral response psychoactive drug human present study assess subjective physiological effect amphetamine early late follicular phase menstrual cycle nineteen healthy regularly cycle woman participate four session receive amphetamine amph mg oral placebo early late follicular phase two menstrual cycle early follicular phase level estrogen progesterone low whereas late follicular phase estrogen level high progesterone remain low dependent measure include self report questionnaire physiological measure plasma hormone level subjective physiological effect amph affect menstrual cycle phase however subject report great unpleasant stimulation amph less unpleasant sedation late follicular phase early follicular phase result provide limit evidence high level estrogen late follicular phase alter subjective effect amph normal healthy woman,Justice AJ,2000,Pharmacol Biochem Behav,https://doi.org/10.1016/s0091-3057(00)00218-5,10899363,Justice AJ; De Wit H,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000704: Analysis of Variance; D001007: Anxiety; D001519: Behavior; D000697: Central Nervous System Stimulants; D003913: Dextroamphetamine; D004334: Drug Administration Schedule; D004967: Estrogens; D005221: Fatigue; D005260: Female; D005498: Follicular Phase; D006439: Hemodynamics; D006801: Humans,,,https://openalex.org/W1994527877,106,17,1,1471,229,9,en,en
false,low dose amphetamine salt adult attention deficit hyperactivity disorder,effective treatment attention deficit hyperactivity disorder adhd adult still define pediatric study suggest mixed amphetamine salt product adderall safe effective treatment childhood form adhd presently report scientific literature concern safety efficacy adderall adult adhd focus study twenty four outpatient mean age year dsm iv adhd administer adderall open label fashion start mg p b titration accord clinical response across week period relative spouse patient complete serial checklist include copeland symptom checklist brown attention deficit disorder scale prospectively collect data analyze retrospectively thirteen patient respond positive manner adderall base clinical global impression improvement scale score mean end dose responder mg day mg kg day intent treat analysis reveal decrease mean copeland score p mean brown score drop p nine patient poor responder nonresponders adderall acute anxiety symptom occur patient comorbid anxiety diagnosis adderall may effective agent treatment adult form adhd positive response occur relatively low least individual however adderall may precipitate anxiety vulnerable individual study require,Horrigan JP,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0604,10901338,Horrigan JP; Barnhill LJ,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000367: Age Factors; D000553: Ambulatory Care; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D015897: Comorbidity; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D001523: Mental Disorders; D010865: Pilot Projects; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome",,,https://openalex.org/W1972107216,77,7,1,1646,282,12,en,en
false,electrocardiographic abnormality patient treat clozapine,article abstractbackground cardiovascular side effect ofclozapine uncommon systematic study theseeffects perform study review data onthe electrocardiographic ecg abnormality patient treatedwith clozapine method sixty one patient treat withclozapine select seoul national universityhospital treatment resistant schizophrenia clinic retrospective chart review conduct identify ecgabnormalities cardiovascular side effect result prevalence ecg abnormality inpatient use antipsychotic clozapinewas baseline increase significantly commencement clozapine treatment among patientswithout baseline ecg abnormality show new onset ecgabnormalities use clozapine normal ecg previousantipsychotic medication reduce risk new onset ecgabnormalities whereas increase age find increase therisk occurrence orthostatic hypotension tachycardiawas relate development ecg abnormality ofthe newly develop abnormality little clinicalsignificance tend occur initial phaseof treatment patient ecg normalize despite thecontinued use clozapine clozapine increase correct qtinterval qtc dose dependent fashion however clinicalsignificance observation uncertain pathologicprolongation qtc find rare conclusion although substantial portion ofpatients treat clozapine develop ecg abnormality mostof abnormality benign hinder furthertreatment,Kang UG,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0609,10901343,Kang UG; Kwon JS; Ahn YM; Chung SJ; Ha JH; Koo YJ; Kim YS,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D003024: Clozapine; D015897: Comorbidity; D004305: Dose-Response Relationship, Drug; D004562: Electrocardiography; D005260: Female; D006331: Heart Diseases; D006801: Humans; D007024: Hypotension, Orthostatic; D008297: Male; D008875: Middle Aged; D015995: Prevalence; D012044: Regression Analysis; D012189: Retrospective Studies; D012737: Sex Factors; D013610: Tachycardia",,,https://openalex.org/W2019575676,69,7,1,1695,244,13,en,en
false,small dose clonidine prolongs postoperative analgesia sciatic femoral nerve block ropivacaine foot surgery,evaluate effect add small dose clonidine ropivacaine peripheral nerve block asa physical status ii patient undergo hallux valgus repair combine sciatic femoral nerve block randomly allocate double blind fashion receive block placement ml either ropivacaine alone group ropivacaine n ropivacaine plus microg kg clonidine group ropivacaine clonidine n hemodynamic variable oxygen saturation level sedation well time require achieve surgical block time first analgesic request record blind observer time surgical blockade require min group patient ropivacaine clonidine group sedate patient ropivacaine group min block placement difference oxygen saturation hemodynamic variable degree pain measure first analgesic request consumption postoperative analgesic observe two group mean time block placement first request pain medication short group ropivacaine h th th percentile h group ropivacaine clonidine h th th percentile h p conclude add microg kg clonidine ropivacaine provide h delay first request pain medication hallux valgus repair clinically relevant side effect prospective randomize double blind study demonstrate provide combine sciatic femoral nerve block hallux valgus repair addition microg kg clonidine ropivacaine prolong duration postoperative analgesia h slight short live increase degree sedation hemodynamic adverse effect,Casati A,2000,Anesth Analg,https://doi.org/10.1097/00000539-200008000-00029,10910854,Casati A; Magistris L; Fanelli G; Beccaria P; Cappelleri G; Aldegheri G; Torri G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000577: Amides; D000700: Analgesics; D000779: Anesthetics, Local; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005267: Femoral Nerve; D006215: Hallux Valgus; D006801: Humans; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010149: Pain, Postoperative; D011446: Prospective Studies; D000077212: Ropivacaine; D012584: Sciatic Nerve",,,https://openalex.org/W1989064293,127,16,1,1857,315,8,en,en
false,risperidone treatment stutter,randomize double blind placebo control study conduct assess efficacy risperidone treatment developmental stuttering adult eight subject receive placebo eight receive risperidone mg daily night increase maximum mg day week treatment decrease measure stutter severity great risperidone group placebo group treatment difference significant p important measure percentage syllable stutter risperidone group reduction baseline score percentage syllable stutter time stutter percentage total time speak overall stuttering severity significant p change score fourth measure stutter duration significant significant decrease occur placebo group among eight patient risperidone group five respond best mg day stutter recur high remain three patient respond well increase risperidone risperidone generally well tolerate result small study indicate risperidone may effective treatment developmental stutter find need confirm large trial,Maguire GA,2000,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200008000-00013,10917410,Maguire GA; Riley GD; Franklin DL; Gottschalk LA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D018967: Risperidone; D013342: Stuttering,,,https://openalex.org/W2052152483,43,6,1,1359,231,10,en,en
false,double blind placebo control study risperidone addition serotonin reuptake inhibitor refractory obsessive compulsive disorder,date control study find drug haloperidol efficacious augment response patient obsessive compulsive disorder ocd refractory serotonin reuptake inhibitor sri monotherapy patient comorbid chronic tic disorder show preferential response report describe first control study risperidone addition patient ocd refractory treatment sri alone seventy adult patient primary dsm iv diagnosis ocd receive week treatment sri thirty six patient refractory sri randomize double blind manner week risperidone n placebo n addition behavioral rating include yale brown obsessive compulsive scale obtain baseline throughout trial placebo treat patient subsequently receive identical open label trial risperidone addition study completers risperidone treat patient responder mean daily dose mg compare placebo addition group p seven patient receive open label risperidone addition respond risperidone addition superior placebo reduce ocd p depressive p anxiety p symptom difference response ocd patient without comorbid diagnosis chronic tic disorder schizotypal personalty disorder mild transient sedation risperidone well tolerated result suggest ocd patient without comorbid chronic tic disorder schizotypal personality disorder may respond addition low dose risperidone ongoing sri therapy,McDougle CJ,2000,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.57.8.794,10920469,McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D015897: Comorbidity; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009771: Obsessive-Compulsive Disorder; D010919: Placebos; D018967: Risperidone; D012569: Schizotypal Personality Disorder; D012702: Serotonin Antagonists; D017367: Selective Serotonin Reuptake Inhibitors; D020323: Tics; D016896: Treatment Outcome",,,https://openalex.org/W2159990726,137,14,1,1725,298,10,en,en
false,olanzapine severe gilles de la tourette syndrome week double blind cross study vs low dose pimozide,select four patient severe gilles de la tourette syndrome high frequency tic two ten per minute vocalization lack comorbidity patient age year undergo week double blind cross study olanzapine mg daily v low dose pimozide mg daily reduction rating scale score syndrome highly significant mg olanzapine v basal v mg pimozide significant mg olanzapine v mg pimozide moderate sedation report one patient olanzapine treatment three complain minor motor side effect sedation pimozide treatment end study patient opt olanzapine treatment,Onofrj M,2000,J Neurol,https://doi.org/10.1007/s004150070173,10929273,Onofrj M; Paci C; D'Andreamatteo G; Toma L,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010868: Pimozide; D010890: Pirenzepine; D005879: Tourette Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W2084272802,114,17,1,749,138,5,en,en
false,treatment men major depression,report compare response cognitive behavioral therapy cbt pharmacotherapy sequential cohort men dsm iii r major depression patient enrol consecutive standardized week treatment protocol conduct research clinic first group n treat beck model cbt whereas second group n receive randomize open label treatment either fluoxetine n bupropion n crossover alternate medication permit week treatment antidepressant nonresponders patient group well match prior treatment outcome include remission nonresponse rate well independent clinical evaluation self report measure depressive symptom despite limit statistical power detect difference treatment depress men treat pharmacotherapy significantly great improvement continuous dependent measure significantly low rate nonresponse e v difference favor pharmacotherapy late emerge partially explain cross nonresponders alternate medication advantage pharmacotherapy cbt also tend large among subgroup patient chronic depression result prior research compare pharmacotherapy cbt may influence composition study group particularly gender composition choice antidepressant comparators interaction factor prospective study utilize flexible dose modern antidepressant necessary sequential trial dissimilar medication need confirm find,Thase ME,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0702,10937603,Thase ME; Friedman ES; Fasiczka AL; Berman SR; Frank E; Nofzinger EA; Reynolds CF,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000928: Antidepressive Agents; D016642: Bupropion; D015928: Cognitive Behavioral Therapy; D003866: Depressive Disorder; D005473: Fluoxetine; D006801: Humans; D008297: Male; D017286: Polysomnography; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W1976935772,38,6,1,1721,269,8,en,en
false,comparative efficacy risperidone clozapine treatment patient refractory schizophrenia schizoaffective disorder,clozapine effective patient refractory schizophrenia whereas efficacy risperidone remain unknown retrospective study examine relative efficacy drug chronically institutionalized patient refractory conventional antipsychotic agent total patient different time period receive adequate trial clozapine risperidone meet inclusion criterion minimum dose duration trial include clozapine minimum dose mg day maintain least week risperidone minimum dose mg day least week information obtain systematic retrospective chart review blindly rat psychiatrist use point clinical global impression improvement cgi scale overall clinical state along specific symptom domain positive symptom negative symptom aggressive behavior mean sd dose mg day clozapine mg day risperidone fourteen patient classify responder clozapine respond risperidone cgi score specific symptom domain response rate clozapine positive symptom negative symptom aggressive behavior risperidone response rate positive symptom negative symptom aggressive behavior result study support utility first give risperidone trial treatment algorithm refractory patient good risk benefit profile compare clozapine clozapine however remain gold standard management patient,Sharif ZA,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n0707,10937608,Sharif ZA; Raza A; Ratakonda SS,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000374: Aggression; D003024: Clozapine; D004334: Drug Administration Schedule; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012189: Retrospective Studies; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2087408262,136,17,1,1770,314,6,en,en
false,pr medikation im rahmen einer tiva bei kieferchirurgischen operationen vergleich der perioperativen verl ufe nach clonidin versus midazolam,effect currently favour preanaesthetic drug benzodiazepine alpha adrenoceptor agonist perioperative course inadequately investigate new way perform anaesthesia recently introduce drug e g remifentanil therefore clonidine midazolam use premedication maxillo facial surgery total intravenous anesthesia perioperative course analyze thirty patient asa include present doubleblinded prospective study minute preoperatively patient get oral premedication microgram kg clonidine microgram kg midazolam anaesthesia standardized procedure propofol remifentanil rocuronium perform induction anaesthesia infusion remifentanil regulate use spectral edge frequency target sef hz efficiency premedication well emergence recovery assess use establish standardized test perioperative stress response assess record effect haemodynamic parameter nibp heart rate holter ecg refer effect premedication sedation anxiety difference group clonidine group require low remifentanil rate keep steady target sef time emergence recovery significantly different even occurrence ponv va postoperative analgetic requirement differ two group however incidence postoperative shiver significantly high midazolam group intraoperatively value map quite equal group however heart rate significantly low clonidine group postoperatively map well heart rate low clonidine group furthermore midazolam group significantly higher cumulative duration tachycardia heart rate min follow descripted medium percentage clonidine sec midazolam sec remifentanil supplement anesthesia especially postoperative period benefit use clonidine compare premedication midazolam,Frank T,2000,Anasthesiol Intensivmed Notfallmed Schmerzther,https://doi.org/10.1055/s-2000-5946,10949680,Frank T; Thieme V; Radow L,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000771: Anesthesia, Intravenous; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008874: Midazolam; D019647: Oral Surgical Procedures; D010149: Pain, Postoperative; D020250: Postoperative Nausea and Vomiting; D011229: Preanesthetic Medication; D011446: Prospective Studies",,,https://openalex.org/W1993412546,141,17,1,2266,364,20,de,en
false,amphetamine abuse pregnancy environmental factor outcome year,aim study assess influence social environmental factor school performance behavioural problem among year old child expose amphetamine foetal life study group comprise cohort child suffer intrauterine exposure amphetamine due maternal drug abuse group follow since birth examine regular interval information regard academic performance child gather school authority psychosocial environment child determine interview information obtain social authority child attend school within state school system year behind age mean grade significantly low classmate behavioural problem mention social authority documentation one third child regardless whether child place foster home reside biological mother positive significant correlation find maternal age outcome child well therapy pregnancy outcome whilst several environmental factor particularly child first four year correlate negatively outcome psychosocial factor early life influence outcome year positive effect intervention pregnancy illustrate importance early identification preferable pregnancy,Eriksson M,2000,Scand J Public Health,https://doi.org/10.1177/140349480002800212,10954143,Eriksson M; Jonsson B; Steneroth G; Zetterström R,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000661: Amphetamine; D002648: Child; D002653: Child Behavior Disorders; D015331: Cohort Studies; D002658: Developmental Disabilities; D005260: Female; D005500: Follow-Up Studies; D005581: Foster Home Care; D006801: Humans; D007231: Infant, Newborn; D008297: Male; D008431: Maternal-Fetal Exchange; D009357: Neonatal Abstinence Syndrome; D011247: Pregnancy; D012574: Schools; D012940: Social Problems; D012947: Social Work; D013548: Sweden",,,https://openalex.org/W1977255624,87,12,1,1542,249,11,en,en
false,new long act methylphenidate concerta,,,2000,Med Lett Drugs Ther,,10980811,,article,D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002986: Clinical Trials as Topic; D003692: Delayed-Action Preparations; D003913: Dextroamphetamine; D005252: Fees, Pharmaceutical; D006207: Half-Life; D006801: Humans; D008774: Methylphenidate; D013997: Time Factors",,,,45,8,1,0,0,0,en,
false,centrally act antihypertensive drug emergence sympathetic inhibition treatment hypertension,central regulation sympathetic nervous system play important role maintenance blood pressure subset patient essential hypertension sympathetic activation may contribute development maintenance hypertension unlike first generation centrally active antihypertensive drug second generation may superior selectivity imidazoline receptor selective binding vasomotor center lack effect differentiate moxonidine clonidine respect monoxidine superior side effect profile little sedation dry mouth clinical trial show moxonidine effective angiotensin convert enzyme inhibitor eg enalapril captopril b blocker e g atenolol calcium channel blocker e g long act nifedipine diuretic eg hydrochlorothiazide low blood pressure superior tolerability thus central modulation sympathetic nervous system emerge excite target blood pressure reduction give multiple adverse effect sympathetic stimulation various disease process include congestive heart failure moxonidine may next therapeutic option management hypertension prevention target organ dysfunction,Benedict CR,1999,Curr Hypertens Rep,https://doi.org/10.1007/s11906-999-0038-1,10981082,Benedict CR,article,D016428: Journal Article; D016454: Review,D000818: Animals; D000959: Antihypertensive Agents; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D016032: Randomized Controlled Trials as Topic; D013564: Sympathetic Nervous System; D016896: Treatment Outcome,,,https://openalex.org/W1964044084,112,14,1,1327,209,7,en,en
false,efficacy olanzapine acute bipolar mania subtitle double blind placebo control study subtitle,compare efficacy safety olanzapine v placebo treatment acute bipolar mania four week randomize double blind parallel study total patient dsm iv diagnosis bipolar disorder manic mixed randomize olanzapine mg n placebo n primary efficacy measure young mania rating scale mrs total score response euthymia define priori least improvement baseline end point score less end point mr total score respectively safety assess use adverse event extrapyramidal symptom eps rating scale laboratory value electrocardiogram vital sign weight change olanzapine treat patient demonstrate statistically significant great mean sd improvement mr total score placebo treat patient respectively p evident first postbaseline observation week randomization maintain throughout study last observation carry forward olanzapine treat patient demonstrate high rate response v respectively p euthymia v respectively p placebo treat patient statistically significant difference epss group however olanzapine treat patient statistically significant great mean sd weight gain placebo treat patient v kg respectively also experience treatment emergent somnolence patient v respectively olanzapine demonstrate great efficacy placebo treatment acute bipolar mania generally well tolerate,Tohen M,2000,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.57.9.841,10986547,Tohen M; Jacobs TG; Grundy SL; McElroy SL; Banov MC; Janicak PG; Sanger T; Risser R; Zhang F; Toma V; Francis J; Tollefson GD; Breier A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D012893: Sleep Wake Disorders; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2135399947,118,26,1,1785,330,9,en,en
false,mazindol treatment negative symptom,hypodopaminergic hyponoradrenergic pathophysiology may basis primary secondary negative symptom schizophrenia hypothesis enhance neurotransmission system would therapeutic negative symptom test compare mazindol placebo double blind cross design trial outcome follow mazindol supplementation comparable placebo supplementation f p result deficit non deficit schizophrenia subject similar affect whether concurrent antipsychotic drug treatment clozapine fluphenazine haloperidol efficacy hypothesis support either primary secondary negative symptom,Carpenter WT,2000,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(00)00115-9,10989263,Carpenter WT; Breier A; Buchanan RW; Kirkpatrick B; Shepard P; Weiner E,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000704: Analysis of Variance; D018592: Cross-Over Studies; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008454: Mazindol; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012044: Regression Analysis; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W2057274111,39,5,1,729,111,5,en,en
false,optimal dose intrathecal clonidine add sufentanil plus bupivacaine labour analgesia,purpose combination intrathecal g sufentanil plus mg bupivacaine useful induce labour analgesia albeit short duration slow onset supplementation regimen effect clonidine duration analgesic action investigate method forty eight healthy parturients randomly assign three group receive g group c g c g c clonidine addition g sufentanil plus mg bupivacaine labour analgesia quality pain relief assess visual analogue scale author occurrence side effect also evaluate request additional analgesia result clonidine c c produce long duration analgesia c mean sd v min p also c c produce rapid onset high quality analgesia c p cephalad level sensory block high c c median v p low c median v p side effect sedation hypotension occur frequently c either c c v v respectively p conclusion optimal dose intrathecal clonidine enhance labour analgesia current sufentanil bupivacaine regimen g view side effect profile dose great g clonidine unlikely useful,Sia AT,2000,Can J Anaesth,https://doi.org/10.1007/bf03019667,10989857,Sia AT,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D016362: Analgesia, Obstetrical; D000701: Analgesics, Opioid; D000779: Anesthetics, Local; D001794: Blood Pressure; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D010147: Pain Measurement; D011247: Pregnancy; D017409: Sufentanil",,,https://openalex.org/W2165966939,95,13,1,1451,298,11,fr,en
false,low dose olanzapine levodopa induce dyskinesia,assess usefulness low dose olanzapine mg day levodopa induced dyskinesia lid patient pd ten patient pd lid take part randomize placebo control double blind crossover trial patient receive week course olanzapine placebo treatment phase week washout dyskinesia assess baseline treatment period acute dopaminergic challenge unify pd rating scale updrs questionnaire patient also keep dyskinesia diary last day prior assessment difference dyskinesia reduction olanzapine compare placebo measure objective dyskinesia rating scale mean percentage reduction abnormal involuntary movement score versus p similar difference demonstrate patient diary mean reduction versus p updrs item compare placebo treatment olanzapine result significant increase time measure patient diary versus report adverse event versus include increase parkinsonism versus nonsignificant report increase drowsiness low dose olanzapine effective reduce dyskinesia pd even low result unacceptable increase parkinsonism time,Manson AJ,2000,Neurology,https://doi.org/10.1212/wnl.55.6.795,10993998,Manson AJ; Schrag A; Lees AJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001569: Benzodiazepines; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D007980: Levodopa; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine",,,https://openalex.org/W2084188456,52,6,1,1414,250,7,en,en
false,bipolar disorder therapeutic maintenance treatment,although care receive bipolar patient occur maintenance phase relatively little empirical data available guide long term treatment decision review literature pertain key question relate use pharmacotherapy maintenance phase bipolar disorder double blind trial reasonable sample size restrict bipolar patient address modest range question mostly relate use lithium one rigorous multicenter trial find valproate prophylactic benefit study valproate alone combination suggest efficacy equivalent lithium perhaps great carbamazepine data available combination treatment sparse moderately encouraging maintenance treatment standard antidepressant medication appear destabilize bipolar patient particularly follow mixed episode although bipolar patient may benefit combine treatment mood stabilizer standard antidepressant medication current knowledge allow confident selection bipolar patient might benefit clozapine perhaps atypical antipsychotic promise option maintenance treatment evaluate double blind trial numerous agent use maintenance treatment primarily adjunct lithium valproate carbamazepine information largely anecdotal uncontrolled study design maintenance trial remain imperfect art conclusion must draw cautiously give limited generalizability study design accession sample enrich presume treatment responder randomize patient brief period partial remission abruptly taper prior treatment make attempt distinguish relapse recurrence use formal outcome assessment report hospitalization outcome criterion,Sachs GS,2000,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(00)00991-4,11018228,Sachs GS; Thase ME,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000928: Antidepressive Agents; D018692: Antimanic Agents; D001714: Bipolar Disorder; D000075202: Contraindications; D019468: Disease Management; D004359: Drug Therapy, Combination; D006801: Humans; D008094: Lithium; D018579: Patient Selection; D017410: Practice Guidelines as Topic; D016032: Randomized Controlled Trials as Topic; D013974: Thyroxine",,,https://openalex.org/W1970891546,52,6,1,1944,290,12,en,en
false,oral clonidine premedication change efficacy simulate epidural test dose sevoflurane anesthetize child,caudal epidural anesthesia often use adjunct general anesthesia postoperative pain relief child anesthetize child epinephrine isoproterenol reliable indicator detect accidental intravascular injection test dose oral clonidine useful premedicant pediatric anesthesia modifies hemodynamic response sympathomimetics include catecholamine aim current study determine whether oral clonidine premedication alter efficacy simulate intravascular test dose contain epinephrine isoproterenol sevoflurane anesthetize child one hundred twenty child age yr randomly divide six group control saline control epinephrine control isoproterenol clonidine saline clonidine epinephrine clonidine isoproterenol three clonidine group receive oral clonidine microg kg dosage error correct premedication whereas three control group receive premedication anesthesia maintain sevoflurane level minimum alveolar concentration hemodynamics stable ml kg lidocaine contain epinephrine mg kg isoproterenol ng kg intravenously give two epinephrine isoproterenol group respectively simulate intravascular injection test dose saline group receive saline alone instead test dose heart rate blood pressure wave amplitude electrocardiogram record administration study drug subsequent analysis test solution contain epinephrine increase heart rate systolic blood pressure wave amplitude oral clonidine effect elevation variable response epinephrine isoproterenol contain test dose produce prominent increase heart rate less pronounced increase systolic blood pressure wave amplitude oral clonidine also fail modify isoproterenol induce hemodynamic wave change calculate sensitivity specificity epinephrine isoproterenol base new heart rate criterion positive beat min unaltered oral clonidine premedication epinephrine isoproterenol reliable marker detect accidental intravascular injection test dose sensitivity specificity base new heart rate criterion sevoflurane anesthetize child data suggest oral clonidine premedication alter efficacy simulate epidural test dose contain epinephrine isoproterenol,Shiga M,2000,Anesthesiology,https://doi.org/10.1097/00000542-200010000-00013,11020745,Shiga M; Nishina K; Mikawa K; Uesugi T; Maekawa N; Obara H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000322: Adrenergic Agonists; D000316: Adrenergic alpha-Agonists; D000318: Adrenergic beta-Agonists; D000700: Analgesics; D000767: Anesthesia, Epidural; D000769: Anesthesia, Inhalation; D018685: Anesthetics, Inhalation; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004347: Drug Interactions; D004562: Electrocardiography; D004837: Epinephrine; D006339: Heart Rate; D006801: Humans; D007223: Infant; D007275: Injections, Intravenous; D007545: Isoproterenol; D008738: Methyl Ethers; D011229: Preanesthetic Medication; D012680: Sensitivity and Specificity; D000077149: Sevoflurane",,,https://openalex.org/W2033450140,122,15,1,2607,389,14,en,en
false,preoperative clonidine attenuate stress response emergence anesthesia,investigate whether single preoperative iv dose clonidine blunts hemodynamic hyperadrenergic response intubation also extubation randomize double blind placebo control study asa physical status ii patient age schedule noncardiac elective surgery patient randomly assign either receive clonidine microg kg iv immediately anesthesia induction placebo insertion g cannula large cubital vein determination plasma catecholamine use local anesthesia insertion radial artery catheter measure blood pressure bp use local anesthesia transthoracic echocardiography determine cardiac output co heart rate hr mean arterial pressure map co plasma catecholamine concentration measurement perform induction baseline intubation min intubation surgery extubation min extubation intubation map hr co low clonidine group compare baseline measurement map co increase less clonidine group intubation extubation map low clonidine group co map increase less compare baseline measurement clonidine group compare measurement surgery co less clonidine group extubation p result single preoperative iv dose clonidine microg kg blunt hemodynamic response due extubation noncardiac surgery intermediate duration,Zalunardo MP,2000,J Clin Anesth,https://doi.org/10.1016/s0952-8180(00)00167-7,11025232,Zalunardo MP; Zollinger A; Spahn DR; Seifert B; Pasch T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000769: Anesthesia, Inhalation; D001794: Blood Pressure; D002302: Cardiac Output; D002395: Catecholamines; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007442: Intubation, Intratracheal; D008297: Male; D008875: Middle Aged; D011229: Preanesthetic Medication; D013312: Stress, Physiological; D013564: Sympathetic Nervous System",,,https://openalex.org/W2049481213,82,9,1,1585,266,9,en,en
false,low dose intrathecal clonidine combine sufentanil analgesic drug abdominal gynecological surgery,determine whether low dose spinal clonidine either alone combine sufentanil would provide effective analgesia follow abdominal surgery supplement bupivacaine spinal anesthesia randomize double blind study gynecological surgery teach hospital asa physical status ii patient undergo gynecological abdominal surgery spinal anesthesia patient randomly assign one four group prospectively study examine anesthesia analgesia adverse effect control group receive saline test drug sufentanil group receive microg sufentanil clonidine group receive microg clonidine sufentanil clonidine group receive microg sufentanil plus microg clonidine group receive intrathecal mg bupivacaine ml plus intrathecal test drug ml concept visual analog scale va introduce patient premedicated intravenous midazolam rescue analgesic available group demographically sensory block pinprick min high clonidine sufentanil clonidine group compare control group p anesthetic time bromage score also long clonidine sufentanil clonidine group compare control sufentanil group p time first rescue analgesic short control group compare group p number im diclofenac dose injection hour high control group compare group p incidence adverse effect ephedrine consumption similar among group intrathecal microg clonidine dos expand anesthesia sensory block duration motor block provide analgesia,Julião MC,2000,J Clin Anesth,https://doi.org/10.1016/s0952-8180(00)00171-9,11025234,Julião MC; Lauretti GR,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000700: Analgesics; D000701: Analgesics, Opioid; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D013509: Gynecologic Surgical Procedures; D006801: Humans; D007278: Injections, Spinal; D010147: Pain Measurement; D010149: Pain, Postoperative; D020250: Postoperative Nausea and Vomiting; D011446: Prospective Studies; D017409: Sufentanil",,,https://openalex.org/W2083445031,109,13,1,1809,300,11,en,en
false,dose proportional stereospecific pharmacokinetics methylphenidate deliver use osmotic control release oral delivery system,methylphenidate hydrochloride hcl frequently use treatment attention deficit hyperactivity disorder adhd study conduct healthy subject evaluate dose range pharmacokinetics mg methylphenidate hcl deliver use oral osmotic control release formulation oros plasma concentration l methylphenidate fold low methylphenidate whereas plasma concentration phenyl piperidine acetic acid ppa l ppa major metabolite methylphenidate comparable mean auc inf value methylphenidate ng h ml mg respectively increase dose proportionally auc inf value l methylphenidate methylphenidate ng h ml mg dose group respectively contrast auc inf value l ppa comparable dose normalize l methylphenidate plasma concentration time profile three treatment group superimposable similarly dose normalized plasma concentration l ppa superimposable methylphenidate metabolism measure ratio methylphenidate auc inf ppa auc inf l methylphenidate auc inf l ppa auc inf similar three dose group indicate methylphenidate metabolism affect increase dose oros methylphenidate hcl exhibit dose proportional linear pharmacokinetics,Modi NB,2000,J Clin Pharmacol,https://doi.org/10.1177/009127000004001008,11028253,Modi NB; Wang B; Noveck RJ; Gupta SK,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008968: Molecular Conformation; D009995: Osmosis; D012737: Sex Factors",,,https://openalex.org/W2099530687,140,15,1,1525,264,10,en,en
false,neurologic side effect neuroleptic nai patient treat haloperidol risperidone,,Meibach RC,2000,Neurology,https://doi.org/10.1212/wnl.55.7.1069,11061283,Meibach RC,article,D016420: Comment; D016422: Letter,D014150: Antipsychotic Agents; D006220: Haloperidol; D006801: Humans; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W4240032338,94,11,1,0,0,0,en,
false,low dose oral clonidine premedication intraocular surgery retrobulbar anesthesia,purposewe investigate whether low dose oral clonidine premedication elective intraocular surgery retrobulbar anesthesia effective term anxiolysis sedation stable hemodynamics low intraocular pressure perioperative endocrine stress response methodsin prospective randomise double blind study patient schedule elective intraocular surgery receive either mg clonidine n match placebo n orally minute retrobulbar anesthesia main study parameter sedation anxiolysis hemodynamics intraocular pressure additionally mediator endocrine stress response measure five time patient clonidine placebo resultsafter clonidine patient show sedation placebo show sedation p clonidine produce effective anxiolysis erlanger anxiety scale point vs point operation p systolic blood pressure significantly low clonidine effect mean diastolic blood pressure small statistically significant norepinephrine cortisole plasma concentration significantly low clonidine intraocular pressure significantly low p clinically relevant adverse effect observe e g inappropriate sedation hypotension mmhg bradycardia bpm hypoxemia spo conclusionsoral low dose clonidine produce light sedation significant anxiolysis stable hemodynamics attenuate endocrine response perioperative stress thus clonidine seem sufficient increase patient comfort intraocular surgery might even offer clinically worthwhile benefit stable hemodynamics reduce response perioperative stress,Weindler J,2000,Eur J Ophthalmol,https://doi.org/10.1177/112067210001000310,11071034,Weindler J; Kiefer RT; Rippa A; Wiech K; Ruprecht KW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D000700: Analgesics; D000772: Anesthesia, Local; D000779: Anesthetics, Local; D002387: Cataract Extraction; D003000: Clonidine; D016292: Conscious Sedation; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D009915: Orbit; D011292: Premedication; D011446: Prospective Studies; D013732: Test Anxiety Scale",,,https://openalex.org/W2198259144,93,11,1,1813,284,10,en,en
false,augmentation sulpiride schizophrenic patient partially responsiveto clozapine,schizophrenic patient partially responsive clozapine pose therapeutic challenge circumstance clinician would consider add second antipsychotic present case report review evidence efficacy augmentation strategy single case report literature review total number patient study case report combine clozapine antipsychotic small one randomize control trial find addition sulpiride clozapine result clinical improvement patient randomize control study augmentation clozapine therapy need provide scientific justification clinical practice,Stubbs JH,2000,Acta Psychiatr Scand,https://doi.org/10.1034/j.1600-0447.2000.102005390.x,11098812,Stubbs JH; Haw CM; Staley CJ; Mountjoy CQ,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D014150: Antipsychotic Agents; D003024: Clozapine; D004359: Drug Therapy, Combination; D006801: Humans; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D012563: Schizophrenia, Paranoid; D013469: Sulpiride; D016896: Treatment Outcome",,,https://openalex.org/W2052196529,88,10,1,741,108,5,en,en
false,randomise fellow eye comparison effectiveness dorzolamide apraclonidine intraocular pressure follow phacoemulsification cataract surgery,compare effectiveness dorzolamide apraclonidine intraocular pressure iop follow phacoemulsification cataract surgery prospective randomise study comprise eye consecutive patient age relate cataract schedule cataract surgery eye patient eye high degree cataract randomly assign receive one drop either dorzolamide apraclonidine immediately surgery fellow eye operate later receive treatment cataract surgery perform superior mm sutureless frown incision phacoemulsification implantation three piece pmma intraocular lens iop measure pre operatively well h h week post operatively mean pre operative iop significantly different group dorzolamide group mmhg apraclonidine group mmhg p h post operatively mean iop significantly low dorzolamide apraclonidine group mmhg v mmhg p iop increase mmhg h post operatively occur eye dorzolamide group eye apraclonidine group p h post operatively week post operatively difference find group dorzolamide effective apraclonidine prevent early post operative iop increase follow phacoemulsification cataract surgery,Rainer G,2000,Eye (Lond),https://doi.org/10.1038/eye.2000.198,11116699,Rainer G; Menapace R; Findl O; Georgopoulos M; Kiss B; Heinze G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D002257: Carbonic Anhydrase Inhibitors; D003000: Clonidine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D018918: Phacoemulsification; D011446: Prospective Studies; D013449: Sulfonamides; D013876: Thiophenes",,,https://openalex.org/W2049724887,157,18,1,1549,270,8,en,en
false,risperidone versus haloperidol psychotic patient disturb neuroleptic induce extrapyramidal symptom double blind multi center trial,randomize double blind multi center trial start compare severity extrapyramidal symptom eps risperidone haloperidol treatment schizophrenic patient disturb eps previous neuroleptic treatment additional objective trial compare antipsychotic effectiveness two treatment use antiparkinsonian medication effect flexible risperidone haloperidol compare psychotic patient chronic schizophrenia disturb neuroleptic induced eps risperidone patient haloperidol trial complete patient risperidone group woman men haloperidol group woman men adequate antipsychotic effect obtain patient treatment primary aim trial compare parkinsonism measure extrapyramidal syndrome rating scale esr treatment risperidone haloperidol two primary parameter select change baseline bad score treatment esr ii parkinsonism esr vi clinical global impression severity parkinsonism cgi severity parkinsonism well risperidone p parkinsonism total score tend good risperidone p double blind treatment use antiparkinson medication risperidone haloperidol double blind treatment phase patient use antiparkinson medication risperidone haloperidol large reduction parkinsonism risperidone group due difference use anti parkinsonian medication group schizophrenic patient disturb eps previous neuroleptic treatment strong reduction parkinsonism observe risperidone haloperidol,Heck AH,2000,Schizophr Res,https://doi.org/10.1016/s0920-9964(00)00009-8,11120421,Heck AH; Haffmans PM; de Groot IW; Hoencamp E,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D010054: Brief Psychiatric Rating Scale; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012720: Severity of Illness Index",,,https://openalex.org/W2105805259,148,17,1,1920,321,10,en,en
false,depression child adolescent,depression among child adolescent common frequently unrecognized affect percent prepubertal child percent adolescent clinical spectrum disease range simple sadness major depressive bipolar disorder risk factor include family history depression poor school performance evaluation include complete medical assessment rule underlie medical cause structure clinical interview various rating scale pediatric symptom checklist helpful determine whether child adolescent depress evidence base treatment guideline literature limit psychotherapy appear useful child adolescent mild moderate depression tricyclic antidepressant selective serotonin reuptake inhibitor medical therapy study limit basis latter agent well tolerate necessarily efficacious risk school failure suicide quite high depressed child adolescent prompt referral close collaboration mental health professional often necessary,Son SE,2000,Am Fam Physician,https://doi.org/10.1037/e558732011-001,11126856,Son SE; Kirchner JT,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000293: Adolescent; D000928: Antidepressive Agents; D000929: Antidepressive Agents, Tricyclic; D002648: Child; D003863: Depression; D003866: Depressive Disorder; D003937: Diagnosis, Differential; D005260: Female; D006801: Humans; D008297: Male; D010353: Patient Education as Topic; D000297: Psychology, Adolescent; D002666: Psychology, Child; D012017: Referral and Consultation; D012307: Risk Factors; D017367: Selective Serotonin Reuptake Inhibitors; D013664: Teaching Materials",,,https://openalex.org/W1537019936,38,5,1,1191,185,11,en,en
false,effect steady state bupropion pharmacokinetics lamotrigine healthy subject,study objective evaluate effect steady state bupropion sr sustain release bup pharmacokinetics single mg dose lamotrigine ltg design randomize open label two way crossover study set clinical study ltd fort lauderdale florida patient twelve healthy subject intervention treatment ltg mg steady state bup mg twice day treatment b ltg mg measurement main result pharmacokinetics ltg determine noncompartmental method use plasma urine concentration geometric least square mean ratio confidence interval calculate treatment comparison safety assessment include clinical laboratory test vital sign adverse event monitoring pharmacokinetic parameter ltg significantly different treatment five subject experience seven mild potentially drug related adverse event insomnia nausea headache facial pain fatigue depression resolve spontaneously conclusion steady state bup cause clinically relevant change pharmacokinetics single dose ltg,Odishaw J,2000,Pharmacotherapy,https://doi.org/10.1592/phco.20.19.1448.34866,11130217,Odishaw J; Chen C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000927: Anticonvulsants; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D004347: Drug Interactions; D005260: Female; D006801: Humans; D000077213: Lamotrigine; D008297: Male; D008875: Middle Aged; D014227: Triazines",,,https://openalex.org/W1996854327,92,12,1,1153,194,17,en,en
false,comparison oral clonidine oral midazolam preanesthetic medication pediatric tonsillectomy patient,compare effect oral clonidine microg kg midazolam mg kg preanesthetic sedation postoperative recovery profile child tonsillectomy without adenoidectomy double blind double dummy study design asa physical status ii child age yr randomize receive combination either clonidine placebo group placebo midazolam group b min min respectively induction anesthesia child clonidine group exhibit intense anxiety separation induction anesthesia via mask measure modify yale preoperative anxiety score also significantly low mean intraoperative arterial blood pressure short surgery anesthesia emergence time decrease need supplemental oxygen recovery compare midazolam group however clonidine group large postoperative opioid requirement maximum excitement pain score base child hospital eastern ontario scale phase postanesthetic care unit difference two group time discharge readiness postoperative emesis unanticipated hospital admission rate postdischarge maximum pain score h analgesic requirement percentage parent completely satisfy child preoperative experience significantly high midazolam group difference parental satisfaction recovery period conclude condition study oral midazolam superior oral clonidine preanesthetic medication patient population compare preanesthetic sedation postoperative recovery oral clonidine microg kg midazolam mg kg child tonsillectomy clonidine group great preoperative anxiety short surgery anesthesia time require postoperative analgesia delay recovery discharge time differ midazolam superior clonidine oral preanesthetic medication patient,Fazi L,2001,Anesth Analg,https://doi.org/10.1097/00000539-200101000-00011,11133600,Fazi L; Jantzen EC; Rose JB; Kurth CD; Watcha MF,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000233: Adenoidectomy; D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D014151: Anti-Anxiety Agents; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006993: Hypnotics and Sedatives; D008297: Male; D008874: Midazolam; D010149: Pain, Postoperative; D010919: Placebos; D011229: Preanesthetic Medication; D014068: Tonsillectomy",,,https://openalex.org/W2098191930,117,16,1,2154,347,12,en,en
false,clonidine combine long act local anesthetic prolong postoperative analgesia brachial plexus block induce hemodynamic change,clonidine brachial plexus block prolongs analgesia local anesthetic short intermediate duration perform prospective randomize double blind study determine efficacy adverse effect clonidine mix long act local anesthetic postoperative analgesia sixty adult patient underwent elective rotator cuff repair use interscalene brachial plexus block combine general anesthesia randomly divide one follow three group placebo n interscalene block ml bupivacaine epinephrine ml saline complete ml saline im controlateral shoulder control n interscalene block ml bupivacaine epinephrine ml saline complete microg ml clonidine im clonidine n interscalene block ml bupivacaine epinephrine microg ml clonidine complete ml saline im anesthesia hemodynamic variable fractional expire isoflurane concentration feiso record follow postoperative variable assess duration interscalene block quality pain relief visual analog scale side effect consumption morphine patient control analgesia device h patient characteristic comparable anesthesia mean arterial pressure heart rate feiso significantly decrease clonidine control group compare placebo group duration analgesia define time elapse interscalene injection first morphine request min placebo min control min clonidine group pain score consumption morphine h h show difference among three group conclude add microg clonidine interscalene block prolong analgesia induce ml bupivacaine epinephrine decrease mean arterial blood pressure heart rate clonidine brachial plexus block improve postoperative analgesia mixed long lasting anesthetic nevertheless without clonidine bupivacaine interscalene block provide long lasting analgesia approximately h,Culebras X,2001,Anesth Analg,https://doi.org/10.1097/00000539-200101000-00038,11133627,Culebras X; Van Gessel E; Hoffmeyer P; Gamulin Z,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000700: Analgesics; D000769: Anesthesia, Inhalation; D018685: Anesthetics, Inhalation; D000779: Anesthetics, Local; D001794: Blood Pressure; D001917: Brachial Plexus; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D004357: Drug Synergism; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D007530: Isoflurane; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010919: Placebos; D011446: Prospective Studies",,,https://openalex.org/W1990570354,159,22,1,2330,409,12,en,en
false,comparison meperidine clonidine urapidil treatment postanesthetic shivering,postanesthetic shiver treat many type drug compare effect meperidine clonidine urapidil postanesthetic shiver sixty patient shiver recovery general anesthesia treat randomize double blind fashion mg meperidine iv mg clonidine iv mg urapidil iv three separate group patient shiver stop within min treatment repeat clonidine replace saline second dose rectal temperature arterial blood pressure heart rate sao vigilance monitor clonidine stop shiver patient single dose meperidine stop shiver patient patient need second dose urapidil less effective first dose stop shiver six patient second dose effective another six drug ineffective patient meperidine clonidine nearly effective treat postanesthetic shivering without negative side effect comparison urapidil effective patient treat p implication patient shiver recovery general anesthesia treat randomize double blind fashion meperidine clonidine urapidil meperidine clonidine effective whereas urapidil effective patient treat,Schwarzkopf KR,2001,Anesth Analg,https://doi.org/10.1097/00000539-200101000-00051,11133640,Schwarzkopf KR; Hoff H; Hartmann M; Fritz HG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000317: Adrenergic alpha-Antagonists; D000328: Adult; D000701: Analgesics, Opioid; D000762: Anesthesia Recovery Period; D000768: Anesthesia, General; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008614: Meperidine; D010100: Oxygen; D010879: Piperazines; D012768: Shivering",,,https://openalex.org/W2092790708,100,14,1,1446,255,12,en,en
false,novel augmentation strategy treat resistant major depression,objective treatment resistant depression significant public health concern drug switch augmentation often produce limited result author hypothesize fluoxetine could augment olanzapine successfully treat resistant depression method week double blind study conduct patient diagnose recurrent nonbipolar treatment resistant depression without psychotic feature subject randomly assign one three group olanzapine plus placebo fluoxetine plus placebo olanzapine plus fluoxetine result fluoxetine monotherapy produce minimal improvement various scale rate severity depression benefit olanzapine monotherapy modest olanzapine plus fluoxetine produce significantly great improvement either monotherapy one measure significantly great improvement olanzapine monotherapy measure week significant difference treatment group extrapyramidal measure significant adverse drug interaction conclusion olanzapine plus fluoxetine demonstrate superior efficacy treat resistant depression compare either agent alone,Shelton RC,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.1.131,11136647,Shelton RC; Tollefson GD; Tohen M; Stahl S; Gannon KS; Jacobs TG; Buras WR; Bymaster FP; Zhang W; Spencer KA; Feldman PD; Meltzer HY,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000553: Ambulatory Care; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D003866: Depressive Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005473: Fluoxetine; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D017367: Selective Serotonin Reuptake Inhibitors; D016896: Treatment Outcome",,,https://openalex.org/W2114693958,69,9,1,1220,171,9,en,en
false,manage adhd general practice n trial help,pilot single patient trial design improve decision make stimulant use attention deficit hyperactivity disorder adhd general practice patient previously stabilise dexamphetamine enrol general practice undertook six week patient randomise double blind placebo control crossover comparison dexamphetamine placebo adhd rating scale complete weekly self parent teacher three four patient clear responder dexamphetamine include noncompleter result still demonstrate clear response result clinically useful case management confirm three patient change one cease dexamphetamine prescribe stimulant medication child diagnose adhd find respond limit use worrisome drug respond minimises use benefit,Duggan CM,2000,Aust Fam Physician,,11140235,Duggan CM; Mitchell G; Nikles CJ; Glasziou PP; Del Mar CB; Clavarino A,article,"D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005194: Family Practice; D006801: Humans; D008297: Male,,,https://openalex.org/W1527279017,58,13,2,963,156,5,en,en
false,impact risperidone seclusion restraint state psychiatric hospital,evaluate impact risperidone seclusion restraint patient state psychiatric facility shortly risperidone release patient hospital least month prior receive risperidone subsequently receive risperidone least month form cohort mirror image design use duration maximum year year initiation risperidone hospital population receive either risperidone clozapine time period use comparison trend seclusion restraint seventy four patient schizophrenia meet inclusion criterion risperidone group statistically significant decrease number seclusion hour sd sd event sd sd per person per month risperidone treatment compare prerisperidone treatment period p comparison group also evidence decrease measure time period risperidone treat cohort achieve proportionally great reduction similar trend toward reduction restraint measure risperidone treatment compare prerisperidone achieve statistical significance comparison group also show slightly decrease use restraint study period risperidone appear positive impact seclusion state hospital psychiatric population data support positive impact risperidone violence find study violence aggression major factor affect morale among psychiatric patient staff benefit regard result antipsychotic drug treatment salutary patient family health care provider,Chengappa KN,2000,Can J Psychiatry,https://doi.org/10.1177/070674370004500907,11143833,Chengappa KN; Levine J; Ulrich R; Parepally H; Brar JS; Atzert R; Brienzo R; Gopalani A,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000374: Aggression; D015331: Cohort Studies; D005260: Female; D006778: Hospitals, Psychiatric; D006783: Hospitals, State; D006801: Humans; D008297: Male; D008875: Middle Aged; D010356: Patient Isolation; D011569: Psychiatric Status Rating Scales; D012149: Restraint, Physical; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome; D014754: Violence",,,https://openalex.org/W161868037,80,12,1,1854,308,10,en,en
false,clozapine induce agranulocytosis hereditary polymorphism clozapine metabolize enzyme association myeloperoxidase cytochrome p,pathomechanisms drug induce agranulocytoses unclear however study point genetic determinant drug induce agranulocytoses clozapine induce agranulocytosis ca may regard idiosyncratic drug reaction preclinical clinical characteristic study aspect genetic background ca far polymorphism specific metabolize enzyme system clozapine examine thirty one schizophrenic patient ca schizophrenic comparison subject without adverse effect underwent genotyping recently discover g polymorphism myeloperoxidase mpo gene cytochrome p neither mpo mutation specific genotype cytochrome p associate ca equally distribute among ca patient control thus data suggest lack evidence association ca genetically variable activity specific drug metabolizing enzyme however may due statistical reason thus study great ca sample necessary draw final conclusion genetically base hypothesis,Dettling M,2000,Pharmacopsychiatry,https://doi.org/10.1055/s-2000-8359,11147929,Dettling M; Sachse C; Müller-Oerlinghausen B; Roots I; Brockmöller J; Rolfs A; Cascorbi I,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000380: Agranulocytosis; D014150: Antipsychotic Agents; D003024: Clozapine; D019389: Cytochrome P-450 CYP2D6; D005260: Female; D005838: Genotype; D006801: Humans; D008297: Male; D008875: Middle Aged; D009195: Peroxidase; D011110: Polymorphism, Genetic; D012559: Schizophrenia",,,https://openalex.org/W2038607166,156,17,1,1181,181,8,en,en
true,control clinical trial bupropion attention deficit hyperactivity disorder adult,objective despite increase recognition attention deficit hyperactivity disorder adhd adult paucity control pharmacological trial demonstrate effectiveness compound use treatment particularly nonstimulants author report result control investigation determine anti adhd efficacy bupropion adult patient dsm iv adhd method double blind placebo control randomize parallel week trial compare patient receive sustain release bupropion mg b n patient receive placebo n author use standardize structure psychiatric instrument diagnosis adhd measure improvement use separate assessment adhd depression anxiety symptom baseline weekly visit result subject male enrol study complete study bupropion treatment associate significant change adhd symptom week endpoint reduction exceed effect placebo reduction analysis use cutoff good reduction denote response subject receive bupropion improve compare subject receive placebo similarly analysis use clinical global impression scale score subject receive bupropion report much improve improve compare subject receive placebo conclusion result indicate clinically statistically significant effect bupropion improve adhd adult result suggest therapeutic role bupropion armamentarium agent adhd adult validate continuity pharmacological responsivity adhd across lifespan,Wilens TE,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.2.282,11156812,Wilens TE; Spencer TJ; Biederman J; Girard K; Doyle R; Prince J; Polisner D; Solhkhah R; Comeau S; Monuteaux MC; Parekh A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000367: Age Factors; D018687: Antidepressive Agents, Second-Generation; D001289: Attention Deficit Disorder with Hyperactivity; D016642: Bupropion; D015897: Comorbidity; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D001523: Mental Disorders; D008875: Middle Aged; D010919: Placebos; D016896: Treatment Outcome",,,https://openalex.org/W2116058617,95,13,1,1810,312,12,en,en
false,double blind comparison olanzapine versus clozapine schizophrenic patient clinically eligible treatment clozapine,treatment schizophrenic patient fail respond adequate trial neuroleptic drug major challenge clozapine one treatment option however universally effective limit use safety concern introduction new agent performance relative clozapine great clinical interest primary objective study evaluate efficacy safety olanzapine versus clozapine among treatment resistant dsm iv schizophrenic patient study primarily design demonstrate noninferiority olanzapine compare clozapine week double blind treatment conclusion base one side low confidence limit treatment effect observe primary efficacy variable positive negative syndrome scale panss total mean change baseline end point panss total score use last observation carry forward technique show agent comparably effective neuroleptic resistant patient e demonstrate noninferiority olanzapine compare clozapine overall significantly olanzapine treat patient discontinue adverse event clozapine treat counterpart p among spontaneously report adverse event increase salivation constipation dizziness nausea report significantly often among clozapine treat patient whereas dry mouth report often among olanzapine treat patient olanzapine demonstrate noninferior clozapine good tolerate among resistant schizophrenic patient clinically eligible treatment clozapine,Tollefson GD,2001,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(00)01026-x,11163780,Tollefson GD; Birkett MA; Kiesler GM; Wood AJ; Lilly Resistant Schizophrenia Study Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001794: Blood Pressure; D001835: Body Weight; D003024: Clozapine; D004311: Double-Blind Method; D004351: Drug Resistance; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010349: Patient Compliance; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013997: Time Factors",,,https://openalex.org/W2089602570,129,15,1,1722,269,7,en,en
false,plan ritalin trial tot head uncharted water,u scientist gear major clinical trial intend measure effect popular controversial drug use treat attention deficit hyperactivity disorder methylphenidate ritalin previously untested population child age run ethical concern use young subject clinical trial scientist involve study admit concern drug effect child still develop personality brain well inability give inform consent believe trial way answer concern rise use drug among population,Marshall E,2000,Science,https://doi.org/10.1126/science.290.5495.1280,11185396,Marshall E,article,D016433: News,"D001289: Attention Deficit Disorder with Hyperactivity; D001675: Bioethics; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D006801: Humans; D007258: Informed Consent; D008774: Methylphenidate; D009315: National Institute of Mental Health (U.S.); D018579: Patient Selection; D016032: Randomized Controlled Trials as Topic; D014481: United States",,,https://openalex.org/W1634536803,58,9,1,703,124,4,en,en
false,refractory schizophrenia atypical antipsychotic,treatment resistant refractory schizophrenia difficult define condition largely unknown prevalence year clozapine standard treatment condition recognize unequivocally effective however clozapine sometimes poorly tolerate potential severe toxicity partly result atypicals recently evaluate treatment refractory schizophrenia order evaluate evidence base relate drug treatment refractory schizophrenia develop refractoriness rating base previous work use rating assess trial atypicals schizophrenia unresponsive least one drug overall clozapine consistently show effective refractory schizophrenia even stringently define data relate olanzapine risperidone equivocal best evidence suggest less effective clozapine essentially cogent evidence support use atypical refractory schizophrenia clozapine remain drug choice condition,Taylor DM,2000,J Psychopharmacol,https://doi.org/10.1177/026988110001400411,11198061,Taylor DM; Duncan-McConnell D,article,D016428: Journal Article; D017418: Meta-Analysis,D014150: Antipsychotic Agents; D004311: Double-Blind Method; D004351: Drug Resistance; D019317: Evidence-Based Medicine; D006801: Humans; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D012189: Retrospective Studies; D012559: Schizophrenia,,,https://openalex.org/W2104404988,52,5,1,1149,188,10,en,en
false,ziprasidone short term treatment patient schizoaffective disorder result two double blind placebo control multicenter study,study assess efficacy ziprasidone treatment schizoaffective disorder data take subset patient schizoaffective disorder derive two separate double blind placebo control parallel group multicenter study total hospitalized patient acute episode schizoaffective disorder randomly assign receive either fixed oral ziprasidone mg day n mg day n mg day n mg day n placebo n week mean baseline endpoint change brief psychiatric rating scale bprs total bprs core clinical global impression severity scale cgi bprs depressive bprs manic montgomery sberg depression rating scale total score compare placebo ziprasidone group neurological simpson angus barnes akathisia abnormal involuntary movement scale aim side effect also assess significant dose related improvement primary efficacy variable bprs total bprs core cgi bprs manic item observe ziprasidone treatment combine analysis data study p ziprasidone mg day significantly effective placebo improve mean bprs total bprs core bprs manic cgi score p mg day ziprasidone significantly effective placebo improve mean cgi score p incidence individual adverse event generally low treatment group dose related addition significant difference observe baseline endpoint mean change simpson angus aim score placebo ziprasidone mg day result suggest ziprasidone may efficacy treatment affective well psychotic symptom schizoaffective disorder low side effect burden,Keck PE,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200102000-00007,11199944,Keck PE; Reeves KR; Harrigan EP; Ziprasidone Study Group,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009069: Movement Disorders; D010879: Piperazines; D011618: Psychotic Disorders; D013844: Thiazoles; D016896: Treatment Outcome,,,https://openalex.org/W2033616909,153,20,1,1928,343,11,en,en
false,effect concomitant phenytoin administration steady state pharmacokinetics quetiapine,quetiapine fumarate seroquel newly introduce atypical antipsychotic demonstrate efficacy treatment positive negative symptom schizophrenia extensively metabolize predominantly cytochrome p therefore concurrent administration drug induce inhibit enzyme may affect quetiapine pharmacokinetics study demonstrate potent cytochrome p enzyme inducer phenytoin indeed mark effect metabolism quetiapine result fold increase clearance administer concomitantly patient dsm iv diagnose schizophrenia schizoaffective disorder bipolar disorder result indicate dosage adjustment quetiapine may necessary two drug give concurrently caution may require administer drug inhibit induce cytochrome particularly p,Wong YW,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200102000-00016,11199955,Wong YW; Yeh C; Thyrum PT,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000704: Analysis of Variance; D000927: Anticonvulsants; D014150: Antipsychotic Agents; D001714: Bipolar Disorder; D003987: Dibenzothiazepines; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D006801: Humans; D008297: Male; D008875: Middle Aged; D010672: Phenytoin; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D012559: Schizophrenia",,,https://openalex.org/W2019559657,102,12,1,923,137,5,en,en
false,preliminary study bupropion sustain release smoke cessation patient chronic posttraumatic stress disorder,study conduct evaluate effect bupropion sustain release sr smoke cessation patient chronic posttraumatic stress disorder ptsd fifteen veteran chronic ptsd desire stop smoking enrol week double blind evaluation bupropion sr placebo patient randomly assign ratio receive either bupropion sr placebo bupropion sr initiate mg daily day increase final dose mg twice daily mg daily total ten patient receive bupropion sr five receive placebo nine patient receive bupropion sr already treat least one psychotropic medication one ten patient complete study medication side effect eighty percent patient receive bupropion sr successfully stop smoke end week maintain smoke cessation study endpoint week month follow patient receive bupropion sr maintain smoke cessation one five patient receive placebo stop smoke maintain smoke cessation month follow bupropion sr generally well tolerate combination psychotropic medication bupropion sr may effective help patient desire quit smoking also concomitant anxiety disorder ptsd,Hertzberg MA,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200102000-00017,11199956,Hertzberg MA; Moore SD; Feldman ME; Beckham JC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D002908: Chronic Disease; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D016540: Smoking Cessation; D013313: Stress Disorders, Post-Traumatic; D016896: Treatment Outcome",,,https://openalex.org/W2317880809,127,16,1,1461,265,12,en,en
false,effect bupropion sustain release sexual functioning nocturnal erection healthy men,many antidepressant know cause adverse sexual effect bupropion antidepressant report adverse sexual effect study sexual side effect often confound psychiatric medical condition affect sexual function study effect bupropion subjective objective sexual functioning measure healthy men thirteen men without psychiatric medical illness complete week placebo control double blind crossover trial bupropion sustain release mg day subject week washout period trial sexual function measure use validate self administer questionnaire rigiscan instrument measure nocturnal penile tumescence rigidity difference find self report sexual function number erection total erection time penile rigidity subject take bupropion compare take placebo baseline find support bupropion subjective adverse sexual side effect affect nocturnal erection healthy men,Labbate LA,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200102000-00018,11199957,Labbate LA; Brodrick PS; Nelson RP; Lydiard RB; Arana GW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D010410: Penile Erection; D020018: Sexual Dysfunctions, Psychological",,,https://openalex.org/W2014921574,99,13,1,1099,168,9,en,en
false,intramuscular ziprasidone compare intramuscular haloperidol treatment acute psychosis,article abstractbackground day randomize open label multicenter international study compare efficacy tolerability intramuscular ziprasidone haloperidol transition oral treatment hospitalize patient acute psychotic agitation relate dsm iii r diagnosis method patient receive day flexible dose ziprasidone n haloperidol n follow oral treatment day initial ziprasidone dose mg subsequent mg could give every hour maximum daily dose mg need follow oral ziprasidone mg day haloperidol dos mg give entry follow mg every hour maximum daily dose mg need oral haloperidol mg day result mean reduction brief psychiatric rating scale bprs total bprs agitation item clinical global impression severity scale score statistically significantly great p p p respectively ziprasidone treatment compare haloperidol treatment reduction score also occur group follow transition oral treatment ziprasidone associate low incidence movement disorder reduce requirement anticholinergic medication oral treatment compare haloperidol movement disorder scale score improve ziprasidone oral treatment deteriorate haloperidol adverse event rare treatment conclusion ziprasidone significantly effective reduce symptom acute psychosis well tolerate haloperidol particularly movement disorder transition ziprasidone oral ziprasidone effective well tolerate,Brook S,2000,J Clin Psychiatry,https://doi.org/10.4088/jcp.v61n1208,11206599,Brook S; Lucey JV; Gunn KP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D010054: Brief Psychiatric Rating Scale; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006760: Hospitalization; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D011618: Psychotic Disorders; D012720: Severity of Illness Index; D013844: Thiazoles; D016896: Treatment Outcome",,,https://openalex.org/W2077206280,101,12,1,1933,353,26,en,en
false,effect methylphenidate sensitivity reinforcement child diagnose attention deficit hyperactivity disorder application match law,behavior child diagnose attention deficit hyperactivity disorder adhd hypothesize result decreased sensitivity consequence compare typical child present study examine sensitivity reinforcement boy diagnose adhd use match law provide precise quantitative measurement construct experiment also evaluate effect methylphenidate mph sensitivity reinforcement child adhd subject complete math problem earn token four different variable interval vi schedule reinforcement present random order medicate nonmedicated condition result show medicate condition match function subject result higher asymptotic value indicate overall elevation behavior rate condition variance account match law also high medicate condition suggest behavior closely track change rate reinforcement take mph compare placebo medicate condition reinforce efficacy response contingent token decrease result discus respect quantify behavioral change extent drug interact prevail contingency e schedule value influence behavioral variability,Murray LK,2000,J Appl Behav Anal,https://doi.org/10.1901/jaba.2000.33-573,11214032,Murray LK; Kollins SH,article,D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011340: Problem Solving; D011582: Psychological Theory; D011897: Random Allocation; D012055: Reinforcement Schedule; D012054: Reinforcement, Psychology; D012680: Sensitivity and Specificity; D012720: Severity of Illness Index; D013997: Time Factors",,,https://openalex.org/W2130207379,162,22,1,1415,216,8,en,en
false,test ability child attention deficit hyperactivity disorder accurately report effect medication behavior,child attention deficit hyperactivity disorder adhd often treat central nervous system stimulant make evaluation medication effect important topic apply behavior analyst assessment protocol emphasize informant report direct observation child behavior little know extent child accurately report medication effect double blind placebo control procedure use examine whether child adhd could recognize effect medication child give math worksheet complete min session medication placebo child complete self evaluation form end session rating compare observe behavior academic performance result indicate child able accurately report medication status level great chance whereas accuracy report child relate dosage level difference behavior presence adverse effect implication result placebo control research self monitoring dosage level accuracy training discus,Ardoin SP,2000,J Appl Behav Anal,https://doi.org/10.1901/jaba.2000.33-593,11214033,Ardoin SP; Martens BK,article,D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000124: Achievement; D001289: Attention Deficit Disorder with Hyperactivity; D001294: Attitude to Health; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D012647: Self-Assessment,,,https://openalex.org/W2110248622,142,20,1,1222,190,7,en,en
false,clozapine treatment drug induce psychosis parkinson disease result week open label extension psyclops trial,objective report result week prospective open label extension week multicenter placebo control double blind psyclops psychosis clozapine treatment parkinsonism trial extension examine chronic safety efficacy clozapine treatment drug induce psychosis parkinson disease pd background psychosis serious late complication pd may harbinger increase mortality clozapine first atypical antipsychotic show several small open label study improve psychosis without worsen motor symptom recently confirm double blind psyclops trial method patient complete double blind portion psyclops evaluate original randomize treatment clozapine placebo study medication stop start clozapine patient treatment group evaluate every week week period use standardized measure psychosis pd result mean dose clozapine mg day originally treat placebo improve significantly brief psychiatric rating scale clinical global score psychosis degree group originally randomize clozapine double blind study group maintain response week end combine double blind open label portion worsen motor feature measure unify parkinson disease rating scale eighteen patient either hospitalize die trial common reason pulmonary conclusion low dose clozapine effective treat drug induce psychosis without worsen motor feature pd response maintain least month patient psychosis pd previously describe group high risk morbidity mortality high risk continue despite antipsychotic therapy mov disord movement disorder society,Factor SA,2001,Mov Disord,https://doi.org/10.1002/1531-8257(200101)16:1<135::aid-mds1006>3.0.co;2-q,11215574,Factor SA; Friedman JH; Lannon MC; Oakes D; Bourgeois K; Parkinson Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D010054: Brief Psychiatric Rating Scale; D003024: Clozapine; D004311: Double-Blind Method; D006801: Humans; D010300: Parkinson Disease; D011446: Prospective Studies; D011605: Psychoses, Substance-Induced; D016896: Treatment Outcome",,,https://openalex.org/W2060220011,143,24,1,2044,339,21,en,en
false,olanzapine,unlabelled olanzapine thienobenzodiazepine derivative second generation atypical antipsychotic agent prove efficacy positive negative symptom schizophrenia compare conventional antipsychotic great affinity serotonin ht dopamine receptor large well control trial patient schizophrenia relate psychosis olanzapine mg day significantly superior haloperidol mg day overall improvement psychopathology rating scale treatment depressive negative symptom comparable effect positive psychotic symptom year risk relapse rehospitalisation significantly low olanzapine haloperidol treatment first double blind comparative study week olanzapine risperidone olanzapine mg day prove significantly effective risperidone mg day treatment negative depressive symptom overall psychopathology symptom contrast preliminary result week control study suggest risperidone mg day superior olanzapine mg day positive anxiety depressive symptom p although consistent first study agent demonstrate similar efficacy measure overall psychopathology improvement general cognitive function see olanzapine treatment year control study patient early phase schizophrenia significantly great change see either risperidone haloperidol however preliminary result week trial show comparable cognitive enhance effect olanzapine risperidone treatment patient schizophrenia schizoaffective disorder several study indicate olanzapine benefit symptom aggression agitation study strongly support effectiveness olanzapine treatment depressive symptomatology olanzapine associate significantly extrapyramidal symptom haloperidol risperidone addition olanzapine associate risk agranulocytosis see clozapine clinically significant hyperprolactinaemia see risperidone prolongation qt interval common adverse effect report olanzapine bodyweight gain somnolence dizziness anticholinergic effect constipation dry mouth transient asymptomatic liver enzyme elevation comparison haloperidol adverse event report significantly frequently olanzapine patient dry mouth bodyweight gain increase appetite compare risperidone bodyweight gain occur significantly frequently olanzapine high acquisition cost olanzapine offset reduction treatment cost inpatient outpatient service schizophrenia pharmacoeconomic analysis indicate olanzapine significantly increase may even decrease overall direct treatment cost schizophrenia compare haloperidol compare risperidone olanzapine also report decrease overall treatment cost despite several fold high daily acquisition cost drug olanzapine treatment improve quality life patient schizophrenia related psychosis great extent haloperidol broadly extent risperidone conclusion olanzapine demonstrate superior antipsychotic efficacy compare haloperidol treatment acute phase schizophrenia treatment patient first episode treatment resistant schizophrenia reduce risk adverse event therapeutic superiority compare haloperidol risperidone treatment negative depressive symptom support choice olanzapine first line option management schizophrenia acute phase maintenance treatment response,Bhana N,2001,Drugs,https://doi.org/10.2165/00003495-200161010-00011,11217867,Bhana N; Foster RH; Olney R; Plosker GL,article,D016428: Journal Article; D016454: Review,"D000293: Adolescent; D000368: Aged; D000818: Animals; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002648: Child; D002675: Child, Preschool; D003072: Cognition Disorders; D003362: Cost-Benefit Analysis; D003577: Cytochrome P-450 Enzyme System; D003863: Depression; D004347: Drug Interactions; D006220: Haloperidol; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011788: Quality of Life; D016032: Randomized Controlled Trials as Topic; D011985: Receptors, Serotonin; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2002013308,10,1,1,4090,613,19,es,en
false,long term olanzapine treatment weight change weight related health factor schizophrenia,weight change weight related health factor nonfasting serum glucose serum cholesterol diastolic blood pressure level analyze patient dsm iii r schizophrenia relate disorder receive treatment olanzapine year comparison make patient treat haloperidol baseline body mass index bbmi kg dose mg day investigate predictor long term weight change experience olanzapine treatment analysis retrospectively examine patient receive olanzapine patient receive haloperidol week study patient randomly assign either olanzapine mg day haloperidol mg day week acute therapy patient continue year either double blind open label olanzapine therapy double blind haloperidol therapy mean weight gain olanzapine treat patient observe median year trend toward plateau first week treatment last observation carry forward mean weight change kg lb median kg lb significantly high haloperidol treat patient whose mean weight gain kg lb year p patient high bbmi gain significantly less weight treatment olanzapine light counterpart bbmi p effect olanzapine dose weight significant p median serum glucose endpoint significantly associate p weight change olanzapine median serum cholesterol diastolic blood pressure olanzapine treat patient endpoint show relationship weight change statistically p clinically significant difference incidence elevate serum glucose cholesterol diastolic blood pressure olanzapine haloperidol therapy group different p mean weight gain olanzapine treatment trend toward plateau initial week treatment significant gain year high bbmi predictive low long term weight gain dose significant predictor great long term weight change relationship weight change glucose statistically significant association weight change change cholesterol well change diastolic blood pressure statistically significant consider clinically relevant base range observe,Kinon BJ,2001,J Clin Psychiatry,,11247108,Kinon BJ; Basson BR; Gilmore JA; Tollefson GD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D001835: Body Weight; D002784: Cholesterol; D003971: Diastole; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2138404641,97,13,1,2651,449,13,en,en
true,compare guanfacine dextroamphetamine treatment adult attention deficit hyperactivity disorder,objective study compare efficacy alpha agonist guanfacine dextroamphetamine treatment adult attention deficit hyperactivity disorder adhd seventeen adult outpatient meet dsm iv criterion adhd participate double blind placebo control crossover study compare drug effect adhd symptom measure change include dsm iv adhd behavior checklist adult copeland symptom checklist adult attention deficit disorder cognitive measure attention include stroop control oral word association test use letter c f l cowat cfl version trial drug administer daily titered optimal maximum efficacy minimum side effect data collect drug significantly reduce adhd symptom dsm iv adult behavior checklist adult placebo p stroop color subscale show significant improvement drug p color word measure show significant improvement guanfacine p average dose guanfacine sd common side effect guanfacine fatigue subject discontinue drug trial preliminary study indicate guanfacine may well tolerate treatment option adult adhd,Taylor FB,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200104000-00015,11270920,Taylor FB; Russo J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D018759: Adrenergic Uptake Inhibitors; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005260: Female; D016316: Guanfacine; D006801: Humans; D008297: Male; D008875: Middle Aged; D011581: Psychological Tests,,,https://openalex.org/W2018897037,110,11,1,1386,244,10,en,en
false,effectiveness second generation antipsychotic patient treatment resistant schizophrenia review meta analysis randomize trial,author conduct review meta analysis study compare efficacy tolerability typical second generation antipsychotic patient treatment resistant schizophrenia systematic search reveal control study involve independent patient include review seven study compare clozapine typical antipsychotic meta analysis perform examine clozapine effect overall psychopathology response rate extrapyramidal symptom tardive dyskinesia meta analysis confirm treatment resistant schizophrenic patient favorable outcome treat clozapine rather typical antipsychotic reflect brief psychiatric rating scale total score categorical response rate scale assessment negative symptom score simpson angus rating scale score compliance rate clozapine also confer benefit sick treatment resistant schizophrenic patient patient treat olanzapine also favorable outcome regard categorical response compliance rate aggregate result meta analysis indicate clozapine exhibit superiority typical antipsychotic term efficacy measure improvement overall psychopathology safety term reduce extrapyramidal side effect however magnitude clozapine treatment effect consistently robust efficacy data second generation antipsychotic treatment patient refractory schizophrenia inconclusive therefore grow need consider new different treatment strategy whether adjunctive monotherapeutic schizophrenia continue resistant partially responsive treatment,Chakos M,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.4.518,11282684,Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B,article,D016428: Journal Article; D017418: Meta-Analysis,D000293: Adolescent; D000328: Adult; D017668: Age of Onset; D014150: Antipsychotic Agents; D010054: Brief Psychiatric Rating Scale; D003024: Clozapine; D005260: Female; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2115115146,149,17,1,1851,269,7,en,en
false,mri study basal ganglion volume first episode schizophrenia patient treat risperidone,basal ganglion may contribute extrapyramidal movement disorder affective disturbance cognitive deficit schizophrenia basal ganglia volume putatively affect antipsychotic medication purpose study determine long term effect risperidone treatment cohort first episode patient schizophrenia subject patient first episode schizophrenia patient chronically treat typical antipsychotic healthy comparison subject scan magnetic resonance image baseline first episode patient receive year continuous risperidone treatment comparison subject rescanned caudate putamen globus pallidus volume determine coronal image baseline caudate putamen globus pallidus volume significantly large chronically treated patient untreated first episode subject comparison subject volume differ first episode patient healthy comparison subject basal ganglion volume unchanged year exposure risperidone first episode subject extrapyramidal movement disorder present majority chronically treat patient one third never medicate first episode patient baseline group first episode patient exhibit abnormality basal ganglion volume basal ganglia volume affect exposure risperidone movement disorder observe first episode chronically treated patient suggest effect illness medication,Lang DJ,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.4.625,11282699,Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Honer WG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001479: Basal Ganglia; D001480: Basal Ganglia Diseases; D002421: Caudate Nucleus; D005260: Female; D005917: Globus Pallidus; D006801: Humans; D008137: Longitudinal Studies; D008279: Magnetic Resonance Imaging; D008297: Male; D011699: Putamen; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2137891689,102,14,1,1678,242,10,en,en
false,comparison long term outcome first episode schizophrenia follow treatment risperidone typical antipsychotic,article abstractbackground report assess efficacyand tolerability risperidone involve patient previouslytreated typical antipsychotic patient morelikely great resistance intolerance treatment thus restrict interpretation impact new treatmentmight course schizophrenia possibly biasingthe result present study examine relativeeffectiveness risperidone typical antipsychotic inpatient treat first episode schizophrenia method cohort patient groupsof first episode dsm iii r dsm iv schizophrenia patientsmatched age gender length illness length oftreatment treat either typical antipsychotic orrisperidone minimum year compare number ofoutcome dimension course treatment atfollow treatment allocation random patient werejudged compliant medication patient treat withtypical antipsychotic follow statisticallynonsignificantly long time mean v year result six patient typicalantipsychotic group admit hospital within thefirst year follow index admission compare patient risperidone group admit month patientsin risperidone group show statistically significantlylower length first hospitalization p utilizationof inpatient bed course treatment p use anticholinergic medication p nostatistically significant difference symptom level eitherduring course treatment follow use ofantidepressant antianxiety mood stabilize drug inchanges live circumstance employment conclusion find confirm leastequal long term efficacy typical antipsychotic andrisperidone possible advantage risperidone indecreased service utilization decrease use ofanticholinergic drug,Malla AK,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n0308,11305704,Malla AK; Norman RM; Scholten DJ; Zirul S; Kotteda V,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D004359: Drug Therapy, Combination; D004651: Employment; D005260: Female; D005500: Follow-Up Studies; D006760: Hospitalization; D006801: Humans; D007902: Length of Stay; D008297: Male; D010359: Patient Readmission; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012917: Social Adjustment; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W1540364236,128,16,1,2074,320,10,en,en
false,analysis qtc interval olanzapine treatment patient schizophrenia relate psychosis,may temporal association antipsychotic prolongation heart rate correct qt interval qtc represent delay ventricular repolarization qtc prolongation significantly exceed normal intra individual interindividual variation may increase risk ventricular tachydysrhythmias especially torsade de pointes therefore sudden cardiac death electrocardiogram record obtain part safety assessment olanzapine control randomize clinical trial n analyze analysis conduct characterize change qtc temporally associate olanzapine compare placebo haloperidol risperidone acutely psychotic patient dsm iii r dsm iv characterize variability temporal course qtc patient population change baseline minimum maximum qtc test significance baseline acute phase endpoint change mean qtc test significance within treatment difference olanzapine comparators possibility linear relationship dose olanzapine mean change qtc well incidence treatment emergent prolongation qtc change msec baseline msec endpoint test incidence maximum qtc msec treatment approximately equal incidence qtc msec baseline result analysis suggest olanzapine therapeutically administer patient schizophrenia relate psychosis contribute qtc prolongation result potentially fatal ventricular arrhythmia,Czekalla J,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n0310,11305706,Czekalla J; Beasley CM; Dellva MA; Berg PH; Grundy S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D001569: Benzodiazepines; D004562: Electrocardiography; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D008133: Long QT Syndrome; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2110233387,109,15,1,1693,263,5,en,en
false,effect amantadine weight gain olanzapine treatment,patient treat olanzapine may gain weight especially first month therapy amantadine mg day start patient mean weight gain kg olanzapine treatment patient weight stabilise month lose average kg clinical deterioration occur adverse effect report observation merit confirmation randomise control trial,Floris M,2001,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(01)00072-4,11313165,Floris M; Lejeune J; Deberdt W,article,D016430: Clinical Trial; D016428: Journal Article,D000328: Adult; D000547: Amantadine; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015259: Dopamine Agents; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D015430: Weight Gain,,,https://openalex.org/W2088710565,63,9,1,441,76,5,en,en
false,diagnosis management attention deficit hyperactivity disorder child,massachusetts college pharmacy health science boston massachusetts department pharmacy child hospital boston massachusetts usa department general pediatrics child hospital boston massachusetts usa correspondence kelly kirby pharmd mchps boston longwood avenue boston usa e mail email protect,Kirby K,2001,Curr Opin Pediatr,https://doi.org/10.1097/00008480-200104000-00019,11317065,Kirby K; Floriani V; Bernstein H,article,D016428: Journal Article; D016454: Review,"D000317: Adrenergic alpha-Antagonists; D000929: Antidepressive Agents, Tricyclic; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans",,,https://openalex.org/W2334410811,81,9,1,362,71,2,en,en
false,double blind placebo control case study use donepezil improve cognition schizoaffective disorder patient functional mri correlate,cognitive impairment multiple domain common patient schizophrenia may powerful determinant poor functional ability quality life report double blind placebo control cross study donepezil augmentation schizoaffective disorder patient stabilize olanzapine pharmacotherapy patient show significant improvement several cognitive measure increase activation prefrontal cortex basal ganglion functional mri donepezil augmentation addition donepezil augmentation result reduction depressive symptom significant improvement functional ability quality life study donepezil augmentation neuroleptic schizophrenia warrant,Risch SC,2001,Neurocase,https://doi.org/10.1093/neucas/7.2.105,11320158,Risch SC; McGurk S; Horner MD; Nahas Z; Owens SD; Molloy M; Gilliard C; Christie S; Markowitz JS; DeVane CL; Mintzer J; George MS,article,D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001479: Basal Ganglia; D001569: Benzodiazepines; D001921: Brain; D001931: Brain Mapping; D003072: Cognition Disorders; D018592: Cross-Over Studies; D000077265: Donepezil; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D007189: Indans; D008279: Magnetic Resonance Imaging; D008297: Male; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010880: Piperidines; D010890: Pirenzepine; D017397: Prefrontal Cortex; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D011788: Quality of Life",,,https://openalex.org/W2144550125,155,23,1,777,111,5,en,en
false,reduktion der okul ren pulsamplitude unter apraclonidin prospektive doppelt maskierte studie probanden,alpha agonist apraclonidin lower effective intraocular pressure ischemia gain increase importance pathogenesis glaucoma therefore antiglaucomatous drug also investigate regard influence ocular hemodynamics double mask randomize clinical trial apraclonidin eye drop apply health subject twice daily day control group healty volunteer receive placebo medication naci accord protocol iop heart rate blood pressure ocular pulse amplitude obf lab uk measure baseline minute instillation one eye drop day therapy minute acute instillation statistical analysis wilcoxon test paried sample use apraclonindin treated subject iop drop significantly p mm hg mm hg control group show significant reduction p p mm hg mm hg control group pulse amplitude remain constant one week therapy apralonidin intraocular pressure drop expect health volunteer observe reduction pulse amplitude pulse amplitude however could negative effect long term therapy patient chronic open angle glaucoma,Kuba GB,2001,Klin Monbl Augenheilkd,https://doi.org/10.1055/s-2001-13079,11322056,Kuba GB; Austermann P,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000328: Adult; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2008088032,110,14,1,1440,259,8,de,en
false,randomize double blind study risperidone olanzapine treatment schizophrenia schizoaffective disorder,objective safety efficacy risperidone olanzapine compare double blind trial use widely accept clinical practice method subject n meet dsm iv criterion schizophrenia schizoaffective disorder randomly assign receive mg day risperidone mean modal dose mg day mg day olanzapine mean modal dose mg day week result two study group similar baseline except olanzapine group slightly young risperidone group seventy five percent participant complete trial treatment difference proportion dropout similar proportion risperidone olanzapine group report extrapyramidal symptom respectively severity extrapyramidal symptom low group group difference total positive negative syndrome scale score score five positive negative syndrome scale factor improve group week subject complete study endpoint subject include dropout overall treatment difference efficacy comparison individual factor find significant difference endpoint week however improvement positive negative syndrome scale factor positive symptom anxiety depression great risperidone olanzapine increase body weight see olanzapine participant risperidone participant conclusion treatment well tolerate efficacious frequency severity extrapyramidal symptom similar two treatment group great reduction severity positive affective symptom see risperidone olanzapine treatment among study completers measure olanzapine superior great weight gain associate olanzapine risperidone treatment,Conley RR,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.5.765,11329400,Conley RR; Mahmoud R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2032448955,123,16,1,2016,327,15,en,en
false,sustain release bupropion selective serotonin reuptake inhibitor induce sexual dysfunction randomize double blind placebo control parallel group study,author compare low dose sustain release bupropion placebo sexual dysfunction induce selective serotonin reuptake inhibitor ssri thirty adult receive ssri least week euthymic sexual dysfunction determine total score great possible arizona sexual experience scale randomly assign receive either mg day sustain release bupropion placebo p week significant difference sustain release bupropion placebo group measure change arizona sexual experience scale hamilton depression rating scale score side effect future study compare high bupropion treat sexual dysfunction include great number subject,Masand PS,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.5.805,11329407,Masand PS; Ashton AK; Gupta S; Frank B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D007172: Erectile Dysfunction; D005260: Female; D006801: Humans; D007989: Libido; D008297: Male; D010410: Penile Erection; D017367: Selective Serotonin Reuptake Inhibitors; D020018: Sexual Dysfunctions, Psychological; D016896: Treatment Outcome; D014621: Vagina",,,https://openalex.org/W2061519055,167,19,1,838,129,1,en,en
false,adjonction de clonidine la lidoca ne pour anesth sie locor gionale intraveineuse,evaluate effect addition clonidine lidocaine postoperative pain intravenous regional anaesthesia double blind prospective study forty five patient randomly allocate two group group n receive mg kg lidocaine add saline group n receive mg kg lidocaine add clonidine microgram postoperative analgesia assess use visual analogue pain score vaps time first analgesic request incidence side effect tourniquet release note analysis variance kruskall wallis chi test use statistical analysis p value consider significant age asa class duration type surgery tourniquet time sensory block duration comparable two group time first antalgic request deflation tourniquet similar two group min versus min vaps score low p clonidine group versus incidence side effect comparable two group addition clonidine microgram lidocaine intravenous regional anaesthesia improve postoperative analgesia limit short lasting manner,Samkaoui MA,2001,Ann Fr Anesth Reanim,https://doi.org/10.1016/s0750-7658(01)00357-4,11332061,Samkaoui MA; Bouaggad A; al Harrar R; Bouderka MA; Abbassi O,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000704: Analysis of Variance; D000771: Anesthesia, Intravenous; D000772: Anesthesia, Local; D000779: Anesthetics, Local; D000894: Anti-Inflammatory Agents, Non-Steroidal; D003000: Clonidine; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D007660: Ketoprofen; D008012: Lidocaine; D008297: Male; D010147: Pain Measurement; D010149: Pain, Postoperative",,,https://openalex.org/W2032749888,90,13,1,1271,230,7,fr,en
false,incidence extrapyramidal symptom treatment olanzapine haloperidol risperidone result observational study,analyze incidence extrapyramidal symptom eps concomitant use anticholinergic drug outpatient diagnose schizophrenia treat olanzapine olz comparison haloperidol hal risperidone ri routine clinical practice condition analysis carry basis information obtain efeso study observational prospective study carry outpatient diagnose schizophrenia treat olanzapine compare antipsychotic agent use clinical practice incidence eps olz treat group compare haloperidol risperidone treatment group patient include analyze present work study duration month data collect psychiatrist mental health care area percentage patient present least one adverse event ae p less olz group compare hal ri subgroup low percentage patient treat olz present eps comparison ri hal subgroup p low rate patient olz group receive anticholinergic treatment compare ri hal subgroup p case olz treat patient present low incidence eps require less anticholinergic treatment hal ri treat patient result obtain naturalistic condition coincide conclusion reach randomize clinical trial carry prior marketing olz,Sacristán JA,2001,Actas Esp Psiquiatr,,11333516,Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM,article,D016428: Journal Article,"D000328: Adult; D000553: Ambulatory Care; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004359: Drug Therapy, Combination; D020820: Dyskinesias; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010349: Patient Compliance; D010890: Pirenzepine; D011446: Prospective Studies; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W159075688,136,21,1,1645,306,6,en,en
false,moxonidine controversy,initially consider moxonidine like clonidine act central adrenoceptors reduce blood pressure characterisation imidazoline bind site distinct adrenoceptors consensus become moxonidine act predominantly imidazoline receptor rostral ventrolateral medulla lower blood pressure moxonidine act prejunctional adrenoceptors sympathetic nerve end decrease noradrenaline release may contribute ability low blood pressure predominant site action moxonidine may also depend route administration imidazoline receptor predominant central adrenoceptors predominant systemic administration controversy mechanism site action moxonidine ongoing animal model moxonidine low blood pressure reduce cardiac hypertrophy remodelling reduce cardiac arrhythmia increase blood flow cerebral ischaemia moxonidine also beneficial effect animal model diabetes kidney disease moxonidine increase sodium water excretion rat human animal study indicate moxonidine may useful treatment glaucoma reduce intra ocular pressure animal study show moxonidine may also effective pain ethanol withdrawal human pharmacokinetics moxonidine one compartment model first order absorption renal elimination major route elimination individual titration moxonidine need patient renal impairment overwhelm evidence moxonidine safe effective antihypertensive large clinical trial moxonidine heart failure moxcon stop excessive death moxonidine group moxonidine use patient heart failure obvious reason stop use antihypertensive development clinical u,Doggrell SA,2001,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.2.2.337,11336590,Doggrell SA,article,D016428: Journal Article; D016454: Review,"D000322: Adrenergic Agonists; D000818: Animals; D000959: Antihypertensive Agents; D004195: Disease Models, Animal; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D054755: Imidazoline Receptors; D016032: Randomized Controlled Trials as Topic; D051381: Rats; D011955: Receptors, Drug; D013045: Species Specificity; D016896: Treatment Outcome",,,https://openalex.org/W2156576111,28,4,1,2027,333,15,en,en
false,toward individualize evidence base medicine five n trial methylphenidate geriatric patient,investigate efficacy methylphenidate depress apathetic geriatric patient five n trial individual cross double blind randomize trial department geriatrics university medical center nijmegen two nursing home nijmegen netherlands patient suffer depression due general medical condition n depression resistant antidepressive drug n chronic apathy due mild moderate severe dementia n methylphenidate mg bid placebo two subsequent day week randomize treatment block montgomery asberg depression rating scale madrs apathy evaluation scale aes clinician aes informant barthel index semiquantitative checklist adverse effect among three depress patient two show significant improvement madrs p p alpha one patient apathy show significant improvement aes clinician informant p p one apathetic patient trial stop aes could complete none patient show significant change barthel index side effect develop n trial useful evaluate efficacy methylphenidate depress apathetic geriatric patient single patient trial useful tool pharmacotherapeutic decision make frail old subject,Jansen IH,2001,J Am Geriatr Soc,https://doi.org/10.1046/j.1532-5415.2001.49092.x,11347795,Jansen IH; Olde Rikkert MG; Hulsbos HA; Hoefnagels WH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D018592: Cross-Over Studies; D003863: Depression; D004311: Double-Blind Method; D004341: Drug Evaluation; D019317: Evidence-Based Medicine; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate",,,https://openalex.org/W2044122355,108,17,1,1398,249,6,en,en
false,detect improvement quality life symptomatology schizophrenia,instrument base score often use outcome measure however little know change score mean term clinical assessment improvement deterioration purpose report determine much change standard instrument score represent clinically detectable improvement deterioration veteran affair va cooperative study clozapine refractory schizophrenia evaluate patient clozapine haloperidol symptom quality life scale complete baseline week month among patient judge improve clinician average percentage change percent decrease positive negative syndrome scale panss score percent increase quality life scale qls score across followup period change mean seven point item score panss qls major gain clinically assess improvement much good associate percent decline panss score percent increase qls score change mean seven point item score respectively thus modest change psychometric scale assess symptom quality life reflect clinically detectable improvement,Cramer J,2001,Schizophr Bull,https://doi.org/10.1093/oxfordjournals.schbul.a006869,11354590,Cramer J; Rosenheck R; Xu W; Henderson W; Thomas J; Charney D; Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000328: Adult; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D011594: Psychometrics; D011788: Quality of Life; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D014728: Veterans,,,https://openalex.org/W2154125298,76,10,1,1267,225,9,en,en
false,weight gain month schizophrenia patient comparison olanzapine risperidone,weight gain frequently accompany treatment antipsychotic order determine whether new antipsychotic agent differ respect weight gain compare two cohort patient dsm iv schizophrenia newly start treatment either risperidone olanzapine obtain informed consent data regard body weight height cull exist medical record patient patient treatment group baseline body weight close time start new medication body mass index bmi weight kg height square compare body weight bmi follow month treatment significant change mean body weight bmi group treat risperidone baseline weight kg follow kg match pair p n baseline bmi follow match pair p n however group treat olanzapine significant increase mean body weight bmi baseline weight kg follow kg match pair p baseline bmi follow match pair p naturalistic study treatment olanzapine associate mean weight gain kg baseline patient schizophrenia treatment risperidone associate mean weight change,Ganguli R,2001,Schizophr Res,https://doi.org/10.1016/s0920-9964(00)00080-3,11356587,Ganguli R; Brar JS; Ayrton Z,article,D003160: Comparative Study; D016428: Journal Article,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015992: Body Mass Index; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D018967: Risperidone; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W2018689362,95,15,1,1501,298,8,en,en
false,response relation baseline anxiety level major depressive disorder treat bupropion sustain release sertraline,objective determine pretreatment anxiety level associate preferential response bupropion sustain release n sertraline n week randomize acute phase treatment study agent comparable antidepressant activity comparable anxiolytic effect use intent treat sample baseline anxiety level relate antidepressant efficacy differentiate responder agent time clinically significant anxiolysis differentiate treatment group responder agent result contradict commonly hold unsubstantiated belief clinically depress anxious patient serotonergic antidepressant especially anxiolytic patient preferentially benefit antidepressant anxiolytic effect selective serotonin reuptake inhibitor thus clinical decision select two agent treat depress outpatient rest either level pretreatment anxiety anticipation rapid complete anxiolysis,Rush AJ,2001,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(00)00249-9,11377926,Rush AJ; Trivedi MH; Carmody TJ; Donahue RM; Houser TL; Bolden-Watson C; Batey SR; Ascher JA; Metz A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001007: Anxiety; D016642: Bupropion; D003865: Depressive Disorder, Major; D018765: Dopamine Uptake Inhibitors; D005260: Female; D006801: Humans; D008297: Male; D008609: Mental Status Schedule; D008875: Middle Aged; D017367: Selective Serotonin Reuptake Inhibitors; D020280: Sertraline; D016896: Treatment Outcome",,,https://openalex.org/W2127783813,131,18,1,1122,169,6,en,en
false,randomize controlled trial risperidone treatment aggression hospitalize adolescent subaverage cognitive ability,article abstractbackground risperidone atypicalantipsychotic drug block dopamine well serotoninreceptor system present study design examine theefficacy safety risperidone week double blind randomize parallel group design treatment aggressionin adolescent primary diagnosis dsm iv disruptivebehavior disorder subaverage intelligence method randomly assign adolescent boy subject slightly subaverage iq borderline iq mild mental retardation whowere hospitalize treatment psychiatric disordersassociated severe aggression receive risperidone orplacebo main efficacy measure clinical globalimpressions severity illness scale cgi modify overtaggression scale oas aberrant behavior checklist abc side effect measure use extrapyramidalsymptom rating scale esr result mean daily dose risperidone atthe end treatment mg range mg risperidone compare placebo associate significantimprovements cgi p school abcoverall hyperactivity scale p weekwashout follow week trial statistically significantworsening find risperidone group cgi scale oas abc extrapyramidal symptom absent orvery mild risperidone treatment transient tiredness waspresent drug treat subject untowardeffects include sialorrhea nausea slight weight gain mean body weight risperidone group clinicallyrelevant change find laboratory parameter electrocardiogram heart rate blood pressure conclusion result suggest thatrisperidone may effective severe aggression adolescentswith disruptive behavior disorder subaverage intelligence result consistent report suggest itseffectiveness treat severe aggression adolescent ingeneral,Buitelaar JK,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n0405,11379837,Buitelaar JK; van der Gaag RJ; Cohen-Kettenis P; Melman CT,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000374: Aggression; D014150: Antipsychotic Agents; D019958: Attention Deficit and Disruptive Behavior Disorders; D001480: Basal Ganglia Diseases; D015897: Comorbidity; D004311: Double-Blind Method; D005260: Female; D006760: Hospitalization; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2066448639,139,18,1,2081,333,13,en,en
false,long term olanzapine therapy treatment bipolar disorder,olanzapine demonstrate efficacy treatment acute mania double blind placebo control trial describe result open label extension one trial week double blind study patient dsm iv bipolar disorder olanzapine superior placebo treatment acute manic symptom patient enter double blind phase week study patient continue week open label extension efficacy measurement include young mania rating scale ymrs item hamilton rating scale depression ham clinical global impression scale bipolar version positive negative syndrome scale safety measurement include simpson angus scale barnes akathisia scale abnormal involuntary movement scale complete throughout analysis consider treatment result start first olanzapine dose adjunctive lithium fluoxetine allow open label extension mean length olanzapine treatment month mean modal dose mg day significant mean improvement ymrs total score baseline endpoint p observe treatment patient experience remission manic symptom ymrs total score subsequently relapse ymrs total score significant improvement ham score observe p forty one percent patient maintain olanzapine monotherapy common treatment emergent adverse event report somnolence depression weight gain year olanzapine therapy either monotherapy combination lithium fluoxetine patient bipolar disorder demonstrate significant improvement mania depression symptom favorable safety profile double blind control study need confirm result,Sanger TM,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n0410,11379842,Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D003866: Depressive Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008094: Lithium; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D012890: Sleep; D016896: Treatment Outcome; D015430: Weight Gain",,,https://openalex.org/W2006917640,67,10,1,2014,343,12,en,en
false,late term smoke cessation despite initial failure evaluation bupropion sustain release nicotine patch combination therapy placebo,purpose study evaluate efficacy long term use bupropion sustain release sr nicotine patch combination treatment patient initially fail treatment post hoc analysis multicenter double blind randomize placebo control clinical trial smoker patient randomly assign week treatment placebo n bupropion sr n nicotine patch n combination nicotine patch bupropion sr n study originally design follow period week analysis short term success define smoke cessation day therapy long term success define smoke cessation day therapy patient achieve short term success evaluate long term success week end treatment month year start study mean age smoker year majority patient white female study subject smoke average cigarette per day among patient initially fail treatment first week treatment bupropion sr alone combination nicotine patch produce significant increase successful smoke cessation rate week bupropion sr combination nicotine patch placebo month bupropion sr combination nicotine patch placebo month bupropion sr combination nicotine patch placebo p bupropion sr combination v nicotine patch placebo among patient initially fail treatment continue therapy bupropion sr either alone combination nicotine patch result significantly high short long term smoke cessation rate treatment nicotine patch alone placebo,Jamerson BD,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80023-0,11394732,Jamerson BD; Nides M; Jorenby DE; Donahue R; Garrett P; Johnston JA; Fiore MC; Rennard SI; Leischow SJ,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000279: Administration, Cutaneous; D000328: Adult; D016642: Bupropion; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D009538: Nicotine; D016540: Smoking Cessation; D014029: Tobacco Use Disorder; D017211: Treatment Failure; D016896: Treatment Outcome",,,https://openalex.org/W2073891038,147,22,1,1932,384,8,en,en
false,intramuscular im ziprasidone mg effective reduce acute agitation associate psychosis double blind randomize trial,rationale intramuscular im conventional antipsychotic benzodiazepine effective short term treatment acutely agitate psychotic patient may associate adverse effect short act im formulation novel antipsychotic ziprasidone may offer advantage conventional agent develop objective compare ziprasidone im mg n mg n acute control short term management agitate psychotic patient method prospective randomize double blind h study assess efficacy use behavioral activity rating scale bar panss bar validate rating scale assessment treatment response acute agitation associate psychosis follow initial dose three could give h apart need h period result mean bar score decrease min first mg im dose statistically significantly low mg group min post dose improvement mg dose increase h maintain least h post dose p two hour first injection almost patient receive ziprasidone mg bar responder compare one third receive mg ziprasidone p calm effect ziprasidone also evident significant reduction panss agitation item p cgi severity h p ziprasidone well tolerate ziprasidone im mg associate eps dystonia akathisia respiratory depression excessive sedation conclusion ziprasidone im mg substantially significantly reduce symptom acute agitation patient psychotic disorder ziprasidone mg im well tolerate produce dystonia akathisia,Daniel DG,2001,Psychopharmacology (Berl),https://doi.org/10.1007/s002130000658,11401000,Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation; D011618: Psychotic Disorders; D013844: Thiazoles",,,https://openalex.org/W2158988332,137,22,1,1886,337,14,en,en
false,bupropion sr worsen mood marijuana withdrawal human,rationale symptom withdrawal daily marijuana smoke include increased rating irritability depression similar mood symptom report cigarette smoker nicotine abstinence objective give successful use sustain release bupropion treat nicotine dependence study investigate maintenance bupropion influence symptom marijuana withdrawal compare maintenance placebo method marijuana smoker n maintain outpatient active mg day placebo mg day bupropion day maintain inpatient bupropion dose day first inpatient day participant smoke active marijuana delta tetrahydrocannabinol thc time day remain inpatient day participant smoke placebo marijuana thc time day participant maintain outpatient alternate dose bupropion day follow second inpatient residential stay parallel first medication administration double blind mood psychomotor task performance food intake sleep measure daily inpatient phase order active placebo bupropion maintenance counterbalance group result bupropion behavioral effect participant smoke active marijuana placebo marijuana smoke e active marijuana withdrawal rating irritability restlessness depression trouble sleep increase bupropion compare placebo maintenance conclusion data suggest bupropion show promise potential treatment medication marijuana dependence,Haney M,2001,Psychopharmacology (Berl),https://doi.org/10.1007/s002130000657,11401006,Haney M; Ward AS; Comer SD; Hart CL; Foltin RW; Fischman MW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000339: Affect; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D002188: Cannabis; D004435: Eating; D005260: Female; D006801: Humans; D008297: Male; D011597: Psychomotor Performance; D012890: Sleep; D012907: Smoking; D012919: Social Behavior; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W1970664643,63,9,1,1694,270,13,en,en
false,effect olanzapine haloperidol serum prolactin level male schizophrenic patient,propose new atypical antipsychotic cause minimal prolactin prl elevation compare traditional antipsychotic agent spare dopamine blockade within brain tuberoinfundibular tract aim study compare effect olanzapine haloperidol prl secretion male schizophrenic patient twenty nine male schizophrenic inpatient include study fifteen give olanzapine fix dose mg day po give haloperidol fix dose mg day po week week drug washout period fifteen age match healthy control subject use control group prl level measure week treatment period patient end th week prl value observe olanzapine treatment significantly less observe haloperidol different control significant positive correlation prl value severity extrapyramidal side effect haloperidol group six week treatment period data indicate short term olanzapine treatment dos mg day po cause minimal elevation prl secretion male schizophrenic patient contrast haloperidol find consistent previous report may attribute olanzapine differential effect dopamine neurotransmission,Esel E,2001,Psychoneuroendocrinology,https://doi.org/10.1016/s0306-4530(01)00016-6,11403983,Esel E; Basturk M; Saffet Gonul A; Kula M; Tayfun Turan M; Yabanoglu I; Sofuoglu S,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011388: Prolactin; D012559: Schizophrenia,,,https://openalex.org/W2012800223,94,13,1,1467,242,10,en,en
false,pharmacological control opioid induce pruritus quantitative systematic review randomize trial,numerous drug use prevent treat opioid induce pruritus surgical set relative efficacy well understood method employ involve systematic search medline embase cochrane library bibliography without language restriction june full report randomize comparison intervention think anti pruritic active compare placebo treatment control surgical include labour patient receive opioids number patient pruritus analyse use relative risk number need treat confidence interval twenty two trial patient analyse two trial patient low dose propofol treatment establish pruritus propofol anti pruritic effect compare intralipid prophylaxis trial average incidence pruritus control range mu receptor antagonist efficacious intravenous naloxone microg kg h relative risk confidence interval number need treat prevent pruritus compare control oral naltrexone mg relative risk number need treat naltrexone mg less effective mg work different intravenous epidural nalbuphine regimen relative risk number need treat intravenous nalmefene mg anti pruritic intravenous epidural droperidol mg efficacious relative risk number need treat lack evidence anti pruritic efficacy prophylactic propofol epidural intrathecal epinephrine epidural clonidine epidural prednisone intravenous ondansetron intramuscular hydroxyzine naloxone naltrexone nalbuphine droperidol efficacious prevention opioid induce pruritus minimal effective remain unknown lack valid data efficacy intervention treatment establish pruritus,Kjellberg F,2001,Eur J Anaesthesiol,https://doi.org/10.1046/j.0265-0215.2000.00826.x,11412287,Kjellberg F; Tramèr MR,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D000078182: Systematic Review","D000701: Analgesics, Opioid; D002986: Clinical Trials as Topic; D006801: Humans; D009270: Naloxone; D009292: Narcotic Antagonists; D011537: Pruritus",,,https://openalex.org/W2131776074,105,13,1,2097,351,10,en,en
false,cancer fatigue one drug fail pipeline,,McNeil C,2001,J Natl Cancer Inst,https://doi.org/10.1093/jnci/93.12.892,11416103,McNeil C,article,D016433: News,D002986: Clinical Trials as Topic; D003863: Depression; D003907: Dexamethasone; D005221: Fatigue; D006801: Humans; D009369: Neoplasms; D017374: Paroxetine; D011239: Prednisolone; D017367: Selective Serotonin Reuptake Inhibitors; D017211: Treatment Failure,,,https://openalex.org/W2161678978,59,12,1,0,0,0,en,
false,dose response relationship clonidine add postoperative continuous epidural infusion ropivacaine child,epidurally administer clonidine enhance quality duration postoperative analgesia use adjunct local anesthetic child investigate dose response relationship epidural clonidine add continuous postoperative epidural infusion ropivacaine use observer blind design pediatric patient yr old randomly give postoperative epidural infusion plain ropivacaine mg kg h group r ropivacaine mg kg h plus clonidine microg kg h group rc ropivacaine mg kg h plus clonidine microg kg h group rc ropivacaine mg kg h plus clonidine microg kg h group rc clear dose response relationship could identify continuous infusion epidural clonidine clonidine dosage microg kg h range provide improve postoperative analgesia reduce child hospital eastern ontario pain score increase time first supplemental analgesic demand reduce total number supplemental analgesic first h surgery analgesia improve without sign increase sedation side effect adjunct use epidural clonidine dosage range microg kg h appear effective safe use child addition clonidine microg kg h continuous epidural infusion ropivacaine find improve postoperative pain relief child clinically significant sign sedation side effect observe,De Negri P,2001,Anesth Analg,https://doi.org/10.1097/00000539-200107000-00016,11429342,De Negri P; Ivani G; Visconti C; De Vivo P; Lonnqvist PA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000577: Amides; D015360: Analgesia, Epidural; D000758: Anesthesia; D000779: Anesthetics, Local; D002675: Child, Preschool; D003000: Clonidine; D016292: Conscious Sedation; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D006801: Humans; D007223: Infant; D008297: Male; D010149: Pain, Postoperative; D000077212: Ropivacaine",,,https://openalex.org/W2093771771,125,16,1,1684,350,21,en,en
true,placebo control study guanfacine treatment child tic disorder attention deficit hyperactivity disorder,study evaluate efficacy safety guanfacine treat child tic disorder attention deficit hyperactivity disorder adhd subject specialty tic disorder clinic randomly assign receive week treatment guanfacine placebo double blind condition follow visit occur every week safety monitoring dose adjustment thirty four medication free subject boy three girl mean age year adhd combine type tic disorder participate week treatment guanfacine associate mean improvement total score teacher rat adhd rating scale compare improvement placebo nine subject receive guanfacine blindly rat clinical global improvement scale either much improve much improve compare none subject receive placebo mean score parent rat hyperactivity index improve guanfacine group placebo group significant difference continuous performance test commission error decrease omission error guanfacine group compare increase commission error omission error placebo group tic severity decrease guanfacine group compare placebo group one guanfacine subject sedation withdraw week guanfacine associate insignificant decrease blood pressure pulse guanfacine appear safe effective treatment child tic disorder adhd,Scahill L,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.7.1067,11431228,Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D015897: Comorbidity; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D016316: Guanfacine; D006801: Humans; D008297: Male; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D013663: Teaching; D013981: Tic Disorders; D016896: Treatment Outcome,,,https://openalex.org/W2164549762,133,18,1,1647,287,9,en,en
false,dropout rate randomise antipsychotic drug trial,rationale assume new atypical drug improve treatment compliance due adverse effect data support assumption scarce objective aim study study attrition rate randomise control trial oral administration conventional antipsychotic drug atypical antipsychotic drug placebo method database schizophrenia module cochrane library utilise present study data cochrane module collect identify relevant randomise control trial several electronic database source number dropout define patient leave study preterm due reason result data treatment group consist randomise subject drug trial enter analysis one third subject drop trial dropout rate significantly increase calendar year year trial publication type drug trial length remain statistically significant contributor dropout rate model incorporate year publication trial length placebo group group treat conventional antipsychotic significantly high attrition rate group treat atypical drug clozapine treat group exclude analysis statistically significant advantage atypical drug conventional drug remain conclusion trial data implicate good compliance achieve favour atypical drug rather conventional alternative treatment schizophrenia however effect find group treat atypical antipsychotic clozapine include analysis study find evidence statistically significant superiority acceptability novel atypical drug compare conventional antipsychotic,Wahlbeck K,2001,Psychopharmacology (Berl),https://doi.org/10.1007/s002130100711,11432684,Wahlbeck K; Tuunainen A; Ahokas A; Leucht S,article,D016428: Journal Article; D017418: Meta-Analysis,"D014150: Antipsychotic Agents; D016208: Databases, Factual; D006801: Humans; D010352: Patient Dropouts; D016032: Randomized Controlled Trials as Topic; D012107: Research Design",,,https://openalex.org/W1981210131,53,7,1,1921,299,15,en,en
false,qualitative assessment neurological safety antipsychotic drug analysis risperidone database,neurological side effect antipsychotic agent limit use drug development new antipsychotic agent focus reduce risk extrapyramidal symptom eps well effective symptom control qualitative analysis eps perform use extrapyramidal symptom rating scale esr data double blind risperidone trial esr factor analysis maximum change esr score compare risperidone haloperidol placebo group factor analysis reveal five factor group comparison show difference placebo mg day risperidone group parkinsonism tremor akathisia sialorrhea likely occur haloperidol placebo risperidone mg day similar result note maximum change esr score risperidone dos mg day acute eps severity lay placebo haloperidol group severity tardive dyskinesia great patient receive placebo receive either active treatment result describe derive post hoc analysis exist database conclusion must remain tentative provide definitive answer eps assessment future study refine accurately predict type eps expect give agent clinical practice,Fleischhacker WW,2001,Pharmacopsychiatry,https://doi.org/10.1055/s-2001-14282,11434401,Fleischhacker WW; Lemmens P; van Baelen B,article,D003160: Comparative Study; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D002986: Clinical Trials as Topic; D016208: Databases, Factual; D004311: Double-Blind Method; D005163: Factor Analysis, Statistical; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2078536491,113,17,1,1398,229,8,en,en
false,effect long term treatment antipsychotic serum leptin level,abnormal regulation adipocyte derive hormone leptin could play role body weight gain induce antipsychotic study effect long term antipsychotic treatment leptin level patient schizophrenia serum leptin level determine patient chronic schizophrenia number healthy subject control gender age body mass index leptin level differ patient control leptin level patient schizophrenia correlate weight gain even control current weight show association clinical variable antipsychotic class tend exert different effect leptin level among atypicals olanzapine induce great increase elevation leptin level induce chronic antipsychotic treatment attribute weight gain mechanism could involve,Herrán A,2001,Br J Psychiatry,https://doi.org/10.1192/bjp.179.1.59,11435270,Herrán A; García-Unzueta MT; Amado JA; de La Maza MT; Alvarez C; Vázquez-Barquero JL,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D002908: Chronic Disease; D005260: Female; D006801: Humans; D020738: Leptin; D008297: Male; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W2082322888,73,10,1,909,139,3,en,en
false,meta analysis compare new antipsychotic drug treatment schizophrenia evaluate indirect approach,background meta analysis useful method assess efficacy new antipsychotic drug compare old drug placebo however trial directly compare novel drug objective purpose study evaluate method indirect meta analysis apply data olanzapine versus haloperidol risperidone versus haloperidol enable comparison olanzapine risperidone method publish randomize control trial rcts risperidone olanzapine haloperidol identify literature search medline current content healthstar database review data brief psychiatric rating scale bprs total score positive negative syndrome scale panss negative subscale percentage patient use anticholinergic drug percentage patient drop due lack efficacy side effect cause extract combine use indirect method find compare direct comparative study olanzapine risperidone result literature search yield rcts compare risperidone haloperidol compare olanzapine haloperidol trial directly compare olanzapine risperidone find trial change bprs total panss negative subscale score tend high olanzapine respectively difference statistically significant indirect meta analysis yield similar result change bprs total score panss negative subscale score tend high olanzapine respectively difference statistically significant indirect meta analysis rate anticholinergic drug use great among patient treat risperidone among patient treat olanzapine p direct comparative rct rate high among patient treat risperidone p dropout rate similar patient treat risperidone treat olanzapine analysis conclusion indirect meta analysis study compare olanzapine haloperidol risperidone haloperidol yield conclusion similar find direct comparative rct olanzapine risperidone,Sauriol L,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80082-5,11440294,Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't","D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002986: Clinical Trials as Topic; D004359: Drug Therapy, Combination; D006220: Haloperidol; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W2101619662,118,15,1,2394,397,15,en,en
false,comparative study mortality rate cardiac dysrhythmias post marketing surveillance study sertindole two atypical antipsychotic drug risperidone olanzapine,sertindole serdolect atypical antipsychotic voluntarily suspend european union follow regulatory concern report serious cardiac dysrhythmias sudden unexpected death report cause death frequency prolongation rate correct qt interval qtc cardiac dysrhythmias patient prescribe sertindole compare patient treat two atypical antipsychotic patient england prescribe atypical antipsychotic general practitioner drug immediate post marketing period identify use observational cohort technique prescription event monitor mortality rate sertindole cohort compare comparator cohort use standardized mortality ratio incidence rate ratio cardiovascular event review follow identify case prolongation qtc interval statistically significant difference mortality rate sertindole comparator cohort although confidence interval ci wide due small number sertindole cohort much small number patient prescribe sertindole antipsychotic six case prolongation qtc interval identify patient ci treat sertindole one unspecified electrocardiogram change comparator cohort patient study contribute understand occurrence prolongation qtc interval clinical use sertindole incidence similar clinical trial although statistically significant difference show mortality rate sertindole comparator cohort sertindole cohort small rule association use drug cardiovascular death,Wilton LV,2001,J Psychopharmacol,https://doi.org/10.1177/026988110101500212,11448085,Wilton LV; Heeley EL; Pickering RM; Shakir SA,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D001569: Benzodiazepines; D015331: Cohort Studies; D003645: Death, Sudden; D004562: Electrocardiography; D005062: European Union; D005260: Female; D006801: Humans; D007093: Imidazoles; D007211: Indoles; D008133: Long QT Syndrome; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011358: Product Surveillance, Postmarketing; D018967: Risperidone; D012737: Sex Factors",,,https://openalex.org/W2044429484,185,24,1,1883,294,10,en,en
false,double blind placebo control trial clonidine hyperactive child mental retardation,week double blind randomize placebo control trial oral clonidine three fix mcg kg day use crossover design conduct child hyperkinetic disorder mean age year comorbid mental retardation parent rating parent symptom questionnaire clinician rating hillside behaviour rating scale show mark dose relate response clonidine hyperactivity impulsivity inattention drowsiness common side effect clonidine wear nd th week case thus clonidine safe effective medication young hyperkinetic child comorbid mental retardation,Agarwal V,2001,Ment Retard,https://doi.org/10.1352/0047-6765(2001)039<0259:dbpcto>2.0.co;2,11448249,Agarwal V; Sitholey P; Kumar S; Prasad M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003000: Clonidine; D015897: Comorbidity; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D010552: Personality Assessment",,,https://openalex.org/W2178541554,99,12,1,713,126,6,en,en
false,olanzapine treatment post traumatic stress disorder pilot study,atypical antipsychotic olanzapine may efficacious treat post traumatic stress disorder ptsd symptom conduct week double blind placebo control evaluation patient randomize either olanzapine placebo initial dosage mg day titrate maximum mg day eleven patient complete study patient group show improvement ptsd symptom group difference treatment response observe high placebo response rate find treatment tolerate well although olanzapine treatment group weight gain olanzapine fare good placebo preliminary study treatment ptsd lack difference olanzapine placebo may part due olanzapine effective ptsd alternatively small sample size high placebo response certain form ptsd chronicity ptsd symptom patient,Butterfield MI,2001,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-200107000-00003,11459333,Butterfield MI; Becker ME; Connor KM; Sutherland S; Churchill LE; Davidson JR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010865: Pilot Projects; D010890: Pirenzepine; D013313: Stress Disorders, Post-Traumatic; D016896: Treatment Outcome",,,https://openalex.org/W1983805393,76,12,1,1005,173,7,en,en
true,adult adhd,many adult adhd respond stimulant therapy control medication assessment report administer effortful work memory task four half day session double blind methylphenidate level mg dose response curve establish individually fifteen patient display favorable response one level medication achieve correct response less variability placebo dose level elicit optimal performance patient unlike monitor self report objective medication assessment offer expeditious approximation ultimate optimal dose potentially save patient week ineffective excessive dosage regime,Kinsbourne M,2001,Ann N Y Acad Sci,https://doi.org/10.1111/j.1749-6632.2001.tb05785.x,11462747,Kinsbourne M; De Quiros GB; Tocci Rufo D,article,D016428: Journal Article; D016454: Review,"D001245: Association Learning; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D004305: Dose-Response Relationship, Drug; D006801: Humans; D016896: Treatment Outcome",,,https://openalex.org/W2010661621,10,2,1,774,126,5,en,en
false,clonidine prevents sevoflurane induce agitation child,double blind trial male child age yr undergo circumcision randomly assign receive clonidine microg kg iv placebo anesthetic induction induction maintenance anesthesia use sevoflurane sole anesthetic pain treatment penile block perform surgery surgery incidence severity agitation measure observation period h severe agitation treat midazolam placebo clonidine treat patient agitation observe p patient placebo group agitation grade severe whereas none patient clonidine group develop severe agitation p postoperative period heart rate blood pressure significantly decrease clonidine treat patient p conclude clonidine effectively prevent agitation sevoflurane anesthesia recovery sevoflurane anesthesia may complicate presence agitation pediatric patient clonidine microg kg iv anesthetic induction effectively reduce incidence agitation without result clinically relevant bradycardia hypotension,Kulka PJ,2001,Anesth Analg,https://doi.org/10.1213/00000539-200108000-00019,11473855,Kulka PJ; Bressem M; Tryba M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D018685: Anesthetics, Inhalation; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D008297: Male; D008738: Methyl Ethers; D008874: Midazolam; D011595: Psychomotor Agitation; D000077149: Sevoflurane",,,https://openalex.org/W2095016438,60,6,1,1224,199,9,en,en
false,randomize placebo control trial lofexidine hydrochloride chronic pelvic pain woman,background hypothesise orally active adrenoceptor agonist lofexidine hydrochloride would ameliorate chronic pelvic pain woman method randomize placebo control parallel group trial undertake university hospital gynaecology clinic woman pelvic pain least month duration eligible randomize use seal envelope system receive mg lofexidine hydrochloride twice daily week placebo outcome measure summary daily diary visual analog scale pain va point self rating scale result woman randomize lofexidine complete study compare randomize placebo intention treat analysis show lofexidine group achieve great reduction va compare placebo group ci summary diary va closely correlated conclusion within limit small study power detect substantial effect conclude lofexidine hydrochloride effective treatment chronic pelvic pain,Stones RW,2001,Hum Reprod,https://doi.org/10.1093/humrep/16.8.1719,11473971,Stones RW; Bradbury L; Anderson D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000082: Acetaminophen; D000316: Adrenergic alpha-Agonists; D000894: Anti-Inflammatory Agents, Non-Steroidal; D015992: Body Mass Index; D002908: Chronic Disease; D003000: Clonidine; D003061: Codeine; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D017699: Pelvic Pain; D010919: Placebos; D016896: Treatment Outcome",,,https://openalex.org/W2096019576,96,13,1,1120,180,1,en,en
false,double blind randomize prospective evaluation efficacy safety risperidone versus haloperidol treatment schizoaffective disorder,relative efficacy safety risperidone versus haloperidol treatment schizoaffective disorder study sixty two patient depress type bipolar type enter three site randomize double blind week trial risperidone mg day haloperidol mg day train raters assess baseline weekly end study level psychopathology positive negative syndrome scale panss item hamilton rating scale depression ham clinician administer rating scale mania car author unable statistically distinguish risperidone haloperidol amelioration psychotic manic symptom addition difference worsen mania two agent either subgroup e depress bipolar subgroup total panss risperidone produce mean decrease point baseline compare point decrease haloperidol total car scale risperidone haloperidol produce mean change score point respectively car mania subscale point respectively additionally risperidone produce mean decrease point baseline item ham compare point decrease haloperidol patient severe depressive symptom e ham baseline score risperidone produce least mean improvement patient comparison patient receive haloperidol haloperidol produce significantly extrapyramidal side effect result dropout cause side effect difference risperidone haloperidol reduce psychotic manic symptom group patient schizoaffective disorder risperidone demonstrate propensity precipitate mania well tolerate haloperidol subject high baseline ham score e risperidone produce great improvement depressive symptom haloperidol,Janicak PG,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200108000-00002,11476119,Janicak PG; Keck PE; Davis JM; Kasckow JW; Tugrul K; Dowd SM; Strong J; Sharma RP; Strakowski SM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001714: Bipolar Disorder; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone,,,https://openalex.org/W2060953871,156,22,1,2104,364,13,en,en
false,double blind randomize comparison efficacy safety intramuscular injection olanzapine lorazepam placebo treat acutely agitate patient diagnose bipolar mania,rapid act intramuscular formulation atypical antipsychotic available quickly calm agitate patient bipolar disorder study agitate patient bipolar mania randomly assign receive one three injection atypical antipsychotic olanzapine mg first two injection mg third injection benzodiazepine lorazepam mg first two injection mg third injection placebo placebo first two injection olanzapine mg third injection within hour period agitation measure baseline every minute first hour hour first injection use positive negative syndrome scale excite component subscale two additional agitation scale hour first injection patient treat olanzapine show significantly great reduction score agitation scale compare patient treat either placebo lorazepam hour first injection olanzapine remain statistically superior placebo reduce agitation patient acute mania whereas patient treat lorazepam significantly different treat placebo olanzapine furthermore significant difference among three treatment group observe safety measure include treatment emergent extrapyramidal symptom incidence acute dystonia qtc interval change find suggest intramuscular olanzapine safe effective treatment reduce acute agitation patient bipolar mania,Meehan K,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200108000-00006,11476123,Meehan K; Zhang F; David S; Tohen M; Janicak P; Small J; Koch M; Rizk R; Walker D; Tran P; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000339: Affect; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D018680: Cholinergic Antagonists; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D007273: Injections, Intramuscular; D008140: Lorazepam; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation; D016896: Treatment Outcome",,,https://openalex.org/W2037172357,196,29,1,1619,264,7,en,en
false,evaluation risperidone drug interaction,risperidone atypical antipsychotic drug widely use treatment psychosis associate schizophrenia alzheimer disease psychiatric disorder polypharmacology necessary condition optimal treatment many patient comorbid psychiatric medical illness one concern raise widespread use multiple concurrent pharmacotherapies potential drug drug interaction adversely affect patient outcome accordingly biomedical literature review report drug interaction involve risperidone clinical significance report evaluate additionally potential risperidone participate drug interaction evaluate consider drug pharmacokinetic property control study case report indicate risperidone low potential metabolic drug interaction drug inhibit cytochrome p cyp induce inhibit cyp may alter risperidone plasma concentration clinical significance interaction seem minimal adherence guideline design dosage regimen limit effect drug drug interaction patient status contribute optimal pharmacotherapy risperidone,DeVane CL,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200108000-00008,11476125,DeVane CL; Nemeroff CB,article,D016428: Journal Article; D017418: Meta-Analysis,D000927: Anticonvulsants; D000928: Antidepressive Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001798: Blood Proteins; D002317: Cardiovascular Agents; D018680: Cholinergic Antagonists; D003577: Cytochrome P-450 Enzyme System; D004347: Drug Interactions; D005765: Gastrointestinal Agents; D006801: Humans; D008099: Liver; D011485: Protein Binding; D018967: Risperidone,,,https://openalex.org/W2047647486,46,6,1,1282,196,8,en,en
false,double blind comparative study clozapine risperidone management severe chronic schizophrenia,prospective double blind multicenter parallel group study compare efficacy safety therapeutic clozapine risperidone patient severe chronic schizophrenia poor previous treatment response male female patient age year meet dsm iv criterion schizophrenia study requirement poor previous treatment response n randomly assign double blind treatment either clozapine risperidone administer week increase increment primary efficacy measure magnitude improvement brief psychiatric rating scale bprs clinical global impression cgi score adverse event record throughout study magnitude improvement mean bprs cgi score baseline end study significantly great clozapine group risperidone group statistically significant difference favor clozapine also see secondary efficacy measure positive negative syndrome scale calgary depression scale psychotic depression scale psychotic anxiety scale adverse event profile similar treatment group low risk extrapyramidal symptom clozapine group clozapine show superior efficacy risperidone patient population treatment equally well tolerate demonstrate adverse event profile although expect clozapine associate low risk extrapyramidal symptom risperidone,Azorin JM,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.8.1305,11481167,Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D012307: Risk Factors; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2167573026,111,15,1,1554,236,6,en,en
true,efficacy mixed amphetamine salt compound adult attention deficit hyperactivity disorder,report control trial mixed amphetamine salt compound adderall dextroamphetamine sulfate dextro levoamphetamine sulfate dextroamphetamine aspartate levoamphetamine aspartate dextroamphetamine saccharate treatment adult attention deficit hyperactivity disorder adhd week randomize double blind placebo control crossover study adderall well characterize adult satisfy full dsm iv criterion adhd childhood onset persistent symptom adulthood medication titrate mg twice day outcome measure include adhd rating scale clinical global impression score comorbid psychiatric disorder assess test potential effect treatment outcome treatment adderall average oral dose mg administer daily effective well tolerate drug specific improvement adhd symptom highly significant overall decrease adhd rating scale p sufficiently robust detectable parallel group comparison restrict first week protocol p percentage subject improve reduction adhd rating scale significantly high adderall treatment placebo v p adderall effective well tolerate short term treatment adult adhd work need evaluate long term effect adderall amphetamine compound treatment adult adhd,Spencer T,2001,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.58.8.775,11483144,Spencer T; Biederman J; Wilens T; Faraone S; Prince J; Gerard K; Doyle R; Parekh A; Kagan J; Bearman SK,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000367: Age Factors; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D001523: Mental Disorders; D008875: Middle Aged; D009483: Neuropsychological Tests; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome,,,https://openalex.org/W2169861403,102,12,1,1550,267,7,en,en
false,attention deficit hyperactivity disorder adult,,Gadow KD,2001,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.58.8.784,11483145,Gadow KD; Weiss M,article,D016420: Comment; D016428: Journal Article,D000328: Adult; D000367: Age Factors; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D015897: Comorbidity; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D006801: Humans; D001523: Mental Disorders; D018579: Patient Selection; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2092817031,50,4,1,0,0,0,en,
false,randomize double blind placebo control trial docosahexaenoic acid supplementation child attention deficit hyperactivity disorder,determine whether docosahexaenoic acid dha supplementation month decrease symptom attention deficit hyperactivity disorder adhd sixty three year old child adhd receive effective maintenance therapy stimulant medication assign randomly double blind fashion receive dha supplementation mg placebo month outcome variable include plasma phospholipid fatty acid pattern score laboratory measure inattention impulsivity test variable attention child color trail test take stimulant medication score parental behavioral rating scale child behavior checklist conners rating scale difference group month dha supplementation placebo administration determine analysis variance control age baseline value outcome variable ethnicity adhd subtype plasma phospholipid dha content dha supplement group fold high end study placebo group vs mol total fatty acid p despite statistically significant improvement objective subjective measure adhd symptom month period dha supplementation mg decrease symptom adhd,Voigt RG,2001,J Pediatr,https://doi.org/10.1067/mpd.2001.116050,11487742,Voigt RG; Llorente AM; Jensen CL; Fraley JK; Berretta MC; Heird WC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002652: Child Behavior; D004281: Docosahexaenoic Acids; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D010743: Phospholipids,,,https://openalex.org/W2111614110,150,16,1,1356,225,4,en,en
false,steady state pharmacokinetics tolerability modafinil give alone combination methylphenidate healthy volunteer,potential pharmacokinetic pk drug drug interaction modafinil methylphenidate steady state investigate open label randomize single period study healthy male female volunteer subject receive modafinil daily orally day mg day mg day day half subject also receive mg methylphenidate orally hour modafinil dose pk profile modafinil obtain day compare two group statistically significant difference treatment group mean change pk parameter modafinil parameter metabolite also similar group treatment well tolerate result indicate administration low dose methylphenidate hour treatment modafinil appearto alterthe steady state pharmacokinetics modafinil healthy volunteer,Hellriegel ET,2001,J Clin Pharmacol,https://doi.org/10.1177/00912700122010690,11504278,Hellriegel ET; Arora S; Nelson M; Robertson P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D000077408: Modafinil",,,https://openalex.org/W2108866348,132,16,1,998,168,7,en,en
false,therapy smoke cessation antidepressant nicotine replacement counsel implication treatment patient chronic obstructive pulmonary disease,small percentage smoker state want stop smoking next half year succeed due addictive nature smoke cigarette also psychological social factor approximately people use nicotine replacement therapy return smoking time therefore interest non nicotine pharmacotherapy increase considerably recent year antidepressant bupropion nortriptyline compare placebo particularly effective smoke cessation aid relative risk rr nortriptyline ci rrbupropion ci combine strategy nicotine replacement therapy counsel antidepressant bupropion nortriptyline counsel physiological well psychological aspect smoke cessation treat seem effective although smoke cessation see single important way prevent deterioration lung function stage chronic obstructive pulmonary disease copd little research conduct amongst copd patient especially use antidepressant bupropion nortriptyline seem particularly interesting treatment patient copd smoke cigarette major risk factor development disease also copd patient high normal prevalence depression furthermore association find smoke cigarette depression presence depression depressive symptom appear important cause relapse,Wagena EJ,2001,Ned Tijdschr Geneeskd,,11512420,Wagena EJ; Huibers MJ; van Schayck CP,article,D016428: Journal Article; D016454: Review,"D000279: Administration, Cutaneous; D000928: Antidepressive Agents; D003131: Combined Modality Therapy; D003376: Counseling; D006801: Humans; D008173: Lung Diseases, Obstructive; D009538: Nicotine; D018722: Nicotinic Agonists; D016032: Randomized Controlled Trials as Topic; D055502: Secondary Prevention; D012907: Smoking; D016540: Smoking Cessation; D000074606: Smoking Prevention",,,https://openalex.org/W106464869,179,26,1,1687,287,10,en,en
false,placebo control comparison effect sexual functioning bupropion sustain release fluoxetine,many antidepressant associate sexual dysfunction side effect may lead patient dissatisfaction noncompliance treatment study compare efficacy tolerability effect sexual functioning bupropion sustain release bupropion sr selective serotonin reuptake inhibitor fluoxetine multicenter randomize double blind double dummy parallel group study patient recurrent major depression treat bupropion sr mg fluoxetine mg placebo week depression sexual functioning status assess site specific trained investigator weekly clinic visit tolerability assess primarily monitor adverse event four hundred fifty six patient participate study receive bupropion sr fluoxetine placebo majority patient group complete study bupropion sr n fluoxetine n placebo n bupropion sr fluoxetine similarly effective treatment depressive symptom begin week continue throughout study significantly fluoxetine treat patient experience orgasm dysfunction patient receive bupropion sr placebo p similar result see patient define clinical responder decrease baseline item hamilton rating scale depression ham total score p experience remission depression ham total score p various time point worsen sexual function sexual desire disorder sexual arousal disorder dissatisfaction sexual functioning satistied baseline frequently associate fluoxetine treatment bupropion sr placebo active treatment well tolerate bupropion sr fluoxetine similarly effective well tolerate treatment depression fluoxetine however frequently associate sexual dysfunction compare bupropion sr bupropion sr may appropriate initial choice treatment depression patient concern sexual functioning,Coleman CC,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80090-4,11519769,Coleman CC; King BR; Bolden-Watson C; Book MJ; Segraves RT; Richard N; Ascher J; Batey S; Jamerson B; Metz A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008297: Male; D015337: Multicenter Studies as Topic; D010349: Patient Compliance; D017060: Patient Satisfaction; D012735: Sexual Dysfunction, Physiological",,,https://openalex.org/W2096527989,114,15,1,2224,372,8,en,en
false,methylphenidate oros formulation,methylphenidate cns stimulant think block reuptake dopamine noradrenaline norepinephrine presynaptic neuron sustain release oros formulation drug develop use child attention deficit hyperactivity disorder adhd child age year adhd maximum plasma concentration oros methylphenidate mg reach approximately hour adult plasma concentration time profile oros methylphenidate differ markedly sustain release immediate release ir methylphenidate formulation clinical trial involve child adhd daily oros methylphenidate mg significantly effective placebo demonstrate effect similar ir methylphenidate mg time daily reduce symptom adhd oros methylphenidate demonstrate sustain efficacy year noncomparative study involve child adhd clinical trial oros formulation methylphenidate tolerability profile similar ir methylphenidate,Keating GM,2001,CNS Drugs,https://doi.org/10.2165/00023210-200115060-00006,11524026,Keating GM; McClellan K; Jarvis B,article,D016428: Journal Article,D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002986: Clinical Trials as Topic; D018765: Dopamine Uptake Inhibitors; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate,,,https://openalex.org/W1967870254,35,7,2,1133,186,7,en,en
false,relative efficacy propose space shuttle antimotion sickness medication,space motion sickness estimate affect space flight participant nasa moment propose combination promethazine ephedrine p e one scopolamine dextroamphetamine give orally well transdermally apply scopolamine ta preventive ameliorative measure report double blind study test early phase action efficacy transdermal scopolamine transderm tm v alza corporation compare detail oral medication motion sickness resistance test standardize head movement accelerate degree sec maximum rotation degree sec intermediate plateau min degree sec permit weight motion sickness protection system influence cardiovascular psychological subjective objective visual parameter change document three therapeutic mode relative impact various modality operational experimental component space mission discus comparison intramuscularly administer promethazine backup therapeutic mode suggest space shuttle use also include,Hordinsky JR,1982,Acta Astronaut,https://doi.org/10.1016/0094-5765(82)90065-0,11541691,Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000279: Administration, Cutaneous; D000284: Administration, Oral; D000328: Adult; D000337: Aerospace Medicine; D000932: Antiemetics; D000697: Central Nervous System Stimulants; D003913: Dextroamphetamine; D004311: Double-Blind Method; D004341: Drug Evaluation; D004359: Drug Therapy, Combination; D004809: Ephedrine; D019416: Head Movements; D006439: Hemodynamics; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D011398: Promethazine; D011581: Psychological Tests; D012399: Rotation; D012601: Scopolamine; D018489: Space Motion Sickness; D018544: Weightlessness Countermeasures",,,https://openalex.org/W2085566841,79,10,1,1236,204,7,en,en
false,retract article urapidil prevent postanesthetic shivering dose range study,investigate effect mg x kg mg x kg mg x kg urapidil incidence severity postanesthetic shiver one hundred fifty patient asa iii schedule elective abdominal urologic orthopedic surgery standardize general anesthesia randomly allocate one five group group n use double blind protocol group receive mg x kg urapidil group b mg x kg urapidil group c mg x kg urapidil group microg x kg clonidine positive control group group e saline placebo negative control group postanesthetic shiver score use five point scale twelve patient group group b nine group c three group group e show sign postanesthetic shiver postanesthetic shiver significantly decrease clonidine group compare three urapidil group placebo group significantly less patient treat clonidine need anti shiver therapy significant difference urapidil placebo group therapeutic intervention hemodynamic effect require group time extubation time discharge prolong clonidine group urapidil show beneficial effect shiver evaluate whereas prophylactic administration clonidine effective prevent postanesthetic shivering,Piper SN,2001,Can J Anaesth,https://doi.org/10.1007/bf03016688,11546713,Piper SN; Fent MT; Röhm KD; Maleck WH; Suttner SW; Boldt J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000328: Adult; D000368: Aged; D000768: Anesthesia, General; D000959: Antihypertensive Agents; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D012768: Shivering",,,https://openalex.org/W50977444,91,13,1,1473,277,7,en,en
false,antipsychotic induce extrapyramidal syndrome,compare risk extrapyramidal syndrome eps patient use risperidone use low potency conventional antipsychotic drug apds outpatient clinical practice measure use anticholinergic medication try replicate result previous clinical trial compare risperidone high potency apds data obtain pharmo database contain filled prescription community dwell people netherlands patient age year newly treat apds define mutually exclusive cohort accord apd first prescribe patient apd exposure follow first prescription anticholinergic medication censor apd prescribe interrupt switch estimate relative risk risperidone commonly use low potency high potency apds use cox proportional hazard model adjust age gender dose potential confounders patient newly prescribe antipsychotic drug overall incidence rate anticholinergic drug therapy per person year dose dependent prescribed antipsychotic low accordance previous trial risperidone show low risk eps high potency apds haloperidol rr ci observe low eps rate low potency apds risperidone v thioridazine rr ci risperidone v pipamperone rr ci reduce eps rate observe compare risperidone high potency antipsychotic haloperidol may apply comparison low potency drug,Schillevoort I,2001,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280100302,11549212,Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D018680: Cholinergic Antagonists; D003625: Data Collection; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D012306: Risk; D018967: Risperidone,,,https://openalex.org/W2116898303,46,3,1,1743,282,7,en,en
false,treatment symptom schizophrenia combine analysis double blind study compare risperidone haloperidol antipsychotic agent,combine data efficacy available double blind short term maximum week trial compare risperidone antipsychotic patient chronic schizophrenia patient receive risperidone n antipsychotic n haloperidol n frequently prescribe antipsychotic efficacy assessment include positive negative syndrome scale panss total subscale positive symptom negative symptom general psychopathology cluster cognitive affective symptom item anxiety hostility score endpoint mean decrease baseline panss total score significantly great patient receive risperidone antipsychotic p subset receive haloperidol p risperidone treat patient show significantly great decrease positive p negative p general psychopathology p score patient receive antipsychotic haloperidol score cognition affective symptom anxiety hostility improve significantly p patient receive risperidone receive antipsychotic haloperidol efficacy data patient acute exacerbation available seven trial risperidone n antipsychotic n include haloperidol n endpoint mean decrease baseline panss total score significantly great patient receive risperidone antipsychotic p include haloperidol p risperidone treat patient also show great decrease positive symptom score receive antipsychotic p haloperidol reduction panss total score risperidone haloperidol antipsychotic achieve respectively panss reduction patient respectively reduction patient respectively find consistent early finding show risperidone efficacious haloperidol reduce symptom schizophrenia,Glick ID,2001,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-200109000-00003,11552769,Glick ID; Lemmens P; Vester-Blokland E,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,"D014150: Antipsychotic Agents; D002986: Clinical Trials as Topic; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006220: Haloperidol; D006801: Humans; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2006456852,157,21,1,2270,414,12,en,en
false,bupropion weight loss investigation efficacy tolerability overweight obese woman,basis clinical observation bupropion facilitate weight loss investigate efficacy tolerability drug overweight obese adult woman total overweight obese body mass index kg woman include core component study randomize double blind placebo control comparison week bupropion placebo start mg gradual dose increase maximum mg twice daily subject prescribe kcal balance diet compliance monitor food diary responder continue treatment double blind manner additional week total week additional single blind follow treatment total year subject receive bupropion achieve great mean weight loss last observation carry forward analysis first week study p n bupropion treatment compare n placebo treatment complete week comparison n v n respectively p bupropion subject lose baseline body weight compare placebo group p continuation phase bupropion responder complete week achieve weight loss fat accounting weight lose change bone mineral density assess dxa bupropion generally well tolerated sample bupropion effective placebo achieve weight loss week overweight obese adult woman preliminary study initial responder bupropion benefit far continuation phase,Gadde KM,2001,Obes Res,https://doi.org/10.1038/oby.2001.71,11557835,Gadde KM; Parker CB; Maner LG; Wagner HR; Logue EJ; Drezner MK; Krishnan KR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D019440: Anti-Obesity Agents; D016642: Bupropion; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D002149: Energy Intake; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008875: Middle Aged; D009765: Obesity; D016896: Treatment Outcome; D015431: Weight Loss,,,https://openalex.org/W2024415314,102,16,1,1830,359,10,en,en
false,sustain release bupropion pharmacologic relapse prevention smoke cessation,smoke relapse common successful pharmacologic treatment smoke cessation previous study examine long term drug therapy use expressly prevention smoke relapse evaluate efficacy bupropion prevent smoke relapse randomize placebo control trial healthy community volunteer motivate quit smoke smoke least cigarette per day participant receive open label sustain release bupropion mg week participant abstinent throughout week open label treatment randomly assign receive bupropion mg placebo week subsequently follow additional year conclusion medication phase participant briefly counsel follow visit end open label bupropion treatment participant abstinent smoke self report abstinence confirm expire air carbon monoxide concentration part per million less point prevalence smoke abstinence significantly high bupropion group placebo group end week drug therapy v respectively p week v p differ final week follow visit v median time relapse significantly great bupropion recipient placebo recipient day vs day p continuous abstinence rate high bupropion group placebo group study week week randomization v p differ group week weight gain significantly less bupropion group placebo group study week kg v kg p kg v kg p person stop smoke week bupropion treatment sustain release bupropion month delay smoke relapse result less weight gain,Hays JT,2001,Ann Intern Med,https://doi.org/10.7326/0003-4819-135-6-200109180-00011,11560455,Hays JT; Hurt RD; Rigotti NA; Niaura R; Gonzales D; Durcan MJ; Sachs DP; Wolter TD; Buist AS; Johnston JA; White JD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D016642: Bupropion; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D012008: Recurrence; D016540: Smoking Cessation; D000074606: Smoking Prevention; D015430: Weight Gain,,,https://openalex.org/W2153803359,88,9,1,2057,376,8,en,en
false,effect levodopa combination physiotherapy functional motor recovery stroke prospective randomise double blind study,functional disability generally cause hemiplegia stroke physiotherapy use way improve motor function patient however administration amphetamine addition exercise improve motor recovery animal probably increase concentration norepinephrine central nervous system aim ascertain whether levodopa could enhance efficacy physiotherapy hemiplegia prospective randomise placebo control double blind study enrol primary stroke patient first week patient receive single levodopa mg placebo daily combination physiotherapy second week patient physiotherapy quantitatively assess motor function every week rivermead motor assessment rma six patient exclude analysis non neurological complication motor recovery significantly improve week drug intervention levodopa rma improve point compare placebo result independent initial degree impairment p advantage levodopa group maintain study endpoint week levodopa stop end study total rma score gain levodopa group point compare placebo group p single dose levodopa well tolerate give combination physiotherapy enhance motor recovery patient hemiplegia view minimal side effect levodopa possible add stroke rehabilitation,Scheidtmann K,2001,Lancet,https://doi.org/10.1016/s0140-6736(01)05966-9,11564483,Scheidtmann K; Fries W; Müller F; Koenig E,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D015259: Dopamine Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007980: Levodopa; D008297: Male; D008875: Middle Aged; D009048: Motor Skills; D026741: Physical Therapy Modalities; D020521: Stroke; D000071939: Stroke Rehabilitation,,,https://openalex.org/W2098079895,141,21,1,1645,277,11,en,en
false,bupropion sr naturalistic treatment elderly patient major depression,bupropion immediate release ir bupropion sustain release sr frequently use treat geriatric depression cardiovascular gastrointestinal sexual adverse effect seek examine efficacy dose pattern bupropion naturalistic cohort elderly subject major depression md elderly year patient unipolar md dsm iv enrol duke mental health clinical research center study depression late life prescribe bupropion sr ir alone combination antidepressant agent week montgomery asberg depression rating scale madrs score clinical global impression cgi severity score use define response sample responder madrs achieve partial cgi complete cgi remission md week among patient treat bupropion sr monotherapy mean range maximal daily dose achieve mg mg among treat bupropion ir mean range maximum daily dose achieve mg mg subject monotherapy md subject responder madrs achieve full partial remission response rate differ statistically among high low medical comorbidity naturalistic week study geriatric md patient high low medical comorbidity respond well bupropion bupropion sr elderly patient four eight week acute treatment period may insufficient find suggest nearly elderly depressed subject tertiary center may need combination therapy course illness control randomize study establish long term efficacy optimal dose newer antidepressant geriatric depression urgently need,Steffens DC,2001,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.424,11571765,Steffens DC; Doraiswamy PM; McQuoid DR,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000368: Aged; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D015897: Comorbidity; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D005852: Geriatric Psychiatry; D006801: Humans; D008297: Male; D016896: Treatment Outcome",,,https://openalex.org/W2097140449,84,12,1,1900,354,10,en,en
false,clozapine haloperidol moderately refractory schizophrenia,despite demonstrate efficacy clozapine severely refractory schizophrenia question remain regard efficacy primary negative symptom comparison moderate dose first generation antipsychotic adverse effect long term trial study examine efficacy partially responsive community base patient compare clozapine moderate dose haloperidol extend treatment month randomize double blind week trial compare clozapine n haloperidol n subject schizophrenia treat community set collaborate clinical facility enrol subject treat haloperidol significantly likely discontinue treatment lack efficacy treat clozapine high proportion clozapine treat subject meet priori criterion improvement compare haloperidol treat subject significantly great improvement see symptom psychosis hostile suspiciousness anxiety depression think disturbance total score measure brief psychiatric rating scale difference detect negative symptom use brief psychiatric rating scale schedule assessment negative symptom subject treat clozapine experience excess salivation dizziness sweat less dry mouth decrease appetite treat haloperidol compare first generation antipsychotic give moderate dose clozapine offer substantial clinical benefit treatment refractory subject treat community advantage see broad range symptom extend negative symptom,Kane JM,2001,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.58.10.965,11576036,Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000855: Anorexia; D014150: Antipsychotic Agents; D010054: Brief Psychiatric Rating Scale; D003024: Clozapine; D004244: Dizziness; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome; D014987: Xerostomia",,,https://openalex.org/W2083680124,64,7,1,1765,273,8,en,en
false,association olanzapine induce weight gain increase body fat,objective goal study explore pathophysiology weight gain treatment olanzapine schizophrenia method author use prospective control open study compare body weight body mass index relate biological measure mentally physically healthy volunteer olanzapine treat patient schizophrenia weight eat behavior leptin serum level body mass index body composition assess week observation period result significant increase body weight leptin serum level percentage body fat see patient treat olanzapine drug free comparison group show significant change weight gain antipsychotic treatment olanzapine mainly attributable increase body fat patient lean body mass change conclusion addition original finding increase body fat mainly responsible olanzapine induce weight gain find confirm result obtain study show increase body weight serum leptin level treatment second generation antipsychotic,Eder U,2001,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.158.10.1719,11579009,Eder U; Mangweth B; Ebenbichler C; Weiss E; Hofer A; Hummer M; Kemmler G; Lechleitner M; Fleischhacker WW,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000273: Adipose Tissue; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001823: Body Composition; D015992: Body Mass Index; D005247: Feeding Behavior; D005260: Female; D006801: Humans; D020738: Leptin; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W2002082564,74,11,1,1178,192,6,en,en
false,randomize control trial oros methylphenidate day child attention deficit hyperactivity disorder,new day methylphenidate mph formulation concerta methylphenidate hcl extend release tablet oros mph develop study conduct determine safety efficacy oros mph multicenter randomize clinical trial child attention deficit hyperactivity disorder adhd n subtypes age year randomize placebo n immediate release methylphenidate ir mph time day tid dose every hour n oros mph day qd n double blind day trial outcome multiple domain assess data analyze use analysis variance kaplan meier product limit estimate time study cessation primary time point analysis last available patient visit use last observation carry forward child oros ir mph group show significantly great reduction core adhd symptom child placebo true end week end treatment basis mean teacher parent iowa conners rating ir mph tid oros mph qd differ significantly direct comparison forty eight percent placebo group discontinue early compare ir mph oros mph group respectively treatment core adhd symptom oros mph dose qd ir mph dose tid superior placebo significantly different attention deficit hyperactivity disorder methylphenidate oros concerta,Wolraich ML,2001,Pediatrics,https://doi.org/10.1542/peds.108.4.883,11581440,Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001066: Appetite; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010919: Placebos; D012044: Regression Analysis; D012890: Sleep; D020323: Tics; D016896: Treatment Outcome,,,https://openalex.org/W2063286745,121,15,1,1550,289,7,en,en
false,conners parent rating scale critical review literature,conners parent rating scale cpr undergo considerable amount scrutiny subsequent refining reshape revise since development longitudinal scrutiny ultimately lead reliable valid assessment tool leave behind wake literature fill misinformation ambiguity multiple version conners rating scale cr misuse inaccurate reporting researcher create body literature difficult interpret mislead researcher clinician review aim clarify issue regard proper use cpr diagnostic instrument research tool,Gianarris WJ,2001,Clin Psychol Rev,https://doi.org/10.1016/s0272-7358(00)00085-4,11584516,Gianarris WJ; Golden CJ; Greene L,article,D016428: Journal Article; D016454: Review; D023361: Validation Study,D000316: Adrenergic alpha-Agonists; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002653: Child Behavior Disorders; D003000: Clonidine; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010290: Parents; D016032: Randomized Controlled Trials as Topic; D011795: Surveys and Questionnaires,,,https://openalex.org/W2032877009,70,13,1,707,125,4,en,en
false,safety profile bupropion chronic obstructive pulmonary disease,despite unquestionable transcendence control tobacco habit chronic obstructive pulmonary disease copd patient tashkin colleague may p tashkin dp kanner r bailey w et al smoke cessation patient chronic obstructive pulmonary disease double blind placebo control randomised trial lancet summary full text full text pdf pubmed scopus google scholar report effect sustain release bupropion promote abstinence smoker disorder surprisingly behaviour bupropion previously study situation renal hepatic insufficiency different cardiovascular disease tashkin colleague double blind randomise placebo control trial patient mild moderate copd report continuous abstinence rate week significantly high bupropion group placebo group vs self report adverse event profile population much frequency quality previous bupropion study hurt rd sachs dpl glover ed et al comparison sustain release bupropion placebo smoke cessation n engl j med crossref pubmed scopus google scholar conclude bupropion well tolerate effective aid smoke cessation people mild moderate copd opinion however safety profile bupropion copd patient sufficiently study principally tashkin colleague trial include patient mild copd patient enrol treatment group moderate copd moreover researcher repeat pulmonary function test study find effect bupropion lung function particularly relevant feature unknown effect bupropion respiration regulatory system main alteration experience copd patient regulation respiration reduction sensitivity hypoxia hypercapnia become severe patient also acute respiratory insufficiency cherniack n control breathe copd cherniack n chronic obstructive pulmonary disease wb saunders philadelphia google scholar mechanism decrease chemo sensitivity different neurotransmitter involve sensitivity peripheral chemoreceptor carotid body depend equilibrium excitatory neurotransmitter serotonin acetylcholine p substance endotheline inhibitory neurotransmitter dopamine norepinephrine nitric oxide cherniack ns control breathe copd cherniack n chronic obstructive pulmonary disease wb saunders philadelphia google scholar glutamate amino butyric acid neurotensin tachy quinine participate neuro regulation central chemoreceptor addition dopamine opposite effect central chemoreceptor set carotid body stimulate response receptor hypoxia decrease sensitivity carotid body copd disease fundamentally attribute increase stimulation dopaminergic receptor osanai akiba fujiuchi et al depression peripheral chemosensitivity dopaminergic mechanism patient obstructive sleep apnoea syndrome eur respir j crossref pubmed scopus google scholar fact prove circumstance administration dopaminergic antagonist restore response patient hypoxia hypercapnia whereas receive dopamine agonist chemosensitivity worsen osanai akiba fujiuchi et al depression peripheral chemosensitivity dopaminergic mechanism patient obstructive sleep apnoea syndrome eur respir j crossref pubmed scopus google scholar bupropion selective inhibitor neuronal recapture catecholamine norepinephrine dopamine minimum effect recapture indolamines serotonin inhibit action monoamine oxidase benowitz nl peng mw non nicotine pharmacotherapy smoke cessation mechanism prospect drug google scholar whether drug could induce deterioration respiration regulatory system copd patient unclear alteration could substantial clinical relevance involve tolerance chronic hypoxaemia copd patient well development hypercapnia ventilatory insufficiency safety profile bupropion chronic obstructive pulmonary diseaseauthors reply full text pdf,García-Río F,2001,Lancet,https://doi.org/10.1016/s0140-6736(01)06128-1,11586978,García-Río F; Serrano S; Mediano O; Alonso A; Villamor J,article,D016420: Comment; D016422: Letter,"D016642: Bupropion; D018765: Dopamine Uptake Inhibitors; D006801: Humans; D008173: Lung Diseases, Obstructive; D016032: Randomized Controlled Trials as Topic; D016540: Smoking Cessation",,,https://openalex.org/W1992787738,69,9,1,4802,766,24,en,en
false,use medication event monitoring system estimate medication compliance patient schizophrenia,determine feasibility use medication event monitoring system mem estimate medication compliance patient schizophrenia schizoaffective disorder fourteen consecutive patient admit psychiatric inpatient hospital schizophrenia schizoaffective disorder meet eligibility requirement give inform consent random assignment either risperidone typical antipsychotic treatment medication upon discharge hospital dispense bottle mem cap record number bottle open date time open first patient ask return monthly data download next ask return weekly first month every week thereafter also pay return bottle mem data collect month period hospital readmission data patient medication compliance data collect patient first month patient drop second third patient drop month mean compliance rate first month range next first month compliance rate significantly low subsequently readmitted hospital n p electronic monitoring device use estimate compliance medication regimen patient severe schizophrenic disorder methodological improvement make increase data recovery compliance discus,Diaz E,2001,J Psychiatry Neurosci,,11590972,Diaz E; Levine HB; Sullivan MC; Sernyak MJ; Hawkins KA; Cramer JA; Woods SW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D014150: Antipsychotic Agents; D016903: Drug Monitoring; D004349: Drug Packaging; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D010359: Patient Readmission; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012646: Self Administration; D016312: Treatment Refusal,,,https://openalex.org/W2291231306,111,16,1,1649,288,5,en,en
false,influence stimulant sedative fatigue tunnel vision risk factor drive pilot,computerize task use two study examine influence stimulant sedative fatigue single target divide attention response different part visual field drug effect evaluate time repeat behavioral subjective measure ascend descend drug level first study fully rest participant receive placebo alprazolam mg dextroamphetamine mg alprazolam impairs performance whereas dextroamphetamine induces enhancement tunnel vision study expose participant fatigue fatigue repeat measure crossover design four independent group subsequently receive placebo dextroamphetamine mg caffeine mg alcohol fatigue stimulant performance enhance effect whereas impairment alcohol severe fatigue alcohol modest effect caffeine effect dextroamphetamine significantly enhance divided attention performance coincident tunnel vision participant rate drug effect stimulate less sedate fatigue implication transportation safety discuss actual potential application research include driver pilot training,Mills KC,2001,Hum Factors,https://doi.org/10.1518/001872001775900878,11592671,Mills KC; Spruill SE; Kanne RW; Parkman KM; Zhang Y,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000428: Alcohol Drinking; D000525: Alprazolam; D000704: Analysis of Variance; D001334: Automobile Driving; D001359: Aviation; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004242: Diving; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004347: Drug Interactions; D005221: Fatigue; D005260: Female; D006801: Humans; D006993: Hypnotics and Sedatives; D008297: Male; D012016: Reference Values; D012307: Risk Factors; D012680: Sensitivity and Specificity; D014786: Vision Disorders",,,https://openalex.org/W2117197072,107,19,1,1279,206,11,en,en
false,effect olanzapine neurocognitive functioning medication refractory schizophrenia,neurocognitive deficit endure characteristic schizophrenia remain prominent patient whose positive symptom decrease treatment typical neuroleptic recent research report olanzapine improve cognitive functioning relapse schizophrenia follow outpatient set whether olanzapine effect improve cognitive function chronic schizophrenic hospitalize long period time show poor response conventional atypical neuroleptic establish study investigate cognitive function chronic medication refractory schizophrenic treat olanzapine haloperidol double blind study wk follow open olanzapine study several additional month patient evaluate psychopathology rating scale battery neuropsychological test baseline end double blind end open label phase study end double blind phase significant difference olanzapine haloperidol except trend improvement wisconsin card sort test olanzapine significant traditional correct significance level additional month treatment olanzapine mg statistical analysis show significant improvement overall neuropsychological test performance specific cognitive task assess verbal memory however open label result difficult interpret definitively lack comparison drug group olanzapine dose escalation time neurocognitive change correlate change psychopathology assess panss sans score,Smith RC,2001,Int J Neuropsychopharmacol,https://doi.org/10.1017/s146114570100253x,11669086,Smith RC; Infante M; Singh A; Khandat A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002908: Chronic Disease; D003071: Cognition; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008568: Memory; D008875: Middle Aged; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2137628013,94,10,1,1787,269,9,en,en
false,plasma lidocaine concentration continuous thoracic epidural anesthesia clonidine premedication child,report concern oral clonidine effect epidural lidocaine child therefore perform study assess concentration plasma lidocaine major metabolite monoethylglycinexylidide megx child receive continuous thoracic epidural anesthesia oral clonidine premedication ten pediatric patient age yr randomly allocate control clonidine microg kg group n anesthesia induce maintain sevoflurane oxygen air fio epidural puncture tube carefully perform th intervertebral space initial dose lidocaine mg kg inject catheter epidural space follow mg x kg x h plasma concentration lidocaine megx measure min min every min h initiation continuous epidural injection concentration lidocaine megx measure use high pressure liquid chromatography ultraviolet detection hemodynamic variable similar member control clonidine group anesthesia clonidine group show significantly small lidocaine concentration p concentration megx tend small plasma clonidine group initial h initiation epidural infusion conclusion oral clonidine preanesthetic medication dose microg kg decrease plasma lidocaine concentration child oral clonidine decrease plasma lidocaine concentration child find may clinical implication patient receive continuous epidural anesthesia additionally perhaps additional margin safety regard lidocaine toxicity gain use oral clonidine child receive epidural lidocaine,Inomata S,2001,Anesth Analg,https://doi.org/10.1097/00000539-200111000-00016,11682384,Inomata S; Tanaka E; Miyabe M; Kakiuchi Y; Nagashima A; Yamasaki Y; Nakayama S; Baba Y; Toyooka H; Okuyama K; Kohda Y,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000700: Analgesics; D000767: Anesthesia, Epidural; D000769: Anesthesia, Inhalation; D018685: Anesthetics, Inhalation; D000779: Anesthetics, Local; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004347: Drug Interactions; D006801: Humans; D007223: Infant; D008012: Lidocaine; D008297: Male; D008738: Methyl Ethers; D011229: Preanesthetic Medication; D000077149: Sevoflurane; D013904: Thoracic Vertebrae; D013520: Urologic Surgical Procedures",,,https://openalex.org/W2030925538,120,13,1,1862,312,13,en,en
false,prolong postoperative analgesia caudal anaesthesia ropivacaine child ketamine versus clonidine,aim study determine whether caudal ketamine clonidine prolong analgesia together ropivacaine sixty three boy age year undergo minor surgery allocate order receive one three solution caudal anaesthesia group r receive mg x kg ropivacaine group c mg x kg ropivacaine clonidine microg x kg group k mg x kg ropivacaine ketamine mg x kg postoperative analgesia assess cheops last min group k p compare min group c min group r significant difference group incidence haemodynamic respiratory alteration motor block sedation study demonstrate ketamine mg x kg add caudal ropivacaine provide well postoperative analgesia clonidine without clinically significant side effect,De Negri P,2001,Paediatr Anaesth,https://doi.org/10.1046/j.1460-9592.2001.00742.x,11696143,De Negri P; Ivani G; Visconti C; De Vivo P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000577: Amides; D015360: Analgesia, Epidural; D000762: Anesthesia Recovery Period; D000778: Anesthetics, Dissociative; D000779: Anesthetics, Local; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007223: Infant; D007649: Ketamine; D010149: Pain, Postoperative; D011446: Prospective Studies; D015656: Respiratory Mechanics; D000077212: Ropivacaine",,,https://openalex.org/W2074484173,121,16,1,940,183,2,en,en
false,analgesia circumcision paediatric population comparison caudal bupivacaine alone bupivacaine plus two clonidine,clonidine often use improve duration quality analgesia produce caudal epidural blockade although optimum dose clonidine bupivacaine remain uncertain compare effect clonidine microg x kg add bupivacaine mg x kg bupivacaine alone male child undergo elective circumcision trend towards increase duration analgesia increase dose clonidine group b bupivacaine min c bupivacaine clonidine microg x kg min c bupivacaine clonidine microg x kg min although difference statistically significant mean time arousal anaesthesia significantly prolong clonidine microg kg group c min group c min group b min supplementary analgesic requirement incidence adverse effect low difference group paediatric circumcision general anaesthesia addition clonidine microg x kg low volume ml x kg caudal anaesthetic limited clinical benefit child undergo circumcision,Sharpe P,2001,Paediatr Anaesth,https://doi.org/10.1046/j.1460-9592.2001.00748.x,11696146,Sharpe P; Klein JR; Thompson JP; Rushman SC; Sherwin J; Wandless JG; Fell D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000698: Analgesia; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D002045: Bupivacaine; D002648: Child; D002675: Child, Preschool; D002944: Circumcision, Male; D003000: Clonidine; D006801: Humans; D007223: Infant; D008297: Male; D010147: Pain Measurement; D010149: Pain, Postoperative",,,https://openalex.org/W1965302235,138,20,1,1220,241,3,en,en
false,olanzapine,unlabelled olanzapine thienobenzodiazepine derivative psychotropic agent show efficacy treatment patient bipolar disorder olanzapine multireceptorial binding profile include great affinity serotonin ht dopamine receptor olanzapine mg day demonstrate significantly great antimanic efficacy placebo two double blind randomise week trial patient bipolar disorder either manic mixed episode without psychotic feature additionally one trial improvement cognitive function hostility superior olanzapine cohort severely depress rapid cycling patient improvement manic depressive symptom manic symptom superior olanzapine compare placebo significant improvement baseline symptom mania depression cognitive functioning hostility see olanzapine week extension phase study double blind trial olanzapine mg day appear similar antimanic efficacy oral lithium mg twice daily treatment patient pure mania week small study patient acute manic mixed episode olanzapine mg day appear effective oral valproate semisodium divalproex sodium mg day week study least effective oral haloperidol mg day week study preliminary result large week placebo control study suggest olanzapine mg day combination mood stabiliser lithium valproate semisodium provide effective augmentation antimanic treatment patient bipolar disorder benefit see first week adverse event report significantly often olanzapine placebo somnolence dry mouth dizziness bodyweight gain comparison valproate semisodium somnolence dry mouth increase appetite bodyweight gain olanzapine generally well tolerate clinically relevant abnormality laboratory test vital sign electrocardiogram result conclusion olanzapine demonstrate superior efficacy compare placebo short term treatment patient bipolar disorder manic mixed episode without psychotic feature generally well tolerate accord preliminary data antimanic efficacy olanzapine appear similar haloperidol good valproate semisodium patient bipolar disorder experience manic mixed episode among nonpsychotic patient manic mixed episode olanzapine appear superior haloperidol available data support choice olanzapine option short term management mania patient bipolar disorder manic mixed episode without psychotic feature,Bhana N,2001,CNS Drugs,https://doi.org/10.2165/00023210-200115110-00005,11700151,Bhana N; Perry CM,article,D016428: Journal Article; D016454: Review,D000818: Animals; D001569: Benzodiazepines; D001714: Bipolar Disorder; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D017367: Selective Serotonin Reuptake Inhibitors,,,https://openalex.org/W2021377035,10,1,1,2960,479,14,es,en
false,double blind randomize trial bupropion sr treatment neuropathic pain,evaluate effectiveness safety bupropion sustain release sr treatment neuropathic pain single center outpatient randomize double blind placebo control crossover study consist two phase forty one nondepressed patient neuropathic pain spend week phase random order receive identical tablet mg bupropion sr placebo patient instruct take one tablet daily week follow one tablet twice daily week patient take bupropion sr neuropathic pain relief improve much improve patient one patient become pain free mean average pain score baseline remain unchanged end week placebo decrease point p therapy bupropion sr pain relief bupropion sr significant week p continue throughout week p significant decrease interference pain quality life observe patient receive bupropion sr compare placebo side effect experience bupropion sr dose limit consist primarily dry mouth insomnia headache gastrointestinal upset tremor constipation dizziness placebo control crossover trial show bupropion sr mg daily effective well tolerate treatment neuropathic pain,Semenchuk MR,2001,Neurology,https://doi.org/10.1212/wnl.57.9.1583,11706096,Semenchuk MR; Sherman S; Davis B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D016642: Bupropion; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009437: Neuralgia; D010147: Pain Measurement",,,https://openalex.org/W1989410928,84,13,1,1466,257,7,en,en
false,effect risperidone aberrant behavior person developmental disability double blind crossover study use multiple measure,efficacy atypical antipsychotic risperidone evaluate treatment aberrant behavior e g aggression self injury individual developmental disability double blind crossover design use compare risperidone placebo week trial month follow phase base reduction mean aberrant behavior checklist community total score participant identify responder naturalistic observation subset five individual show participant risperidone effective reduce aberrant behavior side effect include weight gain participant sedation participant advantage conduct comprehensive analysis effect medication aberrant behavior discus,Zarcone JR,2001,Am J Ment Retard,https://doi.org/10.1352/0895-8017(2001)106<0525:eoroab>2.0.co;2,11708938,Zarcone JR; Hellings JA; Crandall K; Reese RM; Marquis J; Fleming K; Shores R; Williams D; Schroeder SR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D000368: Aged; D000374: Aggression; D002648: Child; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D008875: Middle Aged; D018967: Risperidone; D016728: Self-Injurious Behavior; D016896: Treatment Outcome",,,https://openalex.org/W2145300678,145,21,2,826,140,6,en,en
false,risperidone versus haloperidol treatment acute exacerbation chronic inpatient schizophrenia randomize double blind study,purpose study compare efficacy safety risperidone haloperidol treatment resistant chronic schizophrenic patient subject n meet dsm iii criterion schizophrenia randomly assign receive mg day risperidone mg day haloperidol week clinical efficacy determine use positive negative syndrome scale panss side effect treatment emergent symptom scale tess risperidone produce mean reduction total panss score compare mean reduction haloperidol group p analysis change three subscores panss reveal general psychopathology negative subscores significantly improve risperidone group compare haloperidol group side effect risperidone group show significantly low tess total score well nervous system symptom subscore cardiovascular symptom subscore compare haloperidol group risperidone appear effective well tolerate antipsychotic drug treatment refractory chinese schizophrenia haloperidol,Zhang XY,2001,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-200111000-00002,11712620,Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D044466: Asian People; D002908: Chronic Disease; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D007297: Inpatients; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W1996970257,144,19,1,1186,195,7,en,en
false,loss dopamine transporter methamphetamine abuser recovers protract abstinence,methamphetamine popular drug abuse neurotoxic dopamine da terminal administer laboratory animal study methamphetamine abuser also document significant loss da transporter use marker da terminal associate slow motor function decrease memory extent loss da transporter predispose methamphetamine abuser neurodegenerative disorder parkinsonism unclear may depend part degree recovery assess effect protract abstinence loss da transporter striatum methamphetamine abuser use positron emission tomography c threo methylphenidate da transporter radioligand brain da transporter five methamphetamine abuser evaluate short abstinence month retested protract abstinence month show significant increase protract abstinence caudate putamen although performance test observe association da transporter show improvement effect significant da transporter increase abstinence could indicate methamphetamine induce da transporter loss reflect temporary adaptive change e downregulation loss reflect da terminal damage terminal recover remain viable terminal increase synaptic arborization neuropsychological test improve extent suggest increase da transporter sufficient complete function recovery find treatment implication suggest protract abstinence may reverse methamphetamine induce alteration brain da terminal,Volkow ND,2001,J Neurosci,https://doi.org/10.1523/jneurosci.21-23-09414.2001,11717374,Volkow ND; Chang L; Wang GJ; Fowler JS; Franceschi D; Sedler M; Gatley SJ; Miller E; Hitzemann R; Ding YS; Logan J,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D019969: Amphetamine-Related Disorders; D002421: Caudate Nucleus; D002531: Cerebellum; D050483: Dopamine Plasma Membrane Transport Proteins; D005260: Female; D006801: Humans; D008297: Male; D008562: Membrane Glycoproteins; D026901: Membrane Transport Proteins; D008694: Methamphetamine; D008774: Methylphenidate; D009419: Nerve Tissue Proteins; D009483: Neuropsychological Tests; D011699: Putamen; D013997: Time Factors; D014055: Tomography, Emission-Computed",,,https://openalex.org/W2144176813,92,11,1,1812,288,9,en,en
false,euglycemic clamp study clozapine induce diabetic ketoacidosis,objective describe fifth case clozapine induce diabetic ketoacidosis dka complete resolution abnormal glucose metabolism discontinuation clozapine assess oral glucose tolerance test ogtt first serially study marker pancreatic autoimmunity demonstrate insulin resistance use euglycemic clamp study reduce pancreatic insulin reserve use intravenous glucose tolerance test ivgtt clozapine induce diabetes mellitus dka ogtt normal systematically review previously describe case clozapine induce diabetes mellitus dka case summary year old white man without past family history diabetes mellitus present dka eight month clozapine therapy mg twice daily treatment dka discontinuation clozapine glucose tolerance concurrent serum insulin concentration revert normal measure two ogtt perform day resolution dka discussion antiislet cell antibody antiglutamic acid decarboxylase antibody human insulin antibody negative two separate occasion euglycemic clamp study demonstrate insulin resistance manifest glucose disposal rate approximately mean normal value ivgtt demonstrate low rate glucose disappearance k g diminish first phase insulin response ogtt normal indicate impairment insulin sensitivity reduction cell function day discontinuance clozapine adverse reaction consider probable accord naranjo probability scale conclusion occurrence case dka new worsen diabetes mellitus patient use clozapine suggest causal relationship hypothesize mechanism clozapine may produce glucose intolerance may require preexist latent defect insulin secretion insulin action administration clozapine patient may develop worsen insulin resistance may fail mount appropriate compensatory cell insulin secretion degree insulin resistance consequence hyperglycemia develop persistence result glucose toxicity suppress cell insulin secretion combine defect insulin secretion sensitivity know synergistic lead development abnormal glucose tolerance clinically manifest spectrum range impair glucose tolerance severe hyperglycemia dka patient start clozapine carefully follow development worsen diabetes mellitus regardless dose drug,Avram AM,2001,Ann Pharmacother,https://doi.org/10.1345/aph.10424,11724088,Avram AM; Patel V; Taylor HC; Kirwan JP; Kalhan S,article,"D002363: Case Reports; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D001327: Autoimmune Diseases; D001786: Blood Glucose; D001835: Body Weight; D003024: Clozapine; D016883: Diabetic Ketoacidosis; D015309: Glucose Clamp Technique; D005951: Glucose Tolerance Test; D006801: Humans; D008297: Male; D012563: Schizophrenia, Paranoid",,,https://openalex.org/W2114637662,65,7,1,2752,431,13,en,en
false,neostigmine combine bupivacaine clonidine sufentanil spinal labor analgesia,previously find spinal clonidine prolongs labor analgesia combine spinal bupivacaine sufentanil seek determine whether addition spinal neostigmine drug would far enhance labor analgesia use combine spinal epidural technique patient randomize receive hyperbaric spinal injection bupivacaine mg plus clonidine microg sufentanil microg without neostigmine microg pain maternal hemodynamics fetal heart rate nausea pruritus sedation motor block sensory level pinprick maternal oxygen saturation assess regularly specify interval spinal injection additional analgesia request duration spinal analgesia similar group min control group versus min neostigmine group likewise pain score duration labor apgar score side effect similar group except patient administer neostigmine experience significantly nausea vomit vs p conclude spinal neostigmine microg produce severe nausea potentiate duration spinal analgesia labor woman spinal bupivacaine clonidine sufentanil spinal neostigmine microg adjunct spinal bupivacaine clonidine sufentanil produce severe nausea fail potentiate analgesia labor woman,D'Angelo R,2001,Anesth Analg,https://doi.org/10.1097/00000539-200112000-00048,11726444,D'Angelo R; Dean LS; Meister GC; Nelson KE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D000328: Adult; D015360: Analgesia, Epidural; D016362: Analgesia, Obstetrical; D000700: Analgesics; D000701: Analgesics, Opioid; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D002045: Bupivacaine; D003000: Clonidine; D004357: Drug Synergism; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D009388: Neostigmine; D011247: Pregnancy; D017409: Sufentanil",,,https://openalex.org/W2038752218,91,13,1,1461,243,7,en,en
false,dose response study clonidine local anesthetic mixture peribulbar block comparison three,clonidine prolongs anesthesia analgesia local anesthetic various neural block well duration retrobulbar block assess dose response relationship clonidine add lidocaine peribulbar block sixty patient undergo cataract surgery give peribulbar block ml lidocaine hyaluronidase either saline control clonidine microg kg clon microg kg clon microg kg clon dose onset duration lid globe akinesia globe anesthesia analgesia postoperative analgesic requirement adverse effect hypotension bradycardia hypoxia sedation dizziness record success rate onset block comparable group duration lid globe akinesia globe anesthesia analgesia significantly p prolong patient receive microg kg clonidine compare control group perioperative pain score analgesic requirement significantly less group microg kg clonidine increase duration anesthesia analgesia significantly hypotension dizziness observe patient receive microg kg clonidine compare group conclude microg kg clonidine mixture lidocaine significantly prolong duration anesthesia analgesia peribulbar block limit side effect study effect addition microg kg clonidine lidocaine hyaluronidase mixture onset duration peribulbar block perioperative analgesia dose microg kg produce significant increase duration anesthesia analgesia minimal side effect,Madan R,2001,Anesth Analg,https://doi.org/10.1097/00000539-200112000-00056,11726451,Madan R; Bharti N; Shende D; Khokhar SK; Kaul HL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D002387: Cataract Extraction; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005123: Eye; D005260: Female; D006801: Humans; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D009407: Nerve Block",,,https://openalex.org/W2027845805,114,19,1,1773,292,11,en,en
false,clonidine provide opioid spar effect stable hemodynamics renal integrity laparoscopic cholecystectomy,background carbon dioxide pneumoperitoneum cause hemodynamic stress response decrease urine output activate renin angiotensin aldosterone system raas clonidine potent antihypertensive drug suppress raas method effect clonidine mg kg saline hemodynamics neuroendocrine response renal parameter compare healthy patient undergo laparoscopic cholecystectomy result heart rate arterial blood pressure plasma renin activity low pneumoperitoneum patient clonidine difference urine output urine oxygen tension reflect medullary perfusion antidiuretic hormone group n acetyl b glucosaminidase marker proximal tubular damage minimally elevate clonidine conclusion clonidine enable stable hemodynamics prevent activation raas see unchanged plasma renin activity clonidine may beneficial laparoscopy patient hypertension cardiovascular renal disease,Laisalmi M,2001,Surg Endosc,https://doi.org/10.1007/s004640090126,11727145,Laisalmi M; Koivusalo AM; Valta P; Tikkanen I; Lindgren L,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D017081: Cholecystectomy, Laparoscopic; D003000: Clonidine; D004311: Double-Blind Method; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007273: Injections, Intramuscular; D007677: Kidney Function Tests; D008875: Middle Aged; D011028: Pneumoperitoneum, Artificial; D011292: Premedication; D011446: Prospective Studies; D012083: Renin; D012084: Renin-Angiotensin System",,,https://openalex.org/W2059447981,118,14,1,1077,161,8,en,en
false,amisulpride,unlabelled amisulpride substitute benzamide derivative second generation atypical antipsychotic low enhance dopaminergic neurotransmission preferentially block presynaptic dopamine autoreceptors high amisupride antagonise postsynaptic dopamine receptor preferentially limbic system rather striatum thereby reduce dopaminergic transmission patient acute exacerbation schizophrenia recommend dosage amisulpride mg day although dosage mg day may administer comparative trial amisulpride administer within range mg day effective haloperidol mg day flupenthixol mg day risperidone mg day patient acute exacerbation schizophrenia predominantly positive symptom amisulpride effective haloperidol equally effective risperidone control negative symptom amisulpride mg day effective haloperidol risperidone flupenthixol control affective symptom patient randomise double blind trial involve patient predominantly negative symptom schizophrenia amisulpride mg day effective placebo amisulpride effective maintenance therapy patient chronic schizophrenia long term treatment amisulpride associate improvement quality life social functioning amisulpride generally well tolerate well control trial neurological tolerability profile include rating extrapyramidal symptom scale amisulpride mg day superior conventional antipsychotic haloperidol flupenthixol similar atypical antipsychotic risperidone low dosage amisulpride mg day incidence adverse event include extrapyramidal symptom report amisulpride similar placebo conclusion comparative trial amisulpride mg day show efficacy reduce overall symptomatology positive symptom similar conventional antipsychotic new atypical antipsychotic patient acute exacerbation schizophrenia moreover effective alleviation negative affective symptom low association extrapyramidal symptom loss cognitive function conventional antipsychotic long term efficacy justifies consideration use high dosage amisulpride group patient consequently dosage amisulpride recommend patient acute exacerbation schizophrenia mg day although dosage mg day may administer low dosage amisulpride mg day consider management patient negative symptom schizophrenia amisulpride first line treatment option management schizophrenia acute phase maintenance treatment response,Curran MP,2001,Drugs,https://doi.org/10.2165/00003495-200161140-00014,11735643,Curran MP; Perry CM,article,D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D000284: Administration, Oral; D000327: Adsorption; D000077582: Amisulpride; D014150: Antipsychotic Agents; D002908: Chronic Disease; D004305: Dose-Response Relationship, Drug; D016527: Drug Costs; D006801: Humans; D009490: Neurosecretory Systems; D011594: Psychometrics; D011788: Quality of Life; D016032: Randomized Controlled Trials as Topic; D011954: Receptors, Dopamine; D012559: Schizophrenia; D013469: Sulpiride; D014018: Tissue Distribution; D016896: Treatment Outcome",,,https://openalex.org/W2059867716,11,1,1,3099,472,18,fr,en
false,antipsychotic risk sudden cardiac death,case report link antipsychotic drug sudden cardiac death consistent dose relate electrophysiologic effect association confirm control study conduct retrospective cohort study tennessee medicaid enrollee include many antipsychotic user also computer file describe medication use comorbidity study conduct introduction risperidone thus include new atypical agent cohort include person person year follow include person year current moderate dose antipsychotic use mg thioridazine equivalent person year current low dose antipsychotic use person year use past year person year use cohort confirm sudden cardiac death calculate multivariate rate ratio adjust potential confounding factor current moderate dose antipsychotic use compare nonuse multivariate rate ratio confidence interval p great current low dose rate ratio confidence interval p former rate ratio confidence interval p use among cohort member severe cardiovascular disease current moderate dose user fold confidence interval increase rate relative comparable nonusers p result additional death per person year follow patient prescribe moderate antipsychotic large relative absolute increase risk sudden cardiac death although study data demonstrate causality suggest potential adverse cardiac effect antipsychotic consider clinical practice particularly patient cardiovascular disease,Ray WA,2001,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.58.12.1161,11735845,Ray WA; Meredith S; Thapa PB; Meador KG; Hall K; Murray KT,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D002318: Cardiovascular Diseases; D002423: Cause of Death; D015331: Cohort Studies; D016757: Death, Sudden, Cardiac; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D012189: Retrospective Studies; D012306: Risk; D013714: Tennessee",,,https://openalex.org/W2146506439,51,8,1,1967,319,8,en,en
false,clozapine use patient schizophrenia risk diabetes hyperlipidemia hypertension,numerous case report link clozapine development diabetes mellitus hyperlipidemia patient schizophrenia however investigator unable clearly demonstrate association compare control group receive conventional antipsychotic medical pharmacy claim iowa medicaid program use compare incidence rate diabetes hyperlipidemia hypertension patient receive clozapine patient receive conventional antipsychotic eg haloperidol chlorpromazine hydrochloride use retrospective cohort design logistic regression use compare incidence rate adjust age sex duration available follow significant difference overall incidence rate diabetes hyperlipidemia hypertension observe patient receive clozapine v conventional antipsychotic however among young patient age year clozapine administration associate significantly increase relative risk diabetes confidence interval hyperlipidemia confidence interval hypertension confidence interval data suggest clozapine may independent cause diabetes hyperlipidemia instead act effect modifier susceptible population increase weight affect insulin secretion resistance find require confirmation set patient population atypical antipsychotic risperidone olanzapine quetiapine fumarate potential long term medical economic implication early induction diabetes hyperlipidemia patient schizophrenia warrant far study,Lund BC,2001,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.58.12.1172,11735847,Lund BC; Perry PJ; Brooks JM; Arndt S,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000367: Age Factors; D014150: Antipsychotic Agents; D015984: Causality; D003024: Clozapine; D015331: Cohort Studies; D016001: Confidence Intervals; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D015994: Incidence; D007484: Iowa; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D012189: Retrospective Studies; D012306: Risk; D012559: Schizophrenia",,,https://openalex.org/W1968777066,103,16,1,1794,278,6,en,en
false,double blind randomise comparison risperidone haloperidol treatment behavioural psychological symptom chinese dementia patient,behavioural psychological symptom bpsd common course dementia present severe problem patient caregiver assess therapeutic efficacy safety haloperidol risperidone treat bpsd chinese dementia patient week double blind randomise comparison haloperidol risperidone treatment conduct patient dsm iv diagnosis dementia alzheimer type vascular dementia randomly assign receive flexible mg day haloperidol risperidone clinical response evaluate use cohen mansfield agitation inventory cmai behavioral pathology alzheimer disease rating scale behave ad simpson angus scale functional assessment stag cantonese version mini mental state examination mean last week mg day haloperidol mg day risperidone haloperidol risperidone significantly reduce severity bpsd score cmai behave ad significant group difference haloperidol treat patient show worsen simpson angus scale significant change measure risperidone treat patient low dose haloperidol risperidone well tolerate associate reduction severity frequency behavioural symptom subject dementia risperidone may favourable risk benefit profile view low propensity induce extrapyramidal symptom,Chan WC,2001,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.504,11748775,Chan WC; Lam LC; Choy CN; Leung VP; Li SW; Chiu HF,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000544: Alzheimer Disease; D015140: Dementia, Vascular; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006723: Hong Kong; D006801: Humans; D008297: Male; D018967: Risperidone; D012920: Social Behavior Disorders; D016896: Treatment Outcome",,,https://openalex.org/W1987355763,155,20,1,1539,229,6,en,en
false,dose range exploratory study effect ethyl eicosapentaenoate patient persistent schizophrenic symptom,objective test effect ethyl eicosapentaenoate e e persistent ongoing symptom patient receive different type anti schizophrenic drug typical antipsychotic new atypical antipsychotic clozapine patient dsm iv define schizophrenia study clozapine new atypical drug typical antipsychotic placebo g day e e give week addition background medication main assessment change baseline week panss sub scale treatment related side effect adverse biochemical haematological effect patient g day e e show significant reduction triglyceride level elevate clozapine patient give g day e e improvement panss sub scale also large placebo effect patient typical new atypical antipsychotic difference active treatment placebo patient clozapine contrast little placebo response clinically important statistically significant effect e e rating scale effect great g day positive relationship improvement rating scale rise red blood cell arachidonic acid concentration,Peet M,2002,J Psychiatr Res,https://doi.org/10.1016/s0022-3956(01)00048-6,11755456,Peet M; Horrobin DF; E-E Multicentre Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D015118: Eicosapentaenoic Acid; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010975: Platelet Aggregation Inhibitors; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2102023134,125,15,1,1348,228,10,en,en
false,therapeutic effect pirenzepine clozapine induce hypersalivation randomize double blind placebo control cross study,objective study investigate efficacy pirenzepine treatment clozapine induce hypersalivation pirenzepine report counteract hypersalivation selective antagonistic activity muscarinic receptor stimulate clozapine twenty patient clozapine induce hypersalivation undergo random order double blind placebo control cross trial last week pirenzepine placebo investigation week washout period severity hypersalivation assess use objective measure saliva production monitor diameter wet surface tissue paper place patient pillow study show pirenzepine significant therapeutic effect hypersalivation compare placebo suggest hypersalivation induce clozapine might neurobiological basis muscarinic receptor,Bai YM,2001,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200112000-00012,11763010,Bai YM; Lin CC; Chen JY; Liu WC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D018727: Muscarinic Antagonists; D010890: Pirenzepine; D012798: Sialorrhea,,,https://openalex.org/W2080482632,137,17,1,965,139,5,en,en
false,comparison relative safety efficacy tolerability quetiapine risperidone outpatient schizophrenia psychotic disorder quetiapine experience safety tolerability quest study,publish direct comparative study tolerability efficacy atypical antipsychotic agent perform relatively homogeneous population may typical patient see clinical practice quetiapine experience safety tolerability quest study compare relative safety tolerability efficacy quetiapine risperidone outpatient broad range psychotic symptom multicenter month open label randomize clinical trial patient randomize ratio receive quetiapine risperidone adjust maximize efficacy minimize adverse event extrapyramidal symptom eps assess eps checklist adverse event record efficacy assess use clinical global impression cgi scale positive negative symptom scale panss hamilton rating scale depression ham total patient randomize quetiapine risperidone mean prescribe dos study period mg quetiapine mg risperidone end month eps decline treatment group quetiapine treat patient significantly less likely require dose adjustment concurrent anti eps medication p common adverse event quetiapine risperidone group somnolence respectively dry mouth dizziness overall tolerance side effect drug measure dropout rate comparable visit high percentage quetiapine treat patient show improvement cgi scale significant group difference panss end point quetiapine treat patient significantly low ham score p result study suggest quetiapine effective risperidone treatment psychotic symptom effective depressive symptom may favorable eps profile comparable overall tolerability,Mullen J,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(00)89080-3,11768836,Mullen J; Jibson MD; Sweitzer D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010045: Outpatients; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2141441326,227,35,1,2089,363,11,en,en
false,pharmacotherapies attention deficit hyperactivity disorder expect cost analysis,attention deficit hyperactivity disorder adhd common childhood neurobehavioral disorder characterize inattention hyperactivity impulsivity prevalence estimate elementary school child generally range adhd frequently treat psychostimulant medication show improve cognitive behavioral outcome child goal study estimate total expect cost treatment management school age child adhd use commonly prescribed pharmacotherapies methylphenidate immediate release extend release mph ir er methylphenidate immediate release mph ir metadate cd brand mph ir er concerta brand mph er ritalin brand mph ir adderall combination dextroamphetamine amphetamine salt literature review clinical assessment use question survey instrument use capture information clinical characteristic adhd include common treatment regimen clinical management patient pathway care component care meta analysis provide response rate commonly use pharmacotherapies metadate cd mph ir adderall information clinical assessment meta analysis use populate decision analytic model compute total expect cost comparator average total annual expect cost per patient metadate cd concerta mph ir er mph ir ritalin adderall metadate cd low total expect cost adderall high total expect cost among adhd pharmacotherapies evaluate difference attributable difference drug acquisition cost need school dose twice daily thrice daily medication,Marchetti A,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(00)89086-4,11768842,Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans; D008774: Methylphenidate,,,https://openalex.org/W2115190836,86,7,1,1855,299,7,en,en
false,pharmacovigilance olanzapine result post marketing surveillance study patient england,olanzapine atypical antipsychotic indicate treatment schizophrenia analyse adverse event aes report primary practice england dispense prescription issue december may provide exposure data questionnaire send general practitioner provide outcome frequently report aes drowsiness sedation n extrapyramidal disorder n unspecified side effect n event high incidence density first month reason stop drowsiness sedation n incidence density id weight gain n id malaise lassitude n id extrapyramidal disorder common elderly population year id risk per patient compare year id risk per patient serious suspect adverse reaction neuroleptic malignant syndrome n angioneurotic ooedema n eight report diabetes mellitus assess possibly due olanzapine diabetes mellitus unlabelled ae possible signal generate prescription event monitoring,Biswasl PN,2001,J Psychopharmacol,https://doi.org/10.1177/026988110101500405,11769820,Biswasl PN; Wilton LV; Pearcel GL; Freemantle S; Shakir SA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002648: Child; D015331: Cohort Studies; D004739: England; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011247: Pregnancy; D011358: Product Surveillance, Postmarketing; D012559: Schizophrenia; D012737: Sex Factors; D011795: Surveys and Questionnaires",,,https://openalex.org/W2083724014,111,16,1,1146,214,10,en,en
false,fluoxetine olanzapine resistant depression,back table content previous article next article letter editorfull accessfluoxetine olanzapine resistant depressionfranco benazzi franco benazzisearch paper author forli italypublished online jan http doi org appi ajp aboutsectionsview epub toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail editor read article richard c shelton et al report superior efficacy olanzapine plus fluoxetine treat resistant nonpsychotic unipolar depression compare either agent alone investigation two main phase week open label trial fluoxetine follow week double blind trial nonresponders fluoxetine alone randomly assign receive olanzapine alone fluoxetine alone fluoxetine plus olanzapine patient group receive olanzapine alone stop take fluoxetine day random assignment week treatment fluoxetine plus olanzapine produce mark improvement depression symptom significantly much great see olanzapine alone fluoxetine alone mark improvement persist remainder week double blind trial follow week open label extension period interest find seem difficult understand group receive olanzapine alone stop take fluoxetine day random assignment fluoxetine active metabolite norfluoxetine take many week disappear bloodstream discontinuation group receive olanzapine alone continue significant plasma level fluoxetine least first week double blind trial therefore observe marked difference response olanzapine alone compare response olanzapine plus fluoxetine double blind trial seem difficult understand treatment similar furthermore small group n examine may lead significant difference among group cause chance alone replication much large group use selective serotonin reuptake inhibitor short half life could produce clear result reference shelton rc tollefson gd tohen stahl gannon k jacob tg bura wr bymaster fp zhang w spencer ka feldman pd meltzer hy novel augmentation strategy treat resistant major depression j psychiatry link google scholar schatzberg af nemeroff cb american psychiatric press textbook psychopharmacology nd ed washington dc american psychiatric press google scholar rothman kj greenland modern epidemiology nd ed philadelphia lippincott williams wilkins google scholar figuresreferencescited bydetailscited bynone volume issue january page metric history publish online january publish print january,Benazzi F,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.1.155,11772722,Benazzi F,article,D003160: Comparative Study; D016422: Letter; D016420: Comment,"D001569: Benzodiazepines; D003865: Depressive Disorder, Major; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005473: Fluoxetine; D006801: Humans; D008657: Metabolic Clearance Rate; D000077152: Olanzapine; D010890: Pirenzepine; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2168136389,50,6,1,3077,493,16,en,en
false,dolasetron prevent postanesthetic shivering retract,design study assess efficacy dolasetron compare clonidine placebo prophylaxis postanesthetic shiver include patient undergoing elective abdominal urologic surgery patient randomly assign one three group group n use double blind study protocol group receive mg dolasetron group b microg kg clonidine group c saline placebo medication give induction anesthesia postanesthetic shivering judge use five point scale clonidine group show shiver whereas dolasetron placebo group respectively symptom free clonidine dolasetron significantly reduce incidence severity shiver conclude clonidine effective prevent shiver give surgery whereas dolasetron dose use effective shivering irregular muscular fasciculation last long common complication secondary general anesthesia compare dolasetron clonidine establish antishivering drug prevention postanesthetic shivering dolasetron mg effective,Piper SN,2002,Anesth Analg,https://doi.org/10.1097/00000539-200201000-00020,11772810,Piper SN; Röhm KD; Maleck WH; Fent MT; Suttner SW; Boldt J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000005: Abdomen; D000700: Analgesics; D000758: Anesthesia; D001831: Body Temperature; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007211: Indoles; D008297: Male; D008875: Middle Aged; D010149: Pain, Postoperative; D011183: Postoperative Complications; D011446: Prospective Studies; D011807: Quinolizines; D012702: Serotonin Antagonists; D012768: Shivering; D013520: Urologic Surgical Procedures",,,https://openalex.org/W3026225515,61,7,1,1249,215,10,en,en
false,epidural administration low dose morphine combine clonidine postoperative analgesia lumbar disc surgery,study evaluate efficacy side effect low dose epidural morphine combine clonidine postoperative pain relief lumbar disc surgery patient accept procedure epidural catheter insert l l level general anesthesia induce propofol sufentanil maintain sevoflurane n emergence anesthesia epidural analgesia initiate accord two randomly assign protocol mg morphine microg clonidine group mg bupivacaine microg clonidine group b ml saline piritramide administer first postoperative hour use patient control analgesia device pca follow parameter record piritramide consumption first hour pain rest first postoperative hour first night first mobilization visual analogue scale va occurrence drowsiness motor blockade respiratory depression nausea vomit itch micturition problem bladder catheterization epidural administration morphine clonidine significantly improve postoperative pain relief reduce piritramide consumption compare epidural bupivacaine clonidine side effect differ group except high incidence micturition problem group occurrence bladder catheterization significantly high group conclude low dose epidural morphine combine clonidine offer well postoperative analgesia bupivacaine clonidine excellent analgesic condition obtain expense high incidence difficulty initiate micturition,Bonhomme V,2002,J Neurosurg Anesthesiol,https://doi.org/10.1097/00008506-200201000-00001,11773815,Bonhomme V; Doll A; Dewandre PY; Brichant JF; Ghassempour K; Hans P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D000328: Adult; D015360: Analgesia, Epidural; D016058: Analgesia, Patient-Controlled; D000700: Analgesics; D000701: Analgesics, Opioid; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D002045: Bupivacaine; D003000: Clonidine; D017586: Diskectomy; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008159: Lumbar Vertebrae; D008297: Male; D008875: Middle Aged; D009020: Morphine; D010149: Pain, Postoperative; D010892: Pirinitramide; D014546: Urinary Catheterization; D014555: Urination Disorders",,,https://openalex.org/W2006119755,122,15,1,1806,301,11,en,en
false,comparison risperidone haloperidol prevention relapse patient schizophrenia,prevention relapse major goal maintenance treatment patient psychotic disorder perform long term comparison new atypical antipsychotic drug risperidone old conventional neuroleptic drug haloperidol term rate relapse patient schizophrenia schizoaffective disorder double blind prospective study site randomly assign adult outpatient stable condition chronic schizophrenia schizoaffective disorder receive treatment flexible either risperidone haloperidol minimum one year patient underwent randomization data exclude receive study medication data patient one site exclude sponsor janssen research foundation concern integrity data median duration treatment day risperidone group day haloperidol group p patient assign risperidone assign haloperidol remain analysis percent percent respectively discontinue treatment reason relapse kaplan meier estimate risk relapse end study percent risperidone group percent haloperidol group p risk ratio relapse haloperidol cox model percent confidence interval p early discontinuation treatment reason frequent among haloperidol treat patient risk ratio percent confidence interval patient risperidone group great reduction mean severity psychotic symptom extrapyramidal side effect haloperidol group adult outpatient clinically stable schizophrenia schizoaffective disorder low risk relapse treat risperidone treat haloperidol,Csernansky JG,2002,N Engl J Med,https://doi.org/10.1056/nejmoa002028,11777998,Csernansky JG; Mahmoud R; Brenner R; Risperidone-USA-79 Study Group,article,"D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D018572: Disease-Free Survival; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D016016: Proportional Hazards Models; D012306: Risk; D018967: Risperidone; D012559: Schizophrenia; D055502: Secondary Prevention,,,https://openalex.org/W2081069399,104,15,1,2045,349,7,en,en
false,efficacy olanzapine combination valproate lithium treatment mania patient partially nonresponsive valproate lithium monotherapy,week double blind randomize placebo control trial conduct determine efficacy combine therapy olanzapine either valproate lithium compare valproate lithium alone treat acute manic mixed bipolar episode primary objective evaluate efficacy olanzapine mg v placebo add ongoing mood stabilizer therapy measure reduction young mania rating scale ymrs score patient bipolar disorder n manic mixed episode inadequately responsive week lithium valproate therapy randomize receive cotherapy olanzapine mood stabilizer monotherapy placebo mood stabilizer olanzapine cotherapy improve patient ymrs total score significantly monotherapy v p clinical response rate improvement ymrs significantly high cotherapy v p olanzapine cotherapy improve item hamilton depression rating scale hamd total score significantly monotherapy vs point p patient mixed episode moderate severe depressive symptom dsm iv mixed episode hamd score baseline olanzapine cotherapy improve hamd score point compare monotherapy p extrapyramidal symptom simpson angus scale barnes akathisia scale abnormal involuntary movement scale significantly change baseline end point either treatment group treatment emergent symptom significantly high olanzapine cotherapy group include somnolence dry mouth weight gain increase appetite tremor slur speech compare use valproate lithium alone addition olanzapine provide superior efficacy treatment manic mixed bipolar episode,Tohen M,2002,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.59.1.62,11779284,Tohen M; Chengappa KN; Suppes T; Zarate CA; Calabrese JR; Bowden CL; Sachs GS; Kupfer DJ; Baker RW; Risser RC; Keeter EL; Feldman PD; Tollefson GD; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000328: Adult; D018692: Antimanic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D016651: Lithium Carbonate; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome; D014635: Valproic Acid",,,https://openalex.org/W2090784587,161,23,1,1921,328,7,en,en
false,pilot double blind dose comparison study risperidone drug naive first episode schizophrenia,article abstractletter editor sir efficacy safety risperidone patient first episode schizophrenia demonstrate open trial control study however optimal dose risperidone population remain controversial open trial kopala et al low mg day n associate good outcome high mg day n another small scale open trial also report similar find double blind study emsley et al mean final daily dose risperidone mg n haloperidol mg n another study mean daily dose mg risperidone n mg haloperidol n recommendation low mg day high mg day find literature note previous trial limit value include random assignment fix risperidone,Lane HY,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n1214c,11780884,Lane HY; Chang WH; Chiu CC; Huang MC; Lee SH; Chen JY,article,D016430: Clinical Trial; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010865: Pilot Projects; D018967: Risperidone; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1999617843,101,13,1,976,200,8,en,en
false,systematic review adjunct intravenous regional anesthesia surgical procedure,review use adjunct intravenous regional anesthesia ivra surgical procedure term intraoperative effect efficacy block tourniquet pain postoperative analgesia systematic search medline embase reference list randomize control double blind study use adjunct ivra surgical procedure conduct data collect intraoperative effect onset offset quality block tourniquet pain postoperative effect pain intensity analgesic consumption side effect record statistical significance indicate original report likely clinical relevance take account arrive judgment overall benefit twenty nine study meet inclusion criterion data study subject include adjunct use opioids fentanyl meperidine morphine sufentanil tramadol non steroidal anti inflammatory drug nsaid ketorolac tenoxicam acetyl salicylate clonidine muscle relaxant atracurium pancuronium mivacurium alkalinization sodium bicarbonate potassium temperature good evidence recommend nsaid general ketorolac particular improve postoperative analgesia clonidine microg kg also appear improve postoperative analgesia prolong tourniquet tolerance opioids poor route meperidine mg substantial postoperative benefit expense postdeflation nausea vomit dizziness muscle relaxant improve intraoperative motor block aid fracture reduction use nsaid clonidine adjunct ivra improve postoperative analgesia muscle relaxant improve motor block,Choyce A,2002,Can J Anaesth,https://doi.org/10.1007/bf03020416,11782326,Choyce A; Peng P,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,"D000759: Adjuvants, Anesthesia; D000765: Anesthesia, Conduction; D000771: Anesthesia, Intravenous; D006801: Humans; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W130007184,91,12,1,1719,268,9,en,en
true,bupropion sr v methylphenidate v placebo attention deficit hyperactivity disorder adult,despite increase recognition attention deficit hyperactivity disorder adhd adult control trial demonstrate effectiveness pharmacological treatment particularly nonstimulants one control trial find bupropion sr effective placebo treatment adhd adult conduct control study contrast effectiveness bupropion sr methylphenidate placebo adhd adult randomize double blind parallel design use study follow day placebo lead adhd dsm iv subject year old randomize bupropion methylphenidate placebo week methylphenidate titrate week maximum dose mg kg divide bupropion titrate week maximum dose mg mg p response rate base clinical global impression improvement rating patient receive bupropion methylphenidate placebo respectively difference response rate active treatment placebo statistically significant p neuropsychological test demonstrate trend favor drug treatment measure immediate recall verbal fluency bupropion sr may viable clinical alternative adult adhd investigation need,Kuperman S,2001,Ann Clin Psychiatry,https://doi.org/10.1023/a:1012239823148,11791949,Kuperman S; Perry PJ; Gaffney GR; Lund BC; Bever-Stille KA; Arndt S; Holman TL; Moser DJ; Paulsen JS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D018663: Adrenergic Agents; D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D016642: Bupropion; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D012720: Severity of Illness Index; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W2085799036,100,14,1,1373,231,10,en,en
false,risk extrapyramidal syndrome haloperidol risperidone olanzapine,objective compare risk extrapyramidal syndrome eps risperidone olanzapine haloperidol take account patient past antipsychotic drug use past eps method data obtain pharmo database contain fill prescription community dwell people netherlands define cohort first time user haloperidol risperidone olanzapine age year first day treatment assess occurrence eps define first use antiparkinsonian agent estimate relative risk eps risperidone olanzapine versus haloperidol use cox proportional hazard model patient subdivide accord prior use antipsychotic antiparkinsonian drug result identify patient start treatment haloperidol risperidone olanzapine prior use antipsychotic plus antiparkinsonian medication significantly frequent among user risperidone olanzapine use haloperidol respectively p within subgroup comparable treatment history patient use risperidone olanzapine show reduce risk eps compare haloperidol although find reach statistical significance rr however observe patient use risperidone experience eps past rr ci conclusion general observe reduce risk eps risperidone olanzapine compare haloperidol within subgroup patient similar treatment history however add value risperidone patient experience eps past need far study,Schillevoort I,2001,Ann Pharmacother,https://doi.org/10.1345/aph.1a068,11793611,Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D015331: Cohort Studies; D004347: Drug Interactions; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D009426: Netherlands; D000077152: Olanzapine; D010890: Pirenzepine; D012307: Risk Factors; D018967: Risperidone,,,https://openalex.org/W2168030456,77,11,1,1791,309,12,en,en
false,bupropion versus selective serotonin reuptake inhibitor treatment depression,compare benefit risk bupropion selective serotonin reuptake inhibitor ssri adult depression medline september embase august psyclnfo august international pharmaceutical abstract august cianhl database search reference select citation review article manufacturer also screen include study randomize double blind control trial evaluate bupropion versus ssri depression adult study assess independently duplicate discrepancy resolve consensus data report absolute weight mean difference relative risk confidence interval compare bupropion relative ssri data combine present qualitatively six full length study include citation identify ssri comparators fluoxetine sertraline paroxetine difference hamilton rating scale depression ham clinical global impression scale improvement illness cgi find data able quantitatively combine absolute weight mean difference ci cgi severity illness ci hamilton rating scale anxiety measurement relative risk bupropion compare ssri ci ci ci nausea diarrhea somnolence respectively sexual arousal disorder orgasmic dysfunction sexual desire disorder occur less bupropion ssri relative risk ci ci ci respectively bupropion ssri similar effectiveness however bupropion associate less nausea diarrhea somnolence sexual dysfunction,Nieuwstraten CE,2001,Ann Pharmacother,https://doi.org/10.1345/aph.1a099,11793630,Nieuwstraten CE; Dolovich LR,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000328: Adult; D000368: Aged; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2121675770,84,9,1,1913,343,10,en,en
false,risperidone treatment tourette syndrome double blind placebo control trial,double blind placebo control trial perform determine efficacy tolerability week treatment risperidone management adolescent adult patient tourette syndrome twenty four patient randomly assign treatment risperidone dos mg day assign placebo dosage medication increase fix increment first week double blind treatment thereafter flexible dose regimen accord clinical response risperidone median dose mg day range mg day find significantly p superior placebo global severity rating tourette syndrome severity scale proportion patient improve least one point seven point scale risperidone group placebo group treatment risperidone accompany improvement global functioning patient average average impairment baseline measure global assessment function scale respect extrapyramidal symptom score measure extrapyramidal symptom rating scale hypokinesia tremor increase risperidone group effect tremor largely confine subject high baseline tremor score significant difference dystonic reaction dyskinetic movement subjective parkinsonism akathisia risperidone increase obsessive compulsive symptom fatigue somnolence common adverse event associate risperidone,Dion Y,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200202000-00006,11799340,Dion Y; Annable L; Sandor P; Chouinard G,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009460: Neurologic Examination; D018967: Risperidone; D005879: Tourette Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W2008219589,91,13,1,1620,265,10,en,en
false,clinical advantage amisulpride treatment acute schizophrenia,five study conduct atypical anti psychotic amisulpride mg day involve patient acute exacerbation schizophrenia four study short term week double blind study one month open randomize comparison amisulpride improve positive symptom consistently change pronounced haloperidol flupenthixol risperidone amisulpride show rapid onset action compare haloperidol improvement negative symptom effective comparator optimum response obtain amisulpride dos mg day long term study confirm usefulness amisulpride maintenance treatment schizophrenia clear advantage haloperidol lead well functioning quality life amisulpride cause neurological side effect conventional anti psychotic less weight gain risperidone crucial factor long term compliance,Burns T,2001,J Int Med Res,https://doi.org/10.1177/147323000102900601,11803729,Burns T; Bale R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D000077582: Amisulpride; D014150: Antipsychotic Agents; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012559: Schizophrenia; D013469: Sulpiride; D016896: Treatment Outcome",,,https://openalex.org/W2112915464,74,10,1,1024,155,5,en,en
false,adjunctive high dose glycine treatment schizophrenia,glycine agonist brain n methyl aspartate receptor cross blood brain barrier follow high dose oral administration previous study significant improvement negative cognitive symptom observe group schizophrenic patient receive high dose glycine addition antipsychotic treatment study evaluate degree symptom improvement might relate alteration antipsychotic drug level additional group subject glycine treatment associate fold increase serum glycine level similar observe previously significant reduction negative symptom observe glycine treatment serum antipsychotic level significantly alter significant clinical effect observe despite fact majority subject receive atypical antipsychotic clozapine olanzapine early study improvement persist follow glycine discontinuation,Javitt DC,2001,Int J Neuropsychopharmacol,https://doi.org/10.1017/s1461145701002590,11806864,Javitt DC; Silipo G; Cienfuegos A; Shelley AM; Bark N; Park M; Lindenmayer JP; Suckow R; Zukin SR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000596: Amino Acids; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005998: Glycine; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2112218294,62,8,1,1005,149,8,en,en
false,pharmacological treatment postoperative shiver quantitative systematic review randomize control trial,shiver frequent complication postoperative period relative efficacy intervention use treatment postoperative shivering well understood perform systematic search medline embase cochrane library hand search language august full report randomize comparison pharmacological antishivering intervention active placebo control postoperative period dichotomous data absence shiver treatment adverse effect extract original report relative risk rr number need treat nnt calculate confidence interval ci use fixed effect model data trial adult receive active intervention control analyze antishivering efficacy depend active regimen length follow efficacy meperidine mg clonidine g ketanserin mg doxapram mg report least three trial significantly effective control min nnt meperidine mg shiver compare placebo rr ci min nnt meperidine mg rr ci nnt clonidine g rr ci nnt doxapram mg rr ci nnt ketanserin mg rr ci min nnt meperidine mg rr ci min nnt ketanserin mg rr ci long term outcome data lack enough data alfentanil fentanyl morphine nalbuphine lidocaine magnesium metamizol methylphenidate nefopam pentazocine tramadol draw meaningful conclusion report adverse drug reaction sparse two shiver patient need treat meperidine mg clonidine g doxapram mg one stop shivering within min would continue shiver receive placebo,Kranke P,2002,Anesth Analg,https://doi.org/10.1097/00000539-200202000-00043,11812718,Kranke P; Eberhart LH; Roewer N; Tramèr MR,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D000078182: Systematic Review","D000316: Adrenergic alpha-Agonists; D000701: Analgesics, Opioid; D003000: Clonidine; D006801: Humans; D007650: Ketanserin; D008012: Lidocaine; D008614: Meperidine; D011183: Postoperative Complications; D016032: Randomized Controlled Trials as Topic; D012768: Shivering",,,https://openalex.org/W2007838750,118,14,1,2118,437,16,en,en
false,effect olanzapine dimension schizophrenia derive factor analysis,article abstractbackground choice drug treat patient schizophrenia one critical clinical decision controversy exist differential efficacy olanzapine data source study selection raw data registrational double blind random assignment study olanzapine compare placebo haloperidol obtain eli lilly company meta analysis method analysis covariance intent treat last observation carry forward endpoint score use assess efficacy brief psychiatric rating scale bprs positive negative syndrome scale panss total score factor derive factor analysis negative symptom positive symptom disorganize thought impulsivity hostility anxiety depression result olanzapine produce statistically significantly great reduction schizophrenic symptom haloperidol p total score bprs panss factor well almost item olanzapine induce response rate equal induce haloperidol first week end study produce great percentage responder compare haloperidol olanzapine produce somewhat great response symptom responsive haloperidol markedly well response symptom unresponsive haloperidol difference favor olanzapine occur equal degree subgroup examine incidence parkinsonism akathisia follow olanzapine treatment extremely low statistically distinguishable placebo conclusion olanzapine produce great improvement haloperidol particularly benefit much large number item factor extrapyramidal side effect akathisia olanzapine treatment statistically indistinguishable effect see placebo,Davis JM,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n1003,11816864,Davis JM; Chen N,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,"D000328: Adult; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005163: Factor Analysis, Statistical; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011594: Psychometrics; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2027349043,89,14,1,1908,296,11,en,en
false,bupropion sr sertraline differ effect anxiety depress patient,examine effect bupropion sustain release sr sertraline anxiety outpatient recurrent dsm iv define major depressive disorder retrospective analysis conduct use pool data identical week acute phase double blind placebo control parallel group study bupropion sr n sertraline n placebo n symptom anxiety depression measure use item hamilton rating scale anxiety ham item hamilton rating scale depression ham respectively percentage reduction baseline ham total score treatment week calculate determine whether time onset anxiolytic activity differ among antidepressant responder agent central nervous system cns adverse event tabulate bupropion sr sertraline comparably effective superior placebo reduce depressive symptom differ effect anxiety symptom antidepressant responder reduction baseline ham score group show mark comparable reduction ham score baseline exit difference bupropion sr sertraline median time week reach clinically significant anxiolytic effect reduction baseline ham score cns adverse event comparable bupropion sr sertraline except somnolence common sertraline treat patient bupropion sr sertraline comparable antidepressant anxiolytic effect equally rapid onset clinically significant anxiolytic activity difference activate effect antidepressant selection agent base either anticipation differential anxiolytic activity differential cns side effect profile,Trivedi MH,2001,J Clin Psychiatry,https://doi.org/10.4088/jcp.v62n1005,11816866,Trivedi MH; Rush AJ; Carmody TJ; Donahue RM; Bolden-Watson C; Houser TL; Metz A,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001008: Anxiety Disorders; D016642: Bupropion; D015897: Comorbidity; D003692: Delayed-Action Preparations; D003865: Depressive Disorder, Major; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010555: Personality Inventory; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies; D020280: Sertraline; D016896: Treatment Outcome",,,https://openalex.org/W2009767613,88,15,1,1900,314,10,en,en
false,effect clonidine schizophrenic patient primary polydipsia,pilot study conduct schizophrenic patient primary polydipsia determine tolerability add clonidine exist antipsychotic drug regimen seek evidence antidipsic effect three patient chronic schizophrenia primary polydipsia underwent open control prospective trial treatment clonidine g day trial last month analysis variance use test change dependent variable case case basis blood pressure pulse decline significantly dose dependent manner fluid intake assess measurement weight h urine volume affect hypotension bradycardia limit extent dose clonidine could increase lack evident effect clonidine polydipsia small sample inconsistent result two recent study clonidine patient schizophrenia primary polydipsia provide little overall support effectiveness clonidine treatment primary polydipsia associate schizophrenia,Delva NJ,2002,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/s0278-5846(01)00246-9,11817518,Delva NJ; Chang A; Hawken ER; Lawson JS; Owen JA,article,"D002363: Case Reports; D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000704: Analysis of Variance; D002908: Chronic Disease; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004327: Drinking Behavior; D006801: Humans; D008297: Male; D010865: Pilot Projects; D011446: Prospective Studies; D012559: Schizophrenia; D013894: Thirst; D014869: Water Intoxication",,,https://openalex.org/W77044274,70,9,1,1127,180,6,en,en
false,efficacy clonidine prevention perioperative myocardial ischemia,belief clonidine may effective reduce perioperative myocardial ischemic event although result several trial conflict aim current study provide systematic review randomize controlled trial test efficacy clonidine regard data collect medline search english language study publish manual search bibliography retrieve article total study assess accord selection criterion study design population intervention outcome quality score system seven study finally include meta analysis homogeneity establish q value data combine use fix effect model pool odds ratio calculate subgroup analysis base type surgery administration route also perform qualify result result express odds ratio confidence interval heterogeneity outcome data negative trial pool odds ratio confidence interval subgroup analysis clonidine reduce incidence myocardial ischemia patient undergo cardiac noncardiac surgery rate bradycardia similar clonidine placebo group meta analysis suggest perioperative clonidine reduces cardiac ischemic episode patient know risk coronary arterial disease without increase incidence bradycardia therefore find strongly justify plan execution definitive study seek benefit clonidine,Nishina K,2002,Anesthesiology,https://doi.org/10.1097/00000542-200202000-00016,11818763,Nishina K; Mikawa K; Uesugi T; Obara H; Maekawa M; Kamae I; Nishi N,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D000078182: Systematic Review",D000316: Adrenergic alpha-Agonists; D002986: Clinical Trials as Topic; D003000: Clonidine; D006801: Humans; D007431: Intraoperative Complications; D017202: Myocardial Ischemia; D015203: Reproducibility of Results; D012107: Research Design,,,https://openalex.org/W2052980033,73,9,1,1668,271,12,en,en
false,amisulpride unusual atypical antipsychotic meta analysis randomize control trial,atypical profile new antipsychotic clozapine olanzapine quetiapine risperidone link combine antagonism serotonin ht dopamine receptor although amisulpride highly selective receptor antagonist assume atypical property well purpose article compare atypical profile amisulpride ht antagonists randomize control trial compare amisulpride conventional antipsychotic placebo patient schizophrenia identify include meta analysis mean effect size find amisulpride compare update meta analysis ht antagonist eighteen randomize controlled trial amisulpride n find study acutely ill patient prove consistently effective conventional antipsychotic global schizophrenic symptom measure brief psychiatric rating scale negative symptom amisulpride date atypical antipsychotic several study patient suffer predominantly negative symptom publish four study amisulpride significantly effective placebo three small study conventional antipsychotic comparators show trend favor amisulpride regard amisulpride associate clearly low use antiparkinsonian medication dropout due adverse event conventional antipsychotic result cast doubt notion combine ht antagonism reason new antipsychotic medication effective negative symptom extrapyramidal side effect,Leucht S,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.2.180,11823257,Leucht S; Pitschel-Walz G; Engel RR; Kissling W,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000077582: Amisulpride; D014150: Antipsychotic Agents; D006801: Humans; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013469: Sulpiride; D016896: Treatment Outcome,,,https://openalex.org/W2115125760,97,15,1,1795,303,9,en,en
false,clozapine olanzapine risperidone haloperidol treatment patient chronic schizophrenia schizoaffective disorder,author compare efficacy safety three atypical antipsychotic clozapine olanzapine risperidone one another haloperidol treatment patient chronic schizophrenia schizoaffective disorder double blind trial inpatient history suboptimal treatment response randomly assign treatment clozapine olanzapine risperidone haloperidol week week escalation fix dose period follow week variable dose period clozapine risperidone olanzapine haloperidol result statistically significant improvement total score positive negative syndrome scale improvement see total negative symptom score clozapine olanzapine superior haloperidol atypical drug particularly olanzapine clozapine associate weight gain effect atypical antipsychotic population statistically significant clinically modest overall pattern result suggest clozapine olanzapine similar general antipsychotic efficacy risperidone may somewhat less effective clozapine effective treatment negative symptom however difference among treatment small,Volavka J,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.2.255,11823268,Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010343: Patient Admission; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2121612791,136,19,1,1298,195,6,en,en
false,use ecology drug use motivation methamphetamine user admit substance abuse treatment facility los angeles,methamphetamine user circumstance surround drug use article provide foundation future ethnographic study collaborative clinician researcher assessment use describe use ecology drug use motivation user admit treatment public los angeles county facility use ecology data include variety street name first introduction use drug use history access sell manufacture route administration unwanted result use participant use behavior year treatment use motivation data describe client use substitute stimulant cope mental distress stay awake enhance sexual experience lose weight qualitative case study illustrate find demonstrate complex inter relation society culture psyche soma shape use time,von MC,2002,J Addict Dis,https://doi.org/10.1300/j069v21n01_05,11831499,von MC; Brecht ML; Anglin MD,article,"D002363: Case Reports; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D019969: Amphetamine-Related Disorders; D000697: Central Nervous System Stimulants; D015331: Cohort Studies; D005260: Female; D006801: Humans; D008137: Longitudinal Studies; D015141: Los Angeles; D008297: Male; D008694: Methamphetamine; D016320: Substance Abuse Treatment Centers,,,https://openalex.org/W1839387700,125,18,1,956,164,5,en,en
false,effect modafinil steady state single dose pharmacokinetic profile warfarin healthy volunteer,modafinil report produce concentration relate suppression cyp c activity vitro primary culture human hepatocytes determine whether effect occur vivo pharmacokinetics warfarin investigate single oral racemic warfarin mg coumadin placebo control single blind single period study volunteer subject receive oral dose warfarin prior administration modafinil mg day follow mg day placebo receive another week treatment treatment modafinil significantly alter pharmacokinetics r warfarin relative placebo since warfarin predominantly metabolize via cyp c result indicate mark suppression cyp c activity vitro translate similar effect clinically however limitation arise investigation single warfarin preclude global conclusion potential subtle interaction chronic warfarin administration,Robertson P,2002,J Clin Pharmacol,https://doi.org/10.1177/00912700222011120,11831544,Robertson P; Hellriegel ET; Arora S; Nelson M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000925: Anticoagulants; D019540: Area Under Curve; D001559: Benzhydryl Compounds; D001711: Biotransformation; D000697: Central Nervous System Stimulants; D002851: Chromatography, High Pressure Liquid; D004347: Drug Interactions; D005260: Female; D006801: Humans; D019934: International Normalized Ratio; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D010349: Patient Compliance; D011517: Prothrombin Time; D016037: Single-Blind Method; D013237: Stereoisomerism; D014859: Warfarin",,,https://openalex.org/W2147600411,112,16,1,1083,184,6,en,en
false,usefulness olanzapine levodopa induce psychosis patient parkinson disease,evaluate antipsychotic efficacy olanzapine olz patient parkinson disease pd drug induce psychosis dip repercussion motor function ten patient woman men diagnose pd dip age year range pd duration year range treat chronically levodopa per day receive dose mg olz daily data concern improvement psychosis worsen motor function base positive negative symptom scale panss unify parkinson disease rating scale updrs motor psychotic symptom improve patient improvement almost total seven patient increase levodopa dose olz significant worsen motor function report one patient none patient agranulocytosis blood monitor two patient present weight gain seven patient improve cognitive status conclude olz study may efficacy dip appear pd induce worsen motor function patient,Chacón JR,2002,Neurologia,,11834192,Chacón JR; Durán E; Durán JA; Alvarez M,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D006801: Humans; D007980: Levodopa; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010300: Parkinson Disease; D010890: Pirenzepine; D011446: Prospective Studies; D011605: Psychoses, Substance-Induced",,,https://openalex.org/W1006836439,98,16,1,1121,207,7,en,en
false,methylphenidate isomer approve fda,journal article methylphenidate isomer approve fda get access cheryl thompson cheryl thompson search work author oxford academic google scholar american journal health system pharmacy volume issue february page http doi org ajhp publish february,,2002,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/59.3.230,11862632,,article,D016433: News,D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D017277: Drug Approval; D006801: Humans; D008774: Methylphenidate; D016032: Randomized Controlled Trials as Topic; D013237: Stereoisomerism,,,https://openalex.org/W2915378946,38,5,1,338,55,1,en,en
true,treatment adhd child tic,treatment child attention deficit hyperactivity disorder adhd tourette syndrome problematic methylphenidate mph commonly use drug treat adhd report worsen tic clonidine clon commonly prescribe alternative unproven efficacy author conduct multicenter randomize double blind clinical trial child adhd chronic tic disorder randomly administer clon alone mph alone combine clon mph placebo x factorial design subject participate week week clon placebo dose titration week add mph placebo dose titration week maintenance therapy thirty seven child administer mph alone administer clon alone administer clon mph administer placebo primary outcome measure adhd conners abbreviate symptom questionnaire teacher significant improvement occur subject assign clon p assign mph p compare placebo great benefit occur combine clon mph p clon appear helpful impulsivity hyperactivity mph appear helpful inattention proportion individual subject report worsen tic adverse effect high treat mph administer clon alone placebo compare placebo measure tic severity lessen active treatment group follow order clon mph clon alone mph alone sedation common clon treatment report moderate severe sedation otherwise drug tolerate well include absence evident cardiac toxicity methylphenidate clonidine particularly combination effective adhd child comorbid tic prior recommendation avoid methylphenidate child concern worsen tic unsupported trial,Tourette's Syndrome Study Group,2002,Neurology,https://doi.org/10.1212/wnl.58.4.527,11865128,Tourette's Syndrome Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003000: Clonidine; D016001: Confidence Intervals; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011795: Surveys and Questionnaires; D013981: Tic Disorders; D016896: Treatment Outcome",,,https://openalex.org/W2266471137,39,7,1,2066,372,9,en,en
false,obsessive compulsive symptom treatment olanzapine risperidone,article abstractobjective determine whether severity obsessive compulsive symptom ocs differs treatment olanzapine risperidone establish whether duration antipsychotic treatment relate severity ocs method conduct prospective study consecutively hospitalize young patient mean age year dsm iv schizophrenia relate disorder n treat olanzapine risperidone olanzapine risperidone randomly prescribe patient drug naive treat typical antipsychotic admission n patient start olanzapine n risperidone treatment n prior admission continue medication show initial clinical response patient prior admission start olanzapine n risperidone n show response suffer adverse effect switch admission risperidone olanzapine respectively medical record parent patient reveal information duration treatment compliance olanzapine risperidone prior admission yale brown obsessive compulsive scale ybocs administer admission week thereafter result baseline week assessment ocs find evaluable case meet dsm iv criterion obsessive compulsive disorder difference ocs find patient randomly assign olanzapine risperidone subject treat olanzapine assessment significantly p severe ocs week subject treat risperidone assessment duration treatment olanzapine significantly p relate severity ocs conclusion difference short term propensity olanzapine risperidone induce exacerbate ocs however severity ocs associate duration treatment olanzapine,de Haan L,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0203,11874209,de Haan L; Beuk N; Hoogenboom B; Dingemans P; Linszen D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015897: Comorbidity; D005260: Female; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D009426: Netherlands; D009771: Obsessive-Compulsive Disorder; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2007416161,78,8,1,1982,338,13,en,en
false,acute tryptophan depletion schizophrenic patient treat clozapine,,George TP,2002,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.59.3.291,11879174,George TP; Potenza MN; Degen K; Sernyak MJ; Woods S; McDougle CJ,article,"D016430: Clinical Trial; D016422: Letter; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001921: Brain; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012701: Serotonin; D014364: Tryptophan,,,https://openalex.org/W2104310885,75,9,1,0,0,0,en,
false,psychopharmacology aggression meta analysis stimulant effect overt covert aggression relate behavior adhd,determine meta analysis effect size stimulant overt covert aggression relate behavior child attention deficit hyperactivity disorder adhd separately stimulant effect core symptom adhd review literature reveal study meet inclusion exclusion criterion meta analysis study yield independent effect overt aggression independent effect covert aggression overall weight mean effect size overt covert aggression relate behavior adhd comorbid conduct disorder associate diminish stimulant effect size overt aggression stimulant effect aggression relate behavior adhd effect size similar core symptom adhd,Connor DF,2002,J Am Acad Child Adolesc Psychiatry,https://doi.org/10.1097/00004583-200203000-00004,11886019,Connor DF; Glatt SJ; Lopez ID; Jackson D; Melloni RH,article,D016428: Journal Article; D017418: Meta-Analysis,D000293: Adolescent; D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D019955: Conduct Disorder; D005260: Female; D006801: Humans; D008297: Male,,,https://openalex.org/W1984246160,127,17,2,811,118,3,en,en
false,mirtazapine yohimbine olanzapine augmentation therapy serotonin reuptake associate female sexual dysfunction randomize placebo control trial,background many agent propose potential treatment ssri associate sexual dysfunction placebo control trial report method month baseline evaluation pre menopausal woman moderate severe sexual dysfunction associate institution fluoxetine therapy randomize augmentation therapy placebo n mirtazapine n yohimbine n olanzapine n week period outcome measure use daily diary biweekly self report assessment computer assist structure interview result baseline orgasm severely impaired week statistically significant improvement measure overall group patient however difference treatment group isolate treatment difference observe patient self report overall sexual function olanzapine superior placebo structure interview sexual satisfaction item mirtazapine inferior placebo conclusion drug assess consistently associate difference placebo result study support uncontrolled report efficacy agent premenopausal woman,Michelson D,2002,J Psychiatr Res,https://doi.org/10.1016/s0022-3956(01)00060-7,11886692,Michelson D; Kociban K; Tamura R; Morrison MF,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000317: Adrenergic alpha-Antagonists; D000328: Adult; D000929: Antidepressive Agents, Tricyclic; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008803: Mianserin; D000078785: Mirtazapine; D000077152: Olanzapine; D017060: Patient Satisfaction; D010890: Pirenzepine; D010919: Placebos; D017697: Premenopause; D017367: Selective Serotonin Reuptake Inhibitors; D012735: Sexual Dysfunction, Physiological; D016896: Treatment Outcome; D015016: Yohimbine",,,https://openalex.org/W1978647001,157,20,1,1245,200,8,en,en
false,time study discontinuation relapse compliance atypical conventional antipsychotic schizophrenia relate disorder,clearly clarify efficacy atypical antipsychotic compare conventional antipsychotic add data outcome patient diagnose schizophrenia two large international clinical trial compare olanzapine haloperidol n olanzapine risperidone n study comprise double blind placebo control random assignment trial health outcome report include time discontinuation trial ii clinical relapse iii time drug non compliance outcome measure time discontinuation due adverse event lack efficacy olanzapine show superiority haloperidol difference compare risperidone patient initial response significant difference olanzapine haloperidol outcome measure use either week relapse rate ii time first non compliance use measure study discontinuation relapse non compliance one trial atypical antipsychotic olanzapine superior haloperidol second trial difference olanzapine risperidone,Glick ID,2002,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-200203000-00004,11890188,Glick ID; Berg PH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D012008: Recurrence; D018967: Risperidone; D012559: Schizophrenia; D013375: Substance Withdrawal Syndrome; D016019: Survival Analysis; D013997: Time Factors; D016896: Treatment Outcome; D016312: Treatment Refusal,,,https://openalex.org/W1988730368,138,19,1,1182,198,6,en,en
false,adrenergic agonist opioid withdrawal,paper present main finding systematic cochrane review effectiveness alpha adrenergic agonist manage opioid withdrawal original systematic review include control trial compare alpha adrenergic agonist another form treatment placebo participant primarily opioid dependent ten study compare treatment regime base alpha adrenergic agonist one base reduce methadone withdrawal intensity similar marginally great alpha adrenergic agonist sign symptom withdrawal occur resolve early treatment participant stay treatment longer methadone likelihood complete withdrawal similar slightly less clonidine lofexidine clonidine associate adverse effect reduce methadone three study compare alpha adrenergic agonist clonidine lofexidine lofexidine reduce blood pressure extent clonidine otherwise similar clonidine participant stay treatment long methadone regime may provide great opportunity psychosocial intervention methadone regime may preferable withdrawal outpatient set risk relapse heroin use high use methadone may also facilitate transfer maintenance treatment completion withdrawal become unlikely well prepared withdrawal seek early resolution withdrawal symptom alpha adrenergic agonist treatment may prefer clonidine lofexidine appear equally effective inpatient set low incidence hypotension make lofexidine suit use outpatient setting,Gowing LR,2002,Addiction,https://doi.org/10.1046/j.1360-0443.2002.00037.x,11895270,Gowing LR; Farrell M; Ali RL; White JM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review; D000078182: Systematic Review",D000316: Adrenergic alpha-Agonists; D003000: Clonidine; D016001: Confidence Intervals; D018849: Controlled Clinical Trials as Topic; D006801: Humans; D008691: Methadone; D009294: Narcotics; D016017: Odds Ratio; D009293: Opioid-Related Disorders; D013375: Substance Withdrawal Syndrome; D016896: Treatment Outcome,,,https://openalex.org/W2095305874,61,19,1,1779,266,11,en,en
false,comparison short term hypotensive effect side effect unilateral brimonidine apraclonidine patient elevate intraocular pressure,purpose compare short term ocular hypotensive efficacy side effect brimonidine apraclonidine patient elevate intraocular pressure iop method perform double mask placebo control study compare efficacy application brimonidine apraclonidine effect iop systemic blood pressure heart rate newly diagnose ocular hypertensive patient effect untreated fellow eye ocular side effect also determine measurement perform h instillation one drop result brimonidine apraclonidine significantly reduce iop baseline observation time significant difference observe treatment group iop decrease significantly untreated fellow eye brimonidine group hour check hour check apraclonidine group compare placebo blood pressure heart rate decrease significantly brimonidine group compare placebo apraclonidine affect blood pressure heart rate differently placebo pupil diameter interpalpebral fissure width significantly increase apraclonidine group brimonidine group significant difference overall incidence foreign body sensation burn sting dry mouth treatment group conclusion short term brimonidine effective reduce iop patient elevate iop equivalent efficacy apraclonidine hand significant change blood pressure heart rate observe brimonidine change apraclonidine group,Yüksel N,2002,Ophthalmologica,https://doi.org/10.1159/000048296,11901288,Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D000068438: Brimonidine Tartrate; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005902: Glaucoma, Open-Angle; D006339: Heart Rate; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D011810: Quinoxalines; D016896: Treatment Outcome",,,https://openalex.org/W1965346204,158,21,1,1838,353,13,en,en
false,double blind placebo control trial donepezil adjunctive treatment risperidone cognitive impairment schizophrenia,background despite beneficial effect atypical antipsychotic cognition improvement return schizophrenic patient normative standard cognitive function therefore treatment need consider subtle change cholinergic function schizophrenic patient provide rationale test effectiveness cholinesterase inhibitor treat cognitive impairment schizophrenia method give week double blind placebo control trial donepezil mg mg adjunctive treatment risperidone conduct total schizophrenic patient result neither mg mg dose donepezil produce significant improvement cognitive measure compare placebo conclusion possible nicotinic receptor desensitization produce chronic tobacco use patient render nicotinic receptor refractory effect increase agonist activity produce donepezil alternative treatment allosterically potentiate ligand enhance activity sensitize nicotinic receptor presence acetylcholine,Friedman JI,2002,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(01)01342-7,11904128,Friedman JI; Adler DN; Howanitz E; Harvey PD; Brenner G; Temporini H; White L; Parrella M; Davis KL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D003072: Cognition Disorders; D000077265: Donepezil; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007189: Indans; D008297: Male; D008875: Middle Aged; D009483: Neuropsychological Tests; D010880: Piperidines; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2063097051,134,18,1,1167,176,7,en,en
false,safety pharmacokinetics quetiapine coadministered haloperidol risperidone thioridazine,effect haloperidol risperidone thioridazine pharmacokinetics side effect profile quetiapine investigate patient schizophrenia schizoaffective disorder bipolar disorder single center two period multiple dose open label randomize trial one two week period quetiapine escalate mg twice daily bid patient treat least day target quetiapine dose subsequently enter combination therapy period receive haloperidol mg bid risperidone mg bid thioridazine mg bid day day dose escalation key assessment include pharmacokinetics quetiapine steady state area curve within dose interval auctss maximum cmaxss minimum cminss observe plasma concentration oral clearance cl f well uku side effect rating scale score safety evaluation neither risperidone haloperidol significant effect quetiapine pharmacokinetics however thioridazine produce statistically significant change decrease least square mean value auctss cmaxss cminss respectively increase cl f increase follow adverse event note coadministration somnolence risperidone insomnia dry mouth three coadministered therapy dizziness thioridazine uku side effect item become bad patient coadministration period include sedation increase sleep duration result laboratory test electrocardiogram vital sign measurement reveal clinically important change clinical stability maintain good tolerability transition quetiapine monotherapy period coadministration haloperidol risperidone thioridazine coadministration either haloperidol risperidone important effect steady state pharmacokinetics quetiapine thioridazine significantly increase oral clearance quetiapine increase dos quetiapine may necessary control psychotic symptom thioridazine coadministered quetiapine,Potkin SG,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200204000-00004,11910256,Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001714: Bipolar Disorder; D003987: Dibenzothiazepines; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013881: Thioridazine",,,https://openalex.org/W2053574680,112,15,1,2265,382,13,en,en
false,effect fluoxetine imipramine pharmacokinetics tolerability antipsychotic quetiapine,effect fluoxetine imipramine pharmacokinetics nonpsychiatric side effect profile quetiapine fumarate investigate patient schizophrenia schizoaffective disorder bipolar disorder multicenter two period multiple dose open label randomize trial week period patient titrate mg twice daily dose quetiapine patient treat least day target dose enter combination therapy period receive fluoxetine mg daily imipramine mg twice daily day key assessment include pharmacokinetic analysis quetiapine udvalg kliniske unders gelser uku side effect rating scale safety evaluation e g adverse event electrocardiogram laboratory test vital sign fluoxetine increase quetiapine area plasma concentration time curve hour interval maximum plasma concentration dose interval c max minimum plasma concentration end dose interval although decrease oral clearance change c max statistically although clinically significant imipramine affect pharmacokinetics quetiapine overall score uku side effect rating scale improve combination therapy either agent statistically significant deterioration observe item safety assessment clinically remarkable event imipramine associate complete leave bundle branch block one patient unexpected side effect report conclusion combination therapy quetiapine fluoxetine imipramine minimal effect quetiapine pharmacokinetics well tolerate,Potkin SG,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200204000-00011,11910263,Potkin SG; Thyrum PT; Alva G; Carreon D; Yeh C; Kalali A; Arvanitis LA; Pharmacokinetic Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D014150: Antipsychotic Agents; D001714: Bipolar Disorder; D003987: Dibenzothiazepines; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D005473: Fluoxetine; D006801: Humans; D007099: Imipramine; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D012559: Schizophrenia",,,https://openalex.org/W2093758454,108,14,1,1780,310,11,en,en
false,anxiolytic effect novel antipsychotic ziprasidone compare diazepam subject anxious dental surgery,novel atypical antipsychotic ziprasidone pharmacologic profile notable potent agonism serotonin ht receptor antagonism ht receptor reuptake inhibition norepinephrine ht receptor agonism particular suggest anxiolytic activity ziprasidone show preliminary efficacy treat symptom anxiety associate psychotic disorder study anxiolytic efficacy ziprasidone evaluate nonpsychotic subject anxious undergo minor dental surgery compare single oral dose mg ziprasidone n mg diazepam n placebo n randomize parallel group double blind study peak anxiolytic effect ziprasidone compare placebo similar diazepam late onset hour postdose anxiolytic effect ziprasidone significantly great placebo p somewhat great diazepam diazepam show significantly great anxiolytic effect placebo hour p hour sedative effect ziprasidone never great placebo whereas diazepam significantly great placebo hour postdose ziprasidone generally well tolerate one patient report treatment related adverse event nausea vomit unlike diazepam ziprasidone cause reduction blood pressure dystonia extrapyramidal syndrome akathisia postural hypotension see ziprasidone thus ziprasidone may possess anxiolytic effect addition antipsychotic property,Wilner KD,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200204000-00016,11910268,Wilner KD; Anziano RJ; Johnson AC; Miceli JJ; Fricke JR; Titus CK,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D001143: Arousal; D016854: Dental Anxiety; D003975: Diazepam; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D011292: Premedication; D013844: Thiazoles; D016896: Treatment Outcome,,,https://openalex.org/W2053520601,125,17,1,1688,293,12,en,en
false,evolve role topiramate among mood stabilizer management bipolar disorder,objective topiramate structurally novel anticonvulsant evaluate neurological condition migraine neuropathic pain essential tremor also psychiatric condition bipolar disorder bulimia post traumatic stress disorder schizoaffective disorder addition obesity article focus use topiramate bipolar disorder method pharmacological profile topiramate compare establish putative mood stabilizer rationale use bipolar disorder present data open clinical trial topiramate depression mania rapid cycling bipolar disorder summarize preliminary data one pilot dose find double blind random assignment placebo control week parallel group study two topiramate acute bipolar mania report safety data regard topiramate review finally potential place agent bipolar illness consider result pharmacological advantage topiramate low protein bind minimal hepatic metabolism mainly unchanged renal excretion h half life minimal drug interaction open clinical study suggest response refractory bipolar mania response refractory bipolar depression mainly add treatment open clinical study topiramate rapid cycling subject comorbid bulimia substance abuse post traumatic stress migraine obesity report effectiveness primary efficacy endpoint data change baseline mr total score placebo control random assignment parallel group phase ii dose find study statistically significant however antidepressant associate mania sample subject exclude control study post hoc analyse indicate high dose mg day topiramate treatment group show statistically significant reduction endpoint mr change score compare placebo p adverse effect topiramate bipolar subject include attention concentration memory problem fatigue sedation transient paraesthesia nausea anorexia subject experience word find difficulty weight loss may see several topiramate treat subject bipolar disorder conclusion topiramate appear show promise addition agent available treat bipolar disorder definitive control data efficacy topiramate acute continuation phase well prophylaxis either monotherapy combination treatment bipolar disorder ongoing result await,Chengappa KN,2001,Bipolar Disord,https://doi.org/10.1034/j.1399-5618.2001.30501.x,11912568,Chengappa KN; Gershon S; Levine J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016454: Review,D000085: Acetates; D000208: Acute Disease; D000588: Amines; D000927: Anticonvulsants; D018692: Antimanic Agents; D001714: Bipolar Disorder; D002220: Carbamazepine; D003509: Cyclohexanecarboxylic Acids; D005632: Fructose; D000077206: Gabapentin; D006801: Humans; D000077213: Lamotrigine; D008094: Lithium; D016032: Randomized Controlled Trials as Topic; D000077236: Topiramate; D014227: Triazines; D014635: Valproic Acid; D005680: gamma-Aminobutyric Acid,,,https://openalex.org/W2063347068,98,15,1,2738,442,17,en,en
false,reduce burden care alzheimer disease amelioration delusion theft drug therapy,abstract background delusion theft delusion involve theft possession one frequent neuropsychiatric manifestation alzheimer disease ad objective current study investigate presence extent delusion drug treatment group ad patient consequent effect burden care caregiver method study open label cohort design delusion study consist involve theft possession sixteen ad patient serve subject order assess efficacy risperidone administration reduction elimination delusion caregiver burden evaluate use zarit caregiver burden interview zbi administration risperidone week administration case delusion theft eliminate reduce result burden care caregiver significantly reduce p elimination reduction delusion theft conclusion delusion theft consider major factor increase burden care treatment appropriate drug therapy therefore great importance continuation satisfactory care home copyright john wiley son ltd,Shigenobu K,2002,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.551,11921147,Shigenobu K; Ikeda M; Fukuhara R; Maki N; Hokoishi K; Nebu A; Komori K; Tanabe H,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D017028: Caregivers; D017281: Cost of Illness; D003702: Delusions; D005260: Female; D006801: Humans; D007406: Interview, Psychological; D007564: Japan; D008297: Male; D009483: Neuropsychological Tests; D018967: Risperidone; D013800: Theft; D016896: Treatment Outcome",,,https://openalex.org/W2076623245,118,21,1,1323,230,9,en,en
false,comparison rapidly act intramuscular olanzapine lorazepam placebo double blind randomize study acutely agitate patient dementia,double blind study investigate efficacy safety rapid act intramuscular olanzapine treat agitation associate alzheimer disease vascular dementia h olanzapine mg mg lorazepam mg show significant improvement placebo panss excite component panss ec agitation calmness evaluation scale ace mg olanzapine lorazepam show superiority placebo cohen mansfield agitation inventory h olanzapine group maintain superiority placebo panss ec lorazepam olanzapine mg lorazepam improve ace score placebo simpson angus mini mental state examination score change significantly baseline sedation ace adverse event laboratory analytes significantly different placebo treatment significant difference among treatment group see extrapyramidal symptom correct qt interval either h h significant difference among treatment group see vital sign include orthostasis intramuscular injection olanzapine may therefore provide substantial benefit rapidly treat inpatient acute dementia relate agitation,Meehan KM,2002,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(01)00365-7,11927174,Meehan KM; Wang H; David SR; Nisivoccia JR; Jones B; Beasley CM; Feldman PD; Mintzer JE; Beckett LM; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000368: Aged; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003704: Dementia; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007273: Injections, Intramuscular; D008140: Lorazepam; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation",,,https://openalex.org/W1969071740,153,22,1,1291,208,8,en,en
false,steady state pharmacokinetics tolerability modafinil administer alone combination dextroamphetamine healthy volunteer,potential drug drug interaction modafinil dextroamphetamine steady state investigate open label randomize single period studyin healthy male female volunteer subject receive modafinil orally daily day mg day mg day day half subject also receive dextroamphetamine mg orally hour modafinil sample pharmacokinetic pk profile obtain day mean change pk parameter modafinil two circulate metabolite two group statistically significantly different except cmax modafinil acid adverse event obtain two group similar mild moderate nature result indicate administration low dose dextroamphetamine dose regimen alter steady state pharmacokinetics modafinil combination similar tolerability profile modafinil alone,Hellriegel ET,2002,J Clin Pharmacol,https://doi.org/10.1177/00912700222011382,11936571,Hellriegel ET; Arora S; Nelson M; Robertson P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D003913: Dextroamphetamine; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D018709: Statistics, Nonparametric",,,https://openalex.org/W2060130670,141,16,1,1006,172,8,en,en
false,clonidine coadjuvant eye surgery comparison peribulbar versus oral administration,determine whether administration peribulbar oral clonidine would enhance analgesia anesthesia ophthalmologic surgery randomize double blind study teach hospital asa physical status ii adult patient schedule unilateral ophthalmologic surgery peribulbar block patient assign one group premedicated oral ml volume clonidine placebo peribulbar eye block consist local anesthetic plus ml test drug control group cg receive oral saline premedication peribulbar saline test drug clonidine eye group clo eye g receive oral saline peribulbar microg clonidine clonidine oral group clo oral g receive oral microg clonidine peribulbar saline clonidine eye oral group clo eye oral g oral microg clonidine peribulbar microg clonidine perioperative assessment include anesthesia analgesia blood cortisol adverse effect group demographically similar latency time onset peribulbar block shorter clo eye g compare cg p cg present high blood pressure level throughout surgery compare others p time first rescue analgesic longer patient receive peribulbar clonidine compare cg p analgesic consumption lesser clo eye g compare cg p blood cortisol level higher intraoperative period group preoperative v intraoperative value p despite high intraoperative blood cortisol level microg peribulbar clonidine decrease onset time anesthesia microg peribulbar clonidine prolong time first rescue analgesic patient peribulbar block without increase frequency adverse effect conversely oral administration clonidine alone enhance anesthesia analgesia follow eye block suggest local mechanism action clonidine,Barioni MF,2002,J Clin Anesth,https://doi.org/10.1016/s0952-8180(01)00371-3,11943529,Barioni MF; Lauretti GR; Lauretti-Fo A; Pereira NL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D000284: Administration, Oral; D000368: Aged; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006854: Hydrocortisone; D007267: Injections; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D013508: Ophthalmologic Surgical Procedures; D010149: Pain, Postoperative; D011229: Preanesthetic Medication",,,https://openalex.org/W1970297325,91,13,1,2058,351,13,en,en
false,augmentation von selektiven serotonin wiederaufnahme hemmern ssri mit atypischen antipsychotika der depressionsbehandlung,treatment severe depression represent difficult task daily psychiatric practice certain case augmentation therapy order improve efficacy ssri useful recently become possible use atypical antipsychotic ssri augmentation option add exist strategy treatment depression primary systematic study show encouraging result review possibility ssri augmentation additionally administer risperidone olanzapine critically discuss,Weimer E,2002,Fortschr Neurol Psychiatr,https://doi.org/10.1055/s-2002-24644,11948436,Weimer E; Braus DF; Cavus I; Thome J,article,D016428: Journal Article; D016454: Review,"D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003866: Depressive Disorder; D004359: Drug Therapy, Combination; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D018967: Risperidone; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2082919302,126,13,1,550,87,5,de,en
false,systematic review use atypical antipsychotic autism,conventional antipsychotic medication commonly prescribe patient autistic spectrum disorder however high incidence severe adverse reaction highlight need find favourable treatment atypical antipsychotic may combine efficacy ameliorate autistic symptom low incidence adverse reaction article review use atypical antipsychotic autistic disorder particular focus behaviour cognition physical well thirteen study use risperidone three use olanzapine one use clozapine one use amisulpride one use quetiapine identify firm conclusion draw due limitation study however indication risperidone may effective reduce hyperactivity aggression repetitive behaviour often without induce severe adverse reaction olanzapine clozapine may also effective however little evidence use amisulpride quetiapine population randomize trial require clarify effectiveness agent,Barnard L,2002,J Psychopharmacol,https://doi.org/10.1177/026988110201600113,11949778,Barnard L; Young AH; Pearson J; Geddes J; O'Brien G,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,D014150: Antipsychotic Agents; D001321: Autistic Disorder; D001519: Behavior; D002986: Clinical Trials as Topic; D003071: Cognition; D006801: Humans; D009483: Neuropsychological Tests; D011569: Psychiatric Status Rating Scales,,,https://openalex.org/W1970298334,67,11,1,1111,172,8,en,en
false,use olanzapine elderly patient psychotic disorder review,number elderly person psychosis increase increase geriatric population olanzapine one new atypical antipsychotic efficacy positive negative symptom safer side effect profile compare conventional antipsychotic manuscript describe pharmacology efficacy tolerability study adverse effect dose consideration elderly study need fully assess efficacy safety olanzapine elderly current research support role olanzapine treat elderly patient schizophrenia schizoaffective disorder behavioral psychological symptom dementia,Madhusoodanan S,2001,Ann Clin Psychiatry,https://doi.org/10.1023/a:1014674018039,11958362,Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O,article,D016428: Journal Article; D016454: Review,D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W2028343784,74,13,1,685,101,5,en,en
false,review pharmacotherapy adult attention deficit hyperactivity disorder,despite increase recognition attention deficit hyperactivity disorder adhd adult use pharmacotherapeutics remain less establish systematic review literature identify study n subject stimulant study non stimulant medication n subject include antidepressant antihypertensive amino acid wake promote agent treatment adhd adult study stimulant antidepressant demonstrate significant short term improvement adhd symptom compare placebo adult methylphenidate mph amphetamine immediate onset action whereas adhd response pemoline antidepressant appear delay response amphetamine mph appear dose dependent control data nicotonic noradrenergic compound appear promise considerable variability diagnostic criterion dose parameter response rate various study control condition aggregate literature show stimulant noradrenergic antidepressant clinically statistically significant beneficial effect treat adhd adult,Wilens TE,2002,J Atten Disord,https://doi.org/10.1177/108705470100500401,11967475,Wilens TE; Spencer TJ; Biederman J,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review; D000078182: Systematic Review",D000328: Adult; D000928: Antidepressive Agents; D000959: Antihypertensive Agents; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D018678: Cholinergic Agents; D006801: Humans,,,https://openalex.org/W2000804661,88,11,1,1191,175,5,en,en
false,ziprasidone fifth atypical antipsychotic,objective review pharmacology pharmacokinetics clinical efficacy adverse effect ziprasidone treatment schizophrenia data source information select medline search july october english language medical literature use ziprasidone search term manual search pertinent journal article reference request medical information pfizer access web site food drug administration also perform study selection available publish information regard pertinent characteristic ziprasidone consider selection data extraction pharmacology pharmacokinetic study select provide comprehensive description characteristic clinical investigation evaluate design sample size diagnosis duration outcome data investigation select author review author data synthesis ziprasidone benzisothiazolyl piperazine type atypical antipsychotic share serotonin dopamine ht profile available atypical antipsychotic ziprasidone demonstrate vitro activity ht receptor agonist weak inhibitor serotonin norepinephrine reuptake data support ziprasidone clinically meaningful inhibitor serotonin norepinephrine reuptake oral bioavailability ziprasidone take food approximately half life approximately hour protein bind extensive twelve metabolite identify yet consider primary metabolite metabolism ziprasidone aldehyde oxidase produce metabolite potential pharmacologic activity cyp also contribute metabolism ziprasidone clinical study support ziprasidone efficacious treatment patient acute exacerbation schizophrenia schizoaffective disorder daily permit clinical trial range mg dose mg superior placebo future research effort direct toward refractory schizophrenia cognitive impairment schizophrenia affective anxiety symptom associate schizoaffective disorder bipolar disorder adverse effect characteristic ziprasidone commonly include headache nausea somnolence infrequent effect include extrapyramidal symptom weight gain ziprasidone report cause average qtc prolongation approximately msec patient report manufacturer measure qtc interval msec conclusion ziprasidone safe efficacious atypical antipsychotic acute management schizophrenia efficacy data safety data ziprasidone support use first line treatment schizophrenia however potential effect ventricular repolarization relegate second line status patient comorbid cardiovascular risk,Caley CF,2002,Ann Pharmacother,https://doi.org/10.1345/aph.1a053,11978164,Caley CF; Cooper CK,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001835: Body Weight; D006261: Headache; D006801: Humans; D007273: Injections, Intramuscular; D008133: Long QT Syndrome; D009325: Nausea; D010879: Piperazines; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D013844: Thiazoles; D016896: Treatment Outcome; D015430: Weight Gain",,,https://openalex.org/W2129997607,45,6,1,3099,485,20,en,en
false,double blind placebo control dose response comparison intramuscular olanzapine haloperidol treatment acute agitation schizophrenia,intramuscular im formulation olanzapine develop rapid act im atypical antipsychotic drug currently available united state treat acute agitation patient schizophrenia recently hospitalize acutely agitate patient schizophrenia n randomize receive im injection olanzapine mg haloperidol mg placebo within hour dose response relationship im olanzapine reduction agitation assess measure reduction positive negative syndrome scale excite component panss ec score hour first injection safety assess record adverse event extrapyramidal symptom scale electrocardiogram hour first injection olanzapine exhibit dose response relationship reduction agitation f p mean panss ec reduction hour first injection olanzapine mg mg mg mg superior placebo p v olanzapine mg p olanzapine dose haloperidol dose mg olanzapine cause great reduction agitation placebo minute first injection difference treatment group hypotension frequently report adverse event clinically relevant change qtc interval great incidence treatment emergent parkinsonism treatment im haloperidol p p mg p im olanzapine placebo p intramuscular olanzapine dose mg per injection exhibit dose response relationship rapid treatment acute agitation patient schizophrenia demonstrate favorable safety profile,Breier A,2002,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.59.5.441,11982448,Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2027198501,156,19,1,1958,368,7,en,en
false,continuation phase treatment bupropion sr effectively decrease risk relapse depression,first control continuation phase study year total treatment evaluate safety efficacy bupropion sr decrease risk relapse depression patient respond bupropion sr patient recurrent major depression treat bupropion sr mg day week open label phase responder base clinical global impression scale improvement illness score enter randomize double blind phase receive bupropion sr mg day placebo week randomization relapse define point investigator intervene withdraw patient study treat depression four hundred twenty three patient randomize statistically significant difference favor bupropion sr placebo see time treatment intervention depression survival curve compare log rank test p statistically significant separation bupropion sr placebo begin double blind week p adverse event bupropion sr treat patient account discontinuation open label double blind phase respectively bupropion sr show effective well tolerate decrease risk relapse depression week,Weihs KL,2002,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(01)01317-8,11983189,Weihs KL; Houser TL; Batey SR; Ascher JA; Bolden-Watson C; Donahue RM; Metz A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D012307: Risk Factors; D055502: Secondary Prevention; D013997: Time Factors",,,https://openalex.org/W2036764488,103,14,1,1345,220,6,en,en
false,pilot randomize open label trial assess safety pharmakokinetic parameter co administration rivastigmine risperidone dementia patient behavioral disturbance,majority patient alzheimer disease ad vascular dementia display addition cognitive impairment various degree behavioral disturbance use cholinesterase inhibitor treatment cognitive impairment dementia become widespread many patient treat concomitantly cholinesterase inhibitor anti psychotic drug ameliorate behavioral disturbance despite widespread use combination clinical practice safety tolerability combination therapy evaluate control clinical trial pilot study examine effect addition risperidone mg day patient rivastigmine mg day vice versa patient suffer ad vascular dementia randomize open label rivastigmine risperidone alone combination week adverse event cause co administration assess clinically relevant adverse interaction observe preliminary result indicate rivastigmine risperidone safely co administer confirmation result large clinical trial study warrant,Weiser M,2002,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.599,11994888,Weiser M; Rotmensch HH; Korczyn AD; Hartman R; Cicin-Sain A; Anand R; Rivastigmine-Risperidone Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D002219: Carbamates; D002800: Cholinesterase Inhibitors; D003704: Dementia; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D048448: Phenylcarbamates; D018967: Risperidone; D000068836: Rivastigmine; D012920: Social Behavior Disorders",,,https://openalex.org/W2058864393,189,24,1,1211,184,6,en,en
false,phenylpropanolamine appear promote weight loss patient schizophrenia gain weight clozapine treatment,weight gain common side effect clozapine treatment may expose patient obesity associate health risk propose concomitant treatment appetite suppressant phenylpropanolamine ppa would lead decrease appetite therefore loss weight week double blind randomize placebo control trial ppa mg day outpatient treatment refractory schizophrenia dsm iv stable clozapine treatment least month gain baseline body weight since start clozapine patient evaluate adverse effect weigh weekly positive negative syndrome scale panss assessment short dietary quiz blood index complete monthly sixteen patient equally randomly assign receive ppa placebo group differ mean age baseline weight dose clozapine baseline panss score percent weight gain since start clozapine significant effect treatment weight df p significant change either total panss score df p positive negative symptom cluster score remain variable phenylpropanolamine mg day well tolerate effective reverse establish weight gain associate clozapine treatment stable outpatient schizophrenia,Borovicka MC,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0412,12000209,Borovicka MC; Fuller MA; Konicki PE; White JC; Steele VM; Jaskiw GE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000553: Ambulatory Care; D014150: Antipsychotic Agents; D001067: Appetite Depressants; D003024: Clozapine; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D009765: Obesity; D010665: Phenylpropanolamine; D010865: Pilot Projects; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012107: Research Design; D012559: Schizophrenia; D016896: Treatment Outcome; D015430: Weight Gain; D015431: Weight Loss,,,https://openalex.org/W2054864170,135,18,1,1453,257,7,en,en
false,treatment adhd neurofibromatosis type,forty six child neurofibromatosis type nf find satisfy diagnostic criterion attention deficit hyperactivity disorder adhd detail comparison make among child nf adhd male female mean age year sd control child nf male female mean age year sd control child adhd male mean age year sd normally develop control child male mean age year sd child nf adhd low iq score among four group test variable attention tova score poorer nf adhd adhd control group two non adhd group nf adhd rat significantly poor child behavior checklist cbcl nf control group administrate low mg methylphenidate nf adhd group significantly improve tova score obtain one year follow yield significantly improve cbcl score result show high incidence adhd nf support association adhd learn social problem child nf demonstrate stimulant medication lead improvement cognitive academic social problem child nf adhd,Mautner VF,2002,Dev Med Child Neurol,https://doi.org/10.1017/s0012162201001876,12005317,Mautner VF; Kluwe L; Thakker SD; Leark RA,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001519: Behavior; D000697: Central Nervous System Stimulants; D002648: Child; D004305: Dose-Response Relationship, Drug; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007361: Intelligence Tests; D007858: Learning; D008297: Male; D008774: Methylphenidate; D009456: Neurofibromatosis 1; D009483: Neuropsychological Tests; D011930: Reaction Time; D012016: Reference Values; D012919: Social Behavior; D013647: Task Performance and Analysis; D016896: Treatment Outcome",,,https://openalex.org/W2117296940,45,7,1,1330,257,9,en,en
false,antipsychotic induce weight gain therapeutic response differential association,study investigate association antipsychotic induce weight gain therapeutic response haloperidol three commonly use atypical neuroleptic medication schizophrenia schizoaffective disorder subject patient enrol double blind experiment duration week compare therapeutic efficacy haloperidol n clozapine n olanzapine n risperidone n absolute relative gain body weight body mass index bmi determine entire duration double blind treatment period therapeutic response assess total score individual subscales positive negative symptom scale compare pretreatment baseline result indicate olanzapine clozapine therapeutic response closely relate absolute relative gain weight gain bmi association weight gain therapeutic response find risperidone haloperidol find suggest patient likely maximal benefit olanzapine clozapine treatment symptom alleviation high risk clinically significant increase weight gain,Czobor P,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200206000-00003,12006893,Czobor P; Volavka J; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Cooper TB; Chakos M; Lieberman JA,article,"D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D016009: Chi-Square Distribution; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011618: Psychotic Disorders; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W1975087639,86,10,1,1246,210,6,en,en
false,anxiety depression symptom response methylphenidate child attention deficit hyperactivity disorder tic disorder,study examine response methylphenidate child attention deficit hyperactivity disorder adhd chronic multiple tic disorder primary goal determine child anxiety depression symptom show less favorable response treatment subject prepubertal child participate week double blind placebo control methylphenidate crossover evaluation treatment effect assess direct observation child behavior public school clinic setting rating scale complete parent teacher clinician laboratory analogue task little evidence group data child anxiety depression symptom respond clinically different manner methylphenidate youngster exhibit symptom particularly school observation core feature adhd seem difference child without comorbid anxiety depression symptom drug response likely explain difference pretreatment level negativistic behavior e symptom oppositional defiant disorder conduct disorder methylphenidate appear effective management adhd behavior child mild moderate anxiety depression symptom nevertheless much research remain perform area,Gadow KD,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200206000-00007,12006897,Gadow KD; Nolan EE; Sverd J; Sprafkin J; Schwartz J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000704: Analysis of Variance; D001007: Anxiety; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D003863: Depression; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D013981: Tic Disorders,,,https://openalex.org/W2023595986,138,17,1,1369,209,7,en,en
false,sex difference clinical response olanzapine compare haloperidol,current disagreement whether men woman respond differently typical atypical antipsychotic medication study reanalyzed large international clinical trial olanzapine olz compare haloperidol hal test sex difference treatment response control illness chronicity menopausal status hypothesize woman would show great response either medication men particularly among first admission premenopausal woman dsm iii r schizophrenia inpatient woman men randomly assign week trial olz v hal longitudinal random effect model use test interaction sex medication chronicity menopausal status treatment response find show woman olanzapine great drop overall symptomatology week group level symptomatology remain low throughout week trial sex difference treatment response olanzapine compare haloperidol part dependent chronicity woman menopausal status first episode woman haloperidol exhibit increase symptomatology week trial compare male counterpart multiply hospitalize woman well treatment response haloperidol male counterpart woman olanzapine significantly well treatment response men regardless chronicity finally premenopausal woman significantly well treatment response postmenopausal woman regardless treatment chronicity,Goldstein JM,2002,Psychiatry Res,https://doi.org/10.1016/s0165-1781(02)00028-8,12007591,Goldstein JM; Cohen LS; Horton NJ; Lee H; Andersen S; Tohen M; Crawford A; Tollefson G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000367: Age Factors; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012737: Sex Factors; D016896: Treatment Outcome,,,https://openalex.org/W1987324111,76,10,1,1606,257,10,en,en
false,effect body weight bupropion sustain release patient major depression treat week,background short term study demonstrate modest weight reduce weight neutral effect among patient receive bupropion sustain release sr treatment depression objective study conduct evaluate long term effect bupropion sr body weight patient depression method analysis conduct within long term relapse prevention study patient major depression whose depression respond open label treatment bupropion sr randomize week double blind treatment bupropion sr mg placebo patient categorize body mass index bmi follow bmi bmi bmi bmi result four hundred twenty three patient enrol double blind phase study receive bupropion sr receive placebo end open label phase follow mean weight loss see bmi group bmi kg bmi kg bmi bmi kg end double blind treatment mean change baseline weight follow bmi kg bmi kg bmi kg bmi kg rate change body weight double blind phase statistically significant compare baseline bmi p analysis covariance conclusion modest mean weight loss increase increase baseline body weight observe long term bupropion sr treatment find analysis suggest bupropion sr may appropriate therapeutic option normal weight overweight patient depression concern weight gain,Croft H,2002,Clin Ther,https://doi.org/10.1016/s0149-2918(02)85141-4,12017410,Croft H; Houser TL; Jamerson BD; Leadbetter R; Bolden-Watson C; Donahue R; Metz A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D018687: Antidepressive Agents, Second-Generation; D015992: Body Mass Index; D016642: Bupropion; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015430: Weight Gain",,,https://openalex.org/W2030933485,107,16,1,1706,313,11,en,en
false,effect olanzapine prolactin level female patient schizophrenia treat risperidone,study conduct prospectively examine effect switch risperidone olanzapine female schizophrenia patient experience menstrual disturbance galactorrhea sexual dysfunction twenty female patient dsm iv schizophrenia take risperidone suffer menstrual disturbance galactorrhea sexual dysfunction enrol patient switch risperidone olanzapine week period treat olanzapine additional week serum prolactin concentration examine every week positive negative syndrome scale panss abnormal involuntary movement scale aim simpson angus scale extrapyramidal symptom sa question dickson glazer sexual functioning scale administer evaluate efficacy extrapyramidal side effect sexual reproductive function baseline endpoint week serum prolactin level decrease significantly p follow switch risperidone olanzapine score panss aim sa endpoint also significantly decrease p compare baseline patient experience improvement menstrual functioning perception sexual side effect olanzapine reverse hyperprolactinemia risperidone treat female schizophrenic patient associate decrease amenorrhea improve cycle regularity decrease sexual side effect woman attribute antipsychotic medication study suggest switch olanzapine safe effective alternative method patient antipsychotic induce hyperprolactinemia associate sexual reproductive dysfunction long term follow study warrant particular attention course sexual reproductive dysfunction,Kim KS,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0506,12019665,Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000568: Amenorrhea; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D005260: Female; D005687: Galactorrhea; D006801: Humans; D006966: Hyperprolactinemia; D008599: Menstruation Disturbances; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011388: Prolactin; D011446: Prospective Studies; D018967: Risperidone; D012559: Schizophrenia; D020018: Sexual Dysfunctions, Psychological; D016896: Treatment Outcome",,,https://openalex.org/W2009394319,104,14,1,1871,276,9,en,en
false,clinical predictor response clozapine treatment ambulatory patient schizophrenia,despite advent new atypical antipsychotic clozapine remain important option treatment patient poor response conventional antipsychotic clinician would well serve clinical characteristic could identify predict favorable response clozapine study address issue report inconsistent result association clinical characteristic sustain response investigate partially treatment refractory outpatient dsm iii r diagnosis chronic schizophrenia assign clozapine treatment double blind haloperidol control long term week study clozapine response define decrease brief psychiatric rating scale bprs psychosis factor score sustain consecutive rating difference responder nonresponders regard select baseline variable analyze test chi test addition cox regression analysis perform identify variable best predict response clozapine treatment clozapine responder rat less severely ill show less degree negative symptom demonstrate extrapyramidal side effect baseline compare nonresponders addition high bprs total score control effect variable associate response cohort partially treatment refractory outpatient favorable response clozapine associate characteristic describe less severely ill patient history patient affect response clozapine,Umbricht DS,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0508,12019667,Umbricht DS; Wirshing WC; Wirshing DA; McMeniman M; Schooler NR; Marder SR; Kane JM,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000553: Ambulatory Care; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D010054: Brief Psychiatric Rating Scale; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011336: Probability; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W2032769473,96,12,1,1650,248,8,en,en
false,retrospective comparison weight lipid glucose change risperidone olanzapine treat inpatient,metabolic side effect increasingly note therapy novel antipsychotic dearth comprehensive comparative data area goal retrospective study examine change weight parameter fast glucose fast lipid long term inpatient treat either risperidone olanzapine retrospective study perform review chart patient oregon state hospital salem treat july august compare metabolic outcome first year therapy either risperidone olanzapine data analyze also age sex concurrent use lithium valproate include analysis patient least year old baseline weight obtain within week drug initiation baseline fast triglyceride cholesterol glucose obtain within month prior drug initiation year treatment week patient meet criterion drug cohort risperidone n olanzapine n include patient diagnosed diabetes mellitus prior onset treatment among patient year old olanzapine patient n experience significantly great increase year metabolic parameter risperidone group n except weight variable triglyceride mg dl olanzapine versus mg dl risperidone p cholesterol mg dl olanzapine versus mg dl risperidone p glucose mg dl olanzapine versus mg dl risperidone p patient year age concurrent use lithium valproate associate great weight gain drug group difference statistically significant olanzapine cohort neither weight change use lithium valproate associate increase glucose lipid among year old either drug olanzapine therapy associate significantly great increase fast glucose lipid level nongeriatric adult patient risperidone increase correlate change weight parameter appropriate monitoring fast glucose serum lipid level consider extend treatment atypical antipsychotic,Meyer JM,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0509,12019668,Meyer JM,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000927: Anticonvulsants; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001786: Blood Glucose; D001835: Body Weight; D003920: Diabetes Mellitus; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005951: Glucose Tolerance Test; D006760: Hospitalization; D006801: Humans; D006949: Hyperlipidemias; D050356: Lipid Metabolism; D008055: Lipids; D008094: Lithium; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D017063: Outcome Assessment, Health Care; D010890: Pirenzepine; D012189: Retrospective Studies; D018967: Risperidone; D012559: Schizophrenia; D014635: Valproic Acid",,,https://openalex.org/W1987040047,119,16,1,2342,404,8,en,en
false,nicotine dependence role antidepressant anxiolytic,addictive nature cigarette smoke appreciate past two decade prior publication dsm iii excessive tobacco use consider psychiatric problem require treatment smoke recognize serious medical problem since thefirst surgeon general report smoke health important development year follow report growth knowledge regard physiological effect regular tobacco use importance nicotine main pharmacological ingredient tobacco body information culminate surgeon general report recognize chronic tobacco use form addictive behavior nicotine like drug abuse reinforce psychoactive effect lead repeat self administration nicotine stimulate release several neurotransmitter include dopamine norepinephrine acetylcholine hydroxytryptamine gamma aminobutyric acid gaba endorphins effect dopaminergic reward system nicotine exerts psychoactive effect increase sense enjoyment norepinephrinergic effect nicotine may account increase attentiveness improve performance repetitive task anxiolytic effect likely mediate gaba endorphin,Sullivan MA,2002,Curr Opin Investig Drugs,,12020058,Sullivan MA; Covey LS,article,D016428: Journal Article; D016454: Review,"D000437: Alcoholism; D014151: Anti-Anxiety Agents; D000928: Antidepressive Agents; D001008: Anxiety Disorders; D001289: Attention Deficit Disorder with Hyperactivity; D016642: Bupropion; D003863: Depression; D006801: Humans; D012559: Schizophrenia; D016540: Smoking Cessation; D013313: Stress Disorders, Post-Traumatic; D014029: Tobacco Use Disorder",,,https://openalex.org/W135207046,66,10,1,1407,231,9,en,en
false,full day adhd symptom control last home homework,,,2000,Pediatr Nurs,,12026370,,article,D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D017277: Drug Approval; D006801: Humans; D008774: Methylphenidate; D010552: Personality Assessment; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome; D014481: United States; D014486: United States Food and Drug Administration",,,https://openalex.org/W4300515302,65,13,1,0,0,0,en,
false,hypnotic analgesic effect oral clonidine sevoflurane anesthesia child dose response study,although clonidine hypnotic analgesic action dose relationship action still unknown clinical set clonidine use premedication child study asa physical status child age range yr subject randomly divide two group minimum alveolar anesthetic concentration mac awake group n mac tetanus group n patient receive one dose clonidine microg kg orally min arrival operate room anesthesia induce maintain sevoflurane oxygen air tracheal intubation end tidal sevoflurane decrease stepwise start verbal command give patient mac awake determine patient also investigate mac tetanus determine transcutaneous electric tetanic stimulation tracheal intubation patient observe motor response transcutaneous electric tetanic stimulus ulnar nerve sevoflurane concentration decrease stepwise start initial reduction mac tetanus steep mac awake clonidine reduce mac tetanus maximal dose microg kg whereas mac awake already reduce microg kg conclude separate dose response relationship oral clonidine present regard hypnotic analgesic effect child undergo sevoflurane anesthesia separate dose response relationship oral clonidine find regard hypnotic analgesic effect child undergo sevoflurane anesthesia,Inomata S,2002,Anesth Analg,https://doi.org/10.1097/00000539-200206000-00019,12032011,Inomata S; Kihara S; Miyabe M; Sumiya K; Baba Y; Kohda Y; Toyooka H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000700: Analgesics; D000768: Anesthesia, General; D018685: Anesthetics, Inhalation; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D005260: Female; D006801: Humans; D006993: Hypnotics and Sedatives; D008297: Male; D008738: Methyl Ethers; D011650: Pulmonary Alveoli; D000077149: Sevoflurane",,,https://openalex.org/W2055459899,117,17,1,1652,279,10,en,en
false,insomnia child,insomnia child nonspecific impair symptom may result normal developmental change psychosocial duress sleep disorder psychiatric disorder medical disorder substance misuse adverse effect medication careful clinical assessment insomnia child may include use symptom rating scale laboratory test medical assessment short long term treatment insomnia child involve management etiological factor associate syndrome control treatment study pediatric insomnia limit publish study psychosocial psychopharmacological treatment young child directive parent education behavior modification technique effective short term treatment insomnia young child may prefer treatment extrinsic insomnia well important adjunctive treatment insomnia symptom two benzodiazepine flurazepam delorazepam chlordesmethyldiazepam one antihistamine niaprazine one phenothiazine alimemazine trimeprazine show effective short term treatment insomnia young child although none agent u food drug administration approval pediatric insomnia short act benzodiazepine may role brief treatment pediatric insomnia associate anxiety mood disorder psychosis aggression medication induce activation anticipatory anxiety associate medical procedure however tachyphylaxis risk misuse preclude long term use benzodiazepine treatment insomnia child new hypnotic appear well tolerate benzodiazepine study adult may role combine psychosocial treatment pediatric insomnia treatment intrinsic pediatric insomnia may additionally involve chronotherapy medical management,Younus M,2002,Paediatr Drugs,https://doi.org/10.2165/00128072-200204060-00006,12038875,Younus M; Labellarte MJ,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D000293: Adolescent; D001521: Behavior Therapy; D002648: Child; D002675: Child, Preschool; D019454: Chronotherapy; D002986: Clinical Trials as Topic; D005260: Female; D006801: Humans; D006993: Hypnotics and Sedatives; D008297: Male; D011619: Psychotropic Drugs; D007319: Sleep Initiation and Maintenance Disorders",,,https://openalex.org/W1634436568,20,3,1,1964,304,10,en,en
false,beneficial antipsychotic effect celecoxib add therapy compare risperidone alone schizophrenia,abnormality immune system schizophrenia describe however important find high level activate cytokine csf sign cns inflammation controversial author conduct trial new selective cyclooxygenase inhibitor celecoxib immunomodulatory drug schizophrenic patient evaluate therapeutic effect prospective double blind evaluation patient acute exacerbation schizophrenia randomly assign either risperidone plus celecoxib risperidone plus placebo washout period patient receive mg day risperidone plus placebo receive risperidone plus mg day celecoxib week treatment effect calculate analysis covariance significant difference group age sex duration severity disease psychopathology risperidone dose plasma level week group patient show significant improvement score positive negative syndrome scale subscales however celecoxib group show significantly great improvement total score additional treatment celecoxib significant positive effect therapeutic action risperidone regard total schizophrenia psychopathology moreover fact treatment immunomodulatory drug show beneficial effect schizophrenia symptom indicate immune dysfunction schizophrenia epiphenomenon relate pathomechanism disorder however nonimmunological therapeutic effect celecoxib mediate n methyl aspartic acid receptor take account,Müller N,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.6.1029,12042193,Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000894: Anti-Inflammatory Agents, Non-Steroidal; D014150: Antipsychotic Agents; D000068579: Celecoxib; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011720: Pyrazoles; D018967: Risperidone; D012559: Schizophrenia; D012720: Severity of Illness Index; D013449: Sulfonamides; D016896: Treatment Outcome",,,https://openalex.org/W2171149822,107,13,1,1732,264,9,en,en
false,olanzapine induce weight gain patient first episode schizophrenia double blind placebo control study fluoxetine addition,since olanzapine induce weight gain may attributable antagonistic activity olanzapine serotonin c receptor author hypothesize might attenuate addition selective serotonin reuptake inhibitor fluoxetine first episode hospitalize schizophrenia patient n randomly assign week double blind study olanzapine mg day coadministered either fluoxetine mg day n placebo n group receive olanzapine plus fluoxetine show significantly less improvement positive disorganize symptom dimension group receive olanzapine plus placebo two group demonstrate similar substantial gradual weight gain result suggest fluoxetine coadministration clinically ineffective attenuate olanzapine induce weight gain,Poyurovsky M,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.6.1058,12042201,Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015992: Body Mass Index; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005473: Fluoxetine; D006760: Hospitalization; D006801: Humans; D008297: Male; D009765: Obesity; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D017367: Selective Serotonin Reuptake Inhibitors; D016896: Treatment Outcome; D015430: Weight Gain",,,https://openalex.org/W2052699080,140,17,1,854,121,2,en,en
false,efficacy olanzapine risperidone treatment refractory schizophrenia among long stay state hospital patient,author study efficacy olanzapine risperidone among patient treatment refractory schizophrenia hospitalize five year suitable candidate clozapine trial patient systematically reassess give olanzapine risperidone part second chance program patient group show significant improvement score item brief psychiatric rating scale three month forty four percent patient olanzapine group percent risperidone group discharge supervise residence basis clinical improvement value reassess long stay patient treatment refractory schizophrenia give systematic trial new medication become available,Dinakar HS,2002,Psychiatr Serv,https://doi.org/10.1176/appi.ps.53.6.755,12045315,Dinakar HS; Sobel RN; Bopp JH; Daniels A; Mauro S,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015331: Cohort Studies; D005260: Female; D006778: Hospitals, Psychiatric; D006783: Hospitals, State; D006801: Humans; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D009518: New York; D000077152: Olanzapine; D010351: Patient Discharge; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2100435960,117,13,1,850,129,5,en,en
false,attention deficit hyperactivity disorder methylphenidate dose response analysis parent child comparison somatic complaint,author examine parent child rating somatic complaint child attention deficit hyperactivity disorder adhd receive four mg mg mg mg methylphenidate mph context double blind placebo control within subject crossover experimental design result indicate parent child rating somatic complaint decrease linear fashion baseline level function increase mph dose show minimal variation across mph condition statistical comparison specific somatic complaint indicate minimal agreement parent child contrast nearly identical parent child dose response curve paradoxical finding somatic complaint associate mph importance obtain child perception mph treatment implication measure somatic complaint discus,Rapport MD,2002,J Atten Disord,https://doi.org/10.1177/108705470200600103,12045757,Rapport MD; Randall R; Moffitt C,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D013001: Somatoform Disorders; D011795: Surveys and Questionnaires",,,https://openalex.org/W2043162170,136,14,1,911,144,4,en,en
false,improve outcome schizophrenia potential importance eps neuroleptic dysphoria,despite half century antipsychotic drug treatment outcome therapy schizophrenia remain disappointing relapse rehospitalization limit fulfilment social role suicide remain frequent economic cost high current relapse rate may two three time high could achieve optimal use therapy poor compliance treatment consider significant preventable cause poor outcome turn likely influence patient experience drug treatment evidence extrapyramidal symptom eps particularly akathisia neuroleptic dysphoria associate poor compliance poor treatment outcome atypical antipsychotic low risk eps standard antipsychotic risperidone olanzapine ziprasidone show evidence dose related increase eps clozapine quetiapine demonstrate placebo level incidence eps across dose range quetiapine require regular blood monitoring mandate clozapine result patient survey indicate high degree patient satisfaction treatment research need possible wider use medication low eps high patient acceptability could promote good compliance improve outcome schizophrenia treatment,Gerlach J,2002,Ann Clin Psychiatry,https://doi.org/10.1023/a:1015276028425,12046640,Gerlach J,article,D016428: Journal Article; D016454: Review,"D000339: Affect; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D005116: Extrapyramidal Tracts; D006801: Humans; D010349: Patient Compliance; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W1966631647,94,14,1,1387,229,9,en,en
false,phenomenology risk factor new onset diabetes mellitus diabetic ketoacidosis associate atypical antipsychotic analysis publish case,case report small retrospective study suggest atypical antipsychotic agent may associate new onset type ii diabetes mellitus dm diabetic ketoacidosis dka however report often provide limit information demographic variable age gender ethnicity relationship weight gain time course analyze publish case new onset dm dka follow initiation atypical antipsychotic treatment patient receive clozapine olanzapine quetiapine risperidone eighty seven percent patient male african american forty two percent patient present dka manifest weight gain time presentation dm dka although overweight antipsychotic therapy eighty four percent present within month within month commence atypical antipsychotic dka cohort significantly young age less overweight baseline high proportion woman dm alone without significant difference distribution ethnicity weight gain family history dm duration exposure atypical agent clinician aware potential risk new onset dm dka patient take atypical antipsychotic utilize appropriate clinical laboratory monitoring prevent serious adverse event,Jin H,2002,Ann Clin Psychiatry,https://doi.org/10.1023/a:1015228112495,12046641,Jin H; Meyer JM; Jeste DV,article,"D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D014150: Antipsychotic Agents; D003924: Diabetes Mellitus, Type 2; D016883: Diabetic Ketoacidosis; D006801: Humans; D011618: Psychotic Disorders; D012307: Risk Factors",,,https://openalex.org/W2136957299,167,24,1,1417,243,8,en,en
false,clinical profile atypical antipsychotic risperidone,stimulate dawkins colleague remington kapur call develop clinical profile new atypical antipsychotic drug matte critique perform two set analysis risperidone first reanalyzed data north american risperidone trial risperidone superior haloperidol equal degree patient without deficit syndrome patient paranoid nonparanoid schizophrenia treatment resistant treatment responsive patient patient hospitalize long short period patient without weight gain moreover risperidone effective haloperidol symptom nonresponsive responsive haloperidol effect negative symptom independent effect extrapyramidal symptom effective treat depression schizophrenia second perform meta analysis control risperidone trial risperidone consistently effective conventional antipsychotic treat positive negative symptom,Davis JM,2002,Schizophr Bull,https://doi.org/10.1093/oxfordjournals.schbul.a006925,12047021,Davis JM; Chen N,article,D016428: Journal Article,"D014150: Antipsychotic Agents; D004409: Dyskinesia, Drug-Induced; D006801: Humans; D009460: Neurologic Examination; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2134399699,58,8,1,1102,177,4,en,en
false,placebo control trial bupropion smoke cessation schizophrenia,schizophrenic patient high rate cigarette smoking compare general population compare sustain release sr bupropion placebo smoke cessation patient schizophrenic disorder also examine antipsychotic class predict smoke cessation outcome bupropion thirty two subject meet dsm iv criterion schizophrenia schizoaffective disorder nicotine dependence randomize bupropion sr bup mg day placebo pla outcome include treatment retention smoke abstinence rate expire breath carbon monoxide co level psychotic symptom medication side effect bupropion significantly increase trial endpoint day point prevalence smoke abstinence rate compare placebo bup pla chi df p reduce co level trial medication x time interaction z p positive schizophrenia symptom alter bup negative symptom significantly reduce atypical antipsychotic drug treatment enhance smoke cessation response bup major side effect dry mouth gastrointestinal symptom headache insomnia result suggest bup enhances smoke abstinence rate compare pla nicotine dependent schizophrenic smoker bup well tolerate safe use patient atypical antipsychotic may enhance smoke cessation outcome bup,George TP,2002,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(02)01339-2,12079730,George TP; Vessicchio JC; Termine A; Bregartner TA; Feingold A; Rounsaville BJ; Kosten TR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016540: Smoking Cessation; D014029: Tobacco Use Disorder; D016896: Treatment Outcome",,,https://openalex.org/W2030465413,78,11,1,1475,251,7,en,en
false,newer atypical antipsychotic medication comparison clozapine systematic review randomize trial,aim study evaluate effectiveness new atypical antipsychotic drug comparison clozapine schizophrenia publication language search relevant database randomize control trial compare clozapine new atypical drug include review meta analysis include eight study short duration newer atypical drug broadly similar clozapine improvement measure use psychosis symptom rating scale global index trend clozapine effective others positive symptom less effective negative symptom adverse effect profile clozapine new atypical drug dissimilar clozapine produce fatigue hypersalivation orthostatic dizziness new atypical drug exception olanzapine produce extrapyramidal symptom result obtain study relatively small amount patient equal effectiveness tolerability new atypical drug comparison clozapine yet demonstrate trial sufficient power long duration measure clinically important outcome urgently need,Tuunainen A,2002,Schizophr Res,https://doi.org/10.1016/s0920-9964(01)00212-2,12084413,Tuunainen A; Wahlbeck K; Gilbody S,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review; D000078182: Systematic Review,D014150: Antipsychotic Agents; D003024: Clozapine; D006801: Humans; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2000978410,108,15,1,1260,202,8,en,en
false,week comparison ziprasidone haloperidol outpatient stable schizophrenia,ziprasidone novel antipsychotic unique pharmacologic profile study compare ziprasidone conventional antipsychotic haloperidol outpatient stable schizophrenia three hundred one outpatient stable chronic subchronic schizophrenia dsm iii r randomize participate double blind multicenter parallel group clinical study compare flexible dose oral ziprasidone mg day n haloperidol mg day n week patient assess use positive negative syndrome scale panss clinical global impression severity illness scale montgomery asberg depression rating scale simpson angus scale barnes akathisia scale abnormal involuntary movement scale modal dose endpoint mg day ziprasidone mg day haloperidol improvement mean efficacy variable ziprasidone haloperidol observe significantly patient categorize negative symptom responder reduction panss negative subscale score ziprasidone group compare haloperidol group p ziprasidone clear advantage haloperidol evaluation movement disorder change body weight negligible treatment pattern laboratory cardiovascular change observe ziprasidone haloperidol effective reduce overall psychopathology ziprasidone demonstrate effective treatment negative symptom well tolerate haloperidol ziprasidone appear offer effective alternative haloperidol long term treatment stable outpatient schizophrenia,Hirsch SR,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0609,12088164,Hirsch SR; Kissling W; Bäuml J; Power A; O'Connor R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D009325: Nausea; D010879: Piperazines; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D007319: Sleep Initiation and Maintenance Disorders; D013844: Thiazoles; D016896: Treatment Outcome; D014839: Vomiting,,,https://openalex.org/W2005567237,92,12,1,1734,269,9,en,en
false,child adhd motor dysfunction compare child adhd,purpose study identify group difference child attention deficit hyperactivity disorder motor dysfunction adhd md adhd evaluate medication responsiveness adhd md sixty three child male female mean age year month sd year month undergo triple blind placebo control crossover study evaluate two dose level methylphenidate mg kg mg kg dosage error correct twice daily placebo forty nine trial complete nineteen child adhd md adhd behavior function assess home school treatment effect assess use abbreviate symptom questionnaire parent teacher child adhd md likely severe adhd combine type neurodevelopmental behavioral problem group child linear dose response medication placebo low high evidence group dose interaction overall group effect home school lack group effect suggest child respond medication like subgroup,Tervo RC,2002,Dev Med Child Neurol,https://doi.org/10.1017/s0012162201002250,12088306,Tervo RC; Azuma S; Fogas B; Fiechtner H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D019957: Motor Skills Disorders; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2111188301,78,12,1,1176,203,9,en,en
false,prevalence obesity lipid glucose abnormality outpatient prescribe clozapine,individual schizophrenia standardise mortality rate double general population addition suicide high rate cardiovascular respiratory disease contribute raise mortality rate although clozapine report improve psychotic symptom decrease suicide rate attention recently focussed potential increase cardiovascular risk factor include obesity dyslipidemia diabetes mellitus study aim ascertain prevalence risk factor cohort irish outpatient treat clozapine,Leonard P,2002,Ir Med J,,12090443,Leonard P; Halley A; Browne S,article,D016428: Journal Article,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001786: Blood Glucose; D002784: Cholesterol; D003024: Clozapine; D003430: Cross-Sectional Studies; D005260: Female; D006801: Humans; D006937: Hypercholesterolemia; D015228: Hypertriglyceridemia; D008297: Male; D008875: Middle Aged; D009765: Obesity; D010045: Outpatients; D014280: Triglycerides,,,https://openalex.org/W51529496,91,13,1,595,90,4,en,en
false,combination mood stabilizer risperidone haloperidol treatment acute mania double blind placebo control comparison efficacy safety,study assess efficacy safety risperidone adjunctive agent mood stabilizer treatment acute mania week randomize double blind placebo control study include bipolar disorder patient current manic mixed episode receive mood stabilizer lithium divalproex placebo risperidone haloperidol primary efficacy measure young mania rating scale assessment use brief psychiatric rating scale clinical global impression scale safety measure trial discontinue placebo group patient risperidone group patient haloperidol group patient mean modal mg day sd risperidone mg day sd haloperidol significantly great reduction young mania rating scale score endpoint time see risperidone group haloperidol group compare placebo group young mania rating scale total score improve risperidone haloperidol patient psychotic feature without psychotic feature baseline extrapyramidal symptom rating scale total score endpoint significantly high haloperidol patient placebo patient antiparkinsonian medication receive patient placebo risperidone haloperidol group respectively risperidone plus mood stabilizer efficacious mood stabilizer alone efficacious haloperidol plus mood stabilizer rapid control manic symptom well tolerate,Sachs GS,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.7.1146,12091192,Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D018692: Antimanic Agents; D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001714: Bipolar Disorder; D010054: Brief Psychiatric Rating Scale; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006220: Haloperidol; D006801: Humans; D008094: Lithium; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D016896: Treatment Outcome; D014635: Valproic Acid",,,https://openalex.org/W2128746746,163,24,1,1682,291,8,en,en
false,cell mediate immune response mdma user repeat dose administration,bstract acute administration methylenedioxymethamphetamine mdma ecstasy produce time dependent immune dysfunction human recreational use mdma generally include repeat drug consumption often association drug alcohol cannabis laboratory set repeat mdma administration healthy mdma consumer produce time dependent immune dysfunction similar observe ingestion single dose first two administration parallel time course mdma induce cortisol stimulation kinetics mdma plasma concentration significant decrease cd helper cell simultaneous increase natural killer nk cell decrease functional responsiveness lymphocyte mitogenic stimulation observe response second dose either long lasting compare first dose disproportionate show parallelism cortisol mdma plasma concentration circumstance extend critical period immunocompetence highly impaired result mdma use accumulation mdma body poor metabolizer induce high immunomodulatory effect statistically significant difference nk cell function compare extensive metabolizers basal value lymphocyte subset examine population recreational mdma user participate different clinical trial alteration several immunological parameter observe absolute number lymphocyte particular lymphocyte cd helper cell subset show trend toward reduce value although cell count within normal limit contrast nk cell mdma consumer reduce one third healthy person statistically significant decrease affect immune parameter record year observation period subgroup recreational mdma user permanent alteration immunologic homeostasis may result impairment general health subsequent increase susceptibility infection immune relate disorder,Pacifici R,2002,Ann N Y Acad Sci,https://doi.org/10.1111/j.1749-6632.2002.tb04183.x,12105117,Pacifici R; Zuccaro P; Farré M; Pichini S; Di Carlo S; Roset PN; Palmi I; Ortuño J; Menoyo E; Segura J; de la Torre R,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D019969: Amphetamine-Related Disorders; D001782: Blood Donors; D015496: CD4-Positive T-Lymphocytes; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006801: Humans; D007111: Immunity, Cellular; D007694: Killer Cells, Natural; D018817: N-Methyl-3,4-methylenedioxyamphetamine; D016032: Randomized Controlled Trials as Topic; D012016: Reference Values; D006377: T-Lymphocytes, Helper-Inducer",,,https://openalex.org/W1519857898,78,10,1,2131,322,12,en,en
true,efficacy adderall methylphenidate attention deficit hyperactivity disorder drug placebo drug drug response curve analysis naturalistic study,stimulant medication many year pharmacological treatment choice child adult attention deficit hyperactivity disorder adhd recently several study document efficacy new stimulant adderall although initial study provide useful information clinician treat adhd child method data presentation provide limited information clinical significance drug effect thus address issue clinical significance complete drug placebo response curve analysis blind placebo control study adderall methylphenidate mph result show efficacy adderall mph improve function see throughout full range improvement score drug prevent worsen majority patient lead improvement well normal range analysis also highlight important subgroup placebo responder suggest future research focus predict robust placebo response adhd patient,Faraone SV,2002,Int J Neuropsychopharmacol,https://doi.org/10.1017/s1461145702002845,12135536,Faraone SV; Short EJ; Biederman J; Findling RL; Roe C; Manos MJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D001519: Behavior; D000697: Central Nervous System Stimulants; D002648: Child; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010290: Parents; D011569: Psychiatric Status Rating Scales; D012574: Schools; D011795: Surveys and Questionnaires; D016896: Treatment Outcome",,,https://openalex.org/W2080231392,162,22,1,1080,177,7,en,en
false,postoperative pain relief follow intrathecal bupivacaine combine intrathecal oral clonidine,purpose present study evaluate postoperative analgesic adverse effect equal oral intrathecal clonidine spinal anaesthesia bupivacaine plain forty five asa iii orthopaedic patient schedule osteosynthesis traumatic femur fracture randomise double blind fashion one group patient receive mg plain bupivacaine intrathecally group b intrathecal mixture bupivacaine mg clonidine mg group cit group cpo oral clonidine mg administer min intrathecal injection bupivacaine mg oral intrathecal clonidine prolong time first request analgesic min respectively vs min group b p total h pca morphine dose significantly low group cit mg compare group b cpo mg map decrease significantly first hour intrathecal clonidine first h oral clonidine hr decrease cit th th postoperative hour first h cpo p degree sedation pronounce group cpo first h four patient pruritus group b addition intrathecal clonidine prolong analgesia decrease morphine consumption postoperatively oral clonidine hypotension pronounce oral intrathecal clonidine intrathecal clonidine therefore recommend,Dobrydnjov I,2002,Acta Anaesthesiol Scand,https://doi.org/10.1034/j.1399-6576.2002.460709.x,12139535,Dobrydnjov I; Axelsson K; Samarütel J; Holmström B,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000700: Analgesics; D000775: Anesthesia, Spinal; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D001794: Blood Pressure; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005264: Femoral Fractures; D005593: Fracture Fixation, Internal; D006339: Heart Rate; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D008875: Middle Aged; D010149: Pain, Postoperative",,,https://openalex.org/W2087721708,103,12,1,1571,290,9,en,en
true,experimental comparison pycnogenol methylphenidate adult attention deficit hyperactivity disorder adhd,twenty four adult year old attention deficit hyperactivity disorder adhd combine type study double blind placebo control crossover study pycnogenol methylphenidate pycnogenol antioxidant derive bark french maritime pine tree methylphenidate standard pharmaceutical intervention adhd anecdotal report suggest pycnogenol improve concentration adult adhd without adverse side effect participant receive pycnogenol methylphenidate placebo three week randomize counterbalanced order although adhd symptom improve treatment neither methylphenidate pycnogenol outperform placebo control measure self report rating scale rating scale complete individual significant computerize continuous performance test conservative dosage level relatively brief length treatment may contribute absence significant difference among treatment condition implication future research note,Tenenbaum S,2002,J Atten Disord,https://doi.org/10.1177/108705470200600201,12142861,Tenenbaum S; Paull JC; Sparrow EP; Dodd DK; Green L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000276: Adjuvants, Immunologic; D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D005419: Flavonoids; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D010936: Plant Extracts; D012720: Severity of Illness Index",,,https://openalex.org/W2073497495,125,16,1,1091,165,8,en,en
false,efficacy adderall attention deficit hyperactivity disorder meta analysis,stimulant medication many year pharmacological treatment choice child adult attention deficit hyperactivity disorder adhd several study show adderall efficacious measure inattention hyperactivity impulsivity aggression disruptive behavior academic productivity although study provide useful information clinician treat adhd child adult variability efficacy among different type measure use within study comprehensively examine thus provide clear picture conclusion draw study perform meta analysis data six available study standard release adderall show efficacious symptom inattention hyperactivity impulsivity aggression well global rating efficacy significant clinician parent teacher rating fix best dose design,Faraone SV,2002,J Atten Disord,https://doi.org/10.1177/108705470200600203,12142863,Faraone SV; Biederman J,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D006801: Humans; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W1929285963,83,9,1,988,158,6,en,en
false,switch olanzapine previous antipsychotic,open label multicenter randomize study compare efficacy safety switch moderately ill asian patient schizophrenia current regimen antipsychotic medication atypical antipsychotic olanzapine use either direct switch method start taper switch method asian inpatient outpatient dsm iv schizophrenia n currently treat predominantly typical antipsychotic switch olanzapine initial dose mg day week patient randomly assign group direct switch group n receive olanzapine start taper switch group n receive olanzapine usual antipsychotic decrease first week successful switch define complete week therapy without worsen symptom clinical global impression severity illness scale cgi extrapyramidal side effect simpson angus scale overall efficacy assess use positive negative syndrome scale panss safety assess record adverse event measure vital sign statistically significant p improvement baseline endpoint occur switch group cgi score panss total score subscores however significant difference observe switch group efficacy measure technique comparable rate successful switch direct switch v start taper switch frequency treatment emergent adverse event similar switch group clinically significant difference laboratory value vital sign weight gain occur switch group p group statistically different switch group show statistically significant p improvement baseline endpoint simpson angus scale barnes akathisia scale moderately ill asian patient schizophrenia may experience decrease symptom severity improvement extrapyramidal symptom switch current medication olanzapine therapy,Lee CT,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0706,12143912,Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001210: Asia, Southeastern; D001569: Benzodiazepines; D004334: Drug Administration Schedule; D005006: Ethnicity; D005202: Asia, Eastern; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W1982134688,52,6,1,2156,350,9,en,en
false,risperidone child autism serious behavioral problem,atypical antipsychotic agent block postsynaptic dopamine serotonin receptor advantage traditional antipsychotic medication treatment adult schizophrenia may beneficial child autistic disorder serious behavioral disturbance however data safety efficacy atypical antipsychotic agent child limit conduct multisite randomize double blind trial risperidone compare placebo treatment autistic disorder accompany severe tantrum aggression self injurious behavior child year old primary outcome measure score irritability subscale aberrant behavior checklist rating clinical global impression improvement cgi scale eight week total child boy girl mean sd age year randomly assign receive risperidone child placebo treatment risperidone eight week dose range mg per day result percent reduction irritability score compare percent decrease placebo group p rate positive response define least percent decrease irritability score rating much improve much improve cgi scale percent risperidone group child positive response percent placebo group p risperidone therapy associate average weight gain kg compare kg placebo p increase appetite fatigue drowsiness dizziness drool common risperidone group placebo group p comparison two third child positive response risperidone eight week benefit maintain six month risperidone effective well tolerate treatment tantrum aggression self injurious behavior child autistic disorder short period trial limit inference adverse effect tardive dyskinesia,McCracken JT,2002,N Engl J Med,https://doi.org/10.1056/nejmoa013171,12151468,McCracken JT; McGough J; Shah B; Cronin P; Hong D; Aman MG; Arnold LE; Lindsay R; Nash P; Hollway J; McDougle CJ; Posey D; Swiezy N; Kohn A; Scahill L; Martin A; Koenig K; Volkmar F; Carroll D; Lancor A; Tierney E; Ghuman J; Gonzalez NM; Grados M; Vitiello B; Ritz L; Davies M; Robinson J; McMahon D; Research Units on Pediatric Psychopharmacology Autism Network,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D014150: Antipsychotic Agents; D001321: Autistic Disorder; D002648: Child; D002652: Child Behavior; D002675: Child, Preschool; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D018967: Risperidone; D016896: Treatment Outcome",,,https://openalex.org/W1968430210,67,9,1,2203,400,9,en,en
false,spotlight ziprasidone schizophrenia schizoaffective disorder,unlabelled ziprasidone novel antipsychotic agent pharmacological profile distinct currently available novel classical antipsychotic preclinical study ziprasidone predict efficacy positive negative affective symptom schizophrenia favourable tolerability profile include low propensity induce extrapyramidal adverse effect drug administer orally patient acute exacerbation schizophrenia schizoaffective disorder publish week randomise double blind trial give twice daily dosage mg day ziprasidone produce significantly great improvement overall symptomatology placebo large study ziprasidone mg day also significantly effective placebo reduce negative symptom mg day significantly effective placebo improve depressive symptom patient associate clinically significant depression data week trial indicate ziprasidone mg day similar efficacy haloperidol mg day ziprasidone mg day effective placebo respect prevention impend relapse improvement negative symptom stable patient chronic schizophrenia treat year addition significantly ziprasidone haloperidol recipient achieve negative symptom response week study involve stable patient chronic subchronic schizophrenia general oral ziprasidone well tolerate overall incidence adverse event similar placebo importantly drug low propensity induce extrapyramidal effect negligible effect bodyweight ziprasidone associate slight prolongation qtc interval clinical significance yet clear drug appear associate sustain elevation plasma prolactin level preliminary data indicate long term oral ziprasidone treatment well tolerate ziprasidone novel antipsychotic currently available rapid act intramuscular formulation short term treatment intramuscular ziprasidone effective well tolerate patient acute agitation associate psychosis addition intramuscular ziprasidone reduce agitation score significantly great extent haloperidol study involve patient acute agitation associate psychosis conclusion ziprasidone promise new antipsychotic show significant efficacy oral treatment patient schizophrenia schizoaffective disorder drug well tolerate low propensity induce extrapyramidal effect negligible effect bodyweight addition intramuscular ziprasidone show efficacy good tolerability treatment acute agitation associate psychotic disorder,Gunasekara NS,2002,CNS Drugs,https://doi.org/10.2165/00023210-200216090-00005,12153335,Gunasekara NS; Spencer CM; Keating GM,article,D016428: Journal Article; D016454: Review,D014150: Antipsychotic Agents; D006801: Humans; D010879: Piperazines; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D013844: Thiazoles; D016896: Treatment Outcome,,,https://openalex.org/W1993001064,71,9,1,3017,454,19,en,en
false,effect methylphenidate functional magnetic resonance relaxometry cerebellar vermis boy adhd,author use functional magnetic resonance imaging fmri test effect methylphenidate steady state blood volume midline vermis cerebellum boy attention deficit hyperactivity disorder adhd region select observe significantly small child adhd also preclinical study vermis show modulate forebrain dopamine system influence locomotor activity contain significant density dopamine transporter relaxometry use indirectly assess blood volume cerebellum hemisphere midline vermis boy adhd administer placebo one three different methylphenidate continuously week relaxation time value inversely proportional local cerebral blood volume week treatment within hour boy afternoon dose test drug efficacy perform use objective measure activity moderate high methylphenidate increase relaxation time rate dependent manner increase relaxation time active child adhd reduce relaxation time subject adhd objectively hyperactive preliminary study support role vermis adhd suggest research need clarify relationship vermal size vermal blood flow stimulant response developmental pathophysiology adhd,Anderson CM,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.8.1322,12153824,Anderson CM; Polcari A; Lowen SB; Renshaw PF; Teicher MH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002531: Cerebellum; D002648: Child; D004305: Dose-Response Relationship, Drug; D006801: Humans; D008279: Magnetic Resonance Imaging; D008297: Male; D008774: Methylphenidate; D010919: Placebos; D012039: Regional Blood Flow",,,https://openalex.org/W2101637343,114,16,1,1513,259,5,en,en
false,double blind placebo control study risperidone treatment disruptive behavior child subaverage intelligence,short term efficacy safety risperidone treatment disruptive behavior examine well characterize cohort child subaverage intelligence week multicenter double blind parallel group study child age year severely disruptive behavior subaverage intelligence iq inclusive subject receive mg kg per day risperidone oral solution placebo priori primary efficacy measure change score baseline endpoint conduct problem subscale nisonger child behavior rating form risperidone group show significantly great improvement placebo group conduct problem subscale nisonger child behavior rating form week endpoint change score respectively risperidone also associate significantly great improvement placebo nisonger child behavior rating form subscales endpoint well aberrant behavior checklist subscales irritability lethargy social withdrawal hyperactivity behavior problem inventory aggressive destructive behavior subscale visual analogue scale troublesome symptom clinical global impression change score common adverse effect report risperidone treatment headache somnolence extrapyramidal symptom profile risperidone comparable placebo mean weight increase kg kg occur risperidone placebo group respectively risperidone effective well tolerate treatment severely disruptive behavior child subaverage iq,Aman MG,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.8.1337,12153826,Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL; Risperidone Disruptive Behavior Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000374: Aggression; D014150: Antipsychotic Agents; D019958: Attention Deficit and Disruptive Behavior Disorders; D002648: Child; D015897: Comorbidity; D019955: Conduct Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D010552: Personality Assessment; D010919: Placebos; D018967: Risperidone; D016896: Treatment Outcome,,,https://openalex.org/W2133752375,136,17,1,1741,269,7,en,en
false,assessment independent effect olanzapine risperidone risk diabetes among patient schizophrenia population base nest case control study,quantify association olanzapine diabetes population base nested case control study unite kingdom base general practice research database comprise million patient follow patient diagnose treat schizophrenia incident case diabetes match control diagnosis treatment diabetes patient take olanzapine significantly increase risk develop diabetes non user antipsychotic odds ratio confidence interval take conventional antipsychotic patient take risperidone non significant increase risk develop diabetes non user antipsychotic take conventional antipsychotic olanzapine associate clinically important significant increase risk diabetes,Koro CE,2002,BMJ,https://doi.org/10.1136/bmj.325.7358.243,12153919,Koro CE; Fedder DO; L'Italien GJ; Weiss SS; Magder LS; Kreyenbuhl J; Revicki DA; Buchanan RW,article,D003160: Comparative Study; D016428: Journal Article,D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D016022: Case-Control Studies; D015331: Cohort Studies; D003920: Diabetes Mellitus; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D000077152: Olanzapine; D010890: Pirenzepine; D012044: Regression Analysis; D012307: Risk Factors; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2160802754,160,22,1,936,142,3,en,en
false,randomize double blind placebo control parallel group study sli adderall xr child attention deficit hyperactivity disorder,sli adderall xr component extend release capsule formulation adderall design produce therapeutic effect last throughout day morning dose primary objective study assess efficacy safety sli compare placebo treatment attention deficit hyperactivity disorder adhd child naturalistic school home set secondary objective assess diurnal variation response base morning afternoon assessment multicenter randomize double blind parallel group placebo control trial conduct site week washout previous stimulant medication patient randomize receive single daily morning placebo sli mg mg mg week participant age year inclusive satisfy diagnostic statistical manual mental disorder fourth edition criterion diagnosis adhd include primary efficacy parameter conners global index scale teacher secondary efficacy parameter include conners global index scale parent clinical global impression scale improvement parent global assessment improvement safety assess record adverse event laboratory test vital sign visit study physical examination electrocardiogram perform screen end study five hundred eighty four child randomize include intent treat population complete entire study intention treat analysis conners global index scale teacher conners global index scale parent score reveal significant improvement morning afternoon late afternoon behavior active treatment group versus placebo active treatment group show significant dose relate improvement behavior baseline clinical global impression scale improvement parent global assessment improvement show sli superior placebo treatment end confirm dose response relationship improvement sli dose incidence spontaneously report adverse event low similar active treatment placebo sli produce consistent dose related improvement measure efficacy extend release nature sli formulation show continue significant improvement afternoon assessment teacher afternoon late afternoon assessment parent time course therapeutic effect sli suggest medication efficacious daily treatment child adhd,Biederman J,2002,Pediatrics,https://doi.org/10.1542/peds.110.2.258,12165576,Biederman J; Lopez FA; Boellner SW; Chandler MC,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002940: Circadian Rhythm; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011581: Psychological Tests; D012574: Schools; D013995: Time,,,https://openalex.org/W2029569572,150,20,1,2752,425,15,en,en
false,chronic daily headache prophylaxis tizanidine double blind placebo control multicenter outcome study,assess efficacy tizanidine hydrochloride versus placebo adjunctive prophylactic therapy chronic daily headache chronic migraine migrainous headache tension type headache tizanidine alpha adrenergic agonist inhibit release norepinephrine spinal cord brain antinociceptive effect independent endogenous opioid system previous open label study suggest drug may effective treatment chronic daily headache two hundred patient complete week single blind placebo baseline period fulfil selection criterion randomize tizanidine placebo ninety two patient complete least week treatment tizanidine n placebo n patient complete week treatment tizanidine n placebo n patient meet diagnostic criterion migraine international headache society either chronic migrainous headache chronic tension type headache tizanidine slowly titrate week mg maximum dose tolerate mean mg sd median range divide equally three dose interval per day overall headache index headache day x average intensity x duration hour day primary end point tizanidine show superior placebo reduce overall headache index p well mean headache day per week p severe headache day per week p average headache intensity p peak headache intensity p mean headache duration p mean percentage improvement last week treatment tizanidine versus placebo versus headache index p versus severe headache day p versus headache duration p versus peak headache intensity p versus average headache intensity p versus total headache day p patient receive tizanidine also score high rating overall headache improvement visual analog scale p statistically significant difference outcome patient chronic migraine versus migrainous tension type headache adverse effect report patient include somnolence dizziness dry mouth asthenia dropout due adverse event differ significantly tizanidine placebo result support tizanidine effective prophylactic adjunct chronic daily headache include migraine migrainous headache tension type headache result also suggest possible importance alpha adrenergic mechanism underlie pathophysiology spectrum headache disorder,Saper JR,2002,Headache,https://doi.org/10.1046/j.1526-4610.2002.02122.x,12167135,Saper JR; Lake AE; Cantrell DT; Winner PK; White JR,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D002908: Chronic Disease; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D020773: Headache Disorders; D006801: Humans; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome,,,https://openalex.org/W2070011903,113,15,1,2898,547,12,en,en
false,comparison caudal intravenous clonidine prevention agitation sevoflurane child,child sevoflurane anaesthesia associate postanaesthetic agitation treat mainly opioids compare effectiveness epidural v clonidine prevention postanaesthetic agitation eighty child age yr asa ii receive standardize general anaesthesia inhale sevoflurane caudal epidural block bupivacaine ml kg minor surgery child assign randomly four group clonidine microgram kg add caudal bupivacaine ii clonidine microgram kg add caudal bupivacaine iii clonidine microgram kg v caudal bupivacaine iv caudal block bupivacaine clonidine control blind observer assess behaviour child first postoperative hour secondary end point time fitness discharge postanaesthesia care unit haemodynamic respiratory variable incidence agitation group ii iii iv respectively p group ii iii compare group iv first hour surgery patient group ii iii significantly low score agitation group iv patient time fitness discharge differ four group clonidine microgram kg prevent agitation sevoflurane anaesthesia independently route administration effect clonidine appear dose dependent epidural dose microgram kg fail reduce,Bock M,2002,Br J Anaesth,https://doi.org/10.1093/bja/88.6.790,12173195,Bock M; Kunz P; Schreckenberger R; Graf BM; Martin E; Motsch J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D017109: Akathisia, Drug-Induced; D000700: Analgesics; D018685: Anesthetics, Inhalation; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007268: Injections, Epidural; D007275: Injections, Intravenous; D008297: Male; D008738: Methyl Ethers; D013511: Minor Surgical Procedures; D010149: Pain, Postoperative; D011183: Postoperative Complications; D000077149: Sevoflurane",,,https://openalex.org/W2169878395,108,15,1,1544,272,10,en,en
false,topiramate versus bupropion sr add mood stabilizer therapy depressive phase bipolar disorder preliminary single blind study,antiepileptic drug aeds commonly employ treatment bipolar disorder efficacy tolerability topiramate novel anticonvulsant bupropion sr add mood stabilizer therapy compare single blind condition rater blind patient meet dsm iv criterion bipolar ii depression total patient hamilton depression rating scale hdrs score randomize receive escalate either topiramate mg day bupropion sr mg day week data analyze intent treat basis use last observation carry forward method percentage patient meet priori response criterion decrease baseline mean hdrs total score significant topiramate bupropion sr p p respectively baseline demographic clinical parameter comparable two treatment group mean study medication mg day sd mg day topiramate treat group mg day sd mg day bupropion sr treat group significant comparable reduction depressive symptom observe baseline endpoint follow topiramate bupropion sr treatment accord reduction hdrs total mean hdrs score significantly decrease baseline endpoint group p however difference topiramate treat group bupropion sr treat group significant p topiramate bupropion sr generally well tolerate thirteen patient discontinue study lack efficacy due withdrawal consent follow side effect six topiramate four bupropion sr treat group case affective switch either arm weight loss experience patient group mean weight loss endpoint kg bupropion sr kg topiramate p p respectively preliminary data suggest adjunctive topiramate may reduce depressive symptom severity acute bipolar depression antidepressant efficacy compound require confirmation via double blind placebo control investigation,McIntyre RS,2002,Bipolar Disord,https://doi.org/10.1034/j.1399-5618.2002.01189.x,12180276,McIntyre RS; Mancini DA; McCann S; Srinivasan J; Sagman D; Kennedy SH,article,D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D000328: Adult; D000927: Anticonvulsants; D018692: Antimanic Agents; D001714: Bipolar Disorder; D016642: Bupropion; D003866: Depressive Disorder; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005260: Female; D005632: Fructose; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D016037: Single-Blind Method; D000077236: Topiramate; D016896: Treatment Outcome",,,https://openalex.org/W2029639141,147,22,1,2397,441,12,en,en
false,bupropion pharmacologic relapse prevention smoking,aim study identify predictor successful relapse prevention smoker receive long term sustain release bupropion smoker n interested stop smoking enrol week open label bupropion phase abstinent subject end treatment eligible proceed n randomize active bupropion placebo week follow additional year best overall predictor less relapse smoking assignment active bupropion aggregate result indicate bupropion prescribe diverse population smoker expect comparable result medication effect independent predictor except old age gain minimal weight open label phase predictor successful relapse prevention include low baseline smoking rate fagerstr tolerance questionnaire score initiation smoke old age data encourage others perform similar pharmacologic relapse prevention study pharmacotherapies,Hurt RD,2002,Addict Behav,https://doi.org/10.1016/s0306-4603(01)00188-5,12188588,Hurt RD; Wolter TD; Rigotti N; Hays JT; Niaura R; Durcan MJ; Gonzales D; Sachs DP; Johnston JA; Offord KP,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D016642: Bupropion; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D055502: Secondary Prevention; D016540: Smoking Cessation; D000074606: Smoking Prevention,,,https://openalex.org/W145449476,57,7,1,1123,182,8,en,en
false,analgesic efficacy bilateral combine superficial deep cervical plexus block administer thyroid surgery general anesthesia,study evaluate analgesic efficacy combine deep superficial cervical plexus block patient undergo thyroidectomy general anesthesia purpose patient undergo elective thyroid surgery randomize receive bilateral combine deep superficial cervical block ml per side saline group n ropivacaine group n ropivacaine plus clonidine g ml group n deep cervical plexus block perform single injection ml c level superficial cervical plexus block consist subcutaneous injection ml behind lateral border sternocleidomastoid muscle surgery number additional alfentanil bolus significantly reduce group compare group v p surgery opioid non opioid analgesic requirement also significantly reduce group p first h except one patient group experience transient anesthesia brachial plexus side effect note group conclude combine deep superficial cervical plexus block effective technique alleviate pain immediately thyroidectomy,Aunac S,2002,Anesth Analg,https://doi.org/10.1097/00000539-200209000-00039,12198064,Aunac S; Carlier M; Singelyn F; De Kock M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000577: Amides; D000768: Anesthesia, General; D000779: Anesthetics, Local; D002572: Cervical Plexus; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010147: Pain Measurement; D010149: Pain, Postoperative; D000077212: Ropivacaine; D013961: Thyroid Gland",,,https://openalex.org/W2061550880,148,19,1,1306,249,7,en,en
false,selegiline second look six year later risky parkinson disease,reference treatment parkinson disease levodopa plus peripheral dopadecarboxylase inhibitor benserazide carbidopa selegiline type b maoi market france since saw indication extend cover single agent therapy early stage parkinson disease combination levodopa onset complication levodopa therapy initial clinical file fail show selegiline benefit indication new data trial involve hundred untreated patient show selegiline postpone need levodopa therapy month fail substantially alter progression parkinson disease clinical trial retrospective epidemiological study patient advance parkinson disease show excess mortality selegiline side effect selegiline similar antiparkinsonian drug amphetamine notable side effect include cardiovascular problem postural hypotension atrial fibrillation arterial hypertension selegiline cause serotoninergic syndrome arterial hypertension must combine pethidine tramadol bupropion sumatriptan zolmitriptan naratriptan concurrent treatment serotonin reuptake inhibitor antidepressant also avoid give moderate effect selegiline parkinson disease possibility slight increase mortality justification prescribe medication patient parkinson disease whatever stage parkinson disease justification start patient selegiline patient already take selegiline continue take feel clear benefit free risk factor early mortality especially cardiovascular disease,,2002,Prescrire Int,,12199263,,article,D016428: Journal Article,"D000978: Antiparkinson Agents; D002986: Clinical Trials as Topic; D003362: Cost-Benefit Analysis; D004359: Drug Therapy, Combination; D005602: France; D006801: Humans; D007980: Levodopa; D008996: Monoamine Oxidase Inhibitors; D010300: Parkinson Disease; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies; D012642: Selegiline; D016896: Treatment Outcome",,,https://openalex.org/W4299901040,77,17,2,1892,323,12,en,en
false,anaesthetic postoperative analgesic effect spinal clonidine additive prilocaine transurethral resection urinary bladder tumour,alpha adrenoceptor agonist clonidine potent central antinociceptive property study design investigate effect combine subarachnoid administration clonidine prilocaine spinal block postoperative analgesia transurethral resection tumour urinary bladder control prospective double blind study enrol patient schedule elective transurethral resection bladder tumour spinal anaesthesia prilocaine patient randomly assign receive intrathecal injection prilocaine mg alone control group combination clonidine microgram assess haemodynamic change non invasive arterial pressure heart rate pulse oximetry upper level block onset duration sensory motor block postoperative analgesia adverse effect statistically significant difference demographic data heart rate onset time level sensory motor block analgesia last significantly longer clonidine group versus min p duration motor block long clonidine group min control group min p duration sensory block also longer clonidine group min control group min p patient recovery room need metamizol dipyrone clonidine group control group arterial pressure decrease significantly clonidine group min block addition clonidine microgram prilocaine mg subarachnoid anaesthesia increase duration sensory motor block reduce need additional postoperative analgesic provide excellent analgesia h recovery transurethral resection bladder tumour,Santiveri X,2002,Eur J Anaesthesiol,https://doi.org/10.1017/s0265021502000959,12200949,Santiveri X; Arxer A; Plaja I; Metje MT; Martínez B; Villalonga A; López M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000700: Analgesics; D000775: Anesthesia, Spinal; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D003000: Clonidine; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D010149: Pain, Postoperative; D011318: Prilocaine; D011446: Prospective Studies; D001749: Urinary Bladder Neoplasms",,,https://openalex.org/W2092031333,154,21,1,1951,331,8,en,en
false,optimal dose atypical antipsychotic adult review current evidence,review describe dose strategy use optimize beneficial effect atypical antipsychotic medication difference manufacturer recommend dose actual clinical practice reconcile use evidence pivotal double blind randomize registration study randomize clinical trial case series case report clozapine perhaps olanzapine plasma level correlate therapeutic response risperidone plasma level correlate therapeutic response may relate occurrence extrapyramidal symptom information relate optimal dose quetiapine ziprasidone limit clinical practice mean daily dose risperidone decrease whereas olanzapine increase percentage patient receive quetiapine manufacturer recommend maximum high would expect far illustrate dose range establish registration study may reflect need day day practice,Citrome L,2002,Harv Rev Psychiatry,https://doi.org/10.1080/10673220216279,12202454,Citrome L; Volavka J,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D014150: Antipsychotic Agents; D002986: Clinical Trials as Topic; D004348: Drug Labeling; D011307: Drug Prescriptions; D006783: Hospitals, State; D006801: Humans; D017891: Pharmacoepidemiology; D011618: Psychotic Disorders; D016896: Treatment Outcome",,,https://openalex.org/W1988672159,85,14,1,1058,157,6,en,en
false,effect caffeine development behavior infancy childhood review publish literature,medline literature behavioral effect caffeine infant child review little recent work area generally caffeine well tolerate usual dietary amount evidence individual differ susceptibility caffeine related adverse effect turn may influence consumption overall effect caffeine child seem modest typically innocuous,Castellanos FX,2002,Food Chem Toxicol,https://doi.org/10.1016/s0278-6915(02)00097-2,12204387,Castellanos FX; Rapoport JL,article,D016428: Journal Article; D016454: Review,"D000293: Adolescent; D002110: Caffeine; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D002657: Child Development; D002675: Child, Preschool; D006801: Humans; D006948: Hyperkinesis; D007223: Infant; D007231: Infant, Newborn",,,https://openalex.org/W2049048406,110,18,1,452,76,4,en,en
false,comparison sustain release bupropion placebo smokeless tobacco cessation,evaluate potential efficacy bupropion sustain release use combination minimal counsel moist snuff cessation male double blind placebo control month trial active treatment group n receive bupropion sr mg qd day first day begin day day week mg b placebo group n receive tablet qd day begin day day tablet b bupropion mg day b produce significantly high quit rate smokeless tobacco cessation end treatment week placebo p bupropion sr appear effective smokeless tobacco cessation,Glover ED,2002,Am J Health Behav,https://doi.org/10.5993/ajhb.26.5.7,12206448,Glover ED; Glover PN; Sullivan CR; Cerullo CL; Hobbs G,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D016642: Bupropion; D003692: Delayed-Action Preparations; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D009042: Motivation; D010919: Placebos; D014029: Tobacco Use Disorder; D014030: Tobacco, Smokeless; D016896: Treatment Outcome",,,https://openalex.org/W2314119296,87,11,1,720,136,4,en,en
false,drug treatment conduct disorder young people,although conduct disorder cd common psychiatric disorder youth community encompass one third one half referral child adolescent clinic license drug date treatment cd neither europe u aim paper review research data available use medication cd young people identify future direction research review control study six open trial investigate compound mainly belong three class psychotropic drug mood stabilizer neuroleptic stimulant six five six control study respectively lithium document treatment positive study conventional neuroleptic commonly prescribe positive study atypical neuroleptic appear promise positive study methylphenidate improve cd symptom even absence adhd positive study sparse research conduct response antidepressant evidence effective role pharmacotherapy cd still limit treatment multimodal individualize patient specific condition,Gérardin P,2002,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(02)00042-1,12208553,Gérardin P; Cohen D; Mazet P; Flament MF,article,D003160: Comparative Study; D016428: Journal Article,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000927: Anticonvulsants; D014150: Antipsychotic Agents; D002220: Carbamazepine; D000697: Central Nervous System Stimulants; D002648: Child; D002653: Child Behavior Disorders; D002675: Child, Preschool; D003000: Clonidine; D019955: Conduct Disorder; D006801: Humans; D008094: Lithium; D016032: Randomized Controlled Trials as Topic; D014635: Valproic Acid",,,https://openalex.org/W2048935910,50,8,1,1204,213,10,en,en
false,dexmethylphenidate,dexmethylphenidate comprise enantiomer pharmacologically effective isomer racemic methylphenidate indicate treatment patient age year attention deficit hyperactivity disorder adhd week double blind trial child adhd significantly great improvement baseline teacher rat swanson nolan pelham snap adhd score see dexmethylphenidate methylphenidate recipient compare placebo recipient addition significantly dexmethylphenidate methylphenidate recipient compare placebo recipient much improve much improve accord clinical global impression improvement illness scale score study parent rat snap adhd score decrease significantly great extent dexmethylphenidate recipient pm pm methylphenidate recipient pm compare placebo recipient significantly dexmethylphenidate placebo recipient fail treatment double blind treatment withdrawal trial child adhd v noncomparative study child adhd symptom adhd assess teacher parent control entire school day dexmethylphenidate recipient respectively median duration effect hour respectively dexmethylphenidate generally well tolerate child adhd adverse event consistent know associate agent contain methylphenidate,Keating GM,2002,Drugs,https://doi.org/10.2165/00003495-200262130-00009,12215063,Keating GM; Figgitt DP,article,D016428: Journal Article; D016454: Review,D000042: Absorption; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D064699: Dexmethylphenidate Hydrochloride; D018765: Dopamine Uptake Inhibitors; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D016032: Randomized Controlled Trials as Topic; D013237: Stereoisomerism; D016896: Treatment Outcome,,,https://openalex.org/W3191454018,18,1,1,1589,248,7,en,en
false,adhd brazil dsm iv criterion culturally different population,diagnosis attention deficit hyperactivity disorder adhd recognize different country culture baumgaertel et al baumgaertel wolraich ml dietrich comparison diagnostic criterion attention deficit disorder german elementary school sample j acad child adolesc psychiatry abstract full text pdf pubmed scopus google scholar reid reid r assessment adhd culturally different group use behavioral rating scale sch psychol rev google scholar rohde et al rohde la biederman j busnello ea et al adhd school sample brazilian adolescent study prevalence comorbid condition impairment j acad child adolesc psychiatry abstract full text pdf pubmed scopus google scholar inasmuch dsm become widely use clinical research set classification system mental disorder baumgaertel et al baumgaertel wolraich ml dietrich comparison diagnostic criterion attention deficit disorder german elementary school sample j acad child adolesc psychiatry abstract full text pdf pubmed scopus google scholar validity adhd criterion evaluate culture different country even important one consider cultural factor may modulate clinical manifestation disruptive behavior disorder livingston livingston r cultural issue diagnosis treatment adhd j acad child adolesc psychiatry abstract full text pdf pubmed scopus google scholar reid reid r assessment adhd culturally different group use behavioral rating scale sch psychol rev google scholar,Rohde LA,2002,J Am Acad Child Adolesc Psychiatry,https://doi.org/10.1097/00004583-200209000-00014,12218435,Rohde LA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001289: Attention Deficit Disorder with Hyperactivity; D001938: Brazil; D002648: Child; D003469: Culture; D005260: Female; D006801: Humans; D008297: Male; D008370: Manuals as Topic; D012015: Reference Standards; D015203: Reproducibility of Results; D012680: Sensitivity and Specificity,,,https://openalex.org/W1980110135,72,12,1,1847,335,16,en,en
false,somatic treatment depressive illness child adolescent,numerous somatic intervention study potential treatment depressive disorder child adolescent include antidepressant medication light therapy electro convulsive therapy alternative therapy available evidence suggest several somatic intervention hold promise potentially safe effective treatment depress youth however still much learn intervention article review know need learn somatic treatment pediatric depression,Findling RL,2002,Child Adolesc Psychiatr Clin N Am,https://doi.org/10.1016/s1056-4993(02)00010-x,12222083,Findling RL; Feeny NC; Stansbrey RJ; DelPorto-Bedoya D; Demeter C,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000293: Adolescent; D000928: Antidepressive Agents; D002648: Child; D003866: Depressive Disorder; D004565: Electroconvulsive Therapy; D005260: Female; D006801: Humans; D008297: Male; D013000: Psychiatric Somatic Therapies,,,https://openalex.org/W2138664032,70,9,1,570,85,4,en,en
false,switch conventional novel antipsychotic drug result prospective naturalistic study,examine long term consequence switch patient conventional novel antipsychotic drug patient perspective prospective single blind naturalistic study cohort subject n schizophrenia schizo affective disorder dsm iv switch conventional neuroleptic drug either risperidone n olanzepine n quetiapine n monitor period year ensue natural history transition treatment chart outcome include symptom side effect subjective tolerability drug impact quality life document standardize rating scale majority subject benefit switch novel antipsychotic drug though preferred return original neuroleptic others eventually require clozapine therapy novel antipsychotic drug significantly tolerate good positive impact treatment adherence psychosocial functioning quality life among novel drug risperidone significantly well improve negative symptom olanzepine particularly well tolerate effective comorbid anxiety depressive symptom patient treat quetiapine report side effect show significantly great improvement neurocognitive deficit novel antipsychotic emerge drug choice view overall effectiveness though conventional neuroleptic clozapine continue limit distinct role management schizophrenia challenge clinician lie match patient clinical biochemical profile drug pharmacological action order achieve optimum outcome,Voruganti L,2002,Schizophr Res,https://doi.org/10.1016/s0920-9964(01)00309-7,12223251,Voruganti L; Cortese L; Owyeumi L; Kotteda V; Cernovsky Z; Zirul S; Awad A,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003987: Dibenzothiazepines; D005260: Female; D006801: Humans; D008297: Male; D015999: Multivariate Analysis; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011618: Psychotic Disorders; D011788: Quality of Life; D000069348: Quetiapine Fumarate; D018967: Risperidone; D012559: Schizophrenia; D016037: Single-Blind Method,,,https://openalex.org/W2168513289,101,14,1,1791,290,6,en,en
false,extrapyramidal symptom profile japanese patient schizophrenia treat olanzapine haloperidol,previous clinical trial clearly show superiority olanzapine haloperidol improvement extrapyramidal symptom eps schizophrenic patient primary purpose study compare eps profile japanese schizophrenic patient treat atypical antipsychotic olanzapine typical antipsychotic haloperidol measure drug induce extrapyramidal symptom scale diepss diepss consist eight individual parameter one global assessment overall severity use evaluate patient enrol week study primary safety analysis maximum change could either decrease increase baseline diepss total score secondary analysis include change baseline maximum diepss total score change baseline endpoint locf diepss total score rank sum maximum change could either decrease increase baseline diepss individual item incidence treatment emergent eps adverse event use diepss scale also analyze olanzapine group show statistically significant superiority haloperidol group primary analysis p secondary analysis also demonstrate olanzapine superiority diepss total parkinsonism akathisia overall severity score p categorical analysis treatment emergent akathisia parkinsonism syndrome endpoint show improvement olanzapine group worsen haloperidol group result study suggest olanzapine caucasian population safe treatment japanese patient chronically ill schizophrenia,Inada T,2002,Schizophr Res,https://doi.org/10.1016/s0920-9964(01)00314-0,12223254,Inada T; Yagi G; Miura S,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D007564: Japan; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia; D018709: Statistics, Nonparametric",,,https://openalex.org/W1984981206,110,13,1,1704,280,10,en,en
false,attention deficit hyperactivity disorder child,,Ramchandani P,2002,Clin Evid,,12230649,Ramchandani P; Joughin C; Zwi M,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003000: Clonidine; D003131: Combined Modality Therapy; D003913: Dextroamphetamine; D006801: Humans; D008774: Methylphenidate; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,,53,7,1,0,0,0,en,
false,schizophrenia,,Lawrie S,2002,Clin Evid,,12230716,Lawrie S; McIntosh A,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D014150: Antipsychotic Agents; D001521: Behavior Therapy; D003024: Clozapine; D003131: Combined Modality Therapy; D005196: Family Therapy; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W4300574626,14,2,1,0,0,0,en,
false,menopausal symptom,,Morris E,2002,Clin Evid,,12230782,Morris E; Rymer J,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000368: Aged; D002979: Climacteric; D003000: Clonidine; D015914: Estrogen Replacement Therapy; D005260: Female; D006801: Humans; D008875: Middle Aged; D009652: Norpregnenes; D045167: Progesterone Congeners; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W4302433600,20,3,1,0,0,0,en,
false,cost effectiveness comparison tizanidine baclofen management spasticity,objective baclofen tizanidine use treatment muscle spasticity spinal origin effectiveness cost adverse effect profile differ paper set estimate cost effectiveness drug impact change baclofen tizanidine design simplify realistic model physician behaviour patient response develop decision tree populate data derive available publish clinical comparative trial consider patient spasticity cause multiple sclerosis spinal cord injury outcome measure use cost per successfully treat day std cost estimate perspective uk national health service value result expect cost cohort patient year estimate pound baclofen pound tizanidine estimate number std tizanidine baclofen overall cost effectiveness manage spasticity use baclofen tizanidine similar pound pound per std respectively incremental cost effectiveness ice use tinzanidine alternative baclofen first line treatment pound per std sensitivity analysis find model robust change key parameter conclusion drug cost determine factor make treatment choice cost effectiveness ratio similar product,Rushton DN,2002,Pharmacoeconomics,https://doi.org/10.2165/00019053-200220120-00003,12236804,Rushton DN; Lloyd AC; Anderson PM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001418: Baclofen; D003000: Clonidine; D003362: Cost-Benefit Analysis; D006801: Humans; D009125: Muscle Relaxants, Central; D009128: Muscle Spasticity; D006113: United Kingdom",,,https://openalex.org/W1984000290,88,11,1,1516,259,12,en,en
false,olanzapine treatment dopamimetic induced psychosis patient parkinson disease,study elderly patient demonstrate antipsychotic efficacy favorable safety profile olanzapine report result two placebo control double blind study olanzapine treatment dopamimetic drug induce psychosis patient parkinson disease pd patient treat olanzapine placebo week dopamimetic therapy hold constant olanzapine initiate mg day mg day increase allow every day maximum dose mg day olanzapine patient show significant improvement baseline positive symptom efficacy measure significant treatment group difference observe olanzapine perform significantly bad placebo study unify parkinson disease rating scale updrs total motor activity daily live scale updrs tremor item complication score correct qt interval vital sign body weight significantly different placebo find demonstrate superior efficacy olanzapine treatment dopamimetic induced psychosis pd initial dose titration schedule mild baseline level psychosis may account find future study involve gradual dose titration need explore olanzapine optimum use patient pd treatment related psychosis,Breier A,2002,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(02)01392-6,12242060,Breier A; Sutton VK; Feldman PD; Kadam DL; Ferchland I; Wright P; Friedman JH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015259: Dopamine Agents; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010300: Parkinson Disease; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011605: Psychoses, Substance-Induced; D016896: Treatment Outcome",,,https://openalex.org/W2072511042,97,14,1,1412,215,7,en,en
false,comparative efficacy adderall methylphenidate attention deficit hyperactivity disorder meta analysis,methylphenidate currently widely prescribe medication attention deficit hyperactivity disorder several study use active comparator medication evaluate efficacy new stimulant adderall prior study show adderall superior placebo suggest least effective standard release form methylphenidate long duration action although initial study provide useful information clinician treat child attention deficit hyperactivity disorder difficult interpret find vary among study among different type measure use within study provide clear picture conclusion draw study perform meta analysis data four available study suggest adderall small statistically significant advantage standard release form methylphenidate advantage observe symptom measure global rating strong global rating effect adderall significant clinician parent rating teacher rating significant fix dose best dose design,Faraone SV,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200210000-00005,12352269,Faraone SV; Biederman J; Roe C,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D016896: Treatment Outcome",,,https://openalex.org/W2335556316,113,12,1,1251,191,7,en,en
false,risperidone decrease crave relapse individual schizophrenia cocaine dependence,examine efficacy atypical neuroleptic decrease crave drug relapse protract withdrawal individual dually diagnose schizophrenia cocaine dependence conduct week open label pilot study compare risperidone typical neuroleptic sample withdrawn cocaine dependent schizophrenia patient preliminary result suggest individual treat risperidone significantly less cue elicit crave substance abuse relapse study completion far show trend toward great reduction negative global symptom schizophrenia atypical neuroleptic may help reduce crave relapse population future research include rigorous double blind placebo control study class medication,Smelson DA,2002,Can J Psychiatry,https://doi.org/10.1177/070674370204700710,12355680,Smelson DA; Losonczy MF; Davis CW; Kaune M; Williams J; Ziedonis D,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D019970: Cocaine-Related Disorders; D015897: Comorbidity; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009042: Motivation; D010865: Pilot Projects; D011569: Psychiatric Status Rating Scales; D012008: Recurrence; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W2106493693,99,12,1,817,108,3,en,en
false,adjunctive olanzapine ssri resistant combat relate ptsd double blind placebo control study,objective posttraumatic stress disorder ptsd particularly combat veteran chronic illness often refractory standard pharmacological intervention need test adjunctive treatment boost response method subject patient ptsd minimally responsive week treatment selective serotonin reuptake inhibitor ssri maximum tolerate dose outcome compare among subject whose treatment augment week double blind olanzapine placebo administration result olanzapine augmentation associate statistically significantly great reduction placebo specific measure posttraumatic stress depressive sleep disorder symptom clinician rat global response rate however significantly differ group conclusion likely first double blind placebo control study adjunct ssri ptsd despite small group size find suggest role olanzapine atypical antipsychotic treat ssri resistant ptsd sleep symptom may especially benefit,Stein MB,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.10.1777,12359687,Stein MB; Kline NA; Matloff JL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003130: Combat Disorders; D003866: Depressive Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005473: Fluoxetine; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D017374: Paroxetine; D010890: Pirenzepine; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D017367: Selective Serotonin Reuptake Inhibitors; D020280: Sertraline; D012893: Sleep Wake Disorders; D016896: Treatment Outcome",,,https://openalex.org/W2116042849,102,12,1,1129,176,9,en,en
false,olanzapine treatment dopaminergic induce hallucination,atypical antipsychotic medication low affinity receptor consider useful alternative treat drug induce hallucination parkinson disease pd conduct double blind placebo control unforced titration parallel design study drug placebo randomization ratio use olanzapine mg day effect pd patient drug induce hallucination perform extensive battery neuropsychological test unify parkinson disease rating scale updrs assessment time baseline week start medication sixteen patient olanzapine mean dose mg night placebo complete study compare placebo performance updrs item think disorder structure interview hallucination tend improve drug neither reach statistical significance neuropsychological test battery show significant difference total updrs motor score p time tap p worsen drug compare placebo bradykinesia p gait p item updrs largely account deterioration completion study patient randomly assign drug continue olanzapine mean dose mg day however last recorded visit patient expose drug include originally randomly assign placebo remain olanzapine patient pd low dose olanzapine significantly improve hallucination worsen motor function,Ondo WG,2002,Mov Disord,https://doi.org/10.1002/mds.10217,12360554,Ondo WG; Levy JK; Vuong KD; Hunter C; Jankovic J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003072: Cognition Disorders; D018491: Dopamine Agonists; D004311: Double-Blind Method; D005260: Female; D006212: Hallucinations; D006801: Humans; D007406: Interview, Psychological; D008297: Male; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010300: Parkinson Disease; D010890: Pirenzepine",,,https://openalex.org/W2033871682,60,5,1,1610,288,11,en,en
false,opioid detoxication general anesthesia,antagonist precipitate opioid detoxification general anaesthesia use extensively since introduction use antagonist believe shorten detoxification period administration opioid dependent follow violent activation adrenergic system result development acute withdrawal syndrome patient usually treat clonidine reduce subjective discomfort procedure conduct anaesthesia exist literature one may conclude despite ten year development currently sufficient evidence effectiveness antagonist precipitate opioid detoxification general anaesthesia conduct modern anaesthesiological management randomise clinical trial necessary document advantage detoxification method compare conventional treatment,Zemtsovski MJ,2002,Ugeskr Laeger,,12362827,Zemtsovski MJ; Trosko O; Schmidt H,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000768: Anesthesia, General; D019317: Evidence-Based Medicine; D006801: Humans; D008658: Inactivation, Metabolic; D007262: Infusions, Intravenous; D008991: Monitoring, Physiologic; D009270: Naloxone; D009271: Naltrexone; D009292: Narcotic Antagonists; D009293: Opioid-Related Disorders; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2400964927,47,8,1,930,135,7,en,en
false,efficacy safety aripiprazole haloperidol versus placebo patient schizophrenia schizoaffective disorder,aripiprazole investigational agent treat schizophrenia novel pharmacologic profile present study investigate efficacy safety tolerability aripiprazole haloperidol compare placebo week double blind randomize study conduct u center july june compare aripiprazole mg day mg day placebo haloperidol mg day active control fix agent administer day throughout study total patient primary dsm iv diagnosis schizophrenia schizoaffective disorder randomize efficacy measure include positive negative syndrome scale panss total panss positive panss negative panss derive brief psychiatric rating scale bprs core clinical global impression cgi severity illness mean cgi improvement score safety tolerability evaluation include extrapyramidal symptom eps weight gain serum prolactin level qtc interval dos aripiprazole haloperidol mg produce statistically significant p improvement baseline panss total panss positive panss derive bprs core cgi severity score significantly low cgi improvement score endpoint compare placebo aripiprazole mg haloperidol mg significantly improve panss negative score compare placebo aripiprazole haloperidol separate placebo panss total score week unlike haloperidol aripiprazole associate significant eps prolactin elevation endpoint compare placebo statistically significant difference mean change body weight across treatment group versus placebo patient receive aripiprazole experience clinically significant increase qtc interval aripiprazole effective positive negative symptom safe well tolerated potential treatment schizophrenia schizoaffective disorder,Kane JM,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n0903,12363115,Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D001480: Basal Ganglia Diseases; D001835: Body Weight; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004569: Electroencephalography; D005260: Female; D006220: Haloperidol; D006801: Humans; D006966: Hyperprolactinemia; D008133: Long QT Syndrome; D008297: Male; D010879: Piperazines; D010919: Placebos; D011388: Prolactin; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D015363: Quinolones; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D055502: Secondary Prevention; D016896: Treatment Outcome,,,https://openalex.org/W2010741426,126,16,1,2048,328,10,en,en
false,severe ventricular arrhythmia sudden death neuroleptic,neuroleptic prolong qt interval risk torsades de pointes ventricular tachycardia syncope sudden death adverse reaction dose dependent publish case involve phenothiazine especially thioridazine neuroleptic also involve include recent drug risperidone olanzapine hide neuroleptic cisapride injectable domperidone carry risk effect know several decade degree risk associate various neuroleptic still poorly know epidemiological data available cornerstone prevention cardiac arrhythmia patient treat neuroleptic weigh carefully indication prescribe low effective dose monitor ecg patient also screen precipitate factor risk factor torsades de pointes combination drug favour torsades de pointes provoke pharmacokinetic interaction,,2002,Prescrire Int,,12378746,,article,D016428: Journal Article,"D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D015331: Cohort Studies; D003645: Death, Sudden; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D005602: France; D006801: Humans; D028642: Mentally Ill Persons; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W4300425143,63,9,1,1051,178,8,en,en
false,extended release methylphenidate ritalin la,extended release formulation methylphenidate ritalin la cns stimulant inhibit dopamine noradrenaline norepinephrine reuptake presynaptic neuron develop use patient attention deficit hyperactivity disorder adhd child adhd healthy male adult extend release methylphenidate mg rapidly absorb demonstrate two distinct peak plasma concentration approximately hour apart absorption pharmacokinetics extend release methylphenidate mg closely mimic immediate release methylphenidate mg give two hour apart permit daily administration week randomise double blind placebo control trial evaluable child age year adhd symptom improve significantly great extent extend release methylphenidate mg daily placebo extended release methylphenidate improve inattention hyperactivity symptom effective child combine inattentive hyperactive impulsive type predominantly inattentive type adhd clinical trial safety tolerability profile extend release methylphenidate consistent immediate release formulation,Lyseng-Williamson KA,2002,Drugs,https://doi.org/10.2165/00003495-200262150-00012,12381228,Lyseng-Williamson KA; Keating GM,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003692: Delayed-Action Preparations; D018765: Dopamine Uptake Inhibitors; D006801: Humans; D008774: Methylphenidate; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2084187081,48,9,2,1293,183,6,en,en
false,aripiprazole,aripiprazole quinolinone derivative first new class atypical antipsychotic drug partial agonist activity dopamine serotonin ht receptor also antagonist ht receptor patient acute relapse schizophrenia schizoaffective disorder aripiprazole mg day least effective haloperidol mg day similar efficacy risperidone mg day well design week placebo control trial negative symptom improve early aripiprazole risperidone group efficacy aripiprazole observe week several trial sustain throughout study period aripiprazole superior placebo week trial patient stable chronic schizophrenia week trial involve patient acute relapse disease aripiprazole similar haloperidol assess time failure maintain response superior ameliorate negative depressive symptom incidence extrapyramidal symptom aripiprazole therapy similar risperidone placebo low haloperidol compare placebo proportion patient increase plasma prolactin level qtc prolongation similar patient treat aripiprazole mg day significantly increase haloperidol risperidone,McGavin JK,2002,CNS Drugs,https://doi.org/10.2165/00023210-200216110-00008,12383035,McGavin JK; Goa KL,article,D016428: Journal Article; D016454: Review,D000818: Animals; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D002986: Clinical Trials as Topic; D003071: Cognition; D006801: Humans; D015201: Meta-Analysis as Topic; D010879: Piperazines; D015363: Quinolones; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W3191110341,12,1,1,1415,231,9,fr,en
false,epinephrine clonidine improve intrathecal sufentanil analgesia total hip replacement,compare analgesia intrathecal sufentanil alone sufentanil epinephrine microg sufentanil clonidine microg patient total hip replacement endpoint onset duration action perform randomize double blind study patient elective total hip arthroplasty use continuous spinal anaesthesia soon pain score high cm visual analogue scale report sufentanil microg alone sufentanil microg epinephrine microg sufentanil microg clonidine micro g ml normal saline give intrathecally pain score rescue analgesia diclofenac morphine adverse effect respiratory depression postoperative nausea vomit itch observe h surgery time pain score sd v v min time low pain score v v min time first dose systemic analgesic pain score v v min similar three group adverse effect analgesic requirement first h also similar total hip replacement three analgesic regimen give good analgesia comparable onset duration action minor adverse effect,Fournier R,2002,Br J Anaesth,https://doi.org/10.1093/bja/aef222,12393356,Fournier R; Van Gessel E; Weber A; Gamulin Z,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000700: Analgesics; D000701: Analgesics, Opioid; D019644: Arthroplasty, Replacement, Hip; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D010147: Pain Measurement; D010149: Pain, Postoperative; D017409: Sufentanil",,,https://openalex.org/W2098493279,103,14,1,1294,257,4,en,en
false,role magnetic resonance image assessment patient establish multiple sclerosis,,Filippi M,2002,Neurol Sci,https://doi.org/10.1007/s100720200032,12398067,Filippi M,article,D016428: Journal Article; D016454: Review,"D001921: Brain; D003937: Diagnosis, Differential; D006801: Humans; D008279: Magnetic Resonance Imaging; D009103: Multiple Sclerosis; D013116: Spinal Cord; D013118: Spinal Cord Diseases",,,https://openalex.org/W334913013,105,16,1,0,0,0,en,
false,young adult follow hyperactive child self report psychiatric disorder comorbidity role childhood conduct problem teen cd,report psychiatric disorder present young adult follow mean age year year follow comorbidity among large sample hyperactive h n community control cc n child h group significantly high risk nondrug psychiatric disorder cc group vs h group meet criterion adhd major depressive disorder histrionic antisocial passive aggressive borderline personality disorder follow cc group severity childhood conduct problem contribute risk passive aggressive borderline antisocial personality disorder affect risk antisocial personality control severity teen conduct disorder cd also contribute risk disorder examination comorbidity among disorder indicate presence either borderline antisocial personality disorder significantly increase risk major depression significant personality disorder hyperactive group receive various form mental health treatment since leave high school control group result suggest hyperactive child significant risk least nondrug disorder young adulthood principally major depression several personality disorder risk largely mediate severity cd adolescence,Fischer M,2002,J Abnorm Child Psychol,https://doi.org/10.1023/a:1019864813776,12403150,Fischer M; Barkley RA; Smallish L; Fletcher K,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D015897: Comorbidity; D019955: Conduct Disorder; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007407: Interviews as Topic; D008297: Male; D001523: Mental Disorders; D010290: Parents; D011569: Psychiatric Status Rating Scales; D012044: Regression Analysis; D012650: Self Disclosure",,,https://openalex.org/W1497698943,152,24,1,1522,278,8,en,en
false,chan et al double blind randomise comparison risperidone haloperidol treatment behavioural psychological symptom chinese dementia patient int j geriatr psychiatry,international journal geriatric psychiatryvolume issue p letter editor chan et al double blind randomise comparison risperidone haloperidol treatment behavioural psychological symptom chinese dementia patient int j geriatr psychiatry onalaja correspond author onalaja old age psychiatry caludon centre coventry ukconsultant old age psychiatry caludon centre walsgrave hospital clifford bridge road coventry cv te uk search paper authora k jainer k jainer st michael hospital south warwickshire combine nhs trust uksearch paper author onalaja correspond author onalaja old age psychiatry caludon centre coventry ukconsultant old age psychiatry caludon centre walsgrave hospital clifford bridge road coventry cv te uk search paper authora k jainer k jainer st michael hospital south warwickshire combine nhs trust uksearch paper author first publish october http doi org gps citation aboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url abstract available article cite literature volume issue november page relatedinformation,Onalaja D,2002,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.722,12404659,Onalaja D; Jainer AK,article,D016420: Comment; D003160: Comparative Study; D016422: Letter,D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D002681: China; D004311: Double-Blind Method; D006220: Haloperidol; D006801: Humans; D001523: Mental Disorders; D015337: Multicenter Studies as Topic; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone,,,https://openalex.org/W2060053037,227,47,2,1728,281,6,en,en
false,olanzapine huntington disease open label study,aim prospective open label study assess efficacy olanzapine motor symptom huntington disease hd olanzapine administrate nine patient genetically confirm hd increase satisfactory clinical effect appearance side effect patient evaluate baseline day treatment use motor scale unify hd rating scale uhdrs patient improve significantly subscores uhdrs include fine motor task although patient need rather high dose mg per day adverse effect report patent spontaneously observe directly investigator high dose olanzapine seem useful choreatic hd patient double blind placebo control trial appear warrant definitively establish symptomatic value olanzapine hd,Bonelli RM,2002,Clin Neuropharmacol,https://doi.org/10.1097/00002826-200209000-00007,12410058,Bonelli RM; Mahnert FA; Niederwieser G,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006816: Huntington Disease; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W1986745638,56,10,1,898,154,7,en,en
true,daily atomoxetine treatment child adolescent attention deficit hyperactivity disorder randomize placebo control study,author assess efficacy daily atomoxetine administration treatment child adolescent attention deficit hyperactivity disorder adhd double blind study child adolescent adhd n age range year randomly assign receive week treatment either atomoxetine administer daily placebo outcome among atomoxetine treat patient superior placebo treatment group assess investigator parent teacher rating treatment effect size similar observe previous atomoxetine study use twice daily dose parent diary rating suggest drug specific effect sustain late day discontinuation due adverse event low less treatment group serious safety concern observe daily administration atomoxetine effective treatment child adolescent adhd,Michelson D,2002,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.159.11.1896,12411225,Michelson D; Allen AJ; Busner J; Casat C; Dunn D; Kratochvil C; Newcorn J; Sallee FR; Sangal RB; Saylor K; West S; Kelsey D; Wernicke J; Trapp NJ; Harder D,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000928: Antidepressive Agents; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D010552: Personality Assessment; D011437: Propylamines; D016896: Treatment Outcome,,,https://openalex.org/W2123980944,147,18,1,991,157,4,en,en
false,serum glucose lipid change course clozapine treatment effect concurrent adrenergic antagonist treatment,examine effect long term clozapine treatment concurrent treatment beta adrenergic antagonist clozapine induce weight gain serum glucose lipid measure fifty subject meet dsm iii r criterion schizophrenia schizoaffective disorder participate week double blind comparison haloperidol clozapine year open label clozapine trial available serum glucose lipid level weight glucose lipid laboratory value measure baseline throughout double blind year long study significant increase serum triglyceride total cholesterol glucose level course clozapine treatment significant change high density lipoprotein hdl low density lipoprotein ldl propranolol atenolol additive effect change total cholesterol triglyceride propranolol pronounce effect propranolol atenolol significant effect serum glucose level significant correlation triglyceride hdl level change clozapine associate weight gain study significant correlation change serum total cholesterol ldl glucose weight gain clozapine therapy adverse effect glucose lipid homeostasis clozapine induce change serum glucose likely due inherent pharmacological property clozapine concurrent beta adrenergic receptor antagonist treatment may additive effect serum lipid clozapine associate weight gain also play modest role triglyceride increase,Baymiller SP,2003,Schizophr Res,https://doi.org/10.1016/s0920-9964(02)00158-5,12413642,Baymiller SP; Ball P; McMahon RP; Buchanan RW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001262: Atenolol; D001786: Blood Glucose; D003024: Clozapine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006220: Haloperidol; D006801: Humans; D008055: Lipids; D008297: Male; D011433: Propranolol; D011618: Psychotic Disorders; D012559: Schizophrenia; D018709: Statistics, Nonparametric; D015430: Weight Gain",,,https://openalex.org/W2098394821,132,19,1,1683,256,11,en,en
false,risperidone mg day vs mg day first episode acutely psychotic patient,aim study examine difference improvement clinical psychopathology fine motor function risperidone first episode acutely psychotic patient double blind fix dose study acutely psychotic neuroleptic naive patient admit first time meet dsm iv criterion schizophrenia schizophreniform disorder schizoaffective disorder randomly assign mg day risperidone treatment efficacy measure use brief psychiatric rating scale scale assessment negative symptom clinical global impression scale social occupational functioning assessment scale fine motor function assess use computerized device vienna test system compare control group healthy subject match age gender educational level treatment mg risperidone daily significantly reduce positive p negative p symptom week although significant difference motor movement measure use barnes akathisia scale simpson angus scale computerized fine motor assessment show significantly less motor dysfunction mg day group week significant correlation plasma concentration active moiety find data psychopathology fine motor function risperidone differ term clinical improvement mg day dose produce fine motor dysfunction result suggest dose low mg day risperidone may effective patient first episode psychosis,Merlo MC,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1006,12416598,Merlo MC; Hofer H; Gekle W; Berger G; Ventura J; Panhuber I; Latour G; Marder SR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D001480: Basal Ganglia Diseases; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D006801: Humans; D009048: Motor Skills; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2014627839,80,14,1,1711,281,6,en,en
false,effect methylphenidate prepulse inhibition attend ignored prestimuli among boy attention deficit hyperactivity disorder,rationale objective present study investigate attentional modification prepulse inhibition startle among boy without attention deficit hyperactivity disorder adhd two hypothesis test whether adhd associate diminish prepulse inhibition attend prestimuli ignore prestimuli whether methylphenidate selectively increase prepulse inhibition attend prestimuli among boy adhd method participant boy adhd control participant complete tone discrimination task two session separate week adhd boy administer methylphenidate mg kg one session placebo session randomize double blind fashion series tone db half hz half hz participant pay attend one pitch ignore bilateral eyeblink electromyogram startle response record response acoustic probe db white noise present follow onset two third tone one third intertrial interval result relative control boy adhd exhibit diminish prepulse inhibition onset attend ignore prestimuli follow placebo administration methylphenidate selectively increase prepulse inhibition attend prestimuli among boy adhd level comparable control receive methylphenidate conclusion data consistent hypothesis adhd involve diminish selective attention suggest methylphenidate ameliorate symptom adhd least part alter early attentional mechanism,Hawk LW,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-002-1235-7,12417963,Hawk LW; Yartz AR; Pelham WE; Lock TM,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001767: Blinking; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D004576: Electromyography; D006801: Humans; D007266: Inhibition, Psychological; D008297: Male; D008774: Methylphenidate; D010897: Pitch Discrimination; D013216: Reflex, Startle",,,https://openalex.org/W329940318,149,18,1,1734,282,10,en,en
false,cognitive enhance effect modafinil healthy volunteer,rationale modafinil novel wake promote agent show similar clinical profile conventional stimulant methylphenidate therefore interested assess whether modafinil unique pharmacological mode action might offer similar potential cognitive enhancer without side effect commonly experience amphetamine like drug objective main aim study evaluate cognitive enhance potential novel agent use comprehensive battery neuropsychological test method sixty healthy young adult male volunteer receive either single oral dose placebo mg mg modafinil prior perform variety task design test memory attention randomise double blind subject design use result modafinil significantly enhance performance test digit span visual pattern recognition memory spatial planning stop signal reaction time performance improvement complement slow latency three test delay match sample decision make task spatial planning task subject report feel alert attentive energetic drug effect clearly dose dependent except see stop signal paradigm contrast previous find methylphenidate significant effect drug spatial memory span spatial work memory rapid visual information process attentional set shift additionally effect paired associate learn identify conclusion data indicate modafinil selectively improve neuropsychological task performance improvement may attributable enhanced ability inhibit pre potent response effect appear reduce impulsive respond suggest modafinil may benefit treatment attention deficit hyperactivity disorder,Turner DC,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-002-1250-8,12417966,Turner DC; Robbins TW; Clark L; Aron AR; Dowson J; Sahakian BJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001559: Benzhydryl Compounds; D001794: Blood Pressure; D003071: Cognition; D003657: Decision Making; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D008297: Male; D008568: Memory; D000077408: Modafinil; D018696: Neuroprotective Agents; D010147: Pain Measurement; D010364: Pattern Recognition, Visual; D011581: Psychological Tests",,,https://openalex.org/W66447799,62,8,1,1979,312,14,en,en
false,assessment independent effect olanzapine risperidone exposure risk hyperlipidemia schizophrenic patient,new antipsychotic agent exhibit superior safety profile compare conventional antipsychotic agent term extrapyramidal symptom previous study suggest association olanzapine treatment hyperlipidemia evaluate association use large health care database study derive england wale base general practice research database compose million subject follow june september total individual diagnose schizophrenia identify match nested case control design use conditional logistic regression use derive adjust odds ratio control sex age medication disease condition influence lipid level antipsychotic drug exposure define receipt least prescription antipsychotic medication within month date diagnosis hyperlipidemia incident case hyperlipidemia cohort match control subject olanzapine use associate nearly fold increase odds develop hyperlipidemia compare antipsychotic exposure confidence interval ci p fold increase compare receive conventional agent ci p risperidone associate increase odds hyperlipidemia compare antipsychotic exposure ci p conventional antipsychotic exposure ci p observe strong association olanzapine exposure hyperlipidemia schizophrenic patient possible metabolic consequence olanzapine use give serious consideration treat physician,Koro CE,2002,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.59.11.1021,12418935,Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW,article,D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article,"D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D016022: Case-Control Studies; D004739: England; D005260: Female; D006801: Humans; D006949: Hyperlipidemias; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D000077152: Olanzapine; D010890: Pirenzepine; D011358: Product Surveillance, Postmarketing; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D014852: Wales",,,https://openalex.org/W2051108113,135,19,1,1852,317,10,en,en
false,cardiac arrest ventricular arrhythmia patient take antipsychotic drug cohort study use administrative data,examine rate cardiac arrest ventricular arrhythmia patient treat schizophrenia non schizophrenic control cohort study outpatient use administrative data u medicaid program patient schizophrenia treat clozapine haloperidol risperidone thioridazine control group patient glaucoma control group patient psoriasis diagnosis cardiac arrest ventricular arrhythmia patient treat schizophrenia high rate cardiac arrest ventricular arrhythmia control rate ratio range overall thioridazine associate increase risk compare haloperidol rate ratio confidence interval however thioridazine show increase risk event mg p linear dose response relation p increase risk cardiac arrest ventricular arrhythmia patient treat schizophrenia could due disease treatment overall risk thioridazine bad haloperidol thioridazine may however high risk high although finding could due chance reduce cardiac risk thioridazine prescribe low dose need obtain optimal therapeutic effect,Hennessy S,2002,BMJ,https://doi.org/10.1136/bmj.325.7372.1070,12424166,Hennessy S; Bilker WB; Knauss JS; Margolis DJ; Kimmel SE; Reynolds RF; Glasser DB; Morrison MF; Strom BL,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D003024: Clozapine; D015331: Cohort Studies; D016001: Confidence Intervals; D016757: Death, Sudden, Cardiac; D005260: Female; D006220: Haloperidol; D006323: Heart Arrest; D006801: Humans; D008297: Male; D008484: Medicaid; D008875: Middle Aged; D018967: Risperidone; D012559: Schizophrenia; D013881: Thioridazine; D014481: United States",,,https://openalex.org/W2027879784,120,16,1,1365,227,6,en,en
false,effect stimulant medication eeg child attention deficit hyperactivity disorder,rationale stimulant medication commonly use treatment attention deficit hyperactivity disorder adhd north america australia although still entirely know medication work objective study aim investigate effect stimulant medication eeg child combine subtype adhd method initial eeg record eye close rest condition fourier transform provide absolute relative power estimate delta theta alpha beta band theta alpha theta beta ratio also calculate subject place month trial stimulant second eeg record end trial result adhd group significantly great absolute delta theta less posterior absolute beta relative theta less relative alpha control group typical eeg study child adhd use stimulant medication result normalisation eeg primarily evident change theta beta band conclusion result suggest stimulant act increase cortical arousal child adhd normalise brain activity,Clarke AR,2002,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-002-1205-0,12424551,Clarke AR; Barry RJ; Bond D; McCarthy R; Selikowitz M,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000293: Adolescent; D001143: Arousal; D001289: Attention Deficit Disorder with Hyperactivity; D001921: Brain; D000697: Central Nervous System Stimulants; D002648: Child; D016000: Cluster Analysis; D003913: Dextroamphetamine; D004569: Electroencephalography; D005583: Fourier Analysis; D006801: Humans; D008774: Methylphenidate; D011594: Psychometrics,,,https://openalex.org/W4247532918,101,12,1,1224,210,8,en,en
false,psychotropic neurotropic agent dermatology unapproved u dosage indication,several antiepileptic drug aeds approve u food drug administration treatment bipolar disorder valproic acid divalproex lamotrigine carbamazepine cutaneous neuropathic pain syndrome carbamazepine gabapentin pregabalin aeds may effective management chronic pruritus include pruritus due systemic disease include uremia neuropathic pain neuropathic pruritus complex cutaneous sensory syndrome especially central nervous system cns sensitization play role management emotional dysregulation resultant repetitive self excoriation cutaneous self injury patient repetitively stimulate manipulate integument regulate emotion prurigo nodularis lichen simplex chronicus skin pick disorder trichotillomania management dermatologic clinical manifestation associate autonomic nervous system activation hyperhidrosis urticaria flush often occur conjunction psychiatric disorder prominent autonomic activation dysregulation eg social anxiety disorder posttraumatic stress disorder certain anticonvulsant direct therapeutic effect eg psoriasis currently use aeds case largely experimental gabapentin dosage range mg daily widely study aed mood stabilizer dermatology especially effective situation cns sensitization mediate factor large scale control study aeds dermatology necessary,Koo JY,2002,Clin Dermatol,https://doi.org/10.1016/s0738-081x(02)00267-5,12435529,Koo JY; Ng TC,article,D016428: Journal Article; D016454: Review,"D003879: Dermatologic Agents; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D017277: Drug Approval; D004348: Drug Labeling; D004363: Drug Utilization; D005260: Female; D006801: Humans; D008297: Male; D009414: Nerve Growth Factors; D011379: Prognosis; D011602: Psychophysiologic Disorders; D011619: Psychotropic Drugs; D016032: Randomized Controlled Trials as Topic; D018570: Risk Assessment; D018967: Risperidone; D012680: Sensitivity and Specificity; D012871: Skin Diseases; D016896: Treatment Outcome; D014481: United States; D014486: United States Food and Drug Administration",,,https://openalex.org/W2083925186,92,14,1,1597,258,4,en,en
false,depression dysphoria adult adolescent patient tourette disorder treat risperidone,article abstractbackground depression common comorbid condition patient tourette disorder risperidone usually know induce dysphoria depression patient treat psychiatric disorder previous short term week trial risperidone tourette disorder report incidence depression method retrospective study carry adult adolescent patient tourette disorder tourette syndrome classification study group diagnosis receive risperidone jan dec allan memorial institute mcgill university health centre montreal quebec canada chart patient examine evidence risk factor dsm iv define major depressive disorder mdd dysphoria result seventeen patient develop mdd include patient later commit suicide patient become dysphoric take risperidone nine patient develop mdd relapse e patient history depression prior take risperidone remainder new case e patient previous history depression positive personal history mdd factor significantly p predict development depression take risperidone seventy percent develop mdd dysphoria discontinue risperidone specifically result adverse event conclusion mdd dysphoria commonly occur cohort adult adolescent tourette disorder patient treat risperidone particularly patient previous history depression depression dysphoria frequent reason risperidone discontinuation,Margolese HC,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1115,12444819,Margolese HC; Annable L; Dion Y,article,D023362: Evaluation Study; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D003863: Depression; D003865: Depressive Disorder, Major; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D011792: Quebec; D012008: Recurrence; D012189: Retrospective Studies; D012307: Risk Factors; D018967: Risperidone; D005879: Tourette Syndrome",,,https://openalex.org/W2086266927,107,16,1,1797,308,10,en,en
false,olanzapine v haloperidol treatment elderly chronic schizophrenia patient,data support use atypical antipsychotic aa base study young adult patient present study open label naturalistic follow study olanzapine treatment v haloperidol elderly chronic schizophrenia patient mehtod patient mean age year mean disease duration year meet dsm iv criterion schizophrenia randomly assign olanzapine n haloperidol n treatment acute exacerbation primary outcome measure rating clinical global impression cgi scale positive negative symptom scale panss group difference compute use analysis covariance panss total score decrease baseline treatment olanzapine decrease haloperidol treatment f p panss negative subscale decrease baseline olanzapine treatment increase deteriorate haloperidol treatment f p cgi decrease baseline olanzapine haloperidol treatment v decrease olanzapine group significantly great f p mean weight increase group without statistical difference group elderly chronic schizophrenia patient olanzapine treatment superior haloperidol reduce negative symptom well less induction extrapyramidal symptom eps,Barak Y,2002,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/s0278-5846(01)00322-0,12452546,Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W1989726234,85,11,1,1487,248,8,en,en
false,dose strategy clozapine fluvoxamine cotreatment,lu mong liang md lane hsien yuan md phd jann michael w pharmd chang wen ho md author information,Lu ML,2002,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200212000-00016,12454566,Lu ML; Lane HY; Jann MW; Chang WH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016422: Letter; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D014150: Antipsychotic Agents; D003024: Clozapine; D004359: Drug Therapy, Combination; D016666: Fluvoxamine; D006801: Humans; D008297: Male; D012559: Schizophrenia",,,https://openalex.org/W2322021487,54,5,1,109,26,1,en,en
false,economic assessment quetiapine haloperidol patient schizophrenia partially responsive conventional antipsychotic,many patient schizophrenia exhibit partial response conventional antipsychotic agent make difficult treat adequately analysis model cost effectiveness quetiapine compare haloperidol partial responder schizophrenia outcome data partial responder international schizophrenia evaluation prize clinical trial compare quetiapine haloperidol partial responder schizophrenia define diagnostic statistical manual mental disorder fourth edition combine data literature construct markov model model use calculate treatment outcome total direct treatment cost perspective united kingdom national health service year prize study show quetiapine treatment result high response rate good tolerability haloperidol treatment benefit potential improve compliance reduce relapse rate model show high acquisition cost quetiapine offset low cost medication hospitalization medical service total treatment cost year pound quetiapine pound haloperidol cost save pound favor quetiapine quetiapine treat patient also spend long response state experience relapse sensitivity analysis show result robust across range condition quetiapine potential improve outcome compare haloperidol partial responder schizophrenia slightly low total cost high acquisition cost quetiapine offset save medical cost quetiapine could significantly improve management patient group without increase economic burden health service,Tilden D,2002,Clin Ther,https://doi.org/10.1016/s0149-2918(02)80069-8,12462294,Tilden D; Aristides M; Meddis D; Burns T,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D014150: Antipsychotic Agents; D003365: Costs and Cost Analysis; D003987: Dibenzothiazepines; D006220: Haloperidol; D006801: Humans; D008390: Markov Chains; D018803: Models, Economic; D000069348: Quetiapine Fumarate; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1997694625,140,17,1,1866,280,9,en,en
false,pharmacokinetic safety assessment galantamine risperidone two drug administer alone together,explore steady state pharmacokinetic profile coadministration galantamine risperidone open label randomize single center two way crossover drug drug interaction study conduct healthy elderly subject age year old result show risperidone administer galantamine change bioavailability galantamine steady state addition systemic exposure risperidone active moiety risperidone plus hydroxyrisperidone clinically relevant component risperidone treatment affect galantamine coadministration systemic exposure increase approximately risperidone decrease hydroxyrisperidone active metabolite risperidone galantamine risperidone safe well tolerate administer either alone together thus dose adjustment either risperidone orgalantamine necessary two drug administer together dose range evaluate,Huang F,2002,J Clin Pharmacol,https://doi.org/10.1177/0091270002042012005,12463729,Huang F; Lasseter KC; Janssens L; Verhaeghe T; Lau H; Zhao Q,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D019540: Area Under Curve; D001682: Biological Availability; D002800: Cholinesterase Inhibitors; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D005260: Female; D005702: Galantamine; D008401: Gas Chromatography-Mass Spectrometry; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008875: Middle Aged; D000068882: Paliperidone Palmitate; D011743: Pyrimidines; D018967: Risperidone; D013997: Time Factors",,,https://openalex.org/W2075009263,125,17,1,1036,157,5,en,en
false,amisulpride v risperidone chronic schizophrenia result month double blind study,multicenter double blind randomize study evaluate efficacy safety functional effect two atypical antipsychotic amisulpride risperidone patient chronic schizophrenia dsm iv recent worsen symptom plan non inferiority trial patient receive amisulpride mg day risperidone mg day six month amisulpride demonstrate inferior risperidone respect decrease positive negative syndrome scale panss total score baseline side confidence interval symptomatic improvement measure brief psychiatry rating scale bprs panss positive subscale bech rafaelsen melancholia scale similar group amisulpride significantly p superior risperidone term response improvement panss bprs total score much much improve clinical global impression scale also demonstrate well functional effect subjective response treatment well tolerate similar low incidence extrapyramidal symptom however amisulpride associate less weight gain endocrine sexual symptom,Sechter D,2002,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(02)00375-5,12464464,Sechter D; Peuskens J; Fleurot O; Rein W; Lecrubier Y; Amisulpride Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D000077582: Amisulpride; D000704: Analysis of Variance; D016009: Chi-Square Distribution; D002908: Chronic Disease; D016001: Confidence Intervals; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D016037: Single-Blind Method; D013469: Sulpiride,,,https://openalex.org/W2005025328,92,12,1,1243,213,7,en,en
false,la rachianesth sie chez l enfant tude comparative de la bupivaca ne hyperbare avec et sans clonidine,evaluate effect intrathecal clonidine child prospective randomise study child year old randomise two group receive either hyperbaric bupivacaine hyperbaric bupivacaine add clonidine microgram kg assess quality length motor sensory block side effect clonidine hypotension bradycardia sedation clonidine associate prolongation motor block min v min p difference significant postoperative analgesia longer clonidine group min v min mean sd p clonidine associate high incidence hypotension v bradycardia v data suggest intrathecal clonidine microgram kg associate extend duration postoperative analgesia moderate side effect,Kaabachi O,2002,Ann Fr Anesth Reanim,https://doi.org/10.1016/s0750-7658(02)00704-9,12471781,Kaabachi O; Ben Rajeb A; Mebazaa M; Safi H; Jelel C; Ben Ghachem M; Ben Ammar M,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D002045: Bupivacaine; D002648: Child; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D009407: Nerve Block; D011184: Postoperative Period; D011446: Prospective Studies",,,https://openalex.org/W2063547155,103,17,1,911,161,5,fr,en
false,remifentanil clonidine propofol versus sufentanil propofol anesthesia coronary artery bypass surgery,compare remifentanil clonidine propofol regimen conventional sufentanil propofol anesthesia randomize nonblinded trial single university hospital male patient schedule coronary artery bypass graft cabg surgery control group anesthesia induce microg kg sufentanil mg kg etomidate preoxygenation propofol microg kg min sufentanil microg kg h start endotracheal intubation sufentanil stop aortic decannulation remifentanil clonidine group anesthesia start remifentanil microg kg min follow etomidate mg kg propofol start microg kg min endotracheal intubation clonidine infusion start microg h patient receive piritramide mg kg metamizole mg kg transitional analgesia group propofol infusion reduce microg kg min skin closure stop assist spontaneous breathe lead adequate gas exchange main outcome recovery time somatic variable plasma catecholamine level self record pain nausea vomit patient remifentanil clonidine group extubated earlier low plasma epinephrine norepinephrine level transitional analgesia remifentanil clonidine patient similar postoperative analgesic use self report pain side effect score compare sufentanil propofol regimen anesthetic regimen cabg surgery combine remifentanil clonidine propofol provide similar hemodynamics remifentanil clonidine regimen reduces catecholamine level hastens recovery anesthesia,Gerlach K,2002,J Cardiothorac Vasc Anesth,https://doi.org/10.1053/jcan.2002.128415,12486650,Gerlach K; Uhlig T; Hüppe M; Kraatz E; Saager L; Schmitz A; Dörges V; Schmucker P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000759: Adjuvants, Anesthesia; D000316: Adrenergic alpha-Agonists; D000368: Aged; D000701: Analgesics, Opioid; D000762: Anesthesia Recovery Period; D019162: Anesthetics, Combined; D018686: Anesthetics, Intravenous; D002395: Catecholamines; D003000: Clonidine; D001026: Coronary Artery Bypass; D006439: Hemodynamics; D006801: Humans; D007431: Intraoperative Complications; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D015742: Propofol; D000077208: Remifentanil; D017409: Sufentanil",,,https://openalex.org/W2126511338,104,9,1,1763,264,10,en,en
false,modafinil treatment daytime sleepiness parkinson disease double blind randomize crossover placebo control polygraphic trial,assess therapeutic efficacy modafinil treatment increase daytime sleepiness patient parkinson disease pd double blind randomize placebo control crossover study two week treatment block separate week washout phase tertiary parkinson disease care center sleep laboratory university hospital neurology department fifteen patient idiopathic pd daytime sleepiness epworth sleepiness score es administration placebo modafinil single morning dose randomize crossover order modafinil dose mg first mg second treatment week baseline end treatment block sleepiness evaluate use subjective perceive sleepiness es objective measure maintenance wakefulness test twelve patient complete study male female mean age year mean disease duration year epworth score significantly improve modafinil compare placebo p latency sleep maintenance wakefulness test significantly alter modafinil treatment minute placebo minute modafinil p data give mean standard deviation median range result study suggest modafinil improve daytime sleepiness pd patient least subjective behavioral level modafinil treatment may consider ed pd patient otherwise treatable cause excessive daytime sleepiness ed absent,Högl B,2002,Sleep,https://doi.org/10.1093/sleep/25.8.62,12489899,Högl B; Saletu M; Brandauer E; Glatzl S; Frauscher B; Seppi K; Ulmer H; Wenning G; Poewe W,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D006970: Disorders of Excessive Somnolence; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D000077408: Modafinil; D010300: Parkinson Disease; D017286: Polysomnography; D012720: Severity of Illness Index; D014851: Wakefulness,,,https://openalex.org/W138931730,149,21,1,1681,301,6,en,en
false,extrapyramidal symptom profile assess drug induce extrapyramidal symptom scale comparison western scale clinical double blind study schizophrenic patient treat either olanzapine haloperidol,superiority olanzapine haloperidol respect decrease incidence treatment emergent extrapyramidal syndrome eps patient schizophrenia demonstrate study conduct japan western country eps measurement use western country include simpson angus barnes akathisia abnormal involuntary movement scale drug induce extrapyramidal symptom scale diepss use japan aim study clarify diepss capture eps profile baseline prevalence treatment emergent incidence eps japanese schizophrenic patient treat olanzapine haloperidol retrospectively compare assess diepss prevalence incidence eps primarily caucasian schizophrenic patient treat olanzapine haloperidol specifically prevalence incidence dyskinesia akathisia parkinsonism compare japanese trial international trial examine appropriate definition use diepss derive assume comparable prevalence incidence syndrome would observe difference residual antipsychotic exposure initiation study treatment account incidence eps syndrome odds ratio observe similar two study indicate appropriate criterion clinical diagnosis eps syndrome could establish base diepss preliminary retrospective work suggest diepss use operationally define presence absence make clinical diagnosis specific eps syndrome,Inada T,2003,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-200301000-00007,12490774,Inada T; Beasley CM; Tanaka Y; Walker DJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D003937: Diagnosis, Differential; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D000077152: Olanzapine; D010890: Pirenzepine; D015995: Prevalence; D011569: Psychiatric Status Rating Scales; D012189: Retrospective Studies; D012559: Schizophrenia",,,https://openalex.org/W2080718548,232,29,1,1698,262,7,en,en
false,effect divalproex combine olanzapine risperidone patient acute exacerbation schizophrenia,double blind randomize multicenter study investigate use divalproex antipsychotic agent patient hospitalize acute exacerbation schizophrenia patient n meet dsm iv criterion schizophrenia randomly assign receive olanzapine monotherapy risperidone monotherapy divalproex plus olanzapine divalproex plus risperidone day divalproex initiate mg kg day titrate day maximum dosage mg kg day olanzapine risperidone respectively initiate mg day titrate first day respective target fix daily dosage mg day improvement baseline observe evaluation point throughout day treatment period two combination therapy two antipsychotic monotherapy group statistically significant treatment difference favor combination therapy soon day positive negative syndrome scale panss total score derive brief psychiatric rating scale bprsd total score well panss bprsd subscales find confirm post hoc repeat measure analysis variance treatment difference favor combination therapy observe panss total p panss positive scale score p combination therapy antipsychotic monotherapy well tolerate treatment divalproex combination atypical antipsychotic agent result early improvement range psychotic symptom among acutely hospitalize patient schizophrenia evaluation warrant confirm find,Casey DE,2003,Neuropsychopharmacology,10.1038/sj.npp.1300023,12496955,Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D018692: Antimanic Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D014635: Valproic Acid",,,,117,17,1,1678,268,9,en,en
false,modafinil reduces excessive somnolence enhances mood patient myotonic dystrophy,evaluate potential modafinil reduce excessive daytime somnolence ed enhance index quality life mood patient myotonic dystrophy dm forty patient dm randomize receive modafinil placebo day use double blind cross design trial subject complete handgrip strength test spirometry quality life measure rand day subject complete epworth sleepiness scale e stanford sleepiness scale profile mood state pom es score low take modafinil mean mm confidence limit mm compare placebo mm mm p mean score also low modafinil trial placebo trial p pom indicate modafinil decrease fatigue inertia p increase vigor activity tension anxiety p index total mood disturbance score also decrease modafinil trial compare placebo p rand quality life measure energy p health change p significantly enhance modafinil treatment phase change maximal grip strength force expire volume second detect course study headache frequently report adverse event four patient withdraw study three side effect two modafinil ingestion one placebo ingestion modafinil reduces somnolence improve mood patient dm,MacDonald JR,2002,Neurology,https://doi.org/10.1212/01.wnl.0000037481.08283.51,12499477,MacDonald JR; Hill JD; Tarnopolsky MA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000203: Activities of Daily Living; D000293: Adolescent; D000328: Adult; D000339: Affect; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D005541: Forced Expiratory Volume; D018737: Hand Strength; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009223: Myotonic Dystrophy; D009460: Neurologic Examination; D011446: Prospective Studies; D011788: Quality of Life; D012894: Sleep Stages",,,https://openalex.org/W2069882113,92,12,1,1674,324,10,en,en
false,potential cardiotoxicity antipsychotic drug assess heart rate variability,antipsychotic drug cardiac effect consequence pharmacological action recently thioridazine subject restrict indication notice sertindole license withdrawn concern potential cardiotoxicity development new atypical agent heart rate correct qt effect evaluate unclear predictive clinically significant cardiotoxicity sudden death heart rate variability hrv potential index cardiotoxicity find decrease follow antidepressant clozapine study acute hrv change follow antipsychotic agent sixteen healthy male volunteer receive risperidone mg olanzapine mg thioridazine mg placebo randomize cross design subjective effect psychomotor function assay h linear summary statistic non linear scatterplot measure hrv evaluate continuous electrocardiogram record h differential effect single three antipsychotic drug hrv find independent sedative effect olanzapine increase thioridazine decrease hrv risperidone effect hrv sensitive acute effect antipsychotic may prove reliable index potential cardiotoxicity study healthy volunteer patient antipsychotic medication valuable,Silke B,2002,J Psychopharmacol,https://doi.org/10.1177/026988110201600410,12503835,Silke B; Campbell C; King DJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D016292: Conscious Sedation; D004311: Double-Blind Method; D006331: Heart Diseases; D006339: Heart Rate; D006801: Humans; D008297: Male; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010890: Pirenzepine; D011237: Predictive Value of Tests; D011597: Psychomotor Performance; D011930: Reaction Time; D018570: Risk Assessment; D018967: Risperidone; D013881: Thioridazine,,,https://openalex.org/W2085969248,89,12,1,1495,243,11,en,en
false,efficacy olanzapine social anxiety disorder pilot study,base evidence suggest anxiolytic property atypical antipsychotic olanzapine study conduct evaluate whether olanzapine may efficacious treat social anxiety disorder sad study week double blind placebo control evaluation olanzapine monotherapy patient dsm iv diagnosis sad randomize either olanzapine n placebo n initial dose mg day titrate maximum mg day baseline endpoint score brief social phobia scale bsps social phobia inventory spin liebowitz social anxiety scale sheehan disability scale well clinical global impression improvement rating compare olanzapine versus placebo seven subject complete week study four olanzapine group three placebo group intent treat analysis olanzapine yield great improvement placebo primary measure bsps p spin p treatment well tolerate although olanzapine group drowsiness dry mouth olanzapine placebo associate negligible weight gain olanzapine superior placebo primary outcome measure preliminary study sad additional study olanzapine treatment sad warrant,Barnett SD,2002,J Psychopharmacol,https://doi.org/10.1177/026988110201600412,12503837,Barnett SD; Kramer ML; Casat CD; Connor KM; Davidson JR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010698: Phobic Disorders; D010865: Pilot Projects; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales,,,https://openalex.org/W1984770623,64,11,1,1366,239,10,en,en
false,efficacy new generation antipsychotic treatment schizophrenia,advent new atypical antipsychotic medication revolutionize pharmacologic treatment schizophrenia psychotic disorder contrast old conventional antipsychotic agent atypical medication broad spectrum efficacy great efficacy negative cognitive mood symptom low risk extrapyramidal symptom eps tardive dyskinesia due concern surround hematological safety adverse effect clozapine use principally patient refractory treatment antipsychotic agent three universally available atypical agent risperidone olanzapine quetiapine collectively constitute antipsychotic prescription usa despite broad popularity medication rapid adoption general clinical practice limit data compare regard overall efficacy also efficacy specific symptom domain address question two separate analysis undertake first publish short term randomize control clinical trial agent schizophrenia schizoaffective disorder review extent improvement across agent compare amount improvement particular agent across different study vary average improvement similar agent efficacy parameter consider secondly randomize control clinical trial directly compare two agent patient schizophrenia schizoaffective disorder analyze three trial industry sponsor identify difference methodology small difference efficacy minority measure comparison undertaken preponderance data suggest difference efficacy data thus far support assertion differential efficacy risperidone olanzapine quetiapine clear difference side effect profile briefly summarize,Tandon R,2003,Psychoneuroendocrinology,https://doi.org/10.1016/s0306-4530(02)00110-5,12504069,Tandon R; Jibson MD,article,D016428: Journal Article; D016454: Review,D014150: Antipsychotic Agents; D002986: Clinical Trials as Topic; D006801: Humans; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W2127126926,77,10,1,2138,337,11,en,en
false,quetiapine associate increase prolactin secretion contrast haloperidol,typical antipsychotic drug frequently cause hyperprolactinemia even galactorrhea addition side effect may result noncompliance antipsychotic treatment capacity avoid hyperprolactinemia accept one atypical criterion aim present study compare effect haloperidol commonly use antipsychotic quetiapine novel antipsychotic agent use turkey serum prolactin prl level study consist female diagnose schizophrenia accord diagnostic statistical manual mental disorder th ed dsm iv thirty five patient drug free period least week include randomize quetiapine n haloperidol n treatment group patient assess brief psychiatric rating scale bprs positive negative syndrome scale panss extrapyramidal symptom rating scale esr prl level measure begin sixth week study treatment group exhibit significant improvement clinical sign evaluate bprs panss significant difference prl level group begin study control prolactin prl level significantly low quetiapine compare haloperidol group quetiapine group patient exhibit galactorrhea observe two patient haloperidol group galactorrhea relate hyperprolactinemia present study reveal quetiapine associate increase prl secretion contrast conventional antipsychotic haloperidol,Atmaca M,2002,Arch Med Res,https://doi.org/10.1016/s0188-4409(02)00403-4,12505103,Atmaca M; Kuloglu M; Tezcan E; Canatan H; Gecici O,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D005260: Female; D005687: Galactorrhea; D006220: Haloperidol; D006801: Humans; D006966: Hyperprolactinemia; D008875: Middle Aged; D011388: Prolactin; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D013997: Time Factors,,,https://openalex.org/W2105559357,92,13,1,1634,272,10,en,en
false,analgesic effect interscalene block use clonidine analgesic shoulder arthroscopy,use sole analgesic clonidine produce analgesia central neural blockade intraarticular injection axillary block study seek determine whether interscalene clonidine induces analgesia shoulder arthroscopy forty patient schedule shoulder arthroscopy prospectively include double blind study use nerve stimulator technique interscalene catheter insert patient randomly divide two group interscalene group n receive clonidine micro g ml saline catheter ml subcutaneous saline systemic group n receive ml saline catheter clonidine micro g ml subcutaneously patient underwent general anesthesia surgery completion arthroscopy patient receive via patient control analgesia demand bolus ml ropivacaine catheter h lockout period postoperative pain measure every h use visual analog scale va h additional postoperative analgesia available parenteral nalbuphine require va va score recovery room significantly high systemic group compare interscalene group p analgesic duration significantly longer interscalene group p ropivacaine consumption significantly less systemic group p significant difference observe group nalbuphine consumption side effect comparable two group clonidine administer via interscalene catheter enhance analgesia compare systemic administration nevertheless adverse effect clonidine dose limit use routine management postoperative analgesia,Iskandar H,2003,Anesth Analg,https://doi.org/10.1097/00000539-200301000-00052,12505963,Iskandar H; Benard A; Ruel-Raymond J; Cochard G; Manaud B,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000577: Amides; D016058: Analgesia, Patient-Controlled; D000700: Analgesics; D000701: Analgesics, Opioid; D000779: Anesthetics, Local; D001182: Arthroscopy; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009266: Nalbuphine; D009407: Nerve Block; D010147: Pain Measurement; D017933: Peripheral Nervous System; D000077212: Ropivacaine; D012782: Shoulder",,,https://openalex.org/W2069576953,99,14,1,1858,312,14,en,en
false,placebo control trial find association olanzapine exacerbation bipolar mania,publish case report describe apparent induction exacerbation manic like symptom treatment atypical antipsychotic olanzapine risperidone date report uncontrolled clinical experience therefore clarify whether atypical antipsychotic cause manic like state simply fail prevent presumably bipolar patient would increase risk putative adverse event therefore evaluate potential olanzapine exacerbate symptom mania compare placebo treatment bipolar mania two inpatient double blind randomize trial investigate efficacy olanzapine mg daily versus placebo treatment acute mania combine two hundred fifty four subject participate placebo n olanzapine n two study severity mania quantify item young mania rating scale mr post hoc analysis double blind therapy week categorical comparison olanzapine placebo group make worsen worsen baseline mr score locf percentage subject exacerbation endpoint worsen placebo olanzapine p worsen placebo olanzapine p worsen placebo olanzapine p mania rating score worsen patient olanzapine therapy however significantly less common olanzapine placebo control data suggest clinical case report occurrence mania treatment olanzapine possibly atypical antipsychotic reflect exacerbation natural history bipolar illness rather adverse pharmacological effect post hoc analysis pool data two different study,Baker RW,2003,J Affect Disord,https://doi.org/10.1016/s0165-0327(02)00335-x,12507747,Baker RW; Milton DR; Stauffer VL; Gelenberg A; Tohen M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D018450: Disease Progression; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2074870716,98,13,1,1887,314,9,en,en
false,treatment attention deficit hyperactivity disorder stimulant contribute drug use abuse year prospective study,objective examine impact stimulant treatment childhood high school risk substance use dependence abuse young adulthood method total clinic refer hyperactive child follow approximately year adulthood mean year old range adolescent age adult follow probands interview use various substance duration stimulant treatment result duration stimulant treatment significantly associate frequency form drug use young adulthood stimulant treat child great risk ever try drug adolescence significantly great frequency drug use young adulthood stimulant treatment high school also influence drug use adulthood except great use cocaine difference longer significant control severity attention deficit hyperactivity disorder conduct disorder childhood adolescence adulthood stimulant treatment either childhood high school associate great risk formal diagnostic statistical manual mental disorder third edition revise drug dependence abuse disorder adulthood treatment stimulant increase risk ever try illegal substance adulthood except cocaine subsequent analysis show elevate risk primarily mediate severity conduct disorder young adulthood stimulant treatment childhood conclusion study concur previous study find compelling evidence stimulant treatment child attention deficit hyperactivity disorder lead increase risk substance experimentation use dependence abuse adulthood,Barkley RA,2003,Pediatrics,https://doi.org/10.1542/peds.111.1.97,12509561,Barkley RA; Fischer M; Smallish L; Fletcher K,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D015897: Comorbidity; D019955: Conduct Disorder; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D011446: Prospective Studies; D012044: Regression Analysis; D018570: Risk Assessment; D019966: Substance-Related Disorders",,,https://openalex.org/W2058530403,136,17,2,1842,296,15,en,en
false,stimulant therapy attention deficit hyperactivity disorder beget later substance abuse meta analytic review literature,concern exist stimulant therapy youth attention deficit hyperactivity disorder adhd may result increase risk subsequent substance use disorder sud investigate long term study pharmacologically treat untreated youth adhd examine later sud outcome search available prospective retrospective study child adolescent adult adhd information relate childhood exposure stimulant therapy later sud outcome adolescence adulthood conduct pubmed supplement data scientific presentation meta analysis use evaluate relationship stimulant therapy subsequent sud youth adhd general address specifically differential effect alcohol use disorder drug use disorder potential effect covariates six study follow adolescence young adulthood include comprise medicate subject unmedicated subject follow least year pool estimate odds ratio indicate fold reduction risk sud youth treat stimulant compare youth receive pharmacotherapy adhd z confidence interval odds ratio find similar reduction risk late drug alcohol use disorder z study report follow adolescence show great protective effect development sud study follow subject adulthood additional analysis show result could account single study publication bias result suggest stimulant therapy childhood associate reduction risk subsequent drug alcohol use disorder,Wilens TE,2003,Pediatrics,https://doi.org/10.1542/peds.111.1.179,12509574,Wilens TE; Faraone SV; Biederman J; Gunawardene S,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000367: Age Factors; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D015897: Comorbidity; D016001: Confidence Intervals; D006801: Humans; D016017: Odds Ratio; D018570: Risk Assessment; D019966: Substance-Related Disorders,,,https://openalex.org/W2131627337,136,17,2,1875,309,7,en,en
false,bupropion treatment tobacco dependence,tobacco use particularly cigarette smoke global pandemic expect morbidity mortality smoke attributable disease continue rise next year order reduce negative impact worldwide health effective therapy aid smoking cessation must provide current smoker treatment tobacco dependence involve combination behavioural therapy pharmacological treatment common pharmacological treatment include nicotine replacement therapy non nicotine medication include antidepressant antidepressant great weight evidence efficacy treatment tobacco dependence bupropion sustain release bupropion approve treatment tobacco dependence country worldwide efficacy bupropion treatment tobacco dependence attribute blockage dopamine reuptake mesolimbic dopaminergic system area brain believe mediate reward nicotine use drug dependence randomise control clinical trial show bupropion approximately double abstinence rate compare placebo addition long term treatment bupropion may reduce delay smoke relapse bupropion also appear effective treatment smoker recently relapse smoker comorbid psychiatric condition bupropion good adverse event profile risk exist serious adverse effect seizure recent postmarketing surveillance report raise safety concern bupropion although causal relationship bupropion report serious adverse event death establish,Hays JT,2003,CNS Drugs,https://doi.org/10.2165/00023210-200317020-00001,12521356,Hays JT; Ebbert JO,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D006801: Humans; D018570: Risk Assessment; D016540: Smoking Cessation; D014029: Tobacco Use Disorder",,,https://openalex.org/W2122522992,49,7,1,1755,267,14,en,en
false,risk diabetes olanzapine use compare risperidone use,relative risk diabetes among patient undergo risperidone treatment compare patient receive olanzapine cohort form patient least prescription either olanzapine n risperidone n january december record r gie de l assurance maladie du qu bec database patient exclude clozapine dispense study period diagnose diabetes begin antipsychotic therapy new diabetes diagnosis make first antipsychotic prescription period tabulate december censor occur date last service date record use service last month follow crude hazard ratio proportional hazard analysis carry patient develop diabetes olanzapine treatment develop diabetes risperidone treatment crude hazard ratio ci p determine age gender haloperidol use control use proportional hazard analysis increase risk diabetes olanzapine relative risperidone ci p proportional hazard analysis adjust duration olanzapine exposure indicate first month olanzapine treatment associate increase risk diabetes ci p adjust age gender haloperidol use compare risperidone olanzapine associate increase risk develop diabetes study require investigate association,Caro JJ,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1208,12523873,Caro JJ; Ward A; Levinton C; Robinson K,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015331: Cohort Studies; D003920: Diabetes Mellitus; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D012189: Retrospective Studies; D012307: Risk Factors; D018967: Risperidone,,,https://openalex.org/W2016019346,72,11,1,1715,310,7,en,en
true,result proof concept placebo control study atomoxetine child attention deficit hyperactivity disorder,atomoxetine nonstimulant drug study treatment attention deficit hyperactivity disorder adhd atomoxetine highly specific inhibitor presynaptic norepinephrine transporter minimal affinity noradrenergic receptor neurotransmitter transporter receptor result proof concept study report test hypothesis selective inhibitor presynaptic norepinephrine uptake would effective treatment adhd school age child two identical week stratify randomize double blind placebo control trial conduct child meet dsm iv criterion adhd primary efficacy outcome measure mean change baseline endpoint attention deficit hyperactivity disorder rating scale adhd r total score secondary efficacy measure include clinical global impression adhd severity cgi adhd conners parent rating scale revise short form cpr r total patient randomize trial combine study n study n stimulant naive patient randomize atomoxetine placebo methylphenidate patient prior stimulant exposure randomize atomoxetine placebo atomoxetine significantly reduce adhd r total score compare placebo study p change cgi adhd study p study p cpr adhd index study p study p also show atomoxetine statistically significantly superior placebo reduce adhd symptom atomoxetine find well tolerate population pediatric patient two study atomoxetine early development confirm atomoxetine specific selective inhibitor noradrenergic uptake effective treatment child adhd addition atomoxetine find well tolerate,Spencer T,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1209,12523874,Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000928: Antidepressive Agents; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011437: Propylamines; D016896: Treatment Outcome,,,https://openalex.org/W2016483680,132,14,1,1940,320,11,en,en
false,comparison efficacy safety tolerability divalproex sodium olanzapine treatment bipolar disorder,study compare efficacy safety tolerability divalproex olanzapine treatment acute mania associate bipolar disorder randomize week double blind parallel group multicenter study include dsm iv define bipolar disorder type patient hospitalize acute mania randomly assign treatment divalproex olanzapine inpatient period day subject follow outpatient dose adjustment permit inpatient period efficacy assess use change baseline mania rating scale mr score day efficacy measure include brief psychiatric rating scale hamilton rating scale depression clinical global impression part severity illness scale primary safety endpoint change baseline weight safety tolerability endpoint include spontaneous adverse event report change baseline laboratory measure vital sign subject n divalproex n olanzapine randomly assign treatment significant difference group find efficacy variable change baseline day mean mr score change baseline day divalproex olanzapine p significantly p great proportion olanzapine treat subject experience somnolence weight gain edema rhinitis speech disorder slur speech adverse event significantly great divalproex group number laboratory measure also demonstrate significant treatment difference clinical significance many uncertain mean body weight change significantly great olanzapine group lb kg divalproex group lb kg p one death occur study olanzapine group diabetic ketoacidosis significant difference efficacy find treatment group divalproex associate favorable adverse event profile significantly less weight gain olanzapine,Zajecka JM,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1210,12523875,Zajecka JM; Weisler R; Sachs G; Swann AC; Wozniak P; Sommerville KW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D014635: Valproic Acid",,,https://openalex.org/W1996463621,127,21,1,2136,363,13,en,en
false,efficacy quetiapine risperidone depressive symptom outpatient psychosis,treatment psychotic symptom patient mood disorder complex challenge antipsychotic medication individual may associate extrapyramidal symptom eps worsen depression functional impairment atypical antipsychotic quetiapine risperidone associate decrease incidence adverse event eps objective study compare efficacy tolerability quetiapine risperidone treatment depressive symptom outpatient psychosis month multicenter open label trial patient randomly assign ratio quetiapine risperidone drug flexibly dose eligible patient psychosis demonstrate several dsm iv diagnosis include schizoaffective disorder bipolar disorder major depressive disorder delusional disorder alzheimer dementia schizophreniform disorder vascular dementia substance abuse dementia patient classify mood disorder bipolar disorder major depressive disorder schizoaffective disorder efficacy assess use positive negative syndrome scale clinical global impression scale hamilton rating scale depression ham use assess level depressive symptom primary tolerability assessment presence absence substantial eps define eps severe enough require alteration treatment total patient randomly assign quetiapine risperidone mean week mg quetiapine mg risperidone although agent produce improvement mean ham score quetiapine produce great improvement risperidone patient p within mood diagnose population incidence substantial eps p least moderate eps p occur significantly less frequently among patient take quetiapine patient non mood diagnosis incidence substantial eps patient take quetiapine take risperidone p however statistically significant result suggest quetiapine may useful agent management depressive symptom patient psychosis,Sajatovic M,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1211,12523876,Sajatovic M; Mullen JA; Sweitzer DE,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000553: Ambulatory Care; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D018967: Risperidone",,,https://openalex.org/W2025243014,96,12,1,2324,373,13,en,en
false,open study olanzapine fluoxetine psychotic major depressive disorder,although atypical antipsychotic agent commonly use treatment psychotic depression publish prospective study use condition aim study assess interim analysis efficacy atypical antipsychotic agent olanzapine combination selective serotonin reuptake inhibitor antidepressant agent fluoxetine enrol patient woman men mean sd age year dsm iv define major depressive disorder psychotic feature open trial olanzapine mg day plus fluoxetine mg day patient assess visit item hamilton rating scale depression psychotic mood module structure clinical interview dsm iv axis disorder patient edition report result first week treatment twenty two enrol patient complete week open trial drop drop due side effect patient n meet criterion melancholic feature n delusion alone n hallucination alone n report delusion hallucination addition overall rate response intent treat group follow depression response rate n psychosis response rate n psychotic depression response rate n psychotic depression remission rate n combination olanzapine fluoxetine appear promise safe effective treatment psychotic depression double blind study need confirm impression,Matthews JD,2002,J Clin Psychiatry,https://doi.org/10.4088/jcp.v63n1212,12523877,Matthews JD; Bottonari KA; Polania LM; Mischoulon D; Dording CM; Irvin R; Fava M,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003865: Depressive Disorder, Major; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders",,,https://openalex.org/W1968455975,82,12,1,1758,350,7,en,en
false,schizoaffective disorder clinical symptom present day approach treatment,th century serious mental disorder divide two group accord symptomatology course disorder individual dominate disturbance perception think cognition basically diagnose schizophrenic individual mood disturbance basically diagnose affective disorder however patient fit neatly either category jocob kasanin introduce term schizoaffective psychosis scientific discussion involve possibility schizoaffective disorder conceptualize accurately follow type schizophrenia type affective disorder unique disorder separate schizophrenia bipolar disorder arbitrary categorization clinical symptom mark continuum schizophrenia affective illness heterogeneous collection interforms schizophrenia affective disorder however diagnosis schizoaffective disorder include dsm iv tr icd schizoaffective disorder list category schizophrenia psychotic disorder differential diagnosis include basically either schizophrenia affective disorder epidemiological status schizoaffective disorder somewhat uncertain compare schizophrenia dilemma relate diagnosis classification disorder treatment schizoaffective disorder comprises psychotropic medication supportive psychotherapy social care rehabilitation important group psychotropic medication antipsychotic antidepressant mood stabilizer atypical antipsychotic first line medication schizoaffective disorder due pharmacological property case schizoaffective disorder combination atypical antipsychotic antidepressant seem useful novel antidepressant priority combination mention peculiarity mechanism action antidepressant important combination mood stabilizer seem useful treatment certain type schizoaffective disorder well,Danileviciūte V,2002,Medicina (Kaunas),,12532717,Danileviciūte V,article,D016428: Journal Article; D016454: Review,"D000293: Adolescent; D000077582: Amisulpride; D000818: Animals; D000928: Antidepressive Agents; D000929: Antidepressive Agents, Tricyclic; D018692: Antimanic Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002220: Carbamazepine; D002648: Child; D003937: Diagnosis, Differential; D003987: Dibenzothiazepines; D004285: Dogs; D005260: Female; D006801: Humans; D007093: Imidazoles; D007211: Indoles; D016651: Lithium Carbonate; D008297: Male; D008803: Mianserin; D008875: Middle Aged; D000078785: Mirtazapine; D000077152: Olanzapine; D010879: Piperazines; D010890: Pirenzepine; D010919: Placebos; D011379: Prognosis; D011618: Psychotic Disorders; D000069348: Quetiapine Fumarate; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D013469: Sulpiride; D013844: Thiazoles; D013997: Time Factors",,,https://openalex.org/W97584777,84,13,1,2158,306,17,en,en
false,quetiapine treatment patient posttraumatic stress disorder open trial adjunctive therapy,week open label trial combat veteran meet dsm iv criterion posttraumatic stress disorder ptsd treat atypical antipsychotic quetiapine start dose mg bedtime subsequent titration base tolerability clinical response primary outcome measure use clinician administer ptsd scale cap secondary assessment efficacy include positive negative symptom scale panss hamilton rating scale depression clinical global impression scale safety tolerability evaluation include neurologic rating vital sign assessment treatment emergent side effect eighteen patient enrol study complete week open label treatment dose range quetiapine mg daily average mg significant improvement cap score df composite panss rating baseline endpoint general psychopathology panss depressive symptom hrsd also reduce week end point serious adverse event clinically significant change vital sign neurologic rating preliminary open trial suggest quetiapine well tolerate may efficacy reduce ptsd symptom patient adequate response medication study utilize randomize control trial design large sample size need well define potential role quetiapine atypical antipsychotic treatment ptsd,Hamner MB,2003,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200302000-00003,12544370,Hamner MB; Deitsch SE; Brodrick PS; Ulmer HG; Lorberbaum JP,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D013313: Stress Disorders, Post-Traumatic; D019966: Substance-Related Disorders; D014728: Veterans",,,https://openalex.org/W2056838287,104,15,1,1614,270,12,en,en
true,atomoxetine adult adhd two randomize placebo control study,background attention deficit hyperactivity disorder adhd less study adult child treatment study report date small single center trial assess efficacy atomoxetine new highly selective inhibitor norepinephrine transporter conduct two large multicenter treatment trial method two identical study use randomize double blind placebo control design week treatment period conduct adult dsm iv define adhd assess clinical history confirm structure interview study n study ii n primary outcome measure comparison atomoxetine placebo use repeat measure mixed model analysis postbaseline value conners adult adhd rating scale result study atomoxetine statistically superior placebo reduce inattentive hyperactive impulsive symptom assess primary secondary measure discontinuation adverse event among atomoxetine patient study conclusion atomoxetine appear efficacious treatment adult adhd lack abuse potential may advantage many patient,Michelson D,2003,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(02)01671-2,12547466,Michelson D; Adler L; Spencer T; Reimherr FW; West SA; Allen AJ; Kelsey D; Wernicke J; Dietrich A; Milton D,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000928: Antidepressive Agents; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011437: Propylamines; D016896: Treatment Outcome,,,https://openalex.org/W2053295943,75,11,1,1246,204,8,en,en
false,atypical antipsychotic drug improve cognition schizophrenia,green et al green f marder r glynn mcgurk r wirshing w c wirshing et al neurocognitive effect low dose haloperidol two year comparison risperidone biol psychiatry abstract full text full text pdf pubmed scopus google scholar recently report risperidone low dose haloperidol show modest improvement domain cognition patient schizophrenia could replicate previously report advantage risperidone regard study among minority fail find variety benefit risperidone cognition include several previous study group review see harvey keefe harvey p keefe r study cognitive change patient schizophrenia follow novel antipsychotic treatment j psychiatry crossref pubmed scopus google scholar meltzer mcgurk meltzer h mcgurk r effect clozapine risperidone olanzapine cognitive function schizophrenia schizophr bull crossref pubmed scopus google scholar green et al green f marder r glynn mcgurk r wirshing w c wirshing et al neurocognitive effect low dose haloperidol two year comparison risperidone biol psychiatry abstract full text full text pdf pubmed scopus google scholar study prompt carpenter gold carpenter w gold j another view therapy cognition schizophrenia biol psychiatry abstract full text full text pdf pubmed scopus google scholar argue study report beneficial effect risperidone well atypical antipsychotic drug include clozapine quetiapine olanzapine ziprasidone cognition schizophrenia wrongly conclude drug primary effect improve various domain cognition conclude report benefit cognition agent due removal adverse effect typical neuroleptic drug frequent use anticholinergic drug minimize extrapyramidal side effect evidence adverse effect however conflict cassens et al cassens g inglis k appelbaum p gutheil g neuroleptic effect neuropsychological function chronic schizophrenic patient schizophr bull crossref pubmed scopus google scholar meltzer mcgurk meltzer h mcgurk r effect clozapine risperidone olanzapine cognitive function schizophrenia schizophr bull crossref pubmed scopus google scholar spohn strauss spohn h e strauss e relation neuroleptic anticholinergic medication cognitive function schizophrenia j abnorm psychol crossref pubmed google scholar carpenter gold carpenter w gold j another view therapy cognition schizophrenia biol psychiatry abstract full text full text pdf pubmed scopus google scholar cite methodologic issue failure use double blind methodology random assignment treatment inadequate control learn repeat test high typical antipsychotic drug lack control improvement extrapyramidal symptom eps due inherent advantage atypical antipsychotic drug regard contaminate effect industry sponsorship reason reject evidence atypical antipsychotic drug improve cognition evidence offer support conclusion base specific data cognition study example need double blind methodology nonexistent conflict e g learn effect specific cognitive measure,Meltzer HY,2003,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(02)01790-0,12559661,Meltzer HY; Sumiyoshi T,article,D016420: Comment; D003160: Comparative Study; D016422: Letter,D014150: Antipsychotic Agents; D003072: Cognition Disorders; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D009483: Neuropsychological Tests; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2095416747,63,7,1,3934,690,52,en,en
false,addition droperidol clonidine epidural tramadol shortens onset time increase duration postoperative analgesia,compare tramadol alone combination either tramadol clonidine tramadol droperidol regard analgesic adverse effect ethic committee approval patient inform consent obtain epidural catheter insert preoperatively l interspace asa physical status ii adult patient undergo low abdominal surgery anesthesia standardize patient randomly assign one three group group patient receive tramadol mg group ii td patient receive tramadol mg plus droperidol mg group iii tc patient receive tramadol mg plus clonidine microg total volume ml administer single epidural injection postanesthesia care unit onset time analgesia duration analgesia visual analogue pain score sedation nausea score vital sign side effect record duration analgesia similar td tc group significantly long group p group tc patient display significant increase sedation score decrease blood pressure heart rate compare group p adverse effect observe group td nausea score high tc group p pain score respiration rate spo value similar study group conclude epidural tramadol combination droperidol clonidine prolongs duration analgesia however droperidol appear well alternative adverse effect antiemetic property take consideration,Gürses E,2003,Can J Anaesth,https://doi.org/10.1007/bf03017847,12560305,Gürses E; Sungurtekin H; Tomatir E; Balci C; Gönüllü M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D000759: Adjuvants, Anesthesia; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D015360: Analgesia, Epidural; D000701: Analgesics, Opioid; D003000: Clonidine; D004329: Droperidol; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement; D010149: Pain, Postoperative; D020250: Postoperative Nausea and Vomiting; D014147: Tramadol",,,https://openalex.org/W228963100,130,18,1,1639,292,8,en,en
false,change glucose cholesterol level patient schizophrenia treat typical atypical antipsychotic,objective association hyperglycemia hypercholesterolemia use atypical antipsychotic document case report uncontrolled study author goal assess effect clozapine olanzapine risperidone haloperidol glucose cholesterol level hospitalize patient schizophrenia schizoaffective disorder randomize double blind week trial method one hundred fifty seven patient schizophrenia schizoaffective disorder inpatient four hospital originally include study week trial consist week fix dose period week variable dose period plan assessment include fast glucose cholesterol collect baseline end week period follow week period result one hundred eight patient provide blood sample baseline least one point random assignment clozapine olanzapine risperidone haloperidol treatment trial seven patient diabetes glucose level mg dl baseline data patient use statistical analysis initial week period overall significant increase mean glucose level significant increase glucose level end week fix dose period patient give clozapine n give haloperidol n olanzapine group show significant increase glucose level end week variable dose period n fourteen patient develop abnormal glucose level mg dl trial six clozapine four olanzapine three risperidone one haloperidol cholesterol level increase end week fix dose period patient give clozapine n give olanzapine n cholesterol level also increase end week variable dose period patient give olanzapine n conclusion prospective randomize trial clozapine olanzapine haloperidol associate increase plasma glucose level clozapine olanzapine associate increase cholesterol level mean change glucose cholesterol level remain within clinically normal range approximately patient develop abnormally high glucose level course participation study,Lindenmayer JP,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.2.290,12562575,Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001786: Blood Glucose; D002784: Cholesterol; D003024: Clozapine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006760: Hospitalization; D006801: Humans; D006937: Hypercholesterolemia; D006943: Hyperglycemia; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W2105918612,120,16,1,2513,417,15,en,en
false,attenuation olanzapine induce weight gain reboxetine patient schizophrenia double blind placebo control study,since increase norepinephrine availability may account weight reduce effect appetite suppressant author hypothesize addition selective norepinephrine reuptake inhibitor reboxetine may prevent attenuate olanzapine induce weight gain twenty six patient hospitalize first episode dsm iv schizophrenic disorder participate study addition week treatment olanzapine mg day patient randomly allocate double blind design receive either reboxetine mg day n placebo n ten patient group complete week trial patient give olanzapine reboxetine demonstrate significantly low increase body weight mean kg sd give olanzapine placebo mean kg sd significantly patient olanzapine reboxetine group n olanzapine placebo group n gain least initial weight cutoff clinically significant weight gain addition reboxetine olanzapine treatment safe well tolerate patient group difference reduction hamilton depression scale score see favor olanzapine reboxetine group mean difference sd selective norepinephrine reuptake inhibitor reboxetine may reduce olanzapine induce weight gain schizophrenia patient activation adrenergic system may attenuate weight gain induce atypical antipsychotic agent,Poyurovsky M,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.2.297,12562576,Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D018759: Adrenergic Uptake Inhibitors; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015992: Body Mass Index; D004311: Double-Blind Method; D005260: Female; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D009025: Morpholines; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D000077593: Reboxetine; D012559: Schizophrenia; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W1983662592,134,17,1,1526,236,6,en,en
false,mood stabiliser plus risperidone placebo treatment acute mania,double blind trial examine efficacy combination mood stabiliser atypical antipsychotic acute mania determine efficacy risperidone combination mood stabiliser acute mania patient take mood stabiliser randomise week treatment risperidone n placebo n young mania rating scale ymrs score improve rapidly significantly great reduction week risperidone group compare placebo group end point ymrs score decrease point risperidone placebo group respectively significant improvement v placebo p note risperidone group several clinically meaningful measure additionally post hoc analysis exclude carbamazepine treat patient plasma concentration risperidone active moiety low group reveal significantly great reduction p ymrs score risperidone group placebo group incidence adverse event similar group risperidone superior placebo use combination lithium divalproex acute mania,Yatham LN,2003,Br J Psychiatry,https://doi.org/10.1192/bjp.182.2.141,12562742,Yatham LN; Grossman F; Augustyns I; Vieta E; Ravindran A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D018692: Antimanic Agents; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001714: Bipolar Disorder; D010054: Brief Psychiatric Rating Scale; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D018020: Lithium Compounds; D008140: Lorazepam; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D016896: Treatment Outcome; D016312: Treatment Refusal; D014635: Valproic Acid",,,https://openalex.org/W2179185741,76,12,1,1179,193,5,en,en
false,movement disorder child,bradley l schlaggar md phd jonathan w mink md phd assistant professor neurology radiology pediatrics washington university school medicine st louis child hospital st louis mo associate professor neurology neurobiology anatomy pediatrics chief child neurology university rochester school medicine dentistry golisano child hospital strong rochester ny complete article reader able describe prevalence tic disorder characterize treatment tic disorder explain movement disorder differ autism mental retardation describe use stimulant medication treatment attention deficit hyperactivity disorder associate tic disorder compare contrast dopa responsive dystonia cerebral palsy supreme court justice potter stewart try define obscenity articulate well know shall today attempt define kind material understand embrace b ut know see respect similar comment make movement disorder movement disorder typically define dysfunction implementation appropriate target velocity intend movement dysfunction posture presence abnormal involuntary movement performance normal appear movement inappropriate unintended time movement abnormality due weakness abnormal muscle tone may accompany weakness abnormal tone convention movement disorder divide two major category first hyperkinetic movement disorder sometimes refer dyskinesia term refer abnormal repetitive involuntary movement encompass childhood movement disorder include tic chorea ballismus dystonia myoclonus stereotypies tremor second category hypokinetic movement disorder sometimes refer akinetic rigid disorder primary movement disorder category parkinsonism manifest primarily adulthood parkinson disease one many form secondary parkinsonism hypokinetic disorder relatively uncommon child although ataxia weakness spasticity characterize motor dysfunction common convention entity include among movement disorder review focus dyskinesia represent bulk movement disorder child component,Schlaggar BL,2003,Pediatr Rev,https://doi.org/10.1542/pir.24-2-39,12563038,Schlaggar BL; Mink JW,article,D016428: Journal Article; D016454: Review,D002648: Child; D006801: Humans; D009069: Movement Disorders; D015995: Prevalence,,,https://openalex.org/W2151460347,30,4,1,2625,441,19,en,en
true,childhood behavior disorder injury among child youth population base study,association pediatric behavioral disorder injury generally acknowledge study measure risk injury context large population base study free cohort bias examine association childhood behavior disorder cbds indicate prescription methylphenidate mph variety injury outcome evaluate risk injury among child control know demographic correlate population base database analysis child british columbia bc age december comparison prescribe mph therefore place cbd group n n demographic information collect follow age sex measure socioeconomic status region residence common type childhood injury bc international classification disease ninth revision n code fracture open wound poison toxic effect concussion intracranial burn e code fall postoperative complication motor vehicle accident strike object adverse effect drug suffocation drown bc link health data set bc triplicate prescription program control know demographic correlate odds injury great among treat mph presume behavioral disorder injury characterize either type confidence interval cause confidence interval injury increase risk extend unexpected category injury postoperative complication adverse effect drug child cbds time odds sustain injury variety type variety cause even control know demographic correlate without behavioral disorder risk child extend beyond might directly associate impulsivity overactivity injury prevention strategy aim group child youth would beneficial policy maker account increase risk wide variety injury group child youth,Brehaut JC,2003,Pediatrics,https://doi.org/10.1542/peds.111.2.262,12563049,Brehaut JC; Miller A; Raina P; McGrail KM,article,"D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D002170: Canada; D002648: Child; D002653: Child Behavior Disorders; D002675: Child, Preschool; D016208: Databases, Factual; D011307: Drug Prescriptions; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011159: Population Surveillance; D015995: Prevalence; D012737: Sex Factors; D014947: Wounds and Injuries",,,https://openalex.org/W2070811057,92,13,1,2241,385,6,en,en
false,safety dexamphetamine acute ischemic stroke,amphetamine report enhance recovery experimental stroke result first trial human inconclusive limit information available treatment safety study intend investigate safety tolerability dexamphetamine patient acute cerebral ischemia forty five patient cerebral ischemia enrol within hour onset symptom patient randomize dose level mg orally twice daily placebo consecutive day adverse event blood pressure heart rate body temperature consciousness level functional outcome measure follow daily treatment follow make day month stroke mean systolic diastolic blood pressure heart rate increase mm hg mm hg bpm respectively dexamphetamine treatment compare placebo p difference dexamphetamine placebo regard adverse event body temperature consciousness level treatment benefit dexamphetamine neurological functional outcome p difference maintain follow overall dexamphetamine safe well tolerate patient acute cerebral ischemia blood pressure heart rate increase treatment comparison placebo observation may important future plan amphetamine trial change variable observe interfere clinical outcome suggestion improvement outcome must confirm study,Martinsson L,2003,Stroke,https://doi.org/10.1161/01.str.0000050161.38263.ae,12574563,Martinsson L; Wahlgren NG,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000284: Administration, Oral; D000368: Aged; D001794: Blood Pressure; D001831: Body Temperature; D002545: Brain Ischemia; D003243: Consciousness; D003913: Dextroamphetamine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004341: Drug Evaluation; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D020521: Stroke; D016896: Treatment Outcome",,,https://openalex.org/W2034711575,49,7,1,1641,277,10,en,en
false,development new day formulation methylphenidate treatment attention deficit hyperactivity disorder,duration action immediate release formulation methylphenidate hydrochloride short hour time daily dose think maximize effectiveness across hour day initial sustain release formulation methylphenidate reduce efficacy compare immediate release methylphenidate well accept tachyphylaxis hypothesize account reduce effect ascend drug delivery pattern propose overcome acute tolerance child attention deficit hyperactivity disorder evaluate laboratory school characterize onset duration effect variety methylphenidate regimen proof concept study experimental ascend profile establish initial bolus follow small increase immediate release methylphenidate capsule administer every minute hour two proof product study new oral day formulation deliver methylphenidate osmotic pump process base oros alza corp mountain view calif technology hereafter refer oros methylphenidate conduct pharmacokinetic study pharmacodynamic study experimental ascend profile match effect standard regimen methylphenidate time daily pharmacokinetic study oros methylphenidate treatment produce rapid rise follow increase plasma concentration peak hour administration pharmacodynamic study oros methylphenidate treatment match time daily dose methylphenidate onset duration efficacy study demonstrate translation basic science find acute tolerance clinical methylphenidate clinical application selection new drug delivery pattern methylphenidate approach produce new product oros methylphenidate concerta prove predict rapid onset hour long duration efficacy hour single administration morning,Swanson J,2003,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.60.2.204,12578439,Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002214: Capsules; D000697: Central Nervous System Stimulants; D002648: Child; D002985: Clinical Protocols; D015331: Cohort Studies; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D016503: Drug Delivery Systems; D006801: Humans; D007408: Intestinal Absorption; D008774: Methylphenidate; D010919: Placebos; D013618: Tachyphylaxis; D016896: Treatment Outcome",,,https://openalex.org/W1986046877,124,14,1,2097,321,8,en,en
false,self administer psychosocial treatment child family,self administer psychosocial treatment child health problem potential circumvent barrier traditional model care convenient inexpensive family type problem may effective therapist base care review past research child parent facilitate self administer treatment find strong evidence base exist support format manual multimedia base treatment others inspirational literature support group practical ethical legal issue associate self administer treatment discus well avenue future research psychologist health care system respond opportunity associate self administer treatment child likely affect face profession health child future,Elgar FJ,2003,J Clin Psychol,https://doi.org/10.1002/jclp.10132,12579548,Elgar FJ; McGrath PJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D002648: Child; D002653: Child Behavior Disorders; D002662: Child Health Services; D004992: Ethics, Medical; D005192: Family Health; D006801: Humans; D001523: Mental Disorders; D019212: Multimedia; D010287: Parent-Child Relations; D010353: Patient Education as Topic; D012648: Self Care; D016896: Treatment Outcome",,,https://openalex.org/W2091971788,67,7,1,897,141,5,en,en
false,combination therapy clinical practice lead way,article abstractletter editor sir antipsychotic polypharmacy squander precious resource dr stahl primary recommendation give adequate extend trial atypical antipsychotic alternative combination therapy good advice doubt largely accept clinical practice however recommendation try agent high particularly olanzapine quetiapine suffer difficulty author note combination therapy namely option support good control data atypicality may compromise cost increase dramatically,Welch R,2003,J Clin Psychiatry,https://doi.org/10.4088/jcp.v64n0117a,12590630,Welch R; Snaterse M,article,D016420: Comment; D016422: Letter,"D014150: Antipsychotic Agents; D003024: Clozapine; D004334: Drug Administration Schedule; D016527: Drug Costs; D004359: Drug Therapy, Combination; D006801: Humans; D019338: Polypharmacy; D010818: Practice Patterns, Physicians'; D011570: Psychiatry; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia",,,https://openalex.org/W2011711616,58,10,1,630,101,4,en,en
false,efficacy methylphenidate patient cerebral palsy attention deficit hyperactivity disorder adhd,objective study short term efficacy safety methylphenidate patient dual diagnosis cerebral palsy attention deficit hyperactivity disorder adhd twenty nine patient year old cerebral palsy adhd complete study prospective crossover double blind paradigm patient treat methylphenidate placebo week parent teacher complete modify abbreviate conners rating scale begin study end first second month treatment methylphenidate placebo parent contact weekly report side effect methylphenidate treatment assess teacher rating result significant improvement adhd symptomatology df p however trend improvement note parent rating conclusion study patient continue methylphenidate month side effect minimal exception transient hallucination one patient child cerebral palsy adhd methylphenidate effective render valuable adjunct overall medical therapy,Gross-Tsur V,2002,J Child Neurol,https://doi.org/10.1177/08830738020170121401,12593456,Gross-Tsur V; Shalev RS; Badihi N; Manor O,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002547: Cerebral Palsy; D002648: Child; D002675: Child, Preschool; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D008774: Methylphenidate; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome",,,https://openalex.org/W2156937504,111,15,1,1204,213,9,en,en
false,effect methylphenidate three form response inhibition boy ad hd,current study aim investigate effect three methylphenidate mph placebo inhibition prepotent response inhibition ongoing response interference control attention deficit hyperactivity disorder ad hd b study dose response relation three form response inhibition meet aim follow task select two version stop paradigm inhibition prepotent response circle trace task recently develop follow task inhibition ongoing response stroop color word test eriksen flanker task interference control task administer boy ad hd four treatment condition mg mph mg mph mg mph placebo pseudorandomized multiple blind placebo control within subject design use hypothesize inhibitory control child ad hd improve mph compare placebo however effect significant inhibition prepotent response inhibition ongoing response measure follow task interference control relation treatment condition response linear however linear relation due improve inhibitory control mph compare placebo effect mph dose observe response inhibition measure,Scheres A,2003,J Abnorm Child Psychol,https://doi.org/10.1023/a:1021729501230,12597703,Scheres A; Oosterlaan J; Swanson J; Morein-Zamir S; Meiran N; Schut H; Vlasveld L; Sergeant JA,article,D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D019958: Attention Deficit and Disruptive Behavior Disorders; D000697: Central Nervous System Stimulants; D002648: Child; D002653: Child Behavior Disorders; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006801: Humans; D007266: Inhibition, Psychological; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011930: Reaction Time; D016896: Treatment Outcome",,,https://openalex.org/W2106367437,87,15,1,1418,249,8,en,en
false,effect spinal bupivacaine combination either epidural clonidine bupivacaine administer incision site postoperative outcome patient undergo lumbar laminectomy,spinal anesthesia numerous advantage general anesthesia patient undergo lumbar laminectomy microdisk surgery study evaluate addition epidural clonidine bupivacaine inject incision site postoperative outcome variable patient undergo low spine procedure use spinal anesthesia one hundred twenty patient lumbar spine surgery receive bupivacaine spinal anesthesia supplement g epidural clonidine without incisional bupivacaine epidural placebo plus incisional bupivacaine placebo incisional saline demographic data intraoperative hemodynamics blood loss pain nausea urinary retention hospital discharge variable compare use either analysis variance analysis demographic similar iv fluid blood loss incidence intraoperative bradycardia hypotension different among group postanesthesia care unit pain score low demand analgesic less patient receive clonidine subcutaneous bupivacaine patient receive epidural clonidine also improve postoperative hemodynamics hospital discharge urinary retention variable different conclude epidural clonidine supplement spinal anesthesia produce perioperative complication improve postoperative pain hemodynamic stability patient undergo low spine procedure,Jellish WS,2003,Anesth Analg,https://doi.org/10.1213/01.ane.0000049682.48703.44,12598277,Jellish WS; Abodeely A; Fluder EM; Shea J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000762: Anesthesia Recovery Period; D000767: Anesthesia, Epidural; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D001794: Blood Pressure; D002045: Bupivacaine; D003000: Clonidine; D005260: Female; D006339: Heart Rate; D006801: Humans; D007279: Injections, Subcutaneous; D007796: Laminectomy; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement; D020250: Postoperative Nausea and Vomiting; D013116: Spinal Cord",,,https://openalex.org/W2081284101,203,28,1,1492,222,10,en,en
false,intramuscular preparation antipsychotic,intramuscular formulation antipsychotic sub divide two group basis pharmacokinetic feature short act preparation long act depot preparation short act intramuscular formulation use manage acute psychotic episode hand long act compound also call depot administer antipsychotic maintenance treatment ensure compliance eliminate bioavailability problem relate absorption first pas metabolism adverse effect antipsychotic study particular respect oral versus short long act intramuscular formulation different compound short term intramuscular preparation main risk classical compound hypotension extrapyramidal side effect eps data incidence eps depot formulation controversial study point incidence eps significantly high patient receive depot preparation whereas others show difference oral depot antipsychotic study strategy switch patient oral depot treatment suggest procedure reasonably well tolerate clinical practice depot antipsychotic therapy usually begin oral treatment still administer gradual taper oral dose efficacy pharmacodynamics clinical pharmacokinetics haloperidol decanoate fluphenazine enanthate decanoate clopenthixol decanoate zuclopenthixol decanoate acutard flupenthixol decanoate perphenazine enanthate pipothiazine palmitate undecylenate fluspirilene review addition intramuscular preparation atypical antipsychotic clinical u review olanzapine ziprasidone available short act preparation risperidone date novel antipsychotic available depot formulation date acutely ill agitate psychotic patient treat high parenteral typical antipsychotic often cause serious eps especially dystonic reaction intramuscular formulation novel antipsychotic olanzapine ziprasidone appear good tolerability profile typical compound show equivalent efficacy parenteral typical agent acute treatment psychosis however parenteral depot formulation atypical antipsychotic yet widely available,Altamura AC,2003,Drugs,https://doi.org/10.2165/00003495-200363050-00004,12600227,Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D014150: Antipsychotic Agents; D002090: Butyrophenones; D003692: Delayed-Action Preparations; D006801: Humans; D007273: Injections, Intramuscular; D010640: Phenothiazines; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia",,,https://openalex.org/W2013903790,44,4,1,2484,367,13,en,en
false,switch patient aripiprazole antipsychotic agent multicenter randomize study,rationale switch patient one antipsychotic another lead tolerability problem transient symptom exacerbation important compare switch strategy determine method produce best possible patient outcome objective investigate efficacy safety tolerability three dose strategy switch chronic stable patient schizophrenia current oral antipsychotic monotherapy daily oral aripiprazole monotherapy method patient week open label outpatient study randomize immediate initiation mg day aripiprazole simultaneous immediate discontinuation current antipsychotic immediate initiation mg day aripiprazole taper current antipsychotic week titrate aripiprazole mg day week simultaneously taper current antipsychotic efficacy assessment include panss cgi cgi score safety assessment include adverse event aes record evaluation extrapyramidal symptom eps vital sign ecg clinical laboratory test result efficacy aripiprazole maintain study numerical improvement compare baseline three group overall incidence aes broadly comparable across group aes generally mild moderate severity time limited discontinuation due aes comparable across group deterioration eps occur group reduction body weight plasma prolactin level follow switch aripiprazole comparable across three group conclusion three strategy evaluate use safely switch patient aripiprazole antipsychotic monotherapy furthermore patient symptom may continue improve switch aripiprazole,Casey DE,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-002-1344-3,12610718,Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG; Aripiprazole Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D010879: Piperazines; D015363: Quinolones; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W2067763161,98,13,1,1888,299,16,en,en
false,comparative effectiveness antipsychotic drug,back table content previous article next article letter editorfull accesscomparative effectiveness antipsychotic drugsadityanjee adityanjeesearch paper author minneapolis minn publish online mar http doi org appi ajp aaboutsectionsview epub toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail editor caution need interpret result study dr volavka et al article accompany editorial acknowledge cohort effect rule dose risperidone high funding obtain eli lilly company olanzapine arm study include month study start quetiapine arm although drug become available around time use haloperidol comparison either loxapine molindone comparator first generation antipsychotic drug questionable offer certain advantage first generation antipsychotic author concept suboptimal response less rigorous widely accept criterion kane et al treatment resistance score positive negative syndrome scale require study entry factor may contribute entry treatment responsive patient mild illness high haloperidol mean mg day sd approximately chlorpromazine equivalent unit second phase variable dose justify low mean mg day sd haloperidol efficacious patient acute schizophrenia high cause significant increase extrapyramidal side effect positron emission tomography experiment perform farde et al suggest sufficient dopamine receptor occupancy haloperidol low mg day high haloperidol treatment resistant patient schizophrenia provide advantage base receptor occupancy advantage atypical antipsychotic term efficacy dropout disappear dos mg day haloperidol use optimal dose risperidone mg day therapeutic window poor response result high love et al williams incremental clinical improvement chronic psychosis see dos mg day chlorpromazine equivalent although significant increase adverse reaction observe clinical antipsychotic trial intervention effectiveness study sponsor national institute mental health may offer insight however study also limit include one comparator first generation drug category study comparative effectiveness first generation versus newer antipsychotic definitive without use loxapine molindone treatment arm reference lewis da atypical antipsychotic medication treatment schizophrenia editorial j psychiatry link google scholar kane j honigfeld g singer j meltzer h clozapine treatment resistant schizophrenic double blind comparison chlorpromazine arch gen psychiatry crossref medline google scholar mcevoy jp hogarty ge steingard optimal dose neuroleptic acute schizophrenia control study neuroleptic threshold high haloperidol dose arch gen psychiatry crossref medline google scholar farde l nordstrom al wiesel fa pauli halldin c sedvall g positron emission tomographic analysis central dopamine receptor occupancy patient treat classical neuroleptic clozapine relation extrapyramidal side effect arch gen psychiatry crossref medline google scholar wolkin barouche f wolf ap rotrosen j fowler j shiue cy cooper tb brodie jd dopamine blockade clinical response evidence two biological subgroup schizophrenia j psychiatry link google scholar geddes j freemantle n harrison p bebbington p atypical antipsychotic treatment schizophrenia systematic overview meta regression analysis br med j crossref medline google scholar bollini p pampallona orza mj adam chalmers tc antipsychotic drug bad meta analysis publish randomize control trial psychol med crossref medline google scholar figuresreferencescited bydetailscited bynone volume issue march page metric history publish online march publish print march,Adityanjee,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.3.590-a,12611852,Adityanjee,article,D016420: Comment; D003160: Comparative Study; D016422: Letter,D014150: Antipsychotic Agents; D002908: Chronic Disease; D003024: Clozapine; D015988: Cohort Effect; D015331: Cohort Studies; D006220: Haloperidol; D006801: Humans; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2165847991,48,5,1,4830,802,30,en,en
false,pharmacokinetic safety assessment concurrent administration risperidone donepezil,treatment alzheimer disease sometimes use combination drug dementia frequently associate behavioral symptom risperidone donepezil metabolize cytochrome p raise possibility drug interaction combination therapy objective study determine whether significant drug interaction occur concomitant administration donepezil risperidone open label three way crossover study healthy men randomly assign receive mg risperidone twice daily mg donepezil daily drug consecutive day follow day washout period treatment ratio auc associate confidence interval ci risperidone active moiety define risperidone plus hydroxyrisperidone ratio ci donepezil ratio ci within bioequivalence range treatment ratio cmax associate ci risperidone active moiety ratio ci donepezil ratio ci also within bioequivalence range therefore significant pharmacokinetic difference occur either risperidone active moiety donepezil give alone combination adverse event predominantly headache nervousness somnolence minor comparable treatment group result indicate clinically meaningful drug interaction occur risperidone mg daily donepezil mg daily steady state therefore dosage adjustment require drug combine dosage regimen study additional investigation warrant determine potential interaction elderly patient dementia may eliminate risperidone donepezil slowly thus vulnerable clinical drug interaction young healthy subject examine study,Zhao Q,2003,J Clin Pharmacol,https://doi.org/10.1177/0091270002239827,12616671,Zhao Q; Xie C; Pesco-Koplowitz L; Jia X; Parier JL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D019540: Area Under Curve; D001682: Biological Availability; D018592: Cross-Over Studies; D000077265: Donepezil; D004347: Drug Interactions; D006801: Humans; D007189: Indans; D008297: Male; D010880: Piperidines; D018967: Risperidone,,,https://openalex.org/W2163487223,96,11,1,2016,345,10,en,en
false,neuropsychiatric effect cardiovascular drug therapy,various cardiovascular drug show neuropsychiatric effect harmful therapeutically beneficial patient example sedation mental depression describe patient receive centrally act antihypertensive drug beta adrenergic blocker relate antiadrenergic action contrast antiadrenergic action agent like clonidine use treat opiate alcohol nicotine withdrawal beta blocker use treat symptom performance anxiety migraine psychocardiac disorder antiarrhythmic drug associate delirium digitalis toxicity show cause hallucination mania euphoria depression calcium channel blocker verapamil use adjunctive treatment patient bipolar disorder since neuropsychiatric symptom see patient cardiovascular disease clinician aware possible relationship symptom concurrent cardiovascular drug therapy,Keller S,2003,Cardiol Rev,https://doi.org/10.1097/01.crd.0000053453.89776.2d,12620132,Keller S; Frishman WH,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000924: Anticholesteremic Agents; D002317: Cardiovascular Agents; D002490: Central Nervous System; D004232: Diuretics; D006801: Humans; D001523: Mental Disorders,,,https://openalex.org/W2090204159,55,6,1,1080,164,6,en,en
false,randomize trial modafinil treat subjective daytime sleepiness patient parkinson disease,abstract assess safety efficacy modafinil treatment excessive daytime sleepiness patient parkinson disease pd single site randomize double blind placebo control crossover study pd patient epworth sleepiness scale e score receive either placebo modafinil mg day week follow washout week alternate treatment week e data demonstrate carryover effect change baseline e score compare two treatment period es score placebo group go mean sd modafinil group go p significant carryover effect measure patient clinical global impression change improve modafinil compare placebo p total patient report improvement modafinil placebo significant improvement worsen updrs subscores iii time tap test time vital sign electrocardiogram lab test unchanged modafinil well tolerate data demonstrate small sample size administration mg day modafinil associate side effect modestly effective treatment excessive daytime sleepiness patient pd,Adler CH,2003,Mov Disord,https://doi.org/10.1002/mds.10390,12621632,Adler CH; Caviness JN; Hentz JG; Lind M; Tiede J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D006970: Disorders of Excessive Somnolence; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D000077408: Modafinil; D010300: Parkinson Disease; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D016896: Treatment Outcome; D014851: Wakefulness,,,https://openalex.org/W2012540611,109,15,1,1479,284,12,en,en
false,treatment weight gain fluoxetine olanzapine treat schizophrenic outpatient,significant weight gain side effect associate olanzapine treatment patient investigate efficacy high dose fluoxetine weight reduce agent patient develop early weight gain olanzapine treatment patient gain baseline weight initial week olanzapine treatment n randomize double blind treatment placebo fluoxetine mg day clinical weight weight relate measure assess fluoxetine fail demonstrate weight reduce effect fluoxetine group baseline mean kg sd last mean kg sd placebo group baseline mean kg sd last mean kg sd f df p differential effect psychopathology extrapyramidal side effect weight relate measure placebo fluoxetine group serotonin reuptake inhibitor probably practical option counteract weight gain induce atypical antipsychotic atypical induce weight gain may result mechanism ht reuptake blockade,Bustillo JR,2003,Neuropsychopharmacology,https://doi.org/10.1038/sj.npp.1300089,12629532,Bustillo JR; Lauriello J; Parker K; Hammond R; Rowland L; Bogenschutz M; Keith S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000704: Analysis of Variance; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010045: Outpatients; D010890: Pirenzepine; D011446: Prospective Studies; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W1992683185,88,10,1,1101,181,8,en,en
false,randomize placebo control trial risperidone treatment aggression agitation psychosis dementia,randomize double blind placebo control trial examine efficacy safety risperidone treatment aggression agitation psychosis elderly nursing home patient dementia elderly patient dsm iv diagnosis dementia alzheimer type vascular dementia combination e mixed dementia significant aggressive behavior randomize receive period week flexible dose either placebo risperidone solution maximum mg day outcome measure cohen mansfield agitation inventory cmai behavioral pathology alzheimer disease behave ad rating scale clinical global impression severity cgi change cgi c scale total patient randomize treatment risperidone placebo patient receive least one dose study drug trial complete patient placebo group patient risperidone group mean se dose risperidone mg day primary endpoint study difference baseline endpoint cmai total aggression score show significant reduction aggressive behavior risperidone versus placebo p similar improvement also see cmai total non aggression subscale p behave ad total p psychotic symptom subscale p endpoint cgi cgi c score indicate significantly great improvement risperidone compare placebo p overall risperidone placebo group respectively report least adverse event somnolence urinary tract infection common risperidone treatment whereas agitation common placebo significant difference number patient report extrapyramidal symptom risperidone placebo group treatment low dose mean mg day risperidone result significant improvement aggression agitation psychosis associate dementia,Brodaty H,2003,J Clin Psychiatry,https://doi.org/10.4088/jcp.v64n0205,12633121,Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000374: Aggression; D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D015140: Dementia, Vascular; D004311: Double-Blind Method; D005260: Female; D006707: Homes for the Aged; D006801: Humans; D008297: Male; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation; D012107: Research Design; D018967: Risperidone; D016896: Treatment Outcome",,,https://openalex.org/W1985675058,122,18,1,2140,385,10,en,en
false,low dose risperidone adjunctive therapy irritable aggression posttraumatic stress disorder,increase aggressive behavior occur association posttraumatic stress disorder ptsd study test hypothesis low dose risperidone reduce aggression ptsd relate symptom combat veteran subject male combat veteran ptsd score high cluster hyperarousal patient checklist ptsd military version pcl subject randomly assign either risperidone placebo treatment group drug administer week treatment period double blind manner subject receive either risperidone mg day n match placebo n tablet first week treatment period dose risperidone could increase mg day basis response prerandomization psychotropic regimen continue subject evaluate pcl overt aggression scale modify outpatient oas comparison placebo treatment reduction score baseline last week treatment significantly great oas irritability pcl cluster b intrusive thought subscales pcl total scale result suggest low dose risperidone administration reduce irritability intrusive thought combat relate ptsd,Monnelly EP,2003,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200304000-00012,12640221,Monnelly EP; Ciraulo DA; Knapp C; Keane T,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000374: Aggression; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D006801: Humans; D007508: Irritable Mood; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D013313: Stress Disorders, Post-Traumatic; D016896: Treatment Outcome; D014728: Veterans",,,https://openalex.org/W2063070002,100,12,1,1309,214,11,en,en
false,open label trial modafinil augmentation patient partial response antidepressant therapy,,Markovitz PJ,2003,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-200304000-00017,12640225,Markovitz PJ; Wagner S,article,D016430: Clinical Trial; D016422: Letter,"D000293: Adolescent; D000328: Adult; D000928: Antidepressive Agents; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D003865: Depressive Disorder, Major; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D016896: Treatment Outcome",,,https://openalex.org/W2312189038,105,14,1,0,0,0,en,
false,management attention deficit hyperactivity disorder use effective paradigm,management adhd pose great problem psychologist psychiatrist different behavioural scientist multi model approach combine pharmacologic different non pharmacologic intervention effective form therapy present study theta feedback non pharmacologic technique show beneficial role among low medicate adhd case present study also signify role multi model intervention management adhd,Dixit SP,2002,Indian J Med Sci,,12645162,Dixit SP; Pandey MN; Dubey GP,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D001676: Biofeedback, Psychology; D002648: Child; D003071: Cognition; D003131: Combined Modality Therapy; D005260: Female; D006801: Humans; D008297: Male; D008568: Memory; D008774: Methylphenidate; D011930: Reaction Time; D013826: Theta Rhythm; D016896: Treatment Outcome",,,https://openalex.org/W1588986548,85,12,1,495,77,4,en,en
false,effect antipsychotic sexual dysfunction endocrine functioning,literature review preliminary result new study present show treatment classical antipsychotic well risperidone induces sexual dysfunction patient antipsychotic also frequently induce amenorrhoea galactorrhoea although comparative study rare likely prolactin spar antipsychotic recently show randomized trial olanzapine versus risperidone induce less sexual side effect study become apparent prolactin elevation induce classical antipsychotic risperidone probably factor induce sexual dysfunction amenorrhoea galactorrhoea role factor induce sexual dysfunction like sedation proportional variant blockade testosterone dopamine serotonin discus finally conclude sexual hormonal effect antipsychotic although clearly important often neglect research clinical practice lower dosage switch prolactin spar antipsychotic often reduce sexual side effect amenorrhoea galactorrhoea,Knegtering H,2003,Psychoneuroendocrinology,https://doi.org/10.1016/s0306-4530(02)00130-0,12650685,Knegtering H; van der Moolen AE; Castelein S; Kluiter H; van den Bosch RJ,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D014150: Antipsychotic Agents; D004702: Endocrine Glands; D005260: Female; D006801: Humans; D008297: Male; D011388: Prolactin; D012559: Schizophrenia; D020018: Sexual Dysfunctions, Psychological",,,https://openalex.org/W2049924226,88,13,1,1140,173,6,en,en
false,nizatidine prevention weight gain olanzapine double blind placebo control trial,weight gain associate treatment olanzapine psychotropic agent nizatidine histamine h receptor antagonist propose weight reduce effect double blind trial evaluate efficacy nizatidine limit weight gain patient schizophrenia relate disorder treat olanzapine week initial screening period patient randomize receive olanzapine mg either placebo nizatidine mg b mg b significantly less weight gain observe average week olanzapine nizatidine mg b p compare olanzapine placebo difference statistically significant week nizatidine well tolerate adversely affect clinical outcome nizatidine mg b may early transient effect limit weight gain potential early effect appear diminish eliminate week,Cavazzoni P,2003,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(02)00127-x,12650950,Cavazzoni P; Tanaka Y; Roychowdhury SM; Breier A; Allison DB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001569: Benzodiazepines; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016567: Nizatidine; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia; D015430: Weight Gain",,,https://openalex.org/W2158954031,97,13,1,1014,174,10,en,en
false,intrathecal clonidine add bupivacaine morphine spinal anesthetic improves postoperative analgesia total knee arthroplasty,postoperative pain total knee arthroplasty tka severe complicate early physical therapy test hypothesis intrathecal clonidine would improve postoperative analgesia tka use hyperbaric bupivacaine spinal anesthetic double blind placebo control protocol asa physical status iii patient undergo either single bilateral tka randomize group follow ml solution add mg hyperbaric bupivacaine sterile saline morphine g morphine g clonidine g morphine g clonidine g h postoperatively measure visual analog scale va cumulative iv morphine consumption hemodynamics nausea ancillary drug side effect primary comparison clonidine morphine group versus morphine group find combine administration intrathecal clonidine morphine decrease h iv morphine consumption mg p compare intrathecal morphine alone correspond decrease va score cm h postoperatively p adverse side effect similar among group exception relative hypotension clonidine group postoperative hour conclude coadministration intrathecal clonidine morphine decrease h iv morphine consumption improve h va score compare intrathecal morphine alone,Sites BD,2003,Anesth Analg,https://doi.org/10.1213/01.ane.0000055651.24073.59,12651665,Sites BD; Beach M; Biggs R; Rohan C; Wiley C; Rassias A; Gregory J; Fanciullo G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D019645: Arthroplasty, Replacement, Knee; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D008875: Middle Aged; D009020: Morphine; D010147: Pain Measurement; D010149: Pain, Postoperative; D011446: Prospective Studies",,,https://openalex.org/W1993084691,132,15,1,1537,281,9,en,en
false,smoke withdrawal dynamic ii improve test withdrawal relapse relation,article author assess whether continuously scale symptom parameter derive growth model piasecki et al link smoke long term follow use data large scale clinical trial n result reveal high withdrawal intercept positive linear slope great volatility positively associate relapse cigarette coefficient indicate smoking induce withdrawal reduction negatively relate relapse model key around first lapse smoking destine lapse report severe withdrawal abstinence withdrawal pattern discriminate group define accord lapse duration find complement earlier heterogeneity study implicate pattern change withdrawal symptom time factor strongly associate smoking relapse,Piasecki TM,2003,J Abnorm Psychol,https://doi.org/10.1037/0021-843x.112.1.14,12653410,Piasecki TM; Jorenby DE; Smith SS; Fiore MC; Baker TB,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D016642: Bupropion; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D009538: Nicotine; D012008: Recurrence; D012720: Severity of Illness Index; D012907: Smoking; D016540: Smoking Cessation; D000074606: Smoking Prevention; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W1976972165,80,12,2,887,139,4,en,en
false,evaluation effect lofexidine clonidine naloxone precipitate withdrawal opioid dependent human,examine efficacy lofexidine alpha adrenergic agonist suppress opioid withdrawal symptom opioid dependent human patient laboratory condition use naloxone challenge procedure randomize within subject cross design drug administration take place double blind triple dummy condition bed patient hospital research unit dedicate conduct behavioral pharmacology study eight healthy adult volunteer two female six male history polysubstance abuse current physical dependence opioids participant stabilize onto methadone maintain mg day p throughout study oral placebo lofexidine mg p clonidine mg p test pre treatment combination three intramuscular naloxone mg separate experimental session array physiological index e g heart rate blood pressure pupil diameter well number subjective observer rating scale sensitive opioid withdrawal effect expect lofexidine clonidine produce dose related decrease blood pressure heart rate subjective effect naloxone increase opioid withdrawal sign symptom dose time dependent fashion although lofexidine clonidine reduce cardiovascular response naloxone challenge close inspection data reveal occur extent baseline physiological parameter reduce neither drug significantly modify overall magnitude response naloxone moreover neither lofexidine clonidine suppress subjective discomfort opioid withdrawal significantly reduce autonomic sign opioid withdrawal lacrimation rhinorrhea data suggest lofexidine well tolerate even supratherapeutic acute however failure modify sign symptom opioid withdrawal suggest effective use spontaneous withdrawal require concomitant medication improve therapeutic response,Walsh SL,2003,Addiction,https://doi.org/10.1046/j.1360-0443.2003.00372.x,12653813,Walsh SL; Strain EC; Bigelow GE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000316: Adrenergic alpha-Agonists; D000328: Adult; D003000: Clonidine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D009270: Naloxone; D009292: Narcotic Antagonists; D009294: Narcotics; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W1993917134,116,14,1,2174,333,10,en,en
false,dorzolamide x apraclonidine prevention intraocular pressure spike nd yag laser posterior capsulotomy,evaluate efficacy dorzolamide compare apraclonidine prevention intra ocular pressure iop spike nd yag laser posterior capsulotomy site department ophthalmology state university campinas unicamp general hospital campinas paulo brazil double mask prospective clinical trial eye patient randomly assign receive either dorzolamide h placebo h nd yag laser capsulotomy placebo h apraclonidine h procedure inclusion criterion secondary cataract reduction best correct visual acuity bcva absence manifest suspect glaucoma know hypersensitivity study drug iop measure h h apply laser h h h day statistically significant difference two group regard iop h h procedure h h h day laser treatment p value respectively result study suggest dorzolamide safe effective apraclonidine prevention iop elevation nd yag laser posterior capsulotomy synopsis efficacy dorzolamide compare apraclonidine prevention intraocular pressure spike nd yag laser posterior capsulotomy patient result similar drug,Arieta C,2002,Curr Eye Res,https://doi.org/10.1076/ceyr.25.4.237.13484,12658557,Arieta C; Amaral M; Matuda E; Crosta C; de Carvalho Moreira Filho D; José N,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002257: Carbonic Anhydrase Inhibitors; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007429: Intraocular Pressure; D053685: Laser Therapy; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D011446: Prospective Studies; D013449: Sulfonamides; D013876: Thiophenes; D013997: Time Factors",,,https://openalex.org/W2104226476,122,18,1,1476,276,6,en,en
false,measurement simple reaction time antipsychotic treatment patient schizophrenia,background role simple reaction time schizophrenia extensively report date professional literature however study examine basic reaction time static condition use single measurement aim present study establish whether change occur simple reaction time treatment risperidone olanzapine patient suffer relapse schizophrenia method seventeen patient suffer acute relapse schizophrenia dsm iv criterion twenty match healthy control participate eight week double blind pilot study patient treat conventional antipsychotic seven day admission randomise treatment arm risperidone mg day olanzapine mg day fix dosage first week thereafter flexible dosage remain seven week since difference find reaction time patient treat risperidone olanzapine two treatment group merge statistical analysis compare normal control psychopathological symptom assess use positive negative symptom scale panss extrapyramidal symptom simpson angus scale abnormal involuntary movement scale reaction time measure alpha apparatus connect personal computer assessment measurement conduct four time treatment phase study result reaction time patient significantly long healthy control p eight week treatment reaction time patient significantly improve reach healthy control p furthermore improve reaction time patient correlate improvement psychopathological symptom improve extrapyramidal symptom conclusion result study suggest simple reaction time improve treatment atypical antipsychotic,Kores Plesnicar B,2003,Wien Klin Wochenschr,https://doi.org/10.1007/bf03040274,12658913,Kores Plesnicar B; Zalar B; Tomori M; Krajnc I,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D008297: Male; D009460: Neurologic Examination; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011930: Reaction Time; D012008: Recurrence; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D017524: Slovenia",,,https://openalex.org/W89642468,93,12,1,2091,342,13,en,en
false,clinical trial response dropout rate olanzapine versus risperidone,schizophrenia compare treatment dropout olanzapine risperidone useful well understand relative effectiveness analyze difference rate dropout clinical trial response antipsychotic literature search base medline may analysis include randomize study patient analysis include randomize study n analysis assess clinical study olanzapine n risperidone n odds ratio estimate fix effect model risk treatment discontinuation analysis significantly great risperidone olanzapine v respectively response rate identical drug analysis slightly well pattern maintenance response find olanzapine analysis pattern dropout maintenance remission seem good control olanzapine risperidone,Santarlasci B,2003,Ann Pharmacother,https://doi.org/10.1345/aph.1c291,12659615,Santarlasci B; Messori A,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010349: Patient Compliance; D010352: Patient Dropouts; D010890: Pirenzepine; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W2120173795,76,10,1,996,176,5,en,en
false,ad hd attention deficit hyperactivity syndrome methylphenidate,,Kaga M,2003,No To Hattatsu,,12661098,Kaga M; Miyamoto S,article,D016428: Journal Article,D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D017277: Drug Approval; D006801: Humans; D008774: Methylphenidate; D009313: National Health Programs,,,https://openalex.org/W2466230743,75,13,1,0,0,0,en,
false,verbessert der zusatz von clonidin zur spinalan sthesie die analgetische wirkung niedrig dosierten intrathekalen morphins,objective evaluate influence intrathecal clonidine spinal morphine analgesia adverse effect major orthopaedic surgery method study approve local ethic committee write inform consent asa iii patient schedule hip knee replacement include patient randomly allocate receive either placebo mg morphine mg morphine microg clonidine addition mg bupivacaine intrathecally primary outcome parameter time first opioid request statistical difference calculate u test fisher exact test result clonidine result significant improvement postoperative analgesia mean time first opioid request placebo h mg morphine h mg morphine microg clonidine h respectively clonidine significantly increase rate adverse effect conclusion trial confirm improve analgesia combination intrathecal morphine clonidine due increase adverse effect combination intrathecal clonidine morphine seem reasonable alternative management postoperative pain orthopaedic surgery,Gehling M,2003,Anaesthesist,https://doi.org/10.1007/s00101-003-0459-1,12666001,Gehling M; Tryba M; Lüsebrink T; Zorn A,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000369: Aged, 80 and over; D000701: Analgesics, Opioid; D004311: Double-Blind Method; D004357: Drug Synergism; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D008875: Middle Aged; D009020: Morphine; D019637: Orthopedic Procedures; D010149: Pain, Postoperative",,,https://openalex.org/W2415758914,122,15,1,1270,203,10,de,en
false,bupropion sr smoke cessation,cigarette dependence recognise life threaten disorder treat behavioural support medication bupropion hydrochloride sustain release zyban glaxosmithkline license many country include u canada uk australia continental europe aid smoking cessation usual recommend dose mg b take day prior quit date week afterwards figure vary across country evidence seven double blind placebo control randomised trial show improve success stay cigarette least month percentage point take account estimate subsequent cessation relapse pattern treat untreated smoker improvement life expectancy smoker manage stop estimate cost life year save episode use medication uk u bupropion cns stimulant property common side effect dry mouth sleep disturbance rare serious side effect anaphylactic hypersensitivity reaction seizure estimate drug contraindicate patient hypersensitivity drug metabolite seizure disorder eat disorder severe hepatic cirrhosis history bipolar disorder patient take monoamine oxidase inhibitor extreme caution advise predispose factor may reduce seizure threshold bupropion sustain release nicotine replacement therapy consider first line treatment aid smoking cessation ideally patient also enrol structured behavioural support programme boost chance success,West R,2003,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.4.4.533,12667116,West R,article,D016428: Journal Article; D016454: Review,"D016642: Bupropion; D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D006207: Half-Life; D006801: Humans; D011358: Product Surveillance, Postmarketing; D016032: Randomized Controlled Trials as Topic; D016540: Smoking Cessation; D016896: Treatment Outcome",,,https://openalex.org/W2125741987,34,5,1,1746,288,12,en,en
false,ziprasidone treatment acute bipolar mania three week placebo control double blind randomize trial,study evaluate efficacy tolerability ziprasidone compare placebo treatment adult patient acute bipolar mania patient primary dsm iv diagnosis bipolar disorder current manic mixed episode confirm structure clinical interview dsm iv axis disorder patient edition n randomly assign ratio week double blind treatment ziprasidone mg twice daily placebo efficacy assess schedule affective disorder schizophrenia change version contain mania rating scale positive negative syndrome scale clinical global impression cgi severity scale cgi improvement scale global assessment function scale primary efficacy variable difference baseline endpoint last observation carry forward mean mania rating scale cgi severity scale score ziprasidone placebo group safety evaluation include monitor adverse event vital sign electrocardiogram result clinical laboratory value assessment movement disorder akathisia ziprasidone produce rapid sustain improvement relative baseline placebo primary secondary efficacy measure endpoint significant improvement typically observe within day treatment commence maintain throughout week ziprasidone well tolerate associate low rate extrapyramidal symptom neither weight gain clinically significant change vital sign safety parameter observe ziprasidone ziprasidone monotherapy significantly superior placebo reduce symptom acute mania patient bipolar disorder onset action rapid tolerability ziprasidone generally comparable placebo,Keck PE,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.4.741,12668364,Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K; Ziprasidone in Mania Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000284: Administration, Oral; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D013844: Thiazoles; D016896: Treatment Outcome",,,https://openalex.org/W2099549036,117,18,1,1895,298,7,en,en
false,differential sensitivity acute administration ritalin apormorphine sch raclopride mouse selectively breed hyperactive wheel run behavior,rationale previous study mouse mu domesticus selectively breed high voluntary wheel run suggest hyperactivity associate dysfunction dopaminergic neuromodulatory system high run mouse may represent useful genetic model attention deficit hyperactivity disorder adhd objective test hypothesis mouse four replicate hyperactive line would respond differently methylphenidate ritalin apomorphine non selective dopamine agonist sch selective like dopamine antagonist raclopride selective like dopamine antagonist individual four replicate randomly breed control line method animal habituate week cage attach wheel drug administer via intraperitoneal injection night peak wheel run activity revolution wheel min post injection use quantify drug response result ritalin mg kg mg kg increase wheel run control line decrease run select line low dose mg kg apomorphine reduce wheel run similar amount control select line however high apomorphine mg kg mg kg produce great reduction wheel run control line sch mg kg cause great reduction wheel run control select line raclopride mg kg reduce wheel run similar amount control select line conclusion result support interpretation genetically determine hyperactive wheel run behavior associate alter dopaminergic function mouse model specifically result suggest like like dopamine receptor reduce function high running mouse fact ritalin decrease wheel run select line far support use animal model adhd,Rhodes JS,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-003-1399-9,12669177,Rhodes JS; Garland T,article,"D003160: Comparative Study; D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000818: Animals; D021461: Animals, Outbred Strains; D001058: Apomorphine; D001552: Benzazepines; D001947: Breeding; D004195: Disease Models, Animal; D018491: Dopamine Agonists; D018492: Dopamine Antagonists; D018765: Dopamine Uptake Inhibitors; D004305: Dose-Response Relationship, Drug; D005260: Female; D006948: Hyperkinesis; D008297: Male; D008774: Methylphenidate; D051379: Mice; D009043: Motor Activity; D020891: Raclopride; D012641: Selection, Genetic; D013045: Species Specificity; D013997: Time Factors",,,https://openalex.org/W2150568116,168,24,1,2034,350,11,en,en
false,placebo control study lofexidine treatment child tic disorder attention deficit hyperactivity disorder,study evaluate efficacy safety lofexidine treat child tic disorder attention deficit hyperactivity disorder adhd subject specialty tic disorder clinic randomly assign receive week treatment lofexidine placebo double blind condition follow visit occur every week safety monitoring dose adjustment fourty four medication free subject boy three girl mean age year adhd combine type tic disorder participate week treatment lofexidine associate mean improvement total score teacher rat adhd rating scale compare improvement placebo eleven subject receive lofexidine blindly rat clinical global scale improvement either much improve much improve compare none subject receive placebo mean score parent rat hyperactivity index improve lofexidine group placebo group significant difference continuous performance test commission error decrease omission error lofexidine group compare increase commission error omission error placebo group tic severity decrease lofexidine group compare placebo group one lofexidine subject sedation withdraw week lofexidine associate insignificant decrease blood pressure pulse lofexidine appear safe effective treatment child tic disorder adhd,Niederhofer H,2003,J Psychopharmacol,https://doi.org/10.1177/0269881103017001714,12680748,Niederhofer H; Staffen W; Mair A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,D000293: Adolescent; D000322: Adrenergic Agonists; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D001794: Blood Pressure; D002648: Child; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007407: Interviews as Topic; D008297: Male; D009483: Neuropsychological Tests; D013981: Tic Disorders; D016896: Treatment Outcome,,,https://openalex.org/W2169911167,133,18,1,1652,290,12,en,en
false,placebo control trial risperidone tourette syndrome,objective evaluate efficacy safety risperidone child adult tourette syndrome method week randomize double blind placebo control trial primary outcome measure total tic score yale global tic severity scale ygtss result thirty four medication free subject child adult range age year mean year participate ygtss total tic score similar baseline risperidone v placebo week treatment mean daily dose subject risperidone show reduction tic severity baseline compare reduction placebo patient n f p child randomize risperidone show reduction tic symptom compare decrease child placebo f p two child risperidone show acute social phobia resolve dose reduction one subject result medication discontinuation mean increase body weight kg observe risperidone group compare change placebo f p extrapyramidal symptom clinically significant alteration cardiac conduction time laboratory measure observe conclusion risperidone appear safe effective short term treatment tic child adult tourette syndrome long term study need evaluate durability efficacy safety time,Scahill L,2003,Neurology,https://doi.org/10.1212/01.wnl.0000055434.39968.67,12682319,Scahill L; Leckman JF; Schultz RT; Katsovich L; Peterson BS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001835: Body Weight; D002648: Child; D003943: Diagnostic Techniques, Neurological; D018492: Dopamine Antagonists; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D007172: Erectile Dysfunction; D005260: Female; D006329: Heart Conduction System; D006801: Humans; D008297: Male; D008875: Middle Aged; D010698: Phobic Disorders; D018967: Risperidone; D012720: Severity of Illness Index; D020323: Tics; D005879: Tourette Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W2033074878,62,8,1,1685,382,12,en,en
false,effect nicardipine clonidine cognitive function electroencephalography hypertensive patient,aim study investigate cognitive electroencephalography eeg short term effect calcium antagonist nicardipine compare placebo clonidine know sedative effect act negative control day elderly hypertensive patient memory complaint nicardipine clonidine compare placebo double blind randomize three way cross control study week placebo run period phase ii clinical study carry patient single research centre fifteen elderly year hypertensive patient without dementia memory complaint include psychomotor performance cognition assess use extensive battery validate psychometric test evaluate attention vigilance body sway memory eeg profile cardiovascular parameter measure blood pressure heart rate detrimental effect nicardipine find attention vigilance body sway memory nicardipine produce significant increase alpha eeg energy may indicate possible alert effect contrast clonidine induce well know deleterious sedative effect psychometric test eeg analysis decrease alpha increase delta theta wave two drug produce equivalent decrease blood pressure steady state conclusion clonidine induce well know sedative effect nicardipine impair central nervous system activity may short term alert effect elderly hypertensive patient memory complaint study support hypothesis dissociation blood pressure direct drug effect central nervous system,Denolle T,2002,Fundam Clin Pharmacol,https://doi.org/10.1046/j.1472-8206.2002.00110.x,12685512,Denolle T; Sassano P; Allain H; Bentué-Ferrer D; Breton S; Cimarosti I; Ouatara B; Merienne M; Gandon JM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003000: Clonidine; D003071: Cognition; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011597: Psychomotor Performance,,,https://openalex.org/W2045753938,111,13,1,1779,289,12,en,en
false,reader response zarcone et al effect risperidone aberrant behavior person developmental disability double blind crossover study use multiple measure,,Levitas A,2003,Am J Ment Retard,https://doi.org/10.1352/0895-8017(2003)108<0212:rrtzea>2.0.co;2,12691600,Levitas A,article,D016420: Comment; D016422: Letter,D014150: Antipsychotic Agents; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D008607: Intellectual Disability; D001523: Mental Disorders; D018967: Risperidone,,,https://openalex.org/W2124108980,189,34,3,0,0,0,en,
false,aripiprazole efficacy tolerability profile novel act atypical antipsychotic,aripiprazole late atypical antipsychotic come clinical practice propose mechanism action different agent notably partial agonist action dopamine receptor serotonin ht receptor placebo control comparative trial aripiprazole confirm efficacy positive negative general psychopathology treatment emergent adverse effect appear low aripiprazole associate low propensity extrapyramidal side effect absence hyperprolactinemia low propensity weight gain aripiprazole clinical role determine clinical experience additional phase iv study comparative information agent respect efficacy tolerability profile atypical antipsychotic medication,Buckley PF,2003,Drugs Today (Barc),https://doi.org/10.1358/dot.2003.39.2.799421,12698209,Buckley PF,article,D016428: Journal Article; D016454: Review,D014150: Antipsychotic Agents; D000068180: Aripiprazole; D006801: Humans; D010879: Piperazines; D015363: Quinolones; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W2055595962,88,11,1,807,123,5,en,en
false,atypical conventional antipsychotic drug treatment naive first episode schizophrenia week randomize trial clozapine v chlorpromazine,purport advantage second generation atypical antipsychotic relative first generation antipsychotic examine patient first episode schizophrenia flexible dose study examine efficacy safety randomize double blind week trial compare chlorpromazine cpz clozapine clz treatment naive patient experience first episode schizophrenia inpatient first episode schizophrenia schizophreniform disorder randomize cpz clz follow week dropout primary efficacy measure time first remission proportion time remain remission analysis supplement comparison profile clinical symptom side effect first episode patient achieve remission within year cpz clz kaplan meier estimate median time first remission week clz v week cpz chi p rate first achieve remission odds remission trial almost double clz group comparison cpz group week clz superior many rating scale measure symptom severity cpz superior symptom difference remain significant control eps difference week many symptom difference group longer significantly different generally clz produce side effect cpz particularly extrapyramidal side effect significant difference treatment weight change glucose metabolism prior year untreated psychosis decrease odds achieve remission ci high proportion first episode patient remit within year detect difference proportion first episode patient receive clz cpz achieve remission however first episode patient receive clz remit significantly faster remain remission long subject receive cpz clz group show significantly less symptomatology measure side effect week two treatment group seem converge year long duration untreated psychosis associate low odds achieve remission,Lieberman JA,2003,Neuropsychopharmacology,https://doi.org/10.1038/sj.npp.1300157,12700715,Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D002746: Chlorpromazine; D003024: Clozapine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D012559: Schizophrenia,,,https://openalex.org/W1978251978,151,18,1,2372,406,19,en,en
false,initiate treatment modafinil control excessive daytime sleepiness patient switch methylphenidate open label safety study assess three strategy,rationale modafinil first line wake promote medication useful therapeutic alternative psychostimulant medication excessive daytime sleepiness objective week randomize open label study evaluate three strategy switch patient methylphenidate commonly use psychostimulant modafinil method patient n excessive daytime sleepiness relate narcolepsy receive previous treatment methylphenidate switch methylphenidate modafinil mg day follow mg day without washout period treatment day washout period treatment use taper titrate protocol adverse event record throughout study epworth sleepiness scale score determine end study result majority patient successfully switch modafinil study end point mean epworth sleepiness scale score treatment group three switch strategy well tolerate adverse event mild moderate nature adverse event frequently report modafinil treatment among see previously large scale placebo control study meaningful difference among treatment group frequency severity adverse event relationship modafinil treatment one patient discontinue modafinil treatment treatment related adverse event e moderate headache another patient discontinue due insufficient efficacy conclusion switch methylphenidate modafinil well tolerate without washout period methylphenidate dose gradually taper initiation modafinil therapy daytime wakefulness maintain patient switch methylphenidate modafinil data suggest patient narcolepsy may switch methylphenidate modafinil complication inconvenience,Thorpy MJ,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-002-1343-4,12709775,Thorpy MJ; Schwartz JR; Kovacevic-Ristanovic R; Hayduk R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D000077408: Modafinil; D009290: Narcolepsy; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome; D014851: Wakefulness,,,https://openalex.org/W1542181078,177,23,1,2038,314,14,en,en
false,bupropion sr smoke cessation smoker cardiovascular disease multicentre randomise study,aimto investigate safety efficacy bupropion sustain release bupropion sr promote abstinence smoke subject cardiovascular disease cvd method six hundred twenty nine subject cvd smoke cigarette day randomise double blind multicentre study receive bupropion sr mg twice daily placebo week follow week primary efficacy endpoint continuous abstinence smoke week secondary endpoint continuous abstinence week weekly point prevalence abstinence participant receive brief motivational support safety evaluate throughout study result continuous smoke abstinence rate week significantly high subject receive bupropion sr compare placebo v odds ratio confidence interval ci p continuous abstinence rate week continue double bupropion sr compare placebo v v p weekly point prevalence abstinence significantly high participant receive bupropion sr compare placebo week p group clinically significant change blood pressure heart rate throughout treatment phase overall participant n discontinue study medication due adverse event bupropion sr n placebo n conclusion week bupropion sr treatment twice many smoker cvd quit smoke year compare placebo safety profile bupropion sr similar previously observe general smoking population,Tonstad S,2003,Eur Heart J,https://doi.org/10.1016/s0195-668x(03)00003-4,12714026,Tonstad S; Farsang C; Klaene G; Lewis K; Manolis A; Perruchoud AP; Silagy C; van Spiegel PI; Astbury C; Hider A; Sweet R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D016642: Bupropion; D002318: Cardiovascular Diseases; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012907: Smoking; D016540: Smoking Cessation; D000074606: Smoking Prevention; D016896: Treatment Outcome,,,https://openalex.org/W2100116850,106,16,1,1742,311,2,en,en
false,aripiprazole treatment schizophrenia safety tolerability short term placebo control trial,aripiprazole novel antipsychotic unique mechanism action present pool analysis safety tolerability data complete short term placebo control trial schizophrenia aripiprazole clinical development program data analyze five week double blind multicenter study patient hospitalize acute relapse schizophrenia schizoaffective disorder randomize aripiprazole n placebo n haloperidol n daily aripiprazole range mg safety assessment include adverse event ae report eps scale ecg weight prolactin glucose cholesterol level aripiprazole well tolerate similar ae incidence rate placebo low rate haloperidol akathisia extrapyramidal syndrome somnolence objective eps assessment demonstrate significant difference aripiprazole placebo simpson angus scale sa score dose dependent effect barnes akathisia score significant reduction abnormal involuntary movement scale aim score baseline v placebo p haloperidol show increase sa barnes akathisia score placebo p minimal mean weight change aripiprazole kg haloperidol kg lack qtc prolongation serum prolactin increase haloperidol aripiprazole conclusion aripiprazole show favorable safety tolerability profile low potential eps weight gain prolactin elevation qtc prolongation sedation aripiprazole safety profile may offer benefit schizophrenia treatment,Marder SR,2003,Schizophr Res,https://doi.org/10.1016/s0920-9964(03)00050-1,12729864,Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D010879: Piperazines; D011618: Psychotic Disorders; D015363: Quinolones; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W2033155032,112,15,1,1681,276,11,en,en
false,patient enrol first episode psychosis drug trial representative patient treat routine clinical practice,evidence efficacy antipsychotic medication come primarily control trial select eligible consent patient experimental regiment treatment abuse drug good general health thus clear extent result generalizable individual treat psychotic illness may eligible trial study compare characteristic patient treat large randomize trial person early psychosis cohort large epidemiological study first episode psychosis include patient enrol control trial antipsychotic medication similarly diagnose person suffolk county mental health epidemiological study drug trial exclusion criterion use estimate number patient epidemiological study would ineligible drug trial two sample compare key characteristic thirty three percent n epidemiological sample meet inclusion criterion drug trial due antidepressant treatment n current substance abuse n recent suicide attempt n one reason n significant difference two study sample age onset age gender premorbid function drug trial patient high brief psychiatric rating scale bprs slightly low clinical global impression cgi less formal education epidemiological study patient epidemiological sample would exclude drug trial patient two study similar several key variable,Rabinowitz J,2003,Schizophr Res,https://doi.org/10.1016/s0920-9964(02)00322-5,12729866,Rabinowitz J; Bromet EJ; Davidson M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D015331: Cohort Studies; D003431: Cross-Cultural Comparison; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D009518: New York; D018579: Patient Selection; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D015983: Selection Bias,,,https://openalex.org/W2087687048,125,18,1,1689,279,6,en,en
false,olanzapine v risperidone management schizophrenia randomize double blind trial australia new zealand,improve drug therapy schizophrenia may represent best strategy reduce cost schizophrenia recurrent chronic course disease olanzapine risperidone atypical antipsychotic agent develop meet need report multicenter double blind parallel week study design compare efficacy safety associate resource use olanzapine risperidone australia new zealand study sample consist patient meet dsm iv criterion schizophrenia schizoaffective disorder schizophreniform disorder olanzapine treat patient show significantly great reduction positive negative syndrome scale panss total brief psychiatric rating scale bprs total panss general psychopathology score endpoint compare risperidone treat patient response rate week show significantly great proportion olanzapine treat patient achieve great improvement panss total score compare risperidone treat patient olanzapine risperidone equivalent improvement panss positive negative score clinical global impression severity illness scale cgi endpoint use generic disease specific measure quality life olanzapine treat patient show significant within group improvement measure significant difference observe favor olanzapine risperidone quality life scale qls intrapsychic foundation medical outcome study short form item instrument sf role function limitation emotional subscale score despite relatively small sample size study suggest olanzapine superior risk benefit profile compare risperidone,Gureje O,2003,Schizophr Res,https://doi.org/10.1016/s0920-9964(02)00226-8,12729882,Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001315: Australia; D001569: Benzodiazepines; D003362: Cost-Benefit Analysis; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D016527: Drug Costs; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009313: National Health Programs; D009520: New Zealand; D000077152: Olanzapine; D010890: Pirenzepine; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W1995770312,122,18,1,1799,271,9,en,en
false,relative lack cognitive effect methylphenidate elderly male volunteer,rationale methylphenidate dopaminergic noradrenergic reuptake inhibitor show young healthy adult volunteer produce pronounce effect work memory sustain attention interested assess whether similar improvement could confer upon elderly volunteer order gain complete understanding effect age monoaminergic manipulation work memory attention well explore potential pharmacological intervention attention executive dysfunction disorder age group objective main aim study characterise dose related effect methylphenidate range neuropsychological function elderly healthy volunteer method sixty healthy elderly adult male volunteer receive either single oral dose placebo mg mg methylphenidate prior perform variety task design assess memory attention executive function randomise double blind subject design use result methylphenidate significant cardiovascular subjective effect however unlike young volunteer significant effect drug work memory spatial span spatial work memory response inhibition stop signal sustain attention rapid visual information process see subtle effect latency similar young volunteer identify dos methylphenidate result slow response time set shift decision make conclusion result study demonstrate elderly subject cognitive effect methylphenidate grossly attenuate distinct profile previously describe young volunteer suggest methylphenidate may appropriate pharmacological intervention elderly patient group report age relate cognitive decline,Turner DC,2003,Psychopharmacology (Berl),https://doi.org/10.1007/s00213-003-1457-3,12734634,Turner DC; Robbins TW; Clark L; Aron AR; Dowson J; Sahakian BJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000367: Age Factors; D000368: Aged; D002320: Cardiovascular Physiological Phenomena; D002490: Central Nervous System; D003071: Cognition; D004305: Dose-Response Relationship, Drug; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D009483: Neuropsychological Tests; D010147: Pain Measurement; D011930: Reaction Time; D012307: Risk Factors",,,https://openalex.org/W2013449353,80,11,1,1950,303,10,en,en
false,methylphenidate enhances intracortical inhibition facilitation healthy adult,transcranial magnetic stimulation use investigate effect psychostimulant drug methylphenidate mph motor cortex excitability healthy adult n placebo control crossover design study mph cause enhancement intracortical inhibition well intracortical facilitation enhancement tm parameter unexpected suggest mph exert action motor cortex dopaminergic neurotransmitter system,Kirschner J,2003,Pharmacopsychiatry,https://doi.org/10.1055/s-2003-39049,12734766,Kirschner J; Moll GH; Fietzek UM; Heinrich H; Mall V; Berweck S; Heinen F; Rothenberger A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D004298: Dopamine; D004311: Double-Blind Method; D004576: Electromyography; D019054: Evoked Potentials, Motor; D005260: Female; D006801: Humans; D007395: Interneurons; D008280: Magnetics; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D009044: Motor Cortex; D009433: Neural Inhibition",,,https://openalex.org/W1979347254,89,10,1,494,78,3,en,en
false,new generation antipsychotic versus low potency conventional antipsychotic systematic review meta analysis,clear advantage new generation atypical antipsychotic reduce risk extrapyramidal side effect eps compare conventional compound finding might bias use high potency antipsychotic haloperidol comparator trial aim establish whether new drug induce eps low potency conventional antipsychotic meta analysis randomise control trial new generation antipsychotic compare low potency equivalent less potent chlorpromazine conventional drug include study meet quality criterion b cochrane collaboration handbook assess quality jadad scale primary outcome interest number patient least one eps use risk difference ci measure effect size identify study total participant new generation drug clozapine associate significantly eps rd ci p high efficacy low potency conventional drug reduce frequency eps see olanzapine borderline significance p one inconclusive trial amisulpride quetiapine risperidone investigation ziprasidone sertindole identify evidence indicate zotepine remoxipride lead eps low potency antipsychotic mean dose less mg day chlorpromazine equivalent high risk eps new generation drug group new generation drug moderately efficacious low potency antipsychotic largely irrespective comparator dose use optimum dos low potency conventional antipsychotic might induce eps new generation drug potential advantage efficacy new generation drug factor clinical treatment decision use rather conventional drug,Leucht S,2003,Lancet,https://doi.org/10.1016/s0140-6736(03)13306-5,12747876,Leucht S; Wahlbeck K; Hamann J; Kissling W,article,D016428: Journal Article; D017418: Meta-Analysis; D016454: Review; D000078182: Systematic Review,D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W2098132738,115,13,1,2036,334,12,en,en
false,side effect postoperative epidural analgesia child randomize study compare morphine clonidine,summary background morphine widely use association local anaesthetic postoperative epidural analgesia data prolong use clonidine postoperative analgesia child primary outcome randomize double blind trial compare incidence side effect epidural infusion clonidine morphine association ropivacaine child method institutional approval child age year schedule abdominal surgery epidural catheter place induction general anaesthesia patient randomize two different group initial bolus mg kg ropivacaine either g kg morphine group n g kg clonidine group c n epidural infusion start rate ml kg h patient group receive infusion ropivacaine g ml morphine group c infusion ropivacaine g ml clonidine result two group similar respect age sex weight one patient c group exclude misplacement epidural catheter incidence vomit pruritus significantly high group compare c group versus respectively incidence pain significantly high c group compare group versus well need rescue analgesia medication conclusion epidural clonidine follow significantly low incidence side effect however analgesic effect least use study less potent epidural morphine,Cucchiaro G,2003,Paediatr Anaesth,https://doi.org/10.1046/j.1460-9592.2003.01010.x,12753444,Cucchiaro G; Dagher C; Baujard C; Dubousset AM; Benhamou D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D015360: Analgesia, Epidural; D000700: Analgesics; D000701: Analgesics, Opioid; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D009020: Morphine; D010147: Pain Measurement; D010149: Pain, Postoperative; D013997: Time Factors",,,https://openalex.org/W2059995385,113,15,1,1731,328,13,en,en
false,factorial validity conners parent rating scale revise short form psychiatric outpatient,assess factorial validity item conners parent rating scale revise short form cpr r conners male female psychiatric outpatient year old rat parent confirmatory factor analysis item rating cpr r oppositional cognitive problem hyperactivity scale provide tentative support score scale conners recommend however exploratory principal axis factor analysis item rating find dimension dimension compose item oppositional scale dimension contain remain item attention deficit hyperactivity disorder adhd total symptom scale construct sum rating symptom rating scale find effective hyperactivity scale discriminate youth eventually diagnose adhd discuss result provide alternate way score cpr r screen adhd child adolescent psychiatric outpatient,Kumar G,2003,J Pers Assess,https://doi.org/10.1207/s15327752jpa8003_04,12763699,Kumar G; Steer RA,article,D003160: Comparative Study; D016428: Journal Article; D023361: Validation Study,"D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D039721: Diagnostic and Statistical Manual of Mental Disorders; D005260: Female; D006801: Humans; D008297: Male; D010045: Outpatients; D010290: Parents; D010555: Personality Inventory; D011569: Psychiatric Status Rating Scales; D011594: Psychometrics; D011795: Surveys and Questionnaires; D014481: United States",,,https://openalex.org/W1978851567,103,15,1,1127,207,5,en,en
false,atomoxetine,atomoxetine formerly tomoxetine selective norepinephrine reuptake inhibitor new nonstimulant treatment attention deficit hyperactivity disorder adhd vitro ex vivo vivo study show atomoxetine highly selective antagonist presynaptic norepinephrine transporter little affinity noradrenergic receptor neurotransmitter transporter receptor four randomize placebo control clinical trial conduct week child adolescent adhd atomoxetine total daily dose mg kg administer one two dos daily reduce symptom hyperactivity impulsiveness inattention determine reduction adhd total score atomoxetine versus placebo p atomoxetine also significantly improve adhd subscale rating score p p psychosocial well p adhd relate problem behavior accord parent teacher rating p atomoxetine well tolerate clinical trial discontinuation rate due adverse event low common treatment related adverse event decrease appetite atomoxetine show abuse potential control substance u,Simpson D,2003,Paediatr Drugs,https://doi.org/10.2165/00128072-200305060-00005,12765489,Simpson D; Perry CM,article,D016428: Journal Article; D016454: Review,D000293: Adolescent; D000818: Animals; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D001682: Biological Availability; D001835: Body Weight; D002648: Child; D004334: Drug Administration Schedule; D006207: Half-Life; D006801: Humans; D007408: Intestinal Absorption; D011437: Propylamines; D016032: Randomized Controlled Trials as Topic; D014018: Tissue Distribution,,,https://openalex.org/W4241931919,11,1,1,1294,221,7,en,en
false,impact upon extra pyramidal side effect clinical symptom quality life switch conventional atypical antipsychotic risperidone olanzapine elderly patient schizophrenia,abstract background atypical antipsychotic commonly use management schizophrenia late life evidence suggest induce low rate motor disturbance similar efficacy conventional antipsychotic trial elderly either retrospective small short duration single arm design aim demonstrate effect upon motor side effect efficacy safety quality life qol switch elderly patient schizophrenia conventional antipsychotic olanzapine risperidone method elderly patient schizophrenia randomly allocate olanzapine risperidone follow open label crossover period within group intention treat analysis conduct result patient randomise mean age sd four patient olanzapine patient risperidone fail complete crossover treatment failure odds ratio p mean upon completion switch arm mg sd mg sd olanzapine risperidone respectively arm improvement parkinsonism though olanzapine associate reduction dyskinetic symptom brief psychiatric rating scale scale assessment negative symptom montgomery asberg depression rating scale score improve crossover period arm group difference treatment olanzapine associate good response risperidone psychological domain world health organisation quality life brief qol bref scale p patient olanzapine arm also demonstrate improvement baseline qol bref physical psychological health satisfaction domain risperidone effect quality life qol measure conclusion switch conventional antipsychotic olanzapine risperidone associate improvement core symptom schizophrenia motor side effect subject switch olanzapine likely complete switch process show improvement psychological qol copyright john wiley son ltd,Ritchie CW,2003,Int J Geriatr Psychiatry,https://doi.org/10.1002/gps.862,12766921,Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011596: Psychomotor Disorders; D011788: Quality of Life; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2075039588,207,31,1,2302,393,15,en,en
false,motor time deficit community clinical boy hyperactive behavior effect methylphenidate motor timing,previous paper show community child hyperactive behavior inconsistent control temporal organization motor output study investigate various aspect motor time process clinically diagnose boy attention deficit hyperactivity disorder adhd compare community boy hyperactive behavior control group effect methylphenidate motor time process clinical group adhd double blind cross medication placebo design include week medication clinical group adhd like community group hyperactivity show great variability sensorimotor synchronization sensorimotor anticipation relative control clinical group also impair time perception spar community group hyperactivity persistent acute dose methylphenidate reduce variability sensorimotor synchronization anticipation effect time perception study show motor time function impair clinical community child hyperactivity first study show effectiveness persistent administration methylphenidate deficit motor time adhd child extend use methylphenidate domain attentional inhibitory function domain executive motor timing,Rubia K,2003,J Abnorm Child Psychol,https://doi.org/10.1023/a:1023233630774,12774863,Rubia K; Noorloos J; Smith A; Gunning B; Sergeant J,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D004192: Discrimination, Psychological; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009048: Motor Skills; D012111: Residence Characteristics; D013998: Time Perception",,,https://openalex.org/W2159542284,126,20,1,1481,241,7,en,en
false,selective inhibition child attention deficit hyperactivity disorder stimulant medication,selective inhibition require discrimination auditory signal assess use modification stop signal task selective inhibition assess group clinic refer dsm iv diagnose child attention deficit hyperactivity disorder adhd compare community sample child methylphenidate mph effect selective inhibition assess subset adhd sample participate acute randomize placebo control crossover trial fix dos mph child adhd perform poorly control majority selective stop signal task parameter exhibit anticipatory invalid response less accurate variable response response execution task well slow selective inhibition process mph improve speed inhibition response execution process also reduce variability response execution decrease nonselective inhibition one hand find consistent purport inhibition deficit adhd hand suggest neither impairment mph effect restrict inhibition,Bedard AC,2003,J Abnorm Child Psychol,https://doi.org/10.1023/a:1023285614844,12774864,Bedard AC; Ickowicz A; Logan GD; Hogg-Johnson S; Schachar R; Tannock R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D004192: Discrimination, Psychological; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007266: Inhibition, Psychological; D008297: Male; D008774: Methylphenidate; D011599: Psychopathology",,,https://openalex.org/W61740737,111,14,1,1198,194,6,en,en
false,long act injectable risperidone efficacy safety first long act atypical antipsychotic,objective author assess efficacy safety first long act atypical antipsychotic long act injectable risperidone patient schizophrenia method week multicenter double blind randomize study patient receive intramuscular injection every week placebo long act risperidone mg mg mg primary measure efficacy change total score positive negative syndrome scale result patient enrol enter double blind study receive least one postbaseline assessment mean change score positive negative syndrome scale see endpoint mg risperidone group respectively three change score significantly different see placebo improvement positive negative symptom also significantly great patient receive risperidone long act risperidone well tolerate adverse event relate extrapyramidal symptom spontaneously report patient receive placebo patient mg risperidone group high rate mg mg group severity extrapyramidal symptom mild baseline throughout trial treatment group mean weight change small mg risperidone group kg kg kg respectively injection site pain rat low patient consistent investigator pain rating conclusion long act injectable risperidone efficacious well tolerate provide clinician patient new mode treatment improve outcome long term therapy,Kane JM,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.6.1125,12777271,Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2107962758,103,13,1,1779,311,12,en,en
false,randomize control trial,back table content previous article next article letter editorfull accessrandomized control trialsashok kumar jainer r c psych mohan chawla r c psych ashok kumar jainersearch paper author r c psych warwick u k mohan chawlasearch paper author r c psych kettering u k publish online jun http doi org appi ajp aboutsectionspdf epub toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail editor read great interest article murray b stein colleague report double blind randomized study randomize control trial always cite gold standard detect treatment efficacy however often flaw design immune bias relevance study criticize ground small group size selection bias improper random assignment group author fail provide information many subject initially assess many subject exclude study reason exclusion know rate participation rate response implication generalizability future research selection patient randomize control trial controversial issue context guideline consolidated standard report trial consort state patient assess trial account report accompany diagram explain happen patient involve trial random allocation intervention group remain method ensure group compare equivalent footing outset study thus eliminate allocation confound bias particular article information lack component randomization concealment method improper randomization introduce serious allocation bias assessment quality randomization publish trial consistently find flaw consort guideline emphasize method randomization clearly report also report trial adequate unclear allocation concealment may yield large estimate effect inadequate concealment exaggerated estimate treatment effect reveal meaningful level bias absence adequate information method randomization possibility allocation bias may raise elimination bias would possible author article strictly follow consort guideline finally author fail communicate effect size precisely since present result almost solely p value difficult understand mean possible small effect size become statistically significant evident study however precision effect size rather level significance determine much faith critical reader author result also know response rate remission rate determine clinical importance result reference stein mb kline na matloff jl adjunctive olanzapine ssri resistant combat relate ptsd double blind placebo control study j psychiatry link google scholar begg c cho eastwood horton r moher olkin pitkin r rennie schulz kf simel stroup df improve quality reporting randomize control trial consort statement jama crossref medline google scholar schulz kf chalmers grime da altman dg assess quality randomization report control trial publish obstetrics gynecology journal jama crossref medline google scholar altman dg dore cj randomization baseline comparison clinical trial lancet crossref medline google scholar figuresreferencescited bydetailscited bydepression anxiety vol volume issue june page metric pdf download history publish online june publish print june,Jainer AK,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.6.1189,12777289,Jainer AK; Chawla M,article,D016420: Comment; D016422: Letter,D004311: Double-Blind Method; D017408: Guidelines as Topic; D006801: Humans; D008297: Male; D018579: Patient Selection; D011897: Random Allocation; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D016896: Treatment Outcome,,,https://openalex.org/W2170216666,28,3,1,4378,744,29,en,en
false,reduction excess daytime sleepiness modafinil patient myotonic dystrophy,patient myotonic dystrophy frequently suffer excess daytime sleepiness significant cause disability previous study indicate excess daytime sleepiness occasionally due obstructive sleep apnoea may principally central nervous system origin modafinil successfully use treat narcolepsy central disorder cause excess daytime sleepiness investigate use drug myotonic dystrophy patient excess daytime sleepiness patient recruit clinic population basis screen epworth sleepiness scale patient score invite participate randomize double blind crossover trial modafinil versus placebo four week arm study separate week washout period patient assess polysomnography baseline primary outcome measure change epworth sleepiness scale modify maintenance wakefulness test measure start arm trial week intervention period agreement previous small study sleepiness correlate ctg expansion size treatment modafinil show non significant reduction median epworth sleepiness scale however median maintenance wakefulness test score prolong treatment min p significant adverse cardiac effect drug group patient rest lead h ecg monitoring select patient myotonic dystrophy excess daytime sleepiness may benefit modafinil patient group epworth sleepiness scale may reliable measure sleepiness despite potential cardiac disease patient drug well tolerate adverse effect,Talbot K,2003,Neuromuscul Disord,https://doi.org/10.1016/s0960-8966(03)00030-0,12798791,Talbot K; Stradling J; Crosby J; Hilton-Jones D,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D006970: Disorders of Excessive Somnolence; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009223: Myotonic Dystrophy; D009483: Neuropsychological Tests; D017286: Polysomnography; D011795: Surveys and Questionnaires; D016896: Treatment Outcome,,,https://openalex.org/W2047057465,87,12,1,1879,311,15,en,en
false,calm versus sedative effect intramuscular olanzapine agitate patient,distinct calm rather nonspecific sedation desirable treatment acute agitation double blind study acutely agitate patient schizophrenia n bipolar mania n dementia n treat intramuscular injection hr olanzapine mg haloperidol mg lorazepam mg placebo agitation calmness evaluation scale ace eli lilly co treatment emergent adverse event assess sedation across study patient lorazepam treat bipolar become unarousable significant group difference ace score deep sleep unarousable time across exclude asleep patient agitation remain significantly reduce olanzapine placebo p incidence adverse event indicative sedation significantly different olanzapine versus comparators treatment acute agitation associate schizophrenia bipolar mania dementia intramuscular olanzapine treat patient experience sedation haloperidol lorazepam treat patient experience distinct calm rather nonspecific sedation,Battaglia J,2003,Am J Emerg Med,https://doi.org/10.1016/s0735-6757(02)42249-8,12811711,Battaglia J; Lindborg SR; Alaka K; Meehan K; Wright P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D003704: Dementia; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006220: Haloperidol; D006801: Humans; D006993: Hypnotics and Sedatives; D007273: Injections, Intramuscular; D008140: Lorazepam; D000077152: Olanzapine; D010890: Pirenzepine; D011595: Psychomotor Agitation; D012189: Retrospective Studies; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W2109878299,80,10,1,1203,201,8,en,en
false,differential modulation remifentanil induce analgesia postinfusion hyperalgesia ketamine clonidine human,background experimental study clinical observation suggest possible role opioids induce pain hyperalgesia withdrawal author use new experimental pain model human skin determine time course analgesic hyperalgesic effect mu receptor agonist remifentanil alone combination n methyl aspartate receptor antagonist ketamine alpha receptor agonist clonidine method thirteen volunteer enrol randomize double blind placebo control study transcutaneous electrical stimulation high current density hz mean sd induce acute pain numerical point rating scale stable area mechanical hyperalgesia punctate stimulus touch allodynia magnitude pain area hyperalgesia assess drug infusion remifentanil microg x kg x min ketamine microg x kg x min period min respectively clonidine infusion microg kg min result remifentanil reduce pain area punctate hyperalgesia infusion contrast postinfusion pain hyperalgesia significantly high control infusion ketamine pain hyperalgesia decrease gradually normalize infusion give combination ketamine abolish postinfusion increase punctate hyperalgesia reduce increase pain rating clonidine alone significantly attenuate pain area hyperalgesia however give combination remifentanil clonidine attenuate postinfusion increase pain rating conclusion opioid induced postinfusion hyperalgesia could abolish ketamine suggest n methyl aspartate receptor mechanism contrast elevate pain rating infusion reduce ketamine alleviate alpha receptor agonist clonidine result study suggest different mechanism opioid induce postinfusion antianalgesia secondary hyperalgesia,Koppert W,2003,Anesthesiology,https://doi.org/10.1097/00000542-200307000-00025,12826855,Koppert W; Sittl R; Scheuber K; Alsheimer M; Schmelz M; Schüttler J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000701: Analgesics, Opioid; D000778: Anesthetics, Dissociative; D001794: Blood Pressure; D003000: Clonidine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004558: Electric Stimulation; D006207: Half-Life; D006801: Humans; D006930: Hyperalgesia; D007262: Infusions, Intravenous; D007649: Ketamine; D008297: Male; D010100: Oxygen; D010147: Pain Measurement; D010812: Physical Stimulation; D010880: Piperidines; D017450: Receptors, Opioid, mu; D000077208: Remifentanil; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W2037762739,126,15,1,2089,330,14,en,en
false,tolerability efficacy clozapine combine lithium schizophrenia schizoaffective disorder,safety tolerability clozapine combine lithium investigate potential additive risk well frequent usage clinical practice ten hospitalize schizophrenic schizoaffective patient receive clozapine maintenance therapy partial therapeutic response study randomize control trial cgi panss outcome rating employ cognitive battery administer baseline week lithium placebo administration barnes uku side effect rating laboratory safety data obtain combine lithium clozapine treatment well tolerate except reversible neurotoxic reaction two schizophrenic patient safety measure show significant variation even lithium toxicity total wbc absolute granulocyte count increase lithium decline placebo schizoaffective patient improve lithium cgi panss total negative symptom scale cognitive measure whereas schizophrenic patient lithium add clozapine treatment regimen hospitalize treatment resistant schizoaffective patient appear afford potential benefit without harmful effect schizophrenic patient however afford improvement pose risk lithium toxicity,Small JG,2003,J Clin Psychopharmacol,https://doi.org/10.1097/01.jcp.0000084026.22282.5f,12826983,Small JG; Klapper MH; Malloy FW; Steadman TM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D003024: Clozapine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D018021: Lithium Chloride; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D012559: Schizophrenia",,,https://openalex.org/W2038806808,106,13,1,1326,195,9,en,en
false,sli adderall xr,sli extend release formulation short act adderall racemic mixture dextro levo isomer amphetamine salt drug contain microbeads within sli capsule give double pulse delivery similar achieve two equal short act formulation administer hour apart intent treat analysis week double blind study child attention deficit hyperactivity disorder adhd sli mg daily improve mean morning afternoon behaviour score compare baseline significantly placebo p comparison assess connors global index scale teacher cgis follow treatment cgis score similar report child without adhd study dose response relationship observe increase dosage sli mg weekly interval maximum mg daily result improvement score cgis early morning administration sli double blind study late afternoon score cgis parent similar morning score sli generally well tolerate randomise trial child adhd month overall adverse event mild moderate intensity,McKeage K,2003,CNS Drugs,https://doi.org/10.2165/00023210-200317090-00006,12828502,McKeage K; Scott LJ,article,D016428: Journal Article,D000328: Adult; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002986: Clinical Trials as Topic; D003692: Delayed-Action Preparations; D004338: Drug Combinations; D006805: Human Experimentation; D006801: Humans; D013997: Time Factors,,,https://openalex.org/W2053595410,23,7,1,1332,225,7,en,en
false,atomoxetine selective noradrenaline reuptake inhibitor treatment attention deficit hyperactivity disorder,atomoxetine strattera eli lilly co selective noradrenaline reuptake inhibitor study use treatment attention deficit hyperactivity disorder adhd far two open label seven randomise double blind placebo control clinical trial publish six youth three adult trial show positive response measure primary efficacy measure adhd iv rating scale adhd r conners adult adhd rating scale caars atomoxetine generally well tolerate november fda approve atomoxetine use u treatment adhd child adolescent adult atomoxetine first nonstimulant approve fda treatment adhd first medication approve treatment adult adhd,Kratochvil CJ,2003,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.4.7.1165,12831341,Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ,article,D016428: Journal Article; D016454: Review,D000042: Absorption; D000293: Adolescent; D000328: Adult; D019540: Area Under Curve; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002986: Clinical Trials as Topic; D006207: Half-Life; D006801: Humans; D011437: Propylamines; D016896: Treatment Outcome,,,https://openalex.org/W2101565436,119,13,1,846,152,6,en,en
false,olanzapine versus divalproex sodium treatment acute mania maintenance remission week study,objective double blind trial compare long term efficacy safety medication bipolar disorder author report week comparison olanzapine divalproex method week randomize double blind study compare flexibly dose olanzapine mg day divalproex mg day manic mixed episode bipolar disorder n psychoactive medication allow lorazepam agitation primary efficacy instrument young mania rating scale priori protocol define threshold score inclusion remission relapse analytical technique include mixed model repeat measure analysis variance change baseline fisher exact test two tail categorical comparison kaplan meier estimate time event interest result week mean improvement young mania rating scale score significantly great olanzapine group median time symptomatic mania remission significantly short olanzapine day divalproex day significant difference treatment rate symptomatic mania remission week respectively subsequent relapse mania depression treatment emergent adverse event occur significantly frequently olanzapine treatment somnolence dry mouth increase appetite weight gain akathisia high alanine aminotransferase level divalproex nausea nervousness conclusion week study acute bipolar mania symptomatic remission occur sooner overall mania improvement great olanzapine divalproex rate bipolar relapse differ,Tohen M,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.7.1263,12832240,Tohen M; Ketter TA; Zarate CA; Suppes T; Frye M; Altshuler L; Zajecka J; Schuh LM; Risser RC; Brown E; Baker RW,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000208: Acute Disease; D000328: Adult; D000927: Anticonvulsants; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D055502: Secondary Prevention; D016019: Survival Analysis; D016896: Treatment Outcome; D014635: Valproic Acid,,,https://openalex.org/W2121339106,114,18,1,1810,300,11,en,en
false,clozapine clinical review adverse effect management,clozapine clozaril novel unique prototype atypical tricyclic dibenzodiazepine derivative antipsychotic agent prove effective significantly superior placebo well conventional neuroleptic several placebo control double blind study treatment resistant schizophrenia also find produce incidence extrapyramidal symptom eps low find placebo approximately schizophrenic patient fail respond typical antipsychotic may respond clozapine first major advance mark turn point treatment schizophrenia psychotic disorder since introduction typical antipsychotic agent e chlorpromazine haloperidol respectively introduction clinical study unite state early withdraw approve clinical use united state february risk agranulocytosis novel pharmacological profile lack propensity cause eps short long term u lack effect serum prolactin ameliorative effect tardive dyskinesia result expansion use refractory schizophrenia schizoaffective disorder affective disorder neurological disorder aggression well psychosis patient dementia parkinsonism review cover history pharmacology management side effect fetal neonatal effect clozapine,Iqbal MM,2003,Ann Clin Psychiatry,https://doi.org/10.1023/a:1023228626309,12839431,Iqbal MM; Rahman A; Husain Z; Mahmud SZ; Ryan WG; Feldman JM,article,D016428: Journal Article; D016454: Review,D014150: Antipsychotic Agents; D003024: Clozapine; D005260: Female; D006801: Humans; D007774: Lactation; D011247: Pregnancy; D011248: Pregnancy Complications; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2006536406,63,11,1,1581,261,8,en,en
false,neuropharmacology tbi induce plasticity,purpose report review fundamental study laboratory animal preliminary clinical data suggest certain drug may affect behavioural recovery brain injury laboratory study show systemically administer drug affect specific central neurotransmitter include norepinephrine gaba influence affect recovery predictable manner although drug amphetamine potential enhance recovery others neuroleptic central dopamine receptor antagonist benzodiazepine anti convulsants phenytoin phenobarbital may detrimental one study patient traumatic brain injury receive one combination drug may impair recovery base animal experiment study recover stroke patient true impact class drug well understood care exercise use medication may interfere recovery process patient traumatic brain injury additional research need complete clinical efficacy drug may enhance recovery establish,Goldstein LB,2003,Brain Inj,https://doi.org/10.1080/0269905031000107179,12850953,Goldstein LB,article,D016428: Journal Article; D016454: Review,"D000662: Amphetamines; D000818: Animals; D001930: Brain Injuries; D002491: Central Nervous System Agents; D004338: Drug Combinations; D018682: GABA Agents; D006801: Humans; D023421: Models, Animal; D009473: Neuronal Plasticity; D009638: Norepinephrine; D016032: Randomized Controlled Trials as Topic; D020127: Recovery of Function",,,https://openalex.org/W2006437334,43,4,1,1173,176,4,en,en
false,multicentre randomize double blind placebo control year study bupropion sr smoke cessation,bupropion sustain release bupropion sr show increase smoke cessation success rate u study determine whether bupropion sr combination counsel effective smoke cessation multi country study randomize double blind placebo control trial enrol smoker total receive bupropion sr mg daily week receive placebo total clinic visit telephone contact schedule course year seven week month abstinence rate study outcomes continuous weekly point prevalence smoke abstinence rate significantly high bupropion sr group compare placebo continuous abstinence rate week bupropion sr group compare placebo group odds ratio confidence interval ci p month continuous abstinence rate bupropion sr group placebo group ci p nicotine withdrawal symptom small change measure adverse event high bupropion sr group compare placebo insomnia v dry mouth vs bupropion sr combination counsel increase abstinence rate compare placebo well tolerate,Tønnesen P,2003,J Intern Med,https://doi.org/10.1046/j.1365-2796.2003.01185.x,12859700,Tønnesen P; Tonstad S; Hjalmarson A; Lebargy F; Van Spiegel PI; Hider A; Sweet R; Townsend J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D016642: Bupropion; D003692: Delayed-Action Preparations; D018765: Dopamine Uptake Inhibitors; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009538: Nicotine; D016540: Smoking Cessation; D013375: Substance Withdrawal Syndrome; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2078129420,111,17,1,1383,258,8,en,en
false,aripiprazole antipsychotic novel mechanism action risperidone v placebo patient schizophrenia schizoaffective disorder,aripiprazole dopamine receptor partial agonist partial agonist activity serotonin ht receptor antagonist activity ht receptor multicenter trial examine efficacy safety tolerability aripiprazole patient acute exacerbation schizophrenia schizoaffective disorder week double blind study patient randomize mg n mg n aripiprazole placebo n mg risperidone n efficacy assessment include positive negative syndrome scale panss score clinical global impression score safety tolerability evaluation include extrapyramidal symptom effect weight prolactin correct qt qtc interval aripiprazole mg risperidone mg significantly good placebo efficacy measure separation placebo occur week panss total positive score aripiprazole risperidone panss negative score aripiprazole significant difference aripiprazole placebo mean change baseline extrapyramidal symptom rating scale mean prolactin level decrease aripiprazole significantly increase fold risperidone mean change qtc interval differ significantly placebo active treatment group aripiprazole risperidone group show similar low incidence clinically significant weight gain aripiprazole effective safe well tolerate positive negative symptom schizophrenia schizoaffective disorder first non receptor antagonist clear antipsychotic effect represent novel treatment development psychotic disorder,Potkin SG,2003,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.60.7.681,12860772,Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D001480: Basal Ganglia Diseases; D004311: Double-Blind Method; D005260: Female; D006760: Hospitalization; D006801: Humans; D008297: Male; D010879: Piperazines; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D015363: Quinolones; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2114801996,151,22,1,1780,284,10,en,en
true,cardiovascular effect atomoxetine child adolescent adult,background atomoxetine highly specific presynaptic inhibitor noradrenaline norepinephrine transporter recently approve u treatment patient attention deficit hyperactivity disorder adhd adverse effect cardiovascular system include abnormality heart rate blood pressure cardiac rhythm associate several noradrenergic medication objective elucidate magnitude impact blood pressure pulse elevation patient take atomoxetine study design short term cardiovascular safety child adolescent adult adhd assess five randomise double blind trial duration week atomoxetine n placebo n long term cardiovascular safety child adolescent n assess patient enter open label extension blind continuation follow short term treatment method adverse event blood pressure sit pulse electrocardiogram ecg collect throughout trial qt interval correct heart rate data specific correction factor qtcd derive baseline ecg well standard method result atomoxetine treatment associate small statistically significant increase mean systolic blood pressure adult diastolic blood pressure child adolescent mean pulse rate increase atomoxetine treatment group increase blood pressure pulse tend occur early therapy stabilise return toward baseline upon drug discontinuation significant difference atomoxetine placebo treatment group change qtcd interval study population palpitation adult patient population significant cardiovascular adverse event p occur frequently atomoxetine treatment group placebo group discontinuation due cardiovascular related event uncommon adult group occur child adolescent group conclusion atomoxetine noradrenergic activity increase pulse blood pressure small little clinical significance atomoxetine associate qt interval prolongation cardiovascular effect atomoxetine minimal atomoxetine well tolerate short long term study,Wernicke JF,2003,Drug Saf,https://doi.org/10.2165/00002018-200326100-00006,12862507,Wernicke JF; Faries D; Girod D; Brown J; Gao H; Kelsey D; Quintana H; Lipetz R; Michelson D; Heiligenstein J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000293: Adolescent; D000328: Adult; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D001794: Blood Pressure; D002648: Child; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006329: Heart Conduction System; D006439: Hemodynamics; D006801: Humans; D008297: Male; D011437: Propylamines; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2094270069,74,11,1,2464,402,16,en,en
false,comparison efficacy safety olanzapine versus haloperidol transition intramuscular oral therapy,background acutely agitate patient schizophrenia receive intramuscular im medication typically switch oral po antipsychotic maintenance therapy objective goal study assess efficacy safety olanzapine versus haloperidol transition im po therapy use additional data previously report trial test hypothesis reduction agitation achieve im olanzapine mg im haloperidol mg would maintain follow transition day po olanzapine po haloperidol mg also hypothesize olanzapine would maintain favorble extrapyramidal symptom eps safety profile method multinational hospital country double blind randomize control trial acutely agitate inpatient schizophrenia treat im injection olanzapine mg haloperidol mg hour enter day po treatment period medication mg primary efficacy measurement reduction agitation measure positive negative syndrome scale excite component panss ec score adverse event score eps rating scale assess result total patient men woman mean sd age year enrol patient olanzapine haloported acute dystonia akathisia experience treatment emergent akathisia require anticholinergic panss ec score markedly reduce im period baseline po period baseline hour first im injection yet patient improve far day po treatment sustain alleviation agitation follow transition im po therapy indicate clinician maintain enhance agitation improvement advise switch patient olanzapine haloperidol mg thus sustain alleviation agitation switch im day po treatment achieve olanzapine haloperidol however haloperidol treated patient experience acute dystonia akathisia require anticholinergic olanzapine treat patient im po treatment find keep previous report low risk acute dystonia akathisia treatment im po olanzapine may provide advantage haloperidol rapid calm im atypical antipsychotic subsequent transition po formulation may reduce risk breakthrough symptom could result change antipsychotic may reduce risk acute dystonia akathisia advantage may lessen possibility upset already distressed patient may promote compliance maintenance treatment thus low potential acute episode,Wright P,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80129-7,12867218,Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia",,,https://openalex.org/W2050056114,125,18,1,2957,498,15,en,en
false,tic,purpose review paper review recent literature concern tourette syndrome relate disorder recent find tourette syndrome common disorder child adolescent establish association attention deficit hyperactivity disorder obsessive compulsive disorder number psychiatric disorder autoimmune genetic mechanism implicate pathophysiology syndrome neuroimaging study identify abnormality composition basal ganglion frontal lobe white matter well alteration dopaminergic activity necessary treatment tic successful neuroleptic adrenergic agonist use stimulant child tourette syndrome comorbid attention deficit hyperactivity disorder appear worsen tic summary result recent literature clinician feel comfortable treat child co morbid attention deficit hyperactivity disorder tourette syndrome stimulant medication also establish transient tic common child part non disable child persistent tic behavioural disorder associate may impair success school psychosocial functioning clinician number therapeutic option recent double blind randomize trial clonidine risperidone desipramine show benefit scientist continue search cause tourette syndrome,Pringsheim T,2003,Curr Opin Neurol,https://doi.org/10.1097/01.wco.0000084232.82329.47,12869813,Pringsheim T; Davenport WJ; Lang A,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D001921: Brain; D000697: Central Nervous System Stimulants; D006801: Humans; D013981: Tic Disorders; D014055: Tomography, Emission-Computed; D005879: Tourette Syndrome",,,https://openalex.org/W4237958916,4,1,1,1542,234,10,en,en
false,pilot randomize double blind placebo control study dexamphetamine cocaine dependence,abstract aim establish feasibility conduct placebo control clinical trial dexamphetamine replacement therapy cocaine dependence obtain preliminary data design double blind randomize placebo control trial participant thirty cocaine dependent inject drug user intervention subject assign randomly receive mg day dexamphetamine n placebo n week measurement immunoassay mass spectrometric technique use identify cocaine metabolite urine subject screen use composite international diagnostic interview dsm iv opiate treatment index brief symptom inventory severity dependence scale visual analogue crave scale use collect pre post self report data find treatment retention equivalent group however outcomes favour treatment group improvement observe placebo control group proportion cocaine positive urine sample detect treatment group decline compare change placebo group positive improvement significant group within group analysis reveal treatment group reduce self report cocaine use p reduce criminal activity p reduce crave p reduce severity cocaine dependence p within group improvement find placebo group conclusion definitive evaluation utility dexamphetamine management cocaine dependence feasible warrant,Shearer J,2003,Addiction,https://doi.org/10.1046/j.1360-0443.2003.00447.x,12873248,Shearer J; Wodak A; van Beek I; Mattick RP; Lewis J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000697: Central Nervous System Stimulants; D003042: Cocaine; D019970: Cocaine-Related Disorders; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005240: Feasibility Studies; D005260: Female; D006801: Humans; D008297: Male; D010349: Patient Compliance; D010865: Pilot Projects; D016896: Treatment Outcome,,,https://openalex.org/W2045573797,95,11,1,1621,262,11,en,en
false,estudio de biodisponibilidad comparativa de formulaciones de risperidona existentes en el mercado chileno,bioavailability particular drug vary accord formulation use therefore study comparative bioavailability different formulation drug worthwhile compare bioavailability two risperidone formulation available chilean market bioavailability local risperidone formulation spiron compare original formulation drug risperdal healthy volunteer age year single dose mg give orally use randomize double blind protocol two period fifteen blood sample obtain regular interval h drug administration risperidone plasma level measure high pressure liquid chromatography pharmacokinetic parameter calculate use computer program independent compartmental analysis area curve plasma concentration versus time infinite abc infinity h abc early exposure abc maximal time maximal plasma concentration significantly low spiron half life time time achieve maximal concentration similar two formulation accord bioequivalence test suggest food drug administration fda united state confidence interval difference long transform mean pharmacokinetic parameter formulation risperdal spiron consider interchangeable,Gaete LE,2003,Rev Med Chil,https://doi.org/10.4067/s0034-98872003000500008,12879814,Gaete LE; Solís J; Venegas P; Carrillo MJ; Schatloff O; Saavedra I,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001682: Biological Availability; D002677: Chile; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D018967: Risperidone; D013810: Therapeutic Equivalency,,,https://openalex.org/W2088044233,109,14,1,1469,241,7,es,en
false,comparison tyrosine placebo phentermine caffeine andd amphetamine sleep deprivation,sleep deprivation impair alertness cognitive motor performance hypothesize amino acid tyrosine might reduce deleterious effect sleep deprivation seventy six healthy male age year participate four day protocol include habituation night baseline night h period without sleep recovery night tyrosine mg kg caffeine mg kg phentermine mg amphetamine mg placebo administer double blind randomize fashion compare effect time take fall asleep endocrine response sleep deprivation sleep quantity quality architecture measure polysomnography recovery sleep give h without sleep tyrosine significant effect parameter sleep amphetamine produce mark decrease sleep drive cause deleterious effect many aspect recovery sleep still amphetamine associate increase alertness first recovery day phentermine caffeine decrease sleep drive sleep deprivation phentermine impair rapid eye movement rem recovery sleep tyrosine compare placebo effect sleep related measure stimulate prolactin release,Waters WF,2003,Nutr Neurosci,https://doi.org/10.1080/1028415031000120543,12887139,Waters WF; Magill RA; Bray GA; Volaufova J; Smith SR; Lieberman HR; Rood J; Hurry M; Anderson T; Ryan DH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000293: Adolescent; D000328: Adult; D002110: Caffeine; D000697: Central Nervous System Stimulants; D003913: Dextroamphetamine; D004311: Double-Blind Method; D006185: Habituation, Psychophysiologic; D006801: Humans; D008297: Male; D010645: Phentermine; D010919: Placebos; D012890: Sleep; D012892: Sleep Deprivation; D012895: Sleep, REM; D013997: Time Factors; D014443: Tyrosine",,,https://openalex.org/W2049378802,117,23,1,1296,218,9,en,en
false,effect tyrosine phentermine caffeined amphetamine placebo cognitive motor performance deficit sleep deprivation,cognitive motor performance critical many circumstance impair sleep deprivation administer placebo tyrosine mg kg caffeine mg kg phentermine mg amphetamine mg h follow overnight sleep deprivation compare effect cognitive motor performance healthy young men test visual scanning run memory logical reason mathematical processing stroop task four choice serial reaction time time wall take pursuit track visual vigilance trail b task long term memory evaluate standardized interval sleep deprivation drug performance decrement sleep deprivation occur visual scanning run memory logical reason mathematical processing stroop test time wall test track visual vigilance interestingly sleep deprivation test improve others deteriorate improvement medication follow sleep deprivation see run memory logical reason mathematical processing track visual vigilance although less effective amphetamine tyrosine improve performance several test conclude drug test improve least aspect cognitive motor performance sleep deprivation naturally occur amino acid thus amenable nutritional strategy tyrosine may deserve test,Magill RA,2003,Nutr Neurosci,https://doi.org/10.1080/1028415031000120552,12887140,Magill RA; Waters WF; Bray GA; Volaufova J; Smith SR; Lieberman HR; McNevin N; Ryan DH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000293: Adolescent; D000328: Adult; D002110: Caffeine; D000697: Central Nervous System Stimulants; D003071: Cognition; D003913: Dextroamphetamine; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D009043: Motor Activity; D010645: Phentermine; D010919: Placebos; D012892: Sleep Deprivation; D014443: Tyrosine,,,https://openalex.org/W1999076139,148,27,1,1461,236,9,en,en
false,olanzapine reduces crave alcohol drd vntr polymorphism pharmacotherapy interaction,separate investigation suggest olanzapine antagonist decrease crave prim dose alcohol drd variable number tandem repeat vntr polymorphism influence expression crave prim dose alcohol present study test hypothesis olanzapine may differentially effective reduce cue elicit crave base individual difference drd vntr sample heavy social drinker participant randomly assign receive olanzapine mg control medication cyproheptadine mg prior consume three alcoholic drink participant complete subjective measure crave euphoria drink participant homozygous heterozygous long repeat allele drd vntr classify drd l participant classify drd find indicate olanzapine reduces crave alcohol baseline drd drd l individual reduce crave exposure alcohol cue prim dose alcohol drd l individual,Hutchison KE,2003,Neuropsychopharmacology,https://doi.org/10.1038/sj.npp.1300264,12888781,Hutchison KE; Wooden A; Swift RM; Smolen A; McGeary J; Adler L; Paris L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000339: Affect; D000428: Alcohol Drinking; D016739: Behavior, Addictive; D001569: Benzodiazepines; D016022: Case-Control Studies; D002492: Central Nervous System Depressants; D016009: Chi-Square Distribution; D003463: Cues; D003533: Cyproheptadine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004347: Drug Interactions; D000431: Ethanol; D005260: Female; D006801: Humans; D007206: Individuality; D008297: Male; D018598: Minisatellite Repeats; D000077152: Olanzapine; D010890: Pirenzepine; D011110: Polymorphism, Genetic; D017448: Receptors, Dopamine D2; D050638: Receptors, Dopamine D4; D012702: Serotonin Antagonists; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2159497843,95,13,1,1128,190,5,en,en
true,comparative efficacy two daily methylphenidate formulation ritalin la concerta placebo child attention deficit hyperactivity disorder across school day,objective primary objective compare difference clinical efficacy start dose ritalin la mg start dose concerta mg laboratory school set duration entire school day secondary objective compare ritalin la mg concerta mg ritalin la concerta versus placebo across school day method thirty six child male female age year attention deficit hyperactivity disorder previously stabilize methylphenidate mph complete four way randomize single blind crossover analog classroom study patient evaluate day randomize receive treatment day ritalin la mg concerta mg concerta mg placebo result swanson kotkin agler flynn pelham rating scale skamp attention effect ritalin la mg across morning statistically different concerta mg mg demonstrate change area curve auc first hour pre dose auc ritalinla versus concerta mg p concerta mg p auc change pre dose ritalin la versus concerta mg p concerta mg p skamp deportment auc ritalin la compare concerta mg p concerta mg p auc change pre dose ritalin la compare concerta mg p concerta mg p combine mean auc change pre dose ritalin la compare concerta mg p concerta mg p mean auc change pre dose ritalin la compare concerta mg p concerta mg p math test attempt mean pre dose score ritalin la compare concerta mg mg placebo respectively mean auc change pre dose ritalin la compare concerta mg p concerta mg p math test correct mean pre dose score ritalin la compare concerta mg mg placebo respectively mean auc change pre dose ritalin la compare concerta mg p concerta mg p safety one patient treatment group experience single mild adverse event include abdominal pain nausea dyspnea conclusion ritalin la concerta show effective different release profile formulation result distinct difference effect measure attention deportment,Lopez F,2003,Paediatr Drugs,https://doi.org/10.2165/00148581-200305080-00005,12895137,Lopez F; Silva R; Pestreich L; Muniz R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D018592: Cross-Over Studies; D018765: Dopamine Uptake Inhibitors; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D016037: Single-Blind Method; D013997: Time Factors",,,https://openalex.org/W2031663376,193,35,4,2920,627,15,en,en
false,comparative efficacy safety atypical conventional antipsychotic drug first episode psychosis randomize double blind trial olanzapine versus haloperidol,long term study compare efficacy safety typical atypical antipsychotic medication directly patient first episode psychosis meet criterion schizophrenia relate psychotic disorder study compare acute long term effectiveness haloperidol olanzapine patient first episode psychosis large control clinical trial patient first episode psychosis n randomly assign double blind condition receive haloperidol olanzapine follow week domain measure include psychopathology psychosocial variable neurocognitive functioning brain morphology metabolism report present data clinical measure treatment response safety data week acute treatment phase haloperidol olanzapine associate substantial comparable baseline endpoint reduction symptom severity differ significantly last observation carry forward analysis however mixed model analysis olanzapine treat subject significantly great decrease symptom severity measure positive negative syndrome scale total score negative general scale montgomery asberg depression rating scale measure positive negative syndrome scale positive scale clinical global impression severity rating olanzapine treat patient experience low rate treatment emergent parkinsonism akathisia significantly weight gain compare haloperidol treat patient overall significantly olanzapine treat subject haloperidol treat subject complete week acute phase study versus expect basis previous study olanzapine haloperidol effective acute reduction psychopathological symptom group patient first episode psychosis however olanzapine several relative advantage therapeutic response although nature adverse event differ two agent retention study great olanzapine retention treatment important patient population give risk relapse long term result need determine whether treatment atypical antipsychotic result superior outcome first episode schizophrenia,Lieberman JA,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.8.1396,12900300,Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM; HGDH Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2137984107,174,23,1,2459,357,11,en,en
false,bupropion sustain release treatment tobacco dependence,tobacco use global pandemic common pharmacological treatment tobacco use dependence include nicotine replacement therapy nonnicotine medication bupropion sustain release sr first line nonnicotine medication recommend u public health service clinical practice guideline randomize control clinical trial show bupropion sr double abstinence rate compare placebo long term treatment bupropion sr may reduce delay smoke relapse bupropion sr excellent adverse effect profile although risk exist serious adverse effect seizure risk serious adverse effect associate bupropion sr reduce careful selection patient article review evidence efficacy common adverse effect bupropion sr delineate clinical characteristic patient high risk adverse effect bupropion sr prescribe treatment tobacco use dependence tobacco use global pandemic common pharmacological treatment tobacco use dependence include nicotine replacement therapy nonnicotine medication bupropion sustain release sr first line nonnicotine medication recommend u public health service clinical practice guideline randomize control clinical trial show bupropion sr double abstinence rate compare placebo long term treatment bupropion sr may reduce delay smoke relapse bupropion sr excellent adverse effect profile although risk exist serious adverse effect seizure risk serious adverse effect associate bupropion sr reduce careful selection patient article review evidence efficacy common adverse effect bupropion sr delineate clinical characteristic patient high risk adverse effect bupropion sr prescribe treatment tobacco use dependence united state adult smoke people die year tobacco related diseases center disease control prevention cigarette smoking among adult united state mmwr morb mortal wkly rep pubmed google scholar mcginnis jm foege wh actual cause death united state jama crossref pubmed scopus google scholar estimate billion people worldwide smoke cigarette million people die annually tobaccorelated disease corrao guindon ge sharma n shokoohi df tobacco control country profile american cancer society atlanta ga google scholar smoke prevalence continue increase develop world number annual death attributable cigarette smoke million peto r lopez ad boreham j thun heath jr c mortality smoke develop country indirect estimate national vital statistic oxford university press oxford england google scholar although prevention smoke important long term strategy way reduce stagger expect mortality next year effectively treat tobacco dependence clinical practice guideline recommend combination behavioral pharmacological therapy cigarette smoker motivate stop smoking fiore mc bailey wc cohen sj et al treat tobacco use dependence u dept health human service public health service rockville mdjune available www surgeongeneral gov tobacco treat tobacco use pdfgoogle scholar among recommend first line pharmacotherapies bupropion sustain release sr nonnicotine medication clinical effect bupropion sr mediate blockage reuptake dopamine norepinephrine mesolimbic dopaminergic system locus ceruleus brain ferris rm cooper br mechanism antidepressant activity bupropion j clin psychiatry monogr may google scholar increase level dopamine norepinephrine area hypothesize simulate reward achieve tobacco use reduce withdrawal symptom tobacco use stop shiffman johnston ja khayrallah et al effect bupropion nicotine crave withdrawal psychopharmacology berl crossref pubmed scopus google scholar evidence also suggest bupropion sr may act brain nicotinic receptor antagonist block reinforce effect nicotine slemmer je martin br damaj mi bupropion nicotinic antagonist j pharmacol exp ther pubmed google scholar five randomize control clinical trial hurt rd sachs dp glover ed et al comparison sustain release bupropion placebo smoke cessation n engl j med crossref pubmed scopus google scholar jorenby de leischow sj nides et al control trial sustain release bupropion nicotine patch smoke cessation n engl j med crossref pubmed scopus google scholar tashkin kanner r bailey w et al smoke cessation patient chronic obstructive pulmonary disease double blind placebo control randomised trial lancet abstract full text full text pdf pubmed scopus google scholar gonzales dh nides ferry lh et al bupropion sr aid smoke cessation smoker treat previously bupropion randomize placebo control study clin pharmacol ther crossref pubmed scopus google scholar ahluwalia j harris kj catley okuyemi k mayo sustain release bupropion smoke cessation african american randomize control trial jama crossref pubmed scopus google scholar publish evaluate efficacy bupropion sr treatment tobacco dependence table hay jt ebbert jo bupropion treatment tobacco dependence guideline balance risk benefit cns drug crossref pubmed scopus google scholar metaanalysis bupropion sr smoke cessation estimate combine odds ratio confidence interval month month smoke abstinence compare placebo hughes jr stead lf lancaster antidepressant smoke cessation cochrane database syst rev cd google scholar bupropion sr exhibit significant dose response relationship smoke abstinence within week initiate treatment johnston ja fiedler kelly j glover ed sachs dp grasela th deveaugh geiss j relationship drug exposure efficacy safety bupropion sustain release smoke cessation nicotine tob crossref pubmed scopus google scholar clinical trial bupropion use smoke cessation aid patient typically used bupropion sr week show prevent smoking relapse use year hay jt hurt rd rigotti na et al sustain release bupropion pharmacologic relapse prevention smoke cessation randomize control trial ann intern med crossref pubmed scopus google scholar contrast previous study show benefit treat relapse smoker nicotine replacement therapy retreatment relapse smoker bupropion sr may result increased abstinence rate gonzales dh nides ferry lh et al bupropion sr aid smoke cessation smoker treat previously bupropion randomize placebo control study clin pharmacol ther crossref pubmed scopus google scholar clinical trial show bupropion sr equally effective men woman gonzales bjornson w durcan mj et al effect gender relapse prevention smoker treat bupropion sr j prev med abstract full text full text pdf pubmed scopus google scholar effective among african american ahluwalia js harris kj catley okuyemi k mayo sustain release bupropion smoke cessation african american randomize control trial jama crossref pubmed scopus google scholartable publish randomize control clinical trial bupropion sr treatment tobacco dependence adapt permission hay ebbert copd chronic obstructive pulmonary disease sr sustain release end treatment abstinence comparison bupropion sr mg dosage mo abstinence abstinence rate point prevalence smoke abstinence studyno subjectsduration treatment wk bupropion sr placebo p valuebupropion sr placebo p valuedescription subjectshurt et al hurt rd sachs dp glover ed et al comparison sustain release bupropion placebo smoke cessation n engl j med crossref pubmed scopus google scholar general populationjorenby et al jorenby de leischow sj nides et al control trial sustain release bupropion nicotine patch smoke cessation n engl j med crossref pubmed scopus google scholar general populationtashkin et al tashkin kanner r bailey w et al smoke cessation patient chronic obstructive pulmonary disease double blind placebo control randomised trial lancet abstract full text full text pdf pubmed scopus google scholar copdgonzales et al gonzales dh nides ferry lh et al bupropion sr aid smoke cessation smoker treat previously bupropion randomize placebo control study clin pharmacol ther crossref pubmed scopus google scholar relapsers smoker use bupropion sr smoke cessation subsequently relaped smoke ahluwalia et al ahluwalia j harris kj catley okuyemi k mayo sustain release bupropion smoke cessation african american randomize control trial jama crossref pubmed scopus google scholar urban african american adapt permission hay ebbert hay jt ebbert jo bupropion treatment tobacco dependence guideline balance risk benefit cns drug crossref pubmed scopus google scholar copd chronic obstructive pulmonary disease sr sustain release comparison bupropion sr mg dosage abstinence rate point prevalence smoke abstinence smoker use bupropion sr smoke cessation subsequently relaped smoke open table new tab bupropion sr appear provide additional benefit reduce weight gain often follow smoke abstinence earlier clinical trial modest effect bupropion sr reduce weight gain drugtreatment phase observe however sustain effect appreciate hurt rd sachs dp glover ed et al comparison sustain release bupropion placebo smoke cessation n engl j med crossref pubmed scopus google scholar jorenby de leischow sj nides et al control trial sustain release bupropion nicotine patch smoke cessation n engl j med crossref pubmed scopus google scholar significant effect reduce postcessation weight gain active bupropion sr group show subsequent study hay jt hurt rd rigotti na et al sustain release bupropion pharmacologic relapse prevention smoke cessation randomize control trial ann intern med crossref pubmed scopus google scholar salutary effect bupropion sr weight gain also note treatment depression obesity reimherr fw cunningham la batey sr johnston ja ascher ja multicenter evaluation efficacy safety mg sustain release bupropion tablet versus placebo depress outpatient clin ther abstract full text pdf pubmed scopus google scholar gadde km parker cb maner lg et al bupropion weight loss investigation efficacy tolerability overweight obese woman obes crossref pubmed scopus google scholar anderson jw greenway fl fujioka k gadde km mckenney j neil pm bupropion sr enhances weight loss week double blind placebo control trial obes crossref pubmed scopus google scholar finding may important people concern weight weight gain view barrier smoke abstinence common adverse effect report bupropion sr insomnia dry mouth insomnia may occur individual take bupropion sr dosage mg adverse effect dose related common high dos johnston ja fiedler kelly j glover ed sachs dp grasela th deveaugh geiss j relationship drug exposure efficacy safety bupropion sustain release smoke cessation nicotine tob crossref pubmed scopus google scholar dry mouth occur rate also may dose relate dry mouth appear relate concentration bupropion sr metabolite correlate low body weight johnston ja fiedler kelly j glover ed sachs dp grasela th deveaugh geiss j relationship drug exposure efficacy safety bupropion sustain release smoke cessation nicotine tob crossref pubmed scopus google scholar adverse effect generally well tolerate usually cause medication discontinuation commonly report minor adverse effect include headache nausea anxiety headache nausea associate variably bupropion sr report occur clinical trial frequently placebo active treatment group anxiety report commonly adverse effect frequency anxiety may inversely proportional bupropion sr dose johnston ja fiedler kelly j glover ed sachs dp grasela th deveaugh geiss j relationship drug exposure efficacy safety bupropion sustain release smoke cessation nicotine tob crossref pubmed scopus google scholar may indicate anxiety symptom due nicotine withdrawal withdrawal symptom treat less adequately low bupropion sr active management minor adverse effect usually require improve time clinical trial bupropion sr smoke cessation approximately subject discontinue therapy drug relate adverse effect adverse effect may dose relate alteration dose schedule dose reduction sometimes indicate insomnia example appear relate level bupropion sr plasma patient experience insomnia instruct take first dose early morning second dose mid afternoon ultimately second dose may need eliminate understanding clinical efficacy bupropion sr also may reduce low press report unite kingdom link number death use bupropion sr dobson r antismoking drug come scrutiny death bmj crossref pubmed google scholar however none report death causally connect bupropion sr united state report increase serious adverse effect use bupropion sr connection make use bupropion sr fatal outcome seizure know risk associate use many antidepressant medication immediate release bupropion associate report seizure since first market treatment depression davidson j seizure bupropion review j clin psychiatry pubmed google scholar study bupropion seizure suggest incidence rate seizure approximately seizure risk bupropion appear high immediate release form drug give mg davidson j seizure bupropion review j clin psychiatry pubmed google scholar johnston ja lineberry cg ascher ja et al center prospective study seizure association bupropion j clin psychiatry pubmed google scholar clinical trial use bupropion smoke cessation use sr form drug seizure report clinical trial bupropion sr smoke cessation postmarketing surveillance medicine control agency unite kingdom seizure report estimate rate less patient use bupropion sr zyban safety update doc medicine control agency london englandapril google scholar seizure occur commonly among patient know predisposition seizure table table contraindication use bupropion sr increase risk seizure adapt permission hay ebbert sr sustain release know seizure disorder idiopathic epilepsyfebrile childhood seizuresother seizure disorder eg alcohol withdrawal seizure history serious brain injury close head traumastrokebrain surgeryeating disorder anorexia nervosabulimiadrugs low seizure threshold use bupropion sr combination drug advise undertake great caution potential seizure phenothiazine antipsychotic agentsabrupt withdrawal alcoholbenzodiazepinestheophylline adapt permission hay ebbert hay jt ebbert jo bupropion treatment tobacco dependence guideline balance risk benefit cns drug crossref pubmed scopus google scholar sr sustain release use bupropion sr combination drug advise undertake great caution potential seizure open table new tab bupropion sr also associate recent clinical trial treatment emergent hypertension contrast tricyclic antidepressant bupropion sr virtually free cardiovascular adverse effect however early study bupropion sr associate elevation supine diastolic blood pressure kiev masco hl wenger tl johnston ja batey sr holloman hc cardiovascular effect bupropion nortriptyline depress outpatient ann clin psychiatry crossref pubmed scopus google scholar roose sp dalack gw glassman ah woodring walsh bt giardina eg cardiovascular effect bupropion depress patient heart disease j psychiatry pubmed google scholar postmarketing surveillance manufacturer receive report hypertension associate bupropion sr individual without preexist hypertension treatment emergent hypertension may common patient receive combination therapy bupropion sr nicotine replacement therapy zyban package insert glaxosmithkline research triangle park ncapril google scholar report exist serious adverse effect result uncontrolled hypertension due bupropion sr treatment alone combination nicotine replacement therapy hypersensitivity reaction report bupropion sr rash report less patient take drug may result immediate delay hypersensitivity addition serum sickness like reaction peloso pm baillie c serum sickness like reaction bupropion letter jama crossref pubmed scopus google scholar bupropion induce erythema multiforme lineberry tw peter jr ge bostwick jm bupropion induce erythema multiforme mayo clin proc pubmed scopus google scholar report bupropion sr patient characteristic predict occurrence either immediate delay hypersensitivity reaction recommend use battery question screen patient bupropion sr may inappropriate previous close head trauma annegers jf hauser wa coan sp rocca wa population base study seizure traumatic brain injury n engl j med crossref pubmed scopus google scholar table affirmative answer question suggest predisposition seizure year traumatic event therefore bupropion sr would contraindicate patient patient history seizure include febrile seizure child give bupropion sr predispose condition seizure structural brain abnormality also contraindication use bupropion sr table early clinical trial immediate release bupropion seizure occur subject bulimia therefore current past diagnosis eat disorder anorexia nervosa bulimia contraindication use bupropion sr table screen question determine whether history close head trauma contraindication bupropion sr adapt permission hay ebbert sr sustain release affirmative response item indicate bupropion sr contraindicate increase seizure risk close head trauma result loss consciousness amnesia within past year close head trauma time result loss consciousness amnesia minute close head trauma time result skull fracture close head trauma time result subdural hematoma brain contusion adapt permission hay ebbert hay jt ebbert jo bupropion treatment tobacco dependence guideline balance risk benefit cns drug crossref pubmed scopus google scholar sr sustain release affirmative response item indicate bupropion sr contraindicate increase seizure risk open table new tab patient preexist hypertension measurement blood pressure level recommend assess potential adverse effect arrangement make periodic measurement course therapy hypertension occur bupropion sr discontinue alternative therapy nicotine dependence consider blood pressure treatment institute individual blood pressure level high enough put risk complication still unclear whether withdrawal bupropion sr alone cause blood pressure level return baseline level individual take bupropion sr develop rash symptom suggest delay hypersensitivity reaction immediately discontinue use medicine discontinuation bupropion sr therapy expectant supportive care usually enough treat hypersensitivity reaction behavioral support pharmacological therapy provide help every tobacco user stop smoking base individual readiness attempt quit behavioral support accomplish brief office intervention involve completion ask patient tobacco use advise quit assess willingness make quit attempt assist quit attempt arrange follow fiore mc bailey wc cohen sj et al treat tobacco use dependence u dept health human service public health service rockville mdjune available www surgeongeneral gov tobacco treat tobacco use pdfgoogle scholar recommend first line pharmacological therapy include bupropion sr patient motivate stop smoking aside provide brief behavioral intervention office clinician must able appropriately select patient treatment bupropion sr understand way limit adverse effect drug prescribe suitable dose duration maximum effect cigarette smoker motivate stop smoking offer appropriate pharmacological therapy treatment bupropion sr alone combination nicotine patch produce considerably high longterm smoke abstinence rate use either nicotine patch alone placebo jorenby de leischow sj nides et al control trial sustain release bupropion nicotine patch smoke cessation n engl j med crossref pubmed scopus google scholar however evidence base study clear recommendation make use bupropion sr nicotine replacement therapy research conduct individual previously use nicotine replacement therapy relapse bupropion sr might particularly attractive motivate another attempt quit smoking patient preference may also guide selection bupropion sr individual may prefer use nonnicotine medication aid cessation attempt reliable predictor success bupropion sr efficacy bupropion sr treat nicotine dependence appear independent history major depression alcoholism hayford ke patten ca rummans ta et al efficacy bupropion smoke cessation smoker former history major depression alcoholism br j psychiatry crossref pubmed scopus google scholar convince evidence bupropion sr efficacious either sex gonzales bjornson w durcan mj et al effect gender relapse prevention smoker treat bupropion sr j prev med abstract full text full text pdf pubmed scopus google scholar dale lc glover ed sachs dp et al bupropion smoke cessation predictor successful outcome chest crossref pubmed scopus google scholar patient concern weight gain smoke abstinence may encourage use bupropion sr evidence date indicate bupropion sr appropriate first line treatment cigarette smoker motivate stop contraindication use accord u public health service clinical practice guideline pregnant lactate smoker provide behavioral intervention first fiore mc bailey wc cohen sj et al treat tobacco use dependence u dept health human service public health service rockville mdjune available www surgeongeneral gov tobacco treat tobacco use pdfgoogle scholar unable maintain tobacco abstinence prescribe bupropion sr benefit outweigh risk guideline also recommend although little evidence efficacy clinician may consider prescribe bupropion sr child adolescent smoker motivate quit clinical evidence nicotine dependence fiore mc bailey wc cohen sj et al treat tobacco use dependence u dept health human service public health service rockville mdjune available www surgeongeneral gov tobacco treat tobacco use pdfgoogle scholar recent meta analysis suggest bupropion sr probably effective increase smokeless tobacco abstinence month ebbert jo rowland lc montori vm vickers ks erwin pj dale lc treatment spit tobacco use quantitative systematic review addiction crossref pubmed scopus google scholar clinical trial date assess efficacy bupropion treatment tobacco user pipe cigar smoker appropriate target dosage bupropion sr mg mg twice daily therapy initiate medication start mg day increase mg twice daily steady state blood level reach approximately week initiation medication target quit date smoker approximately week start medication week therapy individual still unable maintain abstinence continue therapy bupropion sr may helpful instead treatment option offer intensified behavioral intervention add increase nicotine replacement therapy choose second line pharmacotherapy clonidine nortriptyline fiore mc bailey wc cohen sj et al treat tobacco use dependence u dept health human service public health service rockville mdjune available www surgeongeneral gov tobacco treat tobacco use pdfgoogle scholar clinical trial duration therapy generally week treatment month bupropion sr appear effective delay relapse smoking hay jt hurt rd rigotti na et al sustain release bupropion pharmacologic relapse prevention smoke cessation randomize control trial ann intern med crossref pubmed scopus google scholar bupropion sr effective safe treatment tobacco use dependence appropriate first line pharmacological treatment smoker motivate stop contraindication use appropriate selection patient bupropion sr monitoring medication prescribe minimize adverse effect combine bupropion sr nicotine patch may increase treatment effectiveness length treatment bupropion sr may short week induction smoke cessation long month aid relapse prevention bupropion sr useful role adjunct behavioral support every clinician engage treatment tobacco use dependence portion article reproduce permission adis international limit auckland new zealand original publication hay ebbert hay jt ebbert jo bupropion treatment tobacco dependence guideline balance risk benefit cns drug crossref pubmed scopus google scholar thank ann b peterson assistance preparation submit manuscript,Hays JT,2003,Mayo Clin Proc,https://doi.org/10.4065/78.8.1020,12911050,Hays JT; Ebbert JO,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D004342: Drug Hypersensitivity; D006801: Humans; D006973: Hypertension; D018579: Patient Selection; D016032: Randomized Controlled Trials as Topic; D014029: Tobacco Use Disorder",,,https://openalex.org/W2043339387,63,8,1,31173,5053,151,en,en
false,randomize trial olanzapine versus placebo symptomatic acute treatment schizophrenic prodrome,background prodromal phase schizophrenic disorder describe prospectively present study aim determine short term efficacy safety olanzapine treatment prodromal symptom compare placebo method double blind randomize parallel group placebo control trial fix flexible dose conduct four site sixty patient meet prodromal diagnostic criterion include attenuate psychotic symptom determine structure interview olanzapine mg daily placebo prescribe week result mixed effect repeat measure analysis treatment time interaction change baseline scale prodromal symptom total score statistically significant post hoc analyse reveal olanzapine placebo difference reach p week p week rating extrapyramidal symptom remain low group significantly different olanzapine patient gain lb versus lb placebo patient p conclusion short term analysis suggest olanzapine associate significantly great symptomatic improvement significantly great weight gain placebo prodromal patient extrapyramidal symptom olanzapine minimal similar placebo future research long term patient need recommendation make regard routine treatment,Woods SW,2003,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(03)00321-4,12915290,Woods SW; Breier A; Zipursky RB; Perkins DO; Addington J; Miller TJ; Hawkins KA; Marquez E; Lindborg SR; Tohen M; McGlashan TH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W1967674108,110,15,1,1485,228,11,en,en
false,serum antimuscarinic activity clozapine treatment,study attempt verify serum antimuscarinic activity relate clozapine dose importantly clozapine plasma concentration explore whether norclozapine serum antimuscarinic activity explore whether antimuscarinic activity relate clozapine side effect compare serum antimuscarinic activity clozapine antiparkinsonian drug antipsychotic patient participate double blind clozapine study h qnb assay use measure serum antimuscarinic activity baseline medication week haloperidol trial week clozapine trial either mg consecutive week clozapine trial remain dos nonresponders clozapine level predict serum antimuscarinic activity well clozapine dose end st clozapine trial correlation level explain variance serum antimuscarinic activity r p n clozapine level good predictor serum antimuscarinic activity patient take mg correct clozapine level within subject correlation norclozapine level serum antimuscarinic activity relatively high significant r f df p constipation significantly associate high serum antimuscarinic activity st clozapine trial clozapine associate clearly high antimuscarinic activity antipsychotic low antiparkinsonians vitro study new clinical study need verify whether norclozapine may significantly contribute antimuscarinic activity clozapine treatment,de Leon J,2003,J Clin Psychopharmacol,https://doi.org/10.1097/01.jcp.0000085405.08426.73,12920408,de Leon J; Odom-White A; Josiassen RC; Diaz FJ; Cooper TB; Simpson GM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D014150: Antipsychotic Agents; D003024: Clozapine; D004311: Double-Blind Method; D006801: Humans; D018727: Muscarinic Antagonists; D011569: Psychiatric Status Rating Scales; D011813: Quinuclidinyl Benzilate; D011976: Receptors, Muscarinic; D012559: Schizophrenia",,,https://openalex.org/W1978094417,56,6,1,1797,312,9,en,en
false,effectiveness rapid initial dose escalation forty milligram per day oral olanzapine acute agitation,patient experience acute decompensation schizophrenia bipolar disorder often present agitate state agitation present barrier therapy interrupt typical physician patient alliance create disruptive even hazardous environment rapid assessment effective treatment necessary manage agitation potentially shorten time recovery one hundred forty eight acutely agitate patient receive either rapid initial dose escalation ride mg oral olanzapine allow day mg day mg thereafter usual clinical practice ucp patient receive mg olanzapine plus mg lorazepam day mg day olanzapine mg thereafter positive negative syndrome scale excite component panss ec poor impulse control tension hostility uncooperativeness excitement measure hour primary measure secondary assessment agitation safety also perform agitation improve significantly baseline treatment group however improvement ride strategy superior ucp ride group improvement superior primary efficacy measure panss excite hour superior agitation measure end double blind treatment treatment well tolerate clinically significant difference safety measure treatment limit oversedation attention improve baseline group study demonstrate value olanzapine treatment acutely agitate patient new approach olanzapine dose expand initial dose range mg may offer superior efficacy rapidly effectively control symptom agitation,Baker RW,2003,J Clin Psychopharmacol,https://doi.org/10.1097/01.jcp.0000085406.08426.a8,12920409,Baker RW; Kinon BJ; Maguire GA; Liu H; Hill AL,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011595: Psychomotor Agitation",,,https://openalex.org/W1973627329,118,19,1,1859,319,9,en,en
false,actigraphic measurement effect single dose haloperidol olanzapine spontaneous motor activity normal subject,quantitatively examine effect haloperidol olanzapine spontaneous motor activity normal subject randomize double blind placebo control medication study normal volunteer n subject receive dose either haloperidol mg n olanzapine mg n placebo n admit hospital next hour subject wear actigraphic monitor record movement second epoch simpson angus extrapyramidal side effect scale sa barnes akathisia scale ba administer hour medication give compare placebo total motor activity decrease olanzapine p haloperidol ns significantly epochs zero movement olanzapine haloperidol placebo non zero epoch mean activity count distribution activity count differ significantly among group positive finding sa ba olanzapine decrease total motor activity increase amount time subject immobile rather affect magnitude movement period activity effect occur dose olanzapine low enough cause clinically observe extrapyramidal side effect result suggest actigraphy useful sensitive noninvasive tool measure effect antipsychotic spontaneous motor activity,Kiang M,2003,J Psychiatry Neurosci,,12921224,Kiang M; Daskalakis ZJ; Christensen BK; Remington G; Kapur S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D006220: Haloperidol; D006801: Humans; D008875: Middle Aged; D009043: Motor Activity; D009127: Muscle Rigidity; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales,,,https://openalex.org/W1484546679,130,18,1,1505,260,7,en,en
false,olanzapine psychotic behavioral disturbance alzheimer disease,evaluate efficacy safety olanzapine treatment psychotic behavioral disturbance alzheimer disease medline january science citation index search perform key search term include olanzapine alzheimer dementia four trial olanzapine subsequent post hoc analysis review three trial find benefit associate olanzapine use fourth trial olanzapine appear effective treat psychotic behavioral disturbance associate alzheimer disease however appropriate dose remain determine benefit olanzapine therapy must weigh adverse effect profile olanzapine alternative treatment option,Schatz RA,2003,Ann Pharmacother,https://doi.org/10.1345/aph.1d050,12921516,Schatz RA,article,D016428: Journal Article; D016454: Review,D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D006801: Humans; D001523: Mental Disorders; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W2154735526,73,9,1,752,117,5,en,en
false,selegiline treatment attention deficit hyperactivity disorder child double blind randomize trial,attention deficit hyperactivity disorder adhd common disorder childhood affect school age child conventional stimulant medication recognize specialist parent useful symptomatic treatment nevertheless approximately adhd child treat respond adequately tolerate associate adverse effect difficulty highlight need alternative safe effective medication treatment disorder selegiline type b monoamine oxidase inhibitor maoi metabolize amphetamine methamphetamine stimulant compound may useful treatment adhd author undertake study evaluate double blind control condition efficacy selegiline adhd child total child adhd define dsm iv randomize selegiline methylphenidate dose age weight adjust basis selegiline mg day year mg day year group methylphenidate mg kg day group week double blind clinical trial principal measure outcome teacher parent adhd rating scale patient assess child psychiatrist baseline day medication start significant difference observe two protocol parent teacher rating scale score although number dropout methylphenidate group high selegiline group significant difference two protocol term dropout decrease appetite difficulty fall asleep headache observe methylphenidate group result study must consider preliminary suggest selegiline may beneficial treatment adhd addition tolerable side effect profile may consider one advantage selegiline treatment adhd,Akhondzadeh S,2003,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/s0278-5846(03)00117-9,12921918,Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D012642: Selegiline",,,https://openalex.org/W2081642360,120,18,1,2006,345,14,en,en
false,integrate analysis acute treatment emergent extrapyramidal syndrome patient schizophrenia olanzapine clinical trial,article abstractbackground frequency severity extrapyramidal syndrome eps evaluate patient dsm iii dsm iv schizophrenia acute phase week randomize double blind control trial integrate olanzapine clinical trial database method retrospective analysis include clinical trial patient november july incidence dystonic parkinsonian akathisia event compare use treatment emergent adverse event data categorical analysis simpson angus scale barnes akathisia scale ba score use anticholinergic medication baseline endpoint change simpson angus scale ba score compare result significantly small percentage olanzapine treat patient experience dystonic event haloperidol p risperidone treat patient p significantly great percentage haloperidol treat patient experienced parkinsonian p akathisia p event olanzapine treat patient categorical analysis simpson angus scale score show significantly haloperidol p risperidone treat patient p develop parkinsonism olanzapine treat patient olanzapine treat patient experience significantly great reduction simpson angus scale score haloperidol p risperidone p clozapine treat p patient categorical analysis ba score show significantly haloperidol treated patient experience treatment emergent akathisia versus olanzapine treat patient p significantly great reduction ba score experience olanzapine treatment versus placebo p haloperidol p risperidone p treatment significantly small percentage olanzapine treat patient receive anticholinergic medication compare haloperidol p risperidone treat patient p compare olanzapine treat patient duration anticholinergic cotreatment significantly long among haloperidol p risperidone treat patient p significantly short among clozapine treat patient p conclusion analysis available data olanzapine clinical trial lend additional support olanzapine favorable eps profile,Carlson CD,2003,J Clin Psychiatry,https://doi.org/10.4088/jcp.v64n0807,12927004,Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D018680: Cholinergic Antagonists; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2031213515,139,16,1,2459,388,13,en,en
false,pharmacologic myocardial protection patient undergo noncardiac surgery quantitative systematic review,brief number drug test clinical trial decrease cardiac complication patient undergo noncardiac surgery compare result study conduct quantitative systematic review medline embase cochrane database search randomize trial assess myocardial ischemia myocardial infarction day cardiac mortality adverse effect data combine use fixed effect model express peto odds ratio confidence interval ci number need treat harm nnt h twenty one trial involve patient include trial use blocker drug patient clonidine mivazerol patient diltiazem verapamil patient nitroglycerin patient trial inactive control direct comparison blocker decrease ischemic episode surgery versus placebo ci nnt surgery versus control ci nnt agonist decrease ischemia surgery versus ci nnt blocker reduce risk myocardial infarction versus ci nnt trial high risk patient include effect agonists myocardial infarction significant versus ci blocker significantly decrease risk cardiac death ci nnt agonists significantly decrease risk cardiac death ci nnt calcium channel blocker nitroglycerin evidence benefit lack common adverse effect bradycardia occur patient receive adrenergic blocker versus control ci nnh implication among drug test randomize control trial blocker clonidine mivazerol effective prevent cardiac complication patient undergo noncardiac surgery blocker high risk patient likely benefit treatment valid study require directly compare efficacy class drug determine dose time duration treatment influence outcome,Stevens RD,2003,Anesth Analg,https://doi.org/10.1213/01.ane.0000074795.68061.16,12933373,Stevens RD; Burri H; Tramèr MR,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review; D000078182: Systematic Review","D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D009202: Cardiomyopathies; D006801: Humans; D011183: Postoperative Complications; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D018570: Risk Assessment; D013514: Surgical Procedures, Operative",,,https://openalex.org/W2165907198,111,13,1,2436,486,17,en,en
false,safety early efficacy oral load divalproex versus standard titration divalproex lithium olanzapine placebo treatment acute mania associate bipolar disorder,previous study examine safety tolerability oral load divalproex sodium treatment acute mania early efficacy dose strategy purpose study evaluate early efficacy oral load divalproex pool analysis subject randomize double blind parallel group active placebo control study use compare efficacy safety tolerability oral load divalproex standard titration divalproex lithium olanzapine placebo subject inpatient diagnose acute mania associate bipolar disorder dsm iii r iv sads change version patient administer oral load divalproex mg kg day day follow mg kg day increase physician discretion standard titration divalproex initiate mg titrate microg ml lithium mg initial dose titrate meq l olanzapine mg q initial dose mg day placebo result demonstrate early efficacy advantage oral load divalproex compare standard titration divalproex day efficacy improve lithium day efficacy difference divalproex load olanzapine divalproex load show great efficacy placebo time point divalproex load well tolerate well tolerate active treatment measure adverse event change laboratory parameter result suggest oral load divalproex lead rapid antimanic effect compare standard titration divalproex lithium placebo well tolerate olanzapine well tolerate lithium standard titration divalproex,Hirschfeld RM,2003,J Clin Psychiatry,https://doi.org/10.4088/jcp.v64n0717,12934987,Hirschfeld RM; Baker JD; Wozniak P; Tracy K; Sommerville KW,article,"D016430: Clinical Trial; D016428: Journal Article; D017418: Meta-Analysis; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D039721: Diagnostic and Statistical Manual of Mental Disorders; D004311: Double-Blind Method; D004361: Drug Tolerance; D005260: Female; D006801: Humans; D008094: Lithium; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D016032: Randomized Controlled Trials as Topic; D012720: Severity of Illness Index; D017186: Titrimetry; D016896: Treatment Outcome; D014635: Valproic Acid,,,https://openalex.org/W2043373511,191,28,1,1827,299,11,en,en
false,placebo control double blind study efficacy safety aripiprazole patient acute bipolar mania,author compare efficacy safety aripiprazole novel antipsychotic placebo treatment patient acute manic mixed episode bipolar disorder week multicenter double blind study randomly assign bipolar disorder patient acute manic mixed episode aripiprazole mg day reduce mg day need tolerability placebo patient remain hospitalize least week primary efficacy measure mean change baseline total score young mania rating scale response define decrease score aripiprazole produce statistically significant mean improvement total score young mania rating scale compare placebo versus respectively produce significantly high response rate versus key efficacy variable response per young mania rating scale clinical global impression bipolar version score severity illness mania change precede phase mania aripiprazole separate placebo day completion rate significantly high aripiprazole placebo versus discontinuation due adverse event differ significantly aripiprazole placebo group significant change body weight versus placebo aripiprazole associate elevate serum prolactin qtc prolongation aripiprazole significantly great efficacy placebo treatment bipolar disorder patient acute manic mixed episode safe well tolerate randomize control trial,Keck PE,2003,Am J Psychiatry,https://doi.org/10.1176/appi.ajp.160.9.1651,12944341,Keck PE; Marcus R; Tourkodimitris S; Ali M; Liebeskind A; Saha A; Ingenito G; Aripiprazole Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D000068180: Aripiprazole; D001480: Basal Ganglia Diseases; D001714: Bipolar Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D010879: Piperazines; D010919: Placebos; D015363: Quinolones; D016896: Treatment Outcome,,,https://openalex.org/W2095635647,120,18,1,1664,282,7,en,en
false,effect methylphenidate desipramine l dopa attention inhibition child attention deficit hyperactivity disorder,objective study investigate effect methylphenidate mph attention inhibition child attention deficit hyperactivity disorder adhd establish relative contribution noradrenergic dopaminergic system effect addition mph two drug administer order affect transmitter system selectively l dopa dopamine da agonist desipramine dmi noradrenaline na uptake inhibitor sixteen child adhd perform stop task laboratory task measure ability inhibit ongoing action double blind randomize within subject design child receive acute clinical dose mph dmi l dopa placebo measure performance plasma determine result indicate inhibition performance improve dmi mph l dopa response time stop signal marginally shorten intake dmi mph decrease omission choice error cause fast reaction time trial without stop tone effect l dopa whatsoever note prolactin level increase hiaa level lower dmi relative placebo suggest effect mph attention due combination noradrenergic dopaminergic mechanism improve inhibition dmi could serotonergically mediate,Overtoom CC,2003,Behav Brain Res,https://doi.org/10.1016/s0166-4328(03)00097-4,14529800,Overtoom CC; Verbaten MN; Kemner C; Kenemans JL; van Engeland H; Buitelaar JK; van der Molen MW; van der Gugten J; Westenberg H; Maes RA; Koelega HS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002755: Choice Behavior; D003891: Desipramine; D015259: Dopamine Agents; D004311: Double-Blind Method; D004791: Enzyme Inhibitors; D006801: Humans; D006897: Hydroxyindoleacetic Acid; D007266: Inhibition, Psychological; D007980: Levodopa; D008297: Male; D008774: Methylphenidate; D011388: Prolactin; D011930: Reaction Time",,,https://openalex.org/W2124747666,137,19,1,1437,243,11,en,en
false,effect educational intervention antipsychotic induce weight gain,assess effect educational intervention antipsychotic induce weight gain among patient schizophrenia quasi experimental seventy patient dsm iv diagnosis schizophrenia schizoaffective disorder enter month study condicted united state participant begin receive olanzapine treatment enter study patient randomly assign intervention group standard care group next month intervention group participate weekly psychoeducation class focus nutrition exercise live healthy lifestyle patient follow additional month assess weight change statistically significant difference weight change two group observe post treatment endpoint endpoint mean weight change intervention group pound mean weight change standard care group pound group men gain significantly weight woman result indicate structure educational intervention might positive effect antipsychotic induce weight gain among patient schizophrenia,Littrell KH,2003,J Nurs Scholarsh,https://doi.org/10.1111/j.1547-5069.2003.00237.x,14562491,Littrell KH; Hilligoss NM; Kirshner CD; Petty RG; Johnson CG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001294: Attitude to Health; D001569: Benzodiazepines; D015992: Body Mass Index; D005260: Female; D007722: Health Knowledge, Attitudes, Practice; D006801: Humans; D008019: Life Style; D008297: Male; D008875: Middle Aged; D024802: Nurse's Role; D015403: Nursing Evaluation Research; D052756: Nutritional Sciences; D009765: Obesity; D000077152: Olanzapine; D010353: Patient Education as Topic; D010890: Pirenzepine; D015397: Program Evaluation; D012559: Schizophrenia; D012657: Self-Help Groups; D015430: Weight Gain",,,https://openalex.org/W2113540412,79,10,1,1203,182,8,en,en
false,clozapine pregnancy,article review relation clozapine pregnancy six case report identify literature pregnant patient receive clozapine novartis basle switzerland pharmacovigilance epidemiology service data nearly case summarize article also describe case patient paranoid schizophrenia hospitalize time age receive clozapine year old daily dosage mg become asymptomatic age become pregnant continued clozapine pregnancy first pregnancy receive insulin due gestational diabetes associate body weight mass bwm n second pregnancy bwm develop diabetes deliver term daughter time report year old two girl well developmental delay psychotic symptom exacerbation plasma concentration clozapine diminishes pregnancy due high hepatic metabolism distribution volume monitor plasma concentration clozapine help adjust dosage case psychotic symptom exacerbation follow recommend increase clozapine dosage add classic antipsychotic like perphenazine trifluoperazine haloperidol diabetes obesity glucose intolerance family history diabetes risk factor develop gestational diabetes follow patient take atypical antipsychotic include constant monitoring blood glucose hb lipid dosage complication labor clozapine increase secretion oxytocine contraction uterine muscle study explain clozapine affect labor exactly case study report use forceps vacuum cesarean stoner describe neonatal convulsion day birth mother receive mg clozapine also lorazepam haloperidol pregnancy newborn withdrawal lorazepam increase risk convulsion also haloperidol diminish convulsion threshold floppy infant syndrome case describe dimichele mother receive daily dosage mg clozapine mg lorazepam time day explain hypotonia stoner report second case mother receive mg clozapine pregnancy give birth child convulsion neither hypotonia case describe concern study child age year stoner dickson year old barnas mention developmental problem similar two daughter patient pharmacovigilance service novarits report malformation report must consider caution since represent pregnancy report spontaneously pharmaceutical company portion pregnancy associate clozapine specific risk mother child attribute use clozapine pregnancy however plasma concentration clozapine high fetus compare mother barnas therefore minimal dosage use since clozapine present maternal milk breast feed avoid advantage use clozapine pregnancy must exceed risk justified continue use medication even data classic antipsychotic e g haloperidol extensive risk psychotic exacerbation high substitution clozapine recommend psychosocial support obstetrical follow must intensive institutional pharmacovigilance service complement one provide industry also case control cohort study essential well estimate long term risk,Nguyen HN,2003,Encephale,,14567163,Nguyen HN; Lalonde P,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007231: Infant, Newborn; D011247: Pregnancy; D011248: Pregnancy Complications; D011256: Pregnancy Outcome; D012559: Schizophrenia",,,https://openalex.org/W245501198,26,6,1,4061,724,35,en,en
false,effectiveness bupropion sustain release smoke cessation health care set,efficacy bupropion hydrochloride sustain release sr zyban smoke cessation evaluate clinical trial include frequent person behavioral counseling actual practice setting determine differential effectiveness bupropion sr combination behavioral intervention minimal moderate intensity actual practice set open label randomize trial year follow large health system group health cooperative base seattle adult smoker n interest quit smoke participant randomly assign receive combination bupropion sr mg behavioral counseling minimal moderate intensity primary outcome measure self report point prevalence day nonsmoking status month follow target quit date secondary outcome include adverse abstinence effect report since begin treatment bupropion sr month significantly high rate nonsmoking observe among receive large bupropion sr dose p month moderate intensity counsel associate significantly high rate nonsmoking p month high dose associate significantly increase frequency self report symptom difficulty sleep p difficulty concentrate p shakiness tremor p gastrointestinal problem p decrease frequency report desire smoke p actual practice set combination bupropion sr minimal moderate counseling associate year quit rate suggest exist health care system substantially decrease tobacco use rate among enrollee provide modest intervention,Swan GE,2003,Arch Intern Med,https://doi.org/10.1001/archinte.163.19.2337,14581254,Swan GE; McAfee T; Curry SJ; Jack LM; Javitz H; Dacey S; Bergman K,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D016642: Bupropion; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016540: Smoking Cessation; D016896: Treatment Outcome,,,https://openalex.org/W2052144884,91,13,1,1855,300,5,en,en
false,effect modafinil sustain attention performance quality life osa patient residual sleepiness treat ncpap,patient obstructive sleep apnea hypopnea syndrome osa h regular user nasal continuous positive airway pressure ncpap therapy continue experience daytime sleepiness impair performance quality life randomize double blind placebo control parallel group study conduct determine effect modafinil sustain attention performance functional quality life osa hs patient residual daytime sleepiness regular user ncpap therapy seventy seven patient receive modafinil mg day week mg day week patient receive match placebo daily week sustain attention performance psychomotor vigilance task pvt functional status quality life use functional outcome sleep questionnaire fosq measure frequency lapse attention pvt performance significantly decrease median slow reaction time significantly improve patient receive ncpap plus modafinil compare receive ncpap plus placebo p number lapse transform p median reaction time p reciprocal slow reaction time treatment ncpap plus modafinil significantly improve fosq total score week vigilance subscale score week activity level subscale score week compare treatment ncpap plus placebo p consistent previous result objective subjective measure sleepiness modafinil use adjunctively improve performance test behavioral alertness reduce functional impairment patient osa h regular user ncpap therapy still experience sleepiness,Dinges DF,2003,Sleep Med,https://doi.org/10.1016/s1389-9457(03)00108-4,14592280,Dinges DF; Weaver TE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001143: Arousal; D001288: Attention; D001559: Benzhydryl Compounds; D045422: Continuous Positive Airway Pressure; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009296: Nasal Cavity; D011597: Psychomotor Performance; D011788: Quality of Life; D012890: Sleep; D020181: Sleep Apnea, Obstructive; D012894: Sleep Stages",,,https://openalex.org/W2161061887,147,22,1,1823,299,4,en,en
false,effectiveness cost olanzapine haloperidol treatment schizophrenia subtitle randomize control trial subtitle,although olanzapine widely adopt treatment choice schizophrenia long term effectiveness cost evaluate control trial comparison standard antipsychotic drug evaluate effectiveness cost impact olanzapine compare haloperidol treatment schizophrenia double blind randomize control trial randomization conduct june june u department veteran affair medical center three hundred nine patient diagnostic statistical manual mental disorder fourth edition diagnosis schizophrenia schizoaffective disorder serious symptom serious dysfunction previous year fifty nine percent fully complete partially complete follow assessment patient randomly assign receive flexibly dose olanzapine mg prophylactic benztropine mg n haloperidol mg n month standardize measure symptom quality life neurocognitive status adverse effect medication veteran affair administrative data interview concern non va service use use estimate cost perspective va health care system society whole ie consumption resource behalf patient significant difference group study retention positive negative total symptom schizophrenia quality life extrapyramidal symptom olanzapine associate reduce akathisia intention treat analysis p low symptom tardive dyskinesia secondary analysis include observation blind treatment study drug small significant advantage also observe measure memory motor function olanzapine also associate frequent report weight gain significantly great va cost range dollar dollar annually difference societal cost somewhat small significant olanzapine demonstrate advantage compare haloperidol combination prophylactic benztropine compliance symptom extrapyramidal symptom overall quality life benefit reduce akathisia improve cognition must balance problem weight gain high cost,Rosenheck R,2003,JAMA,https://doi.org/10.1001/jama.290.20.2693,14645311,Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000328: Adult; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001590: Benztropine; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D017048: Health Care Costs; D006296: Health Services; D006801: Humans; D008297: Male; D008875: Middle Aged; D018727: Muscarinic Antagonists; D009483: Neuropsychological Tests; D000077152: Olanzapine; D010890: Pirenzepine; D011788: Quality of Life; D012559: Schizophrenia; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2168875379,148,30,1,2424,387,7,en,en
false,epidural clonidine analgesia intractable cancer pain,although vast majority patient cancer pain receive effective analgesia standard therapy patient particularly neuropathic pain continue experience severe pain despite large systemic intraspinal opioids animal study suggest intraspinal adrenergic agonist may effective case eighty five patient severe cancer pain despite large dos opioids therapy limit side effect opioids randomize receive double blind manner gmg h epidural clonidine placebo day together rescue epidural morphine pain assess visual analog score va mcgill pain questionnaire daily epidural morphine use success define decrease either morphine use va pain alternative variable either decrease remain constant blood pressure heart rate degree nausea sedation monitor successful analgesia common epidural clonidine placebo particularly prominent neuropathic pain v pain score low end treatment period patient neuropathic pain treat clonidine rather placebo whereas morphine use unaffected clonidine placebo decrease blood pressure heart rate hypotension consider serious complication patient receive clonidine patient receive placebo study confirm find previous animal study show effective potent analgesic property intraspinal adrenergic agonist suggest epidural clonidine may provide effective relief intractable cancer pain particular neuropathic type,Eisenach JC,1995,Pain,https://doi.org/10.1016/0304-3959(94)00209-w,7478682,Eisenach JC; DuPen S; Dubois M; Miguel R; Allin D; Epidural Clonidine Study Group,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D015360: Analgesia, Epidural; D000701: Analgesics, Opioid; D000704: Analysis of Variance; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009020: Morphine; D009369: Neoplasms; D009437: Neuralgia; D010148: Pain, Intractable; D010919: Placebos",,,https://openalex.org/W1968535715,56,7,1,1763,295,12,en,en
false,epidural clonidine sufentanil intraoperative postoperative analgesia,study contrast efficacy side effect epidural clonidine sufentanil perioperative period use randomize prospective double blind study design patient undergo abdominal surgery propofol nitrous oxide anesthesia enrol anesthesia epidural catheter insert l l interspace induction anesthesia patient receive epidurally either clonidine micro gram kg ml infuse min follow micro gram center dot kg center dot h infusion ml h h group sufentanil micro gram kg ml min follow micro gram center dot kg center dot h infusion ml h h group intraoperatively increase arterial blood pressure heart rate respond propofol bolus mg kg treat bolus intravenous iv sufentanil micro gram kg postoperatively iv sufentanil bolus micro gram give patient control analgesia pca device postoperative analgesia assess record iv pca sufentanil requirement patient visual analog scale va h sedation analog scale side effect also record plasma clonidine sufentanil concentration measure min h number reinjections propofol n group v group iv sufentanil n group v group significantly reduce p epidural clonidine group early post operative period pain score rescue analgesic requirement low group discontinuation epidural infusion reduce pca requirement good va score still note group micro gram iv sufentanil group v micro gram group p difference sedation score epidural clonidine sufentanil moderately affected heart rate blood pressure two instance awareness group one episode respiratory depression group report epidural clonidine improve intraoperative hemodynamic stability compare epidural sufentanil substance provide reliable postoperative analgesia longer last residual analgesic effect demonstrate use epidural clonidine substance show different potentially worrying side effect anesth analg,De Kock M,1995,Anesth Analg,https://doi.org/10.1097/00000539-199512000-00007,7486097,De Kock M; Famenne F; Deckers G; Scholtes JL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D000293: Adolescent; D000328: Adult; D015360: Analgesia, Epidural; D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D018686: Anesthetics, Intravenous; D001794: Blood Pressure; D003000: Clonidine; D003243: Consciousness; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006993: Hypnotics and Sedatives; D007430: Intraoperative Care; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement; D010149: Pain, Postoperative; D015742: Propofol; D011446: Prospective Studies; D017409: Sufentanil; D013565: Sympatholytics",,,https://openalex.org/W2036389238,79,9,1,2547,469,17,en,en
false,comparison european american dose regimen schizophrenic patient clozapine efficacy side effect,present comparison result two study patient clozapine american study n hillside hospital glen oak ny european study n innsbruck university clinic innsbruck austria examine efficacy side effect schizophrenic patient atypical neuroleptic substantial difference dose regimen use continent reflect study report question major clinical implication whether high commonly use united state lead good outcome different profile side effect outcome function serum concentration examine result confirm low dose low clozapine blood level less degree side effect austrian cohort compare american sample surprisingly clinical efficacy low dose regimen superior high dose reason anomaly explore,Pollack S,1995,Psychopharmacol Bull,,7491385,Pollack S; Lieberman JA; Fleischhacker WW; Borenstein M; Safferman AZ; Hummer M; Kurz M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001317: Austria; D003024: Clozapine; D004304: Dosage Forms; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D012449: Safety; D012559: Schizophrenia; D013997: Time Factors; D014481: United States",,,https://openalex.org/W2411100212,120,19,1,979,179,8,en,en
false,methylphenidate effect laboratory aggression measure child adhd,study investigate utility point subtraction aggression paradigm psap computerized laboratory analog aggression measure measure effect methylphenidate mph aggressive respond child dsm iii r diagnosis attention deficit hyperactivity disorder adhd high rating child behavior checklist aggression factor cbcl achenbach result report subject age year test baseline unmedicated condition double blind administration placebo mg kg mph mg kg mph main effect decrease aggressive respond mph find dose related change repeat measure anova f df p post hoc analysis tukey hsd indicate mg kg significantly p different placebo implication use psap future investigation medication aggressive child discus,Casat CD,1995,Psychopharmacol Bull,,7491391,Casat CD; Pearson DA; Van Davelaar MJ; Cherek DR,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004305: Dose-Response Relationship, Drug; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011569: Psychiatric Status Rating Scales",,,https://openalex.org/W2416447474,81,12,1,992,180,7,en,en
false,risperidone versus clozapine treatment schizophrenic patient acute symptom double blind randomize trial,heinrich kurt eckhard klieser erlo lehmann eckhart kinzler helga hruschka risperidone versus clozapine treatment schizophrenic patient acute symptom double blind randomize trial prog neuro psychopharmacol biol psychiat order verify hypothesis risperidone useful therapeutic alternative clozapine author carry randomize double blind trial patient paranoid hallucinatory psychosis treatment last day three group patient receive either mg risperidone n mg risperidone n mg clozapine n daily tolerance mg risperidone globally assess good mg clozapine drop clozapine mostly cause side effect whereas risperidone tend occur therapeutic inefficacy antipsychotic effect highly significant clinically relevant risperidone clozapine,Heinrich K,1994,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/0278-5846(94)90029-9,7509495,Heinrich K; Klieser E; Lehmann E; Kinzler E; Hruschka H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D003024: Clozapine; D004311: Double-Blind Method; D004562: Electrocardiography; D004569: Electroencephalography; D005260: Female; D006801: Humans; D007231: Infant, Newborn; D007555: Isoxazoles; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012563: Schizophrenia, Paranoid",,,https://openalex.org/W1974306858,125,19,1,1011,188,15,en,en
false,risperidone treatment schizophrenia,purpose study investigate safety efficacy risperidone treatment schizophrenic patient determine optimal dose double blind study include schizophrenic patient draw site united state patient randomly assign week treatment placebo one four risperidone mg mg haloperidol daily clinical improvement reduction total score positive negative syndrome scale schizophrenia study end point show patient receive mg risperidone receive mg receive mg receive mg receive haloperidol receive placebo statistically significant difference clinical improvement find mg risperidone versus placebo versus haloperidol positive symptom score significantly low mg risperidone mg haloperidol placebo negative symptom score however reduce significantly compare placebo mg risperidone incidence extra pyramidal side effect measure extrapyramidal symptom rating scale significantly high patient treat mg risperidone mg haloperidol placebo result indicate optimal daily dose risperidone schizophrenic patient study mg dose effective mg incidence extrapyramidal symptom patient receive mg risperidone high patient receive placebo risperidone safe antipsychotic effective positive negative symptom schizophrenia,Marder SR,1994,Am J Psychiatry,https://doi.org/10.1176/ajp.151.6.825,7514366,Marder SR; Meibach RC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W153750880,45,6,1,1764,315,6,en,en
false,methylphendate adhd influence age iq neurodevelopmental status,summary sixty nine child attention deficit hyperactivity disorder adhd underwent blind methyl phenidate trial adhd alone without learn disability additional neurodevelopmental disorder child adhd alone per cent improve significantly methylphenidate differ significantly per cent response rate child adhd neurodevelopmental disorder result confirm add research literature indicate adhd child preschool age co exist neurological disorder may benefit methylphenidate r sum methylph nidate et adhd influence de l ge du qi et de l tat neurod velopmental de essais aveugles de traitement par thylph nidate ont entrepris chez enfants presentant un trouble de ficit attention et hyperactivity adhd dans ca l adhd tait isote avec ou sans trouble de apprentissages et dans le ca restant il avait en plus de trouble neurod velopmentaux nd parmi les enfants avec adhd isol pour cent furent lior significativement par le thylph nidate ceci ne diff rait pa significativement du pour cent taux de r pons chez les enfants avec adhd etc autres trouble nd ce r sultats confirment et ajouterit aux donn e de la litt rature indiquant que les enfants adhd ge pr scolaire avec ou sans trouble neurologique coexistant peuvent b n ficicr du thylph nidate zusammenfassung methylphenidat und adhd einflu von alter iq und entwicklungsneurologischem befund bei kindern mit aufmerksamkeitsst rungen und hyperaktivit adhd wurden blinde behandlungsversuche mit methylphenidat durchgef hrt kindern hatten nur eine adhd mit oder ohne lernschw che und hatten zu tzlich entwicklungsneurologische nd st rungen von den kindern mit adhd allein zeigten prozent eine signifikante besserung auf methylphenidat e bestand kein signifikanter unterschied zur prozent ansprechrate der kinder mit adhd und andercn nd st rungen die ergebnisse best tigen und erg nzen die wissenschaftliche literatur dahingehend da vorschulkinder mit adhd und oder mit gleichzeitig bestehenden neurologischen erkrankungen von der behandlung mit methylphenidat profitieren resumen metilfenidato adhd influencia de la edad ci estatus neuroevolutivo sesenta nueve ni os con alteraci n de la atencion e hiperactividad aah adhd en ingl fueron sometidos una prueba con metilfenidato ciega tenian solo aah con sin dificultad para el aprendizaje tenian adem alteraciones del desarrollo ad de los ni con aah solo por ciento mejoraron significativamente con el metilfenidato esta respuesta diferia significativamente del promedio de respuesta por ciento en ni con aah otra alteracion del desarrollo ad los resultados confirman coadyuvan la literatura indicando que los ni con aah en edad preescolar una alteraci n neurol gica coexistente pueden beneficiarse del metilfenidato,Mayes SD,1994,Dev Med Child Neurol,https://doi.org/10.1111/j.1469-8749.1994.tb11811.x,7525394,Mayes SD; Crites DL; Bixler EO; Humphrey FJ; Mattison RE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000367: Age Factors; D000553: Ambulatory Care; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D002658: Developmental Disabilities; D004334: Drug Administration Schedule; D005260: Female; D006760: Hospitalization; D006801: Humans; D007223: Infant; D007360: Intelligence; D008297: Male; D008774: Methylphenidate; D009420: Nervous System; D016037: Single-Blind Method; D016896: Treatment Outcome",,,https://openalex.org/W1991614460,75,12,1,3059,484,20,en,fr
false,predictor clozapine response schizophrenia,introduction atypical neuroleptic clozapine widespread influence treatment seriously mentally ill patient also new drug development hypothesis pathophysiology schizophrenia clozapine differs traditional neuroleptic lack extrapyramidal side effect eps also distinct profile neurotransmitter receptor affinity work examine clinical biological effect clozapine patient schizophrenia identify presence eps typical neuroleptic treatment consistent predictor subsequent good response clozapine far data suggest clozapine reserve chronically ill patient rather utilize patient less chronic course schizophrenia biological predictor clozapine response consistent dopaminergic serotonergic noradrenergic facet mechanism action,Pickar D,1994,J Clin Psychiatry,,7525541,Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D005476: Fluphenazine; D006719: Homovanillic Acid; D006801: Humans; D006897: Hydroxyindoleacetic Acid; D008297: Male; D011336: Probability; D017981: Receptors, Neurotransmitter; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W144878538,50,7,1,996,159,5,en,en
false,risperidone,risperidone benzisoxazol derivative novel antipsychotic agent combine potent serotonin hydroxytryptamine ht dopamine receptor antagonism development drug stimulate report selective serotonin ht antagonist ritanserin improve negative symptom schizophrenia decrease extrapyramidal symptom combine haloper idol relatively low incidence extrapyramidal symptom risperidone may reflect preferential action mesolimbic rather nigrostriatal dopaminergic pathway recent clinical investigation suggest risperidone least comparable efficacy haloperidol perphenazine improve symptom acute chronic schizophrenia short term administration advantage offer risperidone haloperidol include fast onset antipsychotic action low incidence extrapyramidal effect possibly great efficacy negative symptom schizophrenia benefit prove maintain long term therapy risperidone likely make significant contribution treatment schizophrenia risperidone show high affinity central serotonin ht adrenergic histamine hi dopamine receptor vitro serotonin ht adrenergic oci dopamine receptor vivo rat risperidone increase dopamine turnover striatum nucleus accumbens olfactory tubercle frontal cortex excess require occupancy central dopamine receptor ex vivo suggest possible modulation dopamine turnover serotonin ht receptor blockade risperidone exhibit central serotonin ht neostriatal dopamine antagonistic activity devoid anticholinergic activity several vivo animal model also effective animal behavioural model consider predictive antipsychotic activity e g suppression apomorphine amphetamine induce stereotypy condition avoidance behaviour healthy volunteer risperidone produce alteration sleep architecture similar see selective serotonin ht antagonist ritanserin patient chronic schizophrenia risperidone mg day restore sleep pattern improve sleep efficiency show pronounce ameliorative effect haloperidol follow multiple dose week administration risperidone produce mark sustained increase serum prolactin level schizophrenic patient evidence tolerance effect cardiovascular effect risperidone reflect oc adrenergic antagonistic activity comprise dose related decrease blood pressure reflex tachycardia single multiple dose administration patient schizophrenia appear tolerant hypotensive effect risperidone healthy volunteer risperidone undergoes extensive metabolism hydroxylation oxidative n de alkylation major metabolite hydroxy risperidone display similar pharmacological activity parent compound oxidative metabolism risperidone subject genetic polymorphism oral bioavailability risperidone varies extensive metabolisers slow metabolisers peak plasma risperidone concentration u l achieve within hour single oral dose administration risperidone mg extensive metabolisers plasma concentration risperidone hydroxy risperidone active moiety risperidone hydroxy risperidone linearly relate dosage mg day schizophrenic patient risperidone metabolite extensively distribute throughout body plasma protein bind risperidone approximately volume distribution l kg risperidone primarily excrete via urinary route approximately administer dose recover urine faeces week period postdose plasma elimination half live risperidone hydroxy risperidone extensive metabolisers hour respectively active moiety approximately hour poor metabolisers risperidone extend approximately hour whereas active moiety unchanged renal clearance risperidone reduce patient impaired renal function short term week noncomparative study patient chronic schizophrenia demonstrate mark improvement general symptom brief psychiatric rating scale bprs clinical global impression cgi scale risperidone mg day reduce incidence extrapyramidal symptom antiparkinson drug requirement comparison prior antipsychotic therapy effect appear maintain long term month follow addition risperidone mg day exist antipsychotic therapy tend produce great improvement negative symptom scale assessment negative symptom sans addition placebo recent find several short term week multicentre study patient predominantly chronic schizophrenia suggest risperidone mg day least comparable efficacy haloperidol mg day alleviate positive symptom disease may confer advantage haloperidol faster onset antipsychotic action low incidence extrapyramidal effect possibly great efficacy negative symptom schizophrenia risperidone mg day demonstrate similar antipsychotic efficacy perphenazine mg day short term administration patient acute exacerbation chronic schizophrenia commonly report adverse effect risperidone recent clinical trial include sedation patient insomnia agitation extrapyramidal symptom dizziness anxiety rhinitis incidence extrapyramidal symptom linearly relate dosage mg day therapeutic dosage mg day incidence comparable see placebo significantly less associate haloperidol mg day tardive dyskinesia rarely report long term month risperidone therapy risperidone produce oc adrenergically mediate hypotension however use conservative dose titration schedule divide minimise risk clinically important hypotension significant dose relate weight gain kg week report risperidone mg day titration risperidone dosage recommend start mg orally twice daily increase mg twice daily day dosage may individualise optimum therapeutic dosage mg day dosage mg day appear confer great clinical efficacy associate high incidence extrapyramidal symptom elderly patient impair renal function start dosage mg twice daily increase mg aliquot total dosage mg twice daily recommend,Grant S,1994,Drugs,https://doi.org/10.2165/00003495-199448020-00009,7527327,Grant S; Fitton A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016454: Review,"D000042: Absorption; D000328: Adult; D000368: Aged; D000375: Aging; D000818: Animals; D014150: Antipsychotic Agents; D002490: Central Nervous System; D018592: Cross-Over Studies; D004195: Disease Models, Animal; D004347: Drug Interactions; D006439: Hemodynamics; D006801: Humans; D007555: Isoxazoles; D009490: Neurosecretory Systems; D010880: Piperidines; D018967: Risperidone; D012559: Schizophrenia; D009435: Synaptic Transmission; D014018: Tissue Distribution",,,https://openalex.org/W2018434135,11,1,1,7319,1179,39,en,en
false,cerebrospinal fluid monoamine metabolite boy attention deficit hyperactivity disorder,cerebrospinal fluid csf plasma urinary monoamine metabolite determine boy age attention deficit hyperactivity disorder adhd level csf hydroxyindoleacetic acid hiaa homovanillic acid hva methoxy hydroxyphenylglycol mhpg metabolite serotonin dopamine norepinephrine respectively correlate significantly behavioral measure aggression impulsivity hyperactivity however correlation unexpected direction example csf hiaa correlate positively brown goodwin lifetime history aggression scale hva csf positively correlate several measure hyperactivity replicability find well possible socioenvironmental effect predictive value csf monoamine prepubertal hyperactivity subject ongoing study,Castellanos FX,1994,Psychiatry Res,https://doi.org/10.1016/0165-1781(94)90076-0,7527565,Castellanos FX; Elia J; Kruesi MJ; Gulotta CS; Mefford IN; Potter WZ; Ritchie GF; Rapoport JL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000374: Aggression; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003913: Dextroamphetamine; D004311: Double-Blind Method; D006719: Homovanillic Acid; D006801: Humans; D006897: Hydroxyindoleacetic Acid; D007175: Impulsive Behavior; D008297: Male; D008734: Methoxyhydroxyphenylglycol; D008774: Methylphenidate; D009043: Motor Activity; D018377: Neurotransmitter Agents,,,https://openalex.org/W2042209283,95,10,1,889,140,5,en,en
false,desmopressin risperidone induce enuresis,abstractwe present case report illustrate successful use desmopressin treatment risperidone induce enuresis,Bennett JA,1994,Ann Clin Psychiatry,https://doi.org/10.3109/10401239409148993,7528602,Bennett JA; Keck PE; Wallhausser LJ,article,D002363: Case Reports; D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000281: Administration, Intranasal; D000328: Adult; D014150: Antipsychotic Agents; D003894: Deamino Arginine Vasopressin; D004311: Double-Blind Method; D004775: Enuresis; D005260: Female; D006220: Haloperidol; D006801: Humans; D007555: Isoxazoles; D010880: Piperidines; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2022099515,45,4,1,136,19,1,en,en
false,risperidone clozapine treatment drug resistant schizophrenia neuroleptic induced supersensitivity psychosis,supersensitivity psychosis ssp emerge potential side effect long term neuroleptic therapy similar tardive dyskinesia td six schizophrenic patient ssp consider drug resistant treat risperidone another treat clozapine risperidone treat patient woman rat clinical global impression improvement scale least much improve among clozapine treat patient men find mark response clozapine female patient judge minimally improve hypothesize td also ssp arise destruction cholinergic interneurons striatum consequence prolong neuroleptic administration thus drug induce parkinsonism propose mediate antipsychotic effect dopamine block drug depend integrity cholinergic neuron neuron destroy drug haloperidol lose therapeutic effect contrast atypical neuroleptic like clozapine risperidone reduce dopamine release striatum independently prior production extrapyramidal symptom way may effective psychotic illness unresponsive classical anti neuroleptic present sample patient worth note schizophrenic men good responder clozapine comparison risperidone find efficacious schizophrenic woman,Chouinard G,1994,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/0278-5846(94)90116-3,7531355,Chouinard G; Vainer JL; Bélanger MC; Turnier L; Beaudry P; Roy JY; Miller R,article,D002363: Case Reports; D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D004351: Drug Resistance; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D011569: Psychiatric Status Rating Scales; D011605: Psychoses, Substance-Induced; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012727: Sex Characteristics",,,https://openalex.org/W2067523973,125,13,1,1516,258,16,en,en
false,risperidone versus zuclopenthixol treatment acute schizophrenic episode double blind parallel group trial,double blind randomize multi center parallel group study conduct finland compare efficacy safety risperidone zuclopenthixol patient acute exacerbation schizophrenia schizophreniform disorder ninety eight patient randomly assign treatment risperidone n zuclopenthixol n variable week mean daily risperidone zuclopenthixol end trial mg mg respectively efficacy assess throughout positive negative syndrome scale schizophrenia clinical global impression safety assessment include extrapyramidal symptom rating scale uku side effect rating scale vital sign body weight laboratory screen result indicate risperidone least effective zuclopenthixol treatment acute schizophrenic episode trend towards great improvement overall severity symptom onset action significantly short risperidone zuclopenthixol although general tolerability two drug comparable patient experience extrapyramidal symptom risperidone significantly risperidone treated patient require antiparkinsonian medication,Huttunen MO,1995,Acta Psychiatr Scand,https://doi.org/10.1111/j.1600-0447.1995.tb09781.x,7542829,Huttunen MO; Piepponen T; Rantanen H; Larmo I; Nyholm R; Raitasuo V,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D003006: Clopenthixol; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007555: Isoxazoles; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W2062210283,119,15,1,1305,202,8,en,en
false,risperidone treatment patient chronic schizophrenia multi national multi centre double blind parallel group study versus haloperidol,background study perform order evaluate short term efficacy safety fix risperidone compare haloperidol method multi national parallel group double blind study patient chronic schizophrenia dsm iii r randomly assign risperidone mg haloperidol mg daily week efficacy assess positive negative syndrome scale schizophrenia panss clinical global impression cgi safety primarily extrapyramidal symptom rating scale esr result one thousand three hundred sixty two patient evaluate optimum risperidone mg mg response rate respectively response rate haloperidol treat patient confidence interval ci difference risperidone mg mg haloperidol respectively significant difference cgi score endpoint risperidone mg mg mg mg haloperidol respectively ci difference risperidone mg mg haloperidol respectively mean shift maximum total esr score versus baseline mean confidence interval significantly great haloperidol treat patient risperidone mg group respectively p conclusion risperidone effective antipsychotic treatment chronic schizophrenia mg seem optimal low incidence side effect haloperidol,Peuskens J,1995,Br J Psychiatry,https://doi.org/10.1192/bjp.166.6.712,7545060,Peuskens J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D007555: Isoxazoles; D008297: Male; D010880: Piperidines; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2146438680,154,21,1,1796,383,9,en,en
false,relationship clozapine obsessive compulsive disorder retrospective chart review,emergence obsessive compulsive symptom clozapine treatment report recent case study yet incidence significance find still unclear pending reliable data large sample patient hospital record randomly select inpatient start clozapine treatment mclean hospital july review retrospectively base limit retrospective chart review definitive case patient develop obsessive compulsive disorder ocd whose ocd worsen result clozapine treatment although fluctuation ocd symptom may occur two case unclear whether symptom relate treatment clozapine psychotropic drug undulation natural history ocd definitive relationship ocd symptom clozapine treatment could establish limited study clarification matter await outcome research use prospective methodology,Ghaemi SN,1995,Compr Psychiatry,https://doi.org/10.1016/s0010-440x(95)90071-3,7554870,Ghaemi SN; Zarate CA; Popli AP; Pillay SS; Cole JO,article,D016428: Journal Article,"D000328: Adult; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009771: Obsessive-Compulsive Disorder; D010343: Patient Admission; D011618: Psychotic Disorders; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2167157600,106,15,2,1033,164,6,en,en
false,short term efficacy apraclonidine hydrochloride add maximum tolerated medical therapy glaucoma,purpose determine whether addition topical apraclonidine hydrochloride eye receive maximal medical therapy still inadequate intraocular pressure control schedule undergo surgery could adequately decrease intraocular pressure postpone need intervention method perform prospective day multicentered placebo control double mask parallel study enrol one eye glaucoma patient inadequate intraocular pressure control maximally tolerate medical therapy continue administer maximum medical therapy glaucoma study medication either apraclonidine hydrochloride placebo apraclonidine vehicle patient instruct take study medication every eight hour measure intraocular pressure change intraocular pressure baseline number eye require surgery addition study medication result fifty two patient treat apraclonidine maintain adequate intraocular pressure control throughout study avoid surgery compare patient treat placebo p apraclonidine treatment result significantly patient attain additional reduction intraocular pressure baseline intraocular pressure less equal mm hg p common ocular complication conjunctival hyperemia patient frequent nonocular problem dry mouth four patient conclusion apraclonidine appear safe eye efficacious eye significantly low intraocular pressure use combination maximally tolerate medical therapy delay prevent glaucoma surgery least day treat patient determine whether addition topical apraclonidine hydrochloride eye receive maximal medical therapy still inadequate intraocular pressure control schedule undergo surgery could adequately decrease intraocular pressure postpone need intervention perform prospective day multicentered placebo control double mask parallel study enrol one eye glaucoma patient inadequate intraocular pressure control maximally tolerate medical therapy continue administer maximum medical therapy glaucoma study medication either apraclonidine hydrochloride placebo apraclonidine vehicle patient instruct take study medication every eight hour measure intraocular pressure change intraocular pressure baseline number eye require surgery addition study medication fifty two patient treat apraclonidine maintain adequate intraocular pressure control throughout study avoid surgery compare patient treat placebo p apraclonidine treatment result significantly patient attain additional reduction intraocular pressure baseline intraocular pressure less equal mm hg p common ocular complication conjunctival hyperemia patient frequent nonocular problem dry mouth four patient apraclonidine appear safe eye efficacious eye significantly low intraocular pressure use combination maximally tolerate medical therapy delay prevent glaucoma surgery least day treat patient,Robin AL,1995,Am J Ophthalmol,https://doi.org/10.1016/s0002-9394(14)72655-8,7573299,Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002257: Carbonic Anhydrase Inhibitors; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D008916: Miotics; D009883: Ophthalmic Solutions; D011446: Prospective Studies; D013566: Sympathomimetics; D016896: Treatment Outcome",,,https://openalex.org/W2029524269,106,12,1,3756,626,26,en,en
false,clozapine induced increase plasma level soluble interleukin receptor,increase level soluble interleukin receptor sil r report schizophrenia think indicate prior current activation lymphocytes clozapine antipsychotic drug know associate high risk agranulocytosis immunological process suggest possible pathophysiological factor overview see article alvir et al recently report long term clozapine treatment highly variable duration day increase plasma sil r level single dose typical neuroleptic haloperidol hand influence plasma sil r level cytokine receptor healthy control report herein time course plasma sil r level evaluate prospectively week treatment clozapine ten patient three woman seven men mean sd age year fulfilleddsm iii r criterion schizophrenic disorder,Pollmächer T,1995,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1995.03950220087016,7575109,Pollmächer T; Hinze-Selch D; Mullington J; Holsboer F,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016422: Letter,"D000328: Adult; D000380: Agranulocytosis; D003024: Clozapine; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011446: Prospective Studies; D015375: Receptors, Interleukin-2; D012307: Risk Factors; D012559: Schizophrenia",,,https://openalex.org/W2043853859,78,9,1,1035,202,3,en,en
false,epidemiology adverse hemodynamic event occur clonidine anesthesia prospective open trial intraoperative intravenous clonidine,study objective determine hemodynamic consequence intraoperative clonidine major abdominal surgery design prospective open trial set teach hospital patient consecutive patient schedule major abdominal surgery intervention consecutive patient receive intravenous iv clonidine load dose g kg minute anesthesia induction follow continuous infusion g kg h end surgery fifty two additional patient serve control anesthetic technique consist balance anesthesia isoflurane fentanyl atracurium ecg invasive arterial blood pressure bp expiratory pco pulse oximetry continuously record hemodynamic event define moderate reduction baseline systolic blood pressure sbp heart rate hr decrease beat per minute bpm bpm reduction baseline sbp hr bpm consider important rate duration event record induction recovery require specific treatment note central venous pressure volume fluid infuse urinary output also record measurement main result control patient clonidine patient adverse moderate reduction baseline bp common episode group incidence moderate important similar group duration significantly longer clonidine patient p control patient clonidine patient require specific management p common hypotension without bradycardia neither coexist pathology preoperative medication influence incidence conclusion iv clonidine use routinely anesthesia major abdominal surgery,De Kock M,1995,J Clin Anesth,https://doi.org/10.1016/0952-8180(95)00072-p,7576677,De Kock M; Versailles H; Colinet B; Karthaeuser R; Scholtes JL,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000005: Abdomen; D000316: Adrenergic alpha-Agonists; D000769: Anesthesia, Inhalation; D000771: Anesthesia, Intravenous; D018686: Anesthetics, Intravenous; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002245: Carbon Dioxide; D002496: Central Venous Pressure; D003000: Clonidine; D004562: Electrocardiography; D005260: Female; D005440: Fluid Therapy; D006339: Heart Rate; D006801: Humans; D007022: Hypotension; D015994: Incidence; D007262: Infusions, Intravenous; D007430: Intraoperative Care; D008297: Male; D008875: Middle Aged; D010092: Oximetry; D011446: Prospective Studies; D012119: Respiration; D014556: Urine",,,https://openalex.org/W2012140737,152,21,1,1923,348,19,en,en
false,ici novel atypical antipsychotic early indication safety efficacy patient chronic subchronic schizophrenia,evaluate effect ici hospitalize patient schizophrenia double blind placebo control parallel group rise dose study patient meet diagnostic statistical manual mental disorder third edition revise criterion chronic subchronic schizophrenia total score item brief psychiatric rating scale bprs score clinical global impression cgi severity illness item patient receive day double blind treatment increase ici mg placebo efficacy assess use bprs cgi response treatment define decrease bprs total score baseline extrapyramidal symptom abnormal involuntary movement assess use simpson scale abnormal involuntary movement scale change baseline bprs cgi significantly great end point patient receive ici versus placebo bprs v cgi v p analysis covariance p wilcoxon rank sum test patient ici group respond treatment p versus two patient placebo group mild somnolence occur ici treat patient treatment emergent extrapyramidal symptom dystonic reaction observe ici show efficacy positive negative symptom schizophrenia well tolerate,Fabre LF,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80102-2,7585841,Fabre LF; Arvanitis L; Pultz J; Jones VM; Malick JB; Slotnick VB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003987: Dibenzothiazepines; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016037: Single-Blind Method",,,https://openalex.org/W2171153453,139,22,1,1500,271,11,en,en
false,efficacy safety risperidone long term treatment patient schizophrenia,long term efficacy safety risperidone evaluate patient chronic schizophrenia open label study thirty two patient receive risperidone year receive risperidone year mean dose risperidone mg year follow mg year follow end year improvement find total score positive negative syndrome scale panss four panss factor positive negative excite cognitive clinical global impression scale severity extrapyramidal symptom base score extrapyramidal symptom rating scale also reduce clinical improvement define reduction total panss score show patient end point social functioning assess use modify straus carpenter scale significantly improve year number day spend hospital significantly reduce year treatment number day treatment group home significantly increase conclude treatment risperidone year associate significant reduction symptom schizophrenia improve social function reduction day spend hospital,Lindström E,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80105-7,7585844,Lindström E; Eriksson B; Hellgren A; von Knorring L; Eberhard G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2017910418,92,13,1,1305,236,9,en,en
false,male sexual side effect associate antidepressant descriptive clinical study patient,objective retrospective study add exist body clinical information regard male sexual side effect associate antidepressant chart review thirty four eighty male patient identify report loss libido erectile difficulty anorgasmia delay ejaculation receive pharmacotherapy selective serotonin reuptake blocker fluoxetine paroxetine sertraline tricyclic antidepressant nortriptyline imipramine amitriptyline desipramine clomipramine monoamine oxidase inhibitor phenelzine method author also discuss management sexual side effect wait spontaneous remission reduce dosage level substitute offend drug antidepressant result article underscore underreported nature antidepressant associate sexual dysfunction high incidence ssri associate sexual side effect equal potential cause sexual side effect among three ssri low incidence rate sexual adverse effect bupropion minimal need add antidote side effect manage systematically conclusion finally male sexual side effect occur randomly involve sexual phase randomly treatment approach similar regardless type sexual dysfunction associate antidepressant,Hsu JH,1995,Int J Psychiatry Med,https://doi.org/10.2190/1dhu-y7l7-9gkg-v7wv,7591493,Hsu JH; Shen WW,article,D016428: Journal Article,D000328: Adult; D000368: Aged; D000928: Antidepressive Agents; D003866: Depressive Disorder; D004542: Ejaculation; D007172: Erectile Dysfunction; D006801: Humans; D007989: Libido; D008297: Male; D008875: Middle Aged; D009948: Orgasm; D010410: Penile Erection; D012189: Retrospective Studies; D017367: Selective Serotonin Reuptake Inhibitors,,,https://openalex.org/W2100281583,101,15,1,1425,227,5,en,en
false,pharmacotherapy adult attention deficit hyperactivity disorder,adult attention deficit hyperactivity disorder adhd increasingly recognize disorder associate psychiatric comorbidity impairment although pharmacotherapy serve important role treat adhd concurrent psychiatric disorder child adolescent use pharmacotherapeutics adult adhd remain less establish report effectiveness dose parameter various agent investigate adult adhd review systematic review available literature identify study n subject psychostimulants study nonstimulant medication n subject include antidepressant antihypertensive amino acid treatment adhd adult majority double blind investigation psychostimulants nonstimulant agent generally antidepressant study open condition considerable variability diagnostic criterion dose parameter response rate various study control condition aggregate literature show stimulant clinically statistically significant effect reduce adhd symptom open study nonserotonergic antidepressant tricyclic bupropion monoamine oxidase inhibitor also show moderate anti adhd effect literature appear support use robust stimulant antidepressant adhd adult far control study apply stringent diagnostic criterion outcome methodology necessary define range pharmacotherapeutic option adult adhd j clin psychopharmacol,Wilens TE,1995,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199508000-00006,7593710,Wilens TE; Biederman J; Spencer TJ; Prince J,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D006801: Humans,,,https://openalex.org/W2061059960,65,6,1,1690,255,10,en,en
false,epidural clonidine combine bupivacaine analgesia labor effect mother neonate,double blind study conduct assess efficacy safety epidural clonidine combine bupivacaine analgesia labor two group pregnant healthy woman allocate randomly receive either ml bupivacaine plain solution group b n microgram clonidine group b c n visual analog scale va score measure minute epidural injection patient monitor automate blood pressure device dinamap pulse oximeter fetal heart rate measure cardiotocograph plasma clonidine concentration measure birth mother umbilical cord radioimmunoassay visual analog scale score significantly low patient receive clonidine patient require second epidural injection minute group b minute group b c p visual analog scale score also significantly low group b c group b second injection decrease arterial blood pressure comparable two group patient experience arterial oxygen desaturation bradycardia fetal heart rate decrease group b c time second injection duration labor epidural administration prolong group b c patient compare group b minute minute respectively p apgar score minute similar group plasma clonidine concentration respectively ng ml minute first injection ng ml birth mother plasma umbilical cord concentration ng ml study document clonidine improve epidural bupivacaine analgesia labor demonstrate transfer drug across placenta therefore extensive study require determine incidence possible side effect clonidine neonate,Cigarini I,1995,Reg Anesth,,7605757,Cigarini I; Kaba A; Bonnet F; Brohon E; Dutz F; Damas F; Hans P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000653: Amniotic Fluid; D015360: Analgesia, Epidural; D016362: Analgesia, Obstetrical; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006340: Heart Rate, Fetal; D006439: Hemodynamics; D006801: Humans; D007231: Infant, Newborn; D010100: Oxygen; D010147: Pain Measurement; D010920: Placenta; D011247: Pregnancy",,,https://openalex.org/W41354680,99,16,2,1991,356,12,en,en
false,clozapine decrease smoke patient chronic schizophrenia,puzzle patient schizophrenia show extremely high prevalence cigarette smoke intrigue researcher many year approximately patient schizophrenia smoke hughes et al twice prevalence smoke general population report mcevoy et al heavy smoking associate lack therapeutic response classical antipsychotic haloperidol clozapine may therapeutically effective patient nonresponsive haloperidol kane et al report change occur smoke among group treatment refractory patient schizophrenia switch haloperidol clozapine ongoing double blind trial examine treatment response three distinct clozapine plasma level range,McEvoy J,1995,Biol Psychiatry,https://doi.org/10.1016/0006-3223(94)00365-a,7619979,McEvoy J; Freudenreich O; McGee M; VanderZwaag C; Levin E; Rose J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016540: Smoking Cessation,,,https://openalex.org/W1969441502,66,8,1,840,137,6,en,en
false,effect late afternoon methylphenidate administration behavior sleep attention deficit hyperactivity disorder,objective study evaluate effect behavior sleep methylphenidate mph administer pm child attention deficit hyperactivity disorder adhd methodology twelve child admit child psychiatric inpatient service adhd participate double blind crossover study receive pm dose either mg mph mg mph placebo random order consecutive day rating behavior include adhd symptom pertain period dose administration sleep onset supply nightly hospital staff sleep latency sleep adequacy also assess night result mph result markedly improve behavioral control compare placebo difference mg mg mph mph alter sleep latency observe placebo child often rat less tire awaken night receive mg mph compare mg mph placebo weight loss apparent among patient dinner intake vary third dose condition conclusion morning noon administration stimulant child adhd near universal practice many clinician avoid third late afternoon administration fear induce insomnia study find show child adhd derive substantial symptom reduction mph administer late afternoon untoward effect sleep therefore three time day dose consider child exhibit adhd symptom even adverse effect sleep latency apparent sample overall nonetheless monitor possible aggravation sleep problem weight loss remain sound treatment practice,Kent JD,1995,Pediatrics,https://doi.org/10.1542/peds.96.2.320,7630692,Kent JD; Blader JC; Koplewicz HS; Abikoff H; Foley CA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002652: Child Behavior; D002675: Child, Preschool; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004435: Eating; D005221: Fatigue; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010919: Placebos; D012890: Sleep; D012894: Sleep Stages; D014851: Wakefulness; D015431: Weight Loss",,,https://openalex.org/W1879428650,122,13,1,1806,310,17,en,en
false,isobolographic study epidural clonidine fentanyl cesarean section,although epidural administration clonidine fentanyl provide pain relief surgery interaction two drug examine formally study use isobolographic method determine whether epidurally administer fentanyl clonidine interact additive synergistic manner ninety woman moderate severe pain elective cesarean section epidural anesthesia study use randomize double blind protocol assign patient receive single epidural injection one three fentanyl clonidine fix ratio combination pain relief blood pressure bp heart rate hr sedation measure min injection drug alone combination produce analgesia measure pain relief score reduce need intravenous morphine although effective dose produce analgesia patient ed mixture predict additive interaction differ significantly additivity likely due large variability clonidine alone combination fentanyl produce minor reduction bp affect hr cause sedation fentanyl unlike study rodent clinical study demonstrate synergy fentanyl clonidine could reflect true specie difference difference methodology use nonetheless reduce dose fentanyl clonidine combine excellent analgesia,Eisenach JC,1994,Anesth Analg,https://doi.org/10.1213/00000539-199408000-00014,7639365,Eisenach JC; D'Angelo R; Taylor C; Hood DD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D015360: Analgesia, Epidural; D002585: Cesarean Section; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005260: Female; D005283: Fentanyl; D006801: Humans; D010149: Pain, Postoperative; D011247: Pregnancy; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2047726171,81,11,1,1518,262,11,en,en
false,methylphenidate cognitive flexibility dissociate dose effect hyperactive child,randomize double blind placebo control trial conduct assess acute effect placebo three methylphenidate mph mg kg cognitive flexibility overt behavior child confirm diagnosis attention deficit hyperactivity disorder two underlying cognitive process response inhibition response reengagement assess measure probability speed subject could inhibit response primary task force choice letter discrimination immediately execute response secondary task simple reaction time give signal result indicate mph enhance cognitive flexibility although high dose less effective low enhance response inhibition dissociation dose effect cognitive function behavior demonstrate dose response function change behavior linear whereas function response inhibition u shape find argue typical clinical practice determine response stimulant treatment single measure parent report child behavior,Tannock R,1995,J Abnorm Child Psychol,https://doi.org/10.1007/bf01447091,7642836,Tannock R; Schachar R; Logan G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004193: Discrimination Learning; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007175: Impulsive Behavior; D008297: Male; D008774: Methylphenidate; D010364: Pattern Recognition, Visual; D011930: Reaction Time",,,https://openalex.org/W2061125164,91,11,1,1166,185,5,en,en
false,effect methylphenidate hiv relate depression comparative trial desipramine,report randomize double blind comparative trial desipramine psychomotor stimulant methylphenidate twenty hiv antibody positive patient depressive symptom randomly assign either drug individual dose titration mean daily dose desipramine mg methylphenidate mg daily difference response desipramine methylphenidate statistically significant various measure depression antidepressant effect methylphenidate occur fast desipramine significantly reduce depressive anxious symptomatology blind portion treatment thus methylphenidate relief depressive symptomatology efficacy similar desipramine offer alternative patient unable tolerate standard tricyclic antidepressant therapy dopaminergic effect methylphenidate likely mediate antidepressant effect,Fernandez F,1995,Int J Psychiatry Med,https://doi.org/10.2190/16fh-9ect-y280-vv45,7649718,Fernandez F; Levy JK; Samley HR; Pirozzolo FJ; Lachar D; Crowley J; Adams S; Ross B; Ruiz P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001727: Bisexuality; D003866: Depressive Disorder; D003891: Desipramine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006679: HIV Seropositivity; D018451: Homosexuality, Male; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D010555: Personality Inventory; D012803: Sick Role; D016896: Treatment Outcome",,,https://openalex.org/W2111338885,90,12,1,986,142,8,en,en
false,efficacy guanfacine reduce perioperative hemodynamic change volatile anesthetic requirement,evaluate efficacy guanfacine alpha adrenergic agonist attenuate hemodynamic change associate tracheal intubation extubation provide intraoperative hemodynamic stability reduce inhalation anesthetic requirement patient undergo gynecologic surgery randomize double blind placebo control study inpatient gynecology university hospital woman asa undergo elective abdominal hysterectomy guanfacine placebo supplementation oral guanfacine mg placebo control hour induction anesthesia anesthesia induce thiamylal mg kg vecuronium mg kg maintain isoflurane nitrous oxide n oxygen inspire isoflurane concentration maintain first minute follow induction anesthesia titrate concentration require maintain hemodynamic stability define systolic blood pressure sbp end tidal concentration isoflurane monitor throughout anesthesia completion surgery n isoflurane discontinue follow confirmation recovery anesthesia muscle relaxation endotracheal tube remove patient control group show significant increase sbp diastolic blood pressure dbp heart rate hr associate tracheal intubation mean sem p variable respectively plasma norepinephrine epinephrine concentration increase pg ml pg ml respectively p compare basal value change attenuate patient receive mg guanfacine respectively p variable compare placebo group high inspire concentration isoflurane require control mg guanfacine treat group respectively mg guanfacine treat group hemodynamic stability p coefficient variation hr change surgery placebo guanfacine mg guanfacine mg treat group respectively compare placebo guanfacine mg reduce maximum change mean sem sbp v hr v occur tracheal extubation incidence perioperative complication similar among three group guanfacine mg administer orally prove effective premedicant provide intraoperative hemodynamic stability attenuate increase bp hr associate tracheal intubation extubation reduce anesthetic requirement without increase incidence perioperative complication,Nishina K,1995,J Clin Anesth,https://doi.org/10.1016/0952-8180(95)00005-3,7669311,Nishina K; Mikawa K; Maekawa N; Obara H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D000769: Anesthesia, Inhalation; D002395: Catecholamines; D004311: Double-Blind Method; D005260: Female; D016316: Guanfacine; D006439: Hemodynamics; D006801: Humans; D007430: Intraoperative Care; D007442: Intubation, Intratracheal; D008875: Middle Aged; D014835: Volatilization",,,https://openalex.org/W2126828774,108,13,1,2860,496,13,en,en
false,childhood onset schizophrenia nimh study progress,ongoing study phenomenology genetics neuropsychology physiology eye track autonomic responsivity neuroimaging biochemistry pharmacology childhood onset schizophrenia describe pilot data present first subject differentiation autism spectrum disorder poorly define severe neurodevelopmental disorder need eye track autonomic result similar pattern see later onset schizophrenia possibly strike magnetic resonance image show large leave frontal ventricular horn area schizophrenia subject large leave caudate lack normal caudate asymmetry fluorodeoxyglucose positron emission tomography auditory continuous performance task reveal decrease right parietal occipital glucose metabolic rate schizophrenia subject may secondary poor attentional performance increase glucose metabolic rate three leave frontal region leave parietal region right putamen clozapine effective well tolerate open trial adolescent respond poorly typical neuroleptic subject enrol double blind comparison haloperidol clozapine longitudinal study narrowly define possibly homogeneous group early onset schizophrenia subject relevant current neurodevelopmental theory address role puberty progression pathology continuity discontinuity later onset schizophrenia,Gordon CT,1994,Schizophr Bull,https://doi.org/10.1093/schbul/20.4.697,7701277,Gordon CT; Frazier JA; McKenna K; Giedd J; Zametkin A; Zahn T; Hommer D; Hong W; Kaysen D; Albus KE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001921: Brain; D001931: Brain Mapping; D002648: Child; D003024: Clozapine; D003952: Diagnostic Imaging; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D008297: Male; D009315: National Institute of Mental Health (U.S.); D009483: Neuropsychological Tests; D011698: Pursuit, Smooth; D011930: Reaction Time; D012561: Schizophrenia, Childhood; D014481: United States",,,https://openalex.org/W2115062087,56,8,1,1560,233,7,en,en
false,anticonvulsant hinder clozapine treatment,,Wilson WH,1995,Biol Psychiatry,https://doi.org/10.1016/0006-3223(94)00229-v,7718678,Wilson WH,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000927: Anticonvulsants; D002908: Chronic Disease; D003024: Clozapine; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D004569: Electroencephalography; D004827: Epilepsy; D005260: Female; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2087437935,46,6,1,0,0,0,en,
false,differential effect methylphenidate self reinforcement attention deficit hyperactivity disorder,six boy age year attend tutor class focus read minute morning investigator employ modify latin square design child begin day baseline phase follow six day treatment phase use drug placebo noncontingent reinforcer mg kg methylphenidate mg kg methylphenidate self reinforcement various combination amount academic performance major measure outcome target behavior self reinforcement drug placebo noncontingent reinforcer systematic impact methylphenidate differential effect across record behavior self reinforcement improve target behavior mean effect size self reinforcement combine effect methylphenidate self reinforcement academic performance great either treatment give alone mean effect size,Ajibola O,1995,Behav Modif,https://doi.org/10.1177/01454455950192004,7726818,Ajibola O; Clement PW,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D002648: Child; D003131: Combined Modality Therapy; D004305: Dose-Response Relationship, Drug; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009042: Motivation; D012055: Reinforcement Schedule; D012073: Remedial Teaching; D012919: Social Behavior; D016896: Treatment Outcome",,,https://openalex.org/W2037107705,106,10,1,931,143,7,en,en
false,addition clonidine epidural morphine enhances postoperative analgesia cesarean delivery,randomize double blind dose response study design evaluate effect addition clonidine epidural morphine postoperative analgesia side effect patient undergo cesarean delivery sixty patient undergo cesarean delivery epidural anesthesia randomly divide three equal group receive end surgery epidural analgesic mixture consist ml solution contain mg morphine dilute bupivacaine plus epinephrine microgram clonidine duration analgesia assess pain free interval end surgery patient first analgesic request analgesic mixture repeat patient request hour operation arterial blood pressure heart rate respiratory rate side effect note total amount morphine clonidine deliver also note addition clonidine microgram morphine significantly increase duration postoperative analgesia p versus versus hour reduce mean total dose morphine mg versus mg versus mg p significant difference side effect note low dose clonidine microgram double duration analgesia produce mg morphine dose microgram far increase duration postoperative complete analgesia without increase incidence side effect morphine requirement postoperative period hour greatly reduce addition clonidine analgesic epidural mixture,Capogna G,1995,Reg Anesth,,7727330,Capogna G; Celleno D; Zangrillo A; Costantino P; Foresta S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D015360: Analgesia, Epidural; D001794: Blood Pressure; D002585: Cesarean Section; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D009020: Morphine; D010149: Pain, Postoperative; D011247: Pregnancy; D015656: Respiratory Mechanics",,,https://openalex.org/W48654287,100,13,1,1673,289,7,en,en
false,common drug may influence motor recovery stroke,study laboratory animal indicate certain centrally act drug eg antihypertensive clonidine prazosin neuroleptic dopamine receptor antagonist benzodiazepine anticonvulsant phenytoin phenobarbital impair behavioral recovery focal brain injury even single may long term harmful effect determine whether medication similar negative impact human analyze recovery control patient enrol sygen acute stroke study multicenter study effect gm ganglioside ischemic stroke motor impairment measure motor subscores toronto stroke scale baseline day stroke use data compare motor recovery patient initial motor deficit receive least one drug interfere recovery laboratory study detrimental drug group n patient receive drug neutral drug group n group well balance regard frequency comorbid condition prognostic factor upper extremity motor function repeat measure anova show significant interaction drug group time stroke f p significant p difference group begin day stroke similar trend present low extremity overall difference group significant anova f p drug group influence degree independence activity daily live measure barthel index abstract truncate word,Goldstein LB,1995,Neurology,https://doi.org/10.1212/wnl.45.5.865,7746398,Goldstein LB,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D000704: Analysis of Variance; D002561: Cerebrovascular Disorders; D004311: Double-Blind Method; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009068: Movement; D009132: Muscles; D013997: Time Factors,,,https://openalex.org/W2139176680,54,8,1,1727,317,10,en,en
false,clonidine opiate receptor antagonist treatment heroin addiction,good result detoxification method reach use together clonidine opiate receptor antagonist one hundred fifty two heroin abuse patient study evaluate withdrawal symptom therapy clonidine b clonidine naltrexone c clonidine naloxone placebo treatment result emotional behavioral change involvement psychosocial program evaluate month follow although opiate antagonist able induce slight transient withdrawal sign symptom group patient treat clonidine naltrexone together low percentage catabolites urine improvement mood family relationship furthermore patient underwent long naltrexone treatment show strong involvement psychosocial program even relative demonstrate interest recovery program decrease difficulty accept opiate antagonist treatment different evaluation withdrawal syndrome result early use naltrexone,Gerra G,1995,J Subst Abuse Treat,https://doi.org/10.1016/0740-5472(94)00077-8,7752296,Gerra G; Marcato A; Caccavari R; Fontanesi B; Delsignore R; Fertonani G; Avanzini P; Rustichelli P; Passeri M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005190: Family; D005260: Female; D005500: Follow-Up Studies; D006556: Heroin Dependence; D006801: Humans; D008297: Male; D009270: Naloxone; D009271: Naltrexone; D009460: Neurologic Examination; D010349: Patient Compliance; D012008: Recurrence; D015813: Substance Abuse Detection; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W1983146527,78,11,1,1115,179,6,en,en
false,growth rate growth hormone response growth hormonereleasing hormone challenge slowly grow child chronic administration clonidine,study effect chronic administration clonidine alpha adrenergic agonist growth rate gh response ghrh slowly grow child report clonidine administer dose mg body surface twice daily along month protocol study consist five period growth rate insulin like growth factor basal ghrh stimulate gh level evaluation month pretreatment p month placebo administration po month therapy p month clonidine withdrawal p month therapy reinstatement p difference observe p p parameter consider p significant increase linear growth p v p p observe standard deviation height modify end p growth rate standard deviation height similar record p p reinstatement clonidine therapy new less pronounced rise growth rate find p v p p v p p gh insulin like growth factor ghrh stimulate gh level significantly increase p p p p p similar p p p new increase insulin like growth factor baseline ghrh stimulate gh level observe however significantly low observe p abstract truncate word,Orio F,1995,J Endocrinol Invest,https://doi.org/10.1007/bf03349701,7759787,Orio F; Padovano N; Cinquanta L; Colao A; Merola B; Longobardi S; Rossi E; Esposito V; Orio F; Lombardi G,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000365: Age Determination by Skeleton; D001827: Body Height; D002648: Child; D003000: Clonidine; D005260: Female; D006128: Growth; D013006: Growth Hormone; D013007: Growth Hormone-Releasing Hormone; D006801: Humans; D007334: Insulin-Like Growth Factor I; D008297: Male; D010919: Placebos,,,https://openalex.org/W2072238570,154,20,1,1502,298,11,en,en
false,amphetamine rorschach measure normal subject,abstract twenty two normal undergraduate men administer either amphetamine mg kg mg kg placebo double blind counterbalance design test session exactly three week apart include among measure rorschach test rorschach anxiety think disorder variable measure drug placebo condition result suggest amphetamine cause increase rorschach anxiety index elevate rorschach index think disorder observe dissociation anxiety think disorder rorschach implication role rorschach study anxiety disorder schizophrenic disorder,Perry W,1995,J Pers Assess,https://doi.org/10.1207/s15327752jpa6403_5,7760256,Perry W; Sprock J; Schaible D; McDougall A; Minassian A; Jenkins M; Braff D,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000661: Amphetamine; D001007: Anxiety; D001794: Blood Pressure; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D010919: Placebos; D012392: Rorschach Test,,,https://openalex.org/W2043298250,52,7,1,691,107,5,en,en
false,effect dextroamphetamine methylphenidate calcium magnesium concentration hyperactive boy,level calcium plasma red blood cell mononuclear blood cell level calcium plasma plasma calcium magnesium ratio measure baseline week drug phase double blind placebo control study methylphenidate dextroamphetamine hyperactive boy level magnesium plasma significantly high week dextroamphetamine treatment calcium magnesium ratio significantly low week either drug compare baseline placebo condition change magnesium level red blood cell mononuclear blood cell measure obtain minute morning dose noon last day week phase analysis variance reveal drug effect plasma magnesium calcium magnesium ratio drug x time interaction although change correlate time course acute symptomatic response stimulant therapy decrease ratio may relevant side effect treatment resistance associate stimulant use,Schmidt ME,1994,Psychiatry Res,https://doi.org/10.1016/0165-1781(94)90007-8,7761553,Schmidt ME; Kruesi MJ; Elia J; Borcherding BG; Elin RJ; Hosseini JM; McFarlin KE; Hamburger S,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D001289: Attention Deficit Disorder with Hyperactivity; D001835: Body Weight; D002118: Calcium; D002648: Child; D002940: Circadian Rhythm; D003913: Dextroamphetamine; D004837: Epinephrine; D004906: Erythrocyte Count; D006801: Humans; D008274: Magnesium; D008297: Male; D008774: Methylphenidate; D010919: Placebos,,,https://openalex.org/W2010756522,106,13,1,1165,198,6,en,en
false,treatment attention deficit hyperactivity disorder tourette syndrome double blind placebo control study clonidine desipramine,psychostimulants exacerbate preexist motor phonic tic individual tourette syndrome clinical trial perform examine ability clonidine desipramine modify attention deficit hyperactivity disorder adhd behavior child adhd double blind placebo control protocol use subject serve control receive randomly assign fashion week medication cycle clonidine mg four time daily desipramine mg four time daily placebo thirty seven child adhd age year normal intellect recruit male female complete entire protocol outcome measure adhd include parent teacher child behavior checklist cbcl continuous performance test neuropsychologic test executive function several marker adhd show improve significantly p treatment desipramine parent linear analogue rating parent cbcl hyperactivity subscale teacher cbcl subscales nervous overactive anxious unpopular improvement desipramine always superior note clonidine clinical improvement correlate drug blood level measure tic severity neither drug make tic bad desipramine show statistically significant improvement global linear analogue scale hopkins motor vocal tic severity scale tourette syndrome severity scale yale global tic severity scale clonidine significantly alter tic severity measure result study suggest desipramine may useful alternative treatment symptom adhd child,Singer HS,1995,Pediatrics,https://doi.org/10.1542/peds.95.1.74,7770313,Singer HS; Brown J; Quaskey S; Rosenberg LA; Mellits ED; Denckla MB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003000: Clonidine; D003891: Desipramine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D005879: Tourette Syndrome; D016896: Treatment Outcome,,,https://openalex.org/W2150855904,152,19,1,1782,306,8,en,en
true,double blind crossover comparison methylphenidate placebo adult childhood onset attention deficit hyperactivity disorder,control study methylphenidate hydrochloride adult attention deficit hyperactivity disorder adhd result equivocal discrepancy among study may relate low diagnostic uncertainty lack attention comorbid disorder conduct randomize week placebo control crossover study methylphenidate adult patient dsm iii r adhd use standardize instrument diagnosis separate assessment adhd depressive anxiety symptom robust daily dose methylphenidate hydrochloride mg kg per day find marked therapeutic response methylphenidate treatment adhd symptom exceed placebo response v p response methylphenidate independent gender psychiatric comorbidity anxiety moderate depression family history psychiatric disorder robust dos methylphenidate effective treatment adult adhd,Spencer T,1995,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1995.03950180020004,7771913,Spencer T; Wilens T; Biederman J; Faraone SV; Ablon JS; Lapey K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000553: Ambulatory Care; D001008: Anxiety Disorders; D001289: Attention Deficit Disorder with Hyperactivity; D015897: Comorbidity; D018592: Cross-Over Studies; D003866: Depressive Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005190: Family; D005260: Female; D006801: Humans; D008297: Male; D001523: Mental Disorders; D008774: Methylphenidate; D008875: Middle Aged; D010919: Placebos; D016896: Treatment Outcome,,,https://openalex.org/W1989428478,139,16,1,1006,157,3,en,en
false,efficacy methylphenidate attention deficit hyperactivity disorder child tic disorder,find case report patient questionnaire survey interpret indicate administration stimulant ill advise treatment attention deficit hyperactivity disorder child tic disorder thirty four prepubertal child attention deficit hyperactivity disorder tic disorder receive placebo three dosage methylphenidate hydrochloride mg kg twice daily week double blind condition treatment effect assess use direct observation child behavior simulate clinic base classroom use rating scale complete parent teacher physician methylphenidate effectively suppress hyperactive disruptive aggressive behavior evidence methylphenidate alter severity tic disorder may weak effect frequency motor increase vocal decrease tic methylphenidate appear safe effective treatment attention deficit hyperactivity disorder majority child comorbid tic disorder,Gadow KD,1995,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1995.03950180030005,7771914,Gadow KD; Sverd J; Sprafkin J; Nolan EE; Ezor SN,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D015897: Comorbidity; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010290: Parents; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D013663: Teaching; D013981: Tic Disorders; D016896: Treatment Outcome",,,https://openalex.org/W2092202774,102,12,1,1107,165,3,en,en
false,effectiveness apraclonidine acetazolamide prevent postoperative intraocular pressure spike extracapsular cataract extraction,study effectiveness two prophylactic agent control early postoperative intraocular pressure iop increase cataract surgery fifty four nonglaucomatous patient receive either topical apraclonidine one drop surgery sustain release acetazolamide mg medication completion plan extracapsular cataract extraction ecce mean baseline iop similar among patient randomize apraclonidine acetazolamide control group mm hg mm hg mm hg respectively hour postoperatively iop significantly low apraclonidine group mm hg p nonsignificantly low acetazolamide group mm hg p significantly increase control group mm hg p one eye apraclonidine group six control group iop great mm hg hour statistically significant difference control group whose mean iop remain elevated mm hg p one eye apraclonidine group two acetazolamide group five control group iop great mm hg find significant early iop reduction apraclonidine give topically preoperatively completion plan ecce,Feist RM,1995,J Cataract Refract Surg,https://doi.org/10.1016/s0886-3350(13)80509-3,7791061,Feist RM; Palmer DJ; Fiscella R; Ernest JT; Tripathi R; Torczynski E; Farber M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000086: Acetazolamide; D000284: Administration, Oral; D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000368: Aged; D002387: Cataract Extraction; D003000: Clonidine; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D011292: Premedication",,,https://openalex.org/W2078252530,144,15,1,1329,247,8,en,en
false,postoperative analgesia co administration clonidine morphine intrathecal route patient undergo hip replacement,postoperative analgesia intrathecal co administration clonidine hydrochloride micro gram morphine sulfate mg compare analgesia produce either intrathecal morphine mg sodium chloride patient undergo total hip replacement bupivacaine spinal anesthesia patient control morphine requirement significantly reduce p postoperation clonidine morphine median mg h morphine median mg h compare control saline median mg h however significant additional reduction postoperative analgesic requirement show clonidine morphine combination compare morphine alone visual analog pain score although good group time significantly poor control group h p h p operation compare treatment group significantly poor clonidine morphine group h p h p postoperation mean arterial blood pressure significantly low clonidine morphine group two group p h operation incidence emesis similar clonidine morphine morphine group significantly control group anesth analg,Grace D,1995,Anesth Analg,https://doi.org/10.1097/00000539-199501000-00015,7802307,Grace D; Bunting H; Milligan KR; Fee JP,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D003000: Clonidine; D004338: Drug Combinations; D005260: Female; D006622: Hip Prosthesis; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D009020: Morphine; D010149: Pain, Postoperative; D011182: Postoperative Care",,,https://openalex.org/W1976871454,137,17,1,1357,242,7,en,en
false,cardiovascular effect bupropion nortriptyline depress outpatient,cardiovascular effect bupropion hydrochloride nortriptyline compare double blind randomize week trial adult outpatient major depression week placebo phase patient randomize treatment bupropion mg day nortriptyline mg day nortriptyline treat patient statistically significant heart rate increase assessment determine rr interval electrocardiogram bpm bupropion treat patient small statistically significant increase supine diastolic blood pressure mm hg day mm hg day patient treatment group orthostatic change nortriptyline treat patient symptomatic orthostatic hypotension slow cardiac conduction possibly rate correct repolarization occur patient treat nortriptyline occur patient treat bupropion compare nortriptyline bupropion appear wide safety margin regard cardiovascular effect may particularly true elderly patient preexist cardiovascular disease overdose,Kiev A,1994,Ann Clin Psychiatry,https://doi.org/10.3109/10401239409148989,7804386,Kiev A; Masco HL; Wenger TL; Johnston JA; Batey SR; Holloman LC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001794: Blood Pressure; D016642: Bupropion; D002319: Cardiovascular System; D003866: Depressive Disorder; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D007024: Hypotension, Orthostatic; D008297: Male; D008875: Middle Aged; D009661: Nortriptyline",,,https://openalex.org/W2024858939,82,10,1,1198,187,8,en,en
false,methylphenidate influence early late erp wave adhd child continuous performance test,although frequently report hyperactive child abnormally small p amplitude event relate potential erp normalize stimulant drug methylphenidate mph literature inconsistent concern earlier erp wave aim present study investigate whether normalize effect mg dose mph also apparent early wave n p n besides p twelve attention deficit hyperactivity disorder adhd child perform continuous performance test involve button press response letter x cpt x influence mph double blind placebo control acute dosage design erps record oz pz cz fz expect increase parietal p target nontargets apparent well significant increase percentage hit also significant increase early negative go wave n frontal maximum influence mph wave probably manifestation increase process negativity target stimulus intake stimulant drug effect mph find n p,Verbaten MN,1994,J Abnorm Child Psychol,https://doi.org/10.1007/bf02168938,7822629,Verbaten MN; Overtoom CC; Koelega HS; Swaab-Barneveld H; van der Gaag RJ; Buitelaar J; van Engeland H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002540: Cerebral Cortex; D002648: Child; D004311: Double-Blind Method; D004569: Electroencephalography; D005074: Evoked Potentials, Visual; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011597: Psychomotor Performance; D011930: Reaction Time",,,https://openalex.org/W2093911428,109,17,1,1223,233,8,en,en
false,observation rating tic school set,paper describe find school base tic assessment procedure direct observation teacher rating scale hyperactive child comorbid tic disorder rate motor tic frequency find moderately stable across day school set correlation direct observation tic clinician rating scale generally low moderate range correlation teacher clinician rating scale overall rate hyperactive disruptive behavior associate rate motor tic occurrence behavioral symptom disorder also independent specific interval time,Nolan EE,1994,J Abnorm Child Psychol,https://doi.org/10.1007/bf02168939,7822630,Nolan EE; Gadow KD; Sverd J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009460: Neurologic Examination; D015588: Observer Variation; D010552: Personality Assessment; D012931: Social Environment; D013981: Tic Disorders; D005879: Tourette Syndrome",,,https://openalex.org/W2080149968,51,8,1,669,104,4,en,en
false,effect intravenous dextroamphetamine brain metabolism adult attention deficit hyperactivity disorder adhd preliminary finding,effect brain metabolism intravenous v administration dextroamphetamine assess positron emission tomography pet f fluorodeoxyglucose fdg adult attention deficit hyperactivity disorder adhd hour fdg pet session adult undergo initial scan follow v infusion placebo second scan follow v infusion mg kg dextroamphetamine single blind design subject show increase systolic diastolic blood pressure improve continuous performance task score dextroamphetamine global regional metabolic rate significantly alter stimulant regional global rate normalize metabolic rate three cortical region differ significantly condition individually global metabolism increase subject unchanged decrease stimulant infusion clinical characteristic differentiate patient v infusion dextroamphetamine significantly alter brain metabolism adhd adult preliminary study,Ernst M,1994,Psychopharmacol Bull,,7831459,Ernst M; Zametkin AJ; Matochik JA; Liebenauer L; Fitzgerald GA; Cohen RM,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D001923: Brain Chemistry; D003913: Dextroamphetamine; D005260: Female; D005947: Glucose; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D014055: Tomography, Emission-Computed",,,https://openalex.org/W2419859983,146,20,2,1127,177,12,en,en
false,sympathetic suppression attenuate anomalous response morphine unexplained pain cholecystectomy,anomalous response morphine common patient unexplained pain upper abdomen cholecystectomy may link activation sympathetic nervous system hypothesis sympathetic suppression would attenuate anomalous response morphine test randomize cross trial use standard challenge morphine without pretreatment clonidine microgram orally h prior administration morphine patient complete study pre treatment clonidine decrease plasma concentration noradrenaline dopamine adrenaline respectively associate significant reduction morphine induce pain p nausea p attenuate increase plasma aspartate aminotransferase ast activity p clonidine attenuate anomalous response morphine perhaps effect sympathetic nervous activity plasma concentration catecholamine,Roberts-Thomson IC,1994,Clin Auton Res,https://doi.org/10.1007/bf01826184,7849498,Roberts-Thomson IC; Jonsson JR; Frewin DB,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D002763: Cholecystectomy; D003000: Clonidine; D018592: Cross-Over Studies; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009020: Morphine; D010149: Pain, Postoperative; D013564: Sympathetic Nervous System",,,https://openalex.org/W2031969814,108,12,1,1015,167,5,en,en
false,efficacy methadone versus methadone guanfacine detoxification heroin addict patient,randomize double blind study clinical efficacy methadone v methadone guanfacine assess term evolution opioid withdrawal symptom inpatient detoxification total patient include randomly allocate three different treatment group methadone alone two combined treatment schedule methadone plus mg guanfacine difference observe among three group regard retention rate throughout study period therapy methadone methadone plus guanfacine determine slight increase withdrawal score methadone discontinue however guanfacine unable effectively control methadone associate withdrawal symptom result indicate guanfacine effectively reduce opioid withdrawal symptom,San L,1994,J Subst Abuse Treat,https://doi.org/10.1016/0740-5472(94)90100-7,7869468,San L; Fernandez T; Cami J; Gossop M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D016316: Guanfacine; D006339: Heart Rate; D006556: Heroin Dependence; D006801: Humans; D008297: Male; D008691: Methadone; D009460: Neurologic Examination; D016320: Substance Abuse Treatment Centers; D013375: Substance Withdrawal Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W2062261859,103,13,1,837,129,6,en,en
false,clozapine refractory schizophrenia long term prospective study patient,clozapine dibenzodiazepine derivative potent antipsychotic activity bone marrow suppression result agranulocytosis associate clozapine treatment thus clinical development delay administration drug restrict treatment resistant schizophrenic patient report describe open prospective study effect clozapine symptomatology patient refractory neuroleptic author prospectively follow month dsm iii r schizophrenic patient fail respond various neuroleptic clozapine treatment initiate mean duration illness year various scale use evaluation total bprs bprs positive symptom bprs negative symptom panss positive panss negative realize day month every month significative improvement total bprs bprs positive symptom panss positive note day p p p respectively clozapine produce significant improvement bprs negative symptom panss negative month p p respectively side effect study dry mouth prominent first month wash salivation prevalent within first month beyond agranulocytosis cohort case eosinophilia occur first month patient experience increase total white blood cell count mm weight gain kg affect patient abstract truncate word,Jalenques I,1994,Encephale,,7875111,Jalenques I; Coudert AJ,article,D004740: English Abstract; D016428: Journal Article,D000328: Adult; D003024: Clozapine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008134: Long-Term Care; D008297: Male; D010359: Patient Readmission; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012917: Social Adjustment,,,https://openalex.org/W2412693842,85,14,2,1694,323,11,en,en
false,efficacy apraclonidine adjunct timolol therapy,objective compare intraocular pressure iop lower efficacy apraclonidine hydrochloride use adjunctively timolol maleate patient design multicenter randomize double mask clinical trial adult patient either sex diagnose either open angle glaucoma ocular hypertension enrol study patient use timolol maleate twice daily least week amiops least mm hg great mm hg hour dose eligible study ambaseline iop obtain patient take timolol randomize receive either apraclonidine twice daily addition timolol intraocular pressure measure morning dose hour dose day amonly day result concentration apraclonidine produce significant iop reduction baseline visit p nighttime dose additional mean iop reduction timolol baseline range mm hg reduction respectively hour morning dose additional iop reduction timolol baseline range mm hg respectively difference iop reduction observe apraclonidine concentration loss iop efficacy observe either concentration duration study sensitivity apraclonidine observe nine patient respectively overall therapy discontinue owe ocular nonocular side effect apraclonidine patient respectively conclusion believe apraclonidine equally effective apraclonidine use twice daily first adjunctive drug timolol drug effect maintain least day,Stewart WC,1995,Arch Ophthalmol,https://doi.org/10.1001/archopht.1995.01100030041019,7887841,Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D017024: Chemotherapy, Adjuvant; D003000: Clonidine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004357: Drug Synergism; D004361: Drug Tolerance; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D013999: Timolol",,,https://openalex.org/W1990487896,62,10,1,2064,425,14,en,en
false,influence apraclonidine pilocarpine alone combination post laser trabeculoplasty pressure rise,apraclonidine pilocarpine show effective reduce incidence intraocular pressure iop spike follow argon laser trabeculoplasty additional reduction incidence acute pressure rise might theoretically expect combine two effective agent prospective randomise study compare ability apraclonidine pilocarpine alone combination prevent post laser pressure spike patient receive regular pilocarpine either eye exclude seventy five eye receive either apraclonidine eye pilocarpine eye drug eye apraclonidine instill hour immediately pilocarpine immediately trabeculoplasty iop measure hour follow trabeculoplasty two eye receive combine treatment pressure rise observe frequency significantly low see eye treat apraclonidine alone pilocarpine alone mean fall iop hour significantly great eye receive combine treatment two group,Dapling RB,1994,Br J Ophthalmol,https://doi.org/10.1136/bjo.78.1.30,7906539,Dapling RB; Cunliffe IA; Longstaff S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000318: Adrenergic beta-Agonists; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D003000: Clonidine; D005902: Glaucoma, Open-Angle; D006339: Heart Rate; D006801: Humans; D007429: Intraocular Pressure; D053685: Laser Therapy; D008875: Middle Aged; D010862: Pilocarpine; D011446: Prospective Studies; D014130: Trabeculectomy",,,https://openalex.org/W2099866489,112,16,1,1180,214,10,en,en
false,attention deficit hyperactivity disorder adult,,Shaffer D,1994,Am J Psychiatry,https://doi.org/10.1176/ajp.151.5.633,7909410,Shaffer D,article,"D016421: Editorial; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000293: Adolescent; D000328: Adult; D000367: Age Factors; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D015995: Prevalence,,,https://openalex.org/W2395016593,50,6,1,0,0,0,en,
false,double blind trial bupropion versus desipramine bipolar depression,although treatment bipolar depression frequent clinical problem double blind study treatment bipolar depression scarce case series uncontrolled data suggest antidepressant may differ propensity induce mania efficacy bipolar depression author conduct prospective double blind trial assess efficacy rate treatment emergent mood elevation depress bipolar patient bupropion desipramine add ongoing therapeutic regimen lithium anticonvulsant result assess week acute treatment maintenance treatment year difference find acute efficacy two drug mania hypomania observe desipramine treat patient bupropion treat patient occurrence hypomania mania correlate treatment group kendall tau correlation z p pilot find suggest bupropion less likely induce mood elevation desipramine treatment bipolar depression bupropion desipramine appear similar antidepressant efficacy,Sachs GS,1994,J Clin Psychiatry,,7929019,Sachs GS; Lafer B; Stoll AL; Banov M; Thibault AB; Tohen M; Rosenbaum JF,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000927: Anticonvulsants; D001714: Bipolar Disorder; D016642: Bupropion; D003891: Desipramine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008094: Lithium; D008297: Male; D010865: Pilot Projects; D011446: Prospective Studies",,,https://openalex.org/W1764919821,76,11,1,1174,185,6,en,en
false,pharmacodynamics mdl absence effect pressor response oral tyramine,mdl new irreversible selective inhibitor monoa mine oxidase mao b metabolize amphetamine like compound currently develop treatment parkinson disease double blind placebo control randomize study healthy volunteer n dose receive single oral placebo mg mdl qd two week sensitivity orally administer tyramine determine fast condition drug administration tyramine yield mmhg increase sbp pd compare fold increase tyramine sensitivity end treatment see mdl dose level however within variability range tyramine pressor response mdl selectively inhibit mao b dose mg orally favourable safety profile,Hinze C,1994,J Neural Transm Suppl,https://doi.org/10.1007/978-3-7091-9324-2_49,7931253,Hinze C; Kaschube M; Hardenberg J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000498: Allyl Compounds; D001794: Blood Pressure; D002082: Butylamines; D004311: Double-Blind Method; D006801: Humans; D014439: Tyramine",,,https://openalex.org/W567455060,90,15,1,864,156,5,en,en
false,opioid antagonist effect self injury adult mental retardation response form location determinant medication effect,opioid antagonist naltrexone administer adult severe profound mental retardation extensive history self injurious behavior five minute behavioral sample observe randomly every hour p monday friday four week phase baseline placebo mg mg naltrexone administration day frequent head bang self bite whereas day blow head self bite infrequent self injurious participant sleep hour less per night baseline unaffected naltrexone,Thompson T,1994,Am J Ment Retard,,7946257,Thompson T; Hackenberg T; Cerutti D; Baker D; Axtell S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008607: Intellectual Disability; D008111: Liver Function Tests; D008297: Male; D009271: Naltrexone; D011957: Receptors, Opioid; D016728: Self-Injurious Behavior; D012931: Social Environment",,,https://openalex.org/W345987132,141,21,1,643,107,4,en,en
false,stability neurological sign clozapine treatment,examination effect clozapine neurological sign provide mechanism evaluate relationship extrapyramidal symptom tardive dyskinesia neurological sign change psychopathology change neurological sign score,Buchanan RW,1994,Biol Psychiatry,https://doi.org/10.1016/0006-3223(94)91225-4,7948457,Buchanan RW; Koeppl P; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D009460: Neurologic Examination; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W1965107636,56,7,1,277,39,1,en,en
false,hydrocortisone cream clonidine patch dermatitis,,Tom GR,1994,Ann Pharmacother,,7949510,Tom GR; Premer M,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000279: Administration, Cutaneous; D002986: Clinical Trials as Topic; D003000: Clonidine; D003877: Dermatitis, Contact; D006801: Humans; D006854: Hydrocortisone; D009824: Ointments; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2470340703,51,7,1,0,0,0,en,
false,clozapine tardive dyskinesia observation human animal model study,clozapine long consider useful treatment patient schizophrenia neuroleptic induce delayed onset side effect tardive dyskinesia present data support clinical impression use animal model disorder dyskinetic patient clozapine produce low rate oral dyskinesia laboratory rat month chronic treatment haloperidol vs vacuous chew movement every minute respectively suggest low propensity cause tardive dyskinesia human clozapine compare haloperidol treatment patient tardive dyskinesia clozapine produce significantly great benefit motor symptom month treatment haloperidol p moreover dyskinesia rebound occur equally drug group begin study sustain haloperidol group lose clozapine treat patient data suggest dyskinetic patient lose symptom tardive dyskinesia along dopaminergic hypersensitivity long term clozapine treatment,Tamminga CA,1994,J Clin Psychiatry,,7961550,Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000818: Animals; D014150: Antipsychotic Agents; D003024: Clozapine; D004195: Disease Models, Animal; D004409: Dyskinesia, Drug-Induced; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D008297: Male; D051381: Rats; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W2419309010,82,13,1,1170,188,6,en,en
false,clozapine negative symptom extrapyramidal side effect,importance persistent negative symptom schizophrenia limit factor psychosocial vocational rehabilitation increasingly emphasize result treatment trial new drug development program focus attention negative symptom unfortunately enormous phenomenological overlap negative symptom neuroleptic induce parkinsonism report data cohort clozapine treat patient demonstrate significant correlation measure akinesia anergia despite average drug washout week persistence drug induce parkinsonism confound assessment therapeutic drug effect negative symptom,Kane JM,1994,J Clin Psychiatry,,7961579,Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D001480: Basal Ganglia Diseases; D003024: Clozapine; D005260: Female; D006801: Humans; D008297: Male; D010302: Parkinson Disease, Secondary; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2399069816,62,10,1,715,102,5,en,en
false,dose interval prolongation tetracaine spinal anesthesia oral clonidine human,study design evaluate optimal administration time oral clonidine premedication prolongation tetracaine spinal anesthesia human forty male patient schedule urologic surgery study patient allocate randomly four group give mg isobaric tetracaine group give g triazolam orally h anesthesia group administer g oral clonidine anesthesia h h anesthesia respectively sensory block assess pinprick group significantly prolong time sensory block p compare group however prolong effect oral clonidine apparent group conclude administer within h anesthesia oral clonidine dose g produce significant prolongation tetracaine spinal anesthesia without adverse effect anesth analg,Ota K,1994,Anesth Analg,https://doi.org/10.1213/00000539-199412000-00016,7978435,Ota K; Namiki A; Iwasaki H; Takahashi I,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000775: Anesthesia, Spinal; D001794: Blood Pressure; D003000: Clonidine; D004334: Drug Administration Schedule; D004357: Drug Synergism; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D011467: Prostate; D013748: Tetracaine; D001743: Urinary Bladder",,,https://openalex.org/W1996008385,92,13,1,976,181,10,en,en
false,dose related prolongation tetracaine spinal anesthesia oral clonidine human,comment clonidine dexmedetomidine nonspecific specific receptor agonist decrease release norepinephrine stimulation presynaptic sympathetic neuron decrease sympathetic activity central nervous system reduce minimum alveolar concentration mac inhalational anesthetic study show oral clonidine prolong sensory block spinal anesthesia obtain tetracaine author argue probably occur undefined supraspinal mechanism clonidine alter maximum sensory level spinal anesthesia significantly prolong two four dermatome regression time interest significant hemodynamic effect see significantly decrease heart rate patient receive g high dose use study protocol use study patient undergoing vaginal hysterectomy transurethral resection prostate different use practitioner isobaric spinal anesthesia administer mg tetracaine patient average foot inch tall average sensory level obtain however blood pressure monitor every min first min every min agonist may enhance spinal anesthesia number mechanism may analgesic effect central nervous system similar enhancement mac unlikely use study would lead significant concentration clonidine cerebrospinal fluid finally spinal cord blood flow may alter slow elimination tetracaine experimentally would interest see small intrathecal clonidine dexmedetomidine alter analgesic effect local anesthetic clonidine use clinically antihypertensive catapres anesthesiologist need concern effect mac duration spinal anesthesia concern warrant discontinuation antihypertensive sudden discontinuation may result withdrawal syndrome characterize hypertension tachycardia,Ota K,1994,Anesth Analg,https://doi.org/10.1097/00132586-199506000-00032,7978436,Ota K; Namiki A; Iwasaki H; Takahashi I,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000775: Anesthesia, Spinal; D001794: Blood Pressure; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004357: Drug Synergism; D005260: Female; D006339: Heart Rate; D006801: Humans; D007045: Hysterectomy, Vaginal; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D011467: Prostate; D013748: Tetracaine; D001743: Urinary Bladder",,,https://openalex.org/W2017904992,85,11,1,2168,351,19,en,en
false,balance postoperative analgesia,agonist interaction antinociceptive effect clonidine opioids use reduce opioid requirement surgical patient however clonidine cause mark sedation associate respiratory dysfunction thus benefit use clonidine reduce opioid use respiration questionable double blind randomize study compare analgesic efficacy arterial blood gas pharmacokinetics intravenous iv infusion fentanyl microgram h mixture fentanyl microgram h plus clonidine microgram kg h healthy young adult surgery scoliosis correction oxygen saturation fio respiratory rate monitor well supplemental analgesia demand iv ketoprofen via patient control device pain sedation hemodynamics oxygen naloxone microgram kg min administer respectively three episode oxygen saturation less observe within min paco high mm hg pain relief sedation ketoprofen requirement similar group number episode arterial desaturation less four patient fentanyl group versus none clonidine fentanyl group naloxone require six patient oxygen two patient fentanyl group versus none group receive clonidine dopamine microgram kg min require one patient clonidine fentanyl group correct hypotension mean arterial blood pressure plasma clearance elimination rate constant fentanyl low clonidine fentanyl group fentanyl group abstract truncate word,Bernard JM,1994,Anesth Analg,https://doi.org/10.1213/00000539-199412000-00018,7978437,Bernard JM; Lagarde D; Souron R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000698: Analgesia; D001794: Blood Pressure; D002245: Carbon Dioxide; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004347: Drug Interactions; D005260: Female; D005283: Fentanyl; D006801: Humans; D007206: Individuality; D007262: Infusions, Intravenous; D008297: Male; D010100: Oxygen; D010149: Pain, Postoperative; D010313: Partial Pressure; D011182: Postoperative Care; D012119: Respiration",,,https://openalex.org/W2095923220,32,3,1,1735,294,12,en,en
false,premedication oral transdermal clonidine provide safe efficacious postoperative sympatholysis,study patient undergo elective major non cardiac surgery randomize double blind placebo control clinical trial test hypothesis addition clonidine standardize general anesthetic could safely provide postoperative sympatholysis patient know suspect coronary artery disease patient allocate randomly receive either placebo n clonidine n treatment group receive premedication trans dermal clonidine system mg night prior surgery leave place h mg oral clonidine min surgery clonidine reduce enflurane requirement intraoperative tachycardia myocardial ischemia clonidine patient v placebo p however clonidine decrease heart rate first five postoperative hour incidence postoperative myocardial ischemia clonidine v placebo differ two group patient experience postoperative myocardial ischemia tend high heart rate surgery clonidine significantly reduce plasma level epinephrine p norepinephrine p measure first postoperative morning difference need intravenous fluid therapy antihypertensive therapy surgery number hour spend intensive care set number day spend hospital different two group result suggest large clonidine investigate ability decrease postoperative tachycardia myocardial ischemia anesth analg,Ellis JE,1994,Anesth Analg,https://doi.org/10.1213/00000539-199412000-00019,7978438,Ellis JE; Drijvers G; Pedlow S; Laff SP; Sorrentino MJ; Foss JF; Shah M; Busse JR; Mantha S; McKinsey JF,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000279: Administration, Cutaneous; D000284: Administration, Oral; D000368: Aged; D000758: Anesthesia; D003000: Clonidine; D003327: Coronary Disease; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004562: Electrocardiography; D004737: Enflurane; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009609: Nitrous Oxide; D010919: Placebos; D011182: Postoperative Care; D011292: Premedication; D011941: Receptors, Adrenergic; D012307: Risk Factors; D017409: Sufentanil; D013514: Surgical Procedures, Operative; D013565: Sympatholytics; D014563: Urodynamics",,,https://openalex.org/W2120390261,107,12,1,1686,280,11,en,en
false,prevention phantom pain major low limb amputation epidural infusion diamorphine clonidine bupivacaine,phantom limb pain may appear patient amputation effective treatment perioperative epidural infusion morphine bupivacaine alone combination effective prevent phantom limb pain patient pre exist limb pain serious side effect however make difficult manage general ward clonidine show effective postoperative analgesia apply epidurally mitigate potentially serious side effect drug study combine efficiency prevent phantom limb pain prospective control study patient undergo low limb amputation study group n epidural infusion contain bupivacaine mg clonidine microgram diamorphine mg ml normal saline give ml h h preoperatively maintain least day postoperatively control group n receive demand opioid analgesia pain assess visual analogue scale day month year year follow one patient study group eight patient control group phantom pain p two patient study group versus eight patient control group phantom limb sensation p significant improvement stump pain conclude perioperative epidural infusion diamorphine clonidine bupivacaine safe effective reduce incidence phantom pain amputation,Jahangiri M,1994,Ann R Coll Surg Engl,,7979074,Jahangiri M; Jayatunga AP; Bradley JW; Dark CH,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000671: Amputation, Surgical; D000700: Analgesics; D002045: Bupivacaine; D003000: Clonidine; D004338: Drug Combinations; D005260: Female; D005500: Follow-Up Studies; D003932: Heroin; D006801: Humans; D007263: Infusions, Parenteral; D007866: Leg; D008297: Male; D008875: Middle Aged; D010149: Pain, Postoperative; D010591: Phantom Limb; D011292: Premedication; D011446: Prospective Studies",,,https://openalex.org/W1544197342,124,19,1,1524,274,12,en,en
false,efficacy methylphenidate behavioral intervention classroom behavior child adhd mental retardation,use combination alternate treatment double blind placebo control drug design independent combined effect two behavioral intervention two methylphenidate mph child attention deficit hyperactivity disorder adhd mental retardation mr assess single subject design subject respond positively medication measure increase task behavior first behavioral intervention token economy task behavior ineffective increase either task behavior work accuracy combine placebo however improvement work accuracy realize implementation second behavioral intervention specifically target accuracy independent drug condition current finding highlight positive effect limitation two commonly use treatment modality adhd future study continue extend area investigative effort produce data base knowledge appropriate treatment pharmacological behavioral child adhd mental retardation,Johnson CR,1994,Behav Modif,https://doi.org/10.1177/01454455940184005,7980374,Johnson CR; Handen BL; Lubetsky MJ; Sacco KA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D002648: Child; D002675: Child, Preschool; D003131: Combined Modality Therapy; D004311: Double-Blind Method; D006801: Humans; D008607: Intellectual Disability; D008774: Methylphenidate; D010919: Placebos; D013334: Students; D014040: Token Economy; D016896: Treatment Outcome",,,https://openalex.org/W2068573868,122,16,1,1165,181,6,en,en
false,effect clozapine fluphenazine placebo reaction time measure attention sensory dominance schizophrenia,two reaction time rt paradigm use study clozapine effect sustain selective attention compare fluphenazine placebo chronic schizophrenic patient sensory dominance study via simple choice rts light tone double stimulus trial two stimulus present simultaneously although patient could perform rt task take placebo effect clozapine simple choice rt compare placebo fluphenazine subject treatment show visual dominance faster rt light tone choice double stimulus trial however clozapine reduce mean selective increase rt light clozapine reduce failure respond tone double stimulus trial show due reduction hallucination clozapine generally improve attention may increase ability schizophrenic person process nondominant unattended stimulus possibly increase efficiency resource allocation may partially mediate reduction hallucination,Zahn TP,1994,Schizophr Res,https://doi.org/10.1016/0920-9964(94)90094-9,7986770,Zahn TP; Pickar D; Haier RJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001288: Attention; D001307: Auditory Perception; D003024: Clozapine; D004292: Dominance, Cerebral; D004409: Dyskinesia, Drug-Induced; D005260: Female; D005476: Fluphenazine; D006212: Hallucinations; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011930: Reaction Time; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D014796: Visual Perception",,,https://openalex.org/W1997542359,125,19,1,1143,193,9,en,en
false,clonidine lidocaine inhibition isoflurane induce tachycardia human,rapid increase isoflurane concentration induce tachycardia hypertension increase plasma catecholamine concentration investigate possible mechanism measure hemodynamic response isoflurane administer via mask also administer clonidine premedication lidocaine topically nasal mucosa lidocaine intravenously evaluate effect drug hemodynamic response forty asa physical status patient age yr schedule elective oral surgery participate study thirty patient randomly allocate one three group control group group receive microgram kg oral clonidine premedication group receive ml lidocaine spray nasal mucosa ten patient assign nonrandomly group receive intravenous lidocaine continuously mg kg bolus follow microgram kg min initial randomize experiment test whether systemic lidocaine blunt response inhale isoflurane anesthesia induce thiamylal inhalation isoflurane oxygen via mask begin inspire concentration isoflurane increase every min maximum normocapnia without surgical stimulation heart rate systolic blood pressure measure every minute min isoflurane inhalation plasma catecholamine concentration measure isoflurane concentration control intravenous lidocaine group increase isoflurane concentration significantly increase systolic blood pressure peak change mmhg respectively heart rate peak change beat min respectively change concentration however significantly alter hemodynamics blood pressure heart rate response change isoflurane significantly blunt group receive clonidine peak change mmhg beat min respectively nasal lidocaine peak change mmhg beat min respectively compare control group group plasma epinephrine norepinephrine concentration increase administration isoflurane respectively plasma lidocaine concentration microgram kg nasal lidocaine group micrograms kg intravenous lidocaine group stepwise increase isoflurane concentration elicit hypertension tachycardia well increment plasma catecholamine concentration mask anesthesia nasal administration lidocaine clonidine premedication significantly blunt circulatory response isoflurane intravenous lidocaine significantly weaken response change isoflurane concentration,Tanaka S,1994,Anesthesiology,https://doi.org/10.1097/00000542-199412000-00007,7992901,Tanaka S; Tsuchida H; Namba H; Namiki A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000287: Administration, Topical; D000328: Adult; D000769: Anesthesia, Inhalation; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004837: Epinephrine; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007275: Injections, Intravenous; D007530: Isoflurane; D008012: Lidocaine; D008297: Male; D009638: Norepinephrine; D011229: Preanesthetic Medication; D013610: Tachycardia",,,https://openalex.org/W2056145572,78,9,1,2910,467,14,en,en
false,clonidine useful adjunct methadone gradual detoxification opioid addiction,role clonidine management opioid dependent individual undergo gradual detoxification double blind placebo control trial conduct voluntary patient male female age year specialist drug dependence treatment unit patient enter trial mg methadone daily less randomise receive incremental clonidine increase mg daily mg daily day period gradual methadone detoxification four week thereafter blood pressure monitor severity opioid abstinence assess questionnaire clinical examination half subject withdraw default trial end two week receive clonidine earlier receive dummy medication former one latter systemic hypotension similar proportion subject complete detoxification two group complete detoxification clonidine significantly reduce either symptom objective sign opioid withdrawal find suggest clonidine place adjunct programme gradual opioid detoxification,Ghodse H,1994,Br J Psychiatry,https://doi.org/10.1192/bjp.165.3.370,7994508,Ghodse H; Myles J; Smith SE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008691: Methadone; D008875: Middle Aged; D009460: Neurologic Examination; D009293: Opioid-Related Disorders",,,https://openalex.org/W2029964069,89,13,1,1227,196,5,en,en
false,trazodone antidepressant associate insomnia,author investigate trazodone hypnotic depress patient persistent exacerbate new insomnia take either fluoxetine bupropion seventeen depress patient insomnia take fluoxetine bupropion give either trazodone placebo double blind crossover trial sleep assess self report pittsburgh sleep quality index sleep item yale new hospital depressive symptom inventory improvement trazodone placebo show total pittsburgh index score yale new inventory total sleep score pittsburgh index measure sleep duration yale new inventory measure early morning awaken trend toward improvement yale new inventory item regard middle night awaken subjective sleep quality sleep latency also show trend toward improvement pittsburgh index measure sleep efficiency disturbance yale new inventory item regard difficulty fall asleep unaffected trazodone one patient drop excessive daytime sedation trazodone another drop nonresponse placebo completers experience overall improvement sleep trazodone accord priori criterion whereas experience improvement placebo trazodone effective hypnotic patient antidepressant associate insomnia,Nierenberg AA,1994,Am J Psychiatry,https://doi.org/10.1176/ajp.151.7.1069,8010365,Nierenberg AA; Adler LA; Peselow E; Zornberg G; Rosenthal M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D016642: Bupropion; D016001: Confidence Intervals; D003866: Depressive Disorder; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008297: Male; D010919: Placebos; D012890: Sleep; D007319: Sleep Initiation and Maintenance Disorders; D014196: Trazodone",,,https://openalex.org/W2417756824,48,4,1,1510,229,5,en,en
false,comparison pharmacokinetics pharmacodynamics safety oral catapres transdermal clonidine healthy subject,pharmacokinetic well pharmacodynamic property transdermal clonidine safety compare oral clonidine catapres nippon boehringer ingelheim hyogo japan one patch contain mg clonidine apply right chest day one tablet catapres mg give orally every hour day eight healthy subject study conduct crossover design day interval cross blood urine sample clonidine concentration obtain blood pressure bp measure hour period application hour period initiation catapres therapy plasma concentration clonidine increase gradually application decrease gradually removal whereas parameter increase rapidly absorption phase decrease rapidly elimination phase dosage catapres elimination half life clonidine removal significantly great final dosage catapres significant difference observe maximum plasma concentration area plasma concentration time curve two trial bp low effect catapres differ significantly adverse symptom occur frequently catapres therapy treatment symptom observe plasma clonidine concentration relatively high trial result suggest effective treatment hypertension low incidence adverse symptom abstract truncate word,Fujimura A,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb03996.x,8021335,Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000279: Administration, Cutaneous; D000284: Administration, Oral; D000328: Adult; D001794: Blood Pressure; D003000: Clonidine; D006801: Humans; D008297: Male",,,https://openalex.org/W2095388594,139,23,1,1678,284,11,en,en
false,platelet alpha sub sub adrenergic receptor bind effect amphetamine boy attention deficit hyperactivity disorder,presynaptic inhibitory alpha adrenergic receptor involve regulate release norepinephrine ne negative feedback mechanism mediate ne increase alpha adrenergic receptor activity suggest decrease ne release activity decrease alpha adrenergic activity suggest increase ne release activity large body evidence suggest involvement disturbance ne activity pathophysiology attention deficit hyperactivity disorder adhd childhood platelet alpha adrenergic receptor bind compare boy age diagnosis adhd normal control adhd boy tend low level alpha bind control administration amphetamine double blind placebo control crossover design effect alpha receptor bind adhd boy nonresponders amphetamine low alpha receptor bind compare responder control find suggest normal alpha adrenergic activity adhd boy responder amphetamine possible increase ne release adhd boy nonresponders amphetamine due decrease alpha adrenergic receptor,Shekim WO,1994,Neuropsychobiology,https://doi.org/10.1159/000119074,8022532,Shekim WO; Bylund DB; Hodges K; Glaser R; Ray-Prenger C; Oetting G,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001289: Attention Deficit Disorder with Hyperactivity; D001792: Blood Platelets; D002648: Child; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D009433: Neural Inhibition; D009638: Norepinephrine; D018341: Receptors, Adrenergic, alpha-2; D015016: Yohimbine",,,https://openalex.org/W1963930095,172,47,1,1204,176,8,en,en
false,comparison bupropion trazodone treatment major depression,bupropion trazodone compare two center double blind clinical trial outpatient moderate severe major depression week placebo lead patient randomly assign receive either bupropion n trazodone n week data patient use efficacy analysis dose range mg day bupropion mg day trazodone overall efficacy two drug similar although improvement trazodone treatment group significantly great day effect sleep end treatment bupropion treat patient trazodone treat patient consider much much improve weight measurement time discontinuation indicate lb mean weight loss bupropion treatment group lb mean weight gain trazodone treatment group adverse experience profile bupropion trazodone consistent know pharmacologic profile e activate versus sedate anorexia anxiety report significantly often bupropion treatment group whereas somnolence appetite increase edema report significantly often trazodone treatment group,Weisler RH,1994,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199406000-00004,8027413,Weisler RH; Johnston JA; Lineberry CG; Samara B; Branconnier RJ; Billow AA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D016642: Bupropion; D003866: Depressive Disorder; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D014196: Trazodone,,,https://openalex.org/W1981654934,75,11,1,1313,225,8,en,en
false,n study methylphenidate patient borderline personality disorder attention deficit hyperactivity disorder,,van Reekum R,1994,Can J Psychiatry,https://doi.org/10.1177/070674379403900321,8033025,van Reekum R; Links PS,article,D002363: Case Reports; D016430: Clinical Trial; D016422: Letter; D016449: Randomized Controlled Trial,D000328: Adult; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001883: Borderline Personality Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008774: Methylphenidate,,,https://openalex.org/W2411708760,124,18,1,0,0,0,en,
false,clinical cognitive effect methylphenidate child attention deficit disorder function aggression oppositionality age,child diagnose attention deficit disorder add n add plus aggression oppositionality add n meet add criterion nc n receive methylphenidate placebo consecutive day parent teacher rat group improve medication teacher report less improvement nc add child methylphenidate chronological age generally similar effect sternberg task great accuracy speed especially nontargets low memory load large p b wave event relate potential pronounce slow p b latency memory load great trend early peak target nontargets methylphenidate maturation promote efficient strategy involve differentiate evaluation target nontargets result comparable among add group,Klorman R,1994,J Abnorm Psychol,https://doi.org/10.1037//0021-843x.103.2.206,8040490,Klorman R; Brumaghim JT; Fitzpatrick PA; Borgstedt AD; Strauss J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000374: Aggression; D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D003071: Cognition; D003299: Cooperative Behavior; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D006801: Humans; D008297: Male; D011939: Mental Recall; D008774: Methylphenidate; D011930: Reaction Time",,,https://openalex.org/W2060834407,146,20,1,884,151,5,en,en
false,hiv seroconversion intravenous drug user san francisco,objective examine hiv seroconversion rate risk factor seroconversion change risk behavior time intravenous drug user ivdu san francisco design observational study set methadone maintenance day methadone detoxification program san francisco participant total heterosexual ivdu seronegative first visit see least twice repeater main outcome measure hiv seroconversion rate risk factor seroconversion change behavior result hiv seroconversion rate repeater per person year ppy follow woman versus men significant african american versus white p ppy first third study second p last significant risk factor seroconversion five sexual partner per year hazard ratio hr p use shoot gallery ever hr p less year lifetime methadone maintenance hr p self report intravenous cocaine use fell year shoot gallery use fell proportion five sexual partner fell bleach use rise needle sharer conclusion hiv seroconversion rate ivdu ppy comparable san francisco cohort homosexual men ppy decline hiv seroconversion coincide change risk behavior stable attendance methadone maintenance highly protective seroconversion rate subject year methadone ppy,Moss AR,1994,AIDS,https://doi.org/10.1097/00002030-199402000-00010,8043227,Moss AR; Vranizan K; Gorter R; Bacchetti P; Watters J; Osmond D,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000662: Amphetamines; D015982: Bias; D003042: Cocaine; D015331: Cohort Studies; D015897: Comorbidity; D004203: Disinfection; D004866: Equipment Contamination; D005006: Ethnicity; D005260: Female; D015658: HIV Infections; D006679: HIV Seropositivity; D015528: HIV Seroprevalence; D006556: Heroin Dependence; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D016485: Needle Sharing; D012307: Risk Factors; D012495: San Francisco; D012725: Sexual Behavior; D012747: Sexual Partners; D012973: Sodium Hypochlorite; D016320: Substance Abuse Treatment Centers; D015819: Substance Abuse, Intravenous; D019966: Substance-Related Disorders; D014505: Urban Population",,,https://openalex.org/W2035115682,72,11,1,1694,345,12,en,en
false,quantitative effect typical atypical neuroleptic smooth pursuit eye track schizophrenia,smooth pursuit eye movement spem gain total saccade subtypes saccade quantify visual pursuit track fluphenazine treat patient schizophrenia normal control track repeat patient undergo placebo control double blind crossover comparison fluphenazine clozapine fluphenazine treat patient show significant reduction spem gain significant increase total intrusive anticipatory saccade saccadic amplitude compare control clozapine significantly reduce spem gain significantly increase total catch saccade compare placebo fluphenazine high amplitude intrusive saccade drug free patient predict poor response clozapine suggest intact frontal cortical function may enable optimal clozapine response,Litman RE,1994,Schizophr Res,https://doi.org/10.1016/0920-9964(94)90068-x,8043521,Litman RE; Hommer DW; Radant A; Clem T; Pickar D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001288: Attention; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D005476: Fluphenazine; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D011698: Pursuit, Smooth; D012438: Saccades; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2050307875,105,14,1,877,129,5,en,en
false,tic dyskinesia associate stimulant treatment attention deficit hyperactivity disorder,determine incidence tic dyskinesia examine associate clinical factor child treat stimulant medication attention deficit hyperactivity disorder cross sectional analysis clinic cohort chart review hospital base clinical service within division developmental behavioral pediatrics one hundred twenty two child attention deficit hyperactivity disorder treat stimulant medication child currently recently treat include none determination make medication use medication dosage presence absence time onset history family history incidence child medication trial one child development tourette syndrome age medication dosage history tic family history tic relate onset approximately child attention deficit hyperactivity disorder treat stimulant medication development predominantly transient nature less development chronic tic tourette syndrome personal family tic history medication selection dosage relate onset,Lipkin PH,1994,Arch Pediatr Adolesc Med,https://doi.org/10.1001/archpedi.1994.02170080089017,8044265,Lipkin PH; Goldstein IJ; Adesman AR,article,D016428: Journal Article,"D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D002908: Chronic Disease; D002986: Clinical Trials as Topic; D015331: Cohort Studies; D003430: Cross-Sectional Studies; D003913: Dextroamphetamine; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D015994: Incidence; D008297: Male; D008774: Methylphenidate; D010389: Pemoline; D012189: Retrospective Studies; D013981: Tic Disorders",,,https://openalex.org/W2119599154,100,11,1,1234,198,6,en,en
false,seizure associate clozapine treatment state hospital,seizure associate atypical antipsychotic medication clozapine represent serious side effect treatment premarketing study seizure occur crude rate possible rate character seizure would vary clinical set difference patient population difference manner treatment administer study seizure occur clozapine treatment state psychiatric hospital review medical chart pharmacy record sequential patient start clozapine treatment review period cover month pretreatment year follow patient men woman age year ten men woman least one seizure clozapine treatment seizure occur dose range mg day n mg day n mg day n patient history previous seizure seizure take clozapine anticonvulsant patient history head trauma seizure seizure patient without seizure disorder history head trauma seizure nine patient seizure continue clozapine treatment temporary dose reduction addition anticonvulsant one additional seizure clozapine associate seizure frequent group state hospital patient premarketing study clozapine relate seizure preclude successful treatment clozapine,Wilson WH,1994,J Clin Psychiatry,,8071267,Wilson WH; Claussen AM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000927: Anticonvulsants; D003024: Clozapine; D015331: Cohort Studies; D003702: Delusions; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004341: Drug Evaluation; D004359: Drug Therapy, Combination; D005260: Female; D006778: Hospitals, Psychiatric; D006783: Hospitals, State; D006801: Humans; D008297: Male; D008875: Middle Aged; D019965: Neurocognitive Disorders; D011618: Psychotic Disorders; D012559: Schizophrenia; D012640: Seizures; D016896: Treatment Outcome",,,https://openalex.org/W2411745436,65,10,1,1597,288,12,en,en
false,clonidine treatment tobacco withdrawal comparison nicotine chew gum,objective work carry prospective study effectiveness clonidine nicotine gum treatment tobacco withdrawal sixty smoker randomly distribute two group include tobacco withdrawal program one group receive oral clonidine treatment group give nicotine gum adjuvant therapy group therapy psychotherapy perform end one year significant difference two group regard number subject continue stop smoking also significant difference two group regard symptom tobacco abstinence study relation treatment fulfillment tobacco withdrawal observe clonidine treat group significantly great number success compare nicotine group p,Aparici M,1994,Rev Clin Esp,,8079014,Aparici M; Fernández González AL; Alegría E,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D002638: Chewing Gum; D003000: Clonidine; D005260: Female; D006801: Humans; D008297: Male; D009538: Nicotine; D011446: Prospective Studies; D016540: Smoking Cessation; D013030: Spain; D013375: Substance Withdrawal Syndrome; D014029: Tobacco Use Disorder,,,https://openalex.org/W2403509593,91,17,2,916,155,7,en,en
false,hemodynamic analgesic profile intrathecal clonidine human,epidural clonidine produce effective postoperative analgesia human observe side effect include hypotension bradycardia sedation dryness mouth recent clinical study demonstrate microgram intrathecal clonidine administer postoperatively sole analgesic agent effective produce hypotension sedation animal study provide evidence biphasic effect blood pressure intrathecal clonidine administration data concern effect human currently exist study perform evaluate dose response hemodynamic analgesic profile intrathecal clonidine administer standard surgical intervention without perioperative administration additional analgesic local anesthetic tranquilizer randomize prospective double blind study woman undergo elective cesarean section general anesthesia thiopental nitrous oxide halothane study forty five minute tracheal extubation lumbar intrathecal puncture perform patient receive group group group microgram clonidine postoperative analgesia assess visual analog scale rest deep cough standard time point h time point blood pressure heart rate sedation respiratory rate also record intrathecal clonidine decrease pain three group rest cough shortly injection dose dependent fashion clonidine microgram reduce pain score significantly early rd th min intrathecal injection respectively compare microgram clonidine pain relief define time first request supplemental analgesic patient last min group min group min group significant difference among group p clonidine reduce mean arterial pressure compare baseline group p delay hypotension bradycardia encounter three dose study sedation evident group group patient significantly sedate group patient respiratory rate motor activity low extremity unaffected three group difference significant result demonstrate dose dependent analgesia intrathecal clonidine great microgram nearly immediate analgesic effect observe intrathecal injection microgram clonidine strongly argue spinal rather systemic site action alpha adrenergic agonist microgram intrathecal clonidine relative hemodynamic stability observe suggest pressor effect peripheral site,Filos KS,1994,Anesthesiology,https://doi.org/10.1097/00000542-199409000-00011,8092504,Filos KS; Goudas LC; Patroni O; Polyzou V,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D016362: Analgesia, Obstetrical; D001794: Blood Pressure; D002585: Cesarean Section; D003000: Clonidine; D016292: Conscious Sedation; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007022: Hypotension; D007278: Injections, Spinal; D011247: Pregnancy",,,https://openalex.org/W1966634098,71,9,1,2883,474,15,en,en
false,malleability social impression hyperactive child,role adult social cognition mediate judgment hyperactive child medication related behavior change explore two hundred eight eight undergraduate observe two videotape excerpt hyperactive target boy play group game two peer target take either methylphenidate mg kg excerpt placebo excerpt methylphenidate first follow placebo placebo first follow methylphenidate adult cumulative social evaluation child assess view video segment result indicate observer combine perception two behavior sample composite impression use equal weight average algorithm even child whose behavior improve adult rating undercontrolled behavior continue meet case exceed research cutoff score use identify hyperactive child find suggest actual behavior child attention deficit hyperactivity disorder adhd play influential role shape interpersonal impression perceiver social cognitive process primacy recency integration bias,Granger DA,1993,J Abnorm Child Psychol,https://doi.org/10.1007/bf00916447,8126317,Granger DA; Whalen CK; Henker B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010552: Personality Assessment; D010988: Play and Playthings; D012919: Social Behavior; D012928: Social Desirability; D012938: Social Perception,,,https://openalex.org/W2084661951,58,7,1,1201,185,7,en,en
false,comparison bupivacaine clonidine mixture plain bupivacaine caudal analgesia child paper present part north east thames region anaesthetist society meeting april,randomize double blind study child undergo elective orthopaedic surgery assess clinical value combine clonidine bupivacaine caudal analgesia forty six child age yr allocate randomly two equal group receive bupivacaine ml kg combine either normal saline ml group clonidine micrograms kg normal saline ml group b mean sd duration caudal analgesia group b h h respectively p group b require significantly less supplementary analgesia operation p significant difference incidence side effect two group long duration sedation group b h result partly sedative effect clonidine partly long duration analgesia provide clonidine conclude add bupivacaine clonidine improve efficacy caudal analgesia child,Lee JJ,1994,Br J Anaesth,https://doi.org/10.1093/bja/72.3.258,8130041,Lee JJ; Rubin AP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000082: Acetaminophen; D015360: Analgesia, Epidural; D002045: Bupivacaine; D002420: Cauda Equina; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D004338: Drug Combinations; D006439: Hemodynamics; D006801: Humans; D007223: Infant; D007866: Leg; D009020: Morphine; D009985: Orthopedics; D010149: Pain, Postoperative; D012119: Respiration; D013997: Time Factors",,,https://openalex.org/W2050318078,216,35,1,1010,194,7,en,en
false,clozapine treatment outpatient schizophrenia outcome long term response pattern,purpose study examine effect clozapine treat moderately ill schizophrenic outpatient determine length medication trial need identify responder nonresponders rate clinical response relapse hospitalization level symptomatology function assess chronic schizophrenic outpatient receive clozapine one year patient data relapse hospitalization treatment compare data year treatment eighteen patient meet criterion sustain response responder identify within first four month treatment patient experience significantly relapse hospitalization treatment previous year improvement positive symptom general symptomatology level function reach plateau first six month treatment remain level second six month negative symptom quality life show nonsignificant improvement month result support use clozapine treat chronic residually symptomatic schizophrenic outpatient four month clozapine trial may adequate detect clinical responder population,Breier A,1993,Hosp Community Psychiatry,https://doi.org/10.1176/appi.ps.51.10.1249,8132186,Breier A; Buchanan RW; Irish D; Carpenter WT,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000553: Ambulatory Care; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D008297: Male; D010359: Patient Readmission; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2142067243,94,12,1,1286,193,6,en,en
false,method evaluate methylphenidate child attention deficit hyperactivity disorder acceptability satisfaction compliance,compare two method evaluate methylphenidate mph measure parental acceptance satisfaction compliance treatment twenty four year old child attention deficit hyperactivity disorder adhd randomly assign either blind placebo control medication trial mt typical clinical procedure tcp evaluation nonblind without placebo control rating satisfaction significantly high mt condition tcp condition however parent become accept mph participate evaluation evaluation week month follow approximately case comply treatment however rate compliance differ mt tcp condition,Johnston C,1993,J Pediatr Psychol,https://doi.org/10.1093/jpepsy/18.6.717,8138866,Johnston C; Fine S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D003258: Consumer Behavior; D005260: Female; D006801: Humans; D007175: Impulsive Behavior; D008297: Male; D008774: Methylphenidate; D010342: Patient Acceptance of Health Care; D010349: Patient Compliance; D010552: Personality Assessment,,,https://openalex.org/W2148787938,140,18,1,809,137,5,en,en
false,attention deficit alzheimer disease simulate anticholinergic antihistaminergic drug distinct deficit healthy age,evaluate attention deficit alzheimer disease ad relationship attention deficit associate age medication alter alertness ten patient probable ad healthy old control young control perform covert orient spatial attention task young control perform task additional time ingestion diphenhydramine mg kg reaction time obtain follow valid neutral invalid cue group reaction time short validly cue stimulus long invalidly cue stimulus additionally ad patient perform disproportionately worse follow invalid cue control group young control give diphenhydramine decrease subjective alertness perform bad drug good old control ad patient disproportionate impairment invalid cue ad patient disproportionate problem shift spatial attention compare age match control impaired attentional performance ad simulate young subject ingestion combine antihistamine anticholinergic agent dose sufficient produce significant change alertness,Oken BS,1994,Neurology,https://doi.org/10.1212/wnl.44.4.657,8164820,Oken BS; Kishiyama SS; Kaye JA; Howieson DB,article,"D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D000375: Aging; D000544: Alzheimer Disease; D000704: Analysis of Variance; D001288: Attention; D004155: Diphenhydramine; D005260: Female; D006633: Histamine Antagonists; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D010276: Parasympatholytics; D011930: Reaction Time; D012016: Reference Values,,,https://openalex.org/W1965775561,149,21,1,1242,191,6,en,en
false,utility curriculum base measurement evaluate effect methylphenidate academic performance,two case study conduct investigate utility curriculum base measurement math reading evaluate effect methylphenidate academic performance student diagnose attention deficit hyperactivity disorder follow baseline measurement double blind placebo control procedure employ evaluate student response three level mg mg mg medication result first study suggest curriculum base measure sensitive indicator student response medication find replicate second study second study student follow dose medication base trial phase data follow performance improve compare baseline performance case study suggest research warrant utility curriculum base measurement monitoring evaluate stimulant medication intervention child disorder,Stoner G,1994,J Appl Behav Anal,https://doi.org/10.1901/jaba.1994.27-101,8188554,Stoner G; Carey SP; Ikeda MJ; Shinn MR,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004522: Educational Status; D006801: Humans; D008297: Male; D008433: Mathematics; D008774: Methylphenidate; D011932: Reading",,,https://openalex.org/W2138051516,113,14,1,1004,155,6,en,en
false,oral antihypertensive hypertensive urgency,review data describe use oral antihypertensive agent treatment hypertensive urgency hu medline search english language literature fan search paper evaluate oral antihypertensive hus emergency conduct control uncontrolled study human review emphasis place recent trial evaluate individual agent comparative trial comparative trial demonstrate four currently available oral agent lower blood pressure rapidly predictably nifedipine extensively study clonidine serve traditionally oral agent choice treatment hus agent low blood pressure effectively within first hour dose use also associate adverse effect nifedipine captopril two agent rapid onset within hour may treat hypertensive emergency well urgency clonidine labetalol maximal blood pressure lower effect hour captopril clonidine labetalol nifedipine effective agent treatment hus agent selection base perceive need urgent blood pressure control cause hu concomitant condition definite benefit acute blood pressure lower hus yet demonstrate especially asymptomatic patient control trial less aggressive dose regimen placebo control need perform assess appropriate treatment hus adverse effect,Gales MA,1994,Ann Pharmacother,https://doi.org/10.1177/106002809402800311,8193426,Gales MA,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002216: Captopril; D003000: Clonidine; D005260: Female; D006801: Humans; D006973: Hypertension; D007741: Labetalol; D008297: Male; D009543: Nifedipine; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2116705982,49,5,1,1613,259,9,en,en
false,effect isradipine cyclosporin relate hypertension,evidence calcium antagonist may beneficial effect cyclosporin cya induce hypertension organ transplantation double blind control trial consecutive non diabetic first kidney transplant recipient randomize receive either isradipine dihydropyridine calcium antagonist placebo significant difference age weight gender warm cold ischaemic period original renal disease treatment group treatment start intravenously h transplantation procedure subsequently continue orally month immunosuppressive treatment include oral cya day short course anti lymphocyte immunoglobulin hypertension treat oral labetolol combination guanfacine necessary antihypertensive medication prescribe significantly often vs patient p placebo group stand systolic blood pressure significantly low isradipine group stand diastolic systolic diastolic sit blood pressure similar group month patient mean serum creatinine significantly low isradipine placebo v mumol l p isradipine significantly high dose cya need achieve adequate plasma level vs mg kg day p conclude isradipine effective antihypertensive agent kidney transplantation may influence cya metabolism furthermore isradipine appear ameliorate cya induce nephropathy,van den Dorpel MA,1994,Blood Press Suppl,,8205301,van den Dorpel MA; Zietse R; Ijzermans JN; Schalekamp MA; Weimar W,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D001794: Blood Pressure; D016572: Cyclosporine; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D016030: Kidney Transplantation; D011182: Postoperative Care; D011446: Prospective Studies,,,https://openalex.org/W2429410139,59,8,1,1662,271,13,en,en
false,effect methylphenidate sleep child attention deficit hyperactivity disorder,assess effect methylphenidate hydrochloride sleep pattern child diagnose attention deficit hyperactivity disorder adhd double blind control drug placebo cross design home ten child age year month year month diagnose adhd consecutively recruit compare age sex match normal control methylphenidate hydrochloride mg kg placebo administer child underwent activity monitoring home day treatment baseline follow placebo methylphenidate treatment result three trial stage well age sex match normal control compare short total sleep duration evident methylphenidate treatment compare baseline placebo treatment amount quiet sleep low however significantly among study group compare control whereas difference note methylphenidate treatment night night sleep pattern stability find difference find either child adhd control stage methylphenidate treatment result support notion adhd centrally generate disorder attributable hypoarousal subsequently stimulate motor overactivity methylphenidate appear affect sleep pattern adversely possibly normalize patient adhd,Tirosh E,1993,Am J Dis Child,https://doi.org/10.1001/archpedi.1993.02160360055018,8249952,Tirosh E; Sadeh A; Munvez R; Lavie P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D017286: Polysomnography; D012890: Sleep,,,https://openalex.org/W1966096074,93,11,1,1508,234,7,en,en
false,comparison analgesic effect intrathecal clonidine intrathecal morphine spinal anaesthesia patient undergo total hip replacement,study anaesthetic analgesic property intrathecal clonidine intrathecal morphine patient undergo total hip replacement spinal anaesthesia routine spinal anaesthesia plain bupivacaine ml patient allocate randomly receive intrathecal clonidine morphine saline control adjuvant bupivacaine postoperative analgesic effect measure consumption morphine via patient control analgesia visual analogue pain score intrathecal clonidine intrathecal morphine prolong time first analgesia compare saline mean sd min min min respectively p total morphine consumption first night operation significantly less intrathecal morphine group difference clonidine control group intrathecal clonidine prolong duration spinal analgesia markedly inferior intrathecal morphine provide subsequent postoperative analgesia,Fogarty DJ,1993,Br J Anaesth,https://doi.org/10.1093/bja/71.5.661,8251275,Fogarty DJ; Carabine UA; Milligan KR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000775: Anesthesia, Spinal; D002045: Bupivacaine; D003000: Clonidine; D005260: Female; D006622: Hip Prosthesis; D006801: Humans; D007278: Injections, Spinal; D008297: Male; D008875: Middle Aged; D009020: Morphine; D010147: Pain Measurement; D010149: Pain, Postoperative",,,https://openalex.org/W2134120552,155,20,1,1072,172,7,en,en
false,single dose randomize double blind double dummy cross comparison extradural v clonidine chronic pain,study patient chronic back pain claim benefit previous extradural dose clonidine microgram combine local anaesthetic compare single dose clonidine microgram give either extradural v route double blind randomize double dummy cross fashion power detect difference analgesic effect two route pain intensity pain relief adverse effect mood sedation vital sign assess nurse observer v clonidine produce significantly p great analgesia extradural clonidine one five analgesic outcome measure clonidine give either route produce statistically significant sedation significant decrease arterial pressure heart rate study extradural clonidine significant clinical advantage compare v clonidine clonidine microgram either route produce high incidence adverse effect,Carroll D,1993,Br J Anaesth,https://doi.org/10.1093/bja/71.5.665,8251276,Carroll D; Jadad A; King V; Wiffen P; Glynn C; McQuay H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D015360: Analgesia, Epidural; D001416: Back Pain; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement",,,https://openalex.org/W2152243448,122,18,2,993,168,9,en,en
false,pharmacoepidemiology clozapine inpatient schizophrenia,evaluate clozapine field trial hospitalize patient treatment resistant schizophrenia set consist large state operate public psychiatric system protocol call treat psychiatrist provide symptom adverse effect rating four time follow start drug therapy outcome criterion include sandoz study outcome measure symptom improvement well discharge status one year follow assess validity rating several measure internal consistency determine clozapine therapy start patient symptom data available overall percent n patient improve end one year treatment percent n maintain symptom improvement three evaluation time modest statistically significant improvement week compare baseline brief psychiatric rating scale bprs total score observe patient continue medication n emergence previously unimproved group n explain modest improvement however analysis patient n include dropout significant symptom improvement week low baseline bprs score predict significant symptom improvement week treatment among medicate one year pattern symptom improvement show probability late improvement previously unimproved probability week responder lose improvement result net group gain case end one year percent n cohort discharge percent n transfer another facility continue receive clozapine original patient start clozapine therapy medication discontinue adverse effect percent n white blood cell count wbc decrease agranulocytosis percent n seizures percent n one patient seizure decrease wbc count event e g cardiovascular change fever possible neuroleptic malignant syndrome percent n patient refusal report percent n start treatment although percent patient exhibit improvement week response rate week percent naturalistic study cohort similar major double blind six week control clinical trial clozapine impersistence response symptom follow one year find deserve rigorous evaluation,Zito JM,1993,Ann Pharmacother,https://doi.org/10.1177/106002809302701016,8251696,Zito JM; Volavka J; Craig TJ; Czobor P; Banks S; Vitrai J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D002985: Clinical Protocols; D003024: Clozapine; D015331: Cohort Studies; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D017891: Pharmacoepidemiology; D012559: Schizophrenia,,,https://openalex.org/W2271761770,70,8,1,2678,497,13,en,en
false,change psychopathology dyskinesia neuroleptic withdrawal double blind design,goal study assess time course change psychopathology dyskinesia neuroleptic withdrawal fifteen dsm iii schizophrenic patient abruptly withdraw double blind fashion stable haloperidol treatment weekly rating dyskinesia psychopathology perform week post withdrawal overall increase dyskinesia rating week period p begin week dyskinetic movement finger show significant increase p overall change psychopathology though group appear bimodal patient show significant relapse psychotic symptom neither baseline td psychotic relapse significantly interact change td time schizophrenic patient show increase global dyskinesia rating early within four week neuroleptic withdrawal time course appear associate reemergence psychopathology occur later significant minority patient relapse within time period suggest relative safety brief period neuroleptic withdrawal carefully select patient control set specific goal e g evaluation preparation clozapine need understand risk rapid relapse,Dixon L,1993,Schizophr Res,https://doi.org/10.1016/0920-9964(93)90061-m,8260445,Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D009460: Neurologic Examination; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W2080351188,95,12,1,1387,226,10,en,en
false,change event relate potential stimulant medication child attention deficit hyperactivity disorder,thirty two child attention deficit hyperactivity disorder adhd undergo week double blind medication assessment methylphenidate normal control study use event relate potential erps erps record active electrode visual feature detection task significant age effect find n p p b latency interact group p p b latency significantly longer adhd child baseline test latency difference group child normal control compare adhd child optimal drug dosage determine extensive behavioural cognitive assessment significant distributional effect either group adhd child function medication also significant difference reaction time measure thus erps reflect slow process adhd child normalize appropriate medication,Taylor MJ,1993,Biol Psychol,https://doi.org/10.1016/0301-0511(93)90015-z,8260563,Taylor MJ; Voros JG; Logan WJ; Malone MA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001931: Brain Mapping; D002540: Cerebral Cortex; D002648: Child; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D010364: Pattern Recognition, Visual; D011930: Reaction Time",,,https://openalex.org/W1999831044,119,14,1,1035,170,6,en,en
false,epidural clonidine treatment refractory reflex sympathetic dystrophy,intraspinally administer alpha adrenergic agonist may relieve pain sympathetically maintain pain smp syndrome reflex sympathetically dystrophy rsd spinal peripheral central nervous system action study examine analgesic efficacy side effect epidurally administer clonidine patient severe refractory rsd twenty six patient severe chronic pain consistent rsd study randomize blind placebo control design cervical lumbar epidural catheter insert patient upper low extremity rsd respectively patient receive random order three consecutive day epidural injection clonidine microgram placebo pain visual analog score va mcgill pain questionnaire sedation blood pressure heart rate monitor specify interval h injection patient respond clonidine placebo enter trial open label continuous epidural infusion clonidine microgram h clonidine placebo cause pain relief sedation decrease blood pressure heart rate bolus epidural injection small clonidine dose microgram produce pain relief decrease blood pressure heart rate similar microgram dose less sedation epidural clonidine infuse mean day patient mean rate microgram h sustain analgesia transdermal clonidine demonstrate produce analgesia area surround application site patient smp current study indicate extensive analgesia may obtain epidural administration sedation hypotension may limit bolus epidural clonidine administration rsd role chronic epidural infusion clonidine yet establish,Rauck RL,1993,Anesthesiology,https://doi.org/10.1097/00000542-199312000-00001,8267190,Rauck RL; Eisenach JC; Jackson K; Young LD; Southern J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000700: Analgesics; D001794: Blood Pressure; D002908: Chronic Disease; D003000: Clonidine; D006339: Heart Rate; D006801: Humans; D007268: Injections, Epidural; D010146: Pain; D012019: Reflex Sympathetic Dystrophy",,,https://openalex.org/W2074077348,72,8,1,1903,318,10,en,en
false,transdermal clonidine ameliorate tamoxifen induce hot flash,determine efficacy transdermal clonidine alleviate tamoxifen induce hot flash woman history breast cancer randomize double blind crossover design use prospective study woman history breast cancer receive tamoxifen suffer hot flash potentially eligible protocol study clonidine reduce hot flash frequency degree statistically impressive p clinically moderate reduction baseline also decrease hot flash severity p reduction baseline clonidine relate increase mouth dryness p constipation p itchiness patch p drowsiness p well mean need alleviate hot flash among patient estrogen therapy contraindicate,Goldberg RM,1994,J Clin Oncol,https://doi.org/10.1200/jco.1994.12.1.155,8270972,Goldberg RM; Loprinzi CL; O'Fallon JR; Veeder MH; Miser AW; Mailliard JA; Michalak JC; Dose AM; Rowland KM; Burnham NL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000279: Administration, Cutaneous; D001943: Breast Neoplasms; D002979: Climacteric; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008875: Middle Aged; D011446: Prospective Studies; D013629: Tamoxifen",,,https://openalex.org/W1932045453,69,8,1,854,155,4,en,en
false,epilepsy psychosis schizophrenia,study examine relationship epilepsy psychosis compare clinical eeg neuropathologic data group subject epilepsy psychosis similar information another group patient epilepsy evidence psychotic illness examine blind clinical diagnosis gross microscopic material whole brain specimen patient diagnose epilepsy plus schizophrenia like psychosis nine subject diagnose epilepsy plus epileptic psychosis individual epilepsy epileptic colony community large history psychosis n abstract case history without knowledge pathologic find epileptic colony patient early age onset seizure epileptic colony epileptic psychosis patient frequent seizure epileptic individual community die young age epileptic patient long stay hospital care psychotic epileptic patient large cerebral ventricle excess periventricular gliosis focal cerebral damage compare epileptic patient psychotic illness epileptic patient schizophrenia like psychosis distinguish group significant excess pinpoint perivascular white matter soften find mesial temporal sclerosis temporal lobe epilepsy occur equal frequency psychotic nonpsychotic group generalize seizure occur frequently psychotic epileptic epileptic colony epileptic community epileptic control,Bruton CJ,1994,Neurology,https://doi.org/10.1212/wnl.44.1.34,8290087,Bruton CJ; Stevens JR; Frith CD,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D001921: Brain; D004569: Electroencephalography; D004827: Epilepsy; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D012559: Schizophrenia,,,https://openalex.org/W2036517832,38,6,1,1678,266,9,en,en
false,long term botulinum toxin treatment focal hand dystonia,treat focal hand dystonia patient botulinum toxin injection year eighty one percent patient improve least one injection session sixty five percent injection produce transient weakness follow patient least year start treatment discontinue treatment inadequate response loss response inaccessibility treatment provider expense toxin woman great extent long duration benefit men likely continue treatment mean interval injection session month patient inject toxin combination muscle session dose toxin generally fluctuate within range unit side effect mild transient unrelated long term use botulinum toxin botulinum toxin injection safe effective long term management focal hand dystonia,Karp BI,1994,Neurology,https://doi.org/10.1212/wnl.44.1.70,8290095,Karp BI; Cole RA; Cohen LG; Grill S; Lou JS; Hallett M,article,D016428: Journal Article,D000328: Adult; D000368: Aged; D001905: Botulinum Toxins; D004421: Dystonia; D005260: Female; D006225: Hand; D006801: Humans; D008297: Male; D008875: Middle Aged; D009120: Muscle Cramp; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W2146359394,58,8,1,1004,179,10,en,en
false,methadone combine clonidine versus clonidine alone opiate detoxification,availability use methadone clonidine combination versus clonidine alone opiate detoxification study phase study sequential combination methadone follow clonidine utilize patient present primary diagnosis opiate dependence phase ii study clonidine available medication administer history clinical finding indicate impend acute opiate withdrawal syndrome overall difference phase phase ii group number opiate dependent admission patient complete detoxification patient complete follow rehabilitation program compare however patient phase whose clinical symptomatology warrant use methadone likely complete detoxification program compare patient phase ii receive clonidine difference two group completion follow rehabilitation detoxification clonidine alone likely successful patient prior detoxification experience methadone secondary dependence alcohol sedative tranquilizer present coexist primary opiate dependence diagnosis,Wilson RS,1993,J Subst Abuse Treat,https://doi.org/10.1016/0740-5472(93)90056-8,8308937,Wilson RS; DiGeorge WS,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D017427: Clinical Trial, Phase II; D017428: Clinical Trial, Phase III; D016428: Journal Article; D016449: Randomized Controlled Trial","D000293: Adolescent; D000328: Adult; D003000: Clonidine; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007902: Length of Stay; D008297: Male; D008691: Methadone; D008875: Middle Aged; D009293: Opioid-Related Disorders; D015813: Substance Abuse Detection; D016320: Substance Abuse Treatment Centers; D013375: Substance Withdrawal Syndrome; D016896: Treatment Outcome",,,https://openalex.org/W2075390889,81,10,1,1319,208,8,en,en
false,transdermal clonidine ameliorate post orchiectomy hot flash,determine efficacy transdermal clonidine alleviate post orchiectomy hot flash randomize double blind crossover clinical trial design include men history prostate cancer undergone medical surgical orchiectomy suffer hot flash result study demonstrate clonidine significantly decrease hot flash frequency severity future research necessary find effective mean alleviate hot flash post orchiectomy patient,Loprinzi CL,1994,J Urol,https://doi.org/10.1016/s0022-5347(17)35034-6,8308973,Loprinzi CL; Goldberg RM; O'Fallon JR; Quella SK; Miser AW; Mynderse LA; Brown LD; Tschetter LK; Wilwerding MB; Dose M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002979: Climacteric; D003000: Clonidine; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D009919: Orchiectomy; D011183: Postoperative Complications",,,https://openalex.org/W149320854,67,7,1,530,81,3,en,en
false,spatial orient focused attention attention deficit hyperactivity disorder,abstract seventeen child attention deficit disorder adhd normal control perform two task event relate potential record adhd subject take part two session methylphenidate mp placebo spatial orient task invalidly cue target elicit longer reaction time rt p longer latency great amplitude validly cue target performance similar group early portion p low amplitude invalidly cue target adhd subject mp increase accuracy without affect rt shorten p peak latency increase amplitude early portion focus attention task accuracy great control mp rt differenees attend stimuli elicit great amplitude p n p nonattended stimulus measure unaffected diagnosis medication,Novak GP,1995,Psychophysiology,https://doi.org/10.1111/j.1469-8986.1995.tb01231.x,8524989,Novak GP; Solanto M; Abikoff H,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009949: Orientation; D013028: Space Perception,,,https://openalex.org/W2039919784,83,10,1,962,176,7,en,en
false,one v two apraclonidine prophylaxis intraocular pressure spike argon laser trabeculoplasty,,Birt CM,1995,Can J Ophthalmol,,8529164,Birt CM; Shin DH; Reed SY; McCarty B; Kim C; Frenkel RE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D003000: Clonidine; D005260: Female; D006801: Humans; D053685: Laser Therapy; D008297: Male; D009798: Ocular Hypertension; D011446: Prospective Studies; D014130: Trabeculectomy,,,https://openalex.org/W2341442132,120,19,1,0,0,0,en,
false,comparative study clonidine lidocaine attenuation intraocular pressure increase associate laryngoscopy endotracheal intubation,verify compare efficacy clonidine lidocaine attenuate ocular hypertensive response generate manipulation laryngoscope endotracheal intubation eit prospective double blind study patient undergo non ocular surgery divide group accord pretreatment protocol approximately micrograms kg clonidine orally min surgery b mg kg intravenous lidocaine min eit c control group patient record intraocular pressure iop mean arterial pressure heart rate follow time basal eit immediately eit minute later minute later patient pretreated clonidine significantly low iop level control group measurement time patient pretreated lidocaine low iop induction intubation iop significantly low patient receive lidocaine control group patient eit although iop level lidocaine high clonidine pretreatment oral clonidine effective method prevent increase iop eit effective pretreatment lidocaine therefore use end intravenous lidocaine represent valid alternative emergency case approximate wait time hour contraindicate,Núñez M,1995,Rev Esp Anestesiol Reanim,,8560050,Núñez M; Figueira A; Guerra V; Baños G; Alvarez ML; Rodríguez M,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D007429: Intraocular Pressure; D007442: Intubation, Intratracheal; D007828: Laryngoscopy; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D011229: Preanesthetic Medication; D011446: Prospective Studies; D013565: Sympatholytics; D016896: Treatment Outcome",,,https://openalex.org/W2122171102,160,23,1,1402,227,4,en,en
false,postoperative alpha adrenergic stimulation attenuate protein catabolism,metabolic effect continuous intravenous iv application alpha agonist clonidine evaluate assessment nitrogen economy postaggression endocrine pattern twenty four patient undergo abdominothoracic esophageal cancer resection study thirteen patient alcohol abuse treat postoperatively iv clonidine prevention alcohol withdrawal syndrome eleven patient treat clonidine serve control patient treat standardized manner regard surgical technique balance anesthesia postoperative intensive care treatment include thoracic epidural analgesia bupivacaine fentanyl isonitrogenous isocaloric nutrition comparable patient significantly improve cumulate day nitrogen balance find clonidine treat patient g nitrogen compare control group g nitrogen p main reason improve nitrogen economy may clonidine induced growth hormone gh release pattern insulin like growth factor igf insulin like growth factor bind protein igfbp concentration could support hypothesis,Mertes N,1996,Anesth Analg,https://doi.org/10.1097/00000539-199602000-00008,8561324,Mertes N; Goeters C; Kuhmann M; Zander JF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000437: Alcoholism; D001798: Blood Proteins; D003000: Clonidine; D004938: Esophageal Neoplasms; D005934: Glucagon; D005947: Glucose; D006801: Humans; D007262: Infusions, Intravenous; D007328: Insulin; D018972: Insulin-Like Growth Factor Binding Protein 3; D007334: Insulin-Like Growth Factor I; D008875: Middle Aged; D009584: Nitrogen; D010289: Parenteral Nutrition, Total; D011182: Postoperative Care; D011300: Preoperative Care; D011506: Proteins; D013312: Stress, Physiological; D013514: Surgical Procedures, Operative; D014993: Xylitol",,,https://openalex.org/W2015741539,73,6,1,1228,192,9,en,en
false,cognitive psychomotor effect opioid drug cancer pain management,time come evaluate critically practice cancer pain management assumption base owe patient maximize quality life provide evidence base scientific approach rather anecdotal experience information available opioids effect cognitive psychomotor function although many effect diminish patient stable dose evidence suggest baseline pretreatment level achieve addition relationship measurable effect performance everyday task drive unclear challenge face continue improvement cancer pain control achieve last year management central adverse effect opioids must focus accurate assessment careful titration opioids pain adjuvant analgesic drug non drug measure use whenever possible drug choose contribute exist difficulty appropriate use psychostimulants yet establish relative benefit one opioid another cancer pain,O'Neill WM,1994,Cancer Surv,,8565000,O'Neill WM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000662: Amphetamines; D000701: Analgesics, Opioid; D002047: Buprenorphine; D000697: Central Nervous System Stimulants; D002908: Chronic Disease; D003042: Cocaine; D003061: Codeine; D003071: Cognition; D011431: Dextropropoxyphene; D018765: Dopamine Uptake Inhibitors; D006801: Humans; D008774: Methylphenidate; D009020: Morphine; D009369: Neoplasms; D010146: Pain; D011597: Psychomotor Performance; D016032: Randomized Controlled Trials as Topic; D011930: Reaction Time; D013844: Thiazoles",,,https://openalex.org/W158527622,80,13,1,1219,208,8,en,en
false,different side effect profile risperidone clozapine outpatient schizophrenia schizoaffective disorder pilot study,purpose study compare side effect profile clozapine risperidone subject outpatient schizophrenia schizoaffective disorder clinically stable regimen clozapine time screen undergo randomize order crossover comparison week risperidone treatment week clozapine treatment clinical neurocognitive variable assess raters blind medication status severity side effect determine patient self report side effect measure clinical rating significantly different week treatment two drug patient require benztropine motor effect complain insomnia risperidone sedation clozapine body weight high end clozapine treatment end risperidone treatment exploratory study side effect profile clozapine risperidone consistent different pharmacodynamic profile two drug,Daniel DG,1996,Am J Psychiatry,https://doi.org/10.1176/ajp.153.3.417,8610833,Daniel DG; Goldberg TE; Weinberger DR; Kleinman JE; Pickar D; Lubick LJ; Williams TS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D017109: Akathisia, Drug-Induced; D000553: Ambulatory Care; D003024: Clozapine; D003072: Cognition Disorders; D018592: Cross-Over Studies; D006801: Humans; D009483: Neuropsychological Tests; D010865: Pilot Projects; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012890: Sleep; D007319: Sleep Initiation and Maintenance Disorders; D016896: Treatment Outcome",,,https://openalex.org/W1590531348,139,20,1,1060,165,5,en,en
false,prospective year follow study attention deficit hyperactivity relate disorder,previous cross sectional data show child adolescent attention deficit hyperactivity disorder adhd increase risk comorbid conduct mood anxiety disorder well impairment cognitive social family school function however longitudinal data need confirm initial impression use dsm iii r structure diagnostic interview raters blind diagnosis reexamine psychiatric diagnosis year follow child adhd control addition subject evaluate cognitive achievement social school family function analysis follow find reveal significant difference child adhd control rate behavioral mood anxiety disorder disorder increase markedly baseline follow assessment addition child adhd significantly impaired cognitive family school psychosocial functioning control baseline diagnosis conduct disorder predict major depression bipolar disorder follow anxiety disorder baseline predict anxiety disorder follow result confirm extend previous retrospective result indicate child adhd high risk develop wide range impairment affect multiple domain psychopathology cognition interpersonal school family function find provide support value consider psychiatric comorbidity clinical assessment research protocol involve child adhd,Biederman J,1996,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1996.01830050073012,8624187,Biederman J; Faraone S; Milberger S; Guite J; Mick E; Chen L; Mennin D; Marrs A; Ouellette C; Moore P; Spencer T; Norman D; Wilens T; Kraus I; Perrin J,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000124: Achievement; D000223: Adaptation, Psychological; D000293: Adolescent; D001008: Anxiety Disorders; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002653: Child Behavior Disorders; D015897: Comorbidity; D003866: Depressive Disorder; D005500: Follow-Up Studies; D006801: Humans; D007360: Intelligence; D008297: Male; D001523: Mental Disorders; D011336: Probability; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D012917: Social Adjustment",,,https://openalex.org/W2167367466,93,11,1,1627,243,6,en,en
false,therapy alcohol withdrawal syndrome intensive care unit patient follow trauma,assess effect three different alcohol withdrawal therapy regimens traumatize chronic alcoholic patient respect duration mechanical ventilation frequency pneumonia cardiac disorder intensive care unit icu stay prospective randomize blind control clinical trial university hospital icu multiple injured alcohol dependent patient n transfer icu admission emergency room operative management total patient include study however patient exclude study assignment patient develop actual alcohol withdrawal syndrome randomize one follow treatment regimen flunitrazepam clonidine n chlormethiazole haloperidol n flunitrazepam haloperidol n need administration medication determine use validated measure severity alcohol withdrawal revise clinical institute withdrawal assessment alcohol scale duration mechanical ventilation major intercurrent complication pneumonia sepsis cardiac disorder bleed disorder death document patient differ significantly group regard age revise trauma injury severity score acute physiology chronic health evaluation ii score admission except four patient flunitrazepam clonidine group continue hallucinate revise clinical institute withdrawal assessment alcohol scale decrease initiation therapy icu stay significantly differ group p however mechanical ventilation significantly prolong chlormethiazole haloperidol group p due increased frequency pneumonia p cardiac complication significantly p increase flunitrazepam clonidine group advantage flunitrazepam clonidine regimen respect pneumonia necessity mechanical ventilation however four patient exclude study due ongoing hallucination therapy also cardiac complication increase group thus flunitrazepam haloperidol prefer patient cardiac pulmonary risk study require determine therapy consider,Spies CD,1996,Crit Care Med,https://doi.org/10.1097/00003246-199603000-00009,8625628,Spies CD; Dubisz N; Neumann T; Blum S; Müller C; Rommelspacher H; Brummer G; Specht M; Sanft C; Hannemann L; Striebel HW; Schaffartzik W,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000328: Adult; D000368: Aged; D000427: Alcohol Deterrents; D003422: Critical Care; D004359: Drug Therapy, Combination; D000431: Ethanol; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009104: Multiple Trauma; D011446: Prospective Studies; D012121: Respiration, Artificial; D013375: Substance Withdrawal Syndrome; D015599: Trauma Severity Indices; D016896: Treatment Outcome",,,https://openalex.org/W2058298351,87,12,1,2399,369,12,en,en
false,differential effect clozapine weight control study,study examine whether clozapine induces weight gain haloperidol whether weight gain relate clinical improvement weight symptom outpatient schizophrenia randomly assign double blind treatment either clozapine haloperidol assess weight symptom patient choose take clozapine year follow study end also assess patient treat clozapine gain significantly weight baseline haloperidol treat patient weight gain significantly correlate improvement either positive negative symptom fifty eight percent patient follow year gain least baseline weight weight gain important side effect clozapine unrelated drug differential antipsychotic efficacy,Bustillo JR,1996,Am J Psychiatry,https://doi.org/10.1176/ajp.153.6.817,8633697,Bustillo JR; Buchanan RW; Irish D; Breier A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000553: Ambulatory Care; D003024: Clozapine; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006220: Haloperidol; D006801: Humans; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome; D015430: Weight Gain,,,https://openalex.org/W2465558187,62,10,1,905,143,4,en,en
false,prophylaxis alcohol withdrawal syndrome alcohol dependent patient admit intensive care unit tumour resection,prophylaxis alcohol withdrawal syndrome aws alcohol dependent patient shorten duration stay intensive care unit icu objective study assess effect four different prophylactic regimen duration icu stay prevention aws rate major intercurrent complication alcohol dependent patient admit icu tumour resection total alcohol dependent patient diagnose diagnostic statistical manual mental disorder third revise edition daily ethanol intake g allocate randomly one follow regimen commence admission icu flunitrazepam clonidine chlormethiazole haloperidol flunitrazepam haloperidol ethanol duration icu stay prevention aws incidence tracheobronchitis major intercurrent complication pneumonia sepsis cardiac disorder bleed disorder death document admission patient differ significantly age apache ii multiple organ failure score icu stay incidence aws severity aws revise clinical institute withdrawal assessment alcohol scale major intercurrent complication rate differ significantly group although advantage four regimen respect primary outcome measure pulmonary cardiac patient include study patient chlormethiazole haloperidol group significantly increase incidence tracheobronchitis p probably increase incidence hypersecretion,Spies CD,1995,Br J Anaesth,https://doi.org/10.1093/bja/75.6.734,8672322,Spies CD; Dubisz N; Funk W; Blum S; Müller C; Rommelspacher H; Brummer G; Specht M; Hannemann L; Striebel HW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002719: Chlormethiazole; D003000: Clonidine; D003422: Critical Care; D004067: Digestive System Neoplasms; D018492: Dopamine Antagonists; D004338: Drug Combinations; D000431: Ethanol; D005260: Female; D005445: Flunitrazepam; D018757: GABA Modulators; D006220: Haloperidol; D006801: Humans; D007902: Length of Stay; D008297: Male; D008875: Middle Aged; D011182: Postoperative Care; D011183: Postoperative Complications; D011446: Prospective Studies; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W2099472290,131,17,1,1641,267,8,en,en
false,patienten kontrollierte analgesie mit clonidin und piritramid,unlabelled follow parenteral administration clonidine analgesic effect cerebral spinal level patient control analgesia pca make possible determine equipotent dosage analgesic relate analgesic consumption per time level analgesia obtain comparable patient population therefore study equipotency ratio clonidine piritramide incidence undesired side effect treatment postoperative pain patient undergo maxillo facial surgery method approval local ethic committee inform consent patient age year asa iii study follow randomization patient receive pca device contain either clonidine bolus microgram piritramide bolus mg treatment postoperative pain lockout interval min group postoperative period pain determine use visual analogue scale analgesic consumption sedation haemodynamic parameter respiration rate occurrence undesired side effect document additionally result group comparable distribution biometric data duration anaesthesia asa classification pain level decrease significantly p group first h pca mean arterial pressure heart rate low p clonidine group h pca onset degree sedation p p h high piritramide group nausea vomit frequent p piritramide group group show wide interpatient variation analgesic requirement equipotency ratio clonidine piritramid conclusion intravenous clonidine potent analgesic suitable treatment postoperative pain follow maxillo facial surgery analgesic potency microgram clonidine v equivalent mg piritramide v nausea vomit occur rarely clonidine group deep sedation observe frequently piritramide group owe wide interindividual variation analgesic consumption clonidine dosage adjust actual requirement,Sümpelmann R,1996,Anaesthesist,https://doi.org/10.1007/s001010050245,8678284,Sümpelmann R; Büsing H; Schröder D; Rekersbrink M; Krohn S; Strauss JM,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement; D010149: Pain, Postoperative; D010892: Pirinitramide; D011446: Prospective Studies; D013565: Sympatholytics",,,https://openalex.org/W2017683582,61,6,1,2296,393,17,de,en
false,spinal clonidine produce less urinary retention spinal morphine,conduct double blind randomize study two group patient undergo hip surgery spinal anaesthesia compare incidence urinary retention spinal morphine clonidine patient receive spinal bupivacaine mg combine either clonidine microgram morphine mg operation patient examine micturition bladder distension fail void receive naloxone mg bladder distension persist catheter insert h patient morphine group five clonidine group bladder distension h present seven one patient morphine clonidine group respectively p naloxone give one catheter place one six patient morphine clonidine group respectively p conclude spinal clonidine impair bladder function less extent morphine,Gentili M,1996,Br J Anaesth,https://doi.org/10.1093/bja/76.6.872,8679366,Gentili M; Bonnet F,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000775: Anesthesia, Spinal; D000779: Anesthetics, Local; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006621: Hip Joint; D006801: Humans; D008297: Male; D008875: Middle Aged; D009020: Morphine; D009270: Naloxone; D009292: Narcotic Antagonists; D014546: Urinary Catheterization; D016055: Urinary Retention",,,https://openalex.org/W2168835823,69,9,1,1000,186,5,en,en
false,clozapine eligibility among state hospital patient,connecticut state hospital entire resident population n screen arbitrary target day determine eligibility clozapine sixty percent patient schizophrenia schizoaffective disorder diagnosis meet food drug administration fda approve criterion clozapine use judge review past medication trial record responsible physician eighty eight percent patient medically clear clear percent agree clozapine treatment patient begin clozapine trial percent still take drug month later preliminary find randomized trial clozapine versus usual care n indicate discharge rate associate clozapine usual care differ discharge however patient assign clozapine less likely readmitted hence clozapine may cost effective usual care however save realize state government make front investment approximately million simply give patient hospitalize single day year access clozapine,Essock SM,1996,Schizophr Bull,https://doi.org/10.1093/schbul/22.1.15,8685657,Essock SM; Hargreaves WA; Dohm FA; Goethe J; Carver L; Hipshman L,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D003237: Connecticut; D003362: Cost-Benefit Analysis; D004608: Eligibility Determination; D005260: Female; D006778: Hospitals, Psychiatric; D006783: Hospitals, State; D006801: Humans; D008297: Male; D008875: Middle Aged; D010351: Patient Discharge; D012559: Schizophrenia; D016896: Treatment Outcome; D014481: United States; D014486: United States Food and Drug Administration",,,https://openalex.org/W2014659268,51,6,1,1160,200,8,en,en
false,effect lazabemide progression disability early parkinson disease,lazabemide ro relatively short act reversible selective type b monoamine oxidase inhibitor metabolize amphetamine active compound previously find lazabemide safe well tolerate dosage mg day week study patient early untreated parkinson disease pd assess whether lazabemide influence progression disability untreated pd patient n assign randomization one five treatment group placebo mg mg mg mg day follow systematically year risk reach primary end point onset disability sufficient require levodopa therapy reduce patient receive lazabemide compare placebo treat subject effect consistent among dosage frequency adverse experience differ among treatment group dosage range mg day lazabemide well tolerate delay need levodopa early otherwise untreated pd magnitude pattern benefit similar observe year deprenyl selegiline treatment datatop clinical trial,,1996,Ann Neurol,https://doi.org/10.1002/ana.410400116,8687199,,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D008996: Monoamine Oxidase Inhibitors; D010300: Parkinson Disease; D010848: Picolinic Acids; D016896: Treatment Outcome",,,https://openalex.org/W2077868413,82,13,1,1253,229,9,en,en
false,ici atypical antipsychotic,ici new potentially atypical antipsychotic early phase ii trial antipsychotic well tolerate result suggest efficacy treatment positive negative symptom schizophrenia efficacy safety ici evaluate large scale week multicenter double blind trial hospitalize patient meet dsm iii r criterion chronic subchronic schizophrenia acute exacerbation well criterion randomize ici mg daily n placebo n patient assess weekly use brief psychiatric rating scale bprs scale assessment negative symptom sans clinical global impression scale cgi efficacy simpson scale abnormal involuntary movement scale extrapyramidal side effect eps significant difference p treatment group favor ici identify throughout trial endpoint difference significant analysis covariance bprs factor iv activation sans score marginally significant total bprs bprs factor iii think disturbance bprs positive symptom cluster cgi severity illness item score p respectively ici well tolerate although associate mild transient increase alanine aminotransferase high incidence somnolence anticholinergic effect compare placebo dose range study treatment ici induce eps determine analysis simpson scale total score lack treatment emergent acute dystonic reaction furthermore ici produce sustain level prolactin mean change baseline endpoint microgram l comparable p placebo microgram l find distinguish ici standard antipsychotic confirm preclinical prediction ici atypical antipsychotic,Borison RL,1996,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199604000-00008,8690831,Borison RL; Arvanitis LA; Miller BG,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W1821730900,38,6,1,2053,365,11,fr,en
false,day study efficacy side effect apraclonidine v timolol,compare long term intraocular pressure iop lower efficacy apraclonidine hydrochloride timolol maleate multicenter randomize double mask trial adult patient either sex diagnose open angle glaucoma ocular hypertension enrol follow appropriate washout ocular hypotensive medication morning iop mm hg require entry patient receive apraclonidine time day timolol twice day day intraocular pressure measure morning dose pm hour dose day day medication significantly reduce iop baseline observation time p apraclonidine reduce iop apraclonidine significant difference observe apraclonidine timolol hour dose day significant difference p favour timolol apraclonidine observe hour dose day morning visit follow even dose timolol significantly reduce iop concentration apraclonidine apraclonidine significantly reduce iop use primary ocular hypotensive medication although apraclonidine reduce iop similar degree timolol hour morning dose neither concentration effective reduce morning iop even dose,Stewart WC,1996,Arch Ophthalmol,https://doi.org/10.1001/archopht.1996.01100140146006,8694728,Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D013999: Timolol",,,https://openalex.org/W1977459700,95,20,1,1532,284,7,en,en
false,effect oral clonidine premedication anesthetic requirement hormonal response hemodynamics recovery coronary artery bypass graft surgery patient,study objective examine premedication clonidine affect opioid use hemodynamic effect hormonal response recovery effect design double blind placebo control study set operate room surgical intensive care unit university medical center patient patient undergo elective coronary artery bypass graft cabg surgery intervention patient receive approximately g kg oral clonidine placebo together g kg lorazepam minute prior titrate sufentanil induction anesthesia thirty minute prior cardiopulmonary bypass second dose either approximately g kg clonidine placebo give slurry via nasogastric tube measurement main result opioid use hemodynamic effect hormonal response recovery effect record value ten hemodynamic variable compile even prior surgery prior induction seven additional event compare catecholamine endorphins measure prior induction intubation sternotomy amount sufentanil use induction maintenance total opioid compare time awaken response verbal command compare two group exhibit similar patient demographic cardiopulmonary bypass time duration surgery patient receive clonidine require significantly p less sufentanil induction clonidine g kg v placebo g kg total amount sufentanil clonidine g kg v placebo g kg patient receive clonidine require significantly p less isoflurane mac min v mac min maintain heart rate hr mean arterial pressure map within baseline without significant difference vasoactive drug catecholamine concentration significantly p low patient receive domaine without difference endorphin concentration patient receive clonidine significantly p low hr systolic arterial pressure map systemic vascular resistance prior induction patient receive placebo without difference hemodynamic variable conclusion clonidine decrease opioid use lower hormonal response maintain stable hemodynamics patient undergo cabg sufentanil anesthesia,Howie MB,1996,J Clin Anesth,https://doi.org/10.1016/0952-8180(96)00033-5,8695127,Howie MB; Hiestand DC; Jopling MW; Romanelli VA; Kelly WB; McSweeney TD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000316: Adrenergic alpha-Agonists; D000758: Anesthesia; D000762: Anesthesia Recovery Period; D003000: Clonidine; D001026: Coronary Artery Bypass; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006439: Hemodynamics; D006728: Hormones; D006801: Humans; D008140: Lorazepam; D008297: Male; D008875: Middle Aged; D011229: Preanesthetic Medication; D017409: Sufentanil,,,https://openalex.org/W1997750823,160,23,1,2427,408,18,en,en
false,interaction intrathecal neostigmine epidural clonidine human volunteer,alpha adrenergic agonist think produce analgesia part activate spinal acetylcholine release purpose current study examine interaction intrathecal neostigmine epidural clonidine analgesia side effect human total volunteer receive intrathecal injection dextrose normal saline ns neostigmine microgram n follow h epidural saline clonidine computer control infusion target ng ml cerebrospinal fluid use isobolographic design visual analog scale pain noxious cold stimulus nausea weakness sedation safety variable measure specify interval drug administration first volunteer randomize receive intrathecal hyperbaric neostigmine rather ns receive drug sit position none minimal analgesia h later remain volunteer receive drug lateral position demonstrate dose dependent analgesia foot h later epidural clonidine also cause dose dependent analgesia combination neostigmine clonidine result additive enhancement analgesia enhancement drug side effect reduction clonidine induce hypotension neostigmine inject subject lateral position diminish clonidine induce reduction blood pressure plasma norepinephrine result support enhancement alpha adrenergic analgesia intrathecal neostigmine demonstrate synergy observe animal lack enhancement side effect suggest combination may clinically useful,Hood DD,1996,Anesthesiology,https://doi.org/10.1097/00000542-199608000-00013,8712447,Hood DD; Mallak KA; Eisenach JC; Tong C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000109: Acetylcholine; D000316: Adrenergic alpha-Agonists; D000328: Adult; D015360: Analgesia, Epidural; D001794: Blood Pressure; D002800: Cholinesterase Inhibitors; D003000: Clonidine; D006152: Cyclic GMP; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D006801: Humans; D007268: Injections, Epidural; D007278: Injections, Spinal; D009325: Nausea; D009388: Neostigmine; D019001: Nitric Oxide Synthase; D009638: Norepinephrine; D010147: Pain Measurement; D013268: Stimulation, Chemical",,,https://openalex.org/W2008988249,86,10,1,1742,279,8,en,en
false,carbamazepine use child adolescent feature attention deficit hyperactivity disorder meta analysis,united state approximately child receive psychostimulants treat attention deficit hyperactivity disorder adhd may respond purpose study evaluate report international literature concern efficacy carbamazepine cbz child adhd feature mean meta analysis review world literature locate report deal behavior problem activity level cbz child report provide sufficient pertinent information meta analysis seven open study therapeutic response significant range p two tail test meta analysis use weight variable reveal significant positive correlation r p duration treatment positive outcome three double blind placebo control study treatment effect cbz superiority placebo range p meta analysis three study reveal cbz significantly p effective placebo control target symptom despite general lack attention cbz receive treat adhd preliminary evidence cbz may effective alternate treatment child feature adhd,Silva RR,1996,J Am Acad Child Adolesc Psychiatry,https://doi.org/10.1097/00004583-199603000-00017,8714324,Silva RR; Munoz DM; Alpert M,article,D016428: Journal Article; D017418: Meta-Analysis,"D000927: Anticonvulsants; D001289: Attention Deficit Disorder with Hyperactivity; D002220: Carbamazepine; D002648: Child; D002675: Child, Preschool; D005260: Female; D006801: Humans; D008297: Male; D016896: Treatment Outcome",,,https://openalex.org/W2004241108,120,15,1,1312,220,6,en,en
false,topical apraclonidine hydrochloride eye poorly control glaucoma apraclonidine maximum tolerate medical therapy study group,determine whether addition topical apraclonidine hydrochloride eye receive maximal medical therapy inadequate intraocular pressure iop control schedule undergo surgery could adequately lower iop postpone need surgical intervention prospective day multi center placebo control doublemasked parallel study enrol glaucoma patient inadequate iop control maximally tolerate medical therapy candidate either laser trabeculoplasty invasive surgical intervention enrol one eye per patient continue administer maximum tolerated medical therapy glaucoma patient take study medication every eight hour study medication either apraclonidine hydrochloride placebo apraclonidine vehicle evaluate iop iop change baseline number eye require surgery addition study medication sixty one percent patient treat apraclonidine maintain adequate iop control throughout study avoid additional surgery compare patient treat placebo p apraclonidine treatment result significantly patient achieve either additional reduction iop baseline result iop mm hg p common ocular complication conjunctival hyperemia itch foreign body sensation tear frequent non ocular adverse event relate apraclonidine dry mouth unusual taste perception apraclonidine appear safe efficacious significantly low iop use combination patient maximum tolerate medical therapy delay prevent glaucoma surgery least day approximately treat patient,Robin AL,1995,Trans Am Ophthalmol Soc,,8719690,Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005902: Glaucoma, Open-Angle; D006439: Hemodynamics; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009883: Ophthalmic Solutions; D011446: Prospective Studies",,,https://openalex.org/W1613335745,141,19,2,1856,309,10,en,en
false,efficacy safety risperidone psychotic patient open study,open prospective study undertake determine efficacy safety fix dose mg risperidone psychotic patient hospital patient fulfil dsm r criterion schizophrenia schizoaffective bipolar disorder eligible entry study n patient antipsychotic washout period week start drug fix dose risperidone administer mg brief psychiatric rating scale bprs negative symptom rating scale nsrs abnormal involuntary movement scale use measure psychopathology extrapyramidal side effect five patient drop study two patient become agitate potentially aggressive one patient become restless respond benzodiazepine one drop restlessness respond clonazepam patient complete study per cent reduction bprs nsrs achieve five six patient respectively marginally significant trend towards great reduction magnitude negative symptom four patient require treatment anticholinergic drug risperidone effective resistent psychotic patient agitate impulsive psychotic patient positive symptom may best candidate treatment risperidone average negative symptom respond good positive symptom,Daradkeh TK,1996,J Int Med Res,https://doi.org/10.1177/030006059602400309,8725991,Daradkeh TK; Reda F; Karim L,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D018492: Dopamine Antagonists; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011618: Psychotic Disorders; D018967: Risperidone; D012702: Serotonin Antagonists,,,https://openalex.org/W1921760074,71,12,1,1470,247,12,en,en
false,comparison effect clonidine tyramine methoxamine evoke mydriasis man,report previously clonidine potentiate tyramine evoke mydriasis pain free side cluster headache patient examine whether single oral dose clonidine g also potentiate tyramine evoke mydriasis healthy subject use mydriasis methoxamine directly act sympathomimetic amine control eight healthy male volunteer participate four weekly session first two session experiment effect clonidine placebo mydriasis tyramine hydrochloride eyedrop mm l last two session experiment effect clonidine placebo mydriasis methoxamine hydrochloride eyedrop mm l examine experiment subject allocate drug session accord double blind balance design experiment pupil diameter treat untreated eye record standard ambient light dark h clonidine placebo via binocular infrared television pupillometry salivation dental roll technique systolic diastolic blood pressure sit heart rate self rating mood feel visual analogue scale also measure h ingestion clonidine placebo tyramine methoxamine produce significant mydriasis prominent light condition change rest pupil size mm e mean tyramine light tyramine dark methoxamine light methoxamine dark clonidine produce significant miosis untreated eye prominent light condition change rest pupil size mm e mean experiment light experiment dark experiment light experiment dark clonidine significant effect either tyramine methoxamine evoke mydriasis agreement previous report clonidine significantly reduce salivation g mean e mean experiment experiment systolic blood pressure mm hg experiment experiment diastolic blood pressure mm hg experiment alertness mm experiment anxiety mm experiment indicate presence pharmacodynamically effective tissue level drug result show single oral dose g clonidine cause significant miosis human subject fail potentiate tyramine evoke mydriasis indicate pupil asymptomatic side cluster headache patient affect differently pupil healthy volunteer tyramine clonidine,Bitsios P,1996,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1996.03202.x,8730971,Bitsios P; Langley RW; Szabadi E; Bradshaw CM,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D003000: Clonidine; D006801: Humans; D008297: Male; D008729: Methoxamine; D011680: Pupil; D013565: Sympatholytics; D014439: Tyramine,,,https://openalex.org/W2001370579,91,13,1,2765,491,13,en,en
false,double blind randomise comparison effect epidural clonidine lignocaine combination clonidine lignocaine patient chronic pain,twenty patient chronic pain previously obtain analgesia epidural clonidine lignocaine agree participate double blind crossover study lumbar epidural clonidine g lignocaine mg combination clonidine g lignocaine mg drug give volume ml woman men mean age year range year patient low back leg pain neuropathic pain pelvic pain wegner granulomatosis pain intensity pain relief well sensory motor blockade assess h follow injection combination report best pain relief patient complete three arm study patient report clonidine best patient report none injection provide analgesia patient report lignocaine best spid analysis reveal significant difference combination lignocaine p significant difference totpar analysis reveal significant difference injection injection produce evidence neurological blockade clonidine produce sensory blockade patient motor blockade patient lignocaine produce sensory blockade patient motor patient combination produce evidence neurological blockade patient sensory motor patient overall relationship neurological blockade analgesia report side effect appear relate clonidine data indicate patient chronic pain epidural clonidine supra additive effect behave like co analgesic pure analgesic,Glynn C,1996,Pain,https://doi.org/10.1016/0304-3959(95)00119-0,8740612,Glynn C; O'Sullivan K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D015360: Analgesia, Epidural; D000779: Anesthetics, Local; D002908: Chronic Disease; D003000: Clonidine; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D010146: Pain",,,https://openalex.org/W2025923561,163,24,1,1805,326,11,en,en
false,want get social goal boy adhd comparison boy,twenty seven boy diagnose attention deficit hyperactivity disorder adhd comparison boy participate competitive tetradic interaction task boy individually interview game goal interaction adult observer infer boy social goal videotape interaction social acceptance determine combine positive negative sociometric nomination collect individual interview end summer research program interaction hold self report adhd high aggressive boy prioritize trouble seek fun expense rule great extent adhd low aggressive comparison boy observer judge adhd high aggressive boy seek attention strongly seek fairness less strongly two group self report goal defiance cooperation predict boy end program social stand even interactional behavior subgroup status control statistically observer inferred goal differentially associate social acceptance adhd comparison boy suggest discontinuity peer interaction process differentiation goal behavior integral role child goal peer acceptance discus,Melnick SM,1996,J Abnorm Child Psychol,https://doi.org/10.1007/bf01441483,8743243,Melnick SM; Hinshaw SP,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000374: Aggression; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D003163: Competitive Behavior; D003299: Cooperative Behavior; D018592: Cross-Over Studies; D006040: Goals; D006801: Humans; D007398: Interpersonal Relations; D008297: Male; D008774: Methylphenidate; D015999: Multivariate Analysis; D010379: Peer Group; D010988: Play and Playthings; D011209: Power, Psychological; D011595: Psychomotor Agitation; D012044: Regression Analysis; D012059: Rejection, Psychology; D012925: Social Conformity; D012928: Social Desirability; D012938: Social Perception; D012963: Sociometric Techniques",,,https://openalex.org/W1979285497,88,18,1,1321,194,8,en,en
false,risperidone efficacy safety,article review evidence efficacy effectiveness risperidone person schizophrenia nine publish double blind study compare risperidone another antipsychotic medication placebo conduct acute phase illness risperidone antipsychotic efficacy show consistently superior placebo least comparable haloperidol perphenazine patient acute phase schizophrenia research necessary determine effectiveness risperidone efficacy maintenance treatment treatment refractory deficit state patient,Umbricht D,1995,Schizophr Bull,https://doi.org/10.1093/schbul/21.4.593,8749887,Umbricht D; Kane JM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000208: Acute Disease; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2086362482,32,5,1,662,98,5,en,en
false,efficacy tolerance risperidone various dos report study,risperidone compare double blind study haloperidol perphenazine schizophrenic psychosis accord maximal daily dose achieve risperidone group divide subgroup risperidone efficacy tolerability group compare mutually relation baseline good global antipsychotic efficacy observe statistically significant difference influence productive negative symptom exception significantly pronounce reduction productive catatonic symptom max mg comparison dos high mg daily extrapyramidal symptom less frequent low max mg significantly low occurrence increase muscle tonus tremor find high maximal daily mg antiparkinson drug apply patient case trihexyphenidyl difference reach statistically significant level,Cesková E,1996,Ceska Slov Psychiatr,,8768938,Cesková E; Svestka J,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D010546: Perphenazine; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W64519668,77,17,1,1042,170,6,en,en
false,olanzapine versus placebo haloperidol,olanzapine potential new atypical antipsychotic agent double blind acute phase study compare three dosage range olanzapine mg day olz l mg day olz mg day olz h dosage range haloperidol mg day hal placebo treatment patient meet dsm iii r criterion schizophrenia overall symptomatology improvement brief psychiatric rating scale bprs total olz olz h hal significantly superior placebo positive symptom improvement bprs positive olz olz h hal comparable significantly superior placebo negative symptom improvement scale assessment negative symptom sans composite olz l olz h significantly superior placebo olz h also significantly superior hal common treatment emergent adverse event include somnolence agitation asthenia nervousness acute dystonia observe olanzapine treatment emergent parkinsonism occur olz h approximately one third rate hal akathisia occur olz h approximately one half rate hal prolactin elevation associate olanzapine significantly great observe placebo also significantly less see haloperidol,Beasley CM,1996,Neuropsychopharmacology,https://doi.org/10.1016/0893-133x(95)00069-p,8822534,Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia",,,https://openalex.org/W122505910,41,5,1,1368,240,9,en,en
false,cerebrospinal fluid homovanillic acid predict behavioral response stimulant boy attention deficit hyperactivity disorder,central dopaminergic activity assume play role efficacy stimulant drug attention deficit hyperactivity disorder adhd although support evidence scant study examine baseline cerebrospinal fluid csf boy adhd relation response three different stimulant drug forty five boy dsm iii r diagnose adhd lumbar puncture double blind trial methylphenidate dextroamphetamine placebo sixteen also receive pemoline part subsequent open trial stepwise linear regression determine significant predictor drug response prior report positive significant correlation csf homovanillic acid hva rating hyperactivity placebo replicate new sample boy baseline symptom severity csf hva best predictor stimulant drug response significant independent contribution four ten measure hyperactivity change significantly medication high hva predict good drug response low hva associate worsen measure support mediate role central dopaminergic activity stimulant drug efficacy childhood hyperactivity,Castellanos FX,1996,Neuropsychopharmacology,https://doi.org/10.1016/0893-133x(95)00077-q,8822535,Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D001289: Attention Deficit Disorder with Hyperactivity; D001519: Behavior; D015306: Biogenic Monoamines; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004311: Double-Blind Method; D006719: Homovanillic Acid; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010389: Pemoline; D011569: Psychiatric Status Rating Scales; D012044: Regression Analysis,,,https://openalex.org/W2036466635,137,16,1,1243,197,9,en,en
false,cocaine cigarette comparison risk,summary order provide additional data perspective current clinical policy legal debate surround prenatal use cocaine usa retrospective cohort study conduct examine effect cocaine select perinatal outcome compare relative risk adverse perinatal outcome among user cocaine user cigarette use data large urban perinatal registry relative risk select perinatal outcome determine maternal cocaine user non smoker cigarette use marijuana heroin amphetamine alcohol n cigarette smoker use illicit drug alcohol pregnancy n compare woman record prenatal exposure drug cigarette n cocaine user high risk smoker follow adverse outcome low birthweight relative risk rr confidence interval ci small ge tational age sga rr ci prematurity rr ci abruptio placenta rr ci placenta prae via rr ci perinatal death rr ci smoker use drug experience adverse perinatal outcome cocaine user magnitude risk great cocaine user smoker outcome however give great number cigarette smoker cocaine user population number infant population suffer adverse outcome likely great among offspring cigarette smoker data support current concern risk cocaine current effort provide treatment pregnant cocaine user data also underline continue substantial risk cigarette smoke large number pregnant woman,Kistin N,1996,Paediatr Perinat Epidemiol,https://doi.org/10.1111/j.1365-3016.1996.tb00050.x,8822770,Kistin N; Handler A; Davis F; Ferre C,article,D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study,D000328: Adult; D002641: Chicago; D003042: Cocaine; D015331: Cohort Studies; D005260: Female; D006801: Humans; D009293: Opioid-Related Disorders; D011247: Pregnancy; D011248: Pregnancy Complications; D011256: Pregnancy Outcome; D012042: Registries; D012189: Retrospective Studies; D012306: Risk; D012307: Risk Factors; D012907: Smoking,,,https://openalex.org/W1996884560,45,8,1,1873,354,8,en,en
false,clonidine plus haloperidol treatment schizophrenia psychosis,evidence increase norepinephrine ne production psychotic patient study effect combine alpha adrenergic agonist clonidine haloperidol treatment schizophrenic psychosis twelve hospitalize schizophrenic patient take antipsychotic medication week double blind treatment haloperidol mg day combine either clonidine placebo group receive clonidine significantly improve thought disorder subscale brief psychiatric rating scale p group differ initially level negative symptom control difference statistically analysis covariance change find regard superiority combine clonidine haloperidol conclude large treatment trial combine haloperidol clonidine warrant,Maas JW,1995,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199510000-00009,8830068,Maas JW; Miller AL; Tekell JL; Funderburg L; Silva JA; True J; Velligan D; Berman N; Bowden CL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D014150: Antipsychotic Agents; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2079096576,70,8,1,924,143,5,en,en
false,postoperative analgesia peripheral nerve block podiatric surgery,postoperative analgesia may prolong addition clonidine local anesthetic solution use regional anesthesia purpose study test hypothesis clinical trial patient undergo podiatric surgery study design prospective double blind randomize ninety asa physical status ii patient schedule bunionectomy hammer toe repair randomize receive ankle metatarsal block plain lidocaine group l lidocaine micro gram ml clonidine add group c lidocaine micro gram ml clonidine group c time performance block loss sensation pinprick return sensation pinprick onset postsurgical pain time first oral pain medication intake record begin h completion block visual analog scale va verbal pain score record every min additional postoperative oral pain medication require first h block also record analysis variance anova use analyze intergroup difference va verbal pain score time first report pain time first oral pain medication total amount oral pain medication require repeat measure anova use analyze va verbal pain score overall integrated assessment pain score rescue medication per form adverse event also record group difference among three group regard overall va pain score although group c significantly well verbal pain score first h p also difference time loss return pinprick sensation group c long time first report pain p long time first oral pain medication p low average total dose oral pain medication require p low integrate assessment pain medication p group l patient group c report pain postoperatively p pain medication take p group l group c result suggest statistically significant improvement plain lidocaine one patient group c experience significant hypotension postoperatively ph determination chemical analysis capillary electrophoresis show significant change composition solution clonidine mixed lidocaine store degree c wk compare lidocaine combine clonidine micro gram ml lidocaine local anesthetic block foot surgery significantly increase duration quality postoperative analgesia anesth analg,Reinhart DJ,1996,Anesth Analg,https://doi.org/10.1097/00000539-199610000-00018,8831317,Reinhart DJ; Wang W; Stagg KS; Walker KG; Bailey PL; Walker EB; Zaugg SE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000698: Analgesia; D000700: Analgesics; D000704: Analysis of Variance; D000779: Anesthetics, Local; D000842: Ankle; D003000: Clonidine; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D005534: Foot Diseases; D006215: Hallux Valgus; D006801: Humans; D007022: Hypotension; D008012: Lidocaine; D008297: Male; D008684: Metatarsus; D008875: Middle Aged; D009407: Nerve Block; D010147: Pain Measurement; D010149: Pain, Postoperative; D011446: Prospective Studies; D012677: Sensation; D013997: Time Factors; D014034: Toes",,,https://openalex.org/W2136585568,74,9,1,2786,512,16,en,en
false,antipsychotic anxiolytic property risperidone haloperidol methotrimeprazine schizophrenic patient,subject patient hospitalize acute exacerbation schizophrenia randomly assign receive risperidone mean dose mg day haloperidol mg day methotrimeprazine mg day week clinical improvement define priori reduction total positive negative syndrome scale panss score end point attain risperidone patient haloperidol patient methotrimeprazine patient p reduction total panss clinical global impression scale severity score baseline end point significantly great risperidone patient two group reduction score psychotic anxiety scale significantly great risperidone patient methotrimeprazine patient difference haloperidol methotrimeprazine significant extrapyramidal symptom score extrapyramidal symptom rating scale severe haloperidol patient two group difference apparent risperidone methotrimeprazine patient conclude risperidone effective antipsychotic anxiolytic agent schizophrenic patient j clin psychopharmacol,Blin O,1996,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199602000-00007,8834417,Blin O; Azorin JM; Bouhours P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D014151: Anti-Anxiety Agents; D014150: Antipsychotic Agents; D001007: Anxiety; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008728: Methotrimeprazine; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W1977725618,116,14,1,1304,220,7,en,en
false,efficacy clonidine reduce perioperative haemodynamic change volatile anaesthetic requirement child,oral clonidine give premedicant adult show reduce intraoperative inhalation anaesthetic requirement provide perioperative haemodynamic stability conduct current study ascertain whether beneficial effect clonidine reproduce child prospective randomize double blind control clinical trial child asa age yr receive placebo control microgram kg clonidine microgram kg clonidine orally min induction anaesthesia anaesthesia induce halothane nitrous oxide oxygen via mask maintain halothane nitrous oxide oxygen halothane concentration titrate concentration require maintain haemodynamic stability define blood pressure bp heart rate hr maintenance anaesthesia end tidal concentration halothane monitor throughout anaesthesia completion surgery nitrous oxide halothane discontinue follow confirmation recovery anaesthesia muscle relaxation endotracheal tube remove high inspired concentration halothane require control microgram kg clonidine treat group mean sd respectively microgram kg clonidine treat group haemodynamic stability p clonidine microgram kg significantly reduce intraoperative lability coefficient variation systolic diastolic bp hr compare two regimen oral clonidine premedication dose microgram kg provide intraoperative haemodynamic stability reduce anaesthetic requirement child however unable extrapolate observation young child infant,Nishina K,1996,Acta Anaesthesiol Scand,https://doi.org/10.1111/j.1399-6576.1996.tb04522.x,8836273,Nishina K; Mikawa K; Maekawa N; Obara H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000769: Anesthesia, Inhalation; D018685: Anesthetics, Inhalation; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D006221: Halothane; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D009609: Nitrous Oxide; D011229: Preanesthetic Medication",,,https://openalex.org/W1995385744,123,15,1,1847,303,9,en,en
false,haloperidol block methylphenidate,effect methylphenidate precede moderate dose haloperidol reaction time duration continuous performance test cpt investigate ten male child dsm iii diagnosis attention deficit disorder hyperactivity disorder addh use within subject double blind design effect methylphenidate precede haloperidol reaction time first second block cpt test compare methylphenidate maintain significantly improve reaction time second block cpt test methylphenidate precede placebo precede haloperidol effect observe suggest oppose effect attentional system methylphenidate versus haloperidol study first examine block effect haloperidol course cpt result suggest dopamine system involve maintenance cpt response support incentive motivation theory sustain attention,Levy F,1996,Psychopharmacology (Berl),https://doi.org/10.1007/bf02246413,8853219,Levy F; Hobbes G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D015259: Dopamine Agents; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D006220: Haloperidol; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011930: Reaction Time,,,https://openalex.org/W2319669849,39,5,1,1011,169,6,en,en
false,clonidine adrenaline decrease lignocaine plasma peak concentration epidural injection,clonidine alpha adrenoceptor agonist increasingly use combination lignocaine spinal epidural anaesthesia prolong analgesic effect life adrenaline may decrease lignocaine peak concentration cmax thus lead decrease toxicity however effect clonidine resorption lignocaine systemic circulation epidural space remain establish study pharmacokinetics lignocaine epidural injection lignocaine without clonidine adrenaline drug total body clearance apparent volume distribution similar four group maximum observe concentration cmax markedly increase plain solution group compare group plain lignocaine microgram ml lignocaine adrenaline microgram ml lignocaine clonidine microgram ml lignocaine adrenaline clonidine microgram ml mean result show clonidine decrease lignocaine cmax extent adrenaline,Mazoit JX,1996,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1996.39817.x,8864326,Mazoit JX; Benhamou D; Veillette Y; Samii K,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000779: Anesthetics, Local; D019540: Area Under Curve; D003000: Clonidine; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D004837: Epinephrine; D005260: Female; D006207: Half-Life; D006801: Humans; D007268: Injections, Epidural; D008012: Lidocaine; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged",,,https://openalex.org/W2066278843,98,12,1,1117,189,6,en,en
false,mechanical lesion fimbria fornix rat brain study h magnetic resonance image evidence long lasting dynamic alteration ipsilateral ventricular system,vivo h nmr image employ study dynamic change status tissue water function time mechanical brain injury induce partial unilateral transection fimbria fornix ff rat brain correlate histology change brain tissue reproducibly find distinct region exclusively locate lesioned hemisphere pronounce change concern lateral ventricle ventricular enlargement become evident posterior site transection hour maximal day late time point posterior ventricular expansion reduce lateral ventricle anterior site transection significantly enlarge day continue expand month tissue response site transection mainly involve hippocampal formation thalamus first manifest h sign progressive tissue degeneration apparent long term,Dijkhuizen RM,1996,Eur Neuropsychopharmacol,https://doi.org/10.1016/0924-977x(95)00055-t,8866934,Dijkhuizen RM; Muller HJ; Josephy M; Spruijt BM; Nicolay K,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000818: Animals; D001930: Brain Injuries; D006624: Hippocampus; D008279: Magnetic Resonance Imaging; D009682: Magnetic Resonance Spectroscopy; D008297: Male; D009410: Nerve Degeneration; D051381: Rats; D017208: Rats, Wistar; D013788: Thalamus; D013997: Time Factors; D014867: Water",,,https://openalex.org/W1976328405,179,25,2,1008,170,7,en,en
false,mechanism angiotensin convert enzyme inhibitor related anemia renal transplant recipient,delineate pathogenesis reduction hemoglobin occur renal transplant patient treat angiotensin convert enzyme inhibitor acei azathioprine aza control prospective trial acei withdrawal conduct acei replace nifedipine clonidine kidney transplant patient immunosuppressed aza prednisone enalapril captopril week withdrawal acei aza metabolite renal function parameter hematological parameter include erythropoietin reticulocyte evaluate enalaprilat level measure compare similar patient match transplant function enalapril dosage immunosuppressed cyclosporine prednisone aza metabolite differ significantly presence absence acei enalaprilat level also show significant difference two patient group treat aza cyclosporine hematocrit hemoglobin increase significantly mean sd p g dl p respectively week acei treatment discontinue simultaneously number reticulocyte erythropoietin concentration rise significantly week peak two week p mu ml p respectively conclusion acei related anemia renal transplant recipient seem due erythropoietin lower effect group drug pharmacokinetic interaction aza enalapril likely since plasma enalaprilat level independent immunosuppressive regimen aza metabolite level unchanged presence absence acei several mechanism angiotensin convert enzyme blockade may cause decrease circulate erythropoietin discus,Gossmann J,1996,Kidney Int,https://doi.org/10.1038/ki.1996.398,8872973,Gossmann J; Thürmann P; Bachmann T; Weller S; Kachel HG; Schoeppe W; Scheuermann EH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000740: Anemia; D000806: Angiotensin-Converting Enzyme Inhibitors; D001379: Azathioprine; D016572: Cyclosporine; D004347: Drug Interactions; D015773: Enalaprilat; D004912: Erythrocytes; D004921: Erythropoietin; D005260: Female; D006400: Hematocrit; D006454: Hemoglobins; D006801: Humans; D007166: Immunosuppressive Agents; D007674: Kidney Diseases; D016030: Kidney Transplantation; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013866: Thioguanine,,,https://openalex.org/W2063498586,98,11,1,1993,332,11,en,en
false,small oral dose clonidine reduce incidence intraoperative myocardial ischemia patient vascular surgery,new perioperative myocardial ischemic episode occur absence hypertension tachycardia ability alpha adrenoceptor agonist inhibit central sympathetic outflow may benefit patient coronary artery disease increase myocardial oxygen supply demand ratio randomize double blind study design use patient schedule elective vascular surgical procedure evaluate effect microgram kg oral clonidine n placebo n incidence perioperative myocardial ischemic episode myocardial infarction cardiac death continuous real time segment trend analysis lead ii v perform anesthesia surgery correlate arterial blood pressure heart rate ischemic event dose requirement vasoactive antiischemic drug control blood pressure heart rate well episode myocardial ischemia e catecholamine beta adrenoceptor antagonist nitrate systemic vasodilator fluid volume load record administration clonidine reduce incidence perioperative myocardial ischemic episode p hemodynamic pattern percentage ischemic time number ischemic episode per patient differ nonfatal myocardial infarction develop operation four patient receive placebo compare none receive clonidine day p incidence fatal cardiac event v different dose requirement vasoactive antiischemic drug differ group amount presurgical fluid volume slightly great patient receive clonidine v ml p small oral dose clonidine give prophylactically reduce incidence perioperative myocardial ischemic episode without affect hemodynamic stability patient suspect documented coronary artery disease,Stühmeier KD,1996,Anesthesiology,https://doi.org/10.1097/00000542-199610000-00004,8873539,Stühmeier KD; Mainzer B; Cierpka J; Sandmann W; Tarnow J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D003000: Clonidine; D003327: Coronary Disease; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D007431: Intraoperative Complications; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D014656: Vascular Surgical Procedures",,,https://openalex.org/W2036088088,125,18,1,2035,338,8,en,en
false,methylphenidate attentional training,effectiveness four mg mg mg mg methylphenidate mph attentional training evaluate use neurocognitive instrument continuous performance test match unfamiliar figure test narrow broad band rating scale context double blind placebo control within subject reversal design dizygotic twin girl attention deficit hyperactivity disorder adhd intervention prove effective improve neurocognitive test performance behavior although broad band rating reveal dose response curve different obtain neurocognitive test implication clinical management girl adhd discus,Rapport MD,1996,Behav Modif,https://doi.org/10.1177/01454455960204004,8875814,Rapport MD; Loo S; Isaacs P; Goya S; Denney C; Scanlan S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D003131: Combined Modality Therapy; D004200: Diseases in Twins; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007859: Learning Disabilities; D008774: Methylphenidate; D009043: Motor Activity; D009483: Neuropsychological Tests; D010552: Personality Assessment; D014429: Twins, Dizygotic",,,https://openalex.org/W2104762264,40,4,1,710,106,3,en,en
false,methylphenidate dose twice daily versus three time daily,objective evaluate short term efficacy side effect associate two methylphenidate hydrochloride mph dose pattern method twenty five boy attention deficit hyperactivity disorder adhd participate week triple blind placebo control crossover evaluation mph administer twice b versus thrice per day mean dose mg mg kg dose four dose condition placebo titration gradual increase target dose b use dependent measure obtain weekly basis include parent teacher rating child behavior parent child conflict parent report stimulant side effect child self report mood symptom sleep log laboratory measure attention actigraphic record sleep activity result dose condition result significant effect adhd symptom compare baseline relative placebo dose characterize improvement great number behavioral measure b generally effective titration direct comparison b dose reveal associate great improvement conners parent rating scale impulsivity hyperactivity factor similar marginally significant effect add h teacher rating scale hyperactivity factor analysis clinically significant change favor three time day dose schedule placebo parent teacher rating impulsivity hyperactivity attention compare placebo appetite suppression rat average severe titration condition b condition however number subject exhibit severe appetite suppression differ significantly b schedule although difference sleep duration child b schedule total sleep time appear decrease slightly relative placebo accord parent rating actigraphic assessment significant difference b side effect sleep variable conclusion many child adhd dose may optimal difference acute side effect b mph dose dose schedule select accord severity time course adhd symptom rather anticipation dose schedule related side effect,Stein MA,1996,Pediatrics,https://doi.org/10.1542/peds.98.4.748,8885956,Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001289: Attention Deficit Disorder with Hyperactivity; D002214: Capsules; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D003071: Cognition; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008774: Methylphenidate; D012890: Sleep; D013997: Time Factors,,,https://openalex.org/W1521375496,60,9,1,2542,436,38,en,en
false,minimum dose clonidine add mepivacaine prolongs duration anesthesia analgesia axillary brachial plexus block,study assess minimum dose clonidine require prolong duration anesthesia analgesia axillary brachial plexus blockade eighty patient schedule elective hand surgery divide eight group randomize double blind fashion axillary brachial plexus block perform ml mepivacaine plus epinephrine control group receive clonidine group increase clonidine micro g kg add local anesthetic solution onset time duration anesthesia analgesia postoperative pain score intake analgesic adverse effect record eight group comparable term onset time postoperative pain score analgesic requirement minimum dose clonidine require significantly prolong duration analgesia anesthesia respectively micro g kg side effect sedation drowsiness bradycardia arterial hypotension report conclude dose clonidine require prolong significantly duration anesthesia analgesia axillary brachial plexus blockade micro g kg dose clonidine may use without important report side effect even outpatient anesth analg,Singelyn FJ,1996,Anesth Analg,https://doi.org/10.1097/00000539-199611000-00025,8895283,Singelyn FJ; Gouverneur JM; Robert A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000556: Ambulatory Surgical Procedures; D000698: Analgesia; D000700: Analgesics; D000779: Anesthetics, Local; D001365: Axilla; D001917: Brachial Plexus; D001919: Bradycardia; D003000: Clonidine; D003243: Consciousness; D004311: Double-Blind Method; D017558: Elective Surgical Procedures; D005260: Female; D006225: Hand; D006801: Humans; D007022: Hypotension; D008297: Male; D008619: Mepivacaine; D008875: Middle Aged; D009407: Nerve Block; D010147: Pain Measurement; D010149: Pain, Postoperative; D012894: Sleep Stages; D013997: Time Factors",,,https://openalex.org/W2145688032,135,20,1,1360,237,10,en,en
false,comparative evaluation pilocarpine clonidine versus timolol,presently available antiglaucoma medication either local systemic adverse effect combination drug use increase effectivity compliance also decrease incidence magnitude side effect single dose response open angle glaucoma eye pilocarpine clonidine combination pilocarpine clonidine timolol study double blind mask cross study period twelve hour effectivity combination pilocarpine clonidine significantly either drug alone find similar timolol local systemic adverse effect see,Sihota R,1996,Indian J Ophthalmol,,8916595,Sihota R; Agarwal HC; Rajashekar YL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D001794: Blood Pressure; D003000: Clonidine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D018721: Muscarinic Agonists; D009883: Ophthalmic Solutions; D010862: Pilocarpine; D013999: Timolol",,,https://openalex.org/W1588106727,84,16,1,731,136,5,en,en
false,separate combine effect methylphenidate behavioral intervention disruptive behavior child mental retardation,investigate separate combine effect behavioral intervention methylphenidate ritalin disruptive behavior task engagement child severe profound mental retardation behavioral intervention involve differential reinforcement appropriate behavior guide compliance child demonstrate decrease disruptive behavior improve task engagement response response behavioral intervention two child demonstrate similar improvement response methylphenidate although intervention highly effective participant relative efficacy intervention vary child evidence additive synergistic effect two intervention high efficacy intervention alone limit ability detect effect,Blum NJ,1996,J Appl Behav Anal,https://doi.org/10.1901/jaba.1996.29-305,8926223,Blum NJ; Mauk JE; McComas JJ; Mace FC,article,D002363: Case Reports; D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000374: Aggression; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D002648: Child; D002653: Child Behavior Disorders; D003131: Combined Modality Therapy; D004305: Dose-Response Relationship, Drug; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D008774: Methylphenidate; D010343: Patient Admission; D010552: Personality Assessment; D012055: Reinforcement Schedule; D012931: Social Environment; D016896: Treatment Outcome",,,https://openalex.org/W2150827246,137,18,1,882,133,6,en,en
false,nicotine attention adult attention deficit hyperactivity disorder adhd,nicotine like psychostimulants methylphenidate dextroamphetamine act indirect dopamine agonist improve attention arousal adult adolescent attention deficit hyperactivity disorder adhd smoke much frequently normal individual psychiatric condition perhaps form self medication adhd symptom nicotine might therefore value treatment adhd present study acute double blind crossover administration nicotine placebo smoker n nonsmoker n diagnose adult adhd drug deliver via transdermal patch dosage mg day nonsmoker mg day smoker result indicate significant clinician rat global improvement self rat vigor concentration improve performance chronometric measure attention time accuracy side effect minimal acute result indicate need longer clinical trial comparison stimulant adult adhd treatment,Conners CK,1996,Psychopharmacol Bull,,8927677,Conners CK; Levin ED; Sparrow E; Hinton SC; Erhardt D; Meck WH; Rose JE; March J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D009538: Nicotine; D011379: Prognosis; D011569: Psychiatric Status Rating Scales,,,https://openalex.org/W72468019,80,13,1,1059,173,8,en,en
false,olanzapine versus placebo result double blind fix dose olanzapine trial,olanzapine potential new atypical antipsychotic agent double blind acute phase study compare two dos olanzapine mg day olz mg day olz placebo treatment patient meet dsm iii r criterion schizophrenia brief psychiatric rating scale bprs total score item score overall symptomatology improvement bprs total score positive negative syndrome scale panss total score olz statistically significantly superior placebo positive symptom improvement panss positive score bprs positive score olz statistically significantly superior placebo negative symptom improvement panss negative score olz statistically superior placebo olz clinically comparable placebo efficacy comparison adverse event show overall statistically significant incidence difference anorexia report placebo treat olz treat patient olz treat patient improve baseline respect parkinsonian akathisia symptom change comparable observe placebo dystonias associate olz treatment endpoint incidence patient elevate prolactin value differ statistically significantly placebo treat olz treated patient olanzapine appear safe effective promise atypical antipsychotic candidate,Beasley CM,1996,Psychopharmacology (Berl),https://doi.org/10.1007/bf02245617,8935812,Beasley CM; Sanger T; Satterlee W; Tollefson G; Tran P; Hamilton S,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia,,,https://openalex.org/W2070735132,81,12,1,1531,250,11,en,en
false,relapse follow clozapine withdrawal effect neuroleptic drug cyproheptadine,objective study report effect slow withdrawal clozapine patient neuroleptic responsive schizophrenia end year clinical trial clozapine compare result naturalistic discontinuation clozapine treatment neuroleptic resistant schizophrenic patient nineteen neuroleptic responsive schizophrenic patient receive clozapine withdraw clozapine taper week period without addition typical neuroleptic fifteen neuroleptic responsive patient experience return psychotic symptom clozapine taper severe ten patient withdrawal clozapine carry without prior addition neuroleptic treatment addition neuroleptic prior clozapine withdrawal prevent emergence positive symptom clozapine withdrawal eight patient nevertheless psychotic symptom emerge usually within week discontinue clozapine six eight patient neuroleptic treatment without anticholingergic drug much less effective treat positive symptom patient immediately clozapine withdrawal year previously cyproheptadine non selective serotonin receptor antagonist augment antipsychotic effect neuroleptic four patient relapse follow withdrawal clozapine relieve extrapyramidal symptom fifth patient frequency relapse follow withdrawal clozapine neuroleptic resistant patient significantly low neuroleptic responsive patient,Meltzer HY,1996,Psychopharmacology (Berl),https://doi.org/10.1007/bf02245619,8935814,Meltzer HY; Lee MA; Ranjan R; Mason EA; Cola PA,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D003533: Cyproheptadine; D005260: Female; D006801: Humans; D008297: Male; D010546: Perphenazine; D012559: Schizophrenia; D012702: Serotonin Antagonists; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W2023702380,86,11,1,1739,260,8,en,en
false,clozapine versus typical antipsychotic retro prospective study extrapyramidal side effect,schizophrenic patient long term neuroleptic monotherapy clozapine n perphenazine flupenthixol zuclopentixol control n evaluate extrapyramidal side effect eps blind well side effect mental condition non blind group patient receive neuroleptic treatment total year median present antipsychotic clozapine control drug year thus clozapine treated patient previously receive traditional neuroleptic year median study retrospective year clozapine year control drug mean chart information prospective year video control evaluation eps significantly low prevalence tardive dyskinesia td clozapine treat patient control patient although prior treatment td patient clozapine group p low level td clozapine group relate low induction new case p tendency towards great disappearance td clozapine control group p clozapine treat patient without td start clozapine cease traditional neuroleptic early age td parkinsonian sign see clozapine patient versus control patient mainly hypokinesia tremor versus rigidity versus psychic akathisia find versus motor akathisia versus patient difference significantly favor clozapine clozapine treat patient also less neuroleptic induced emotional indifference depression autonomic side effect control,Peacock L,1996,Psychopharmacology (Berl),https://doi.org/10.1007/bf02245620,8935815,Peacock L; Solgaard T; Lublin H; Gerlach J,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D003024: Clozapine; D005260: Female; D005475: Flupenthixol; D006801: Humans; D008297: Male; D008875: Middle Aged; D010546: Perphenazine; D011446: Prospective Studies; D012559: Schizophrenia,,,https://openalex.org/W2027294868,101,13,1,1780,330,10,en,en
false,cholinergic rebound rapid onset psychosis follow abrupt clozapine withdrawal,follow conduct day inpatient bioequivalence study clozapine schizophrenia patient withdrawal effect abrupt discontinuation clozapine assess thirty patient meet dsm iii r criterion schizophrenia residual type schizophrenia remission enrol study patient evaluate symptom withdrawal effect day clozapine mg day abruptly withdraw patient complete study withdrawal symptom mild withdrawal adverse event agitation headache nausea four patient experience moderate withdrawal adverse event nausea vomit diarrhea one patient experience rapid onset psychotic episode require hospitalization cholinergic rebound likely explanation mild moderate withdrawal symptom easily treat anticholinergic agent mesolimbic supersensitivity well specific property clozapine discus likely cause rapidonset psychosis find consistent previous report withdrawal reaction associate clozapine remind clinician monitor patient closely follow abrupt discontinuation clozapine,Shiovitz TM,1996,Schizophr Bull,https://doi.org/10.1093/schbul/22.4.591,8938913,Shiovitz TM; Welke TL; Tigel PD; Anand R; Hartman RD; Sramek JJ; Kurtz NM; Cutler NR,article,"D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D003024: Clozapine; D003967: Diarrhea; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009325: Nausea; D009460: Neurologic Examination; D011605: Psychoses, Substance-Induced; D011950: Receptors, Cholinergic; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013375: Substance Withdrawal Syndrome; D014839: Vomiting",,,https://openalex.org/W2137941062,83,10,1,1242,189,7,en,en
false,methylphenidate slow reaction child attention deficit disorder error,sternberg memory search task administer placebo methylphenidate child cross situational attention deficit disorder add child cross situational add plus oppositional feature patient marginal add overall stimulant medication enhance accuracy speed addition patient react faster correct response precede error error especially false alarm correct response follow error slowness error reaction may reflect decrease confidence confusion stimulus classification uncertainty may also lead subject respond great caution hence slowly correct response follow error notably methylphenidate increase slow reaction error trial well correct reaction follow error stimulant medication may augment subject persistence uncertain confuse thereby heighten caution promote accuracy succeed trial consistent previous report generality enhancement performance stimulant medication impact methylphenidate comparable three subtypes add study,Krusch DA,1996,J Abnorm Child Psychol,https://doi.org/10.1007/bf01670104,8956088,Krusch DA; Klorman R; Brumaghim JT; Fitzpatrick PA; Borgstedt AD; Strauss J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011930: Reaction Time; D012720: Severity of Illness Index,,,https://openalex.org/W1982871192,101,14,1,1210,189,8,en,en
false,childhood onset schizophrenia,childhood onset schizophrenia rare severe form disorder often treatment refractory study efficacy adverse effect clozapine haloperidol compare child adolescent early onset schizophrenia twenty one patient mean sd age year onset diagnostic statistical manual mental disorder revise third edition define schizophrenia begin age year nonresponsive typical neuroleptic participate study patient randomize week double blind parallel comparison clozapine mean sd final dose mg haloperidol mg clozapine superior haloperidol measure psychosis p positive negative symptom schizophrenia improve however neutropenia seizure major concern date one third group discontinue use clozapine clozapine strike superiority positive negative symptom treatment refractory childhood onset schizophrenia however due possibly increase toxic effect pediatric population close monitoring adverse event essential,Kumra S,1996,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1996.01830120020005,8956674,Kumra S; Frazier JA; Jacobsen LK; McKenna K; Gordon CT; Lenane MC; Hamburger SD; Smith AK; Albus KE; Alaghband-Rad J; Rapoport JL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000367: Age Factors; D017668: Age of Onset; D002648: Child; D002675: Child, Preschool; D003024: Clozapine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006220: Haloperidol; D006801: Humans; D009503: Neutropenia; D011569: Psychiatric Status Rating Scales; D012561: Schizophrenia, Childhood; D012640: Seizures; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W2125778283,29,2,1,1214,198,7,en,en
false,potentiation sufentanil clonidine pcea without basal infusion,sufentanil sufentanil clonidine combination evaluate determine whether basal rate patient control epidural analgesia pcea might affect daily consumption quality analgesia incidence side effect follow caesarean section delivery patient randomly assign receive one four follow pca regimen patient per group relief post operative pain epidural route sufentanil microgram ml nacl demand dose microgram e ml group group without infusion ml hr sufentanil microgram ml clonidine microgram ml demand dose microgram sufentanil microgram clonidine e ml group sc sc without infusion ml hr pca set bard pca pump lock interval min h limit microgram sufentanil microgram clonidine e ml parameter measure analgesic drug consumption number dose demand first h pain score h interval side effect quality sleep concurrent infusion increase dose requirement regardless content syringe consumption sufentanil high patient receive plain solution basal infusion clonidine addition reduce dose requirement significantly receive background infusion patient treat mixture tend reach low pain score receive sufentanil without basal rate patient receive mixture basal rate request significantly additional demand compare three group influence quality sleep since side effect frequently register patient group conclude optimum regimen sufentanil clonidine combination deletion basal rate,Vercauteren MP,1996,Eur J Anaesthesiol,https://doi.org/10.1046/j.1365-2346.1996.d01-412.x,8958487,Vercauteren MP; Saldien V; Bosschaerts P; Adriaensen HA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D002585: Cesarean Section; D003000: Clonidine; D004311: Double-Blind Method; D004357: Drug Synergism; D005260: Female; D006801: Humans; D010147: Pain Measurement; D010149: Pain, Postoperative; D011247: Pregnancy; D017409: Sufentanil",,,https://openalex.org/W1980966948,78,12,1,1954,344,13,en,en
false,effect seroquel quetiapine platelet serotonin bind schizophrenia,faustman william phd ringo david l md phd lauriello john md lim kelvin md pfefferbaum adolf md bardgett mark e phd csernansky john g md author information,Faustman WO,1996,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199612000-00015,8959478,Faustman WO; Ringo DL; Lauriello J; Lim KO; Pfefferbaum A,article,"D016430: Clinical Trial; D016422: Letter; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D001792: Blood Platelets; D003987: Dibenzothiazepines; D004311: Double-Blind Method; D006801: Humans; D007700: Kinetics; D008297: Male; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D011985: Receptors, Serotonin; D012559: Schizophrenia; D012702: Serotonin Antagonists",,,https://openalex.org/W2070635185,83,13,1,177,43,1,en,ceb
false,cerebral glucose metabolism pharmacologic study test retest placebo condition,reliability serial f fluorodeoxyglucose fdg pet scan psychopharmacologic study test use placebo infusion fdg scan obtain min placebo infusion n group two bolus infusion placebo n group subject perform continuous performance task cpt scan cardiovascular measure rating anxiety obtain subject sample determination plasma norepinephrine ne take multiple time point group slight increase apparent global metabolism occur scan group region significantly increase group apparent increase sympathetic activity occur placebo infusion neither ne level anxiety rating cardiovascular measure correlate global regional fd uptake test retest difference global regional glucose metabolism highly consistent across two experimental design increase cerebral glucose metabolism appear occur second scan difference scan small method may offer advantage select psychopharmacologic study,Schmidt ME,1996,J Nucl Med,,8965185,Schmidt ME; Ernst M; Matochik JA; Maisog JM; Pan BS; Zametkin AJ; Potter WZ,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D001007: Anxiety; D001289: Attention Deficit Disorder with Hyperactivity; D001921: Brain; D016022: Case-Control Studies; D003847: Deoxyglucose; D003913: Dextroamphetamine; D005260: Female; D005462: Fluorine Radioisotopes; D019788: Fluorodeoxyglucose F18; D005947: Glucose; D006801: Humans; D008297: Male; D009638: Norepinephrine; D010919: Placebos; D015203: Reproducibility of Results; D013647: Task Performance and Analysis; D014055: Tomography, Emission-Computed",,,https://openalex.org/W2158708557,95,12,1,1212,201,8,en,en
false,effect educational intervention mother male child attention deficit hyperactivity disorder,experimental research study determine whether educational intervention attention deficit hyperactivity disorder adhd would improve mother knowledge adhd feel competence parent low socioeconomic status mother male child age diagnose adhd place methylphenidate randomly select study experimental group mother give week educational intervention adhd remain mother serve control group difference experimental non experimental mother knowledge opinion adhd parental sense competency measure score improve parental satisfaction parental sense competency mother participate educational intervention research finding support idea nurse assist family learn deal child adhd chronic condition,Odom SE,1996,J Community Health Nurs,https://doi.org/10.1207/s15327655jchn1304_1,8973026,Odom SE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002675: Child, Preschool; D005260: Female; D006266: Health Education; D007722: Health Knowledge, Attitudes, Practice; D006801: Humans; D008297: Male; D008875: Middle Aged; D009035: Mothers; D016487: Parenting; D015397: Program Evaluation; D012649: Self Concept; D012737: Sex Factors; D011795: Surveys and Questionnaires",,,https://openalex.org/W1992963936,112,15,1,974,159,6,en,en
false,risperidone treatment chronic schizophrenia multicenter study comparative haloperidol,study design compare efficacy safety five different risperidone fix dose haloperidol patient chronic schizophrenia week single blind placebo washout phase chronic schizophrenic patient randomly assign double blind treatment mg risperidone mg haloperidol daily week efficacy assess throughout study positive negative syndrome scale panss schizophrenia clinical global impression cgi safety assessment include extrapyramidal symptom ratinf scale esr uku side effect rating scale vital sign body weight ecg laboratory screen risperidone bell shape dose response curve optimal therapeutic response occur daily dose mg therapeutic response haloperidol similar see risperidone mg risperidone associate significantly less extrapyramidal symptom haloperidol assess esr effect mirror requirement antiparkinson rescue medication furthermore overall incidence adverse event markedly low optimum dose risperidone haloperidol risperidone least effective haloperidol treatment chronic schizophrenia moreover risperidone associate improve adverse event profile significantly less extrapyramidal symptom beneficial implication patient quality life compliance result agreement result international multicenter trial,López Ibor JJ,1996,Actas Luso Esp Neurol Psiquiatr Cienc Afines,,8984849,López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D004361: Drug Tolerance; D005116: Extrapyramidal Tracts; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016037: Single-Blind Method,,,https://openalex.org/W96402930,102,16,1,1624,259,8,en,en
false,minimal effect dextroamphetamine scopolamine induce cognitive impairment human,central anticholinergic drug scopolamine use model aspect memory impairment occur alzheimer disease age determine whether nonspecific stimulant effect attenuate cognitive impairment induce scopolamine study effect scopolamine stimulant dextroamphetamine young normal volunteer baseline day cognitive testing subject participate two study day receive dextroamphetamine amp mg kg po scopolamine mg iv placebo scopolamine randomize order double blind condition statistically significant difference cognitive test performance two drug condition exception one category retrieval task stimulant effect document occur measure conclude amp dose use attenuate memory impairment induce scopolamine central anticholinergic drug scopolamine use model aspect memory impairment occur alzheimer disease age determine whether nonspecific stimulant effect attenuate cognitive impairment induce scopolamine study effect scopolamine stimulant dextroamphetamine young normal volunteer baseline day cognitive testing subject participate two study day receive dextroamphetamine amp mg kg po scopolamine mg iv placebo scopolamine randomize order double blind condition statistically significant difference cognitive test performance two drug condition exception one category retrieval task stimulant effect document occur measure conclude amp dose use attenuate memory impairment induce scopolamine,Martinez R,1997,Biol Psychiatry,https://doi.org/10.1016/0006-3223(95)00674-5,8988795,Martinez R; Molchan SE; Lawlor BA; Thompson K; Martinson H; Latham G; Weingartner H; Sunderland T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000544: Alzheimer Disease; D001288: Attention; D000697: Central Nervous System Stimulants; D003071: Cognition; D003913: Dextroamphetamine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009483: Neuropsychological Tests; D011930: Reaction Time; D012601: Scopolamine,,,https://openalex.org/W1984700172,91,10,1,1923,314,12,en,en
false,therapeutic effect safety adjunctive risperidone refractory obsessive compulsive disorder ocd,well establish percent patient obsessive compulsive disorder ocd improve adequate trial serotonin uptake inhibitor suis first purpose trial compare short term efficacy safety two different strategy sample treatment refractory ocd patient dose increase ongoing treatment versus addition another sui second purpose investigate short term efficacy safety adjunctive risperidone sui refractory ocd patient thirty three ocd patient unimproved short term treatment clomipramine mg day admit study first part study dose increase clomipramine compare sertraline addition open label manner addition sertraline ongoing treatment appear effective tolerable clomipramine dose increase seven patient consider nonresponders first part study show good clinical improvement good tolerability risperidone augmentation result suggest risperidone addition ongoing suis may useful augment pharmacologic response ocd,Ravizza L,1996,Psychopharmacol Bull,,8993091,Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D002997: Clomipramine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009771: Obsessive-Compulsive Disorder; D018967: Risperidone,,,https://openalex.org/W141608893,106,15,1,1260,209,8,en,en
false,weight gain induce clozapine,patient investigate gain insight incidence time course clozapine induce weight gain n compare weight gain patient treat clozapine n patient treat standard antipsychotic haloperidol n patient treat clozapine gain weight accord definition patient gain weight clozapine side effect apparent within first week treatment deviation normal body weight begin treatment show significant influence weight gain sex severity illness comedication mean clozapine dose degree improvement show influence side effect weight increase significantly high patient treat clozapine patient treat haloperidol,Hummer M,1995,Eur Neuropsychopharmacol,https://doi.org/10.1016/0924-977x(95)80001-i,8998394,Hummer M; Kemmler G; Kurz M; Kurzthaler I; Oberbauer H; Fleischhacker WW,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D012559: Schizophrenia; D015430: Weight Gain,,,https://openalex.org/W1966116421,32,5,1,837,148,6,en,en
true,epilepsy attention deficit hyperactivity disorder methylphenidate safe effective,objective study safety efficacy methylphenidate child dual diagnosis epilepsy attention deficit hyperactivity disorder adhd study design thirty child age year epilepsy adhd study month period initial month study child treat antiepileptic drug aeds remain month methylphenidate add morning dose mg kg underwent neurologic assessment brain compute tomography iq test assessment childhood behavior checklist baseline methylphenidate therapy electroencephalography aed determination continuous performance task cpt test baseline month methylphenidate therapy double blind crossover design use compare effect methylphenidate versus placebo electroencephalogram aed level cpt day test child receive aeds capsule contain either placebo methylphenidate result none child sample seizure free attack take methylphenidate child seizure increase attack whereas show change reduction significant change aed level electroencephalographic find methylphenidate benefit child accord parental report methylphenidate also enhance performance cpt side effect methylphenidate mild transient conclusion methylphenidate effective treat child epilepsy adhd safe child seizure free caution warrant still seizure receive aed therapy,Gross-Tsur V,1997,J Pediatr,10.1016/s0022-3476(97)70308-1,9003849,Gross-Tsur V; Manor O; van der Meere J; Joseph A; Shalev RS,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000927: Anticonvulsants; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004827: Epilepsy; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D013647: Task Performance and Analysis; D016896: Treatment Outcome,,,,93,13,1,1780,304,14,en,en
false,effect clozapine symptom cluster treatment refractory patient,preliminary result double blind clozapine study population chronic psychotic patient state psychiatric facility report thirty treatment refractory schizophrenic patient give diagnosis accord dsm iii r criterion mean age year duration illness year receive mg mg clozapine randomize double blind fashion analyze subject evaluate use brief psychiatric rating scale bprs clinical global impression cgi scale weekly basis week base change cgi score week clozapine treatment subject retrospectively categorize improver n nonimprovers n two group compare change total bprs bprs factor score term total bprs score expect difference two group categorize base change cgi score however total bprs score improver show significant decrease week clozapine treatment analyze four bprs factor improver show improvement think disturbance factor week remain steady week hostility suspiciousness factor improver show improvement across time compare nonimprovers withdrawal retardation factor show improvement group across time whereas anxiety depression factor least influence clozapine observation suggest bprs symptom factor uniformly contribute improvement overall psychopathology observe decrease total bprs score,Abraham G,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199702000-00009,9004057,Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2331532161,77,10,1,1691,293,11,en,en
false,clozapine eligibility effect stringent criterion ethnic gender age subgroup schizophrenic patient,purpose retrospective chart review study determine whether broad stringent criterion differentially impact clozapine eligibility ethnic gender age subgroup schizophrenic patient patient chart select random cluster sample mental health patient know city county san francisco information relate clozapine eligibility abstract train non clinical personnel impact subgroup membership eligibility examine use logistic regression procedure even broad interpretation fda requirement clozapine use asian patient less likely eligible since asian patient meet clozapine treatment requirement stringent eligibility criterion old patient likely exclude eligibility td automatically satisfy treatment criterion young patient likely lose eligibility number require adequate medication trial increase three broad eligibility criterion tend differentially exclude asian patient stringent criterion differentially exclude young old patient,Juarez-Reyes MG,1996,Prog Neuropsychopharmacol Biol Psychiatry,https://doi.org/10.1016/s0278-5846(96)00130-3,9004341,Juarez-Reyes MG; Shumway M; Battle C; Bacchetti P; Hansen MS; Hargreaves WA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000367: Age Factors; D014150: Antipsychotic Agents; D003024: Clozapine; D004608: Eligibility Determination; D005006: Ethnicity; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015588: Observer Variation; D012044: Regression Analysis; D012189: Retrospective Studies; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012737: Sex Factors; D014481: United States; D014486: United States Food and Drug Administration,,,https://openalex.org/W2093610601,117,18,1,1199,186,11,en,en
false,predictive value eosinophilia neutropenia clozapine treatment,myelotoxicity continue hinder widespread use clozapine united state theorize eosinophilia predict later agranulocytosis agranulocytosis occurs due immunologic mechanism study compare rate dyscrasia clozapine treat patient control group forty one patient take clozapine patient take haloperidol monitor period month rate eosinophilia neutropenia compare two treatment group treatment emergent eosinophilia occur frequently haloperidol clozapine treat patient significant difference see group incidence eosinophilia neutropenia find statistical difference rate eosinophilia neutropenia haloperidol clozapine treat patient study support use eosinophilia reliable predictor neutropenia,Ames D,1996,J Clin Psychiatry,https://doi.org/10.4088/jcp.v57n1205,9010121,Ames D; Wirshing WC; Baker RW; Umbricht DS; Sun AB; Carter J; Schooler NR; Kane JM; Marder SR,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D003024: Clozapine; D004311: Double-Blind Method; D004802: Eosinophilia; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D008297: Male; D009503: Neutropenia; D011336: Probability; D012189: Retrospective Studies; D012559: Schizophrenia,,,https://openalex.org/W2007067196,75,9,1,946,134,6,en,en
false,covert visual spatial attention boy attention deficit hyperactivity disorder lateral effect methylphenidate response result parent,report three relate study covert visual spatial orient child attention deficit hyperactivity disorder adhd study examine covert visual spatial orient adhd comparison boy study comprise dose response study methylphenidate adhd group study investigation biological adoptive parent contrast comparison subject n adhd boy age n show slow reaction time overall within condition lateral asymmetry reaction time specifically boys adhd react slowly uncued target leave visual field right visual field response stimuli two visual field differentially affect methylphenidate adhd group medication equalize visual field response uncued target result significant cue dose visual field interaction far medication alter relative cue responsivity two visual field result significant dose visual field interaction validity effect biological parent adhd boy n also show slow reaction time uncued leave visual field target right visual field target addition show slow response invalidly cue target right visual field lateral effect observe adoptive parent adhd boy n biological parent comparison boy n possible abnormal hemispheric asymmetry attention function boy adhd biological parent discus,Nigg JT,1997,Neuropsychologia,https://doi.org/10.1016/s0028-3932(96)00070-x,9025120,Nigg JT; Swanson JM; Hinshaw SP,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000300: Adoption; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003463: Cues; D004305: Dose-Response Relationship, Drug; D007839: Functional Laterality; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011930: Reaction Time; D013028: Space Perception",,,https://openalex.org/W2077812227,152,21,1,1557,263,10,en,en
false,agitate brain injured patient part pathophysiology treatment,management agitation brain injury remain uncertain lack consistent definition poor understand underlie mechanism part review focus definition differential diagnosis assessment part review potential mechanism posttraumatic agitation common intervention strategy intent two part series advocate consistent definition posttraumatic agitation encourage use appropriate assessment monitoring strategy recommend intervention decision base least theoretical understanding relationship specific target behavior probable brain behavior relationship,Mysiw WJ,1997,Arch Phys Med Rehabil,https://doi.org/10.1016/s0003-9993(97)90266-5,9041905,Mysiw WJ; Sandel ME,article,D016428: Journal Article; D016454: Review,D001930: Brain Injuries; D006801: Humans; D018377: Neurotransmitter Agents,,,https://openalex.org/W1986102881,73,12,2,722,108,4,en,en
false,pemoline associate hepatic failure critical analysis literature,pemoline central nervous system cns stimulant approve use part comprehensive medical management attention deficit hyperactivity disorder adhd increase risk acute hepatic failure believe associate pemoline usage raise concern prescription descriptive meta analysis exist scientific literature drug report database undertake provide accurate understand possible risk analysis appear indicate current assumption risk acute hepatic failure pose pemoline usage alone overestimate several recommendation regard hepatic monitoring set pemoline prescription provide,Shevell M,1997,Pediatr Neurol,10.1016/s0887-8994(96)00266-4,9044395,Shevell M; Schreiber R,article,D016428: Journal Article; D016454: Review,D016907: Adverse Drug Reaction Reporting Systems; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D006801: Humans; D017093: Liver Failure; D010389: Pemoline,,,,75,11,1,726,112,5,en,en
false,late intraoperative clonidine administration prevent postanesthetic shivering total intravenous volatile anesthesia,postoperative administration clonidine effective treatment shiver however ability drug stop postanesthetic shiver administer intraoperatively remain controversial furthermore relative efficacy clonidine isoflurane propofol anesthesia remain unknown therefore evaluate incidence postanesthetic shiver patient give clonidine nitrous oxide isoflurane propofol anesthesia clonidine analgesic also evaluate postoperative pain analgesic requirement study patient undergo elective ear nose surgery general anesthesia induce mg kg propofol micro g kg fentanyl mg kg vecuronium general anesthesia maintain isoflurane nitrous oxide one group patient continuous infusion propofol mg center dot kg center dot h administer without nitrous oxide five minute tracheal extubation patient group randomly assign receive saline placebo micro g kg clonidine intravenously postanesthetic shiver evaluate blind investigator postoperative pain assess use visual analog scale post operative shivering observe patient give isoflurane without clonidine patient give propofol without clonidine patient give clonidine shiver clonidine administration significantly reduce postoperative pain incidence postanesthetic shiver significantly less propofol anesthesia isoflurane nitrous oxide anesthesia however late intraoperative bolus administration micro g kg clonidine prevents postoperative shiver patient give either type anesthesia anesth analg,Horn EP,1997,Anesth Analg,https://doi.org/10.1097/00000539-199703000-00028,9052312,Horn EP; Werner C; Sessler DI; Steinfath M; Schulte am Esch J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000769: Anesthesia, Inhalation; D000771: Anesthesia, Intravenous; D003000: Clonidine; D005260: Female; D006801: Humans; D007530: Isoflurane; D008297: Male; D008875: Middle Aged; D009609: Nitrous Oxide; D015742: Propofol; D012768: Shivering",,,https://openalex.org/W2108744789,125,13,1,1833,284,16,en,en
false,perioperative sympatholysis beneficial effect alpha adrenoceptor agonist mivazerol hemodynamic stability myocardial ischemia mcspi europe research group,mivazerol hydrochloride new alpha adrenoceptor agonist vitro animal study demonstrate sympatholytic antiischemic property evaluate safety efficacy mivazerol patient perioperative stress multicenter phase ii clinical trial study hemodynamic stability myocardial ischemia patient coronary artery disease undergoing noncardiac surgery three hundred patient twenty three european medical institution participate placebo control double blind randomize parallel group trial ninety eight give high dose mivazerol micrograms kg h low dose mivazerol microgram kg h placebo continuously intraoperatively h postoperatively blood pressure heart rate monitor h myocardial ischemia assess holter electrocardiography least h induction anesthesia h surgery twelve lead electrocardiogram creatine kinase myocardial band isoenzyme level obtain serially surgery adverse cardiac event assess intraoperative early postoperative h late postoperative h period incidence tachycardia significantly low high dose mivazerol v placebo intraoperative v p early postoperative v p late postoperative period v p also percentage patient treat tachycardia significantly low high dose v placebo early v p late v p postoperative period incidence hypertension significantly low high low vs placebo intraoperative period respectively vs p treatment similar high low respectively vs p incidence bradycardia significantly high dose level placebo drug administration intraoperatively early postoperative late postoperative drug placebo low dose high dose respectively need treatment differ group incidence treatment hypotension similar three group intraoperative myocardial ischemia significantly low high dose mivazerol placebo v respectively p intraoperative data subdivide emergence vs nonemergence period post boc analysis incidence myocardial ischemia significantly low high dose mivazerol placebo emergence v p regard blood pressure heart rate ischemia rebound response occur h discontinuation mivazerol high dose low dose placebo group differ incidence adverse cardiac outcome respectively diagnosis myocardial infarction respectively continuous h perioperative administration mivazerol high risk patient appear relatively safe produce significant hypotension adverse event evidence bradycardia associate adverse clinical event mivazerol decrease incidence treatment tachycardia hypertension myocardial ischemia particularly high stress period therefore salutary effect mivazerol indicate study large scale trial assess mivazerol effect adverse cardiac outcome include death myocardial infarction,,1997,Anesthesiology,,9054253,,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000316: Adrenergic alpha-Agonists; D000368: Aged; D000700: Analgesics; D000777: Anesthetics; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007093: Imidazoles; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D013564: Sympathetic Nervous System,,,https://openalex.org/W4301810886,173,24,3,3733,688,17,en,en
false,effect methylphenidate event relate potential performance attention deficit hyperactivity disorder child auditory visual selective attention task,attention deficit hyperactivity disorder adhd child participate double blind placebo control study effect dosage mg methylphenidate mph auditory visual selective attention task determine present frequent infrequent stimulus relevant irrelevant input channel subject task respond infrequent tone relevant input channel process activity negativity positivity assess task n p n p b peak score auditory task n p n p p p b peak score visual task effect mph prevalent visual auditory condition visual condition mph enhance percentage hit cause high central parietal occipital p b amplitude attend stimulus standard deviant also enhance frontal processing negativity pn auditory task mph influence performance enhance frontal pn well parietal occipital p b amplitude stimulus type adhd child mph ameliorate deficit also improve process difference normal child present attention deficit hyperactivity disorder adhd child participate double blind placebo control study effect dosage mg methylphenidate mph auditory visual selective attention task determine present frequent infrequent stimulus relevant irrelevant input channel subject task respond infrequent tone relevant input channel process activity negativity positivity assess task n p n p b peak score auditory task n p n p p p b peak score visual task effect mph prevalent visual auditory condition visual condition mph enhance percentage hit cause high central parietal occipital p b amplitude attend stimulus standard deviant also enhance frontal processing negativity pn auditory task mph influence performance enhance frontal pn well parietal occipital p b amplitude stimulus type adhd child mph ameliorate deficit also improve process difference normal child present,Jonkman LM,1997,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(96)00115-1,9066993,Jonkman LM; Kemner C; Verbaten MN; Koelega HS; Camfferman G; vd Gaag RJ; Buitelaar JK; van Engeland H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D004569: Electroencephalography; D004585: Electrooculography; D005072: Evoked Potentials, Auditory; D005074: Evoked Potentials, Visual; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011597: Psychomotor Performance; D014888: Wechsler Scales",,,https://openalex.org/W2054824302,172,20,1,2533,480,16,en,en
false,clonidine induction reduce shiver general anaesthesia,postanaesthetic shivering occur patient addition cause discomfort associate deleterious consequence objective investigate effect microgram clonidine induction anaesthesia perioperative core peripheral temperature incidence postanaesthetic shivering patient perception cold sixty asa patient schedule elective orthopaedic limb surgery randomly allocate group receive microgram clonidine iv group receive saline bolus iv induction patient anaesthesia induce fentanyl propofol maintain spontaneous respiration via laryngeal mask airway oxygen nitrous oxide enflurane core nasopharyngeal peripheral dorsal hand temperature record induction min interval nurse unaware treatment group record visible shiver recovery room cognitive function return patient ask grade perception cold cm linear analogue scale high score indicate heat discomfort core temperature decrease peripheral temperature increase group difference group time however low incidence shiver clonidine group vs p patient receive clonidine felt warm thermal comfort score median interquartile range v p clonidine g iv induction anaesthesia reduce incidence shiver patient subjective perception cold emergence general anaesthesia,Buggy D,1997,Can J Anaesth,https://doi.org/10.1007/bf03015363,9067044,Buggy D; Higgins P; Moran C; O'Donovan F; McCarroll M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D000768: Anesthesia, General; D003000: Clonidine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012768: Shivering",,,https://openalex.org/W2141362232,66,8,1,1663,289,9,en,en
false,effect intravenous oral clonidine hemodynamic plasma catecholamine response due endotracheal intubation,investigate effect intravenous iv versus oral clonidine alteration heart rate hr mean arterial pressure map cardiac output co plasma catecholamine due endotracheal intubation design randomize double blind placebo control study set university hospital surgery operating room asa physical status patient randomly assign either receive clonidine g kg iv immediately prior anesthesia induction clonidine g kg orally minute prior anesthesia induction placebo intervention insertion g cannula large cubital vein determination plasma catecholamine use local anesthesia insertion radial artery catheter measure blood pressure bp use local anesthesia transthoracic echocardiography determine co heart rate map co plasma catecholamine concentration measure measurement perform prior induction intubation minute intubation endotracheal intubation map significantly low iv clonidine group compare placebo oral clonidine group cardiac output significantly low iv clonidine group contrast placebo group norepinephnne plasma concentration increase either clonidine group significant alteration epinephrine plasma concentration due intubation observe either group hemodynamics intubation impair clonidine treatment conclusion iv clonidine reduce stress response endotracheal intubation compare placebo oral clonidine dose use less effective blunt hemodynamic stress response iv clonidine,Zalunardo MP,1997,J Clin Anesth,https://doi.org/10.1016/s0952-8180(97)00239-0,9075040,Zalunardo MP; Zollinger A; Spahn DR; Seifert B; Radjaipour M; Gautschi K; Pasch T,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000328: Adult; D001794: Blood Pressure; D002302: Cardiac Output; D002395: Catecholamines; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007275: Injections, Intravenous; D007442: Intubation, Intratracheal; D008297: Male",,,https://openalex.org/W1975463327,121,15,1,1725,278,15,en,en
false,fenfluramine methylphenidate child mental retardation borderline iq clinical effect,double blind placebo control crossover study methylphenidate mg kgday different fenfluramine mg g day child mental retardation borderline iq adhd conduct parent teacher examiner physician rat child relatively significant drug effect condition optimal fenfluramine dose child compare placebo methylphenidate significant improvement occur fenfluramine several parent teacher subscales teacher rat child somewhat improve methylphenidate high dose fenfluramine produce behavior compliance apparently cost cognitive efficiency side effect drowsiness dizziness anorexia occur fenfluramine drug appear effective treatment child adhd mental retardation although possible neurotoxic action fenfluramine recommend gradual phase fenfluramine dosage mg kg day child,Aman MG,1997,Am J Ment Retard,,9083608,Aman MG; Kern RA; Osborne P; Tumuluru R; Rojahn J; del Medico V,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005277: Fenfluramine; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D008774: Methylphenidate; D010349: Patient Compliance; D016896: Treatment Outcome",,,https://openalex.org/W2567998155,105,15,1,1069,174,8,en,en
false,cardiovascular metabolic response clonidine midazolam premedication,double blind placebo control study preoperative cardiovascular metabolic effect intramuscular clonidine midazolam assess forty five asa grade patient n per group undergo plastic surgical procedure randomly allocate receive either placebo clonidine microgram kg midazolam microgram kg drug administer deltoid muscle approximately min prior schedule induction anaesthesia metabolic measurement perform use indirect calorimetry device heart rate blood pressure measure noninvasively pre operative subjective anxiety dryness mouth tiredness assess use visual analogue scale va clonidine increase subjective tiredness significantly placebo clonidine also induce moderate decrease blood pressure heart rate oxygen consumption vo co production energy expenditure ee decrease significantly clonidine midazolam decrease vo ee maximally average base line clonidine midazolam effect long duration clonidine last end min study period conclusion clonidine midazolam effective mean decrease pre operative vo ee,Taittonen M,1997,Eur J Anaesthesiol,https://doi.org/10.1046/j.1365-2346.1997.00103.x,9088819,Taittonen M; Kirvelä O; Aantaa R; Kanto J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D014151: Anti-Anxiety Agents; D003000: Clonidine; D004311: Double-Blind Method; D004562: Electrocardiography; D004734: Energy Metabolism; D005260: Female; D006439: Hemodynamics; D006454: Hemoglobins; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008874: Midazolam; D008875: Middle Aged; D010101: Oxygen Consumption; D011229: Preanesthetic Medication",,,https://openalex.org/W2134575092,79,9,1,1335,216,13,en,en
false,olanzapine versus haloperidol treatment schizophrenia schizoaffective schizophreniform disorder result international collaborative trial,back table content previous article next article full accessolanzapine versus haloperidol treatment schizophrenia schizoaffective schizophreniform disorder result international collaborative trialpublished online apr http doi org ajp aboutsectionsview articleabstractpdf epub toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail view articleabstractobjective international multicenter double blind trial design compare therapeutic profile atypical antipsychotic olanzapine conventional dopamine antagonist haloperidol method total patient site europe north america randomly assign treatment olanzapine n haloperidol n week primary efficacy analysis involve mean change baseline endpoint total score brief psychiatric rating scale bprs secondary analysis include comparison mean change positive negative symptom comorbid depression extrapyramidal symptom overall drug safety result olanzapine demonstrate clinical result superior haloperidol overall improvement accord bprs every secondary measure include depression olanzapine also associate significantly discontinuation treatment due lack drug efficacy adverse event substantially olanzapine treat patient haloperidol treat patient complete week therapy statistically significant advantage olanzapine treatment relate change negative symptom extrapyramidal symptom profile effect prolactin level response rate conclusion olanzapine show superior broad spectrum efficacy treatment schizophrenic psychopathology substantially favorable safety profile haloperidol meet several criterion novel atypical antipsychotic agent figuresreferencescited bydetailscited bydetailing effect polypharmacy psychiatry longitudinal study patient hospitalize depression schizophrenia november european archive psychiatry clinical neuroscience vol half century research antipsychotic schizophrenia scientometric study hotspot node burst trendsneuroscience biobehavioral review vol olanzapine treatment psychosis december zentrales nervensystemthe importance suicide risk formulation schizophrenia december frontier psychiatry vol first patient receive olanzapine recollection october human psychopharmacology clinical experimental vol modulatory effect olanzapine smim phoenixin npq spexin nucb nesfatin gene expression rat brainstem april pharmacological report vol translation cross cultural adaption instrument measure patient well treatment schizophrenia june journal basic clinical physiology pharmacology vol effect olanzapine anxiety relate behaviour male female rat assess day chronic treatment november behavioural pharmacology vol stability phase transition investigation olanzapine polymorphschemical physic letter vol patient factor associate oral generic olanzapine initiation substitution among medicaid beneficiary new user cohort study february current medical research opinion vol evidence base guideline pharmacological treatment schizophrenia update recommendation british association psychopharmacology december journal psychopharmacology vol attenuate psychosis syndrome february cerebellum schizophrenia cerebellum volume reduction theory schizophrenia october crystengcomm vol schizophrenia bulletin vol comparative study olanzapine quetiapine psychotic disorder january journal evidence base medicine healthcare vol world psychiatry vol european archive psychiatry clinical neuroscience vol moj addiction medicine therapy vol frontier neuroscience vol secondary negative symptom review mechanism assessment treatmentschizophrenia research vol olanzapine advantage iloperidone early amelioration symptom schizophrenia randomise parallel group trial april journal evidence base medicine healthcare vol time discontinuation second generation antipsychotic versus haloperidol sulpiride people schizophreniajournal clinical psychopharmacology vol risperidone versus placebo schizophrenia december cochrane database systematic review vol drug safety vol neuroleptic drugsolanzapinepsychiatric clinic north america vol psiquiatr biol gica vol international journal molecular science vol change delusional dimension emotion eight week antipsychotic treatment acute patientspsychiatry research vol pharmaceutical statistic vol scientific report vol ethical human psychology psychiatry vol cl nica e investigaci n en arteriosclerosis vol journal biopharmaceutical statistic vol schizophrenia research treatment vol noninferiority perphenazine v three second generation antipsychotic chronic schizophreniajournal nervous mental disease vol effect ziprasidone olanzapine body composition metabolic parameter open label comparative pilot study july behavioral brain function vol long act injectable antipsychotic evidence effectiveness use february canadian journal psychiatry vol supplexploring experimental computed crystal energy landscape olanzapine march crystal growth design vol inflate effect size thus increase chance produce positive result raise baseline threshold schizophrenia trial schizophrenia research vol current psychiatry report vol drug therapy perspective vol clinical therapeutic vol european journal pharmacology vol european neuropsychopharmacology vol schizophrenia research vol schizophrenia research vol schizophrenia research vol epidemiology psychiatric science vol acta crystallographica section c crystal structure communication vol acta crystallographica section e structure report online vol diabetes obesity metabolism vol long term effect haloperidol olanzapine risperidone plasma prolactin level patient first episode psychosisjournal clinical psychopharmacology vol crystal engineering isostructural quaternary multicomponent crystal form olanzapine july crystal growth design vol evidence base pharmacotherapy schizophreniareduction tardive dyskinesia symptom treatment olanzapine haloperidoljournal clinical psychopharmacology vol prospective observational study safety effectiveness intramuscular psychotropic treatment acutely agitate patient schizophrenia bipolar mania april european psychiatry vol safety efficacy olanzapine monotherapy olanzapine mood stabilizer week treatment manic mixed episode japanese patient bipolar disorder april current medical research opinion vol antipsychotic drug extrapyramidal side effect first episode psychosis systematic review head head comparison november journal psychopharmacology vol supplmetabolism vol journal statistical theory practice vol journal child adolescent psychopharmacology vol asia pacific psychiatry vol world journal biological psychiatry vol randomize open label comparison impact aripiprazole versus risperidone sexual functioning ra study journal clinical psychopharmacology vol effectiveness haloperidol risperidone olanzapine treatment first episode non affective psychosis result randomize flexible dose open label year follow comparison february journal psychopharmacology vol evidence base guideline pharmacological treatment schizophrenia recommendation british association psychopharmacology february journal psychopharmacology vol cochrane database systematic reviewspsychopharmacology vol neurologic clinic vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol solid state nuclear magnetic resonance vol international journal neuropsychopharmacology vol plo one vol clinical drug investigation vol drug age vol international journal psychiatry clinical practice vol sialorrheaurinary incontinenceolanzapine male female adolescent patient schizophrenia relate disordersjournal clinical psychopharmacology vol extrapyramidal side effectsconclusion implication practice policycochrane database systematic reviewshuman psychopharmacology clinical experimental vol biophysical chemistry vol child adolescent psychiatric clinic north america vol psychiatry research vol acta psychiatrica scandinavica vol apply health economics health policy vol belgian schizophrenia outcome survey result year naturalistic study patient stabilise monotherapy olanzapine risperidone haloperidol april european psychiatry vol revista de psiquiatr salud mental vol cost effectiveness simulation analysis schizophrenia instituto mexicano del seguro social assessment typical atypical antipsychoticsrevista de psiquiatr salud mental english edition vol annales dico psychologiques revue psychiatrique vol behavioural brain research vol l enc phale vol journal psychiatric research vol journal psychiatric research vol schizophrenia research vol world journal biological psychiatry vol schizophrenia bulletin vol schizophrenia bulletin vol journal american academy child adolescent psychiatry vol diabetes obesity metabolism vol perspectives psychiatric care vol orvosi hetilap vol olanzapine treatment low body weight obsessive think woman anorexia nervosa randomize double blind placebo control trialhany bissada giorgio tasca ph ann marie barber jacques bradwejn october american journal psychiatry vol review second generation antipsychotic discontinuation first episode psychosisjournal psychiatric practice vol importance open access atypical antipsychotic treatment schizophrenia bipolar disorder european perspective june current medical research opinion vol pharmacological therapyidentifying inter ethnic variation psychotropic response african american ethnic minoritiestroubles taboliques induits par le neuroleptiques atypiques revue de litt ratureannales dico psychologiques revue psychiatrique vol prolactin dopamine connection review article march journal psychopharmacology vol supplcochrane database systematic reviewshuman psychopharmacology clinical experimental vol social psychiatry psychiatric epidemiology vol archive psychiatric nursing vol biophysical chemistry vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol schizophrenia research vol cns spectrum vol international journal psychiatry clinical practice vol journal child adolescent psychopharmacology vol schizophrenia bulletin vol bmc psychiatry vol annals new york academy science vol clinical schizophrenia relate psychosis vol antipsychotic drugsamoxapine antipsychoticjournal clinical psychopharmacology vol clinical implication antipsychotic induce hyperprolactinemia patient schizophrenia spectrum bipolar spectrum disordersjournal clinical psychopharmacology vol eficacia de los antipsic ticos relaci n con la ocupaci n ptima de los receptores may european psychiatry ed espa ola vol neuroreceptor gene polymorphism olanzapine depressive symptom response schizophreniajournal clinical psychopharmacology vol prevalence hyperprolactinaemia naturalistic cohort schizophrenia bipolar outpatient treatment typical atypical antipsychotic november journal psychopharmacology vol antipsychotic efficacy relationship optimal receptor occupancy april european psychiatry vol cause treatment discontinuation schizophrenia treatment olanzapine relative antipsychoticsjournal clinical psychopharmacology vol dr rosenheck colleague replyrobert rosenheckm scott stroupm p h swartzm joseph mcevoym sonia davis dr p h richard e keefeph john k hsiaom j liebermanm april american journal psychiatry vol late life schizophreniapsychopharmacology vol vol european neuropsychopharmacology vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol progress neurotherapeutics neuropsychopharmacology vol journal evaluation clinical practice vol acta psychiatrica scandinavica vol british journal psychiatry vol journal american pharmacist association vol journal american academy psychoanalysis dynamic psychiatry vol expert review pharmacoeconomics outcome research vol arquivos brasileiros de endocrinologia metabologia vol cns drug vol olanzapineclinical trial base cost effectiveness analysis antipsychotic usedaniel polsky ph jalpa doshi ph mark bauer henry glick ph december american journal psychiatry vol symptom domain schizophrenia role atypical antipsychotic agent september journal psychopharmacology vol supplthe use intramuscular benzodiazepine antipsychotic agent treatment acute agitation violence emergency departmentthe journal emergency medicine vol special section catie baseline data interrelationship psychiatric symptom severity medical comorbidity function schizophrenialydia chwastiak p h robert rosenheck joseph p mcevoy richard keefe ph marvin swartz jeffrey lieberman august psychiatric service vol randomize year follow study olanzapine risperidone treatment negative symptom outpatient schizophreniajournal clinical psychopharmacology vol physician switch one antipsychotic agent another journal clinical psychopharmacology vol effectiveness community treatment order treatment schizophrenia oral depot antipsychotic medication clinical outcome november australian new zealand journal psychiatry vol treatment olanzapine risperidone typical antipsychotic drug asian patient schizophrenia june australian new zealand journal psychiatry vol barrier employment people schizophreniarobert rosenheck douglas leslie ph richard keefe ph joseph mcevoy marvin swartz diana perkins p h scott stroup p h john k hsiao jeffrey lieberman march american journal psychiatry vol mejora gradual del tratamiento con agentes antipsic ticos desde los neurol pticos orales tradicionales hasta el primer depot pico may european psychiatry ed espa ola vol antipsychotic medication elderly people schizophrenia january cochrane database systematic review vol cochrane database systematic reviewsstatistics medicine vol psychopharmacology vol neuroleptic drugschild adolescent psychiatric clinic north america vol european neuropsychopharmacology vol journal emergency medicine vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol nature review drug discovery vol neuropsychopharmacology vol neuropsychopharmacology vol nordic journal psychiatry vol american journal addiction vol world journal biological psychiatry vol schizophrenia bulletin vol behavioural pharmacology vol journal psychiatric practice vol cns drug review vol acta psychiatrica scandinavica vol acta psychiatrica scandinavica vol journal automate method management chemistry vol psychiatric bulletin vol folium pharmacologica japonica vol expert opinion pharmacotherapy vol cns drug vol meta analysis drop rate randomise clinical trial compare typical atypical antipsychotic treatment schizophrenia april european psychiatry vol switch antipsychotic updated review focus quetiapine october journal psychopharmacology vol antipsychotic risk diabetes general data review april european psychiatry vol tardive dyskinesia era typical atypical antipsychotic part incidence management strategy patient schizophrenia october canadian journal psychiatry vol antipsychotic agent gradually improve treatment traditional oral neuroleptic first atypical depot april european psychiatry vol dr simpson repliesgeorge simpson july american journal psychiatry vol olanzapine haloperidol residual symptomslieuwe de haan ph nico van beveren july american journal psychiatry vol pharmacotherapy health care cost among patient schizophrenia newly diagnose diabetesdouglas l leslie ph robert rosenheck july psychiatric service vol treatment response olanzapine haloperidol association dopamine receptor occupancy first episode psychosis july canadian journal psychiatry vol association early rapid weight gain change weight one year olanzapine therapy patient schizophrenia relate disordersjournal clinical psychopharmacology vol association weight gain olanzapine plasma concentrationsjournal clinical psychopharmacology vol incidence new onset diabetes mellitus among patient receive atypical neuroleptic treatment mental illnessjournal nervous mental disease vol nutritional intervention prevent weight gain patient commence olanzapine randomizedcontrolled trial june australian new zealand journal psychiatry vol olanzapine schizophrenia april cochrane database systematic review vol comparison large versus small randomize trial mental health relate interventionsdespina g contopoulos ioannidis simon gilbody phil b ch b thomas trikalinos rachel churchill sc ph kristian wahlbeck ph john p ioannidis march american journal psychiatry vol current option management olanzapine associate weight gain february annals pharmacotherapy vol effect olanzapine body composition energy expenditure adult first episode psychosiskaren graham diana perkins lloyd j edward ph robert c barrierjr jeffrey lieberman joyce b harp january american journal psychiatry vol olanzapine treatment residual positive negative symptomsrobert w buchanan patricia ball r n elaine weiner brian kirkpatrick james gold ph robert p mcmahon ph william carpenterjr january american journal psychiatry vol open forum effectiveness versus efficacy second generation antipsychotic haloperidol without anticholinergic comparatorrobert rosenheck january psychiatric service vol pharmacoepidemiology drug safety vol psychopharmacology vol psychopharmacology vol european archive psychiatry clinical neuroscience vol mental health service research vol psychiatrie und psychotherapie vol vol cognitive behavioral practice vol biological psychiatry vol european neuropsychopharmacology vol european neuropsychopharmacology vol international journal law psychiatry vol international journal psychophysiology vol progress neuro psychopharmacology biological psychiatry vol psychiatric clinic north america vol schizophrenia research vol epidemiologia e psichiatria sociale vol international journal psychiatry clinical practice vol world journal biological psychiatry vol journal psychiatric practice vol australian new zealand journal psychiatry vol psychiatry clinical neuroscience vol acta psychiatrica scandinavica vol acta psychiatrica scandinavica vol bmc psychiatry vol british journal psychiatry vol expert opinion pharmacotherapy vol drug metabolism pharmacokinetics vol drug metabolism pharmacokinetics vol pharmacoeconomics vol pharmacoeconomics vol cns drug vol pediatric drug vol selective prescribe atypical antipsychotic october pharmacoepidemiology drug safety vol oral risperidone lorazepam versus oral zuclopenthixol lorazepam treatment acute psychosis emergency psychiatry prospective comparative open label study july journal psychopharmacology vol randomize control double blind multicenter comparison efficacy tolerability ziprasidone olanzapine acutely ill inpatient schizophrenia schizoaffective disordergeorge simpson ira glick peter j weiden steven j romano cynthia siu ph december american journal psychiatry vol physical health monitoring patient schizophreniastephen r marder susan essock ph alexander l miller robert w buchanan daniel e casey john davis john kane jeffrey lieberman nina r schooler ph nancy covell ph scott stroup p h ellen weissman p h donna wirshing catherine hall pharm leonard pogach xavier pi sunyer p h j thomas biggerjr alan friedman david kleinberg steven j yevich p h bonnie davis steven shon august american journal psychiatry vol response vocational rehabilitation treatment first second generation antipsychoticsgary r bond ph hea kim ph piper meyer ph p joseph gibson ph p h sandra tunis ph jovier evans ph paul lysaker ph marion l mccoy ph jerry dincin ph haiyi xie ph january psychiatric service vol european archive psychiatry clinical neuroscience vol efficacy tolerability olanzapine patient schizophrenia lithuania week multicenter open label nonrandomized studycurrent therapeutic research vol psychiatric clinic north america vol journal american medical director association vol american journal emergency medicine vol biological psychiatry vol control clinical trial vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol psychiatry research vol schizophrenia research vol schizophrenia research vol therapeutic drug monitoring vol acta neuropsychiatrica vol psychiatry clinical neuroscience vol psychiatry clinical neuroscience vol psychiatry clinical neuroscience vol value health vol acta psychiatrica scandinavica vol perspectives psychiatric care vol current medical research opinion vol british journal psychiatry vol vol pharmacotherapy vol pharmacoeconomics vol pharmacoeconomics vol cns drug vol disease management health outcome vol assess monitor antipsychotic induced movement disorder hospitalize patient cautionary study january canadian journal psychiatry vol cost comparison olanzapine risperidone treat schizophrenia january annals pharmacotherapy vol double blind randomize placebo control trial olanzapine prevention psychotic relapsejournal clinical psychopharmacology vol effect olanzapine anxiety among patient schizophrenia preliminary findingsjournal clinical psychopharmacology vol diabetic ketoacidosis secondary olanzapine august british journal diabetes vascular disease vol maintenance treatment schizophrenia risperidone haloperidol year outcomesstephen r marder shirley glynn ph william c wirshing donna wirshing doreen ross clifford widmark jim mintz ph robert p liberman karen e blair august american journal psychiatry vol transfer olanzapine breast milk calculation infant drug dose effect breast feed infantssharon j gardiner clin pharm judith h kristensen b pharm evan j begg l peter hackett r c debbie wilson f r n z c p kenneth f ilett ph rolland kohan b b jonathan rampono f r n z c p august american journal psychiatry vol health promotion person schizophrenia atypical medication june journal american psychiatric nurse association vol effect antipsychotic sexual endocrine function woman implication clinical practicejournal clinical psychopharmacology vol pattern antipsychotic anticholinergic prescribe hospital inpatient july journal psychopharmacology vol efficacy second generation antipsychotic treatment schizophreniacurrent psychosis therapeutic report vol long term effectiveness risperidone olanzapine resistant intolerant schizophrenic patient mirror study may acta psychiatrica scandinav,Tollefson GD,1997,Am J Psychiatry,https://doi.org/10.1176/ajp.154.4.457,9090331,Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D015897: Comorbidity; D003866: Depressive Disorder; D004311: Double-Blind Method; D005060: Europe; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D009656: North America; D000077152: Olanzapine; D010352: Patient Dropouts; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W1787454655,163,20,1,29827,5411,563,en,en
false,apraclonidine anterior segment laser surgery,purpose compare efficacy apraclonidine prevent laser induce intraocular pressure iop elevation trabeculoplasty neodymium yag nd yag iridotomy capsulotomy method prospective mask randomize study patient undergo trabeculoplasty patient undergo iridotomy patient undergo capsulotomy surgical eye receive one drop apraclonidine immediately surgery result intraocular pressure reduce hour trabeculoplasty p p group intraocular pressure high baseline great number eye treat eye compare apraclonidine eye p intraocular pressure eye narrow chamber angle reduce eye treat eye treat apraclonidine iridotomy patient chronic angle closure glaucoma iop similar prelaser value eye treat p eye treat apraclonidine p patient undergo capsulotomy pressure significantly low group p apraclonidine group capsulotomy treatment group similar p number eye iop less baseline apraclonidine apraclonidine conclusion single postoperative administration apraclonidine effective concentration prevent iop elevation immediately trabeculoplasty iridotomy capsulotomy,Rosenberg LF,1995,Ophthalmology,https://doi.org/10.1016/s0161-6420(95)30869-x,9097768,Rosenberg LF; Krupin T; Ruderman J; McDaniel DL; Siegfried C; Karalekas DP; Grewal RK; Gieser DK; Williams R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000368: Aged; D000869: Anterior Eye Segment; D003000: Clonidine; D004311: Double-Blind Method; D005901: Glaucoma; D006801: Humans; D007429: Intraocular Pressure; D007498: Iris; D053685: Laser Therapy; D007903: Lens Capsule, Crystalline; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D011183: Postoperative Complications; D011446: Prospective Studies; D014130: Trabeculectomy",,,https://openalex.org/W1511853499,48,6,1,1754,412,10,es,en
false,risperidone treatment schizophrenia meta analysis randomize control trial,study evaluate relative effectiveness side effect risperidone compare conventional neuroleptic treatment schizophrenia meta analysis double blind randomize control trial proportion patient show clinical improvement use medication extrapyramidal side effect eps treatment drop rate change negative panss score measure compare conventional neuroleptic slightly patient risperidone group show clinical improvement v odds ratio confidence interval ci use concomitant medication eps significantly less risperidone group conventional neuroleptic group vs odds ratio ci overall drop rate low risperidone group neuroleptic group vs odds ratio ci difference change negative panss score risperidone haloperidol group ci weight gain tachycardia common patient treat risperidone sensitivity analysis different analytic approach materially change main estimate conclude short term efficacy risperidone comparable neuroleptic treatment schizophrenia associate significantly eps conventional neuroleptic mainly haloperidol,Song F,1997,J Psychopharmacol,https://doi.org/10.1177/026988119701100116,9097896,Song F,article,D016428: Journal Article; D017418: Meta-Analysis,D001480: Basal Ganglia Diseases; D006801: Humans; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2089315440,94,13,1,1497,266,10,en,en
false,clozapine associate diabetes mellitus,article abstractbackground clozapine effective therapy treatment refractory psychosis clozapine associate adverse effect include sedation weight gain sialorrhea palpitation seizure hematologic change agranulocytosis method present four case series clozapine use associate either de novo onset severe exacerbation preexist diabetes mellitus result change glycemic control significantly relate weight gain three patient able continue clozapine therapy experience reduction psychotic symptom conclusion patient family history diabetes mellitus preexist diabetes mellitus may need blood sugar monitor closely initiation clozapine treatment,Popli AP,1997,J Clin Psychiatry,https://doi.org/10.4088/jcp.v58n0304,9108812,Popli AP; Konicki PE; Jurjus GJ; Fuller MA; Jaskiw GE,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D001786: Blood Glucose; D003024: Clozapine; D015897: Comorbidity; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D018149: Glucose Intolerance; D006801: Humans; D006943: Hyperglycemia; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W2039239004,42,5,1,821,129,6,en,en
false,benztropine versus clozapine treatment tremor parkinson disease,four open label study report beneficial effect clozapine tremor idiopathic parkinson disease pd perform double blind crossover trial week washout compare low dose clozapine benztropine treatment tremor pd twenty two subject enrol complete study benztropine clozapine equally effective improve tremor motor score united parkinson disease rating scale mean mg day respectively significant adverse event experience drug leukopenia encounter conclude atypical antipsychotic drug clozapine helpful treatment tremor pd consider drug therapy fail,Friedman JH,1997,Neurology,https://doi.org/10.1212/wnl.48.4.1077,9109903,Friedman JH; Koller WC; Lannon MC; Busenbark K; Swanson-Hyland E; Smith D,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000978: Antiparkinson Agents; D014150: Antipsychotic Agents; D001590: Benztropine; D003024: Clozapine; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010300: Parkinson Disease; D016896: Treatment Outcome; D014202: Tremor",,,https://openalex.org/W2123417347,79,12,1,772,129,6,en,en
false,adverse effect risperidone eye movement activity comparison risperidone haloperidol antipsychotic naive schizophrenic patient,risperidone novel clinically effective atypical antipsychotic medication unique biochemical profile contrast neurophysiological effect new medication typical antipsychotic medication perform quantitative measurement saccadic eye movement series antipsychotic naive schizophrenic patient treat either risperidone haloperidol patient test month treatment match group healthy subject test twice similar time interval risperidone haloperidol associate prolong latency decrease peak velocity accuracy saccadic eye movement detectable week treatment initiation adverse effect risperidone may due lack development acute tolerance powerful serotonergic ht antagonism could responsible disruption brainstem physiology region control saccadic eye movement,Sweeney JA,1997,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(96)00195-9,9138438,Sweeney JA; Bauer KS; Keshavan MS; Haas GL; Schooler NR; Kroboth PD,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D014150: Antipsychotic Agents; D005133: Eye Movements; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D011446: Prospective Studies; D018967: Risperidone; D012438: Saccades; D012559: Schizophrenia,,,https://openalex.org/W2042605422,146,19,1,1004,154,5,en,en
false,nursing home research industry perspective,behavioral disturbance dementia longer tolerate family caregiver become unmanageable nursing home clinician must consider appropriate method treatment behavioral disturbance may respond change patient environment approach caregiver others pharmacologic treatment necessary,Brecher M,1996,Int Psychogeriatr,https://doi.org/10.1017/s1041610297003645,9154590,Brecher M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000544: Alzheimer Disease; D014150: Antipsychotic Agents; D003704: Dementia; D004305: Dose-Response Relationship, Drug; D004992: Ethics, Medical; D005260: Female; D015577: Geriatric Assessment; D006707: Homes for the Aged; D006801: Humans; D008297: Male; D008609: Mental Status Schedule; D008875: Middle Aged; D019965: Neurocognitive Disorders; D009735: Nursing Homes; D011367: Professional Staff Committees; D018967: Risperidone; D012920: Social Behavior Disorders; D016896: Treatment Outcome",,,https://openalex.org/W2128338776,49,7,1,357,57,2,en,en
false,preliminary analysis interactive effect common classroom contingency methylphenidate,assess drug behavior interaction effect year old boy wih attention deficit hyperactivity disorder common classroom antecedent e g seat arrangement consequent e g peer prompt stimuli alternate within school day drug condition methylphenidate v placebo alternate across day result suggest peer attention maintain disruptive behavior methylphenidate absent present,Northup J,1997,J Appl Behav Anal,https://doi.org/10.1901/jaba.1997.30-121,9157096,Northup J; Jones K; Broussard C; DiGiovanni G; Herring M; Fusilier I; Hanchey A,article,D016430: Clinical Trial; D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010379: Peer Group; D012056: Reinforcement, Social; D012931: Social Environment",,,https://openalex.org/W2169137198,104,12,1,467,73,2,en,en
false,effect methylphenidate child attention deficit hyperactivity disorder comparison event relate potential medication responder non responder,event relate potential erps compare among three group subject adhd non responder methylphenidate treatment adhd responder methylphenidate treatment normal control child response methylphenidate determine extensive psychoeducational cognitive assessment week double blind medication assessment erps record week active electrode visual feature detection task semantic classification task significant group effect find n p b latency due long latency adhd child medication difference responder non responder however methylphenidate non responder significantly longer p b latency responder cognitive testing also reveal differential performance medication non responder responder pair associate learning pal task thus cognitive erp measure find differentiate adhd non responder responder methylphenidate treatment,Sunohara GA,1997,Int J Psychophysiol,https://doi.org/10.1016/s0167-8760(97)00746-0,9161888,Sunohara GA; Voros JG; Malone MA; Taylor MJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D004311: Double-Blind Method; D004569: Electroencephalography; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate,,,https://openalex.org/W2085324728,175,21,1,1086,165,8,en,en
false,risperidone effect formulation oral bioavailability,bioavailability risperidone evaluate open label randomize two way crossover study compare mg tablet mg ml oral solution formulation administer single mg dose day washout period treatment healthy men enter study complete treatment period plasma concentration risperidone active moiety risperidone plus active metabolite hydroxyrisperidone determine radioimmunoassay key pharmacokinetic value c max auc ci relative bioequivalence risperidone hydroxyrisperidone active moiety contain within equivalence range log transform data result demonstrate mg ml oral solution mg tablet bioequivalent,Gutierrez R,1997,Pharmacotherapy,,9165565,Gutierrez R; Lee PI; Huang ML; Woestenborghs R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001682: Biological Availability; D018592: Cross-Over Studies; D006801: Humans; D007555: Isoxazoles; D008297: Male; D000068882: Paliperidone Palmitate; D011743: Pyrimidines; D018967: Risperidone; D012996: Solutions; D013607: Tablets; D013810: Therapeutic Equivalency,,,https://openalex.org/W1963115875,60,8,1,836,140,6,en,en
false,olanzapine versus haloperidol acute phase result international double blind olanzapine trial,week acute phase international year double blind study conduct compare three dose range olanzapine mg day mg day mg day fix dose olanzapine mg day dose range haloperidol mg day treatment patient schizophrenia purpose determine whether olanzapine demonstrate dose relate ability decrease overall psychopathology minimal associate extrapyramidal symptom patient schizophrenia high dose olanzapine group show statistically significantly great improvement overall psychopathology base mean change cgi severity score statistically significantly great improvement positive psychotic symptom base mean change bprs positive score panss positive score compare mg day olanzapine group analysis indicate increase dose response curve observe across range olanzapine dose group acute extrapyramidal syndrome report less frequently among olanzapine group compare haloperidol group endpoint mean change simpson angus scale barnes akathisia scale reflect improvement olanzapine treatment group compare worsen haloperidol group olanzapine associate weight gain appear clinically meaningful effect vital sign although olanzapine associate increase prolactin concentration increase transient occur less often less magnitude observe haloperidol,Beasley CM,1997,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(96)00392-6,9169300,Beasley CM; Hamilton SH; Crawford AM; Dellva MA; Tollefson GD; Tran PV; Blin O; Beuzen JN,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia,,,https://openalex.org/W2022528197,101,13,1,1646,249,8,en,en
false,extrapyramidal symptom patient treat risperidone,data extrapyramidal symptom eps arm north american multicenter comparative study risperidone placebo haloperidol analyze subject patient chronic schizophrenia week washout period receive placebo risperidone mg day haloperidol mg day week trial complete patient severity eps assess mean extrapyramidal symptom rating scale esr mean change increase esr score baseline bad score significantly low risperidone group haloperidol group total esr parkinsonism dystonia dyskinesia total parkinsonism hypokinetic symptom questionnaire p several subscales dyskinesia buccolinguomasticatory clinical global impression severity dyskinesia mean change score significantly low risperidone group placebo group p clinically effective risperidone dose mg day mean esr change score significantly different placebo group significant linear relationship note mean change score increase risperidone dose esr subscales nevertheless even mg day risperidone mean change score low haloperidol group linear relationship increase risperidone dose use antiparkinsonian medication also apparent acute dystonic reaction occur patient receive risperidone haloperidol patient severe baseline eps high risk eps study patient low moderate baseline eps conclude low risperidone cause eps recommendation initiation risperidone treatment make,Simpson GM,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199706000-00010,9169965,Simpson GM; Lindenmayer JP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D018967: Risperidone; D012559: Schizophrenia; D011795: Surveys and Questionnaires,,,https://openalex.org/W2329387641,60,7,1,1868,332,11,en,en
false,extrapyramidal symptom tolerability olanzapine versus haloperidol acute treatment schizophrenia,relative lack extrapyramidal symptom eps e syndrome dystonia parkinsonism akathisia dyskinesia one criterion use determine whether antipsychotic atypical extrapyramidal symptom profile novel antipsychotic olanzapine conventional antipsychotic haloperidol compare population patient three well control prospective clinical trial extrapyramidal symptom data analyze patient treat olanzapine mg day patient treat haloperidol mg day week therapy patient monitor weekly three method extrapyramidal symptom assessment detection extrapyramidal adverse event sign symptom casual observation nonprobing inquiry spontaneous report objective rating scale score use concomitant anticholinergic medication emergence eps assess analysis incidence extrapyramidal syndrome category base adverse event incidence extrapyramidal syndrome base categorical analysis rating scale score analysis mean maximum change rating scale score categorical analysis anticholinergic medication use outcome eps assess analysis mean change rating scale score endpoint mean anticholinergic use endpoint olanzapine statistically significantly p p superior haloperidol four analysis relate emergence eps two analysis relate outcome furthermore acute treatment statistically significantly patient treat olanzapine discontinue study extrapyramidal adverse event patient treat haloperidol p olanzapine exhibit statistically significantly low extrapyramidal symptom profile conventional antipsychotic haloperidol comparably effective antipsychotic low extrapyramidal symptom profile olanzapine evident despite statistically significantly frequent use anticholinergic drug among haloperidol treat patient olanzapine treat haloperidol treated patient discontinue eps suggest olanzapine contribute good compliance long term maintenance treatment minimal anticholinergic associate event,Tran PV,1997,J Clin Psychiatry,https://doi.org/10.4088/jcp.v58n0505,9184614,Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004361: Drug Tolerance; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D008297: Male; D000077152: Olanzapine; D010349: Patient Compliance; D010352: Patient Dropouts; D010890: Pirenzepine; D012559: Schizophrenia; D016896: Treatment Outcome,,,https://openalex.org/W1993668511,113,14,1,2429,388,8,en,en
false,quetiapine patient schizophrenia,quetiapine fumarate seroquel ici atypical dibenzothiazepine antipsychotic great affinity hydroxytryptamine ht receptor dopamine receptor efficacy patient schizophrenia show early phase trial maximum dose mg multicenter double blind placebo control trial patient hospitalize chronic subchronic schizophrenia dsm iii r randomize week treatment high dose quetiapine fumarate mg n low dose quetiapine fumarate mg n placebo n brief psychiatric rating scale bprs clinical global impression severity illness item score primary efficacy variable secondary efficacy variable include bprs positive symptom cluster score modify scale assessment negative symptom summary score united state total score negative scale positive negative syndrome scale europe score analyze use analysis covariance change baseline end point last observation carry forward model include baseline score covariate center treatment extrapyramidal symptom assess use simpson angus scale barnes akathisia scale abnormal involuntary movement assess use abnormal involuntary movement scale frequency distribution group change baseline score analyze use chi test patient efficacy quetiapine evaluate receive high dose treatment low dose treatment placebo withdraw trial completion primarily treatment failure significant p bprs p clinical global impression severity illness item p bprs positive symptom cluster difference identify patient receive high dose quetiapine placebo primary efficacy variable end point difference bprs positive symptom cluster score show quetiapine consistency reduce positive symptom reduction negative symptom less consistent high dose quetiapine superior modify scale assessment negative symptom negative scale positive negative syndrome scale quetiapine well tolerate induce extrapyramidal symptom sustain elevation prolactin clinically significant change hematologic parameter quetiapine effective antipsychotic favorable safety profile optimum dose probably great mg,Small JG,1997,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1997.01830180067009,9193196,Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003987: Dibenzothiazepines; D004244: Dizziness; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006261: Headache; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D012890: Sleep; D016896: Treatment Outcome",,,https://openalex.org/W2019879674,41,5,1,2668,446,11,en,en
false,relationship antispasticity effect tizanidine plasma concentration patient multiple sclerosis,spasticity serious problem multiple sclerosis many patient achieve satisfactory response currently available oral antispasticity drug tizanidine hydrochloride alpha noradrenergic agonist show antispasticity effect single center trial patient compare plasma concentration tizanidine objective measure muscle tone patient moderate severe spasticity ten center tertiary referral center specialize treatment patient united state canada randomize double blind placebo control dose response study tizanidine hydrochloride mg one hundred forty two patient spastic take interfere medication antispasticity drug alpha noradrenergic agonist enter trial tizanidine treatment reduce muscle tone significantly show improved ashworth score increase knee swing amplitude record pendulum test correlate significantly plasma concentration placebo significant effect muscle tone dizziness drowsiness dry mouth fatigue report often group treat tizanidine peak plasma concentration tizanidine reduce spasticity therapeutic effect side effect relate plasma drug level,Nance PW,1997,Arch Neurol,https://doi.org/10.1001/archneur.1997.00550180049011,9193208,Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D002170: Canada; D002319: Cardiovascular System; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D009103: Multiple Sclerosis; D009119: Muscle Contraction; D009125: Muscle Relaxants, Central; D012720: Severity of Illness Index; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2065382947,115,15,1,1409,221,4,en,en
false,psychopharmacologic treatment pathologic aggression,pathologic aggression anger extremely heterogeneous phenomenon present variety psychiatric neurologic disorder range brain injury schizophrenia major depressive disorder several researcher attempt link certain form pathologic aggression specific neuropsychiatric condition example whereas repetitive unprovoked assaultive behavior associate brain injury recurrent inappropriate verbal physical response external stimulus consider characteristic mood disorder accompany mark irritability fava pathologic aggression however influence heavily many psychological developmental environmental factor addition underlie medical condition manifestation within subject neuropsychiatric disorder quite variable somewhat unpredictable number neurochemical system include involve gabaergic serotonergic noradrenergic dopaminergic glutaminergic neurotransmission implicate modulation aggressive behavior animal model similarly describe article kavoussi et al elsewhere issue neurochemical study human support modulate role pathologic aggression several system neurotransmitter particular serotonin therefore surprising investigator study effect psychotropic drug animal model human subject effect specific psychotropic agent however vary across different animal model affective aggression human drug e methylphenidate show antiaggressive effect certain population e adolescent attention deficit hyperactivity disorder precipitate aggressive response others e bipolar patient systematic study effect treatment pathologic aggression also complicate fact typically intermittent phenomenon whose occurrence intensity often unpredictable alternative approach clinical trial affect population would study effect particular drug individual undergo pharmacologic challenge recreate laboratory set aggressive response although researcher develop pharmacologic challenge e g yohimbine lactate induce fear panic laboratory among patient history panic attack comparable test study anger attack rage patient history pathologic aggression possible tool investigation chlorophenylpiperazine cpp find induce anger response patient generalize anxiety disorder although patient disorder despite lack approval food drug administration fda drug specifically treatment aggression number currently available drug use purpose fda p david personal communication however recognize pathologic aggression may aspect certain disorder e g bipolar disorder schizophrenia specific drug treatment approve addition pharmaceutical company yet apply approval drug indicate treatment pathologic aggression p david personal communication suggest lack fda approve u certain drug management aggressive patient may stem relative lack market interest field perhaps medicolegal risk relate process lead approval difficult imagine degree concern part legal department pharmaceutical company conduct placebo control clinical trial subject pathologic aggression spite limitation number study anecdotal report guide physician decision concern drug treatment pathologic aggression aim article therefore review drug treatment pathologic aggression addition frequently use instrument assessment pathologic aggression anger review characteristic instrument use clinical trial may affect outcome,Fava M,1997,Psychiatr Clin North Am,https://doi.org/10.1016/s0193-953x(05)70321-x,9196923,Fava M,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000374: Aggression; D000544: Alzheimer Disease; D000786: Anger; D000927: Anticonvulsants; D014150: Antipsychotic Agents; D001289: Attention Deficit Disorder with Hyperactivity; D001569: Benzodiazepines; D001921: Brain; D003866: Depressive Disorder; D004827: Epilepsy; D006801: Humans; D006816: Huntington Disease; D008607: Intellectual Disability; D019965: Neurocognitive Disorders; D010554: Personality Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D017367: Selective Serotonin Reuptake Inhibitors,,,https://openalex.org/W2095565048,54,5,1,4414,708,17,en,en
false,clinical evaluation risperidone treatment schizophrenia week open label multicenter trial,efficacy safety risperidone previously demonstrate control clinical trial hospitalize chronic schizophrenia patient meet strict research criterion present study design evaluate efficacy safety risperidone heterogeneous patient population patient enrol study diagnosis schizophrenia dsm iii r without acute exacerbation patient psychiatric center enter phase iv study complete week trial week dose risperidone titrate mg day maintain week adjust week period clinically necessary dose fix final week period mean dose risperidone endpoint mg day patient evaluate baseline week use clinical global impression scale psychotic symptom assessment scale global assessment function scale significant improvement mean score find measure endpoint comparable result obtain week treatment resistant non treatment resistant patient risperidone generally well tolerate severity extrapyramidal symptom significantly reduce endpoint,Jeste DV,1997,Psychopharmacology (Berl),https://doi.org/10.1007/s002130050289,9203234,Jeste DV; Klausner M; Brecher M; Clyde C; Jones R,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D000368: Aged; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D011569: Psychiatric Status Rating Scales; D011788: Quality of Life; D018967: Risperidone; D012559: Schizophrenia",,,https://openalex.org/W2064015424,112,18,1,1313,218,10,en,en
false,clozapine induce electroencephalogram change function clozapine serum level,specific electroencephalogram eeg change clozapine therapy prospectively study cohort chronic state hospital patient schizophrenia randomly assign one three nonoverlapping clozapine serum level range ng ml ng ml ng ml eeg obtain clozapine institute week treatment fifty three percent patient show eeg change week study period observe three seizure one patient mg serum level ng ml clozapine two patient low clozapine serum level ng ml prior history seizure inadequate valproate coverage thirteen percent patient develop spike relationship dose serum level clozapine fifty three percent patient develop slow eeg compare plasma level ng ml clozapine serum level ng ml lead frequent severe slow eeg slow correlate observe sleepiness although factor sufficient explain severity high dose effect specific electroencephalogram eeg change clozapine therapy prospectively study cohort chronic state hospital patient schizophrenia randomly assign one three nonoverlapping clozapine serum level range ng ml ng ml ng ml eeg obtain clozapine institute week treatment fifty three percent patient show eeg change week study period observe three seizure one patient mg serum level ng ml clozapine two patient low clozapine serum level ng ml prior history seizure inadequate valproate coverage thirteen percent patient develop spike relationship dose serum level clozapine fifty three percent patient develop slow eeg compare plasma level ng ml clozapine serum level ng ml lead frequent severe slow eeg slow correlate observe sleepiness although factor sufficient explain severity high dose effect,Freudenreich O,1997,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(96)00298-3,9209730,Freudenreich O; Weiner RD; McEvoy JP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003024: Clozapine; D015331: Cohort Studies; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004569: Electroencephalography; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012640: Seizures",,,https://openalex.org/W2085719837,86,10,1,2293,396,16,en,en
false,pharmacological management alcohol withdrawal meta analysis evidence base practice guideline american society addiction medicine work group pharmacological management alcohol withdrawal,provide evidence base practice guideline pharmacological management alcohol withdrawal english language article publish july identify medline search substance withdrawal ethyl alcohol review reference identify article article original data human subject structure review determine study design sample size intervention use outcome withdrawal severity delirium seizure completion withdrawal entry rehabilitation adverse effect cost data prospective control trial methodologically sound end point correspond diagnostic statistical manual mental disorder fourth edition abstract independent reviewer underwent meta analysis benzodiazepine reduce withdrawal severity reduce incidence delirium case per patient confidence interval p reduce seizure seizure per patient confidence interval p individualize therapy withdrawal scale result administration significantly less medication shorter treatment p beta blocker clonidine carbamazepine ameliorate withdrawal severity evidence inadequate determine effect delirium seizure phenothiazine ameliorate withdrawal less effective benzodiazepine reduce delirium p seizure p benzodiazepine suitable agent alcohol withdrawal choice among different agent guide duration action rapidity onset cost dosage individualize base withdrawal severity measure withdrawal scale comorbid illness history withdrawal seizure beta blocker clonidine carbamazepine neuroleptic may use adjunctive therapy recommend monotherapy,Mayo-Smith MF,1997,JAMA,https://doi.org/10.1001/jama.278.2.144,9214531,Mayo-Smith MF,article,D016431: Guideline; D016428: Journal Article; D017418: Meta-Analysis; D017065: Practice Guideline,D000319: Adrenergic beta-Antagonists; D000430: Alcohol Withdrawal Delirium; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002220: Carbamazepine; D002986: Clinical Trials as Topic; D003000: Clonidine; D000431: Ethanol; D019317: Evidence-Based Medicine; D017048: Health Care Costs; D006801: Humans; D006993: Hypnotics and Sedatives; D008274: Magnesium; D012720: Severity of Illness Index; D013375: Substance Withdrawal Syndrome; D013831: Thiamine; D016896: Treatment Outcome,,,https://openalex.org/W2042931973,209,26,3,1899,300,7,en,en
false,response clozapine acute mania rapid chlorpromazine,purpose present study compare efficacy clozapine chlorpromazine open label manner give association lithium salt treatment acute mania thirty hospitalize manic patient enter study patient meet dsm iv criterion bipolar disorder manic episode patient complete study three patient drop noneompliance duration study week patient randomly assign two treatment group group n treat clozapine mean dose mg day group n treat chlorpromazine mean dose mg day manic symptomatology rat young rating scale mania yrsm week side effect record dosage record treatment emergent symptom extrapyramidal acute side effect rat simpson angus rating scale perform begin study week treatment two way repeat measure analysis variance yrms score show significant time effect p significant time group interaction p post hoc comparison two group show significant difference week treatment p clozapine treat patient show low yrsm score chlorpromazine treat patient yrsm score end study significantly different patient treat clozapine show rapid trend toward amelioration clinically relevant side effect observe study,Barbini B,1997,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199703000-00006,9219046,Barbini B; Scherillo P; Benedetti F; Crespi G; Colombo C; Smeraldi E,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001714: Bipolar Disorder; D002746: Chlorpromazine; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008094: Lithium; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome",,,https://openalex.org/W2038739154,78,13,1,1571,281,8,en,en
false,diltiazem calcium antagonist partly attenuate effect dextroamphetamine healthy volunteer,calcium antagonist previously show effective treatment mania present study use dextroamphetamine administer human model mania determine whether calcium antagonist diltiazem would prevent dextroamphetamine induced change may help determine whether diltiazem likely useful treatment mania ten healthy volunteer enrol double blind placebo control balance crossover study subject receive either oral diltiazem mg placebo placebo dcxtroamphetamine mg diltiazem dextroamphetamine placebo alone subjective sleep change measure use visual analogue scale attentiveness visual reaction time measure repeatedly diastolic systolic blood pressure result show dextroamphelamine alone produce number subjective change cardiovascular change change reaction time diltiazem significantly attenuate cardiovascular change subjective reaction time change hypothesize finding may represent effect diltiazem noradrenergic neurotransmission result tentatively supportive suggestion diltiazem may clinically useful treatment mania another calcium channel antagonist verapamil,Fabian JE,1997,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199703000-00007,9219047,Fabian JE; Silverstone PH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001143: Arousal; D001288: Attention; D001714: Bipolar Disorder; D002121: Calcium Channel Blockers; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male,,,https://openalex.org/W2030688706,105,15,1,1354,210,11,en,en
false,effect clonidine prolong postoperative sympathetic response,objective surgical trauma result diffuse sympathoadrenal activation think contribute perioperative cardiovascular complication high risk patient regional anesthetic analgesic technique attenuate stress response reduce occurrence rate adverse perioperative event however use postoperative period logistically difficult costly present study undertake evaluate whether transdermal administration alpha sub adrenergic receptor agonist clonidine use pharmacologic mean blunt stress response throughout perioperative period design double blind placebo control clinical trial patient undergo pancreatico biliary surgery set operating room surgical intensive care unit major university teach hospital patient forty patient schedule major upper abdominal surgery intervention patient receive either clonidine mg orally clonidine tt patch even surgery mg orally call operating room match oral transdermal placebo measurement main result heart rate systemic arterial blood pressure plasma catecholamine clonidine interleukin concentration hr urine cortisol nitrogen excretion measure day surgery daily thereafter hr postoperatively preoperative transdermal oral clonidine administration result therapeutic plasma clonidine concentration throughout perioperative period sem micro g ml clonidine reduce preoperative epinephrine norepinephrine concentration plasma catecholamine concentration increase group follow surgery markedly low throughout postoperative period patient receive clonidine patient receive clonidine reduce frequency rate post operative hypertension clonidine effect plasma interleukin concentration urine cortisol excretion urine nitrogen excretion adverse effect clonidine administration observe conclusion combine administration oral transdermal clonidine effectively attenuate catecholamine response surgical stress throughout postoperative study period clonidine administration produce specific sympatholytic effect since element stress response attenuate undesirable side effect note sustain sympatholytic effect observe suggest alpha adrenergic receptor agonist may offer pharmacologic mean modify sympathoadrenal response injury may useful reduce perioperative complication crit care med,Dorman T,1997,Crit Care Med,https://doi.org/10.1097/00003246-199707000-00015,9233740,Dorman T; Clarkson K; Rosenfeld BA; Shanholtz C; Lipsett PA; Breslow MJ,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000279: Administration, Cutaneous; D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D002395: Catecholamines; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006854: Hydrocortisone; D015850: Interleukin-6; D008297: Male; D008875: Middle Aged; D009584: Nitrogen; D011183: Postoperative Complications; D013312: Stress, Physiological; D013514: Surgical Procedures, Operative; D013564: Sympathetic Nervous System; D013565: Sympatholytics",,,https://openalex.org/W2068502888,68,8,1,2749,397,19,en,en
false,comparison fluoxetine bupropion placebo treatment premenstrual dysphoric disorder,serotonergic antidepressant show effective treatment premenstrual dysphoric disorder pmdd efficacy nonserotonergic antidepressant less well study study two center parallel design placebo control randomized trial fluoxetine bupropion placebo woman pmdd thirty four woman pmdd complete month single blind placebo month fluoxetine mg day n bupropion mg three time daily n placebo n clinical global impression cgi scale expand form hamilton rating scale depression ham global assessment scale gas rating obtain premenstrually three treatment cycle three treatment group differ significantly efficacy cgi rating fluoxetine superior bupropion placebo comparison posttreatment pretreatment ham gas score demonstrate significant superior efficacy fluoxetine compare placebo posttreatment ham gas score bupropion intermediate significantly different fluoxetine placebo summary fluoxetine significantly superior bupropion placebo effective treatment pmdd although improvement bupropion note medication well tolerate patient satisfaction far great fluoxetine j clin psychopharmacol,Pearlstein TB,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199708000-00004,9241004,Pearlstein TB; Stone AB; Lund SA; Scheft H; Zlotnick C; Brown WA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D004311: Double-Blind Method; D005260: Female; D005473: Fluoxetine; D006801: Humans; D008875: Middle Aged; D011293: Premenstrual Syndrome; D011569: Psychiatric Status Rating Scales",,,https://openalex.org/W2040316052,100,15,1,1439,244,11,en,en
false,economic health state utility determination schizophrenic patient treat risperidone haloperidol,current study use utility analysis assess economic quality life benefit risperidone patient chronic schizophrenia retrospective analysis perform positive negative syndrome symptom panss data obtain publish canadian multicenter risperidone trial part north american trial cluster analysis apply endpoint panss score include patient n identify three cluster represent patient mild moderate severe symptomatology narrative health state profile write cluster psychiatric nurse washington dc ask assign preference rating one use linear analog standard gamble sg method mean utility value confidence interval obtain sg rating three health state profile mild moderate severe mild health state include majority risperidone mg treat patient rat nurse great utility moderate health state compose majority haloperidol treat patient result utility evaluation sg nurse relate clinical outcome three six drug treatment group n multiply percentage patient three cluster baseline end point receive risperidone mg day haloperidol placebo utility value health state assign cluster gain utility risperidone treat patient time high compare haloperidol treat patient time high compare placebo multiply gain utility treatment remain expected life span men woman find risperidone treat patient obtain twice many quality adjust year haloperidol patient incremental drug treatment cost divide incremental benefit risperidone versus haloperidol find yield favorable generally accept cost utility ratio,Chouinard G,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199708000-00010,9241010,Chouinard G; Albright PS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D002170: Canada; D002908: Chronic Disease; D003362: Cost-Benefit Analysis; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006304: Health Status; D006801: Humans; D008297: Male; D008875: Middle Aged; D019057: Quality-Adjusted Life Years; D012189: Retrospective Studies; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W2331170524,115,14,1,2162,380,10,en,en
false,hepatotoxicity clozapine,two hundred thirty eight patient treat either haloperidol clozapine investigate shed light incidence severity antipsychotic induce liver enzyme increase serum glutamic pyruvic transaminase sgpt increase frequently see treatment group analyze incidence rate patient increase liver enzyme value serum glutamic oxaloacetic transaminase sgpt gamma glutamyl transpeptidase high twice upper limit normal range clozapine treat patient show sgpt increase significantly frequently patient treat haloperidol patient high clozapine plasma level male patient high risk sgpt increase least increase different enzyme remit within first week treatment general author conclude clozapine induce liver enzyme elevation seem common mostly transient phenomenon j clin psychopharmacol,Hummer M,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199708000-00012,9241012,Hummer M; Kurz M; Kurzthaler I; Oberbauer H; Miller C; Fleischhacker WW,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D000410: Alanine Transaminase; D014150: Antipsychotic Agents; D001219: Aspartate Aminotransferases; D056486: Chemical and Drug Induced Liver Injury; D003024: Clozapine; D004798: Enzymes; D005260: Female; D006220: Haloperidol; D006801: Humans; D008111: Liver Function Tests; D008297: Male; D011446: Prospective Studies; D012727: Sex Characteristics,,,https://openalex.org/W2044222093,27,3,1,1050,171,7,en,en
false,desmethylselegiline metabolite selegiline irreversible inhibitor monoamine oxidase type b human,selegiline irreversible selective inhibitor monoamine oxidase type b mao b metabolize desmethylselegiline levomethamphetamine levoamphetamine animal experiment desmethylselegiline also show irreversible inhibitor mao b study investigate inhibitory potential mao b pharmacokinetics desmethylselegiline human double blind crossover trial perform compare effect single dose mg selegiline desmethylselegiline mao b platelet activity urinary excretion phenylethylamine consider parameter mao b inhibition also measure concentration selegiline desmethylselegiline metabolite measure plasma administration two compound ten healthy volunteer participate study clear inhibition platelet mao b compound desmethylselegiline cause inhibition platelet mao b compare cause selegiline maximal inhibition desmethylselegiline reach significantly later desmethylselegiline time reach maximal inhibition max hour selegiline administration max hour platelet mao b activity return baseline level within week thus reflect irreversible nature inhibition compound cumulative hour excretion phenylethylamine low desmethylselegiline selegiline administration three major metabolite selegiline could detect plasma selegiline administration levoamphetamine metabolite desmethylselegiline area concentration time curve time hour auc desmethylselegiline time high selegiline suggest good bioavailability desmethylselegiline desmethylselegiline orally active irreversible inhibitor mao b could possibly use treat parkinson disease way selegiline,Heinonen EH,1997,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1997.tb04342.x,9243353,Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000662: Amphetamines; D000978: Antiparkinson Agents; D001792: Blood Platelets; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D008996: Monoamine Oxidase Inhibitors; D010627: Phenethylamines; D012642: Selegiline,,,https://openalex.org/W1980456506,115,18,1,2094,336,16,en,en
false,double blind comparative study clozapine versus chlorpromazine chinese patient treatment refractory schizophrenia,clozapine show superior effectiveness compare classic neuroleptic treat refractory schizophrenia caucasian efficacy safety chinese adequately study forty chinese schizophrenic patient recruit week double blind comparative trial twenty one patient randomly assign clozapine treatment chlorpromazine treatment average dose mg day clozapine chlorpromazine respectively result show six clozapine treat patient improvement brief psychiatric rating scale score classify responder whereas none chlor promazine treat patient classify responder degree improvement positive symptom negative symptom brief psychiatric rating scale score clozapine group inversely correlate severity negative symptom entry trial two clozapine treat patient withdraw study one leukopenia nausea vomit hypotension chlorpromazine treatment prematurely discontinue two patient jaundice sedation one severe weight loss kg rate moderate severe sialorrhea high clozapine treat patient two clozapine treat patient two chlorpromazine treat patient show significant improvement previously exist tardive dyskinesia one chlorpromazine treat patient exhibit aggravation tardive dyskinesia result study indicate clozapine treatment might advantage chlorpromazine chinese schizophrenic patient refractory typical neuroleptic treatment,Hong CJ,1997,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199705000-00001,9248867,Hong CJ; Chen JY; Chiu HJ; Sim CB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D002746: Chlorpromazine; D003024: Clozapine; D004311: Double-Blind Method; D004351: Drug Resistance; D005260: Female; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W1988897630,127,14,1,1820,279,11,en,en
false,oligoantigenic diet influence hyperactive conduct disorder child control trial,crossover placebo control double blind design use examine effectiveness oligoantigenic diet child hyperactive disruptive behavior disorder effect diet compare yield stimulant medication methylphenidate study conduct inpatient unit department child adolescent psychiatry central institute mental health mannheim change behavior measure standardize situation train raters include behavior assessment test cpt pat free play situation school twelve child show significant behavioral improvement two behavior rating diet relative control diet condition methylphenidate use child yield responder diet amount positive change behavior receive treatment although effective minority child dietary treatment neglect possible access treat hyperactive disruptive child merit investigation,Schmidt MH,1997,Eur Child Adolesc Psychiatry,https://doi.org/10.1007/bf00566671,9257090,Schmidt MH; Möcks P; Lay B; Eisert HG; Fojkar R; Fritz-Sigmund D; Marcus A; Musaeus B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002653: Child Behavior Disorders; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D005503: Food Additives; D006801: Humans; D007073: Immunoglobulin E; D008297: Male; D008774: Methylphenidate; D012720: Severity of Illness Index,,,https://openalex.org/W1976957375,95,10,2,1103,179,8,en,en
false,sense time child adhd effect duration distraction stimulant medication,recent theory adhd predict deficiency sense time disorder two study conduct test prediction evaluate effect interval duration distraction stimulant medication reproduction temporal duration child adhd study adhd child control age year test use time reproduction task subject reproduce interval four trial duration present distraction occur half trial control subject significantly accurate adhd child duration unaffected distraction adhd child contrast significantly less accurate distract group become less accurate increase duration reproduce study ii test three methylphenidate mph placebo time reproduction adhd child adhd child become less accurate increase duration distraction find reduce accuracy less effect mph evident result preliminary study seem support prediction sense time impair child adhd capacity accurately reproduce time interval adhd child seem improve administration stimulant medication,Barkley RA,1997,J Int Neuropsychol Soc,https://doi.org/10.1017/s1355617797003597,9260445,Barkley RA; Koplowitz S; Anderson T; McMurray MB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009483: Neuropsychological Tests; D011569: Psychiatric Status Rating Scales; D013997: Time Factors; D013998: Time Perception,,,https://openalex.org/W2158629929,95,17,1,1379,245,11,en,en
false,dose antipsychotic medication olanzapine,olanzapine new antipsychotic agent serotonin dopamine antagonism action efficacy treat overall psychopathology acute schizophrenia measure bprs total score demonstrate mg day versus placebo mg day range olanzapine comparable superior haloperidol superior efficacy negative depressive symptom show comparison haloperidol olanzapine favorable acute tardive extrapyramidal symptom profile relative haloperidol cause substantially less elevation serum prolactin dose related weight gain asymptomatic mild transaminase elevation occur olanzapine treat patient,Nemeroff CB,1997,J Clin Psychiatry,,9265916,Nemeroff CB,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,"D017109: Akathisia, Drug-Induced; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006220: Haloperidol; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011388: Prolactin; D011569: Psychiatric Status Rating Scales; D016032: Randomized Controlled Trials as Topic; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W149137007,47,6,1,689,99,5,en,en
false,randomize double blind placebo control crossover trial modafinil treatment excessive daytime sleepiness narcolepsy,seventy five patient meet international diagnostic criterion narcolepsy enrol week three period randomize crossover placebo control trial patient receive placebo modafinil mg modafinil mg divide dos morning noon evaluation occur baseline end week period compare placebo modafinil mg significantly increase mean sleep latency maintenance wakefulness test significant difference two modafinil mg also reduce combined number daytime sleep episode period severe sleepiness note sleep log likelihood fall asleep measure epworth sleepiness scale equally reduce modafinil dose level effect nocturnal sleep initiation maintenance architecture effect sleep apnea periodic leg movement neither dose interfere patient ability nap voluntarily day quantity quality nocturnal sleep modafinil produce change blood pressure heart rate either normotensive hypertensive patient significant adverse effect see mg dose associate nausea nervousness either placebo mg dose little mg daily dose modafinil therefore effective well tolerate treatment excessive daytime somnolence narcoleptic person,Broughton RJ,1997,Neurology,https://doi.org/10.1212/wnl.49.2.444,9270575,Broughton RJ; Fleming JA; George CF; Hill JD; Kryger MH; Moldofsky H; Montplaisir JY; Morehouse RL; Moscovitch A; Murphy WF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009290: Narcolepsy; D010919: Placebos; D011930: Reaction Time; D012890: Sleep; D012894: Sleep Stages; D016896: Treatment Outcome; D014851: Wakefulness,,,https://openalex.org/W2007702485,136,18,1,1534,260,11,en,en
false,multiple fix seroquel quetiapine patient acute exacerbation schizophrenia comparison haloperidol placebo,five fix atypical antipsychotic seroquel quetiapine evaluate delineate dose response relationship measure change baseline brief psychiatric rating scale bprs clinical global impression cgi modify scale assessment negative symptom sans summary score compare efficacy tolerability opposite placebo haloperidol three hundred sixty one patient north american center enter double blind placebo control trial acute exacerbation chronic schizophrenia dsm iii r patient complete single blind placebo washout phase randomize double blind treatment quetiapine mg daily haloperidol mg daily placebo evaluate weekly week end point significant difference p analysis covariance adjust mean change baseline identify four high quetiapine placebo bprs total bprs positive symptom cluster cgi severity illness item score quetiapine mg placebo sans summary score difference quetiapine haloperidol significant dose response model show significant linear quadratic function quetiapine dose primary efficacy variable notably significant safety concern identify dose increase quetiapine different placebo across dose range study regard incidence extrapyramidal symptom change prolactin concentration quetiapine well tolerate clinically effective treatment schizophrenia superior placebo comparable haloperidol reduce positive symptom range mg day reduce negative symptom dose mg day,Arvanitis LA,1997,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(97)00190-x,9270900,Arvanitis LA; Miller BG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D003987: Dibenzothiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2060802427,143,24,1,1858,313,10,en,en
false,clozapine withdrawal serotonergic dopaminergic mechanism,baldessarini et al note several case report rapid relapse abrupt withdrawal clozapine therapy mention case suggest mechanism could include follow rapid elimination clozapine brain enhance release dopamine brain stimulation dopamine dopamine receptor may become supersensitive regulate prolonged blockade clozapine therapy suggest basis thioridazine therapy might effective risperidone haloperidol treat clozapine withdrawalinduced relapse thioridazine ability block receptor administer dos similar clozapine carry randomize year trial compare clozapine typical neuroleptic drug usually haloperidol recent onset schizophrenic patient minimal positive symptom prior treatment neuroleptic,Meltzer HY,1997,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1997.01830200094013,9283512,Meltzer HY,article,D016430: Clinical Trial; D016420: Comment; D016422: Letter; D016449: Randomized Controlled Trial,"D003024: Clozapine; D004298: Dopamine; D006801: Humans; D011954: Receptors, Dopamine; D011985: Receptors, Serotonin; D012008: Recurrence; D012559: Schizophrenia; D012701: Serotonin; D013375: Substance Withdrawal Syndrome",,,https://openalex.org/W2081525292,62,8,1,1013,184,4,en,en
false,electrophysiological index information process methylphenidate responder,event relate potential erp study report positive deflection follow stimulus evaluation msec p hyperactive child augment methylphenidate mp study investigate p precede erp component use auditory oddball task attention deficit hyperactivity disorder adhd mismatch negativity negativity msec positivity msec msec p obtain control hyperkinetic child adhd child respond mp test two separate day receive either mp placebo control test difference find group erp component precede p p amplitude significantly large mp placebo differ control mp difference p amplitude unexpectedly occur response require p amplitude increase mp unexpected p suggest mp affect attention regulation,Winsberg BG,1997,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(96)00429-5,9285079,Winsberg BG; Javitt DC; Silipo GS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001289: Attention Deficit Disorder with Hyperactivity; D001519: Behavior; D000697: Central Nervous System Stimulants; D002648: Child; D004569: Electroencephalography; D018913: Event-Related Potentials, P300; D005260: Female; D006801: Humans; D008297: Male; D008606: Mental Processes; D008774: Methylphenidate; D011569: Psychiatric Status Rating Scales",,,https://openalex.org/W2059699110,84,8,1,975,168,9,en,en
false,blind control long term study comparative incidence treatment emergent tardive dyskinesia olanzapine haloperidol,back table content previous article next article full accessblind control long term study comparative incidence treatment emergent tardive dyskinesia olanzapine haloperidolpublished online apr http doi org ajp aboutsectionsview articleabstractpdf toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail view articleabstractobjective tardive dyskinesia serious common complication neuroleptic treatment olanzapine novel antipsychotic agent exhibit regional mesolimbic dopaminergic selectivity broad base pharmacology encompass serotonin dopamine muscarinic adrenergic receptor bind affinity author goal compare incidence tardive dyskinesia among patient receive olanzapine receive conventional dopamine antagonist haloperidol method data analyze three actively control blind long term responder study subject meet dsm iii r criterion schizophrenia schizophreniform disorder schizoaffective disorder treat olanzapine n mg day median day exposure haloperidol n mg day median day exposure evidence tardive dyskinesia baseline subject chronic disease course mean great year significant treatment group difference demographic disease characteristic abnormal involuntary movement scale research diagnostic criterion tardive dyskinesia use define comparative incidence rate long term treatment emergent tardive dyskinesia result incidence newly emergent tardive dyskinesia visit baseline final visit final two clinical assessment statistically significantly low among olanzapine treat patient among haloperidol treat patient conclusion find support atypical extrapyramidal symptom profile potential significantly low risk tardive dyskinesia olanzapine haloperidol among patient require maintenance antipsychotic treatment figuresreferencescited bydetailscited byschizophrenia relate psychosis december japanese society neuropsychopharmacology guideline pharmacological therapy schizophrenia august neuropsychopharmacology report vol recognition management antipsychotic induce parkinsonism old adult narrative review may medicine vol olanzapine induce concurrent tardive dystonia tardive dyskinesia schizophrenia intellectual disability case reportclinical psychopharmacology neuroscience vol antipsychotic reduction cessation antipsychotic specific treatment tardive dyskinesia february cochrane database systematic review vol world psychiatry vol risperidone versus placebo schizophrenia december cochrane database systematic review vol risperidone depot schizophrenia april cochrane database systematic review vol der nervenarzt vol neuroleptic drugsthe art psychotherapy vol asian journal psychiatry vol schizophrenia research vol safety olanzapine use adolescent july expert opinion drug safety vol incidence tardive dyskinesia study pharmacotherapy psychotic depressionjournal clinical psychopharmacology vol synapse vol les cahiers de l ann e g rontologique vol cochrane database systematic reviewsmovement disorder vol synapse vol tardive syndromesrapid improvement neuroleptic induce tardive dyskinesia levetiracetam interictal psychotic patientjournal clinical psychopharmacology vol revista brasileira de psiquiatria vol schizophrenia march neurotoxicity research vol european journal health economics vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol bipolar disorder vol p antipsychotic drugsnaunyn schmiedeberg archive pharmacology vol psychiatry research vol american journal health system pharmacy vol neuroleptic malignant syndrome aripiprazole agitate pediatric patientclinical neuropharmacology vol tardive syndromestardive dyskinesia geriatric patientsaging health vol treatment neuroleptic induce tardive dyskinesia levetiracetamjournal clinical psychopharmacology vol neuroleptic drugschild adolescent psychiatric clinic north america vol nature review drug discovery vol expert opinion pharmacotherapy vol expert opinion pharmacotherapy vol olanzapine versus ziprasidone result week double blind study patient schizophreniaalan breier paul h berg jogin h thakore dieter naber wagner f gattaz patrizia cavazzoni daniel j walker ph suraja roychowdhury ph john kane october american journal psychiatry vol tardive dyskinesia era typical atypical antipsychotic part incidence management strategy patient schizophrenia october canadian journal psychiatry vol cocaine abuse schizophrenic patient treat olanzapine versus haloperidoljournal nervous mental disease vol olanzapine schizophrenia april cochrane database systematic review vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol schizophrenia research vol molecular psychiatry vol bipolar disorder vol journal american geriatrics society vol british journal psychiatry vol british journal psychiatry vol british journal psychiatry vol expert opinion pharmacotherapy vol drug safety vol cns drug vol practical application pharmacotherapy long act risperidone patient schizophreniasamuel j keith luca pani psych beat nick robin emsley ph luis san ph martin turner robert conley paul scully r c psych pierre chue bernard lachaux september psychiatric service vol low risk tardive dyskinesia associate second generation antipsychotic systematic review year studieschristoph u correll stefan leucht john kane march american journal psychiatry vol atypical antipsychotic drug tardive dyskinesia relevance receptor affinity july journal psychopharmacology vol pharmacoeconomics german research article vol european archive psychiatry clinical neuroscience vol efficacy tolerability olanzapine patient schizophrenia lithuania week multicenter open label nonrandomized studycurrent therapeutic research vol schizophrenia research vol biological psychiatry vol control clinical trial vol neuroscience letter vol research developmental disability vol cns spectrum vol pharmacogenomics journal vol vol expert review neurotherapeutics vol drug safety vol muscarinic mechanism antipsychotic atypicalityprogress neuro psychopharmacology biological psychiatry vol pilot study access fitness facility exercise level olanzapine treat patient october canadian journal psychiatry vol psychopharmacology vol biological psychiatry vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol irish journal psychological medicine vol psychiatry clinical neuroscience vol journal neurochemistry vol current opinion psychiatry vol international clinical psychopharmacology vol neurologist vol bipolar disorder vol expert opinion pharmacotherapy vol atypical antipsychotic impact overall health quality life november journal american psychiatric nurse association vol supplantipsychotics law november australian new zealand journal psychiatry vol tardive dyskinesia elderly data prospective studypsychiatric annals vol epidemiology management acute antipsychotic induced movement disorder elderlypsychiatric annals vol antipsychotic medication adherence difference typical atypical agent christian r dolder pharm jonathan p lacro pharm laura b dunn dilip v jeste january american journal psychiatry vol clinical therapeutic vol neuroscience biobehavioral review vol progress neuro psychopharmacology biological psychiatry vol schizophrenia research vol australian new zealand journal psychiatry vol journal neurochemistry vol clinical neuropharmacology vol journal nervous mental disease vol expert review pharmacoeconomics outcome research vol cns drug vol topiramate induce depressionalexandra klufas diane thompson october american journal psychiatry vol agranulocytosis neutropenia typical atypical neurolepticsxiaohong hong xianxian wang october american journal psychiatry vol quetiapine relate tardive dyskinesia nassir ghaemi james ko b october american journal psychiatry vol atypical antipsychotic use treat adolescent young adult developmental disability october canadian journal psychiatry vol rehospitalization rate chronically ill schizophrenic patient discharge regimen risperidone olanzapine conventional antipsychoticsjonathan rabinowitz ph pesach lichtenberg zeev kaplan mordechai mark danielle nahon michael davidson february american journal psychiatry vol mejor de la discinesia tard en una paciente bipolar con olanzapina may european psychiatry ed espa ola vol atypical antipsychotic new direction new challenge treatment schizophreniaannual review medicine vol novel augmentation strategy treat resistant major depressionrichard c shelton gary tollefson ph mauricio tohen dr p h stephen stahl kimberley gannon ph thomas g jacob william r bura b sc frank p bymaster sc wei zhang ph kimberley spencer b sc peter feldman ph herbert meltzer january american journal psychiatry vol synapse vol synapse vol international journal geriatric psychiatry vol international journal geriatric psychiatry vol international journal geriatric psychiatry vol medical clinic north america vol schizophrenia research vol european neuropsychopharmacology vol european neuropsychopharmacology vol psychiatry clinical neuroscience vol clinical neuropharmacology vol journal american academy child adolescent psychiatry vol journal psychiatric practice vol paediatric drug vol olanzapine preclinical clinical profile novel antipsychotic agent june cns drug review vol improvement tardive dyskinesia bipolar patient olanzapine april european psychiatry vol remission tardive dyskinesia change flupenthixol olanzapine april european psychiatry vol low incidence persistent tardive dyskinesia elderly patient dementia treat risperidonedilip v jeste akiko okamoto sc judy napolitano r n john kane rick martinez july american journal psychiatry vol current status tardive dyskinesia june australian new zealand journal psychiatry vol switch antipsychotic therapy june annals pharmacotherapy vol clinical therapeutic vol european neuropsychopharmacology vol child adolescent psychiatric clinic north america vol journal american academy child adolescent psychiatry vol journal psychiatric practice vol vol expert opinion pharmacotherapy vol expert opinion pharmacotherapy vol pharmacotherapy vol drug safety vol drug age vol cns drug vol clinical drug investigation vol world journal biological psychiatry vol world journal biological psychiatry vol postgraduate medicine vol letter editor november canadian journal psychiatry vol olanzapine versus placebo treatment acute maniamauricio tohen dr p h todd sanger ph susan l mcelroy gary tollefson ph k n roy chengappa david g daniel frederick petty ph franca centorrino richard wang ph starr l grundy b sc pharm michael g greaney thomas g jacob stacy r david ph verna toma b olanzapine hgeh study group may american journal psychiatry vol olanzapine psychopharmacology clinical efficacy adverse effect july hospital pharmacy vol atypical antipsychotic part ii adverse effect drug interaction cost june annals pharmacotherapy vol olanzapine versus haloperidol treatment first episode psychosistodd sanger ph jeffery lieberman mauricio tohen dr p h starr grundy b sc pharm charles beasley jr gary tollefson ph january american journal psychiatry vol biological psychiatry vol biological psychiatry vol biological psychiatry vol antipsychotic drugsphysical medicine rehabilitation clinic north america vol current opinion psychiatry vol current opinion psychiatry vol journal clinical psychopharmacology vol american journal geriatric psychiatry vol journal american geriatrics society vol current medical research opinion vol british journal psychiatry vol british journal psychiatry vol british journal psychiatry vol british journal psychiatry vol british journal psychiatry vol emerge drug vol annals internal medicine vol prospective study tardive dyskinesia elderly rate risk factorsmargaret g woerner ph jose j alvir dr p h bruce l saltz jeffrey lieberman john kane november american journal psychiatry vol novel antipsychotic patient care state hospital june annals pharmacotherapy vol typical atypical antipsychotic adolescent schizophrenia efficacy tolerability differential sensitivity extrapyramidal symptom august canadian journal psychiatry vol comment june australian new zealand journal psychiatry vol pediatric clinic north america vol schizophrenia research vol psychiatric bulletin vol volume issue september page metric pdf download history publish online april publish print september,Tollefson GD,1997,Am J Psychiatry,https://doi.org/10.1176/ajp.154.9.1248,9286184,Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006801: Humans; D015994: Incidence; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D010919: Placebos; D011618: Psychotic Disorders; D012559: Schizophrenia; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W1847831565,135,18,1,16847,3210,339,en,en
false,oral clonidine premedication alter efficacy simulate intravenous test dose contain low dose epinephrine awake volunteer,background clonidine premedication modify hemodynamic response sympathomimetics present study design test whether clonidine alter response small intravenous dose epinephrine might use epidural test dose method healthy volunteer four series determination perform random order separate minimum h premedication follow intravenous saline ml premedication follow intravenous test dose contain ml lidocaine microg epinephrine oral clonidine microg kg h hemodynamic determination follow intravenous saline oral clonidine follow intravenous epinephrine contain test dose systolic blood pressure sbp heart rate hr measure continuously symptom associate central nervous system toxicity note result test dose injection hr sbp increase without clonidine premedication confidence interval maximum hr increase without clonidine beat min respectively indicate one could absolutely certain everyone would develop positive hr response hr increase gt beat min volunteer give epinephrine without clonidine volunteer give saline calculate sensitivity specificity positive negative predictive value base conventional hr criterion unaltered clonidine subjective symptom affect clonidine conclusion oral clonidine alter efficacy epinephrine contain test use detect intravascular injection,Tanaka M,1997,Anesthesiology,https://doi.org/10.1097/00000542-199708000-00015,9286892,Tanaka M; Nishikawa T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D001794: Blood Pressure; D003000: Clonidine; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D008297: Male; D011292: Premedication; D013565: Sympatholytics; D014851: Wakefulness",,,https://openalex.org/W2003359037,144,20,1,1763,302,10,en,en
false,comparison epidural butorphanol plus clonidine butorphanol alone postoperative pain relief,epidural butorphanol show produce effective analgesia less side effect morphine relatively short duration clonidine alpha adrenergic agonist report provide correct pain relief epidural administration furthermore epidural clonidine show potentiate analgesic effect epidural morphine present study undertake evaluate analgesic side effect epidural administration ep butorphanol clonidine give consent adult patient schedule abdominal surgery enrol study prior anesthesia induction indwell lumbar epidural catheter place patient receive general anesthesia inhalation anesthetic without narcotic analgesic postoperative period patient first complain pain divide equal group patient randomize double blind fashion group receive ep butorphanol mg group ii receive ep butorphanol mg plus clonidine microgram patient observe pain relief sedation vital sign arterial blood gas study adverse effect h onset pain relief epidural butorphanol begin min peak min duration action last h combination butorphanol clonidine numerically superior pain relief butorphanol first min attain statistical significant difference duration action combination group similar butorphanol alone incidence adverse effect similar group except hypotension pronounce sedation observe group ii study show addition clonidine epidural butorphanol enhance analgesic effect significant manner reduce adverse effect combination seem offer advantage clinical use,Tan PH,1997,Acta Anaesthesiol Sin,,9293649,Tan PH; Chou AK; Perng JS; Chung HC; Lee CC; Mok MS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000701: Analgesics, Opioid; D002077: Butorphanol; D003000: Clonidine; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010149: Pain, Postoperative; D012119: Respiration",,,https://openalex.org/W2410186728,103,14,1,2009,329,10,en,en
false,long term stimulant treatment child attention deficit hyperactivity disorder symptom,want study effect amphetamine symptom attention deficit hyperactivity disorder adhd long period report previous study central stimulant condition sixty two child age year meet dsm iii r symptom criterion adhd participate parallel group design randomize double blind placebo control study amphetamine treatment treatment restrict child pure adhd ie comorbid diagnosis amphetamine group child receive active treatment month amphetamine clearly superior placebo reduce inattention hyperactivity disruptive behavior problem tend lead improve result wechsler intelligence scale child revise treatment failure rate considerably low time treatment failure long amphetamine group adverse effect relatively mild result long term placebo control study central stimulant amphetamine treatment adhd indicate remain positive effect drug month start treatment,Gillberg C,1997,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1997.01830210105014,9294377,Gillberg C; Melander H; von Knorring AL; Janols LO; Thernlund G; Hägglöf B; Eidevall-Wallin L; Gustafsson P; Kopp S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D015746: Abdominal Pain; D000661: Amphetamine; D001289: Attention Deficit Disorder with Hyperactivity; D001714: Bipolar Disorder; D000697: Central Nervous System Stimulants; D002648: Child; D015897: Comorbidity; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006261: Headache; D006801: Humans; D008297: Male; D010919: Placebos; D012893: Sleep Wake Disorders; D016896: Treatment Outcome; D014888: Wechsler Scales,,,https://openalex.org/W2158377281,96,10,1,1176,186,5,en,en
false,national institute mental health collaborative multimodal treatment study child adhd mta,collaborative multimodal treatment study child attention deficit hyperactivity disorder adhd mta first child multisite cooperative agreement treatment study child conduct national institute mental health rockville md examine long term effectiveness medication v behavioral treatment v treatment adhd compare state art treatment routine community care parallel group design child age year adhd site thoroughly assess randomize condition medication alone psychosocial treatment alone combination community comparison first group treat month reassess periodically month designer meet follow challenge frame clinically relevant primary question define target population choice intensity integration combination treatment fair comparison combine scientific control standardization clinical flexibility implement control clinical trial nonclinical set school control others innovative solution include extensive decision algorithm manualized adaptation treatment specific need,Arnold LE,1997,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1997.01830210113015,9294378,Arnold LE; Abikoff HB; Cantwell DP; Conners CK; Elliott G; Greenhill LL; Hechtman L; Hinshaw SP; Hoza B; Jensen PS; Kraemer HC; March JS; Newcorn JH; Pelham WE; Richters JE; Schiller E; Severe JB; Swanson JM; Vereen D; Wells KC,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D002648: Child; D002985: Clinical Protocols; D003131: Combined Modality Therapy; D003657: Decision Making; D003913: Dextroamphetamine; D005260: Female; D006291: Health Policy; D006302: Health Services Research; D006801: Humans; D007099: Imipramine; D008297: Male; D008774: Methylphenidate; D009315: National Institute of Mental Health (U.S.); D018579: Patient Selection; D010389: Pemoline; D012107: Research Design; D014481: United States,,,https://openalex.org/W2157719972,108,17,1,1301,216,6,en,en
false,comparison clozapine haloperidol hospitalize patient refractory schizophrenia,clozapine relatively expensive antipsychotic drug widely use treat patient refractory schizophrenia low incidence extrapyramidal side effect may cause agranulocytosis long term assessment effect symptom social functioning use cost health care conduct randomize one year double blind comparative study clozapine patient haloperidol patient veteran affair medical center participant refractory schizophrenia hospitalize disease day previous year patient receive case management social rehabilitation service clinically indicated clozapine group patient percent continue assign treatment entire year compare percent patient haloperidol group p judge accord positive negative syndrome scale schizophrenia patient clozapine group percent low symptom level haloperidol group follow evaluation mean score v p difference quality life scale significant intention treat analysis significant among patient cross treatment p one year period patient assign clozapine mean day hospitalization psychiatric reason patient assign haloperidol vs day p use outpatient service v unit service p total per caput cost society high clozapine group haloperidol group p per caput cost antipsychotic drug clozapine group haloperidol group p patient assign clozapine less tardive dyskinesia extrapyramidal side effect agranulocytosis develop three patient clozapine group recover fully patient refractory schizophrenia high level hospital use clozapine somewhat effective haloperidol side effect similar overall cost,Rosenheck R,1997,N Engl J Med,https://doi.org/10.1056/nejm199709183371202,9295240,Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D003365: Costs and Cost Analysis; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006760: Hospitalization; D006801: Humans; D007902: Length of Stay; D008297: Male; D010349: Patient Compliance; D011788: Quality of Life; D012559: Schizophrenia,,,https://openalex.org/W2329708303,96,12,1,2256,392,12,en,en
false,long term follow child mental retardation borderline intellectual functioning adhd,fifty two child age year moderate retardation borderline intellectual functioning recontacted month follow participation double blind placebo control trial methylphenidate mph sixty nine percent subject continue prescribe medication behavior control follow sample evidence improvement two third continue rat th percentile hyperactivity index parent conners fact subject receive inpatient psychiatric treatment time initial mph trial follow finally subject high initial rating parent conners conduct problem scale likely suspend school receive inpatient psychiatric treatment subject low initial rating result suggest child adhd mental retardation borderline intellectual function continue exhibit significant symptom associate attention deficit hyperactivity disorder adhd follow early conduct problem predictive continue behavioral difficulty,Handen BL,1997,J Abnorm Child Psychol,https://doi.org/10.1023/a:1025760302598,9304445,Handen BL; Janosky J; McAuliffe S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003071: Cognition; D019955: Conduct Disorder; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008607: Intellectual Disability; D008297: Male; D008774: Methylphenidate; D011379: Prognosis; D016896: Treatment Outcome,,,https://openalex.org/W1574054177,101,12,1,1160,180,6,en,en
false,safety issue use methylphenidate american perspective,methylphenidate widely use psychotropic medication child u well tolerate efficacious treatment attention deficit hyperactivity disorder associate serious adverse effect however abuse methylphenidate purpose experience high hazardous use methylphenidate combination medication increase risk adverse effect drug interaction good communication physician patient family together monitoring increase likelihood methylphenidate therapy effective adverse consequence,Rappley MD,1997,Drug Saf,https://doi.org/10.2165/00002018-199717030-00001,9306050,Rappley MD,article,D016428: Journal Article; D016454: Review,D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D018849: Controlled Clinical Trials as Topic; D015259: Dopamine Agents; D004311: Double-Blind Method; D004347: Drug Interactions; D016903: Drug Monitoring; D006801: Humans; D008774: Methylphenidate; D014481: United States,,,https://openalex.org/W2021434149,67,10,1,654,104,5,en,en
false,bupropion sexual function,many antidepressant agent interfere sexual function purpose single blind prospective study determine sexual side effect positive negative amino ketone antidepressant bupropion group nondepressed diabetic men somatic erectile dysfunction fourteen men participate week protocol consist sequentially week baseline test week placebo week bupropion participant also complete daily weekly questionnaire concern sexual functioning team investigator rat various dimension sexual function every week addition variety physiologic measure relevant either erectile function neural vascular system underlie sexual response assess baseline bupropion treatment result indicate neither subjective objective measure erectile overall sexual functioning worsen bupropion fact several measure suggest trend toward improve sexual functioning furthermore diabetic control unaffected bupropion administration give lack adverse effect sexual function along potential improve erectile response bupropion may provide attractive choice treatment depression diabetic men others sexual dysfunction concern,Rowland DL,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199710000-00003,9315985,Rowland DL; Myers L; Culver A; Davidson JM,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003925: Diabetic Angiopathies; D003929: Diabetic Neuropathies; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D007172: Erectile Dysfunction; D006801: Humans; D018783: Impotence, Vasculogenic; D007989: Libido; D008297: Male; D008875: Middle Aged; D010410: Penile Erection; D011446: Prospective Studies; D016037: Single-Blind Method",,,https://openalex.org/W2094648320,29,4,1,1368,213,9,en,en
false,double blind comparison olanzapine versus risperidone treatment schizophrenia psychotic disorder,olanzapine risperidone second generation antipsychotic agent represent two different pharmacologic strategy although share vitro property differ virtue chemical structure spectrum receptor bind affinity animal neuropharmacology pharmacokinetics vivo neuroimaging profile base difference hypothesize two compound would show distinct safety efficacy characteristic test hypothesis international multicenter double blind parallel group week prospective study conduct patient meet dsm iv criterion schizophrenia schizophreniform disorder schizoaffective disorder result study indicate olanzapine risperidone safe effective management psychotic symptom however olanzapine demonstrate significantly great efficacy negative symptom scale assessment negative symptom summary score well overall response rate decrease positive negative syndrome scale total score furthermore statistically significantly great proportion olanzapine treat risperidone treat patient maintain response week base kaplan meier survival curve incidence extrapyramidal side effect hyperprolactinemia sexual dysfunction statistically significantly low olanzapine treat risperidone treat patient addition statistically significantly adverse event report olanzapine treat patient risperidone treat counterpart thus differential preclinical profile two drug also evident control clinical investigation olanzapine seem risk versus benefit advantage,Tran PV,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199710000-00010,9315992,Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009460: Neurologic Examination; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D011788: Quality of Life; D018967: Risperidone; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1983133139,120,15,1,1819,265,11,en,en
false,clozapine blunts n methyl aspartate antagonist induce psychosis study ketamine,several line evidence suggest glutamatergic n methyl aspartate nmda receptor involve antipsychotic efficacy atypical antipsychotic agent clozapine clinical data interaction clozapine mechanism action nmda receptor function lack secondary paucity pharmacologic probe nmda system utilize double blind placebo control infusion paradigm subanesthetic nmda antagonist ketamine test hypothesis clozapine would blunt ketamine induce psychotic symptom schizophrenic patient ten schizophrenic patient underwent ketamine infusion antipsychotic drug free also treatment clozapine antipsychotic drug free patient experience increase rating positive negative symptom clozapine treatment significantly blunt ketamine induce increase positive symptom data suggest nmda receptor function may involve unique antipsychotic efficacy clozapine,Malhotra AK,1997,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(96)00546-x,9325559,Malhotra AK; Adler CM; Kennison SD; Elman I; Pickar D; Breier A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D004311: Double-Blind Method; D018691: Excitatory Amino Acid Antagonists; D005260: Female; D006801: Humans; D007649: Ketamine; D008297: Male; D011569: Psychiatric Status Rating Scales; D016194: Receptors, N-Methyl-D-Aspartate; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W1972253384,89,10,1,1044,147,7,en,en
false,influence clonidine psychopathological endocrine respiratory effect cholecystokinin tetrapeptide patient panic disorder,influence clonidine pretreatment psychopathological endocrine respiratory effect cholecystokinin tetrapeptide cck characterize patient panic disorder dsm iii r give microgram cck v hour separate study day randomize double blind design additionally infuse microgram clonidine placebo hour cck patient experience symptom attack effect clonidine panic psychopathology blood gas parameter observe cck clonidine condition pituitary release adrenocorticotropin acth prolactin seemingly enhance compare placebo result suggest cck induce panic attack suppressible presynaptic alpha receptor stimulation moreover point synergistic postsynaptic action clonidine cck upon pituitary hormone secretion diverge site action might possibly explain discrepancy psychopathological alteration stress hormone secretion,Kellner M,1997,Psychopharmacology (Berl),https://doi.org/10.1007/s002130050371,9335081,Kellner M; Yassouridis A; Jahn H; Wiedemann K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000316: Adrenergic alpha-Agonists; D000324: Adrenocorticotropic Hormone; D000328: Adult; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D013006: Growth Hormone; D006801: Humans; D006854: Hydrocortisone; D008297: Male; D008875: Middle Aged; D016584: Panic Disorder; D011388: Prolactin; D012119: Respiration; D013758: Tetragastrin,,,https://openalex.org/W1971636180,143,18,1,1065,163,10,en,en
false,comparison sustain release bupropion placebo smoke cessation,trial antidepressant medication smoke cessation mix result conduct double blind placebo control trial sustain release form bupropion smoke cessation exclude smoker current depression history major depression subject randomly assign receive placebo bupropion dose mg per day seven week target quit date target quit date one week begin treatment brief counseling provide base line weekly treatment week self report abstinence confirm carbon monoxide concentration expire air ppm less end seven week treatment rate smoke cessation confirm carbon monoxide measurement percent placebo group percent mg group percent mg group percent mg group p one year respective rate percent percent percent percent rate mg group p mg group p mg group p significantly good placebo group among subject continuously abstinent end treatment mean absolute weight gain inversely associate dose gain kg placebo group kg mg mg group kg mg group p effect treatment observe depression score measure serially beck depression inventory thirty seven subject stop treatment prematurely adverse event frequency similar among group sustain release form bupropion effective smoke cessation accompany reduce weight gain minimal side effect many participant group smoke one year,Hurt RD,1997,N Engl J Med,https://doi.org/10.1056/nejm199710233371703,9337378,Hurt RD; Sachs DP; Glover ED; Offord KP; Johnston JA; Dale LC; Khayrallah MA; Schroeder DR; Glover PN; Sullivan CR; Croghan IT; Sullivan PM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D003863: Depression; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009538: Nicotine; D016540: Smoking Cessation; D013375: Substance Withdrawal Syndrome; D014029: Tobacco Use Disorder; D015430: Weight Gain",,,https://openalex.org/W2317321545,77,10,1,1974,368,13,en,en
false,comparison quetiapine chlorpromazine treatment schizophrenia,week double blind randomize multicentre parallel group study conduct compare efficacy quetiapine seroquel n chlorpromazine n hospitalize patient acute exacerbation subchronic chronic schizophrenia schizophreniform disorder tolerabilities two treatment also compare mean daily quetiapine chlorpromazine end study mg mg respectively treatment effective treatment positive negative symptom trend towards superior efficacy quetiapine quetiapine group low incidence adverse event chlorpromazine group low incidence treatment emergent extrapyramidal symptom quetiapine associate sustain increase serum prolactin clinical data support preclinical profile quetiapine atypical antipsychotic agent,Peuskens J,1997,Acta Psychiatr Scand,https://doi.org/10.1111/j.1600-0447.1997.tb10162.x,9350955,Peuskens J; Link CG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D002746: Chlorpromazine; D003987: Dibenzothiazepines; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012720: Severity of Illness Index; D015430: Weight Gain,,,https://openalex.org/W2119369900,79,11,1,949,155,7,en,en
false,epidural epinephrine clonidine,background know whether epidural epinephrine analgesic effect per se segmental distribution clonidine epidural analgesia effect temporal summation different type noxious stimulus unknown aim study clarify issue method fifteen healthy volunteer receive epidurally l l l l ml either epinephrine microg saline clonidine microg kg saline saline alone three different day randomize double blind cross fashion pain rating electrical stimulation pinprick cold perception record dermatome l l forehead pressure pain tolerance threshold record ear pain threshold single repeat temporal summation electrical stimulation sural nerve determine result epinephrine significantly reduce sensitivity pinprick l l clonidine significantly decrease pain rating electrical stimulation l l sensitivity pinprick cold l l increase pressure pain tolerance threshold increase threshold single repeat stimulation sural nerve conclusion epidural epinephrine clonidine produce segmental hypoalgesia clonidine bolus administer spinal level correspond painful area clonidine inhibit temporal summation elicit repeat electrical stimulation may therefore attenuate spinal cord hyperexcitability,Curatolo M,1997,Anesthesiology,https://doi.org/10.1097/00000542-199710000-00011,9357879,Curatolo M; Petersen-Felix S; Arendt-Nielsen L; Zbinden AM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000328: Adult; D015360: Analgesia, Epidural; D003000: Clonidine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004837: Epinephrine; D005260: Female; D006801: Humans; D008297: Male; D010146: Pain",,,https://openalex.org/W2038368560,35,4,1,1531,255,12,en,en
false,randomise control trial growth effect hydrocortisone congenital adrenal hyperplasia,influence mg daily oral hydrocortisone fludrocortisone mg day growth laboratory find evaluate prospective randomise crossover trial month child hydroxylase deficiency nine non salt loser fludrocortisone stop six month period height velocity significantly decrease treatment mg compare mg sensitive indicator corticosteroid treatment excess dose dependent effect upon plasma concentration hydroxyprogesterone testosterone androstenedione find increased value still detect half determination make mg period height velocity hydroxyprogesterone concentration positively correlate growth hormone response clonidine stimulation insulin like growth factor concentration within reference value difference treatment period withdrawal fludrocortisone result difference non salt loser conclude mg hydrocortisone depress growth child congenital adrenal hyperplasia full suppression even normalisation plasma concentration hydroxyprogesterone androgen consider treatment goal instead indication corticosteroid treatment excess,Silva IN,1997,Arch Dis Child,https://doi.org/10.1136/adc.77.3.214,9370898,Silva IN; Kater CE; Cunha CF; Viana MB,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D019326: 17-alpha-Hydroxyprogesterone; D000293: Adolescent; D000312: Adrenal Hyperplasia, Congenital; D000735: Androstenedione; D001827: Body Height; D002648: Child; D002675: Child, Preschool; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D005260: Female; D006130: Growth Disorders; D006801: Humans; D006854: Hydrocortisone; D007223: Infant; D008297: Male; D006899: Mixed Function Oxygenases; D011446: Prospective Studies; D013739: Testosterone",,,https://openalex.org/W2001909054,96,12,1,1489,247,9,en,en
false,acute long term effect olanzapine compare placebo haloperidol serum prolactin concentration,prolactin elevation common persistent event currently market antipsychotic exclude clozapine elevation associate acute galactorrhea amenorrhea chronic predisposition osteoporosis treatment emergent adverse event one defining criterion atypical antipsychotic relative lack persistent prolactinemia double blind placebo n haloperidol hal mg day n control trial three dose range olanzapine olz l mg day n olz mg day n olz h mg day n treatment schizophrenia afford opportunity assess temporal course influence olanzapine haloperidol serum prolactin concentration consistent potent antagonism haloperidol associate statistically significantly high incidence treatment emergent prolactin elevation see placebo p week therapy expectedly elevation also persistent week contrast olanzapine associate treatment emergent prolactin elevation low magnitude transient week olz h olz olz l treatment group exhibit treatment emergent prolactin elevation mean increase nmol l respectively haloperidol mean increase nmol l olz olz h treatment group week incidence treatment emergent prolactin elevation differ statistically significantly placebo incidence elevation mean increase prolactin concentration less see haloperidol furthermore treatment week three olanzapine group exhibit incidence treatment emergent prolactin elevation comparable placebo statistically significantly less observe haloperidol rapid adaptation observe temporal course prolactin elevation associate olanzapine base categorical analysis treatment emergent high value analysis temporal change mean concentration contrast haloperidol magnitude treatment emergent elevation associate olanzapine minimal rate elevation approximately one half one third observe haloperidol significantly transient olanzapine even high mg day use associate persistent elevation prolactin consistent atypical pharmacologic profile,Crawford AM,1997,Schizophr Res,https://doi.org/10.1016/s0920-9964(97)00036-4,9376336,Crawford AM; Beasley CM; Tollefson GD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D016009: Chi-Square Distribution; D003430: Cross-Sectional Studies; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D006966: Hyperprolactinemia; D008137: Longitudinal Studies; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D012559: Schizophrenia; D017678: Sex Distribution; D013997: Time Factors,,,https://openalex.org/W2038901045,116,16,1,2657,452,15,en,en
false,attention deficit hyperactivity disorder substance abuse relationship implication treatment,attention deficit hyperactivity disorder adhd substance use disorder relate variety way although within child psychiatry literature earlier investigation inconsistent regard link recent prospective study follow hyperactive child normal control adulthood find hyperactive adult history adhd likely control substance use disorder substance abuse literature less consistent regard potential association adhd substance abuse however recent study suggest person substance use disorder particularly cocaine use disorder may likely general population childhood history adhd inconsistency regard association due difference diagnostic criterion type assessment use reliability information obtain potential relationship may exist adhd substance abuse treatment implication clinician pharmacological well nonpharmacological approach deserve investigation pharmacotherapy central component treatment childhood adhd clinician design strategy treat substance use disorder adhd need consider pharmacological intervention present literature pharmacological treatment childhood adhd extensive adult adhd grow information regard treatment cocaine abuse concomitant adhd symptom remain limited,Levin FR,1995,Harv Rev Psychiatry,https://doi.org/10.3109/10673229509017144,9384909,Levin FR; Kleber HD,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002675: Child, Preschool; D019970: Cocaine-Related Disorders; D003131: Combined Modality Therapy; D006801: Humans; D008774: Methylphenidate; D011613: Psychotherapy; D011619: Psychotropic Drugs; D019966: Substance-Related Disorders",,,https://openalex.org/W1968778095,106,12,1,1604,240,9,en,en
false,beta blocker treatment aggression,review assess usefulness beta blocker treatment aggression describe parameter clinical use medline search use term beta blocker aggression propranolol brain injury identify relevant journal article publish english open prospective double blind placebo control study well case report include beta blocker appear effective decrease frequency intensity aggressive outburst associate wide variety condition dementia attention deficit disorder personality disorder korsakoff psychosis posttraumatic stress disorder schizophrenia profound mental retardation autism brain injury general discussion attempt resolve issue surround possible mechanism beta blocker effect review anatomic neurochemical base aggression explore implication clinical use beta blocker,Haspel T,1995,Harv Rev Psychiatry,https://doi.org/10.3109/10673229509017146,9384911,Haspel T,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000374: Aggression; D014150: Antipsychotic Agents; D004347: Drug Interactions; D006801: Humans; D001523: Mental Disorders; D011433: Propranolol; D011595: Psychomotor Agitation; D012701: Serotonin,,,https://openalex.org/W2027867156,45,6,1,1007,163,5,en,en
false,clinical efficacy methylphenidate conduct disorder without attention deficit hyperactivity disorder,background stimulant consider appropriate treatment child conduct disorder cd postulate difference stimulant effect child attention deficit hyperactivity disorder adhd cd lead hypothesis methylphenidate hydrochloride effective adhd would significantly improve symptom cd method randomly assign child cd age year receive methylphenidate hydrochloride mg placebo week behavior evaluate parent teacher clinician report direct classroom observation two third child also meet criterion adhd result contrary prediction rating antisocial behavior specific cd significantly reduce methylphenidate treatment magnitude methylphenidate effect indicate meaningful clinical benefit partialling severity adhd alter significant superiority methylphenidate cd rating specifically p conclusion methylphenidate short term positive effect child adolescent cd key aspect antisocial adjustment appear treatment responsive effect independent severity child initial adhd symptom,Klein RG,1997,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.1997.01830240023003,9400342,Klein RG; Abikoff H; Klass E; Ganeles D; Seese LM; Pollack S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D015897: Comorbidity; D019955: Conduct Disorder; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010290: Parents; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012720: Severity of Illness Index; D013663: Teaching; D016896: Treatment Outcome,,,https://openalex.org/W2139910250,114,14,1,1341,246,11,en,en
false,replacement medication cocaine dependence,agonist replacement medication useful adjunct treatment opiate nicotine dependence systematically examine cocaine dependence result early open trial methylphenidate treatment cocaine dependence equivocal twenty four cocaine dependent subject enrol week double blind placebo control study methylphenidate assignment random intake include day human laboratory procedure subject receive initial methylphenidate placebo subject attend clinic monday friday receive oral methylphenidate mg plus mg sustain release placebo afternoon weekend take home mg sustain release placebo provide medication event monitor system bottle monitor compliance clinic visit include therapy session electrocardiogram self report measure twice weekly urine screen two group equivalent term retention methylphenidate placebo similar cocaine use outcome benzoylecgonine positive urine screen significant adverse effect sufficient permit detection psychoactive effect stimulant energy side effect jitteriness eat less without increase crave additional medication different effect profile study far evaluate replacement model cocaine dependence j clin psychopharmacol,Grabowski J,1997,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199712000-00008,9408812,Grabowski J; Roache JD; Schmitz JM; Rhoades H; Creson D; Korszun A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000697: Central Nervous System Stimulants; D019970: Cocaine-Related Disorders; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate,,,https://openalex.org/W2091487897,45,5,1,1548,252,12,en,en
false,efficacy safety clonidine bupivacaine combination caudal blockade pediatric hernia repair,evaluate analgesic efficacy hemodynamic respiratory safety clonidine add bupivacaine caudal block child age mo mean sem patient schedule ambulatory hernia repair randomly give caudal injection ml kg either saline placebo p group bupivacaine b group bupivacaine plus epinephrine group bupivacaine plus clonidine micro g kg bc group bupivacaine plus clonidine micro g kg bc group postoperative measurement include duration analgesia hemodynamics respiratory monitoring h thereafter parent assess child analgesic requirement home every h h duration analgesia median range significantly long p bc bc group min min respectively compare p b group similarly bc bc group require less additional analgesic within first h group show significant decrease mean arterial pressure compare baseline value difference among group significant bradycardia respiratory depression observe clonidine micro g kg safely add bupivacaine caudal blockade small child ambulatory hernia repair achieve increase duration analgesia compare bupivacaine alone bupivacaine plus epinephrine implication addition clonidine antihypertensive drug analgesic property local anesthetic caudal block prolongs postoperative pain relief reduce need additional pain treatment child hernia operation,Klimscha W,1998,Anesth Analg,https://doi.org/10.1097/00000539-199801000-00011,9428851,Klimscha W; Chiari A; Michalek-Sauberer A; Wildling E; Lerche A; Lorber C; Brinkmann H; Semsroth M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D018712: Analgesics, Non-Narcotic; D000763: Anesthesia, Caudal; D000779: Anesthetics, Local; D001794: Blood Pressure; D002045: Bupivacaine; D002648: Child; D002675: Child, Preschool; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D059685: Herniorrhaphy; D006801: Humans; D007223: Infant; D008297: Male; D011446: Prospective Studies",,,https://openalex.org/W1993204674,109,15,1,1745,322,7,en,en
false,effect methylphenidate attentional function traumatic brain injury,attention deficit traumatic brain injury tbi common disable many pharmacologic agent use ameliorate attention deficit considerable interest focus methylphenidate mp document efficacy attention deficit disorder however clinical study mp subject tbi yield mixed result examine effect mp attentional function individual tbi refer specifically attentional assessment treatment subject study double blind placebo control repeat crossover design use five different task design measure various facet attentional function mp produce significant improvement speed mental processing orient distraction aspect sustain attention measure motor speed unaffected result suggest mp may useful treatment tbi primarily useful symptom attribute slow mental processing,Whyte J,1997,Am J Phys Med Rehabil,https://doi.org/10.1097/00002060-199711000-00002,9431261,Whyte J; Hart T; Schuster K; Fleming M; Polansky M; Coslett HB,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001143: Arousal; D001288: Attention; D001930: Brain Injuries; D000697: Central Nervous System Stimulants; D002648: Child; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D011597: Psychomotor Performance,,,https://openalex.org/W2322532448,79,10,1,1014,164,8,en,en
true,epilepsy attention deficit hyperactivity disorder methylphenidate safe effective,objective study safety efficacy methylphenidate child dual diagnosis epilepsy attention deficit hyperactivity disorder adhd study design thirty child age year epilepsy adhd study month period initial month study child treat antiepileptic drug aeds remain month methylphenidate add morning dose mg kg underwent neurologic assessment brain compute tomography iq test assessment childhood behavior checklist baseline methylphenidate therapy electroencephalography aed determination continuous performance task cpt test baseline month methylphenidate therapy double blind crossover design use compare effect methylphenidate versus placebo electroencephalogram aed level cpt day test child receive aeds capsule contain either placebo methylphenidate result none child sample seizure free attack take methylphenidate child seizure increase attack whereas show change reduction significant change aed level electroencephalographic find methylphenidate benefit child accord parental report methylphenidate also enhance performance cpt side effect methylphenidate mild transient conclusion methylphenidate effective treat child epilepsy adhd safe child seizure free caution warrant still seizure receive aed therapy j pediatr,Gross-Tsur V,1997,J Pediatr,https://doi.org/10.1016/s0022-3476(97)70308-1,9432523,Gross-Tsur V; Manor O; van der Meere J; Joseph A; Shalev RS,article,"D016430: Clinical Trial; D016420: Comment; D018848: Controlled Clinical Trial; D016439: Corrected and Republished Article; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000927: Anticonvulsants; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004827: Epilepsy; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D013647: Task Performance and Analysis; D016896: Treatment Outcome,,,https://openalex.org/W2146994054,93,13,1,1803,311,15,en,en
false,olanzapine trial,,Mattes JA,1998,Am J Psychiatry,10.1176/ajp.155.1.153a,9433359,Mattes JA,article,D003160: Comparative Study; D016422: Letter; D016420: Comment,D014150: Antipsychotic Agents; D001569: Benzodiazepines; D010054: Brief Psychiatric Rating Scale; D006220: Haloperidol; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D012107: Research Design; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,,20,4,1,0,0,0,en,
false,evaluation methylphenidate potential establishing operation common classroom reinforcer,conduct reinforcer assessment boy diagnosis attention deficit hyperactivity disorder alternately receive either placebo previously prescribe methylphenidate purpose evaluate whether methylphenidate alter relative reinforcing effectiveness various stimulus often use classroom base behavioral treatment program e g activity tangible item result show clear difference stimulus reinforcer assessment conduct participant receive methylphenidate compare placebo result suggest methylphenidate might act establish operation common classroom reinforcer implication development evaluation behavioral treatment discus,Northup J,1997,J Appl Behav Anal,https://doi.org/10.1901/jaba.1997.30-615,9433787,Northup J; Fusilier I; Swanson V; Roane H; Borrero J,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D000697: Central Nervous System Stimulants; D002648: Child; D003131: Combined Modality Therapy; D003216: Conditioning, Operant; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D008774: Methylphenidate; D012054: Reinforcement, Psychology; D013663: Teaching; D016896: Treatment Outcome",,,https://openalex.org/W2111715638,108,14,1,774,106,5,en,en
false,comprehensive school base behavioral assessment effect methylphenidate,individualized assessment effect three methylphenidate mph conduct student attention deficit hyperactivity disorder within child classroom use behavioral academic social measure double blind placebo control multielement design use evaluate result result suggest least one dosage mph associate degree improvement child area function compare placebo however degree improvement time vary substantially across dosage area function result suggest mph dosage area child function critical assessment parameter control clinical trial necessary optimize effectiveness treatment mph individual child,Gulley V,1997,J Appl Behav Anal,https://doi.org/10.1901/jaba.1997.30-627,9433788,Gulley V; Northup J,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006801: Humans; D007206: Individuality; D008137: Longitudinal Studies; D008297: Male; D008433: Mathematics; D008774: Methylphenidate; D011932: Reading; D012919: Social Behavior; D013647: Task Performance and Analysis; D016896: Treatment Outcome",,,https://openalex.org/W2134640123,82,9,1,832,133,5,en,en
false,selective serotonin reuptake inhibitor cns drug interaction,potential drug drug interaction psychiatric patient high combination psychopharmacotherapy use treat comorbid psychiatric disorder treat adverse effect medication augment medication effect treat concomitant medical illness interaction pharmacodynamic pharmacokinetic nature paper focus metabolic kinetic interaction selective serotonin reuptake inhibitor ssri central nervous system cns drug evidence clinical significance interaction review special emphasis antipsychotic tricyclic antidepressant benzodiazepine many psychotropic medication affinity cytochrome p cyp enzymes promote elimination transform lipid soluble substance polar compound ssri serve substrate inhibitor enzyme vitro study provide screen method evaluate drug affinity substrate inhibitor inducer cyp enzyme although vitro data important start point predict metabolic kinetic drug interaction case report control experimental study human require fully evaluate clinical significance several factor must consider evaluate clinical significance potential interaction include nature drug activity enzyme site substrate inhibitor inducer b potency estimation inhibitor inducer c concentration inhibitor inducer enzyme site saturability enzyme e extent metabolism substrate enzyme versus alternative metabolic route f presence active metabolite substrate g therapeutic window substrate h inherent enzyme activity individual phenotyping genotyping information level risk individual experience adverse effect e g elderly j epidemiological perspective probability concurrent use paper systematically review vitro vivo evidence drug interaction ssri cns drug potent inhibitor cyp paroxetine fluoxetine potential increase plasma concentration antipsychotic medication metabolise enzyme include perphenazine haloperidol thioridazine risperidone patient cyp extensive metabolisers control study demonstrate perphenazine paroxetine haloperidol fluoxetine fluvoxamine potent inhibitor cyp inhibit metabolism clozapine result high plasma concentration drug interaction ssri tricyclic antidepressant tcas occur fluoxetine paroxetine potent inhibitor cyp increase plasma concentration secondary tertiary tricyclic antidepressant sertraline citalopram less likely effect fluvoxamine increase plasma concentration tertiary tcas fluvoxamine inhibits via cyp cyp c cyp metabolism several benzodiazepine include alprazolam bromazepam diazepam fluoxetine increase plasma concentration alprazolam diazepam inhibit cyp cyp c respectively clinical importance interaction diazepam attenuate presence active metabolite sertraline inhibit enzyme mildely moderately usual therapeutic therefore potential interaction less however vivo evidence minimal paroxetine citalopram unlikely cause interaction benzodiazepine evidence conflict interaction carbamazepine ssri fluoxetine fluvoxamine combination use cautiously accompany monitor adverse event carb,Sproule BA,1997,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199733060-00004,9435993,Sproule BA; Naranjo CA; Brenmer KE; Hassan PC,article,D016428: Journal Article; D016454: Review,"D014151: Anti-Anxiety Agents; D000929: Antidepressive Agents, Tricyclic; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D002491: Central Nervous System Agents; D065607: Cytochrome P-450 Enzyme Inhibitors; D004347: Drug Interactions; D004791: Enzyme Inhibitors; D006801: Humans; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2034821383,65,8,1,4000,643,27,en,en
false,differential effect haloperidol clozapine plasma homovanillic acid elderly schizophrenic patient without tardive dyskinesia,plasma homovanillic acid hva change response challenge several day haloperidol find predictive therapeutic response haloperidol long period treatment twenty six elderly woman give inform consent divide two group without tardive dyskinesia subject day washout dyskinetic nondyskinetic group divide half group give haloperidol clozapine nondyskinetic group brief rise plasma hva decline dyskinetic group change plasma hva neither group challenge clozapine change plasma hva,Andia I,1998,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(97)00257-6,9442340,Andia I; Zumarraga M; Zabalo MJ; Bulbena A; Davila R,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D014150: Antipsychotic Agents; D003024: Clozapine; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006719: Homovanillic Acid; D006801: Humans; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia",,,https://openalex.org/W2057484071,145,19,1,676,116,3,en,en
false,physostigmine prevents postanesthetic shiver meperidine clonidine,background postanesthetic shiver develop many one half patient recover isoflurane anesthesia cholinergic stimulation hypothalamic pituitary adrenal axis adrenal medulla physostigmine enhance secretion arginine vasopressin epinephrine norepinephrine hypothalamus dominant thermoregulatory controller mammal neurotransmitter may involve body temperature control physostigmine administration may influence incidence shiver accordingly author test hypothesis physostigmine administration inhibit postanesthetic shiver efficacy compare saline negative control meperidine clonidine positive control method sixty patient surgery ear nose test general anesthesia induce mg kg propofol mg kg vecuronium microg kg fentanyl maintain isoflurane nitrous oxide end surgery patient randomly assign receive intravenous bolus mg kg physostigmine isotonic saline mg kg meperidine microg kg clonidine heart rate mean arterial blood pressure oxygen saturation visual analog pain score temperature postanesthetic shivering measure recovery result postanesthetic shiver occur patient give saline contrast postanesthetic shiver significantly reduce physostigmine treat patient absent patient give clonidine meperidine conclusion physostigmine inhibit shiver well two establish treatment meperidine clonidine data suggest cholinergic system contribute genesis control postanesthetic shivering,Horn EP,1998,Anesthesiology,https://doi.org/10.1097/00000542-199801000-00018,9447863,Horn EP; Standl T; Sessler DI; von Knobelsdorff G; Büchs C; Schulte am Esch J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000368: Aged; D000758: Anesthesia; D001794: Blood Pressure; D003000: Clonidine; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008614: Meperidine; D008875: Middle Aged; D010830: Physostigmine; D012768: Shivering,,,https://openalex.org/W1990679215,80,9,1,1824,288,13,en,en
false,double blind comparison bupropion sustain release sertraline depress outpatient,sustain release formulation bupropion bupropion sr develop improve pharmacokinetic profile permit less frequent dosing immediate release form evaluate active comparator trial randomize double blind parallel group trial conduct compare efficacy safety bupropion sr sertraline outpatient moderate severe major depressive disorder dsm iv receive bupropion sr mg day sertraline mg day week psychiatric evaluation include hamilton rating scale depression ham hamilton rating scale anxiety ham clinical global impression scale severity illness cgi improvement cgi complete adverse event assess clinic periodically throughout treatment patient orgasm function also assess mean ham ham cgi cgi score improve course treatment bupropion sr group sertraline group group difference observe scale orgasm dysfunction significantly p common sertraline treat patient compare bupropion sr treat patient adverse event nausea diarrhea somnolence sweat also experience frequently p sertraline treat patient difference note two treatment vital sign weight double blind comparison bupropion sr sertraline demonstrate bupropion sertraline similarly effective treatment depression compound relatively well tolerate orgasm dysfunction nausea diarrhea somnolence sweat report frequently sertraline treat patient,Kavoussi RJ,1997,J Clin Psychiatry,https://doi.org/10.4088/jcp.v58n1204,9448656,Kavoussi RJ; Segraves RT; Hughes AR; Ascher JA; Johnston JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D015057: 1-Naphthylamine; D000293: Adolescent; D000328: Adult; D000368: Aged; D000553: Ambulatory Care; D000928: Antidepressive Agents; D016642: Bupropion; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006261: Headache; D006801: Humans; D008297: Male; D008875: Middle Aged; D009325: Nausea; D011569: Psychiatric Status Rating Scales; D020280: Sertraline; D020018: Sexual Dysfunctions, Psychological; D007319: Sleep Initiation and Maintenance Disorders; D016896: Treatment Outcome",,,https://openalex.org/W2008979600,94,11,1,1786,291,8,en,en
false,effect risperidone five dimension schizophrenia derive factor analysis,two double blind trial conduct north america patient chronic schizophrenia receive risperidone haloperidol placebo present study combine data two trial analyze patient randomly assign receive placebo fix risperidone mg day mg day haloperidol week factor analysis score positive negative syndrome scale panss produce five dimension negative symptom positive symptom disorganize think uncontrolled hostility excitement anxiety depression similar five dimension previous factor analytic study panss data mean change symptom reduction panss factor score baseline treatment week significantly great patient receive mg day risperidone patient receive placebo haloperidol advantage risperidone great negative symptom uncontrolled hostility excitement anxiety depression even low dose mg day risperidone significantly p superior haloperidol reduce negative symptom difference outcome risperidone haloperidol panss score relate extrapyramidal symptom risperidone produce significantly p great improvement haloperidol five dimension large group difference negative symptom hostility excitement anxiety depression suggest risperidone serotonin dopamine antagonist qualitatively different effect conventional antipsychotic agent,Marder SR,1997,J Clin Psychiatry,https://doi.org/10.4088/jcp.v58n1205,9448657,Marder SR; Davis JM; Chouinard G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001480: Basal Ganglia Diseases; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005163: Factor Analysis, Statistical; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012563: Schizophrenia, Paranoid; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W2077138902,93,14,1,1639,255,7,en,en
false,randomize trial modafinil treatment pathological somnolence narcolepsy,narcolepsy central nervous system disorder characterize excessive daytime sleepiness cataplexy placebo control double blind randomize parallel group center study assess efficacy safety modafinil new wake promote drug treat sleepiness narcolepsy subject narcolepsy n receive daily modafinil mg placebo week follow open label treatment period subjective sleepiness measure epworth sleepiness scale objective sleepiness assess multiple sleep latency test maintenance wakefulness test level illness measure clinical global impression change modafinil significantly reduce measure sleepiness associate significant improvement level illness medication related adverse experience dose dependent mostly rat mild moderate modafinil take daily well tolerate effective wake promote agent treatment excessive daytime somnolence associate narcolepsy modafinil demonstrate excellent safety profile week open label treatment efficacy maintain suggest tolerance develop long term use modafinil pharmacologically clinically promise compound treatment pathological daytime somnolence,,1998,Ann Neurol,https://doi.org/10.1002/ana.410430115,9450772,,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077408: Modafinil; D009290: Narcolepsy; D011930: Reaction Time; D012894: Sleep Stages; D016896: Treatment Outcome; D014851: Wakefulness",,,https://openalex.org/W2073960829,88,12,1,1408,217,11,en,en
false,new self report scale assessment adolescent psychopathology factor structure reliability validity diagnostic sensitivity,paper describe four study self report problem adolescent male female year age study principal axis factor item cover problem domain reveal six factor comprise variance study use confirmatory factor analysis item reduce set new sample adolescent goodness fit indicator suggest six factor model excellent fit data study use data adolescent use first two study coefficient alpha range median test retest reliability six factor consistent structure correlation matrix across age gender study study criterion validity use additional sample child attention deficit hyperactivity disorder adhd sensitivity specificity high overall diagnostic efficiency new self report scale conners well adolescent self report symptom cass may provide useful component multimodal assessment adolescent psychopathology,Conners CK,1997,J Abnorm Child Psychol,https://doi.org/10.1023/a:1022637815797,9468109,Conners CK; Wells KC; Parker JD; Sitarenios G; Diamond JM; Powell JW,article,"D016428: Journal Article; D016448: Multicenter Study; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D002170: Canada; D005163: Factor Analysis, Statistical; D005260: Female; D006801: Humans; D008297: Male; D011581: Psychological Tests; D011594: Psychometrics; D015203: Reproducibility of Results; D014481: United States",,,https://openalex.org/W29428084,138,21,1,1114,192,11,en,en
false,patient alcohol problem,alcohol use associate many health problem along death annual economic cost billion united state perspective generalist physician term alcohol problem problem cause alcohol may require treatment refers broad array acute chronic medical behavioral social problem may affect patient percent medical surgical patient alcohol problem alcohol use account percent health care cost alcohol problem may acute chronic may range mild,O'Connor PG,1998,N Engl J Med,https://doi.org/10.1056/nejm199802263380907,9475768,O'Connor PG; Schottenfeld RS,article,D016428: Journal Article; D016454: Review,D000428: Alcohol Drinking; D000436: Alcoholics Anonymous; D000437: Alcoholism; D000431: Ethanol; D006801: Humans; D008487: Medical History Taking; D010819: Physician's Role; D012306: Risk; D055502: Secondary Prevention; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W2328373544,30,4,1,617,111,3,en,en
false,modification clinical global impression cgi scale use bipolar illness bp cgi bp,clinical global impression scale cgi modify specifically use assess global illness severity change patient bipolar disorder criticism original cgi address correct inconsistency scale identify time frame comparison clarify definition illness severity change separate assessment treatment side effect illness improvement treatment detail user guide develop train clinician use new cgi bipolar version cgi bp rating severity manic depressive episode degree change immediately precede phase bad phase illness revise scale manual provide focus set instruction facilitate reliability rating mania depression overall bipolar illness treatment acute episode long term illness prophylaxis interrater reliability scale demonstrate preliminary analysis thus modify cgi bp anticipate useful original cgi study bipolar disorder,Spearing MK,1997,Psychiatry Res,https://doi.org/10.1016/s0165-1781(97)00123-6,9481807,Spearing MK; Post RM; Leverich GS; Brandt D; Nolen W,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001714: Bipolar Disorder; D006801: Humans; D015588: Observer Variation; D011569: Psychiatric Status Rating Scales; D012015: Reference Standards; D015203: Reproducibility of Results,,,https://openalex.org/W2030034545,103,21,1,1134,185,6,en,en
false,effect apraclonidine optic nerve head peripapillary retinal blood flow,examine effect apraclonidine optic nerve head onh peripapillary retinal blood flow scan laser doppler flowmetry sldf onh peripapillary retinal blood flow healthy subject measure sldf hour hour unilateral administration apraclonidine fellow eye treat balance salt solution examiner mask eye treat apraclonidine occasion three scan obtain haemodynamic variable volume flow velocity analyse eight location four neural rim four peripapillary retina avoid ophthalmoscopically visible vessel statistical significance change baseline value variable difference measure quantity apraclonidine treat eye fellow eye time point evaluate use wilcoxon sign rank test intraocular pressure reduce significantly apraclonidine treat eye p hour p hour administration volume flow velocity onh peripapillary retinal blood flow significant change baseline value hour hour apraclonidine administration either apraclonidine treat eye p fellow eye p also significant difference find measured quantity apraclonidine treat eye fellow eye time point p single dose topical apraclonidine healthy subject adverse effect onh peripapillary retinal blood flow,Kim TW,1997,Br J Ophthalmol,https://doi.org/10.1136/bjo.81.12.1070,9497467,Kim TW; Kim DM,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000316: Adrenergic alpha-Agonists; D000328: Adult; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007429: Intraocular Pressure; D017078: Laser-Doppler Flowmetry; D008297: Male; D009898: Optic Disk; D012039: Regional Blood Flow; D012171: Retinal Vessels,,,https://openalex.org/W1975916626,86,14,1,1666,297,6,en,en
false,postoperative periduralanalgesie kontinuierliche gegen ber patientenkontrollierter applikation einer niedrig dosierten mischung au sufentanil clonidin und bupivacain,die periduralanalgesie und die patientenkontrollierte intraven se analgesie pca werden meist al goldstandards der postoperativen schmerztherapie einander gegen bergestellt dieser studie sollte dagegen die effizienz einer patientenkontrollierten periduralanalgesie pcea mit der kontinuierlichen periduralen applikationsweise verglichen werden methoden patienten asa iii vor einem elektiven gro en abdominalchirurgischen eingriff wurden randomisiert zwei gruppen zugeteilt alle patienten erhielten eine periduralan sthesie plus intubationsnarkose bereits intraoperativ wurde mit der periduralen infusion einer analgetikamischung bestehend au g ml sufentanil plus g ml clonidin bupivacain begonnen postoperativ erhielten die patienten der gruppe die analgetika kontinuierlich die patienten der gruppe b patientenkontrolliert ber den periduralkatheter ber stunden postoperativ wurden der analgetikaverbrauch da schmerzniveau mittels einer visuellen analogskala sowie parameter der kardiopulmonalen funktion und unerw nschte wirkungen gemessen dar berhinaus befragten wir die patienten zwei tage nach der operation einem standardisierten interview zur analgesiequalit und pers nlichen akzeptanz de analgesieverfahrens ergebnisse ruhig im bett liegende patienten konnten mit beiden applikationsmodi hervorragend analgesiert werden dagegen erzielten wir bei kontinuierlicher gabe der periduralen analgetikamischung w hrend mobilisation oder atemphysiotherapie einen besseren analgetischen effekt va al bei patientenkontrollierter gabe va p dabei beobachteten wir einen signifikant niedrigeren analgetikaverbrauch im falle der patientenkontrollierten periduralen analgetikaapplikation ml v ml p schwere unerw nschte wirkungen registrierten wir keiner der beiden gruppen schlu folgerung den ersten stunden nach gro en abdominalchirurgischen eingriffen f hrt die patientenkontrollierte peridurale analgetikaapplikation zu einem geringeren analgetikaverbrauch verglichen mit kontinuierlicher periduraler infusion w hrend f r beide methoden die ruhe erzielte analgesie gleichwertig ist wird bei mobilisation durch die kontinuierliche analgetikazu fuhr eine bessere analgesie erreicht,Hering R,1997,Anasthesiol Intensivmed Notfallmed Schmerzther,https://doi.org/10.1055/s-2007-995132,9498885,Hering R; Schumacher T; Müller H,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D015360: Analgesia, Epidural; D016058: Analgesia, Patient-Controlled; D000701: Analgesics, Opioid; D019162: Anesthetics, Combined; D000779: Anesthetics, Local; D002045: Bupivacaine; D003000: Clonidine; D005069: Evaluation Studies as Topic; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011182: Postoperative Care; D018709: Statistics, Nonparametric; D017409: Sufentanil; D013565: Sympatholytics; D013997: Time Factors",,,https://openalex.org/W2010021877,169,17,1,2320,308,16,de,de
false,blood biogenic amine clozapine treatment early onset schizophrenia,aim investigation evaluate long term short term effect clozapine treatment plasma biogenic amine psychopathology measure adolescent schizophrenia dsm iii r criterion long term study conduct study sample young patient age year follow mean year neuroleptic treatment study patient receive clozapine patient treat standard neuroleptic medication begin open clinical trial patient already receive clozapine treatment month assessment biochemical psychopathological measure perform six occasion consecutive week interval maintenance treatment clozapine conventional neuroleptic blood level serotonin methoxy hydroxy phenylglycol mhpg norepinephrine epinephrine significantly high clozapine treat patient conventionally treated patient long term treatment high serotonin level associate significantly negative symptom schizophrenia whereas high mhpg level correlate less depression short term effect clozapine assess second independent study sample fail conventional neuroleptic clinical trial last mean year inpatient age year receive clozapine weekly rating psychopathological symptom use standard rating scale perform parallel blood sample measurement biogenic amine serum level clozapine measure obtain week conventional neuroleptic treatment week open label clozapine trial serum level serotonin plasma norepinephrine level significantly high treatment clozapine pretreatment typical neuroleptic comparison plasma epinephrine level responder n nonresponders n clozapine reveal response clozapine predict epinephrine level prior initiation treatment clozapine responder range pg ml nonresponders range pg ml additionally subject respond clozapine show increase mean plasma concentration mhpg epinephrine treatment drug comparison level measure pretreatment typical neuroleptic medication nonresponders clozapine fail show increase finally responder clozapine negative linear relationship negative symptom schizophrenia concentration plasma norepinephrine serum serotonin observe conclusion result demonstrate plasma epinephrine level prior initiation clozapine therapy predict response atypical neuroleptic find derive short term maintenance treatment clozapine suggest involvement norepinephrine epinephrine serotonin therapeutic action atypical neuroleptic clozapine,Schulz E,1997,J Neural Transm (Vienna),https://doi.org/10.1007/bf01273320,9503259,Schulz E; Fleischhaker C; Clement HW; Remschmidt H,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D017668: Age of Onset; D014150: Antipsychotic Agents; D001679: Biogenic Amines; D002851: Chromatography, High Pressure Liquid; D003024: Clozapine; D005260: Female; D006801: Humans; D008297: Male; D012559: Schizophrenia; D013997: Time Factors",,,https://openalex.org/W2081262939,77,9,1,3119,469,18,en,en
false,olanzapine interaction study imipramine,olanzapine atypical antipsychotic agent high affinity serotonin ht c ht ht dopamine receptor depress patient psychotic disorder frequently require treatment concomitant antipsychotic antidepressant medication imipramine pharmacokinetics serve marker hepatic cyp cyp cyp activity open label three way randomize crossover study determine safety pharmacokinetics potential drug interaction olanzapine mg imipramine mg drug administer alone combination nine healthy men age year enrol study psychomotor performance capacity plasma olanzapine imipramine desipramine concentration clinical laboratory test measure pharmacokinetic variable vital sign subjective test liveliness psychomotor outcome analyze use two way anova olanzapine safe sedation postural hypotension minor vital sign alteration occur treatment liveliness questionnaire patient generally report poor less lively score olanzapine alone coadministered imipramine versus baseline score effect disappear within hour administration olanzapine alone combination decrease motor speed task finger tap visual arm random reach compare baseline imipramine treatment peak hour change statistically significant clinical importance marginal olanzapine concentration great imipramine olanzapine affect kinetics imipramine desipramine therefore show metabolic drug interaction involve cyp j clin pharmacol,Callaghan JT,1997,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1997.tb04272.x,9505989,Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D018759: Adrenergic Uptake Inhibitors; D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D018592: Cross-Over Studies; D004347: Drug Interactions; D006801: Humans; D007024: Hypotension, Orthostatic; D007099: Imipramine; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011597: Psychomotor Performance; D016037: Single-Blind Method",,,https://openalex.org/W2136820997,45,6,1,1816,301,17,en,en
false,new atypical antipsychotic,atypical antipsychotic new class agent great promise use elderly reduce propensity cause acute extrapyramidal adverse effect treatment old patient agent however need take consideration age related change pharmacokinetics risk drug drug interaction additionally current evidence efficacy late life psychosis derive largely case series extrapolation result obtain study young patient schizophrenia control clinical study atypical antipsychotic elderly patient urgently need,Sweet RA,1998,Drugs Aging,https://doi.org/10.2165/00002512-199812020-00004,9509290,Sweet RA; Pollock BG,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000368: Aged; D000375: Aging; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D003024: Clozapine; D006801: Humans; D007093: Imidazoles; D007211: Indoles; D000077152: Olanzapine; D010890: Pirenzepine; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D016896: Treatment Outcome,,,https://openalex.org/W2086075809,27,3,1,650,99,4,en,en
false,effect clozapine negative symptom patient schizophrenia minimal positive symptom,effectiveness clozapine treatment negative symptom schizophrenia remain controversial improvement negative symptom invariably accompany improvement positive symptom neurological side effect examine effectiveness treatment clozapine negative symptom cohort patient minimal positive symptom improvement positive negative symptom measure bprs rating subgroup schizophrenic patient n state hospital cohort minimal positive symptom receive clozapine month subgroup significant improvement note composite score three negative symptom item emotional withdrawal blunt affect motor retardation positive depressive symptom remain unchanged remain cohort n show improvement overall psychopathology include positive negative depressive symptom interestingly nearly group discharge hospital find suggest clozapine may beneficial treatment core negative symptom even absence improvement psychopathology effect clozapine may function unique pharmacological profile,Brar JS,1997,Ann Clin Psychiatry,https://doi.org/10.1023/a:1022352326334,9511946,Brar JS; Chengappa KN; Parepally H; Sandman AR; Kreinbrook SB; Sheth SA; Ganguli R,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D015331: Cohort Studies; D003702: Delusions; D003863: Depression; D005260: Female; D006778: Hospitals, Psychiatric; D006783: Hospitals, State; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2034113667,108,16,1,1289,206,9,en,en
false,sulpiride augmentation people schizophrenia partially responsive clozapine,background hypothesise combine regimen clozapine relatively weak dopaminergic antagonist sulpiride selective blocker would demonstrate great antipsychotic efficacy enhance blockade clozapine method twenty eight people schizophrenia previously unresponsive typical antipsychotic partially responsive current treatment clozapine receive double blind mg day sulpiride placebo addition ongoing clozapine treatment clinical status evaluate end week sulpiride addition use brief psychiatric rating scale bprs scale assessment positive symptom sap scale assessment negative symptom hamilton rating scale depression result clozapine sulpiride group exhibit substantially great significant improvement positive negative psychotic symptom half characterise young age low baseline sap score mean reduction bprs sap score respectively conclusion subgroup patient chronic schizophrenia may substantially benefit sulpiride addition clozapine,Shiloh R,1997,Br J Psychiatry,https://doi.org/10.1192/bjp.171.6.569,9519099,Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D018492: Dopamine Antagonists; D004311: Double-Blind Method; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012559: Schizophrenia; D013469: Sulpiride; D016896: Treatment Outcome",,,https://openalex.org/W2166158209,85,10,1,1243,204,6,en,en
false,risperidone versus haloperidol meta analysis efficacy safety,haloperidol widely consider reference standard antipsychotic therapy commonly use comparative study efficacy safety antipsychotic medication comparative clinical trial show novel antipsychotic agent risperidone tend great efficacy e clinical response define reduction total score positive negative syndrome scale haloperidol patient chronic schizophrenia pose less risk extrapyramidal symptom eps use dersimonian laird random effect model analyze pool patient data available randomize double mask comparative trial risperidone haloperidol patient schizophrenia treat least week recommend purpose analysis determine whether significant overall difference rate patient clinical response prescription anticholinergic agent treatment dropout six nine trial reveal literature search meet criterion inclusion meta analysis meta analysis show patient chronic schizophrenia risperidone therapy associate significantly high response rate significantly less prescribing anticholinergic medication significantly low treatment dropout rate haloperidol result demonstrate great treatment efficacy associate risperidone compare haloperidol suggest low incidence eps improve treatment compliance,Davies A,1998,Clin Ther,https://doi.org/10.1016/s0149-2918(98)80034-9,9522104,Davies A; Adena MA; Keks NA; Catts SV; Lambert T; Schweitzer I,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D006220: Haloperidol; D006801: Humans; D010349: Patient Compliance; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology,,,https://openalex.org/W1999564923,71,10,1,1554,236,7,en,en
false,neuroendocrine effect different estradiol progestin regimen postmenopausal woman,new regimen route administration hormonal replacement therapy hrt climateric woman become available since information neuroendocrine effect sequential combine treatment beta estradiol progestin present study evaluate neuroendocrine clinical vasomotor psychological change different sequential combine hrt regimen beta estradiol plus nomegestrol acetate cyproterone acetate vaginal progesterone vasomotor behavioral effect evaluate use kupperman score change plasma endorphin beta end level use marker neuroendocrine effect postmenopausal woman n randomly divide three group ten woman group woman receive continuous beta estradiol mg transdermal group sequentially treat different progestin day month group cyproterone acetate mg p group b nomegestrol acetate mg p group c progesterone mg vaginal cream group healthy fertile woman n serve control month hrt postmenopausal woman undergo evaluation subjective kupperman score two neuroendocrine test naloxone mg v b clonidine mg v plasma beta end level measure min drug injection control woman study administer two neuroendocrine test postmenopausal woman hrt show pathological kupperman change plasma beta end level response clonidine naloxone test score contrary increase significant healthy woman three group treat woman naloxone clonidine test induce significant increase plasma beta end level p month hrt improvement vasomotor psychological symptom show decrease kupperman score present study indicate sequential treatment transdermal beta estradiol progestin matter progestin use restore beta end release improve vasomotor psychological symptom,Stomati M,1997,Maturitas,https://doi.org/10.1016/s0378-5122(97)00073-x,9522320,Stomati M; Bersi C; Rubino S; Palumbo M; Comitini G; Genazzani AD; Santuz M; Petraglia F; Genazzani AR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000279: Administration, Cutaneous; D000284: Administration, Oral; D000726: Androgen Antagonists; D003000: Clonidine; D015331: Cohort Studies; D003534: Cyproterone; D004958: Estradiol; D015914: Estrogen Replacement Therapy; D005260: Female; D006801: Humans; D008535: Megestrol; D008875: Middle Aged; D009270: Naloxone; D009292: Narcotic Antagonists; D009490: Neurosecretory Systems; D017698: Postmenopause; D011374: Progesterone; D045167: Progesterone Congeners; D013565: Sympatholytics; D014622: Vaginal Creams, Foams, and Jellies; D014666: Vasomotor System; D001615: beta-Endorphin",,,https://openalex.org/W2067912704,88,9,1,2217,393,13,en,en
false,intrathecal clonidine combine sufentanil labor analgesia,background intrathecal sufentanil provide rapid onset complete analgesia first stage labor dose require produce effect associate maternal respiratory depression hypotension nausea pruritus clonidine potentiate analgesic effect opioids without increase side effect author want determine efficacy low dos intrathecal clonidine microg combine sufentanil method ninety eight parturient request labor analgesia study combine spinal epidural technique patient randomly assign receive one follow intrathecal solution either microg clonidine n microg clonidine n microg sufentanil n microg sufentanil n microg sufentanil microg clonidine n microg sufentanil microg clonidine n microg sufentanil microg clonidine n microg sufentanil microg clonidine n visual analog score pain blood pressure heart rate sensory level incidence nausea pruritus motor blockade maternal cord blood concentration clonidine record result patient receive microg intrathecal clonidine microg intrathecal sufentanil significantly longer lasting analgesia min v receive microg intrathecal sufentanil alone clonidine level undetectable maternal serum conclusion thirty microgram intrathecal clonidine combine microg intrathecal sufentanil significantly increase duration analgesia first stage labor without adverse maternal fetal effect,Gautier PE,1998,Anesthesiology,https://doi.org/10.1097/00000542-199803000-00015,9523808,Gautier PE; De Kock M; Fanard L; Van Steenberge A; Hody JL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000777: Anesthetics; D003000: Clonidine; D004357: Drug Synergism; D005260: Female; D006801: Humans; D007278: Injections, Spinal; D007743: Labor, Obstetric; D011247: Pregnancy; D011537: Pruritus; D017409: Sufentanil",,,https://openalex.org/W1988716346,67,8,1,1760,310,9,en,en
false,risperidone versus clozapine treatment resistant chronic schizophrenia randomize double blind study,purpose study compare short term efficacy safety risperidone clozapine treatment resistant chronic schizophrenic patient control double blind multicenter study inpatient chronic schizophrenia dsm iii r resistant intolerant conventional neuroleptic randomly assign receive risperidone clozapine week day washout period week dose titration phase dos fix mg day risperidone mg day clozapine week adjust accord patient response final mean mg day risperidone mg day clozapine treatment efficacy safety evaluate several well know rating scale risperidone clozapine significantly reduce severity psychotic symptom score positive negative syndrome scale clinical global impression scale baseline significant group difference endpoint risperidone group clozapine group clinically improve reduction total positive negative syndrome scale score risperidone appear fast onset action group extrapyramidal symptom adverse event severity generally mild neither group show evidence relation drug plasma concentration clinical effectiveness risperidone well tolerated effective medium clozapine patient chronic schizophrenia resistant intolerant conventional neuroleptic,Bondolfi G,1998,Am J Psychiatry,https://doi.org/10.1176/ajp.155.4.499,9545995,Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D017211: Treatment Failure; D016896: Treatment Outcome,,,https://openalex.org/W2040559929,106,12,1,1652,264,8,en,en
false,diagnosis treatment attention deficit hyperactivity disorder child adolescent,deal public professional concern regard possible overprescription attention deficit hyperactivity disorder adhd medication particularly methylphenidate review issue relate diagnosis optimal treatment actual care adhd patient evidence patient misuse adhd medication literature review use national library medicine database search march term attention deficit disorder hyperactivity methylphenidate stimulant stimulant abuse dependence relevant document drug enforcement administration also review english language study deal child elementary school high school age include searched article select make available coauthor review additional article know coauthor add initial list consensus develop among coauthor regard article pertinent issue request resolution call report relevant information article include report diagnostic criterion adhd base extensive empirical research apply appropriately lead diagnosis syndrome high interrater reliability good face validity high predictability course medication responsiveness criterion constitute adhd child broaden grow appreciation persistence adhd adolescence adulthood result child especially girl adolescent adult diagnose treat stimulant medication child treat long period time epidemiologic study use standardize diagnostic criterion suggest school age population elementary high school may suffer adhd although percentage u youth treat adhd low end prevalence range pharmacotherapy particularly use stimulant extensively study generally provide significant short term symptomatic academic improvement little evidence stimulant abuse diversion currently major problem particularly among adhd although recent trend suggest could increase expand production use stimulant although child diagnose adhd insufficient evaluation case stimulant medication prescribe treatment alternative exist little evidence widespread overdiagnosis misdiagnosis adhd widespread overprescription methylphenidate physician,Goldman LS,1998,JAMA,https://doi.org/10.1001/jama.279.14.1100,9546570,Goldman LS; Genel M; Bezman RJ; Slanetz PJ,article,D016428: Journal Article; D016454: Review,"D000293: Adolescent; D000574: American Medical Association; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D015897: Comorbidity; D004363: Drug Utilization; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010818: Practice Patterns, Physicians'; D019966: Substance-Related Disorders; D014481: United States",,,https://openalex.org/W2140513029,95,10,1,2721,418,9,en,en
false,single dose pharmacokinetics modafinil methylphenidate give alone combination healthy male volunteer,modafinil novel wake promote agent develop treatment excessive daytime sleepiness associate narcolepsy open latin square randomize cross study perform healthy male compare pharmacokinetics single dose oral modafinil mg methylphenidate mg administer alone combination blood sample obtain analysis l threo methylphenidate modafinil acid sulfone metabolite pharmacokinetic parameter determine noncompartmental method could evaluate modafinil sulfone due plasma level close assay quantitation limit although sporadic difference plasma concentration observe treatment coadministration modafinil methylphenidate significantly alter plasma concentration modafinil modafinil acid modafinil sulfone methylphenidate enantiomer compare administration agent alone half life maximum concentration c max area concentration time curve auc total clearance cl f apparent volume distribution vd f modafinil c max auc modafinil acid affect concomitant administration methylphenidate small statistically significant increase time c max max observe modafinil modafinil acid methylphenidate coadministration compare modafinil alone modafinil coadministration significantly alter pharmacokinetics l threo methylphenidate except small decrease vd f l threo methylphenidate concomitant methylphenidate may cause delay oral absorption modafinil delay might relevant clinically coadministration alter extent oral absorption disposition either agent therefore pharmacokinetic interaction modafinil methylphenidate would unlikely,Wong YN,1998,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1998.tb04425.x,9549666,Wong YN; King SP; Laughton WB; McCormick GC; Grebow PE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D018663: Adrenergic Agents; D000328: Adult; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004347: Drug Interactions; D006801: Humans; D008297: Male; D008774: Methylphenidate; D008875: Middle Aged; D000077408: Modafinil,,,https://openalex.org/W1994466998,118,15,1,1993,316,11,en,en
false,therapeutic equivalence risperidone give daily twice daily patient schizophrenia,study conduct determine whether daily administration risperidone effective safe twice daily administration double blind week trial patient acute exacerbation accord dsm iii r criterion randomly assign receive risperidone mg daily mg twice daily primary efficacy measure treatment response rate define great reduction total positive negative syndrome scale panss score severity extrapyramidal symptom assess extrapyramidal symptom rating scale percentage patient show treatment response endpoint significantly different group daily twice daily median time first treatment response day group significant reduction panss total subscale score panss derive brief psychiatric rating scale observe group significant group difference extrapyramidal symptom rating scale score differ significantly group clinically relevant change vital sign electrocardiogram clinical laboratory test result either group gradual dosage titration first day treatment well tolerate group median trough plasma concentration risperidone hydroxyrisperidone risperidone plus hydroxyrisperidone significantly low daily twice daily administration median plasma concentration measure within first hour administration tend high daily administration difference affect safety efficacy risperidone risperidone give daily mg effective twice daily administration mg treatment acute exacerbation schizophrenia regimen equally well tolerate,Nair NP,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199804000-00002,9555595,Nair NP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D013810: Therapeutic Equivalency,,,https://openalex.org/W1993833790,102,14,1,1911,302,13,en,en
false,risperidone versus haloperidol amitriptyline treatment patient combine psychotic depressive syndrome,multicenter double blind parallel group trial efficacy risperidone ri compare combination haloperidol amitriptyline hal ami week patient coexist psychotic depressive symptom either schizoaffective disorder depressive type major depression psychotic feature nonresidual schizophrenia major depressive symptom accord dsm iii r criterion total patient ri hal ami include mean daily dosage endpoint mg ri versus mg hal combine mg ami efficacy result patient ri hal ami complete least week double blind treatment reveal treatment group large reduction positive negative syndrome scale derive brief psychiatric rating scale ris hal ami bech rafaelsen melancholia scale total score ri hal ami reduction brief psychiatric rating scale bech rafaelsen melancholia scale score total group significantly large hal ami group ri group p mostly significant difference subgroup patient suffer depression psychotic feature whereas treatment difference diagnostic subgroup significant incidence extrapyramidal side effect assess extrapyramidal symptom rating scale slightly high ri hal ami adverse event report ri hal ami patient result trial suggest therapeutic effect hal ami superior ris total group patient combine psychotic depressive symptom however subgroup difference consider,Müller-Siecheneder F,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199804000-00003,9555596,Müller-Siecheneder F; Müller MJ; Hillert A; Szegedi A; Wetzel H; Benkert O,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000639: Amitriptyline; D000929: Antidepressive Agents, Tricyclic; D014150: Antipsychotic Agents; D003866: Depressive Disorder; D004311: Double-Blind Method; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D018967: Risperidone",,,https://openalex.org/W2024115155,127,17,1,1803,320,8,en,en
false,comment article tran colleague double blind comparison olanzapine versus risperidone treatment schizophrenia psychotic disorder,,Schooler NR,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199804000-00013,9555605,Schooler NR,article,D016422: Letter,D014150: Antipsychotic Agents; D001569: Benzodiazepines; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2323303489,162,24,1,0,0,0,en,
false,comment article tran associate double blind comparison olanzapine versus risperidone treatment schizophrenia psychotic disorder,clinical research operation regulatory affair janssen research foundation titusville new jersey gheuens international clinical r janssen research foundation b beerse belgium grebb,Gheuens J,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199804000-00015,9555606,Gheuens J; Grebb JA,article,D016422: Letter,D014150: Antipsychotic Agents; D001569: Benzodiazepines; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011618: Psychotic Disorders; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2335273090,162,24,1,212,40,2,en,en
false,design clinical trial assessment cardioversion use transesophageal echocardiography acute multicenter study steer publication committee acute study,patient atrial fibrillation af undergo cardioversion increase risk cardioembolic stroke require anticoagulation assessment cardioversion use transesophageal echocardiography acute multicenter study randomize clinical trial patient undergo electrical cardioversion af day duration compare transesophageal guide strategy tee brief anticoagulation conventional anticoagulation strategy patient randomly assign tee guide strategy receive therapeutic anticoagulation tee cardioversion follow week anticoagulation patient thrombus image tee postponement cardioversion continue anticoagulation week undergo repeat tee conventional strategy patient receive week anticoagulation cardioversion follow week anticoagulation cardioversion primary end point event ischemic stroke transient ischemic attack systemic embolization week period enrollment secondary end point major minor bleeding cause mortality successful return maintenance sinus rhythm cost effectiveness analysis base intention treat principle anticipated rate embolism conventional strategy tee guide strategy base publish research complete pilot study acute multicenter study randomize therapy follow estimate patient study site determine relative efficacy tee guide conventional approach electrical cardioversion patient af result investigation important clinical implication management patient af undergoing electrical cardioversion,,1998,Am J Cardiol,,9555778,,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000925: Anticoagulants; D001281: Atrial Fibrillation; D002561: Cerebrovascular Disorders; D003362: Cost-Benefit Analysis; D017548: Echocardiography, Transesophageal; D004554: Electric Countershock; D005260: Female; D006801: Humans; D002546: Ischemic Attack, Transient; D008297: Male; D018579: Patient Selection; D012107: Research Design; D018401: Sample Size",,,https://openalex.org/W4302570971,189,29,2,1817,274,11,en,en
false,reliability validity skamp rating scale laboratory school set,child attention deficit hyperactivity disorder adhd effect methylphenidate investigate pharmacodynamic comparison placebo standard b administration methylphenidate condition teacher complete rating classroom set time choose coincide expect peak trough serum concentration b condition analysis variance anova reveal expect difference two condition laboratory classroom set use standard rating scale conners iowa conners new rating scale skamp specifically measure classroom manifestation adhd psychometric property skamp evaluate calculate test retest reliability calculate correlation standard rating scale establish concurrent validity,Wigal SB,1998,Psychopharmacol Bull,,9564198,Wigal SB; Gupta S; Guinta D; Swanson JM,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D018765: Dopamine Uptake Inhibitors; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D015203: Reproducibility of Results,,,https://openalex.org/W166008495,82,14,1,888,142,6,en,en
false,objective subjective measure pharmacodynamic effect adderall treatment child adhd control laboratory classroom setting,randomize double blind crossover study child attention deficit hyperactivity disorder adhd time course effect four adderall mg inactive placebo control active ritalin control evaluate laboratory classroom set establish subjective teacher rating deportment attention objective score math test measurement take every hour across day addition significant time dose effect adderall significant time day effect document placebo condition subjective measure deportment objective measure performance regression analysis use estimate magnitude baseline effect correlation across time use evaluate test retest reliability measure face time dependent placebo effect placebo time adjustment within subject correlation pair measure use evaluate validity math test measure response stimulant medication,Swanson J,1998,Psychopharmacol Bull,,9564199,Swanson J; Wigal S; Greenhill L; Browne R; Waslick B; Lerner M; Williams L; Flynn D; Agler D; Crowley KL; Fineberg E; Regino R; Baren M; Cantwell D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate,,,https://openalex.org/W92757306,161,24,1,1102,186,6,en,en
false,recovery pediatric brain injury psychostimulant medication beneficial,objective assess effect methylphenidate attention memory behavior process speed psychomotor skill child close head injury design double blind placebo control crossover design set outpatient facility child hospital medical center patient ten pediatric subject identify chart review subject meet baseline score hyperactivity conner hyperactivity index intellectual functioning verbal intelligence quotient achieve minimal score two psychometric test subject evidence head injury focal lesion compute tomography scan sequela report time injury severity injury range mild severe subject medically stable time test mean time post injury year month intervention administration methylphenidate placebo main outcome measure percentage change score calculate assess difference baseline end methylphenidate placebo trial result significant difference methylphenidate placebo measure assess behavior attention memory process speed conclusion result study call question effectiveness methylphenidate pediatric head injury population,Williams SE,1998,J Head Trauma Rehabil,https://doi.org/10.1097/00001199-199806000-00007,9582180,Williams SE; Ris MD; Ayyangar R; Schefft BK; Berch D,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D001288: Attention; D001930: Brain Injuries; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007361: Intelligence Tests; D008297: Male; D008568: Memory; D008774: Methylphenidate; D011597: Psychomotor Performance; D016896: Treatment Outcome",,,https://openalex.org/W2020375162,77,11,1,1332,216,13,en,en
false,effectiveness tolerability tomoxetine adult attention deficit hyperactivity disorder,objective author assess experimental noradrenergic compound tomoxetine alternative treatment adult attention deficit hyperactivity disorder adhd method conduct double blind placebo control crossover study tomoxetine adult well characterize adhd result treatment tomoxetine average oral dose mg day well tolerate drug specific improvement adhd symptom highly significant overall sufficiently robust detectable parallel group comparison restrict first week protocol eleven patient show improvement receive tomoxetine compare two patient improve receive placebo significant tomoxetine associate improvement note neuropsychological measure inhibitory capacity stroop test conclusion preliminary study show tomoxetine effective treat adult adhd well tolerate promise result provide support study tomoxetine extend period treatment,Spencer T,1998,Am J Psychiatry,https://doi.org/10.1176/ajp.155.5.693,9585725,Spencer T; Biederman J; Wilens T; Prince J; Hatch M; Jones J; Harding M; Faraone SV; Seidman L,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000553: Ambulatory Care; D000928: Antidepressive Agents; D000069445: Atomoxetine Hydrochloride; D001289: Attention Deficit Disorder with Hyperactivity; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011437: Propylamines; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome,,,https://openalex.org/W2079590493,100,12,1,1095,164,8,en,en
false,membrane phospholipid hypothesis biochemical basis neurodevelopmental concept schizophrenia,neurodevelopmental hypothesis schizophrenia become important feature research field however major drawback lack biochemical basis might draw diverse observation together suggest membrane phospholipid hypothesis provide biochemical basis neurodevelopmental phospholipid concept offer powerful paradigm guide future research,Horrobin DF,1998,Schizophr Res,https://doi.org/10.1016/s0920-9964(97)00151-5,9589514,Horrobin DF,article,D016428: Journal Article; D016454: Review,"D001921: Brain; D001925: Brain Damage, Chronic; D005260: Female; D006801: Humans; D008563: Membrane Lipids; D019965: Neurocognitive Disorders; D010743: Phospholipids; D011247: Pregnancy; D011297: Prenatal Exposure Delayed Effects; D012307: Risk Factors; D012559: Schizophrenia; D013570: Synaptic Membranes",,,https://openalex.org/W2034194523,111,14,1,429,65,3,en,en
false,short term clinical trial evaluate efficacy combination apraclonidine solution betaxolol suspension,acta ophthalmologica scandinavicavolume issue p free access short term clinical trial evaluate efficacy combination apraclonidine solution betaxolol suspension g lamberti g lamberti eye clinic university ferrara ferrarasearch paper authorb pignalosa b pignalosa eye clinic therapy department university naples naplessearch paper authorr fusco r fusco eye clinic therapy department university naples naplessearch paper authorg pignalosa g pignalosa eye clinic university ferrara ferrarasearch paper authora di govanni di govanni eye clinic therapy department university naples naplessearch paper authora sebastiani sebastiani eye clinic university ferrara ferrarasearch paper author g lamberti g lamberti eye clinic university ferrara ferrarasearch paper authorb pignalosa b pignalosa eye clinic therapy department university naples naplessearch paper authorr fusco r fusco eye clinic therapy department university naples naplessearch paper authorg pignalosa g pignalosa eye clinic university ferrara ferrarasearch paper authora di govanni di govanni eye clinic therapy department university naples naplessearch paper authora sebastiani sebastiani eye clinic university ferrara ferrarasearch paper author first publish may http doi org j tb xaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinked inredditwechat abstract available article volume issue november page referencesrelatedinformation,Lamberti G,1997,Acta Ophthalmol Scand Suppl,https://doi.org/10.1111/j.1600-0420.1997.tb00454.x,9589713,Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D017427: Clinical Trial, Phase II; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial","D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D015784: Betaxolol; D002908: Chronic Disease; D002940: Circadian Rhythm; D003000: Clonidine; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D005902: Glaucoma, Open-Angle; D006801: Humans; D007429: Intraocular Pressure; D008297: Male; D008875: Middle Aged; D009883: Ophthalmic Solutions; D016037: Single-Blind Method; D013535: Suspensions; D016896: Treatment Outcome",,,https://openalex.org/W1993878276,130,19,1,2277,369,15,en,en
false,olanzapine treatment resistant bipolar disorder,background evaluate response olanzapine consecutive patient bipolar disorder inadequately responsive standard psychotropic agent method fourteen patient bipolar disorder dsm iv criterion experience persistent affective symptom inadequately responsive least one standard mood stabilizer treat open label olanzapine one author response assess clinical global impression scale modify use bipolar disorder cgi bp result patient receive olanzapine mean sd dosage range mg day mean sd range day treatment patient display much much overall improvement illness general olanzapine well tolerate common side effect sedation tremor dry mouth appetite stimulation weight gain limitation data obtain nonblindly without randomize control group olanzapine add ongoing psychotropic regimen conclusion olanzapine may antimanic mood stabilize effect patient bipolar disorder generally well tolerate control study olanzapine bipolar disorder appear warrant,McElroy SL,1998,J Affect Disord,https://doi.org/10.1016/s0165-0327(98)00002-0,9609675,McElroy SL; Frye M; Denicoff K; Altshuler L; Nolen W; Kupka R; Suppes T; Keck PE; Leverich GS; Kmetz GF; Post RM,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D014150: Antipsychotic Agents; D001569: Benzodiazepines; D001714: Bipolar Disorder; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D012189: Retrospective Studies,,,https://openalex.org/W2002989575,50,5,1,1280,215,10,en,en
false,double blind control comparison novel antipsychotic olanzapine versus haloperidol placebo anxious depressive symptom accompany schizophrenia,depressive symptom common feature schizophrenia may represent core part illness present associate great overall morbidity mortality monotherapy conventional dopamine antagonist may either worsen bestow limited therapeutic benefit accordingly use adjunctive thymoleptics explore contrast olanzapine olz atypical antipsychotic agent offer distinctive pleotropic pharmacology suggestive broad efficacy profile conventional neuroleptic agent week placebo haloperidol hal control trial randomized subject chronic schizophrenia acute exacerbation three fix dose range olz mg evaluate versus hal mg placebo baseline endpoint change brief psychiatric rating scale include anxiety depression cluster item analyze two dose range olz superior placebo p improve mood status whereas hal contribution selective mesolimbic dopaminergic profile activity release dopamine norepinephrine prefrontal cortex serotonin ht c antagonism may explain differential benefit see olz treatment comorbid anxious depressive symptom schizophrenia,Tollefson GD,1998,Biol Psychiatry,https://doi.org/10.1016/s0006-3223(98)00093-6,9611669,Tollefson GD; Sanger TM; Beasley CM; Tran PV,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001007: Anxiety; D001569: Benzodiazepines; D003863: Depression; D004305: Dose-Response Relationship, Drug; D005260: Female; D006220: Haloperidol; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology",,,https://openalex.org/W2087695137,167,21,1,1389,241,6,en,en
false,clonidine potentiate antipsychotic effect neuroleptic chronically ill patient,clonidine centrally act antihypertensive prescribe widely year decrease central norepinephrine activity clonidine investigate antipsychotic preliminary study clonidine test sole antipsychotic agent perform double blind placebo control crossover study compare placebo plus neuroleptic clonidine plus neuroleptic group chronically psychotic patient drop secondary side effect clonidine withdrew study clonidine dosage vary mg per day concurrent neuroleptic one follow haloperidol thiothixene thioridazine mesoridazine fluphenazine average mg per day haloperidol equivalent symptom monitor use psychiatric symptom assessment scale data provide evidence clonidine neuroleptic combination effective neuroleptic alone group patient data suggest central antinorepinephrine activity neuroleptic potentiate far clonidine,Hedges S,1998,Ann Clin Psychiatry,https://doi.org/10.1023/a:1026194411452,9622044,Hedges S; El-Mallakh RS; Issa F; Elkashef A; Bigelow LB; Wyatt RJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000277: Adjuvants, Pharmaceutic; D000316: Adrenergic alpha-Agonists; D000328: Adult; D014150: Antipsychotic Agents; D002908: Chronic Disease; D003000: Clonidine; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011618: Psychotic Disorders; D016896: Treatment Outcome",,,https://openalex.org/W1997403811,100,14,1,1153,190,10,en,en
false,uso de f rmacos na ndrome de hiperatividade com ficit de aten,sindrome de hiperatividade com ficit de aten shda constitui dist rbio comum na inf ncia podendo advir de fatores ex genos ou end genos os quais respons veis por comprometimento cerebral manifestando se por altera e funcionais sistemas motores perceptivos cognitivos e comportamento comprometendo aprendizagem de crian com potencial intelectual adequado autores estudam de f rmacos estimulantes e antidepressivos na shda usando como par metro de efic cia provas de persist ncia motora,Guardiola A,1997,Arq Neuropsiquiatr,https://doi.org/10.1590/s0004-282x1997000400014,9629412,Guardiola A; Terra AR; Pereira KR; Rotta NT,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000704: Analysis of Variance; D000929: Antidepressive Agents, Tricyclic; D001289: Attention Deficit Disorder with Hyperactivity; D004569: Electroencephalography; D005260: Female; D006801: Humans; D007099: Imipramine; D008297: Male; D008774: Methylphenidate; D009460: Neurologic Examination; D009661: Nortriptyline",,,https://openalex.org/W2015797329,68,11,1,532,82,2,es,pt
false,comparison bd tid dose regimen quetiapine seroquel treatment schizophrenia,quetiapine seroquel ici atypical antipsychotic effective treatment positive negative symptom schizophrenia low propensity cause extrapyramidal symptom compound relatively short plasma elimination half life approximately h however since dopamine receptor occupancy correlate poorly plasma concentration antipsychotic plasma elimination half life may predict either duration clinical effect dose frequency accordingly efficacy tolerability three dose regimen mg day give two three divide dos daily mg day give twice daily compare week double blind randomize multicentre parallel group study study recruit hospitalize men woman age year meet dsm iiir criterion acute exacerbation chronic subchronic schizophrenia six hundred eighteen patient randomly assign treatment quetiapine mg tid n mg bd n comparator dose mg bd n day last day randomize treatment primary timepoint efficacy quetiapine mg day effective mg day mg bd consistently superior mg bd measure efficacy total bprs p cgi severity cgi improvement sans p mg tid statistically significantly superior mg bd respect bprs total score p mg bd mg tid group significantly different respect efficacy measure quetiapine generally well tolerate extrapyramidal symptom eps adverse event generally rare occur similar frequency two mg day group quetiapine associate sustain increase plasma prolactin dose data support atypical profile develop preclinical study show quetiapine effective well tolerate antipsychotic give twice daily,King DJ,1998,Psychopharmacology (Berl),https://doi.org/10.1007/s002130050603,9630000,King DJ; Link CG; Kowalcyk B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D001794: Blood Pressure; D003987: Dibenzothiazepines; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D000069348: Quetiapine Fumarate; D012559: Schizophrenia,,,https://openalex.org/W2088612615,99,18,1,2053,372,12,en,en
false,psychomotor slow negative symptom dopamine receptor availability ibzm spect study neuroleptic treat drug free schizophrenic patient,anhedonia psychomotor slow schizophrenia attribute dysfunction dopaminergic neurotransmission differentiate disease drug induce negative symptom examine eight drug free eight neuroleptic treat schizophrenic patient positive negative symptom extrapyramidal side effect assess use standardize rating scale psa amdp sans reaction time motor speed measure use computer aid system striatal dopamine receptor availability assess use ibzm spect psychomotor reaction time parkinsonism affective flattening avolition increase treat patient relative untreated cohort negatively correlate dopamine receptor availability significant positive correlation find parkinsonism affective flattening psychomotor slow avolition positive symptom significantly associate striatal ibzm bind find support hypothesis neuroleptic induced dopamine blockade striatum mimic certain negative symptom affective flattening avolition indicate psychomotor testing may helpful differentiate disease drug induce negative symptom,Heinz A,1998,Schizophr Res,https://doi.org/10.1016/s0920-9964(98)00003-6,9633833,Heinz A; Knable MB; Coppola R; Gorey JG; Jones DW; Lee KS; Weinberger DR,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000328: Adult; D014150: Antipsychotic Agents; D001549: Benzamides; D001921: Brain; D018492: Dopamine Antagonists; D006220: Haloperidol; D006801: Humans; D008875: Middle Aged; D011596: Psychomotor Disorders; D011759: Pyrrolidines; D011930: Reaction Time; D011954: Receptors, Dopamine; D018967: Risperidone; D012559: Schizophrenia; D015899: Tomography, Emission-Computed, Single-Photon",,,https://openalex.org/W2028194451,153,18,1,1315,188,8,en,en
false,olanzapine compare chlorpromazine treatment resistant schizophrenia,purpose study compare efficacy olanzapine chlorpromazine plus benztropine patient treatment resistant schizophrenia one hundred three previously treatment resistant patient schizophrenia diagnose accord dsm iii r criterion give prospective week trial mg day haloperidol eighty four fail respond trial agree randomly assign week fix dose trial either mg day olanzapine alone mg day chlorpromazine plus mg day benztropine mesylate fifty nine subject complete trial primary outcome measure brief psychiatric rating scale total score positive symptom score scale assessment negative symptom global score clinical global impression score analysis variance subject complete study show difference efficacy two drug seven percent olanzapine treat patient respond accord priori criterion chlorpromazine treat patient respond olanzapine treat patient motor cardiovascular side effect chlorpromazine treat patient extrapyramidal symptom akathisia similar two group although antiparkinsonian drug use olanzapine group olanzapine chlorpromazine show similar efficacy total amount improvement either drug modest olanzapine treat patient side effect chlorpromazine treat patient,Conley RR,1998,Am J Psychiatry,https://doi.org/10.1176/ajp.155.7.914,9659857,Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D017109: Akathisia, Drug-Induced; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D010054: Brief Psychiatric Rating Scale; D002746: Chlorpromazine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006220: Haloperidol; D006261: Headache; D006801: Humans; D008297: Male; D000077152: Olanzapine; D010890: Pirenzepine; D011569: Psychiatric Status Rating Scales; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012894: Sleep Stages; D016896: Treatment Outcome; D014987: Xerostomia",,,https://openalex.org/W2062451323,76,7,1,1572,233,8,en,en
false,clonidine add anesthetic solution enhances analgesia improve oxygenation intercostal nerve block thoracotomy,evaluate effect add clonidine bupivacaine postoperative pain control oxygenation intercostal nerve blockade icb thoracotomy attempt distinguish systemic local effect clonidine icb mg kg bupivacaine perform patient undergo thoracotomy patient randomize one three group control group receive bupivacaine saline icb im injection saline im group receive bupivacaine saline icb im injection micro sign g kg clonidine block group receive bupivacaine micro sign g kg clonidine icb im injection saline blood gas visual analog scale va score analgesic demand determine hourly h arrival postoperative care unit pcu patient block group significantly low va score high arterial oxygen tension low analgesic demand first h pcu compare two group difference note thereafter conclude addition clonidine bupivacaine icb lead short term effect enhance postoperative pain control improve arterial oxygenation probably mediate direct effect nerve implication severe pain thoracotomy lead impair ventilation study effect add clonidine bupivacaine intercostal nerve blockade thoracotomy clonidine administer directly nerve enhance analgesia improve oxygenation short time compare systemic administration control anesth analg,Tschernko EM,1998,Anesth Analg,https://doi.org/10.1097/00000539-199807000-00023,9661556,Tschernko EM; Klepetko H; Gruber E; Kritzinger M; Klimscha W; Jandrasits O; Haider W,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000368: Aged; D000698: Analgesia; D000758: Anesthesia; D000779: Anesthetics, Local; D001794: Blood Pressure; D002045: Bupivacaine; D003000: Clonidine; D004311: Double-Blind Method; D004357: Drug Synergism; D005260: Female; D006339: Heart Rate; D006801: Humans; D007273: Injections, Intramuscular; D008297: Male; D008875: Middle Aged; D009407: Nerve Block; D010100: Oxygen; D010149: Pain, Postoperative; D010313: Partial Pressure; D011446: Prospective Studies; D012996: Solutions; D013908: Thoracotomy",,,https://openalex.org/W2053928110,132,17,1,1667,295,10,en,en
false,effect clonidine midazolam premedication perioperative response ketamine anesthesia,use ketamine sole anesthetic induces mark central sympathetic stimulation cause increase heart rate blood pressure bp oxygen consumption vo alpha agonist benzodiazepine use attenuate potentially harmful ketamine induce response double blind randomize placebo control study design compare perioperative metabolic hemodynamic sympathoadrenal response im clonidine microgram kg midazolam microgram kg premedication ketamine anesthesia vo measure continuously use indirect calorimetry asa physical status patient patient receive ketamine mivacurium fentanyl induction anesthesia anesthesia maintain use ketamine infusion fentanyl bolus v preoperatively vo bp decrease significantly administration clonidine midazolam compare placebo p intraoperatively vo high midazolam group placebo clonidine group p postoperatively significant difference bp vo although stay low level clonidine group whole postoperative period clonidine decrease pre postoperative plasma catecholamine concentration p result indicate midazolam ketamine combination may induce potentially harmful metabolic stimulation whereas sympatholytic effect clonidine ketamine anesthetize patient may beneficial perioperative vo decrease ketamine cause sympathetic stimulation ensue increase oxygen consumption anticipate clonidine might attenuate response measure oxygen consumption patient undergo surgery ketamine anesthesia patient treat clonidine ketamine combination low intra postoperative oxygen consumption treat midazolam ketamine combination,Taittonen MT,1998,Anesth Analg,https://doi.org/10.1097/00000539-199807000-00034,9661567,Taittonen MT; Kirvelä OA; Aantaa R; Kanto JH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000759: Adjuvants, Anesthesia; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000758: Anesthesia; D000778: Anesthetics, Dissociative; D001794: Blood Pressure; D002245: Carbon Dioxide; D003000: Clonidine; D004311: Double-Blind Method; D004347: Drug Interactions; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D007649: Ketamine; D008297: Male; D008874: Midazolam; D008875: Middle Aged; D009638: Norepinephrine; D010100: Oxygen; D010101: Oxygen Consumption; D010919: Placebos; D011292: Premedication",,,https://openalex.org/W2085393224,104,13,1,1976,299,13,en,en
false,clonidine impair redistribution hypothermia induction anesthesia,clonidine commonly give premedication impair normal thermoregulatory response warm cold stimulus depress sympathetic tone study effect premedication clonidine redistribution hypothermia induce induction anesthesia sixteen asa physical status ii patient randomly assign receive either clonidine microgram placebo anesthesia induce min later thiopental fentanyl vecuronium v maintain administration isoflurane monitor central core tympanic temperature skin surface temperature forearm fingertip h induction anesthesia surgery estimate skin blood flow level forearm use laser doppler period core temperature decrease comparably two group patient degree c degree c degree c degree c clonidine placebo group respectively forearm fingertip surface temperature gradient decrease similarly two group evidence cutaneous vasoconstriction laser doppler index fingertip increase similarly two group forearm fingertip temperature gradient conclude premedication clonidine significantly impair profile central hypothermia induce heat redistribution induction anesthesia induction general anesthesia associate redistribution hypothermia study show premedication oral clonidine worsen decrease core temperature result general anesthesia,Bernard JM,1998,Anesth Analg,https://doi.org/10.1097/00000539-199807000-00035,9661568,Bernard JM; Fulgencio JP; Delaunay L; Bonnet F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000768: Anesthesia, General; D001794: Blood Pressure; D001831: Body Temperature; D001833: Body Temperature Regulation; D003000: Clonidine; D005260: Female; D006339: Heart Rate; D006801: Humans; D007035: Hypothermia; D008297: Male; D008875: Middle Aged; D010919: Placebos; D012881: Skin Temperature",,,https://openalex.org/W2001915544,86,11,1,1734,280,13,en,en
false,multicenter evaluation efficacy safety mg sustain release bupropion tablet versus placebo depress outpatient,multicenter randomize double mask placebo control parallel group study compare antidepressant efficacy safety bupropion sustain release sr tablet mg qd mg bid placebo outpatient moderate severe depression study consist week placebo phase follow week active treatment bupropion sr mg mg qd n mg mg bid n placebo n efficacy measure change score item hamilton rating scale depression ham clinical global impression severity illness cgi clinical global impression improvement illness cgi scale safety monitor regular assessment vital sign adverse event well pretreatment posttreatment physical clinical laboratory examination day bupropion sr treatment effective relieve symptom depression placebo compare receive placebo patient bupropion sr mg group significantly reduce symptom treatment day measure item ham cgi cgi scale p bupropion sr well tolerate serious adverse event report bupropion treat patient report adverse event mild moderate intensity clinically significant change vital sign laboratory test result physical finding observe great mean weight loss observe end treatment bupropion sr mg kg bupropion sr mg kg group compare placebo kg find bupropion sr mg administer either twice daily effective placebo treat depression daily dose appear least effective twice daily dose prove true depressed patient may able benefit convenience improve tolerability associate daily dosing,Reimherr FW,1998,Clin Ther,https://doi.org/10.1016/s0149-2918(98)80060-x,9663366,Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D018687: Antidepressive Agents, Second-Generation; D016642: Bupropion; D003692: Delayed-Action Preparations; D003866: Depressive Disorder; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011569: Psychiatric Status Rating Scales",,,https://openalex.org/W2024862901,147,21,1,2034,367,11,en,en
false,effect oral clonidine premedication hemodynamic response sedate nasal fiberoptic intubation,although oral clonidine premedication know reduce hemodynamic response general anesthesia effect hemodynamic response sedate fiberoptic nasal intubation yet examine aim compare effect clonidine premedication hemodynamic response atropine hydroxyzine premedication sedate fiberoptic nasal intubation thirty adult patient randomly assign one two group group patient n premedicated atropine sulfate mg kg hydroxyzine hydrochloride mg kg intramuscularly group patient n premedicated clonidine microgram kg orally compare hemodynamic response sedation level fiberoptic nasal intubation two group significant difference sedation level postoperative complaint two group oral clonidine premedication group blunt hemodynamic change fiberoptic intubation profound hypotension mark bradycardia note group conclude oral clonidine premedication might contribute hemodynamic stability sedate fiberoptic nasal intubation,Yokota S,1998,Nagoya J Med Sci,,9664766,Yokota S; Komatsu T; Yano K; Taki K; Shimada Y,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001285: Atropine; D003000: Clonidine; D016292: Conscious Sedation; D005336: Fiber Optic Technology; D006439: Hemodynamics; D006801: Humans; D006919: Hydroxyzine; D007441: Intubation, Gastrointestinal; D008875: Middle Aged; D011229: Preanesthetic Medication",,,https://openalex.org/W80139857,106,14,1,1224,193,8,en,en
false,methylphenidate therapy improve cognition mood function brain tumor patient,patient malignant glioma develop progressive neurobehavioral deficit course illness cause effect disease effect radiation chemotherapy seek determine whether methylphenidate treatment would improve patient neurobehavioral function despite expect neurologic deterioration thirty patient primary brain tumor underwent neuropsychologic assessment treatment methylphenidate ability function activity daily live magnetic resonance image mri find also document patient assess mg methylphenidate twice daily significant improvement cognitive function observe mg twice daily dose functional improvement include improve gait increase stamen motivation perform activity one case increase bladder control adverse effect minimal immediately resolve treatment discontinue increase seizure frequency majority patient glucocorticoid therapy able decrease dose gain cognitive function ability perform activity observe set progressive neurologic injury document mri half subject study demonstrate improve patient function set progressive neurologic illness methylphenidate widely consider adjuvant brain tumor therapy,Meyers CA,1998,J Clin Oncol,https://doi.org/10.1200/jco.1998.16.7.2522,9667273,Meyers CA; Weitzner MA; Valentine AD; Levin VA,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000293: Adolescent; D000328: Adult; D000339: Affect; D000368: Aged; D001921: Brain; D001932: Brain Neoplasms; D000697: Central Nervous System Stimulants; D003071: Cognition; D005260: Female; D005910: Glioma; D006801: Humans; D008297: Male; D001523: Mental Disorders; D008774: Methylphenidate; D008875: Middle Aged; D009422: Nervous System Diseases; D009483: Neuropsychological Tests; D016896: Treatment Outcome,,,https://openalex.org/W1896466592,87,14,1,1503,223,10,en,en
false,methylphenidate treatment cocaine abuser adult attention deficit hyperactivity disorder,attention deficit hyperactivity disorder adhd common among cocaine abuser seek treatment open trial carry assess efficacy sustain release methylphenidate treatment cocaine abuse among individual adhd twelve patient meet dsm iv diagnostic criterion adult adhd cocaine dependence enter week trial divide daily sustain release methylphenidate range mg addition pharmacotherapy patient also receive individual weekly relapse prevention therapy individual assess weekly adhd symptom vital sign urine toxicology obtain time week patient enter complete least week study complete entire study use semistructured clinical interview self report assessment patient report reduction attention difficulty hyperactivity impulsivity self report cocaine use crave decrease significantly importantly cocaine use confirm urine toxicology also decrease significantly preliminary data suggest close supervision combine intervention sustain release methylphenidate relapse prevention therapy may effective treat individual adult adhd cocaine dependence,Levin FR,1998,J Clin Psychiatry,https://doi.org/10.4088/jcp.v59n0605,9671342,Levin FR; Evans SM; McDowell DM; Kleber HD,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000553: Ambulatory Care; D001289: Attention Deficit Disorder with Hyperactivity; D001521: Behavior Therapy; D003042: Cocaine; D019970: Cocaine-Related Disorders; D003131: Combined Modality Therapy; D015897: Comorbidity; D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010555: Personality Inventory; D010865: Pilot Projects; D011569: Psychiatric Status Rating Scales; D055502: Secondary Prevention; D015813: Substance Abuse Detection,,,https://openalex.org/W2017312379,97,9,1,1350,200,7,en,en
false,double blind placebo control study risperidone adult autistic disorder pervasive developmental disorder,background neurobiological research implicate dopamine serotonin system pathogenesis autism open label report suggest serotonin dopamine antagonist risperidone may safe effective reduce interfere symptom patient autism method thirty one adult age mean sd year autistic disorder n pervasive developmental disorder otherwise specify n participate week double blind placebocontrolled trial risperidone patient treat placebo subsequently receive week open label trial risperidone result person complete study patient treat risperidone categorize responder daily dose mean sd mg com par none placebo group p risperidone superior placebo reduce repetitive behavior p aggression p anxiety nervousness p depression p irritability p overall behavioral symptom autism p objective measurable change social behavior language occur nine patient receive treatment open label risperidone follow double blind placebo phase respond mild transient sedation risperidone well tolerate evidence extrapyramidal effect cardiac event seizure conclusion risperidone effective placebo short term treatment symptom autism adult,McDougle CJ,1998,Arch Gen Psychiatry,https://doi.org/10.1001/archpsyc.55.7.633,9672054,McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000374: Aggression; D014150: Antipsychotic Agents; D001321: Autistic Disorder; D002659: Child Development Disorders, Pervasive; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012720: Severity of Illness Index; D016896: Treatment Outcome; D015430: Weight Gain",,,https://openalex.org/W2118648637,132,17,1,1530,265,2,en,en
false,effect apraclonidine postoperative intraocular hypertension cataract extraction,conduct double mask prospective study evaluate effect apraclonidine postoperative intraocular pressure iop patient undergo extracapsular cataract extraction ecce intraocular lens iol implantation fifty four patient schedule ecce randomly divide three group first group receive one drop apraclonidine topically one hour surgery immediately end procedure second group receive regimen apraclonidine third group receive artificial tear control group iop measure h preoperatively h postoperatively measurement make use goldmann applanation tonometer surgeon know group patient belong preoperative mean iop mmhg first group mmhg second mmhg control group difference significant p mean iop early postoperative visit h significantly low first group mmhg second mmhg control group mmhg p mean postoperative iop h significantly low first group mmhg second mmhg control group mmhg p find indicate topical apraclonidine control early postoperative intraocular hypertension cataract extraction without side effect drop effective,Simşek S,1998,Eur J Ophthalmol,https://doi.org/10.1177/112067219800800203,9673473,Simşek S; Demirok A; Yaşar T; Cinal A; Bayram A; Yilmaz OF,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D002387: Cataract Extraction; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007429: Intraocular Pressure; D019654: Lens Implantation, Intraocular; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D011183: Postoperative Complications; D011446: Prospective Studies; D014065: Tonometry, Ocular",,,https://openalex.org/W4302400554,107,15,1,1634,303,9,en,en
false,response growth hormone attention deficit hyperactivity disorder effect methylphenidate pemoline therapy,determine whether treatment attention deficit hyperactivity disorder adhd methylphenidate hydrochloride pemoline diminish response growth hormone gh therapy patient idiopathic gh deficiency ighd idiopathic short stature iss national cooperative growth study database use identify patient year age ighd iss within group treat methylphenidate pemoline adhd growth response gh treatment change height standard deviation score sd compare patient ighd iss treat adhd use stepwise multiple regression analysis ighd cohort patient treat adhd iss cohort patient treat adhd high percentage male treat adhd cohort ighd cohort change height sd positively associate number year gh treatment parent height body mass index gh injection schedule negatively associate height sd initiation gh therapy age maximum stimulate gh level use methylphenidate pemoline negative effect change height sd magnitude effect small similar effect note iss cohort body mass index use methylphenidate pemoline effect change height sds concurrent adhd therapy associate slight decrease change height sd gh treatment patient ighd iss even ighd magnitude effect small deter use concurrent therapy,Rao JK,1998,Pediatrics,https://doi.org/10.1542/peds.102.s3.497,9685452,Rao JK; Julius JR; Breen TJ; Blethen SL,article,D016428: Journal Article,D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D005260: Female; D006128: Growth; D006130: Growth Disorders; D013006: Growth Hormone; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010389: Pemoline,,,https://openalex.org/W2106031705,119,16,1,1820,339,8,en,en
false,medical claim database design health outcome comparison quetiapine seroquel seroquel trademark property zeneca limit usual care antipsychotic medication,treat schizophrenia expensive prevent rehospitalization patient schizophrenia provide attractive opportunity cost save especially patient revolve door multiple episode schizophrenia reduce occurrence extrapyramidal symptom adverse event associate standard antipsychotic agent may increase compliance reduce rate rehospitalization patient schizophrenia quetiapine seroquel ici zeneca pharmaceutical new dibenzothiazepine antipsychotic agent low propensity extrapyramidal symptom describe unique methodology compare quetiapine usual care medication real world treatment set trial objective determine therapy new atypical antipsychotic agent reduce rate rehospitalization therefore treatment cost use two secondary medical claim database define minimal threshold revolve door status admission per year definition allow trial focus subpopulation schizophrenic patient great potential cost save either new atypical antipsychotic quetiapine usual care therapy describe approach use trial,Hong WW,1998,Schizophr Res,https://doi.org/10.1016/s0920-9964(98)00040-1,9690334,Hong WW; Rak IW; Ciuryla VT; Wilson AM; Kylstra JW; Meltzer HY; Carpenter WT; Lehman A; Arvanitis LA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D016208: Databases, Factual; D003987: Dibenzothiazepines; D016527: Drug Costs; D005260: Female; D006801: Humans; D007345: Insurance Claim Review; D008297: Male; D008875: Middle Aged; D010043: Outcome and Process Assessment, Health Care; D010359: Patient Readmission; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W1705397834,195,28,1,1284,188,8,en,en
false,exploratory haloperidol control dose finding study ziprasidone hospitalize patient schizophrenia schizoaffective disorder,ninety patient schizophrenia schizoaffective disorder accord dsm iii r criterion participate double blind exploratory dose range trial single blind washout period day patient randomly assign receive one four fix dos new antipsychotic ziprasidone n n n n mg day haloperidol mg day n week dose response relationship among ziprasidone group establish improvement clinical global impression severity cgi score p brief psychiatric rating scale bprs total score p intent treat analysis mean change baseline bprs total bprs psychosis core cgi score demonstrate ziprasidone mg day comparable haloperidol reduce overall psychopathology positive symptom superior ziprasidone mg day despite small sample size short duration trial improvement cgi ziprasidone mg day haloperidol mg day statistically significantly great ziprasidone mg day p p respectively percentage patient classify responder bprs total improvement cgi improvement score scale ziprasidone mg day group similar haloperidol group nonsignificantly great ziprasidone mg day group assessment clinical efficacy improvement associate ziprasidone mg day mg day mg day similar concomitant benztropine use time study less frequent ziprasidone mg day haloperidol haloperidol associate sustain hyperprolactinemia unlike ziprasidone transient elevation prolactin return normal within dose interval observe ziprasidone well tolerate incidence adverse event similar group result study suggest ziprasidone mg day effective haloperidol mg day reduce overall psychopathology positive symptom acute exacerbation schizophrenia schizoaffective disorder low potential induce extrapyramidal symptom j clin psychopharmacol,Goff DC,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199808000-00009,9690695,Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004409: Dyskinesia, Drug-Induced; D005260: Female; D006220: Haloperidol; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D009460: Neurologic Examination; D010879: Piperazines; D011569: Psychiatric Status Rating Scales; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D013844: Thiazoles; D016896: Treatment Outcome",,,https://openalex.org/W1988730265,143,15,1,2395,425,12,en,en
false,olanzapine induce reversible priaprism,deirmenjian john md erhart stephen md wirshing donna md spellberg brad j ba wirshing william c md author information,Deirmenjian JM,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199808000-00023,9690708,Deirmenjian JM; Erhart SM; Wirshing DA; Spellberg BJ; Wirshing WC,article,D002363: Case Reports; D016430: Clinical Trial; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,"D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D000077152: Olanzapine; D010890: Pirenzepine; D011317: Priapism; D018967: Risperidone; D012559: Schizophrenia; D016896: Treatment Outcome",,,https://openalex.org/W2315546184,39,3,1,136,31,1,en,de
false,methylphenidate modify impact response frequency stimulus sequence performance event relate potential child attention deficit hyperactivity disorder,twenty six child attention deficit hyperactivity disorder adhd participate double blind trial consist consecutive week placebo methylphenidate mg day mg kg day expect stimulant therapy result moderate weight loss increase somatic complaint teacher parent report reduce inattentiveness aggression oppositionality phase trial patient test choice reaction time task assess two aspect task presumably affect response selection response frequency ratio target nontargets vs stimulus sequence alternation v repetition manipulation yield expect result performance event relate potential erps stimulant treatment increase accuracy speed among young child curtail variability reaction time sample whole however methylphenidate affect erps combination result imply enhancement performance methylphenidate involve demand response selection examine study,Smithee JA,1998,J Abnorm Child Psychol,https://doi.org/10.1023/a:1022698232481,9700516,Smithee JA; Klorman R; Brumaghim JT; Borgstedt AD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D001143: Arousal; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002540: Cerebral Cortex; D002648: Child; D004193: Discrimination Learning; D004569: Electroencephalography; D005071: Evoked Potentials; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010364: Pattern Recognition, Visual; D011597: Psychomotor Performance; D011930: Reaction Time",,,https://openalex.org/W2183256165,188,25,1,1130,181,7,en,en
false,revise conners parent rating scale cpr r factor structure reliability criterion validity,conners parent rating scale cpr popular research clinical tool obtain parental report childhood behavior problem present study introduce revise cpr cpr r norm derive large representative sample north american child use confirmatory factor analysis develop definitive factor structure updated item content reflect recent knowledge development concern childhood behavior problem exploratory confirmatory factor analytic result reveal seven factor model include follow factor cognitive problem oppositional hyperactivity impulsivity anxious shy perfectionism social problem psychosomatic psychometric property revise scale appear adequate demonstrate good internal reliability coefficient high test retest reliability effective discriminatory power advantage cpr r include correspond factor structure conners teacher rating scale revise comprehensive symptom coverage attention deficit hyperactivity disorder adhd relate disorder factor congruence original cpr well similarity parent rating scale discus,Conners CK,1998,J Abnorm Child Psychol,https://doi.org/10.1023/a:1022602400621,9700518,Conners CK; Sitarenios G; Parker JD; Epstein JN,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002653: Child Behavior Disorders; D002675: Child, Preschool; D005260: Female; D006801: Humans; D008297: Male; D010552: Personality Assessment; D011594: Psychometrics; D015203: Reproducibility of Results",,,https://openalex.org/W1514128735,105,20,1,1242,185,6,en,en
false,revision restandardization conners teacher rating scale ctrs r factor structure reliability criterion validity,conners teacher rating scale ctrs commonly use research clinical tool assess child behavior classroom present study introduce revise ctrs ctrs r improve original ctrs establish normative data large representative north american sample derive factor structure use advance statistical technique update item content reflect current conceptualization childhood disorder use confirmatory factor analysis six factor structure find include hyperactivity impulsivity perfectionism inattention cognitive problem social problem oppositionality anxious shy factor reliability scale measure test retest correlation internal consistency generally satisfactory use scale factor discriminate attention deficit hyperactivity disorder normal child percent child correctly classify support validity scale indicate excellent clinical utility similarity difference original ctrs factor structure ctrs r factor structure discus,Conners CK,1998,J Abnorm Child Psychol,https://doi.org/10.1023/a:1022606501530,9700520,Conners CK; Sitarenios G; Parker JD; Epstein JN,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D001289: Attention Deficit Disorder with Hyperactivity; D019958: Attention Deficit and Disruptive Behavior Disorders; D002648: Child; D002653: Child Behavior Disorders; D005260: Female; D006801: Humans; D008297: Male; D015588: Observer Variation; D010552: Personality Assessment; D011594: Psychometrics; D012016: Reference Values; D015203: Reproducibility of Results; D012931: Social Environment,,,https://openalex.org/W1564761171,131,22,1,1190,186,6,en,en
false,psychotropic medication use risk epithelial ovarian cancer,long term use psychotropic medication may increase risk epithelial ovarian cancer increase gonadotropin secretion direct ovarian stimulation adrenergic receptor effect may affect ovarian cancer pathogenesis early case control study find prior use antidepressant benzodiazepine tranquilizer associate fold increase risk epithelial ovarian cancer however study lack detail type psychotropic medication length use categorization specific action medication hypothalamic pituitary ovarian axis new case control study conduct eastern massachusetts new hampshire nh identify woman newly diagnose ovarian cancer may march interview woman diagnose malignant borderline epithelial ovarian tumor control identify random digit dial use town book residential listing name age precinct participant ask provide name medication use month long age first use total month year use psychotropic medication include amphetamine sedative barbiturate anticonvulsant antidepressant antipsychotic self report use psychotropic medication month long associate statistically significant increase risk invasive ovarian cancer odds ratio confidence interval ci relative nonusers risk great whose first use occur premenopausally year ci association largely confine use medication operate dopaminergic mechanism ci gabaergic pathway ci oppose serotoninergic pathway ci result consistent hypothesis psychotropic medication induce gonadotropin secretion turn may increase ovarian cancer risk however study confirm find determine whether apply medication specific neuroendocrine action premature advise change clinical practice conclude medication indeed play role etiology ovarian cancer,Harlow BL,1998,Cancer Epidemiol Biomarkers Prev,,9718222,Harlow BL; Cramer DW; Baron JA; Titus-Ernstoff L; Greenberg ER,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D017677: Age Distribution; D000368: Aged; D002277: Carcinoma; D016022: Case-Control Studies; D015331: Cohort Studies; D016001: Confidence Intervals; D005260: Female; D006801: Humans; D015994: Incidence; D008404: Massachusetts; D008875: Middle Aged; D016017: Odds Ratio; D010051: Ovarian Neoplasms; D011619: Psychotropic Drugs; D012307: Risk Factors; D015996: Survival Rate,,,https://openalex.org/W2119648721,66,10,1,2342,401,12,en,en
false,intrathecal intravenous clonidine reduces experimental thermal capsaicin induce pain hyperalgesia normal volunteer,clonidine approve intraspinal administration treatment neuropathic cancer pain study suggest analgesic effect systemic clonidine administration purpose study compare analgesic effect intrathecal iv clonidine acute noxious stimulation hyperalgesia intradermal capsaicin injection volunteer sixteen healthy volunteer receive intradermal injection capsaicin microg iv intrathecal injection clonidine microg randomize double blind manner pain area mechanical hyperalgesia allodynia determine specify interval addition pain noxious heat stimulation determine capsaicin injection produce pain follow hyperalgesia allodynia intrathecal iv injection microg clonidine reduce capsaicin induce pain area hyperalgesia intrathecal clonidine microg reduce pain heat stimulation whereas iv clonidine group differ hemodynamic sedative effect clonidine data support value intraspinal administration clonidine treatment acute pain pain state associate hyperalgesia similarly suggest analgesia systemic administration alpha adrenergic agonist weak produce sedation reduce blood pressure extent experimental pain condition use study reflect patient acute chronic pain data support spinal rather iv injection clonidine analgesia,Eisenach JC,1998,Anesth Analg,https://doi.org/10.1097/00000539-199809000-00018,9728835,Eisenach JC; Hood DD; Curry R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000316: Adrenergic alpha-Agonists; D000328: Adult; D000700: Analgesics; D001794: Blood Pressure; D002211: Capsaicin; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006358: Hot Temperature; D006801: Humans; D006930: Hyperalgesia; D007275: Injections, Intravenous; D007278: Injections, Spinal; D008297: Male; D010146: Pain",,,https://openalex.org/W4229575174,136,18,1,1666,266,12,en,en
false,prediction stimulant response child attention deficit hyperactivity disorder,discrimination stimulant respond nonresponding group child attention deficit hyperactivity disorder adhd basis demographic neurophysiologic behavioral variable would beneficial clinical theoretical reason previous researcher identify many predictor variable relationship predictor criterion variable generally subtle addition investigation consider relative predictive power variable present study evaluate multivariate relationship several predictor variable response medication child adhd neurologic status inattention overactivity find likely predict good response psychostimulants whether rat parent teacher although number variable predict positive psychostimulant response strength predictive association suggest minimal clinical usefulness,Thomson JB,1998,J Child Adolesc Psychopharmacol,https://doi.org/10.1089/cap.1998.8.125,9730078,Thomson JB; Varley CK,article,D016430: Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D000300: Adoption; D000367: Age Factors; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D002675: Child, Preschool; D005190: Family; D005260: Female; D006801: Humans; D008297: Male; D011153: Population; D011237: Predictive Value of Tests; D012737: Sex Factors; D012959: Socioeconomic Factors",,,https://openalex.org/W2011634732,90,9,1,979,140,6,en,en
false,dosis wirkungsbeziehung von clonidin zu epidural appliziertem ropivacain bei orthop dischen eingriffen der unteren extremit,objective aim study investigate preliminarydose range effect clonidine add ropivacaine epidural analgesia elective orthopedic surgery low limb cause minimum cardiovascular side effect method patient randomly assign receive double blind fashion mixture mg cm height ropivacaine plus saline mg cm ropivacaine plus microgram microgram microgram microgram microgram clonidine epidural analgesia sensory motor function determine define time interval minute heart rate blood pressure control sedation score judge postoperative segment regression pin prick onset pain record result six group comparable demographic data term onset time prolongation analgesia reach min p microgram clonidine min p microgram clonidine min p microgram clonidine compare min saline equal manner segment regression pin prick extend min p microgram clonidine min p microgram clonidine min p microgram clonidine min saline heart rate drop group mean arterial pressure decrease significantly group microgram clonidine sedation score increase continuously saline microgram clonidine conclusion conclude microgram clonidine significantly enhance duration analgesia epidurally administer ropivacaine mean mg time interval long one mg ropivacaine alone side effect form decrease arterial pressure cardiovascular monitoring seem essential enhanced analgesia duration time interval reload epidural anaesthesia increase,Engel JM,1998,Anaesthesist,https://doi.org/10.1007/s001010050597,9740930,Engel JM; Hussmann R; Gürtler KH; Menges T; Hempelmann G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000368: Aged; D000577: Amides; D015360: Analgesia, Epidural; D000779: Anesthetics, Local; D003000: Clonidine; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007866: Leg; D008297: Male; D008875: Middle Aged; D016343: Monitoring, Intraoperative; D019637: Orthopedic Procedures; D000077212: Ropivacaine",,,https://openalex.org/W2087523115,125,13,1,2106,381,16,de,en
false,dopamine transporter occupancy human brain induce therapeutic oral methylphenidate,therapeutic effect methylphenidate treatment attention deficit disorder attribute ability increase synaptic concentration dopamine block dopamine transporter however level dopamine transporter blockade achieve therapeutic methylphenidate know study measure first time dopamine transporter occupancy orally administer methylphenidate human brain rate uptake brain positron emission tomography pet c cocaine use estimate dopamine transporter occupancy different dos oral methylphenidate seven normal subject mean age year sd addition pharmacokinetics oral methylphenidate measure baboon brain use pet c methylphenidate administer orogastric tube minute administration oral methylphenidate produce dose dependent blockade dopamine transporter mean sd mg sd mg sd mg sd mg sd mg estimate dose oral methylphenidate require block dopamine transporter correspond mg kg oral methylphenidate reach peak concentration brain minute administration oral methylphenidate effective block dopamine transporter weight adjust use therapeutically mg kg likely occupy dopamine transporter time reach peak brain uptake oral methylphenidate brain corresponds well report time course reach peak behavioral effect,Volkow ND,1998,Am J Psychiatry,https://doi.org/10.1176/ajp.155.10.1325,9766762,Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Hitzemann R; Pappas N,article,"D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000328: Adult; D000818: Animals; D001289: Attention Deficit Disorder with Hyperactivity; D001921: Brain; D001923: Brain Chemistry; D002250: Carbon Radioisotopes; D002352: Carrier Proteins; D003042: Cocaine; D004298: Dopamine; D018492: Dopamine Antagonists; D050483: Dopamine Plasma Membrane Transport Proteins; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008562: Membrane Glycoproteins; D026901: Membrane Transport Proteins; D008774: Methylphenidate; D009419: Nerve Tissue Proteins; D010215: Papio; D014055: Tomography, Emission-Computed",,,https://openalex.org/W1977634040,104,14,1,1715,304,7,en,en
false,failure clonidine stimulate feed healthy human,adrenergic system involve regulation food intake animal effect feed human unknown hypothesize clonidine administration would stimulate food intake healthy human subject ten men woman physically psychiatrically healthy receive clonidine g kg placebo orally blind balance randomize order consumption liquid test meal measure also serum growth hormone level use secondary measure clonidine effect visual analog scale rating hunger satiety sedation obtain test meal subset five subject also receive g kg clonidine addition two trial describe test meal consumption great follow placebo follow clonidine sedation rating substantially high time point clonidine correlate meal consumption correlation coefficient r p hunger satiety rating differ g kg dose provide different effect feed see placebo contrary hypothesis clonidine stimulate food intake human sedation associate clonidine administration may suppress effect feed,Crow S,1998,Pharmacol Biochem Behav,https://doi.org/10.1016/s0091-3057(98)00127-0,9768566,Crow S; Meller W; Praus B; Raatz S; Mitchell J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000316: Adrenergic alpha-Agonists; D000328: Adult; D001835: Body Weight; D003000: Clonidine; D004311: Double-Blind Method; D004435: Eating; D005260: Female; D006728: Hormones; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2068595430,59,9,1,1295,225,12,en,en
false,effect premedication dose requirement propofol comparison clonidine hydroxyzine,influence single dose clonidine microgram kg hydroxyzine mg kg intraoperative propofol requirement determine male patient asa undergo elective orthopaedic surgery patient randomly allocate receive either clonidine hydroxyzine orally h induction anaesthesia load dose propofol mg kg mivacurium mg kg alfentanil microgram kg anaesthesia maintain standardize propofol infusion supplement nitrous oxide oxygen surgery additional propofol bolus mg kg administer heart rate mean arterial pressure increase compare preinduction value clonidine group demonstrate decrease total propofol requirement p reduction additional propofol bolus p comparison hydroxyzine group intraoperative heart rate mean arterial pressure significantly low clonidine group patient need treatment ephedrine hypotension bradycardia recovery psychomotor function discharge recovery room delay clonidine group study indicate microgram kg clonidine give premedication asa patient reduces intraoperative propofol requirement comparison mg kg hydroxyzine without induce adverse effect recovery haemodynamic stability,Guglielminotti J,1998,Br J Anaesth,https://doi.org/10.1093/bja/80.6.733,9771298,Guglielminotti J; Descraques C; Petitmaire S; Almenza L; Grenapin O; Mantz J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D018686: Anesthetics, Intravenous; D014151: Anti-Anxiety Agents; D001794: Blood Pressure; D003000: Clonidine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004347: Drug Interactions; D006339: Heart Rate; D006801: Humans; D006919: Hydroxyzine; D006993: Hypnotics and Sedatives; D008297: Male; D011229: Preanesthetic Medication; D015742: Propofol; D013565: Sympatholytics",,,https://openalex.org/W2102088080,99,14,1,1479,251,8,en,en
false,epidural fentanyl adrenaline clonidine adjuvant local anaesthetic surgical analgesia meta analyse analgesia side effect,background risk benefit ratio add fentanyl adrenaline clonidine epidural local anaesthetic improve intraoperative analgesia unclear meta analysis perform clarify issue method trial retrieve search consider prospective control epidural analgesia without combine general anaesthesia plan occurrence pain surgery side effect report paper enter meta analysis reach predefined minimum quality score pool odds ratio confidence interval ci compute p consider significant result eighteen trial include analysis fentanyl fentanyl decrease likelihood pain ci p increase incidence pruritus ci p sedation ci p compare control local anaesthetic without fentanyl fentanyl effect respiratory depression nausea vomit apgar score one case respiratory depression newborn observe low number trial select evaluation adrenaline clonidine feasible conclusion analysis current literature show addition fentanyl local anaesthetic intraoperative epidural analgesia safe advantageous reduction incidence pain surgery quantitatively high therefore clinically significant side effect mild randomize control trial perform order clarify role adrenaline clonidine epidural adjuvant surgical analgesia,Curatolo M,1998,Acta Anaesthesiol Scand,https://doi.org/10.1111/j.1399-6576.1998.tb05349.x,9773134,Curatolo M; Petersen-Felix S; Scaramozzino P; Zbinden AM,article,D016428: Journal Article; D017418: Meta-Analysis,"D000759: Adjuvants, Anesthesia; D015360: Analgesia, Epidural; D000779: Anesthetics, Local; D003000: Clonidine; D004837: Epinephrine; D005283: Fentanyl; D006801: Humans; D016239: MEDLINE; D016032: Randomized Controlled Trials as Topic; D013514: Surgical Procedures, Operative; D016896: Treatment Outcome",,,https://openalex.org/W2091953821,146,20,1,1699,295,15,en,en
false,chronic olanzapine sertindole treatment result reduce oral chewing movement rat compare haloperidol,chronic haloperidol treatment typically produce late onset purposeless oral chew movement laboratory rat prevalence chronic clozapine produce movement base phenomenologic pharmacologic similarity rat chew movement human tardive dyskinesia td animal movement often use model tardive dyskinesia td report result association oral chew movement rat chronic administration two new antipsychotic drug olanzapine sertindole antipsychotic drug low incidence acute parkinsonism human study candidate show low tardive dyskinesia risk neither new drug produce significant incidence haloperidol like chew rat movement rating chronic administration differ placebo whereas haloperidol produce prevalence purposeless chew prevalence significantly increase placebo low rate oral dyskinesia rat consistent several preclinical characteristic drug correlate low acute motor side effect clinical trial propose although yet test human animal result predict low td liability drug,Gao XM,1998,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(98)00039-6,9778664,Gao XM; Sakai K; Tamminga CA,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000818: Animals; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D004409: Dyskinesia, Drug-Induced; D006220: Haloperidol; D007093: Imidazoles; D007211: Indoles; D008297: Male; D008409: Mastication; D000077152: Olanzapine; D010890: Pirenzepine; D051381: Rats; D017207: Rats, Sprague-Dawley",,,https://openalex.org/W2049260133,116,16,1,1345,222,8,en,en
false,saturday night fever ecstasy relate problem london accident emergency department,objective report extent nature acute mdma ecstasy relate problem present large london hospital accident emergency e department method computerise attendance record patient attend e department month period retrospectively screen potential case thus identify case note systematically review confirm history mdma use extract relevant data result forty eight consecutive mdma relate case identify year age group majority present early hour weekend consume drug night club mean number tablet consume two almost take mdma polydrug use common half sample concurrently take another illicit substance commonly stimulant amphetamine cocaine wide range adverse clinical feature find common symptom vague non specific feel strange unwell however many patient collapse lose consciousness common sign elicit relate sympathetic overactivity agitation disturb behaviour increase temperature serious complication delirium seizure profound unconsciousness coma commoner mdma use combination substance conclusion young adult present late night weekend exhibit symptom sympathetic overactivity disturb behaviour increased temperature saturday night fever use stimulant dance drug especially mdma suspect mdma use appear occur isolation clinical picture likely complicate multiple rather single drug ingestion pose increase diagnostic management challenge e staff typically represent front line response dance drug relate problem,Williams H,1998,J Accid Emerg Med,https://doi.org/10.1136/emj.15.5.322,9785160,Williams H; Dratcu L; Taylor R; Roberts M; Oyefeso A,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D004636: Emergency Service, Hospital; D006213: Hallucinogens; D006801: Humans; D008131: London; D018817: N-Methyl-3,4-methylenedioxyamphetamine; D019966: Substance-Related Disorders",,,https://openalex.org/W2031713060,95,17,1,1979,343,14,en,en
false,effect methylphenidate aggressive urban child attention deficit hyperactivity disorder,determine efficacy methylphenidate mph clinical population aggressive urban child diagnose attention deficit hyperactivity disorder adhd previous study prepubertal child adhd mph show effective compare placebo eighteen inner city child age year diagnose adhd attend summer treatment program youth disruptive behavior disorder participate double blind placebo trial assessment data obtain staff program parent home base staff rating child behavior program academic classroom child display significant improvement adhd symptom aggressive behavior low high dose mph condition home parent guardian report significant difference placebo mph behavior rating set mph well tolerate side effect find active drug condition,Bukstein OG,1998,J Clin Child Psychol,https://doi.org/10.1207/s15374424jccp2703_10,9789193,Bukstein OG; Kolko DJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000374: Aggression; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D003631: Day Care, Medical; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D010552: Personality Assessment; D012931: Social Environment; D016896: Treatment Outcome; D014505: Urban Population",,,https://openalex.org/W2011733149,101,12,1,999,166,6,en,en
false,full length article,different factor may influence cognitive functioning bipolar disorder effect subsyndromal symptom history psychotic symptomatology substance abuse negative symptomatology chronicity sleep disturbance hormonal factor effect pharmacologic treatment cognition still uncertain insufficient number study examine issue aim study compare neuropsychologic performance treat bipolar patient control include unmedicated patient healthy subject well evaluate possible neurocognitive difference among different atypical antipsychotic total subject include study diagnostic statistical manual mental disorder fourth edition euthymic bipolar patient treat one atypical antipsychotic quetiapine n olanzapine n risperidone n sixteen patient drug free group compare sample drug na patient healthy control group n several clinical neuropsychologic variable especially domain attention verbal memory executive function euthymia define score less young mania rating scale score less hamilton depression rating scale least month group differ age year education sex distribution estimate premorbid iq patient group differ chronicity age onset total number episode number hospitalization difference find regard antipsychotic dosage group bipolar patient perform poorly neuropsychologic measure compare healthy control control hamilton depression rating scale symptom significant change result observe many patient antipsychotic treatment history psychotic symptom perform multivariate analysis covariance control variable bipolar patient take antipsychotic present dose independent significant deficit cognitive task compare healthy control several head head group comparison patient receive quetiapine show good performance learn task short term memory recognition task assess california verbal learning test verbal fluency p result confirm find previous study cognitive deficit bipolar disorder untreated euthymic patient show well cognitive performance patient atypical antipsychotic iatrogenic pharmacologic effect therefore exclude quetiapine seem less associate impairment measure verbal memory olanzapine risperidone suggest use drug bipolar disorder low risk cognitive adverse effect however randomize control trial urgently need give definite answer critical problem,Sax KW,1998,Schizophr Res,https://doi.org/10.1016/s0920-9964(98)00067-x,9789907,Sax KW; Strakowski SM; Keck PE,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D014150: Antipsychotic Agents; D001288: Attention; D003987: Dibenzothiazepines; D004193: Discrimination Learning; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011569: Psychiatric Status Rating Scales; D011597: Psychomotor Performance; D000069348: Quetiapine Fumarate; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W13745184,19,3,1,3059,499,17,en,en
false,effect apraclonidine prevent intraocular pressure elevation nd yag laser posterior capsulotomy,efficacy adverse effect apraclonidine intraocular pressure iop nd yag laser posterior capsulotomy investigate result compare placebo timolol maleate apraclonidine eighty eye randomly assign four group eye double masked design group treat placebo group timolol maleate group apraclonidine group apraclonidine group one hour five minute nd yag laser posterior capsulotomy iop measure applanation tonometry hour baseline iop hour capsulotomy average baseline iop increase respectively mmhg first group hour post treatment significant difference baseline iop hour hour p p p iop increase mmhg second group time difference average baseline iop h measurement significant p p p third group iop decrease mmhg measurement time significant difference average baseline iop hour measurement p p p fourth group iop increase mmhg hour decrease mmhg hour difference significant p p p apraclonidine group compare significant difference average iop hour group hour p p p similarly significant difference average iop time apraclonidine group compare timolol group p p p systemic local side effect see timolol apraclonidine group none apraclonidine conclude apraclonidine effective prevent early elevation iop nd yag laser posterior capsulotomy may offer alternative timolol maleate apraclonidine,Simsek S,1998,Eur J Ophthalmol,https://doi.org/10.1177/112067219800800309,9793771,Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007429: Intraocular Pressure; D053685: Laser Therapy; D007903: Lens Capsule, Crystalline; D008297: Male; D008875: Middle Aged; D009798: Ocular Hypertension; D009883: Ophthalmic Solutions; D018918: Phacoemulsification; D011183: Postoperative Complications; D012189: Retrospective Studies; D013999: Timolol; D016896: Treatment Outcome",,,https://openalex.org/W2432031385,120,18,1,2335,496,12,en,en
false,incidence hypotension bradycardia integrate epidural general anaesthesia epidemiologic observational study consecutive patient italian study group integrate anaesthesia,combine epidural general anaesthesia might theoretically emphasise cardiovascular effect epidural block alone goal present investigation evaluate incidence hypotension bradycardia integrate epidural general anaesthesia multicentric observational study incidence clinical hypotension systolic arterial blood pressure decrease baseline bradycardia heart rate beat min side effect evaluate consecutive patient receive integrate epidural general anaesthesia time induction epidural anaesthesia induction general anaesthesia consider preoperative time general anaesthesia induction consider intraoperative preoperatively hypotension develop patient bradycardia patient intraoperatively hypotension observe patient bradycardia patient hypotension bradycardia influence type surgical procedure type maintenance general anaesthesia inhalational versus total intravenous general anaesthesia level epidural block lumbar versus thoracic frequent patient asa physical status ii iii iv compare patient asa physical status p prophylactic volume preload decrease incidence hypotension p prophylactic atropine epidural block affect incidence bradycardia patient receive epidural clonidine show increase incidence intraoperative bradycardia compare receive p randomize control study advocate order compare incidence hypotension bradycardia integrate anaesthesia epidural block alone result demonstrate use integrate epidural general anaesthesia produce incidence perioperative hypotension bradycardia similar report central block use alone,Fanelli G,1998,Minerva Anestesiol,,9796240,Fanelli G; Casati A; Berti M; Rossignoli L,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000767: Anesthesia, Epidural; D000768: Anesthesia, General; D001919: Bradycardia; D005260: Female; D006801: Humans; D007022: Hypotension; D007558: Italy; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic",,,https://openalex.org/W47291293,202,26,3,2119,336,8,en,en
false,hemodynamic change induce laparoscopy endocrine correlate effect clonidine,investigate endocrine correlate hemodynamic change induce carbon dioxide pneumoperitoneum pno study whether clonidine might modulate hemodynamic change induce pno reduce release catecholamine vasopressin mechanical neurohumoral factor contribute hemodynamic change induce carbon dioxide pno several mediator propose study correlate hemodynamic change change level potential mediator conduct two study include healthy patient schedule elective laparoscopic cholecystectomy first study serial measurement hemodynamics thermodilution technique laparoscopy exsufflation plasma concentration cortisol catecholamine vasopressin renin endothelin prostaglandin measure time point second study patient randomly allocate receive microg kg clonidine infuse h placebo pno hemodynamics plasma level cortisol catecholamine vasopressin measure pno exsufflation peritoneal insufflation result significant reduction cardiac output increase mean arterial pressure systemic pulmonary vascular resistance laparoscopy result progressive significant increase plasma concentration cortisol epinephrine norepinephrine renin vasopressin plasma concentration markedly increase immediately begin pno pno pg ml pno pg ml p profile vasopressin release parallel time course change systemic vascular resistance prostaglandin endothelin change significantly clonidine significantly reduce mean arterial pressure heart rate increase systemic vascular resistance clonidine also significantly reduce catecholamine concentration alter vasopressin cortisol plasma concentration vasopressin catecholamine probably mediate increase systemic vascular resistance observe pno clonidine pno reduce catecholamine release attenuate hemodynamic change laparoscopy,Joris JL,1998,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(98)00406-9,9809953,Joris JL; Chiche JD; Canivet JL; Jacquet NJ; Legros JJ; Lamy ML,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000316: Adrenergic alpha-Agonists; D000328: Adult; D000368: Aged; D002245: Carbon Dioxide; D002395: Catecholamines; D017081: Cholecystectomy, Laparoscopic; D003000: Clonidine; D004703: Endocrine System; D006439: Hemodynamics; D006801: Humans; D006854: Hydrocortisone; D007262: Infusions, Intravenous; D007431: Intraoperative Complications; D019344: Lactic Acid; D010535: Laparoscopy; D008875: Middle Aged; D011028: Pneumoperitoneum, Artificial; D014667: Vasopressins",,,https://openalex.org/W2139653014,95,13,1,2278,336,14,en,en
false,v clonidine prevent post extradural shivering,study efficacy v clonidine prevent shiver healthy patient receive extradural block knee arthroscopy patient randomly allocate two group extradural anaesthesia min baseline group n receive v clonidine microgram kg group ii n receive saline bolus systolic arterial pressure sap heart rate hr oxygen saturation spo cutaneous temperature level sedation record baseline min shiver evaluate blind investigator period min grade moderate severe three patient group shiver compare group ii p patient severe shiver see group ii significant difference group study period sap hr spo cutaneous temperature level sedation conclude preventive use v clonidine microgram kg provide significant reduction incidence post extradural shiver without clinically relevant adverse side effect,Sia S,1998,Br J Anaesth,https://doi.org/10.1093/bja/81.2.145,9813512,Sia S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000316: Adrenergic alpha-Agonists; D000328: Adult; D000767: Anesthesia, Epidural; D001182: Arthroscopy; D003000: Clonidine; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007275: Injections, Intravenous; D007719: Knee Joint; D008297: Male; D011229: Preanesthetic Medication; D012768: Shivering; D013565: Sympatholytics",,,https://openalex.org/W2010447217,49,6,2,1120,219,12,en,en
false,prospective study tobacco smoke substance dependency among sample adhd non adhd participant,study focus audience high risk heavy use licit illicit substance young adult child attention deficit hyperactivity disorder adhd participant study part longitudinal study life history child one third identify hyperactive whose childhood symptom rating medical history use establish diagnostic statistical manual mental disorder rd ed revise dsm iii r adhd diagnosis american psychiatric association objective study center describe developmental history tobacco use among adhd non adhd participant longitudinal sample b characteristic adult pattern tobacco use early adolescence early adulthood c relationship adhd status tobacco substance dependence outcome adult data obtain original participant adhd control lifetime current tobacco use assess child adolescent adult data yield eight measure smoke status study show participant without adhd differ age initiation smoke significant difference age begin smoke regularly age participant adhd contrast age mate control report smoke cigarette daily adulthood proportion participant adhd current smoker continue exceed age mate control among current adult smoker adhd smoke daily compare age mate control significantly different lifetime tobacco dependence rate compare age mate control rate cocaine dependence participant adhd age mate control report significant difference rate daily smoking tobacco dependence adhd use stimulant medication childhood contrast control result interpret support possible link adhd treatment history level tobacco smoke tobacco dependence adulthood,Lambert NM,1998,J Learn Disabil,https://doi.org/10.1177/002221949803100603,9813951,Lambert NM; Hartsough CS,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D016022: Case-Control Studies; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D019970: Cocaine-Related Disorders; D005260: Female; D006801: Humans; D008137: Longitudinal Studies; D008297: Male; D008774: Methylphenidate; D015995: Prevalence; D011446: Prospective Studies; D012307: Risk Factors; D012495: San Francisco; D012651: Self Medication; D012907: Smoking; D019966: Substance-Related Disorders; D014029: Tobacco Use Disorder; D016896: Treatment Outcome",,,https://openalex.org/W2112640823,111,15,1,2246,403,13,en,en
false,sleep disturbance child attention deficit hyperactivity disorder,sleep profile child attention deficit hyperactivity disorder adhd treat fix dose methylphenidate least month compare healthy sibling sleep disturbance assess accord structure sleep questionnaire severity adhd evaluate via conners parent teacher rating scale result indicate significantly child adhd demonstrate single multiple sleep disturbance well high rate specific sleep disorder initial middle insomnia compare sibling correlation find severity adhd disturb sleep sleep duration satisfaction sleep similar two group find raise important question regard association adhd disturbed sleep,Ring A,1998,J Learn Disabil,https://doi.org/10.1177/002221949803100607,9813955,Ring A; Stein D; Barak Y; Teicher A; Hadjez J; Elizur A; Weizman A,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D001289: Attention Deficit Disorder with Hyperactivity; D016009: Chi-Square Distribution; D002648: Child; D002675: Child, Preschool; D005260: Female; D006801: Humans; D015994: Incidence; D008297: Male; D008774: Methylphenidate; D010290: Parents; D011569: Psychiatric Status Rating Scales; D007319: Sleep Initiation and Maintenance Disorders; D012893: Sleep Wake Disorders",,,https://openalex.org/W2094400021,76,7,1,863,138,6,en,en
false,school base methylphenidate placebo protocol,around psychologist educator begin notice increase use methylphenidate student diagnosis attention deficit hyperactivity disorder family physician pediatrician commonly base brief behavioral description parent infrequently use rating scale time present researcher begin explore development school base methodologically sound inexpensive method assess efficacy stimulant medication would ensure reasonable compliance teacher parent student monitor effect medication placebo article focus methodological issue involve choose instrument monitor behavior comprehensive evaluation suggest trial ritalin case examples illustrate problem teacher compliance fill measure supply adequate placebo obtain physician cooperation practical issue provide adequate data without overwhelm time resource participant emerge school base methodology discuss recommendation future effort,Hyman IA,1998,J Learn Disabil,https://doi.org/10.1177/002221949803100609,9813957,Hyman IA; Wojtowicz A; Lee KD; Haffner ME; Fiorello CA; Storlazzi JJ; Rosenfeld J,article,D002363: Case Reports; D016428: Journal Article,D001289: Attention Deficit Disorder with Hyperactivity; D002648: Child; D002652: Child Behavior; D003071: Cognition; D003625: Data Collection; D016903: Drug Monitoring; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D009730: Nursing Assessment; D010290: Parents; D010919: Placebos; D011569: Psychiatric Status Rating Scales; D012573: School Nursing; D012655: Self-Evaluation Programs; D013663: Teaching,,,https://openalex.org/W2043314097,46,4,1,1152,171,6,en,en
false,evaluate medication response adhd,although evidence support use double blind placebo medication trial evaluate methylphenidate mph effect core behavioral symptom attention deficit hyperactivity disorder adhd study demonstrate utility examine mph effect cognitive deficit associate adhd article present technique evaluate behavioral cognitive dose response relationship single subject level analysis case study result multivariate analysis suggest systematic evaluation behavioral cognitive mph dose response relationship could lead accurate mph titration great long term multimodal treatment efficacy,Hale JB,1998,J Learn Disabil,https://doi.org/10.1177/002221949803100610,9813958,Hale JB; Hoeppner JA; DeWitt MB; Coury DL; Ritacco DG; Trommer B,article,"D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D002985: Clinical Protocols; D003071: Cognition; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D015999: Multivariate Analysis; D009483: Neuropsychological Tests; D016896: Treatment Outcome",,,https://openalex.org/W1967153793,38,5,1,697,97,3,en,en
false,use restrict academic task adhd dose response relationship,behavioral assessment technique show make significant contribution evaluation stimulant medication response child attention deficit hyperactivity disorder article examine role behavioral measure consist standardize observation child perform academic like task restrict academic task technique reliable valid repeat administration across medication dosage placebo assist optimize medication dosage individual child give sensitivity dosage effect also allow capture medication relate change area function directly assess parent teacher judgment rating way restrict academic task may great ecological validity result traditional clinic measure finally give idiosyncratic nature stimulant medication effect individual child contribute explication specific child behavioral dose response relationship,Fischer M,1998,J Learn Disabil,https://doi.org/10.1177/002221949803100611,9813959,Fischer M; Newby RF,article,D002363: Case Reports; D016430: Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D000704: Analysis of Variance; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D002652: Child Behavior; D002675: Child, Preschool; D002985: Clinical Protocols; D004305: Dose-Response Relationship, Drug; D004521: Educational Measurement; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D015588: Observer Variation; D010919: Placebos; D011340: Problem Solving; D013647: Task Performance and Analysis",,,https://openalex.org/W2090924057,71,10,1,1081,164,7,en,en
false,medical control intraocular pressure cataract surgery,compare effectiveness medication commonly use prevent intraocular pressure iop elevation early period cataract surgery palo alto veteran affair health care system palo alto california usa prospective study comprise eye patient schedule cataract extraction agree participate patient randomize receive oral acetazolamide mg hour preoperatively oral acetazolamide mg immediately postoperatively apraclonidine hydrochloride drop hour preoperatively artificial tear control group intraocular pressure measure preoperatively hour postoperatively preoperative iop significantly different among group hour postoperatively preoperative acetazolamide significantly effective control medication p hour significant difference among group postoperative iop elevation excess mm hg hour decrease significantly preoperative acetazolamide group eye compare control group eye statistically significant difference iop elevation eye extracapsular cataract extraction phacoemulsification independent treatment group result favor preoperative acetazolamide control postcataract iop elevation method cataract removal affect postoperative iop elevation,Byrd S,1998,J Cataract Refract Surg,https://doi.org/10.1016/s0886-3350(98)80172-7,9818340,Byrd S; Singh K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000086: Acetazolamide; D000284: Administration, Oral; D000287: Administration, Topical; D000316: Adrenergic alpha-Agonists; D000368: Aged; D002257: Carbonic Anhydrase Inhibitors; D002387: Cataract Extraction; D003000: Clonidine; D006801: Humans; D007429: Intraocular Pressure; D009798: Ocular Hypertension; D011446: Prospective Studies",,,https://openalex.org/W2017108058,62,8,1,1485,235,7,en,en
false,clinical neurocognitive effect clozapine risperidone treatment refractory schizophrenic patient,control study compare efficacy clozapine risperidone treatment refractory schizophrenic patient present study investigate efficacy clozapine risperidone psychopathologic neurocognitive measure prospective week open label trial treatment refractory schizophrenic patient state psychiatric hospital thirty five dsm iv schizophrenic patient document history nonresponse typical neuroleptic treat either clozapine risperidone response assess every week independent raters positive negative syndrome scale panss clinical global impression cgi scale neurologic rating scale plasma drug level neurocognitive test administer baseline week clozapine risperidone bring significant p overall improvement psychopathology however clozapine numerically superior risperidone panss total score panss positive negative excitement cognitive factor extrapyramidal side effect minimal clozapine whereas present risperidone patient take risperidone improve significantly begin stage study remain stable thereafter patient take clozapine show gradual improvement occur entire length trial neurocognitive measure show minimal improvement differentiate medication group clozapine risperidone comparably effective across wide spectrum psychopathologic measure efficacy clozapine numerically superior risperidone associate extrapyramidal side effect progressive improvement week treatment period suggest long trial clozapine may prove superior risperidone neuroleptic refractory patient,Lindenmayer JP,1998,J Clin Psychiatry,https://doi.org/10.4088/jcp.v59n1005,9818633,Lindenmayer JP; Iskander A; Park M; Apergi FS; Czobor P; Smith R; Allen D,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D001480: Basal Ganglia Diseases; D003024: Clozapine; D003072: Cognition Disorders; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009483: Neuropsychological Tests; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome,,,https://openalex.org/W2048066278,111,12,1,1931,279,10,en,en
false,clozapine effect force control schizophrenic patient,previously report significant difference force control fc function schizophrenic treat typical antipsychotic drug apd treat clozapine clozapine treatment associate attenuation capacity fine motor control report test retest study treatment refractory patient confirm early find fc deficit due primarily clozapine treatment additional comparison make patient administer fc test repeatedly initial clozapine titration interval week result suggest two distinct clozapine effect distinguish initial transient stage characterize drowsiness subsequent stage dose dependent emerge myoclonic feature,Vrtunski PB,1998,Schizophr Res,https://doi.org/10.1016/s0920-9964(98)00087-5,9824875,Vrtunski PB; Konicki PE; Jaskiw GE; Brescan DW; Kwon KY; Jurjus G,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000704: Analysis of Variance; D014150: Antipsychotic Agents; D003024: Clozapine; D004305: Dose-Response Relationship, Drug; D004831: Epilepsies, Myoclonic; D005260: Female; D006801: Humans; D008297: Male; D011597: Psychomotor Performance; D012559: Schizophrenia",,,https://openalex.org/W2089528901,60,8,1,805,125,5,en,en
false,post marketing study,drug safety research unit dsru centre prescription event monitoring pem england pem study noninterventional observational cohort study monitor safety newly market drug need post marketing surveillance well recognise uk general practice ideal source data pem study general practitioner community base exposure base dispense prescription data england date pem study complete mean cohort size patient dsru database clinical information patient prescribe new drug unlike spontaneous report scheme pem produce incidence rate event report treatment comparative study conduct drug class dsru aggregate outcome data pregnancy expose new drug data child elderly also specifically examine pem data number advantage data computerise general practice database uk pem technique within uk capable monitor newly market drug comprehensive systematic way,Mackay FJ,1998,Drug Saf,https://doi.org/10.2165/00002018-199819050-00002,9825948,Mackay FJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D014150: Antipsychotic Agents; D011307: Drug Prescriptions; D064420: Drug-Related Side Effects and Adverse Reactions; D004812: Epidemiologic Methods; D005260: Female; D006077: Government Agencies; D006801: Humans; D008297: Male; D011358: Product Surveillance, Postmarketing; D018967: Risperidone; D006113: United Kingdom",,,https://openalex.org/W2115624781,22,2,1,1175,201,11,en,en
false,psychopharmacologic treatment acquire attention disorder child brain injury,investigation examine efficacy psychostimulant therapy alleviate neurobehavioral dysfunction attendant pediatric brain injury commonly report neurobehavioral sequela associate head injury pediatric population involve deficit along attentional matrix also common objectively documented neurobehavioral finding among child well adult several investigation adult literature employ use psychostimulants treat psychiatric neuropsychological residuum associate head injury overall result study equivocal suggest beneficial impact general functioning present prospective investigation utilize double blind placebo control cross experimental design examine efficacy methylphenidate treat child acquire attentional disorder secondary brain injury cohort child vary degree head injury recruit participation expect difference drug placebo condition uniformly achieve statistical significance additionally difference performance baseline placebo condition neurobehavioral task attention concentration current find suggest methylphenidate probably psychostimulants cylert adderal wellbutrin dextroamphetamine sulfate extremely effective agent treat attentional disorder secondary brain injury child,Mahalick DM,1998,Pediatr Neurosurg,https://doi.org/10.1159/000028705,9838263,Mahalick DM; Carmel PW; Greenberg JP; Molofsky W; Brown JA; Heary RF; Marks D; Zampella E; Hodosh R; von der Schmidt E,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D001288: Attention; D001289: Attention Deficit Disorder with Hyperactivity; D001930: Brain Injuries; D000697: Central Nervous System Stimulants; D002648: Child; D002675: Child, Preschool; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008774: Methylphenidate; D011446: Prospective Studies",,,https://openalex.org/W2092243419,91,11,1,1563,221,10,en,en
false,oral clonidine premedication enhance pressor response ephedrine spinal anesthesia,clonidine premedication enhance pressor effect ephedrine awake anesthetize patient test hypothesis clonidine augment pressor response ephedrine spinal anesthesia asa physical status ii patient randomly assign either clonidine group n receive oral clonidine approximately microg kg min spinal anesthesia control group n receive clonidine spinal anesthesia perform either l l interspace use hyperbaric tetracaine solution ml blood pressure bp heart rate upper dermatomal level analgesia determine min interval patient supine position tetracaine injection systolic bp decrease prespinal value mm hg iv ephedrine mg kg administer bolus difference duration first dose ephedrine tetracaine injection upper level analgesia group control group min clonidine group min although prespinal preephedrine bp value high control group magnitude increase mean bp ephedrine significantly great clonidine group p conclude oral clonidine premedication augment pressor response iv ephedrine spinal anesthesia pressor effect ephedrine enhance patient give oral clonidine premedication spinal anesthesia,Goyagi T,1998,Anesth Analg,https://doi.org/10.1097/00000539-199812000-00023,9842823,Goyagi T; Tanaka M; Nishikawa T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000775: Anesthesia, Spinal; D001794: Blood Pressure; D003000: Clonidine; D004357: Drug Synergism; D004809: Ephedrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D007022: Hypotension; D008297: Male; D008875: Middle Aged; D011229: Preanesthetic Medication; D014662: Vasoconstrictor Agents",,,https://openalex.org/W2005427161,96,12,1,1536,267,8,en,en
false,central stimulant adult ad hd help,article review five control study efficacy methylphenidate adult attention deficit hyperactivity disorder ad hd five placebo cross design one study patient note side effect whether take methylphenidate placebo fact unlikely study blind diagnostic criterion use two study appropriate accord present knowledge leave three sample subject meet present criterion ad hd one study patient material extremely selective subject belong social class come treatment eligible one study acceptable though perfect design study patient psychiatric clinic difference find methylphenidate placebo two study subject improve methylphenidate follow total subject two sample four continue methylphenidate month two suffer narcolepsy one substance abuser thus efficacy methylphenidate ad hd adult demonstrate present research favour existence,Lie N,1998,Tidsskr Nor Laegeforen,,9857806,Lie N,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,D000328: Adult; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D018849: Controlled Clinical Trials as Topic; D018592: Cross-Over Studies; D006801: Humans; D008774: Methylphenidate; D014481: United States,,,,57,14,3,1297,237,11,en,en
false,die bedeutung de hepatischen cytochrom p system f r die psychopharmakologie,nearly psychotropic drug metabolize hepatic cytochrome p enzymes human isoenzymes involve process activity enzyme modulate number commonly use drug yield potentially hazardous interaction recently introduce selective serotonin reuptake inhibitor potent inhibitor cytochrome p enzyme thus plasma concentration tricyclic antidepressant clozapine might elevate toxic level contrast carbamazepine induces isoenzymes potentiate elimination tricyclic antipsychotic might cause serious risk recurrence depressive psychotic symptom moreover population slow metabolizers cyp group prone increase adverse effect moderately dosed medication review systematically point report predict pharmacokinetic drug interaction psychopharmacology focussing clinical significance,Normann C,1998,Nervenarzt,https://doi.org/10.1007/s001150050368,9859115,Normann C; Hesslinger B; Bauer J; Berger M; Walden J,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,D065607: Cytochrome P-450 Enzyme Inhibitors; D003577: Cytochrome P-450 Enzyme System; D006801: Humans; D008099: Liver; D008657: Metabolic Clearance Rate; D011619: Psychotropic Drugs; D017367: Selective Serotonin Reuptake Inhibitors,,,https://openalex.org/W2027788983,80,8,1,1018,156,10,de,en
false,ziprasidone mg day acute exacerbation schizophrenia schizoaffective disorder week placebo control trial,double blind placebo control multicenter study perform evaluate efficacy safety ziprasidone patient acute exacerbation schizophrenia schizoaffective disorder patient randomize receive ziprasidone mg day mg day placebo day ziprasidone mg day significantly effective placebo improve bprs total cgi bprs depression cluster bprs anergia cluster score p similarly percentage patient classify responder bprs reduction cgi improvement score significantly great ziprasidone mg day compare placebo p number patient experience adverse event similar three treatment group discontinuation due adverse event rare five ziprasidone treat patient frequently report adverse event common either ziprasidone group placebo group dyspepsia constipation nausea abdominal pain notably low incidence extrapyramidal side effect include akathisia postural hypotension pattern laboratory abnormality apparent weight gain ziprasidone treat patient clinically different placebo treat patient simpson angus rating scale barnes akathisia scale aim assessment result indicate ziprasidone mg day effective treatment positive negative affective symptom schizophrenia schizoaffective disorder low side effect burden,Keck P,1998,Psychopharmacology (Berl),https://doi.org/10.1007/s002130050755,9860108,Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D014150: Antipsychotic Agents; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010879: Piperazines; D011618: Psychotic Disorders; D012559: Schizophrenia; D013844: Thiazoles,,,https://openalex.org/W2061276728,136,19,1,1638,270,9,en,en
false,pharmacokinetic interaction carbamazepine olanzapine observation possible mechanism,objective olanzapine novel antipsychotic effective positive negative symptom schizophrenia cause extrapyramidal adverse effect conventional antipsychotic purpose present study assess potential pharmacokinetic interaction olanzapine carbamazepine since agent likely use concomitantly treatment manic psychotic disorder method pharmacokinetics two single therapeutic olanzapine determine healthy volunteer first dose olanzapine mg take alone second dose mg week treatment carbamazepine mg bid measurement urinary beta hydroxycortisol cortisol excretion use endogenous marker confirm induction cyp carbamazepine occur result dose olanzapine give week pretreatment carbamazepine clear rapidly olanzapine give alone olanzapine pharmacokinetic value cmax auc significantly low second dose elimination half life significantly short clearance volume distribution significantly increase conclusion carbamazepine show induce several p cytochrome include cyp cyp since cyp play role metabolic clearance olanzapine interaction may attribute induction cyp carbamazepine lead increase first pas systemic metabolism olanzapine interaction consider clinical significance olanzapine wide therapeutic index change plasma concentration olanzapine within fourfold variation occur without concern safety patient population,Lucas RA,1998,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050527,9860152,Lucas RA; Gilfillan DJ; Bergstrom RF,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D014150: Antipsychotic Agents; D001569: Benzodiazepines; D015415: Biomarkers; D002220: Carbamazepine; D051544: Cytochrome P-450 CYP3A; D003577: Cytochrome P-450 Enzyme System; D004347: Drug Interactions; D006801: Humans; D006854: Hydrocortisone; D008297: Male; D008875: Middle Aged; D006899: Mixed Function Oxygenases; D000077152: Olanzapine; D010890: Pirenzepine",,,https://openalex.org/W2073975093,102,12,1,1823,287,10,en,en
false,multiple outcome assessment study cost effectiveness clozapine treatment refractory schizophrenia department veteran affair cooperative study group clozapine refractory schizophrenia,develop new method combine result multiple outcome domain demonstrate application study cost effectiveness clozapine treat hospitalize patient refractory schizophrenia interview assessment administrative utilization cost data concern patient refractory schizophrenia hospitalize day year study entry va medical center month double blind trial compare clozapine n haloperidol n treatment refractory schizophrenia data standard assessment instrument gather baseline week month use develop composite health index schizophrenia measure address outcome six domain weight patient provider preference cumulative improvement estimate compute area improvement curve measure combine cost data reflect consumption societal resource estimate incremental cost effectiveness ratio clozapine significantly effective haloperidol measure symptom p side effect p nonsignificant trend positive direction community role function p family relationship p social relationship p daily activity p clozapine also effective haloperidol one year cumulative composite health index schizophrenia p weight scheme convert measure bad health good health scale analogous quality adjust life year clozapine find yield small improvement bad health good health unit compare improvement unit haloperidol p average annual cost low clozapine c although clozapine significantly effective haloperidol summary cost effectiveness ratio wide percent confidence interval range method demonstrate approach use conventional disease specific measure evaluate cumulative effectiveness novel treatment psychotic disorder express economic effect cost effectiveness ratio among high hospital user refractory schizophrenia clozapine cost effective standard treatment although magnitude effect small considerable uncertainty cost estimate,Rosenheck R,1998,Health Serv Res,,9865219,Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D003024: Clozapine; D003362: Cost-Benefit Analysis; D004311: Double-Blind Method; D016527: Drug Costs; D006220: Haloperidol; D017721: Hospital Costs; D006787: Hospitals, Veterans; D006801: Humans; D008134: Long-Term Care; D017063: Outcome Assessment, Health Care; D010343: Patient Admission; D011446: Prospective Studies; D011569: Psychiatric Status Rating Scales; D019057: Quality-Adjusted Life Years; D012559: Schizophrenia",,,https://openalex.org/W300180921,220,31,2,2561,427,9,en,en
false,pre anesthetic oral clonidine effective prevent post spinal shivering,shiver common event spinal anesthesia customarily treat rather prevent study design evaluate efficacy oral clonidine premedication prevent post spinal shiver one hundred male asa physical status iii age schedule elective urological surgery spinal anesthesia include study participant randomly divide clonidine control group receive either oral clonidine microgram n placebo n min spinal anesthesia double blind fashion spinal blockade induce heavy bupivacaine dermatomal level near shiver grade none perceptible tension muscle observe mild slight muscle tonus masseter muscle moderate real shiver proximal muscle severe generalize shiver whole body tympanic membrane temperature record min spinal anesthesia data express mean standard deviation chi square student test use p value less consider statistically significant incidence post spinal shivering grade none mild moderate severe show statistically significant difference p clonidine microgram placebo v v v v respectively min immediately spinal anesthesia respective mean tympanic temperature oral clonidine placebo group show difference clonidine v control degree c vs degree c pre anesthetic medication oral clonidine microgram effective prevent post spinal shivering patient undergo elective urological surgery,Mao CC,1998,Acta Anaesthesiol Sin,,9874861,Mao CC; Tsou MY; Chia YY; Chow LH; Chan KH; Lee TY,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000368: Aged; D000775: Anesthesia, Spinal; D003000: Clonidine; D004311: Double-Blind Method; D006801: Humans; D008297: Male; D008875: Middle Aged; D011229: Preanesthetic Medication; D012768: Shivering",,,https://openalex.org/W2436828383,76,10,1,1790,322,12,en,en
false,psilocybin induces schizophrenia like psychosis human via serotonin agonist action,psilocybin indoleamine hallucinogen produce psychosis like syndrome human resemble first episode schizophrenia healthy human volunteer psychotomimetic effect psilocybin block dose dependently serotonin antagonist ketanserin atypical antipsychotic risperidone increase dopamine antagonist typical antipsychotic haloperidol data consistent animal study provide first evidence human psilocybin induce psychosis due serotonin receptor activation independently dopamine stimulation thus serotonin overactivity may involve pathophysiology schizophrenia serotonin antagonism may contribute therapeutic effect antipsychotic,Vollenweider FX,1998,Neuroreport,https://doi.org/10.1097/00001756-199812010-00024,9875725,Vollenweider FX; Vollenweider-Scherpenhuyzen MF; Bäbler A; Vogel H; Hell D,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D004305: Dose-Response Relationship, Drug; D005260: Female; D006213: Hallucinogens; D006801: Humans; D007650: Ketanserin; D008297: Male; D009483: Neuropsychological Tests; D011562: Psilocybin; D011597: Psychomotor Performance; D011930: Reaction Time; D012016: Reference Values; D012559: Schizophrenia; D012702: Serotonin Antagonists; D017366: Serotonin Receptor Agonists",,,https://openalex.org/W1997058647,90,11,1,781,107,4,en,en
false,use psychostimulants pediatric patient,psychostimulant medication long history medical use treatment childhood psychiatric condition bradley report first use psychostimulant medication child administer benzedrine mg day child age year hospitalize severe behavior disorder description year ago medication action child still familiar today probably strike change behavior week benzedrine therapy occur school activity many patient fourteen child respond spectacular fashion different teacher report patient vary age school accomplishment agree great increase interest school material note immediately appear definite drive accomplish much possible school period often spend extra time complete additional work speed comprehension accuracy performance increase case insight school performance generally present though child attribute medication receive early day improvement note school subject appear promptly first day benzedrine give disappear first day discontinue barkley review early research psychostimulant drug hyperactive child include many open double blind study involve hundred subject study involve child perform examine effectiveness methylphenidate control hyperactivity seventy seven percent subject judge improve methylphenidate similar rate improvement find child treat amphetamine study child pemoline study child eight double blind placebo control trial three type psychostimulants mean improvement hyperactive child placebo effect size psychostimulants calculate study approximately large effect size psychotropic medication despite long time use psychostimulants treat attention deficit hyperactivity disorder adhd several question remain psychostimulants interchangeable child selective responder particular psychostimulant data available adderall mixture dextroamphetamine levoamphetamine useful addition agent treat adhd research long act psychostimulants sustain release sr methylphenidate ritalin sr pemoline cylert best way dose psychostimulants danger raise dose high improve behavior fact lead decrease academic productivity call zombie effect way predict child adhd likely respond psychostimulants side effect encounter psychostimulants particular risk hepatic failure pemoline child adhd tic treat safely psychostimulants late data regard effect psychostimulants growth physician manage child adhd must thorough understanding issue involve psychostimulant treatment,Pliszka SR,1998,Pediatr Clin North Am,https://doi.org/10.1016/s0031-3955(05)70063-8,9884676,Pliszka SR,article,D016428: Journal Article; D016454: Review,D000293: Adolescent; D000662: Amphetamines; D001289: Attention Deficit Disorder with Hyperactivity; D000697: Central Nervous System Stimulants; D002648: Child; D006128: Growth; D006801: Humans; D008774: Methylphenidate; D010372: Pediatrics; D010389: Pemoline,,,https://openalex.org/W2069518018,52,8,1,3546,595,28,en,en
false,adrenergic agonist,adrenergic agonist clonidine guanfacine first develop antihypertensive agent use psychiatry treat variety condition although approve food drug administration fda indication yet clear guideline usage data describe efficacy agonist child adolescent psychiatry derive principally open study retrospective review case report several control study plague small sample size consequently investigator argue clinical efficacy safety adrenergic agonist psychiatric treatment child adequately establish nevertheless use medication increase dramatically past decade swanson colleague estimate approximately prescription write clonidine alone treatment attention deficit hyperactivity disorder adhd another prescription write combination methylphenidate clonidine another review indicate child united state medicate combination methylphenidate clonidine psychoactive property adrenergic agonist relate effect noradrenergic na neurotransmitter system direct effect na system also produce indirect effect serotonergic ht dopaminergic da neurotransmission since agonist affect principal monoamine system relate many psychiatric disorder interest clinical effect medication surprise initial use agonist psychiatric indication trace far back cohen colleague first note beneficial effect clonidine amelioration tic begin use alternative neuroleptic treatment tourette disorder benefit also observe reduce motor activity impulsive behavior adhd disorder frequently coexist child one recent study indicate possible role clonidine treatment aggression also suggestion clonidine may role treat several anxiety disorder particularly link occurrence stress traumatic event e post traumatic stress disorder ptsd adult psychiatry clonidine use even wide array disorder include aggression bipolar disorder schizophrenia active psychosis panic disorder withdrawal benzodiazepine social phobia ptsd recently several study demonstrate similar effect use guanfacine treatment adhd prospect sustain duration action adverse effect despite considerable promise agonist many remain skeptical high degree polarization regard agent increase follow report several sudden death child medicate clonidine methylphenidate combination although medication combination review fda causal link medication catastrophic outcome establish controversy spark renew debate efficacy safety agonist time recent interest national level establish extensive scientific data base evaluate efficacy treatment label yet frequently use drug company interest obtain fda approval new indication suggest large systematic trial agent likely undertake near future article review basic neurochemistry neurophysiology agonist examine empiric support use variety neuropsychiatric condition child adolescent author examine safety medication review recent clonidine controversy detail finally author outline basic information clinician regard therapeutic management adverse effect present case vignettes illustrate medication safely effectively use clinical practice,Newcorn JH,1998,Pediatr Clin North Am,https://doi.org/10.1016/s0031-3955(05)70064-x,9884677,Newcorn JH; Schulz K; Harrison M; DeBellis MD; Udarbe JK; Halperin JM,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,D058647: Adrenergic alpha-2 Receptor Agonists; D000316: Adrenergic alpha-Agonists; D001008: Anxiety Disorders; D019958: Attention Deficit and Disruptive Behavior Disorders; D002648: Child; D002985: Clinical Protocols; D003000: Clonidine; D005260: Female; D016316: Guanfacine; D006801: Humans; D008125: Locus Coeruleus; D008297: Male; D013981: Tic Disorders,,,https://openalex.org/W1501686051,22,3,1,4355,711,22,en,en
false,antipsychotic,antipsychotic medication reduce symptom hallucination delusion characterize psychosis use treatment patient schizophrenia year fourteen antipsychotic currently market united state ten consider typical antipsychotic typical antipsychotic equally effective ability reduce symptom psychosis adolescent psychotic illness often treat antipsychotic similar use adult list medication dose adult psychotic disorder show table recently four agent consider atypical antipsychotic become available distinguish typical atypical antipsychotic atypical antipsychotic associate reduce absent risk extrapyramidal side effect epss list medication usual daily dose adult schizophrenia show table agent market use psychotic disorder two medication antipsychotic property currently market neuropsychiatric illness united state pimozide orap label use treatment resistant tourette syndrome whereas amoxapine asendin market antidepressant see table daily antipsychotic mg generally use treat schizophrenia adult vary widely compound medication generally administer large daily mg consider low potency agent e g chlorpromazine thioridazine clozapine similarly medication generally give small daily mg considerd high potency agent e g haloperidol fluphenazine risperidone discus later distinction high low potency compound important consider side effect potency reflect agent ability reduce target symptom psychosis ability treat psychotic illness antipsychotic medication also common reversibly block type dopamine receptor central nervous system see table usual daily dose antipsychotic adult psychotic disorder generally relate medication ability block receptor specifically drug great affinity receptor generally potent low receptor affinity find lead view receptor blockade pivotal treatment psychosis therapeutic antipsychotic bind receptor central nervous system vary degree include muscarinic adrenergic histaminergic h receptor several serotonin receptor discus later antipsychotic blockade receptor cause side effect see agent therapeutic dos,Findling RL,1998,Pediatr Clin North Am,https://doi.org/10.1016/s0031-3955(05)70070-5,9884683,Findling RL; Schulz SC; Reed MD; Blumer JL,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000293: Adolescent; D000328: Adult; D000367: Age Factors; D014150: Antipsychotic Agents; D002648: Child; D002659: Child Development Disorders, Pervasive; D019955: Conduct Disorder; D006801: Humans; D019964: Mood Disorders; D018579: Patient Selection; D010372: Pediatrics; D010554: Personality Disorders; D013981: Tic Disorders",,,https://openalex.org/W1520140903,18,2,1,3103,534,19,en,en
false,olanzapine versus haloperidol treatment first episode psychosis,hypothesize morbidity mortality associate schizophrenia prevent provide effective treatment first episode psychosis hence author examine patient first episode psychosis determine efficacy safety olanzapine haloperidol treatment subpopulation first episode patient n large prospective multicenter international double blind week acute treatment study evaluate patient select pool patient dsm iii r diagnosis schizophrenia schizoaffective disorder schizophreniform disorder also meet following criterion length current psychotic episode year patient year age young onset first psychotic symptom compare haloperidol olanzapine show statistically significantly great reduction brief psychiatric rating scale bprs total negative score positive negative syndrome scale total positive score clinical response define great improvement bprs total score baseline also statistically significantly high olanzapine treat patient haloperidol treat patient olanzapine treat patient far show statistically significant improvement simpson angus scale barnes akathisia scale score haloperidol treat patient show worsening measure compare olanzapine treat multiple episode patient parent study olanzapine treat first episode patient achieve even statistically significantly high response haloperidol treat first episode patient experience statistically significantly extrapyramidal symptom haloperidol treat multiple episode patient patient experience first episode psychosis olanzapine risk benefit profile significantly superior haloperidol study result suggest novel antipsychotic agent olanzapine consider prefer option first episode psychosis basis safety efficacy advantage,Sanger TM,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.1.79,9892301,Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017668: Age of Onset; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D010054: Brief Psychiatric Rating Scale; D004311: Double-Blind Method; D006220: Haloperidol; D006801: Humans; D000077152: Olanzapine; D010890: Pirenzepine; D011446: Prospective Studies; D011618: Psychotic Disorders; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D012720: Severity of Illness Index; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W1971880978,66,7,1,2205,323,8,en,en
false,effect clozapine adjunctive high dose glycine treatment resistant schizophrenia,objective focus study systematic evaluation clinical effect glycine adjunct atypical antipsychotic clozapine treatment schizophrenia method double blind placebo control study patient chronic treatment resistant schizophrenia maintain optimal dos clozapine mg day administer either g day glycine n placebo n week clinical evaluation brief psychiatric rating scale scale assessment negative symptom simpson angus movement scale complete biweekly result use glycine adjunct clozapine effective decrease positive negative symptom contrast patient treat clozapine without glycine reduction positive symptom conclusion preliminary data suggest glycine may interfere antipsychotic efficacy atypical neuroleptic clozapine,Potkin SG,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.1.145,9892314,Potkin SG; Jin Y; Bunney BG; Costa J; Gulasekaram B,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D010054: Brief Psychiatric Rating Scale; D003024: Clozapine; D004359: Drug Therapy, Combination; D005260: Female; D005998: Glycine; D006801: Humans; D008297: Male; D010919: Placebos; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W2072365144,89,10,1,999,166,6,en,en
false,order onset substance abuse depression sample depress outpatient,drug abuse think cause depression serve form self medication depression objective examine whether specific type drug abuse precede follow onset depression retrospective blind case control assessment drug depressive history depress outpatient conduct three hundred seventy five patient major depressive disorder evaluate comorbid drug dependence use structure clinical interview dsm iii r scid select psychiatric outpatient department metropolitan teach hospital group homogeneous class drug dependence include alcohol cannabis cocaine amphetamine lsd hypnosedative opiate polysubstance use determine percent depress patient specific type drug abuse age onset depression onset specific drug abuse mean number lifetime depressive episode patient find alcohol dependence follow onset first life depression year p two tail among polydrug dependent patient drug abuse follow onset depression except lsd coincide onset depression among polydrug user cocaine dependence occur year first major depressive episode p alcohol dependence year onset depression p opiate sedative user least number lifetime depressive episode lsd cocaine user great number conclude alcohol cocaine use sample depress outpatient conform pattern self medication,Abraham HD,1999,Compr Psychiatry,https://doi.org/10.1016/s0010-440x(99)90076-7,9924877,Abraham HD; Fava M,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D017668: Age of Onset; D000428: Alcohol Drinking; D000704: Analysis of Variance; D015984: Causality; D015331: Cohort Studies; D015897: Comorbidity; D003430: Cross-Sectional Studies; D003866: Depressive Disorder; D006801: Humans; D013287: Illicit Drugs; D008297: Male; D008404: Massachusetts; D008875: Middle Aged; D016017: Odds Ratio; D012651: Self Medication; D019966: Substance-Related Disorders,,,https://openalex.org/W2058947119,85,14,1,1713,295,11,en,en
false,combination treatment clozapine paroxetine schizophrenia safety tolerability data prospective open clinical trial,clozapine drug many side effect potentially hazardous outcome e g seizure agranulocytosis carefully monitor show metabolism clozapine may affect concomitant treatment selective serotonin reuptake inhibitor ssri report improve efficacy negative symptomatology clozapine combination ssri therefore prospective open clinical trial perform investigate safety tolerability coadministration clozapine paroxetine control serum concentration clozapine metabolite effect combination treatment psychopathological outcome evaluate total patient suffer schizophrenia schizodepressive disorder predominant negative symptomatology include duration study least week patient initial treatment monotherapy clozapine daily dose mg kg weight two measurement serum concentration clozapine metabolite steady state condition add therapy mg paroxetine initiate concomitant medication allow main find prospective study addition paroxetine monotherapy clozapine well tolerated medication give rise new clinically relevant side effect addition paroxetine serum concentration clozapine major metabolite remain virtually constant result psychopathological measurement indicate clinical improvement although small open study could test efficacy,Anghelescu I,1998,Eur Neuropsychopharmacol,https://doi.org/10.1016/s0924-977x(97)00093-x,9928923,Anghelescu I; Szegedi A; Schlegel S; Weigmann H; Hiemke C; Wetzel H,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D014150: Antipsychotic Agents; D003024: Clozapine; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D017374: Paroxetine; D011446: Prospective Studies; D012559: Schizophrenia; D017367: Selective Serotonin Reuptake Inhibitors",,,https://openalex.org/W2014489054,137,19,1,1703,269,12,en,en
false,prolactin level adverse event patient treat risperidone,hyperprolactinemia common clinical disorder may lead sexual dysfunction galactorrhea may arise variety etiology include use antipsychotic agent presumably dopamine receptor blockade analysis design characterize relationship risperidone serum prolactin level possible clinical sequela data randomize double blind study risperidone patient chronic schizophrenia analyze two large study north american multinational trial include patient woman men pair prolactin level data patient woman men data six adverse event possibly associate increase prolactin level amenorrhea galactorrhea decrease libido woman erectile dysfunction ejaculatory dysfunction gynecomastia decrease libido men risperidone haloperidol produce dose related increase plasma prolactin level men woman among woman risperidone dose correlate adverse event adverse event correlate endpoint prolactin level among men incidence adverse event positively correlate risperidone dose however risperidone dos mg day incidence adverse event significantly high observe patient receive placebo furthermore adverse event men unrelated plasma prolactin level risperidone associate increase serum prolactin level significantly correlate emergence possible prolactin related side effect j clin psychopharmacol,Kleinberg DL,1999,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199902000-00011,9934944,Kleinberg DL; Davis JM; de Coster R; Van Baelen B; Brecher M,article,D016428: Journal Article,D000328: Adult; D014150: Antipsychotic Agents; D005260: Female; D005687: Galactorrhea; D006801: Humans; D008297: Male; D011388: Prolactin; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies; D018967: Risperidone; D012559: Schizophrenia; D012727: Sex Characteristics,,,https://openalex.org/W2015837785,72,10,1,1687,271,10,en,en
false,dexmedetomidine fail block acute hyperdynamic response electroconvulsive therapy,orally administer clonidine mg report decrease acute hypertensive response electroconvulsive therapy ect without prolong early recovery preliminary study design evaluate acute hemodynamic effect investigational alpha adrenergic agonist dexmedetomidine patient undergo series ect treatment six patient undergo series three six consecutive ect treatment study accord randomize double blind placebo control protocol patient receive either saline dexmedetomidine microg kg intravenously min induction anesthesia ect use standardize anesthesia protocol addition assess cardiovascular variable duration seizure activity degree sedation time discharge phase recovery unit assess although dexmedetomidine produce dose related increase level sedation ect procedure fail decrease peak blood pressure heart rate response ect treatment microg kg dexmedetomidine prolong time orientation discharge phase unit result pilot study suggest dexmedetomidine microg kg give intravenously beneficial control acute hyperdynamic response ect,Fu W,1999,Anesthesiology,https://doi.org/10.1097/00000542-199902000-00015,9952147,Fu W; White PF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D018712: Analgesics, Non-Narcotic; D001794: Blood Pressure; D003866: Depressive Disorder; D004311: Double-Blind Method; D004565: Electroconvulsive Therapy; D006801: Humans; D006973: Hypertension; D006993: Hypnotics and Sedatives; D007093: Imidazoles; D020926: Medetomidine; D008875: Middle Aged",,,https://openalex.org/W2033537367,93,11,1,1392,212,4,en,en
false,double blind placebo control ascend dose evaluation pharmacokinetics tolerability modafinil tablet healthy male volunteer,randomize double blind placebo control ascend dose study conduct evaluate pharmacokinetic safety profile increase modafinil dos mg mg mg mg administer orally day period normal healthy male volunteer eight subject six modafinil two placebo randomize four dose group modafinil placebo administer daily day serial blood sample obtain follow administration day day characterization pharmacokinetics trough sample obtain prior dose day assess time reach steady state pharmacokinetic parameter calculate use noncompartmental method modafinil steady state reach three daily modafinil pharmacokinetics dose time independent range mg mg steady state pharmacokinetics modafinil characterize rapid oral absorption rate low plasma clearance ml min volume distribution l kg long half life hr modafinil primarily eliminate metabolism modafinil acid major urinary metabolite stereospecific pharmacokinetics modafinil demonstrate modafinil enantiomer eliminate threefold faster rate l modafinil modafinil mg mg mg generally well tolerate modafinil mg dose panel discontinue day treatment due observation increase blood pressure pulse rate safety data study suggest maximum tolerable single daily oral modafinil dose without titration may mg,Wong YN,1999,J Clin Pharmacol,https://doi.org/10.1177/00912709922007534,9987698,Wong YN; Simcoe D; Hartman LN; Laughton WB; King SP; McCormick GC; Grebow PE,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D001007: Anxiety; D019540: Area Under Curve; D001559: Benzhydryl Compounds; D000697: Central Nervous System Stimulants; D003627: Data Interpretation, Statistical; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006261: Headache; D006801: Humans; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D000077408: Modafinil; D007319: Sleep Initiation and Maintenance Disorders; D013237: Stereoisomerism; D013607: Tablets; D013610: Tachycardia",,,https://openalex.org/W2102196985,150,19,1,1711,295,14,en,en
false,efficacy extrapyramidal side effect new antipsychotic olanzapine quetiapine risperidone sertindole compare conventional antipsychotic placebo meta analysis randomize control trial,objective meta analysis summarize efficacy tolerability new antipsychotic risperidone olanzapine sertindole quetiapine schizophrenia compare placebo conventional antipsychotic main result new drug effective placebo magnitude effect moderate mean effect size r antipsychotic v placebo confidence interval ci n accord study publish date sertindole quetiapine effective haloperidol risperidone olanzapine slightly effective haloperidol treatment global schizophrenic symptomatology respect negative symptom new antipsychotic effective placebo however contrary widespread opinion conventional antipsychotic haloperidol risperidone olanzapine slightly superior sertindole effective accord study fully publish date quetiapine even slightly less effective haloperidol regard new antipsychotic associate less frequent use antiparkinson medication haloperidol risperidone appear slightly less favourable eps profile new antipsychotic methodological limitation review generalizability result expectation future research discus,Leucht S,1999,Schizophr Res,https://doi.org/10.1016/s0920-9964(98)00105-4,9988841,Leucht S; Pitschel-Walz G; Abraham D; Kissling W,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D001569: Benzodiazepines; D003987: Dibenzothiazepines; D004311: Double-Blind Method; D006220: Haloperidol; D006801: Humans; D007093: Imidazoles; D007211: Indoles; D000077152: Olanzapine; D010890: Pirenzepine; D000069348: Quetiapine Fumarate; D016032: Randomized Controlled Trials as Topic; D018967: Risperidone; D012559: Schizophrenia,,,https://openalex.org/W2109481947,219,29,2,1470,245,8,en,en
false,clozapine risperidone chronic schizophrenia effect symptom parkinsonian side effect neuroendocrine response,back table content previous article next article regular articlefull accessclozapine risperidone chronic schizophrenia effect symptom parkinsonian side effect neuroendocrine responsealan f breier anil k malhotra tung ping su debra pinals igor elman caleb adler r todd lafargue allan clifton b david pickar alan f breiersearch paper author anil k malhotrasearch paper author tung ping susearch paper author debra pinalssearch paper author igor elmansearch paper author caleb adlersearch paper author r todd lafarguesearch paper author allan cliftonsearch paper author b david pickarsearch paper author publish online feb http doi org ajp aboutsectionsview articleabstractpdf epub toolsadd favoritesdownload citationstrack citation shareshare onfacebooktwitterlinked inemail view articleabstractobjective clozapine risperidone first two second generation antipsychotic drug approve schizophrenia currently little information comparative efficacy head head clinical trial purpose study examine comparative efficacy clozapine risperidone positive negative symptom depression parkinsonian side effect index neuroendocrine function schizophrenic patient meet priori criterion partial response traditional neuroleptic agent method baseline fluphenazine treatment period patient participate week double blind parallel group comparison effect agent result clozapine superior risperidone positive symptom parkinsonian side effect significant difference drug two measure negative symptom brief psychiatric rating scale total score depression score clozapine patient risperidone patient demonstrate significant reduction fluphenazine baseline positive symptom total symptom depression addition clozapine produce effect plasma prolactin risperidone fluphenazine mean daily week trial mg clozapine mg risperidone conclusion find study indicate drug important difference similarity comparative efficacy chronically ill partially responsive patient schizophrenia research second generation antipsychotic drug patient population address key methodological issue optimal dose treatment duration need clozapine risperidone first two antipsychotic drug new class agent pharmacotherapy schizophrenia class also include olanzapine sertindole quetiapine zipra sidone distinguish typical neuroleptic agent produce clinical efficacy low level parkinsonian side effect none although clozapine risperidone approve food drug administration respectively use worldwide relatively data head head clinical trial assess effect symptom side effect neuroendocrine parameter patient schizophrenia thus basic question pertain comparative efficacy remain unanswered reasonable predict difference clinical efficacy clozapine risperidone strike difference neurochemical property effect animal model even though agent high serotonin ht dopamine bind ratio characteristic share new generation antipsychotic clozapine two order magnitude low affinity dopamine receptor substantially low affinity ht receptor risperidone addition clozapine severalfold great antimuscarinic antihistaminergic effect risperidone primate model acute dystonia clozapine essentially associate dystonia whereas risperidone exhibit dose dependent effect last clinically recommend dos clozapine appear elevate plasma prolactin level data risperidone effect prolactin inconclusive lack prolactin effect parameter propose define atypical profile second generation antipsychotic drug give interest clozapine risperidone decide undertake study comparative efficacy drug positive negative symptom depression parkinsonian symptom neuroendocrine index schizophrenic patient meet priori criterion partial response traditional neuroleptic agent methodpatients participate study enrol section clinical study treatment program national institute health clinical center bethesda md patient meet dsm iv criterion chronic schizophrenia determine interview structure clinical interview dsm iii r best estimate diagnostic meeting information structure diagnostic interview supplement data past psychiatric record available informant patient concurrent drug abuse alcoholism organic brain disorder mental retardation medical condition contraindicate use clozapine risperidone exclude study age range subject year patient meet follow criterion partial response neuroleptic history residual positive negative symptom least week trial therapeutic dose neuroleptic agent least minimum level positive negative symptom time evaluation study least minimum level positive negative symptom prospective trial least week fluphenazine mg day dose adjustment mg day mg day allow order optimize outcome minimum positive symptom level total score least four brief psychiatric rating scale bprs positive symptom item conceptual disorganization hallucination unusual thought content suspiciousness minimum negative symptom level total score scale assessment negative symptom sans least patient stabilize regimen fluphenazine minimum week exception one patient maintain thioridazine mg day history intolerance fluphenazine subgroup total study group undergo drug free period participation research protocol patient randomly assign treatment clozapine risperidone week parallel group double blind comparison trial first week study medication gradually increase mg day clozapine mg day risperidone clinician choice adjustment permit next week within fix limit mg day mg day clozapine mg day mg day risperidone last week period study medication hold constant benztropine mesylate allow extrapyramidal symptom need determine blind psychiatrist blood monitor wbc agranulocytosis draw weekly patient receive drug help maintain blind positive symptom assess sum score four bprs psychosis item indicate addition bprs withdrawal retardation anxiety depression factor score total score item bprs range use sans total score range use assess negative symptom simpson angus rating scale range score use assess parkinsonian symptom item rate salivation omit increase salivation common side effect clozapine part parkinsonian clinical picture hamilton depression rating scale use assess depression symptom parkinsonian rating conduct research psychiatrist blind treatment assignment two patient hamilton depression rating unavailable analysis monthly interrater reliability meeting conduct throughout study minimize rater drift interrater reliability intraclass coefficient symptom scale great venous blood sample draw patient assign clozapine patient assign risperidone last fluphenazine treatment week week double blind treatment sample collect edta contain tube immediately place ice centrifuge plasma separation resultant plasma freeze assay prolactin level assay microparticle enzyme immunoassay intra assay interassay variability respectively growth hormone assay radioimmunoassay intra assay interassay variability respectively cortisol assay fluorescence polarization immunoassay intra assay interassay variability respectively statistical analysis efficacy clozapine efficacy risperidone compare use data end double blind study week baseline rating e last week fluphenazine treatment covariates last week fluphenazine treatment use baseline provide great generalizability find clinical practice e switch atypical antipsychotic chronic neuroleptic treatment maximize uniformity across subject significant difference clozapine risperidone baseline data assumption parallel slope assess analysis covariance secondary within treatment group analysis conduct compare fluphenazine baseline data week data study drug effect size calculate efficacy variable divide treatment difference clozapine change baseline minus risperidone change baseline square root mean square error resultstwenty nine patient enter neuroleptic baseline phase complete week double blind comparative study eight male six female randomly assign clozapine male four female risperidone significant difference two group demographic clinical admission characteristic table nineteen patient underwent drug free period random assignment nine patient subsequently assign clozapine mean drug free day sd patient subsequently assign risperidone mean drug free day sd df p two prospective subject relapse random treatment assignment three successfully change fluphenazine baseline assessment five patient among subject study analysis clozapine superior risperidone bprs positive symptom simpson angus score study drug comparison reveal significant difference two measure negative symptom sans score bprs withdrawal retardation score bprs total score bprs anxiety depression score hamilton depression score table secondary within group analysis compare baseline week score clozapine treat patient reveal significant decrease bprs positive symptom f df p bprs anxiety depression f df p bprs total score f df p hamilton depression score f df p significant difference baseline week score risperidone treated patient use change bprs total score identify categorical responder find five patient assign clozapine three patient assign risperidone meet response criterion df p mean daily dose week mg day sd clozapine mg day sd risperidone three risperidone patient mg day two patient assign clozapine patient assign risperidone receive benztropine extrapyramidal side effect trial df p assumption parallel slope analysis covariance prolactin data f df p growth hormone data f df p meet therefore analysis compare mean change score week minus baseline neuroendocrine data significantly different effect clozapine risperidone prolactin level decrement baseline week clozapine treatment table secondary analysis include male patient prolactin data conduct result still significant df p significant difference drug cortisol growth hormone table discussionthe result study indicate clozapine superior risperidone positive symptom extrapyramidal side effect difference find two measure negative symptom total symptom score depression score clozapine risperidone demonstrate significant reduction fluphenazine baseline value positive symptom total symptom depression addition clozapine produce effect plasma prolactin either risperidone fluphenazine significant difference find growth hormone cortisol data demonstrate clozapine superior efficacy psychosis consistent data previous clinical trial several study clozapine show superiority traditional neuroleptic positive symptom although risperidone demonstrate superiority placebo positive symptom consistently show superiority traditional neuroleptic positive symptom suggest clozapine may effective psychosis schizophrenia particularly chronically ill less neuroleptic responsive population find significant difference two agent negative symptom assess bprs withdrawal retardation subscale sans total score moreover neither drug demonstrate significant reduction negative symptom fluphenazine baseline several previous study agent demonstrate superiority neuroleptic negative symptom however one previous study priori define partially responsive schizophrenic patient clozapine effect negative symptom modest suggest subgroup may relatively treatment resistant negative symptom beyond treatable traditional neuroleptic baseline negative symptom current study determine fluphenazine trial significant difference depression clozapine risperidone group comparative analysis however clozapine treat patient demonstrate reduction fluphenazine baseline depression score consistent previous report note clozapine great efficacy mood symptom comparison neuroleptic drug two comparative clinical trial clozapine risperidone find similar effect symptom klieser et al include patient acute exacerbation symptom meet priori criterion lack response treatment partial response thus difference patient clinical status time study entrance acutely ill versus stabilize fluphenazine patient subtype less chronically ill versus partially unresponsive neuroleptic may account differ result klieser et al study present study difference may contribute discrepant result short treatment period day fix dose arm risperidone mg day mg day clozapine mg day study klieser colleague oppose flexible dosing design optimize clinical outcome current study study bondolfi et al mean daily dose clozapine mg low dose present study north american trial treatment resistant partially responsive patient may account difference result study addition number month previous hospitalization study bondolfi colleague approximately twice current study suggest subject may treatment resistant chronically ill subject bondolfi et al study treatment duration week risperidone dose mg day sociodemographic composition sample roughly similar current study likely explanation discrepant finding low incidence extrapyramidal side effect associate clozapine consistent previous data primate model clinical study casey demonstrate risperidone steep dose response curve induce dystonia nonhuman primates predictive model liability extrapyramidal side effect clinical population contrast even exceedingly high clozapine produce dys tonia primate model clinical population risperidone associate dose dependent induction parkinsonian symptom extrapyramidal side effect occur upper dosage range mg day contrast clozapine rarely associate induction extrapyramidal side effect clinical population even high dosage find low use benztropine clozapine assign patient receive risperidone support favorable extrapyramidal side effect profile clozapine clozapine relative lack effect plasma prolactin level compare risperidone fluphenazine consistent previous report probably attributable agent differential effect dopamine neurotransmission dopaminergic tuberoinfundibular pathway inhibitory effect pituitary prolactin release disrupt administration potent dopaminergic antagonist vitro bind study vivo human image study demonstrate high dopamine bind neuroleptic risperidone comparison clozapine unpublished manuscript su et al moreover normal cultured rat pituitary cell clozapine interfere dopamine mediate prolactin inhibition since antipsychotic drug relate extrapyramidal side effect prolactin elevation tend associate tempt speculate low risperidone induce extrapyramidal side effect would less likely induce prolactin increase caveat consider interpret find study optimal dose risperidone comparative clinical trial unclear accord literature low e mg day associate favorable extrapyramidal side effect profile perhaps good effect negative symptom prescribe trend demonstrate great utilization low risperidone e g mg day even though risperidone assign patient current study excess mg day important examine efficacy low risperidone dose population trial duration week study group size n may limit detection difference specific domain negative symptom rate response patient participate prospective trial fluphenazine establish partial response neuroleptic allow baseline rating psychopathology random assignment drug thus patient baseline value reflect relative clinical stability may contribute less variance potential symptom change baseline time acute exacerbation give priori admission criterion unclear whether find generalizable schizophrenia subgroup conclusion data present indicate two second generation agent important difference similarity efficacy schizophrenic patient partially responsive typical neuroleptic clozapine advantage positive symptom extrapyramidal side effect prolactin level whereas difference negative symptom total symptom depression growth hormone cortisol find future research partially responsive patient address methodological issue optimal dose treatment duration need receive oct revision receive march july aug accept sept experimental therapeutic branch division intramural research program nimh bethesda md address reprint request dr breier eli lilly co lilly corporate center drop code indianapolis email protect e mail table enlarge tabletable enlarge tabletable enlarge tablereferences meltzer hy matsubara lee j c classification typical atypical antipsychotic drug basis dopamine serotonin pki value j pharmacol exp ther medline google scholar schotte janssen pe gommeren w luyten wh van bompel p lesage l de loore k levsen je risperidone compare new reference antipsychotic drug vitro vivo receptor bind psychopharmacology berl crossref medline google scholar leysen je grommeren w eens de chaffoy de courcelles stoof jc janssen paj biochemical profile risperidone new antipsychotic j pharmacol exp ther medline google scholar bymaster fp calligaro falcone jf marsh rd moore na tye nc seeman p wong dt radioreceptor bind profile atypical antipsychotic olanzapine neuropsychopharma cology crossref medline google scholar casey de behavioral effect sertindole risperidone clozapine haloperidol cebu monkey psychopharmacology berl crossref medline google scholar lambert sw van koetsveld pm hofland lj effect clozapine prolactin secretion level lactotroph life sci crossref medline google scholar kane jm cooper tb sachar ej halpern f bailine clozapine plasma level prolactin response psychopharmacology berl crossref google scholar kinon bj lieberman ja mechanism action atypical antipsychotic drug critical analysis psychopharmacology berl crossref medline google scholar spitzer rl williams jbw gibbon first mb instruction manual structure clinical interview dsm iii r scid new york new york state psychiatric institute biometrics research google scholar overall je gorham dr brief psychiatric rating scale psychol rep crossref google scholar andreasen nc negative symptom schizophrenia definition reliability arch gen psychiatry crossref medline google scholar simpson gm angus jws rating scale extrapyramidal side effect acta psychiatr scand suppl crossref medline google scholar hamilton rating scale depression j neurol neurosurg psychiatry crossref medline google scholar phillips l case history data prognosis schizophrenia j nerv ment dis crossref medline google scholar kane j honigfeld g singer j meltzer h clozapine treatment resistant schizophrenic double blind comparison chlorpromazine arch gen psychiatry crossref medline google scholar pickar owen rr litman konicki f gutierrez r rapaport mh clinical biologic response clozapine patient schizophrenia crossover comparison fluphenazine arch gen psychiatry crossref medline google scholar breier buchanan rw kirkpatrick b davis irish summerfelt carpenter wt jr effect clozapine positive negative symptom outpatient schizophrenia j psychiatry link google scholar meltzer hy bernett bastani b ramirez lf effect six month clozapine treatment quality life chronic schizophrenic patient hosp community psychiatry abstract google scholar kumra frazier ja jacobsen lk mckenna k gordon ct lenane mc hamburger sd smith ak albus ke alaghband rad j rapoport j childhood onset schizophrenia double blind clozapine haloperidol comparison arch gen psychiatry crossref medline google scholar marder sr meibach rc risperidone treatment schizophrenia j psychiatry link google scholar claus bollen j decuyper h eneman malfroid peuskens j heylen risperidone versus haloperidol treatment chronic schizophrenic inpatient multicentre double blind comparative study acta psychiatr scand crossref medline google scholar chouinard g jones b remington g bloom addington macewan gw labelle beauclair l arnott w canadian multicenter placebo control study fix risperidone haloperidol treatment chronic schizophrenic patient j clin psychopharmacol crossref medline google scholar matte ja risperidone good evidence efficacy schizophr bull google scholar hoyberg oj fensbo c remvig j lingjaerde sloth nielson salvesen risperidone versus perphenazine treatment chronic schizophrenic patient acute exacerbation acta psychiatr scand crossref medline google scholar carpenter wt jr conley rr buchanan rw breier tamminga ca patient response resource management another view clozapine treatment schizophrenia j psychiatry link google scholar lindenmayer j p grochowski mabugot l clozapine effect positive negative symptom six month trial treatment refractory schizophrenic j clin psychopharmacol crossref medline google scholar klieser e lehmann e kinzler e wurthmann c heinrich k randomize double blind control trial risperidone versus clozapine patient chronic schizophrenia j clin psychopharmacol suppl sgoogle scholar bondolfi g dufour h patris may jp billeter u eap cb baumann p risperidone study group risperidone versus clozapine treatment resistant chronic schizophrenia randomize double blind study j psychiatry link google scholar gelenberg aj psychosis practitioner guide psychoactive drug nd ed edit bassuk el schoonover sc gelenberg aj new york plenum pp google scholar pickar su p weinberger dr coppola r malhotra ak knable mb lee k gorey j bartko jj breier hsiao j individual variation dopamine receptor occupancy clozapine treat patient j psychiatry link google scholar farde l nordstrom l wiesel f pauli halidin c sedvall g positron emission tomographic analysis central dopamine receptor occupancy patient treat classical neuroleptic clozapine relation extrapyramidal side effect arch gen psychiatry crossref medline google scholar figuresreferencescited bydetailscited bywhy olanzapine beat risperidone risperidone beat quetiapine quetiapine beat olanzapine exploratory analysis head head comparison study second generation antipsychoticsstephan john davis katja maino elisabeth jetzinger werner kissling stefan leucht february american journal psychiatry vol clozapine olanzapine risperidone haloperidol treatment patient chronic schizophrenia schizoaffective disorderjan volavka ph pal czobor ph brian sheitman jean pierre lindenmayer leslie citrome p h joseph p mcevoy thomas b cooper miranda chakos jeffrey lieberman february american journal psychiatry vol double blind comparative study clozapine risperidone management severe chronic schizophreniajean michel azorin ren spiegel ph gary remington ph jean marie vanelle jean jacques p r monique giguere ph isabelle bourdeix ph august american journal psychiatry vol effectiveness second generation antipsychotic patient treatment resistant schizophrenia review meta analysis randomize trialsmiranda chakos jeffrey lieberman elaine hoffman ph daniel bradford brian sheitman april american journal psychiatry vol risperidone treatment psychosis end stage friedreich ataxiamatt j salbenblatt randall buzan steven l dubovsky february american journal psychiatry vol bright light therapy effect postpartum depressionmaria corral f r c p c annie kuan b demetra kostaras b sc february american journal psychiatry vol comparison clozapine risperidonerobert hamer ph pippa simpson ph february american journal psychiatry vol volume issue february page metric pdf download history publish online february publish print february,Breier AF,1999,Am J Psychiatry,https://doi.org/10.1176/ajp.156.2.294,9989566,Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D014150: Antipsychotic Agents; D001480: Basal Ganglia Diseases; D002908: Chronic Disease; D003024: Clozapine; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D019382: Human Growth Hormone; D006801: Humans; D006854: Hydrocortisone; D008297: Male; D010302: Parkinson Disease, Secondary; D011388: Prolactin; D011569: Psychiatric Status Rating Scales; D018967: Risperidone; D012559: Schizophrenia; D012565: Schizophrenic Psychology; D016896: Treatment Outcome",,,https://openalex.org/W1821837697,127,18,1,31057,5303,173,en,en
